FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Wagner, B Gorin, Y AF Wagner, Brent Gorin, Yves TI Src tyrosine kinase mediates platelet-derived growth factor BB-induced and redox-dependent migration in metanephric mesenchymal cells SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Article DE mesenchyme; metanephric; migration; Nox4; platelet-derived growth factor ID SMOOTH-MUSCLE-CELLS; FACTOR RECEPTOR-BETA; NADPH OXIDASE 4; SIGNAL-REGULATED KINASE; ANGIOTENSIN-II; PROTEIN-KINASE; MESANGIAL CELLS; ENDOTHELIAL-CELLS; NAD(P)H OXIDASE; DNA-SYNTHESIS AB The adult kidney is derived from the interaction between the metanephric blastema and the ureteric bud. Platelet-derived growth factor (PDGF) receptor beta is essential for the development of the mature glomerular tuft, as mice deficient for this receptor lack mesangial cells. This study investigated the role of Src tyrosine kinase in PDGF-mediated reactive oxygen species (ROS) generation and migration of metanephric mesenchymal cells (MMCs). Cultured embryonic MMCs from wildtype and PDGF receptor-deficient embryos were established. Migration was determined via wound-healing assay. Unlike PDGF AA, PDGF BB-induced greater migration in MMCs with respect to control. This was abrogated by neutralizing an antibody to PDGF BB. Phosphatidylinositol 3-kinase (PI3K) inhibitors suppressed PDGF BB-induced migration. Conversely, mitogen-activated protein kinase/ extracellular signal-regulated kinase (MEK) inhibitors had no effect. Src inhibitors inhibited PDGF-induced cell migration, PI3K activity, and Akt phosphorylation. Adenoviral dominant negative Src (AD DN Src) abrogated PDGF BB-induced Akt phosphorylation. Hydrogen peroxide stimulated cell migration. PDGF BB-induced wound closure was inhibited by the antioxidants N-acetyl-L-cysteine, tiron, and the flavoprotein inhibitor diphenyleneiodonium. These cells express the NADPH oxidase homolog Nox4. Inhibiting Nox4 with antisense oligonucleotides or small interfering RNA (siRNA) suppressed PDGF-induced wound closure. Inhibition of Src with siRNA reduced PDGF BB-induced ROS generation as assessed by 2', 7'-dichlorodihydrofluorescein diacetate fluorescence. Furthermore, PDGF BB-stimulated ROS generation and migration were similarly suppressed by Ad DN Src. In MMCs, PDGF BB-induced migration is mediated by PI3K and Src in a redoxdependent manner involving Nox4. Src may be upstream to PI3K and Nox4. C1 [Wagner, Brent] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Wagner, Brent; Gorin, Yves] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. RP Wagner, B (reprint author), South Texas Vet Hlth Care Syst, Div Nephrol, MC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM wagnerb@uthscsa.edu OI Wagner, Brent/0000-0002-7063-0142 FU American Heart Association [121052]; Department of Veterans Affairs Career Development Award; Department of Veterans Affairs Merit Award; Juvenile Diabetes Research Foundation Grant; National Institute of Diabetes and Digestive and Kidney Diseases [DK-079996] FX This work was supported by a Fellow-to-Faculty Transition Award from the American Heart Association (no. 121052). B. Wagner is supported by a Department of Veterans Affairs Career Development Award and a Department of Veterans Affairs Merit Award. Y. Gorin is supported by a Juvenile Diabetes Research Foundation Grant and National Institute of Diabetes and Digestive and Kidney Diseases Grant DK-079996. NR 91 TC 2 Z9 2 U1 0 U2 3 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD JAN PY 2014 VL 306 IS 1 BP F85 EP F97 DI 10.1152/ajprenal.00371.2013 PG 13 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA 282SL UT WOS:000329193300011 PM 24197068 ER PT J AU Koenigsberg, HW Denny, BT Fan, J Liu, X Guerreri, S Mayson, SJ Rimsky, L New, AS Goodman, M Siever, LJ AF Koenigsberg, Harold W. Denny, Bryan T. Fan, Jin Liu, Xun Guerreri, Stephanie Mayson, Sarah Jo Rimsky, Liza New, Antonia S. Goodman, Marianne Siever, Larry J. TI The Neural Correlates of Anomalous Habituation to Negative Emotional Pictures in Borderline and Avoidant Personality Disorder Patients SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; FUNCTIONAL MRI; CONNECTIVITY; INSULA; DYSREGULATION; EXPOSURE; BEHAVIOR; STIMULI; FMRI AB Objective: Extreme emotional reactivity is a defining feature of borderline personality disorder, yet the neural-behavioral mechanisms underlying this affective instability are poorly understood. One possible contributor is diminished ability to engage the mechanism of emotional habituation. The authors tested this hypothesis by examining behavioral and neural correlates of habituation in borderline patients, healthy comparison subjects, and a psychopathological comparison group of patients with avoidant personality disorder. Method: During fMRI scanning, borderline patients, healthy subjects, and avoidant personality disorder patients viewed novel and repeated pictures, providing valence ratings at each presentation. Statistical parametric maps of the contrasts of activation during repeated versus novel negative picture viewing were compared between groups. Psychophysiological interaction analysis was employed to examine functional connectivity differences between groups. Results: Unlike healthy subjects, neither borderline nor avoidant personality disorder patients exhibited increased activity in the dorsal anterior cingulate cortex when viewing repeated Versus novel pictures. This lack of an increase in dorsal anterior cingulate activity was associated with greater affective instability in borderline patients. In addition, borderline and avoidant patients exhibited smaller increases in insula-amygdala functional connectivity than healthy subjects and, unlike healthy subjects, did not show habituation in ratings of the emotional intensity of the images. Borderline patients differed from avoidant patients in insula-ventral anterior cingulate functional connectivity during habituation. Conclusions: Unlike healthy subjects, borderline patients fail to habituate to negative pictures, and they differ from both healthy subjects and avoidant patients in neural activity during habituation. A failure to effectively engage emotional habituation processes may contribute to affective instability in borderline patients. C1 [Koenigsberg, Harold W.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. James J Peters VA Med Ctr, Bronx, NY USA. CUNY, Queens Coll, Dept Psychol, New York, NY 10021 USA. Chinese Acad Sci, Inst Psychol, Beijing 100101, Peoples R China. RP Koenigsberg, HW (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. EM hwarrenk@nyc.rr.com RI Fan, Jin/A-6716-2009; Liu, Xun/C-2400-2009 OI Fan, Jin/0000-0001-9630-8330; Liu, Xun/0000-0003-1366-8926 FU NIMH [R01 MH077813]; National Center for Research Resources, NIH [5M01 RR00071]; James J. Peters VA Medical Center FX Supported by NIMH grant R01 MH077813 to Dr. Koenigsberg; by the National Center for Research Resources, NIH, for the Mount Sinai General Clinical Research Center (5M01 RR00071); and by the James J. Peters VA Medical Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIMH, NIH, or the U.S. Department of Veterans Affairs. NR 38 TC 20 Z9 20 U1 2 U2 16 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD JAN PY 2014 VL 171 IS 1 BP 82 EP 90 DI 10.1176/appi.ajp.2013.13070852 PG 9 WC Psychiatry SC Psychiatry GA 286OO UT WOS:000329478800015 PM 24275960 ER PT J AU Ebrahimi, R Bakaeen, FG Uberoi, A Ardehali, A Baltz, JH Hattler, B Almassi, GH Wagner, TH Collins, JF Grover, FL Shroyer, AL AF Ebrahimi, Ramin Bakaeen, Faisal G. Uberoi, Abhimanyu Ardehali, Abbas Baltz, Janet H. Hattler, Brack Almassi, G. Hossein Wagner, Todd H. Collins, Joseph F. Grover, Frederick L. Shroyer, A. Laurie TI Effect of Clopidogrel Use Post Coronary Artery Bypass Surgery on Graft Patency SO ANNALS OF THORACIC SURGERY LA English DT Article; Proceedings Paper CT 49th Annual Meeting of the Society-of-Thoracic-Surgeons CY JAN 26-30, 2013 CL Los Angeles, CA SP Soc Thorac Surg ID ASPIRIN PLUS CLOPIDOGREL; INTERNAL MAMMARY ARTERY; EVENTS CURE TRIAL; SAPHENOUS-VEIN; ANTIPLATELET THERAPY; PLATELET INHIBITION; UNSTABLE ANGINA; ON-PUMP; PREVENTION; OUTCOMES AB Background. Clopidogrel use post coronary artery bypass grafting (CABG) has become more popular under the assumption that it improves graft patency. The purpose of this sub-analysis from the Randomized On and Off-Pump Bypass (ROOBY) trial is to evaluate the role of clopidogrel use post CABG to improve graft patency when added to standard aspirin therapy. Methods. The ROOBY trial was a multi-center, randomized, controlled clinical trial that compared on-pump versus off-pump coronary artery bypass grafting (CABG). Clopidogrel use post CABG was left at the discretion of the operator. Detailed data regarding the use and timing of clopidogrel post CABG were collected prospectively, along with 1-year angiograms to evaluate graft status. Results. Of the 2,203 subjects undergoing CABG, 953 patient records had complete clopidogrel use and 1-year angiographic data. Of these, 345 (36.2%) received clopidogrel post CABG prior to discharge. Compared with patients with no post-CABG clopidogrel use, baseline characteristics were similar for the clopidogrel group except for the following: lower preoperative aspirin use (80.2% vs 86.7%, p = 0.009); higher preoperative clopidogrel use (23.5% vs 14.0%, p < 0.001), less on-pump (35.9% vs 55.9%, p < 0.0001); and lower endoscopic vein harvesting (30.8% vs 42.5%, p < 0.001) rates. Overall 1-year graft patency rates were not different between the clopidogrel and no-clopidogrel groups (86.5% vs 85.3%, p = 0.43). Multivariable analyses did not alter these findings. Conclusions. This study suggests that routine post-CABG clopidogrel use may not translate to improved 1-year graft patency. Future studies appear warranted to better define the role of more aggressive antiplatelet therapy post CABG on graft patency and clinical outcomes. (C) 2014 by The Society of Thoracic Surgeons C1 Greater Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA. Michael E DeBakey VA Med Ctr, Houston, TX USA. Baylor Coll Med, Dept Cardiothorac Surg, Houston, TX 77030 USA. Northport VA Med Ctr, Northport, NY USA. Eastern Colorado Hlth Care Syst, Dept Vet Affairs, Denver, CO USA. Univ Colorado, Sch Med, Dept Surg, Aurora, CO USA. Univ Colorado, Sch Med, Dept Med, Aurora, CO USA. VA Med Ctr, Cooperat Studies Program Coordinating Ctr, Perry Point, MD USA. VA Palo Alto Hlth Econ Resource Ctr, Menlo Pk, CA USA. Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA. Zablocki VA Med Ctr, Milwaukee, WI USA. Med Coll Wisconsin, Milwaukee, WI 53226 USA. RP Ebrahimi, R (reprint author), Greater Los Angeles VA Med Ctr, Dept Med, Cardiol Sect 111E, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ebrahimi@ucla.edu RI Shroyer, Annie Laurie/B-8836-2016 OI Shroyer, Annie Laurie/0000-0001-6461-0623 NR 30 TC 14 Z9 16 U1 0 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD JAN PY 2014 VL 97 IS 1 BP 15 EP 21 DI 10.1016/j.athoracsur.2013.08.058 PG 7 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA 282FO UT WOS:000329155900013 PM 24206971 ER PT J AU Hasty, P Livi, CB Dodds, SG Jones, D Strong, R Javors, M Fischer, KE Sloane, L Murthy, K Hubbard, G Sun, LS Hurez, V Curiel, TJ Sharp, ZD AF Hasty, Paul Livi, Carolina B. Dodds, Sherry G. Jones, Diane Strong, Randy Javors, Martin Fischer, Kathleen E. Sloane, Lauren Murthy, Kruthi Hubbard, Gene Sun, Lishi Hurez, Vincent Curiel, Tyler J. Sharp, Zelton Dave TI eRapa Restores a Normal Life Span in a FAP Mouse Model SO CANCER PREVENTION RESEARCH LA English DT Article ID GENETICALLY HETEROGENEOUS MICE; FAMILIAL ADENOMATOUS POLYPOSIS; MESSENGER-RNA TRANSLATION; PROTEIN S6 KINASE; RAPAMYCIN; CANCERS; CELLS; DYSFUNCTION; RESTRICTION; INHIBITORS AB Mutation of a single copy of the adenomatous polyposis coli (APC) gene results in familial adenomatous polyposis (FAP), which confers an extremely high risk for colon cancer. Apc(Min/+) mice exhibit multiple intestinal neoplasia (MIN) that causes anemia and death from bleeding by 6 months. Mechanistic target of rapamycin complex 1 (mTORC1) inhibitors were shown to improve Apc(Min/+) mouse survival when administered by oral gavage or added directly to the chow, but these mice still died from neoplasia well short of a natural life span. The National Institute of Aging Intervention Testing Program showed that enterically targeted rapamycin (eRapa) extended life span for wild-type genetically heterogeneous mice in part by inhibiting age-associated cancer. We hypothesized that eRapa would be effective in preventing neoplasia and extend survival of Apc(Min/+) mice. We show that eRapa improved survival of Apc(Min/+) mice in a dose-dependent manner. Remarkably, and in contrast to previous reports, most of the Apc(Min/+) mice fed 42 parts per million eRapa lived beyond the median life span reported for wild-type syngeneic mice. Furthermore, chronic eRapa did not cause detrimental immune effects in mouse models of cancer, infection, or autoimmunity, thus assuaging concerns that chronic rapamycin treatment suppresses immunity. Our studies suggest that a novel formulation (enteric targeting) of a well-known and widely used drug (rapamycin) can dramatically improve its efficacy in targeted settings. eRapa or other mTORC1 inhibitors could serve as effective cancer preventatives for people with FAP without suppressing the immune system, thus reducing the dependency on surgery as standard therapy. C1 [Hasty, Paul; Livi, Carolina B.; Dodds, Sherry G.; Jones, Diane; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78145 USA. [Hasty, Paul; Livi, Carolina B.; Dodds, Sherry G.; Jones, Diane; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, San Antonio, TX 78145 USA. [Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78145 USA. [Javors, Martin] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78145 USA. [Fischer, Kathleen E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78145 USA. [Murthy, Kruthi; Sun, Lishi; Hurez, Vincent; Curiel, Tyler J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78145 USA. [Hubbard, Gene] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78145 USA. [Hasty, Paul; Murthy, Kruthi; Curiel, Tyler J.; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78145 USA. [Hasty, Paul; Livi, Carolina B.; Strong, Randy; Fischer, Kathleen E.; Sloane, Lauren; Hubbard, Gene; Curiel, Tyler J.; Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78145 USA. [Strong, Randy] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Sharp, ZD (reprint author), UT Hlth Sci Ctr San Antonio, 15355 Lambda Dr, San Antonio, TX 78145 USA. EM hastye@uthscsa.edu; carolina.livi@Agilent.com; curielt@uthscsa.edu; sharp@uthscsa.edu OI Hurez, Vincent/0000-0003-0271-4157 FU NIH [CA123203, AG017242, RC2AG036613, CA54174, P30-AG013319, CA170491]; Holly Beach Public Library; Voelcker Fund FX This work was supported by the following grants from the NIH: CA123203 and AG017242 (to P. Hasty); RC2AG036613 (to Z.D. Sharp, P. Hasty, R. Strong, and T.J. Curiel); CA54174 (to T.J. Curiel, P. Hasty, and Z.D. Sharp); P30-AG013319 (to R. Strong), CA170491, Holly Beach Public Library, and the Voelcker Fund (T.J. Curiel). NR 50 TC 23 Z9 23 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1940-6207 EI 1940-6215 J9 CANCER PREV RES JI Cancer Prev. Res. PD JAN PY 2014 VL 7 IS 1 BP 169 EP 178 DI 10.1158/1940-6207.CAPR-13-0299 PG 10 WC Oncology SC Oncology GA 285YR UT WOS:000329431500018 PM 24282255 ER PT J AU Dakhova, O Rowley, D Ittmann, M AF Dakhova, Olga Rowley, David Ittmann, Michael TI Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo SO CLINICAL CANCER RESEARCH LA English DT Article ID EXPRESSION ANALYSIS; GROWTH; RECURRENCE; TISSUE; CELLS; BMI1; ANGIOGENESIS; SURVIVAL; BENIGN AB Purpose: Marked reactive stroma formation is associated with poor outcome in clinically localized prostate cancer. We have previously identified genes with diverse functions that are upregulated in reactive stroma. This study tests the hypothesis that expression of these genes in stromal cells enhances prostate cancer growth in vivo. Experimental Design: The expression of reactive stroma genes in prostate stromal cell lines was evaluated by reverse transcriptase (RT)-PCR and qRT-PCR. Genes were knocked down using stable expression of short-hairpin RNAs (shRNA) and the impact on tumorigenesis assessed using the differential reactive stroma (DRS) system, in which prostate stromal cell lines are mixed with LNCaP prostate cancer cells and growth as subcutaneous xenografts assessed. Results: Nine of 10 reactive stroma genes tested were expressed in one or more prostate stromal cell lines. Gene knockdown of c-Kit, Wnt10B, Bmi1, Gli2, orCOMPall resulted in decreased tumorigenesis in the DRS model. In all tumors analyzed, angiogenesis was decreased and there were variable effects on proliferation and apoptosis in the LNCaP cells. Wnt10B has been associated with stem/ progenitor cell phenotype in other tissue types. Using a RT-PCR array, we detected downregulation of multiple genes involved in stem/progenitor cell biology such as OCT4 and LIF as well as cytokines such as VEGFA, BDNF, and CSF2 in cells with Wnt10B knockdown. Conclusions: These findings show that genes upregulated in prostate cancer-reactive stroma promote progression when expressed in prostate stromal cells. Moreover, these data indicate that the DRS model recapitulates key aspects of cancer cell/ reactive stroma interactions in prostate cancer. (C)2013 AACR. C1 [Dakhova, Olga; Ittmann, Michael] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [Rowley, David] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA. [Ittmann, Michael] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. RP Ittmann, M (reprint author), Baylor Coll Med, Dept Pathol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA. EM mittmann@bcm.tmc.edu FU National Cancer Institute; P30 Cancer Center support grant [P30 CA125123]; Department of Veterans Affairs Merit Review program FX This work was supported by grants from National Cancer Institute to the Tumor Microenvironment Network (1U54CA126568, DR), the P30 Cancer Center support grant (P30 CA125123) to support the Human Tissue Acquisition and Pathology Core, the Department of Veterans Affairs Merit Review program (to M.M. Ittmann) and by the use of the facilities of the Michael E. DeBakey VAMC. NR 33 TC 8 Z9 8 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD JAN 1 PY 2014 VL 20 IS 1 BP 100 EP 109 DI 10.1158/1078-0432.CCR-13-1184 PG 10 WC Oncology SC Oncology GA 284GC UT WOS:000329303100013 PM 24150235 ER PT J AU Armah, KA Chang, CCH Baker, JV Ramachandran, VS Budoff, MJ Crane, HM Gibert, CL Goetz, MB Leaf, DA McGinnis, KA Oursler, KK Rimland, D Rodriguez-Barradas, MC Sico, JJ Warner, AL Hsue, PY Kuller, LH Justice, AC Freiberg, MS AF Armah, Kaku A. Chang, Chung-Chou H. Baker, Jason V. Ramachandran, Vasan S. Budoff, Matthew J. Crane, Heidi M. Gibert, Cynthia L. Goetz, Matthew B. Leaf, David A. McGinnis, Kathleen A. Oursler, Krisann K. Rimland, David Rodriguez-Barradas, Maria C. Sico, Jason J. Warner, Alberta L. Hsue, Priscilla Y. Kuller, Lewis H. Justice, Amy C. Freiberg, Matthew S. CA VACS Project Team TI Prehypertension, Hypertension, and the Risk of Acute Myocardial Infarction in HIV-Infected and -Uninfected Veterans SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE blood pressure; prehypertension; HIV; myocardial infarction ID ACTIVE ANTIRETROVIRAL THERAPY; INTIMA-MEDIA THICKNESS; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; LARGE COHORT; PREVALENCE; ATHEROSCLEROSIS; ASSOCIATION; PROGRESSION; DATABASE AB Background. Compared to uninfected people, human immunodeficiency virus (HIV)-infected individuals may have an increased risk of acute myocardial infarction (AMI). Currently, HIV-infected people are treated to the same blood pressure (BP) goals (<140/90 or <130/80 mm Hg) as their uninfected counterparts. Whether HIV-infected people with elevated BP have excess AMI risk compared to uninfected people is not known. This study examines whether the association between elevated BP and AMI risk differs by HIV status. Methods. The Veterans Aging Cohort Study Virtual Cohort (VACS VC) consists of HIV-infected and -uninfected veterans matched 1: 2 on age, sex, race/ethnicity, and clinical site. For this analysis, we analyzed 81 026 people with available BP data from VACS VC, who were free of cardiovascular disease at baseline. BP was the average of the 3 routine outpatient clinical measurements performed closest to baseline (first clinical visit after April 2003). BP categories used in the analyses were based on criteria of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Analyses were performed using Cox proportional hazards regression. Results. Over 5.9 years (median), 860 incident AMIs occurred. Low/high prehypertensive and untreated/treated hypertensive HIV-infected individuals had increased AMI risk compared to uninfected, untreated normotensive individuals (hazard ratio [HR], 1.60 [95% confidence interval {CI}, 1.07-2.39]; HR, 1.81 [95% CI, 1.22-2.68]; HR, 2.57 [95% CI, 1.76-3.76]; and HR, 2.76 [95% CI, 1.90-4.02], respectively). Conclusions. HIV, prehypertensive BP, and hypertensive BP were associated with an increased risk of AMI in a cohort of HIV-infected and -uninfected veterans. Future studies should prospectively investigate whether HIV interacts with BP to further increase AMI risk. C1 [Armah, Kaku A.; Chang, Chung-Chou H.; Kuller, Lewis H.; Freiberg, Matthew S.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Chang, Chung-Chou H.; Freiberg, Matthew S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. [Baker, Jason V.] Univ Minnesota, Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA. [Ramachandran, Vasan S.] Boston Univ Sch Med, Cardiol Sect, Framingham Heart Study, Boston, MA USA. [Ramachandran, Vasan S.] Boston Univ Sch Med, Dept Prevent Med & Epidemiol, Boston, MA USA. [Budoff, Matthew J.] Harbor UCLA Med Ctr, Los Angeles, CA USA. [Budoff, Matthew J.] Los Angeles Biomed Res Inst, Los Angeles, CA USA. [Crane, Heidi M.] Univ Washington Sch Med, Seattle, WA USA. [Gibert, Cynthia L.] Vet Affairs VA Med Ctr, Washington, DC USA. [Gibert, Cynthia L.] George Washington Univ Med Ctr, Washington, DC USA. [Goetz, Matthew B.; Leaf, David A.; Warner, Alberta L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew B.; Leaf, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [McGinnis, Kathleen A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Oursler, Krisann K.] Univ Maryland Sch Med, Baltimore VA Med Ctr, Baltimore, MD USA. [Rimland, David] Emory Univ Sch Med, VA Med Ctr, Atlanta, GA USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. [Sico, Jason J.; Justice, Amy C.] Yale Univ Sch Med, West Haven Vet Adm Med Ctr, VA Connecticut Hlth Care Syst, New Haven, CT USA. [Hsue, Priscilla Y.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. RP Freiberg, MS (reprint author), Univ Pittsburgh Sch Med, 230 McKee Pl,Suite 623, Pittsburgh, PA 15213 USA. EM freibergms@upmc.edu OI Goetz, Matthew/0000-0003-4542-992X FU National Heart, Lung, and Blood Institute; National Institute on Alcohol Abuse and Alcoholism at the NIH [HL095136-04, AA013566-10, AA020790, AA020794] FX This work was supported by the National Heart, Lung, and Blood Institute and the National Institute on Alcohol Abuse and Alcoholism at the NIH (grant numbers HL095136-04 to M. S. F. and A. C. J., and AA013566-10, AA020790, and AA020794 to A. C. J.). NR 32 TC 19 Z9 19 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2014 VL 58 IS 1 BP 121 EP 129 DI 10.1093/cid/cit652 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 280QC UT WOS:000329044800027 PM 24065316 ER PT J AU Floyd, LM Holmes, TC Dean, JC AF Floyd, Lisa M. Holmes, Taylor C. Dean, Jesse C. TI Reduced effects of tendon vibration with increased task demand during active, cyclical ankle movements SO EXPERIMENTAL BRAIN RESEARCH LA English DT Article DE Motor control; Movement accuracy; Proprioception; Tendon vibration ID MUSCLE VIBRATION; POSITION SENSE; DIABETIC-NEUROPATHY; AFFERENTS; CONTRACTION; RESPONSES; SPINDLES; HUMANS; STANCE; INFORMATION AB Tendon vibration can alter proprioceptive feedback, one source of sensory information which humans can use to produce accurate movements. However, the effects of tendon vibration during functional movement vary depending on the task. For example, ankle tendon vibration has considerably smaller effects during walking than standing posture. The purpose of this study was to test whether the effects of ankle tendon vibration are predictably influenced by the mechanical demands of a task, as quantified by peak velocity. Twelve participants performed symmetric, cyclical ankle plantar flexion/dorsiflexion movements while lying prone with their ankle motion unconstrained. The prescribed movement period (1, 3 s) and peak-to-peak amplitude (10A degrees, 15A degrees, 20A degrees) were varied across trials; shorter movement periods or larger amplitudes increased the peak velocity. In some trials, vibration was continuously and simultaneously applied to the right ankle plantar flexor and dorsiflexor tendons, while the left ankle tendons were never vibrated. The vibration frequency (40, 80, 120, 160 Hz) was varied across trials. During trials without vibration, participants accurately matched the movement of their ankles. The application of 80 Hz vibration to the right ankle tendons significantly reduced the amplitude of right ankle movement. However, the effect of vibration was smaller during more mechanically demanding (i.e., higher peak velocity) movements. Higher vibration frequencies had larger effects on movement accuracy, possibly due to parallel increases in vibration amplitude. These results demonstrate that the effects of ankle tendon vibration are dependent on the mechanical demand of the task being performed, but cannot definitively identify the underlying physiological mechanism. C1 [Floyd, Lisa M.; Holmes, Taylor C.; Dean, Jesse C.] Med Univ S Carolina, Coll Hlth Profess, Div Phys Therapy, Charleston, SC 29425 USA. [Dean, Jesse C.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP Dean, JC (reprint author), Med Univ S Carolina, Coll Hlth Profess, Div Phys Therapy, 77 President St,MSC700, Charleston, SC 29425 USA. EM deaje@musc.edu OI Dean, Jesse/0000-0003-2034-4217 FU Department of Veterans Affairs [1IK2RX000750] FX This study was partially funded by a grant from the Department of Veterans Affairs, number 1IK2RX000750. NR 48 TC 3 Z9 3 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0014-4819 EI 1432-1106 J9 EXP BRAIN RES JI Exp. Brain Res. PD JAN PY 2014 VL 232 IS 1 BP 283 EP 292 DI 10.1007/s00221-013-3739-2 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 283GE UT WOS:000329233400025 PM 24136344 ER PT J AU Scheuner, MT Hamilton, AB Peredo, J Sale, TJ Austin, C Gilman, SC Bowen, MS Goldzweig, CL Lee, M Mittman, BS Yano, EM AF Scheuner, Maren T. Hamilton, Alison B. Peredo, Jane Sale, Taylor J. Austin, Colletta Gilman, Stuart C. Bowen, M. Scott Goldzweig, Caroline Lubick Lee, Martin Mittman, Brian S. Yano, Elizabeth M. TI A cancer genetics toolkit improves access to genetic services through documentation and use of the family history by primary-care clinicians SO GENETICS IN MEDICINE LA English DT Article DE family history; hereditary cancer; referral ID BRCA2 MUTATION CARRIERS; CONTINUING MEDICAL-EDUCATION; WOMENS HEALTH-CARE; BREAST-CANCER; COLORECTAL-CANCER; LYNCH-SYNDROME; GENOMIC MEDICINE; RISK-ASSESSMENT; OVARIAN-CANCER; DELIVERY AB Purpose: We developed, implemented, and evaluated a multicomponent cancer genetics toolkit designed to improve recognition and appropriate referral of individuals at risk for hereditary cancer syndromes. Methods: We evaluated toolkit implementation in the women's clinics at a large Veterans Administration medical center using mixed methods, including pre-post semistructured interviews, clinician surveys, and chart reviews, and during implementation, monthly tracking of genetic consultation requests and use of a reminder in the electronic health record. We randomly sampled 10% of progress notes 6 months before (n = 139) and 18 months during implementation (n = 677). Results: The toolkit increased cancer family history documentation by almost 10% (26.6% pre- and 36.3% postimplementation). The reminder was a key component of the toolkit; when used, it was associated with a twofold increase in cancer family history documentation (odds ratio = 2.09; 95% confidence interval: 1.39-3.15), and the history was more complete. Patients whose clinicians completed the reminder were twice as likely to be referred for genetic consultation (4.1-9.6%, P < 0.0001). Conclusion: A multicomponent approach to the systematic collection and use of family history by primary-care clinicians increased access to genetic services. C1 [Scheuner, Maren T.; Hamilton, Alison B.; Peredo, Jane; Sale, Taylor J.; Austin, Colletta; Goldzweig, Caroline Lubick; Lee, Martin; Mittman, Brian S.; Yano, Elizabeth M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Scheuner, Maren T.; Goldzweig, Caroline Lubick] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Hamilton, Alison B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Gilman, Stuart C.] Vet Hlth Adm, Off Acad Affiliat, Washington, DC USA. [Bowen, M. Scott] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Lee, Martin; Yano, Elizabeth M.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Scheuner, MT (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM maren.scheuner@va.gov OI Mittman, Brian/0000-0003-3589-9178 FU Centers for Disease Control and Prevention [1U38GD000047] FX This publication was supported by Cooperative Agreement No. 1U38GD000047 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. We thank Muin Khoury for his review of the manuscript (he received no compensation), Lisa V. Rubenstein for her input to the study design and review of implementation activities, Shannon Rhodes for data management and preliminary analyses, and Austin Jones for his contributions to data entry and quality assurance. Rubenstein, Rhodes, and Jones provided these services in their respective roles as employees at the VA Greater Los Angeles Healthcare System. NR 38 TC 11 Z9 11 U1 0 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD JAN PY 2014 VL 16 IS 1 BP 60 EP 69 DI 10.1038/gim.2013.75 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 284GO UT WOS:000329304300009 PM 23765051 ER PT J AU Adappa, ND Zhang, Z Palmer, JN Kennedy, DW Doghramji, L Lysenko, A Reed, DR Scott, T Zhao, NW Owens, D Lee, RJ Cohen, NA AF Adappa, Nithin D. Zhang, Zi Palmer, James N. Kennedy, David W. Doghramji, Laurel Lysenko, Anna Reed, Danielle R. Scott, Thomas Zhao, Nina W. Owens, David Lee, Robert J. Cohen, Noam A. TI The bitter taste receptor T2R38 is an independent risk factor for chronic rhinosinusitis requiring sinus surgery SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Article DE innate immunity; antimicrobial; nitric oxide; mucociliary clearance; endoscopic sinus surgery; genetics ID SOLITARY CHEMOSENSORY CELLS; STAPHYLOCOCCUS-AUREUS; INNATE IMMUNITY; NASAL POLYPS; EXPRESSION; GENETICS; BIOFILMS; DISEASE; PATHOGENESIS; RESPONSES AB BackgroundThe bitter taste receptor T2R38 was recently described to play a role in upper airway innate mucosal defense. When activated by bacterial quorum-sensing molecules, T2R38 stimulates the ciliated epithelial cells to produce nitric oxide (NO), resulting in bactericidal activity and an increase in mucociliary clearance (MCC). Polymorphisms within the T2R38 gene (TAS2R38) confer variability in activation of the receptor yielding dramatic differences in upper airway defensive responses (NO production and accelerated MCC) to microbial stimulation based on genotype. Our objective was to determine whether the nonprotective TAS2R38 polymorphisms, which render the receptor inactive, correlate with medically recalcitrant chronic rhinosinusitis (CRS) necessitating surgical intervention in the context of known risk factors, and thus identify whether the TAS2R38 genotype is an independent risk factor for patients undergoing functional endoscopic sinus surgery (FESS). MethodsCRS patients undergoing primary FESS were prospectively genotyped for TAS2R38. Chi-square analysis was performed on the genotype distribution with respect to other risk factors, including allergies, asthma, nasal polyposis, aspirin sensitivity, diabetes, and smoking exposure. ResultsSeventy primary FESS patients were genotyped demonstrating a statistically significant skewing from the expected distribution of the general population (p < 0.0383). CRS patients with a particular polymorphism seemed less likely to have allergies, asthma, nasal polyposis, aspirin sensitivity, and diabetes, but this did not demonstrate statistical significance. ConclusionOur investigation suggests that TAS2R38 genotype is an independent risk factor for patients failing medical therapy, necessitating surgical intervention. (C) 2013 ARS-AAOA, LLC. C1 [Adappa, Nithin D.; Zhang, Zi; Palmer, James N.; Kennedy, David W.; Doghramji, Laurel; Scott, Thomas; Zhao, Nina W.; Owens, David; Lee, Robert J.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Lysenko, Anna; Reed, Danielle R.] Monell Chem Senses Ctr, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Adappa, ND (reprint author), Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg 5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM Nithin.Adappa@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932; Reed, Danielle/0000-0002-4374-6107; Lee, Robert/0000-0001-5826-6686 FU NIDCD NIH HHS [P30 DC011735] NR 34 TC 40 Z9 40 U1 0 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD JAN PY 2014 VL 4 IS 1 BP 3 EP 7 DI 10.1002/alr.21253 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA 282EF UT WOS:000329152400002 PM 24302675 ER PT J AU Dempsey, JA Xie, AL Patz, DS Wang, D AF Dempsey, Jerome A. Xie, Ailiang Patz, David S. Wang, David TI Physiology in Medicine: Obstructive sleep apnea pathogenesis and treatment-considerations beyond airway anatomy SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Review DE chemosensitivity; collapsible airway; sleep apnea ID GENIOGLOSSAL MUSCLE-ACTIVITY; CHRONIC INTERMITTENT HYPOXIA; CHEYNE-STOKES RESPIRATION; HEART-FAILURE; NREM SLEEP; CAROTID-BODY; REM-SLEEP; LOOP GAIN; PULMONARY RESISTANCE; VENTILATORY CONTROL AB We review evidence in support of significant contributions to the pathogenesis of obstructive sleep apnea (OSA) from pathophysiological factors beyond the well-accepted importance of airway anatomy. Emphasis is placed on contributions from neurochemical control of central respiratory motor output through its effects on output stability, upper airway dilator muscle activation, and arousability. In turn, we consider the evidence demonstrating effective treatment of OSA via approaches that address each of these pathophysiologic risk factors. Finally, a case is made for combining treatments aimed at both anatomical and ventilatory control system deficiencies and for individualizing treatment to address a patient's own specific risk factors. C1 [Dempsey, Jerome A.; Xie, Ailiang] Univ Wisconsin, James B Skatrud Lab Pulm & Sleep Med, Middleton Vet Adm Hosp, Madison, WI 53706 USA. [Dempsey, Jerome A.; Xie, Ailiang] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53706 USA. [Patz, David S.] St Marys Hosp, Dept Med, Grand Junction, CO USA. [Wang, David] Univ Sydney, Woolcock Inst Med Res, Camperdown, NSW, Australia. [Wang, David] Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Camperdown, NSW 2050, Australia. RP Dempsey, JA (reprint author), Univ Wisconsin, 1300 Univ Ave,Rm 4245 MSC, Madison, WI 53706 USA. EM jdempsey@wisc.edu FU National Heart, Lung, and Blood Institute [HL-099724, HL-15469]; Veterans Administration Merit Review FX J. Dempsey and A. Xie were supported by National Heart, Lung, and Blood Institute Grants IIL-099724 and IIL-15469, and by a Veterans Administration Merit Review. NR 95 TC 18 Z9 18 U1 0 U2 9 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD JAN PY 2014 VL 116 IS 1 BP 3 EP 12 DI 10.1152/japplphysiol.01054.2013 PG 10 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 282TI UT WOS:000329196100002 PM 24201709 ER PT J AU Weathington, NM Mallampalli, RK AF Weathington, Nathaniel M. Mallampalli, Rama K. TI Emerging therapies targeting the ubiquitin proteasome system in cancer SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Review ID NF-KAPPA-B; REFRACTORY MULTIPLE-MYELOMA; SINGLE-AGENT CARFILZOMIB; SMALL-MOLECULE INHIBITOR; OPEN-LABEL; DEUBIQUITINATING ENZYME; ALLOSTERIC INHIBITOR; CEREBLON EXPRESSION; BORTEZOMIB; APOPTOSIS AB The ubiquitin proteasome system (UPS) is an essential metabolic constituent of cellular physiology that tightly regulates cellular protein concentrations with specificity and precision to optimize cellular function. Inhibition of the proteasome has proven very effective in the treatment of multiple myeloma, and this approach is being tested for utility in other malignancies. New pharmaceuticals targeting the proteasome itself or specific proximal pathways of the UPS are in development as antiproliferatives or immunomodulatory agents. In this article, we discuss the biology of UPS-targeting drugs, their use as therapy for neoplasia, and the state of clinical and preclinical development for emerging therapeutics. C1 [Weathington, Nathaniel M.; Mallampalli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Dept Med, Pittsburgh, PA 15213 USA. [Weathington, Nathaniel M.; Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, UPMC Montefiore, Dept Med, NW 628, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; NIH R01 [HL096376, HL097376, HL098174]; NIH P01 [HL114453]; US Department of Veterans Affairs FX This material is based upon work supported, in part, by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work was supported by a Merit Review Award from the US Department of Veterans Affairs, NIH R01 grants HL096376, HL097376, and HL098174, and NIH P01 grant HL114453 (to R.K. Mallampalli). NR 71 TC 36 Z9 39 U1 0 U2 22 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD JAN PY 2014 VL 124 IS 1 BP 6 EP 12 DI 10.1172/JCI71602 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 284PX UT WOS:000329333500003 PM 24382383 ER PT J AU Burke, RE Whitfield, E Prochazka, AV AF Burke, Robert E. Whitfield, Emily Prochazka, Allan V. TI Effect of a Hospitalist-Run Postdischarge Clinic on Outcomes SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID PRIMARY-CARE PHYSICIANS; LENGTH-OF-STAY; 30-DAY READMISSION; TRANSITIONAL CARE; PATIENT OUTCOMES; AFTER-DISCHARGE; FOLLOW-UP; CONTINUITY; COMMUNICATION; ASSOCIATION AB BACKGROUNDNew post-discharge strategies to reduce adverse events are needed. OBJECTIVETo determine whether follow-up in a hospitalist-run post-discharge clinic (PDC) decreases post-discharge adverse events when compared to follow-up in a primary care clinic (PCP) or urgent care clinic (UC). DESIGNRetrospective cohort study using propensity scoring in multivariate analysis. PATIENTSConsecutive Veterans discharged home after a nonscheduled admission seen in PDC, UC, or PCP within 30 days of discharge. INTERVENTIONSRecently discharged patients are seen by housestaff who cared for them during the index admission and staffed with a rotating hospitalist in PDC; UC and PCP patients are seen by housestaff or attending ambulatory physicians. MAIN MEASURESThe primary outcome was a composite of hospital readmissions, Emergency Department visits, and mortality 30 days after discharge. KEY RESULTS5085 patients met criteria; 538 followed up in PDC (10.6%), 1848 with their PCP (36.3%), and 2699 in UC (53.1%). Patients following up in PDC were older and had a higher comorbidity burden. ICU exposure was similar between groups. Patients seen in PDC had shorter length of stay (LOS) (PDC, 3.8 days, UC, 5.0 days, PCP, 6.2 days; p = 0.04) and time to first post-discharge visit (PDC, 5.0 days, UC, 9.4 days, PCP, 13.7 days; p < 0.01). There were no differences between groups in the primary outcome in unadjusted or propensity-adjusted multivariate analysis. CONCLUSIONSPatients seen in a hospitalist-run PDC had similar 30-day post-discharge adverse outcome rates despite a 2.4-day shorter LOS compared to patients seen by their PCP. Prospective testing of PDCs is warranted. Journal of Hospital Medicine 2014;9:7-12. (c) 2013 Society of Hospital Medicine C1 [Burke, Robert E.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs Med Ctr, Hosp Med Sect, Denver, CO USA. [Burke, Robert E.; Prochazka, Allan V.] Univ Colorado, Sch Med, Dept Med, Div Gen Internal Med, Denver, CO USA. [Whitfield, Emily; Prochazka, Allan V.] Eastern Colorado Hlth Care Syst, Dept Vet Affairs Med Ctr, Div Ambulatory Care, Denver, CO USA. RP Burke, RE (reprint author), Denver VA Med Ctr, Mailstop 111,1055 Clermont St, Denver, CO 80220 USA. EM robert.burke5@va.gov FU Colorado Research Enhancement Award Program FX Dr. Burke had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Burke was supported by grant funding from the Colorado Research Enhancement Award Program to Improve Care Coordination for Veterans. Initial results of this study were presented at the Society of General Internal Medicine National Meeting in Denver, Colorado, April 24, 2013. NR 28 TC 4 Z9 4 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JAN PY 2014 VL 9 IS 1 BP 7 EP 12 DI 10.1002/jhm.2099 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 284GD UT WOS:000329303200002 PM 24390821 ER PT J AU Cuff, P Schmitt, M Zierler, B Cox, M De Maeseneer, J Maine, LL Reeves, S Spencer, HC Thibault, GE AF Cuff, Patricia Schmitt, Madeline Zierler, Brenda Cox, Malcolm De Maeseneer, Jan Maine, Lucinda L. Reeves, Scott Spencer, Harrison C. Thibault, George E. TI Interprofessional education for collaborative practice: views from a global forum workshop SO JOURNAL OF INTERPROFESSIONAL CARE LA English DT Editorial Material ID DIAGNOSIS C1 [Cuff, Patricia] Natl Acad Sci, Inst Med, Washington, DC 20418 USA. [Schmitt, Madeline] Univ Rochester, Rochester, NY 14627 USA. [Zierler, Brenda] Univ Washington, Seattle, WA 98195 USA. [Cox, Malcolm] US Dept Vet Affairs, Washington, DC USA. [De Maeseneer, Jan] Univ Ghent, B-9000 Ghent, Belgium. [Maine, Lucinda L.] Amer Assoc Coll Pharm, Washington, DC USA. [Reeves, Scott] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Spencer, Harrison C.] Assoc Sch Publ Hlth, Washington, DC USA. [Thibault, George E.] Josiah Macy Jr Fdn, New York, NY USA. RP Cuff, P (reprint author), Natl Acad Sci, Inst Med, Board Global Hlth, Washington, DC 20418 USA. EM PCuff@nas.edu OI Reeves, Scott/0000-0002-0573-0622 NR 13 TC 1 Z9 1 U1 1 U2 4 PU INFORMA HEALTHCARE PI NEW YORK PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA SN 1356-1820 EI 1469-9567 J9 J INTERPROF CARE JI J. Interprofessional Care PD JAN PY 2014 VL 28 IS 1 BP 2 EP 4 DI 10.3109/13561820.2013.828910 PG 3 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 285QE UT WOS:000329407900002 PM 24000878 ER PT J AU Pierre, JF Heneghan, AF Feliciano, RP Shanmuganayagam, D Krueger, CG Reed, JD Kudsk, KA AF Pierre, Joseph F. Heneghan, Aaron F. Feliciano, Rodrigo P. Shanmuganayagam, Dhanansayan Krueger, Christian G. Reed, Jess D. Kudsk, Kenneth A. TI Cranberry Proanthocyanidins Improve Intestinal sIgA During Elemental Enteral Nutrition SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION LA English DT Article DE proanthocyanidins; elemental enteral nutrition; secretory IgA; JAK-STAT ID POLYMERIC IMMUNOGLOBULIN RECEPTOR; TOTAL PARENTERAL-NUTRITION; LYMPHOID-TISSUE; DIETARY PROCYANIDINS; ULCERATIVE-COLITIS; MUCOSAL IMMUNITY; GRAPE SEED; JAK-STAT; T-CELLS; POLYPHENOLS AB Background: Elemental enteral nutrition (EEN) decreases gut-associated lymphoid tissue (GALT) function, including fewer Peyer's patch lymphocytes and lower levels of the tissue T helper 2 (Th2) cytokines and mucosal transport protein polymeric immunoglobulin receptor (pIgR), leading to lower luminal secretory immunoglobulin A (sIgA) levels. Since we recently demonstrated that cranberry proanthocyanidins (PACs) maintain the Th2 cytokine interleukin (IL)-4 when added to EEN, we hypothesized the addition of PACs to EEN would normalize other GALT parameters and maintain luminal levels of sIgA. Methods: Institute of Cancer Research mice were randomized (12/group) to receive chow, EEN, or EEN + PACs (100 mg/kg body weight) for 5 days, starting 2 days after intragastric cannulation. Ileum tissue was collected to measure IL-4 by enzyme-linked immunosorbent assay, pIgR by Western blot, and phosphorylated STAT-6 by microarray. Intestinal wash fluid was collected to measure sIgA by Western blot. Results: Compared with chow, EEN significantly decreased tissue IL-4, phosphorylated STAT-6, and pIgR. The addition of PACs to EEN prevented these alterations. Compared with chow, EEN resulted in significantly lower levels of luminal sIgA. The addition of PACs to EEN increased luminal sIgA levels compared with EEN alone. Conclusions: This study suggests the addition of PACs to EEN may support GALT function and maintain intestinal sIgA levels compared with EEN administration alone. C1 [Pierre, Joseph F.; Heneghan, Aaron F.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Pierre, Joseph F.; Feliciano, Rodrigo P.; Shanmuganayagam, Dhanansayan; Krueger, Christian G.; Reed, Jess D.] Univ Wisconsin, Dept Anim Sci, Reed Res Grp, Madison, WI USA. [Feliciano, Rodrigo P.] Univ Wisconsin, Dept Food Sci, Madison, WI 53706 USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), H4 736 Clin Sci Ctr, 600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu OI Feliciano, Rodrigo/0000-0002-8116-997X FU Biomedical Laboratory Research & Development Service of the Veterans Affairs Office of Research and Development [I01BX001672]; Reed Research Group FX Supported by award I01BX001672 from the Biomedical Laboratory Research & Development Service of the Veterans Affairs Office of Research and Development and the Reed Research Group. NR 53 TC 3 Z9 3 U1 0 U2 6 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0148-6071 EI 1941-2444 J9 JPEN-PARENTER ENTER JI J. Parenter. Enter. Nutr. PD JAN PY 2014 VL 38 IS 1 BP 107 EP 114 DI 10.1177/0148607112473654 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 285AV UT WOS:000329365800012 PM 23359014 ER PT J AU Kwan, SW Mortell, KE Talenfeld, AD Brunner, MC AF Kwan, Sharon W. Mortell, Kelly E. Talenfeld, Adam D. Brunner, Michael C. TI Thermal Ablation Matches Sub lobar Resection Outcomes in Older Patients with Early-stage Non-small Cell Lung Cancer SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID RADIOFREQUENCY ABLATION; MULTICENTER; SURVIVAL; TRIAL; COST AB Purpose: To. compare survival Outcomes of sublobar resection and thermal ablation for early-stage non-small cell lung cancer (NSCLC) in older patients. Materials and Methods: SEER-Medicare linked data for patients with a diagnosis of lung cancer from 2007-2009 were used. Patients >= 65 years old with stage IA or TB NSCLC who were treated with sublobar resection or thermal ablation were identified. Primary outcome was overall survival (OS), and secondary outcome was lung cancer specific survival (LCSS). Demographic and clinical variables were compared. Unadjusted OS and LCSS curves were estimated using the Kaplan-Meier method, and multivariate analysis was performed using the Cox model. OS and LCSS curves for propensity score matched groups were also compared. Results: The final unmatched study population comprised 1,897 patients. Patients Who underwent sublobar resection were significantly younger (P = .006) and significantly less likely to have a comorbidity index > 1 (P = .036), a diagnosis of chronic obstructive pulmonary disease (P = .017), or adjuvant radiation therapy (P < .0001) compared with patients treated with thermal ablation. Unadjusted survival curves of unmatched groups demonstrated significantly better OS (P = .028) and LCSS (P = .0006) in the resection group. Multivariate Cox model adjusting for demographic and clinical variables found no significant difference in OS between the treatment groups (P = .555); a difference in LCSS (hazard ratio = 1.185, P = .026) persisted. Survival curves for matched groups found no significant difference in OS (P = .695) or LCSS (P = .819) between treatment groups. Conclusions: After controlling for selection bias, this study found no difference in OS between patients treated with sublobar resection and thermal ablation. C1 [Kwan, Sharon W.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. [Mortell, Kelly E.] Univ Hosp Cleveland, Dept Radiol, Case Med Ctr, Cleveland, OH 44106 USA. [Talenfeld, Adam D.] Weill Cornell Med Ctr, Dept Radiol, New York, NY USA. [Brunner, Michael C.] Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Dept Radiol, Madison, WI 53792 USA. [Brunner, Michael C.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. RP Kwan, SW (reprint author), Univ Washington, Med Ctr, Dept Radiol, 1959 NE Pacific St,357115, Seattle, WA 98195 USA. EM shakwan@uw.edu FU Society of Interventional Radiology grant award; National Institutes of Health FX This project was supported by a Society of Interventional Radiology grant award. S.W.K. receives research funding from the National Institutes of Health. None of the authors have identified a conflict of interest. NR 27 TC 10 Z9 10 U1 1 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD JAN PY 2014 VL 25 IS 1 BP 1 EP 9 DI 10.1016/j.jvir.2013.10.018 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA 285FU UT WOS:000329379900001 PM 24365502 ER PT J AU Abdel-Mohsen, M Deng, XT Liegler, T Guatelli, JC Salama, MS Ghanem, HEA Rauch, A Ledergerber, B Deeks, SG Guenthard, HF Wong, JK Pillai, SK AF Abdel-Mohsen, Mohamed Deng, Xutao Liegler, Teri Guatelli, John C. Salama, Mohamed S. Ghanem, Hussam El-din A. Rauch, Andri Ledergerber, Bruno Deeks, Steven G. Guenthard, Huldrych F. Wong, Joseph K. Pillai, Satish K. TI Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity In Vivo SO JOURNAL OF VIROLOGY LA English DT Article ID PERSISTENT LCMV INFECTION; ANTIRETROVIRAL ACTIVITY; PEGINTERFERON ALPHA-2A; RESTRICTION FACTORS; EXPRESSION PROFILE; GENE-EXPRESSION; C VIRUS; SUPPRESSION; BLOCKADE AB Alpha interferon (IFN-alpha) suppresses human immunodeficiency virus type 1 (HIV-1) replication in vitro by inducing cell-intrinsic retroviral restriction mechanisms. We investigated the effects of IFN-alpha/ribavirin (IFN-alpha/riba) treatment on 34 anti-HIV-1 restriction factors in vivo. Expression of several anti-HIV-1 restriction factors was significantly induced by IFN-alpha/riba in HIV/ hepatitis C virus (HCV)-coinfected individuals. Fold induction of cumulative restriction factor expression in CD4+ T cells was significantly correlated with viral load reduction during IFN-alpha/riba treatment (r(2) = 0.649; P < 0.016). Exogenous IFN-alpha induces supraphysiologic restriction factor expression associated with a pronounced decrease in HIV-1 viremia. C1 [Abdel-Mohsen, Mohamed; Liegler, Teri; Deeks, Steven G.; Wong, Joseph K.; Pillai, Satish K.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Deng, Xutao; Pillai, Satish K.] Blood Syst Res Inst, San Francisco, CA USA. [Guatelli, John C.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Guatelli, John C.] VA San Diego Healthcare Syst, San Diego, CA USA. [Salama, Mohamed S.; Ghanem, Hussam El-din A.] Ain Shams Univ, Fac Sci, Cairo, Egypt. [Rauch, Andri] Univ Hosp Bern, Dept Infect Dis, CH-3010 Bern, Switzerland. [Rauch, Andri] Univ Bern, Bern, Switzerland. [Ledergerber, Bruno; Guenthard, Huldrych F.] Univ Zurich, Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland. [Wong, Joseph K.; Pillai, Satish K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Pillai, SK (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. EM satish.pillai@ucsf.edu RI Infektiologie, USZ/A-6921-2011; SHCS, int. coll. A/G-4083-2011; SHCS, all/G-4072-2011; Salama, Mohamed/P-7169-2016; Ledergerber, Bruno/B-5656-2009; gunthard, huldrych/F-1724-2011 OI Ledergerber, Bruno/0000-0002-6881-4401; gunthard, huldrych/0000-0002-1142-6723 FU National Institutes of Health [1K01DA024654, R01 AI081668]; University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research [P30 AI027763]; DARE: Delaney AIDS Research Enterprise (DARE) [U19AI096109]; CFAR Network of Integrated Systems [R24 AI067039]; Swiss HIV Cohort Study Project 594; Swiss National Science Foundation [324730-130865, 33CS30-134277]; Swiss HIV Cohort Study Research Foundation FX This study was supported by grants from the National Institutes of Health (1K01DA024654 and R01 AI081668), the University of California, San Francisco-Gladstone Institute of Virology & Immunology Center for AIDS Research (P30 AI027763), the DARE: Delaney AIDS Research Enterprise (DARE; U19AI096109), and the CFAR Network of Integrated Systems (R24 AI067039). Additional support was provided by Swiss HIV Cohort Study Project 594 and Swiss National Science Foundation grant 324730-130865. The Swiss HIV Cohort Study is supported by Swiss National Science Foundation grant 33CS30-134277 and the Swiss HIV Cohort Study Research Foundation. NR 22 TC 11 Z9 11 U1 0 U2 8 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD JAN PY 2014 VL 88 IS 1 BP 763 EP 767 DI 10.1128/JVI.02687-13 PG 5 WC Virology SC Virology GA 282SW UT WOS:000329194600073 PM 24155399 ER PT J AU Clarke, P Leser, JS Quick, ED Dionne, KR Beckham, JD Tyler, KL AF Clarke, Penny Leser, J. Smith Quick, Eamon D. Dionne, Kalen R. Beckham, J. David Tyler, Kenneth L. TI Death Receptor-Mediated Apoptotic Signaling Is Activated in the Brain following Infection with West Nile Virus in the Absence of a Peripheral Immune Response SO JOURNAL OF VIROLOGY LA English DT Article ID CD8(+) T-CELLS; ACUTE FLACCID PARALYSIS; CENTRAL-NERVOUS-SYSTEM; TOLL-LIKE RECEPTOR-3; GENE-EXPRESSION; ANTIVIRAL RESPONSE; RIG-I; INTERFERON; ENCEPHALITIS; NEURONS AB Apoptosis is an important mechanism of West Nile virus (WNV) pathogenesis within the central nervous system (CNS). The signaling pathways that result in WNV-induced apoptotic neuronal death within the CNS have not been established. In this study, we identified death receptor (DR)-induced apoptosis as a pathway that may be important in WNV pathogenesis, based on the pattern of differential gene expression in WNV-infected, compared to uninfected, brains. Reverse transcription-PCR (RTPCR) and Western blotting confirmed that genes involved in DR-induced apoptotic signaling are upregulated in the brain following WNV infection. Activity of the DR-associated initiator caspase, caspase 8, was also increased in the brains of WNV-infected mice and occurred in association with cleavage of Bid and activation of caspase 9. These results demonstrate that DR-induced apoptotic signaling is activated in the brain following WNV infection and suggest that the caspase 8-dependent cleavage of Bid promotes intrinsic apoptotic signaling within the brains of infected animals. Utilization of a novel ex vivo brain slice culture (BSC) model of WNV encephalitis revealed that inhibition of caspase 8 decreases virus-induced activation of caspase 3 and tissue injury. The BSC model allows us to examine WNV-induced pathogenesis in the absence of a peripheral immune response. Thus, our results indicate that WNV-induced neuronal injury in the brain is mediated by DR-induced apoptosis signaling and can occur in the absence of infiltrating immune cells. However, astrocytes and microglia were activated in WNV-infected BSC, suggesting that local immune responses influence WNV pathogenesis. C1 [Clarke, Penny; Leser, J. Smith; Beckham, J. David; Tyler, Kenneth L.] Univ Colorado Denver, Dept Neurol, Aurora, CO 80045 USA. [Beckham, J. David; Tyler, Kenneth L.] Univ Colorado Denver, Dept Infect Dis, Aurora, CO USA. [Tyler, Kenneth L.] Univ Colorado Denver, Dept Med, Aurora, CO USA. [Tyler, Kenneth L.] Univ Colorado Denver, Dept Microbiol, Aurora, CO USA. [Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado Denver, Med Scientist Training Program, Aurora, CO USA. [Quick, Eamon D.; Dionne, Kalen R.; Tyler, Kenneth L.] Univ Colorado Denver, Neurosci Program, Aurora, CO USA. [Tyler, Kenneth L.] Denver VA Med Ctr, Denver, CO USA. RP Clarke, P (reprint author), Univ Colorado Denver, Dept Neurol, Aurora, CO 80045 USA. EM Penny.Clarke@ucdenver.edu OI Tyler, Kenneth/0000-0003-3294-5888 FU NIH [R01 NS076512, R21 AL101064, F30 NS071630, T32 GM008497, U54 AI065357/RMDP009]; VA merit grant; Reuler-Lewin Family Professorship FX This publication was supported by NIH grants R01 NS076512 (K.L.T.), R21 AL101064 (K.L.T.), F30 NS071630 (K.R.D.), T32 GM008497 (K.R.D.), and U54 AI065357/RMDP009 (D.B.) and by a VA merit grant (K.L.T.). K.L.T. is supported by the Reuler-Lewin Family Professorship. NR 50 TC 14 Z9 14 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD JAN PY 2014 VL 88 IS 2 BP 1080 EP 1089 DI 10.1128/JVI.02944-13 PG 10 WC Virology SC Virology GA 282SY UT WOS:000329194900030 PM 24198425 ER PT J AU Gelernter, J Kranzler, HR Sherva, R Almasy, L Koesterer, R Smith, AH Anton, R Preuss, UW Ridinger, M Rujescu, D Wodarz, N Zill, P Zhao, H Farrer, LA AF Gelernter, J. Kranzler, H. R. Sherva, R. Almasy, L. Koesterer, R. Smith, A. H. Anton, R. Preuss, U. W. Ridinger, M. Rujescu, D. Wodarz, N. Zill, P. Zhao, H. Farrer, L. A. TI Genome-wide association study of alcohol dependence: significant findings in African-and European-Americans including novel risk loci SO MOLECULAR PSYCHIATRY LA English DT Article DE alcohol dependence; alcohol-metabolizing enzymes; complex traits; genome-wide association; population differences; population-specific alleles ID DRUG-DEPENDENCE; GENE; SCHIZOPHRENIA; CONSUMPTION; POPULATION; EXPRESSION; DISEASES; CLUSTER; VARIANT; GIRDIN AB We report a GWAS of alcohol dependence (AD) in European-American (EA) and African-American (AA) populations, with replication in independent samples of EAs, AAs and Germans. Our sample for discovery and replication was 16 087 subjects, the largest sample for AD GWAS to date. Numerous genome-wide significant (GWS) associations were identified, many novel. Most associations were population specific, but in several cases were GWS in EAs and AAs for different SNPs at the same locus, showing biological convergence across populations. We confirmed well-known risk loci mapped to alcohol-metabolizing enzyme genes, notably ADH1B (EAs: Arg48His, P = 1.17 x 10(-31); AAs: Arg369Cys, P = 6.33 x 10(-17)) and ADH1C in AAs (Thr151Thr, P = 4.94 x 10(-10)), and identified novel risk loci mapping to the ADH gene cluster on chromosome 4 and extending centromerically beyond it to include GWS associations at LOC100507053 in AAs (P = 2.63 x 10(-11)), PDLIM5 in EAs (P = 2.01 x 10(-8)), and METAP in AAs (P = 3.35 x 10(-8)). We also identified a novel GWS association (1.17 x 10(-10)) mapped to chromosome 2 at rs1437396, between MTIF2 and CCDC88A, across all of the EA and AA cohorts, with supportive gene expression evidence, and population-specific GWS for markers on chromosomes 5, 9 and 19. Several of the novel associations implicate direct involvement of, or interaction with, genes previously identified as schizophrenia risk loci. Confirmation of known AD risk loci supports the overall validity of the study; the novel loci are worthy of genetic and biological follow-up. The findings support a convergence of risk genes (but not necessarily risk alleles) between populations, and, to a lesser extent, between psychiatric traits. C1 [Gelernter, J.; Smith, A. H.] Yale Univ, Sch Med, Dept Psychiat, Div Human Genet, West Haven, CT 06516 USA. [Gelernter, J.; Smith, A. H.] VA CT Healthcare Ctr, West Haven, CT USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Genet, West Haven, CT 06516 USA. [Gelernter, J.] Yale Univ, Sch Med, Dept Neurobiol, West Haven, CT 06516 USA. [Kranzler, H. R.] Univ Penn, Perelman Sch Med, Philadelphia VA Med Ctr, Dept Psychiat, Philadelphia, PA 19104 USA. [Sherva, R.; Koesterer, R.; Farrer, L. A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA. [Almasy, L.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA. [Anton, R.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Preuss, U. W.; Rujescu, D.] Univ Halle Wittenberg, Dept Psychiat, D-06108 Halle, Germany. [Preuss, U. W.; Rujescu, D.] Univ Halle Wittenberg, Dept Psychotherapy, D-06108 Halle, Germany. [Preuss, U. W.; Rujescu, D.] Univ Halle Wittenberg, Dept Psychosomat, D-06108 Halle, Germany. [Ridinger, M.; Wodarz, N.] Univ Med Ctr, Dept Psychiat Psychosomat & Psychotherapy, Regensburg, Germany. [Zill, P.] Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany. [Zhao, H.] Yale Univ, Sch Publ Hlth, Dept Biostat, West Haven, CT USA. [Zhao, H.] Yale Univ, Sch Med, Dept Genet, West Haven, CT 06516 USA. [Farrer, L. A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Farrer, L. A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA. [Farrer, L. A.] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA. [Farrer, L. A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA. [Farrer, L. A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA. [Farrer, L. A.] Boston Univ, Sch Publ Hlth, Dept Neurol, Boston, MA 02215 USA. [Farrer, L. A.] Boston Univ, Sch Publ Hlth, Dept Ophthalmol, Boston, MA 02215 USA. [Farrer, L. A.] Boston Univ, Sch Publ Hlth, Dept Genet & Genom, Boston, MA 02215 USA. [Farrer, L. A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA. [Farrer, L. A.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA. RP Gelernter, J (reprint author), Yale Univ, Sch Med, Dept Psychiat, VA CT 116A2,950 Campbell Ave, West Haven, CT 06516 USA. EM joel.gelernter@yale.edu OI Farrer, Lindsay/0000-0001-5533-4225 FU National Institutes of Health [N01-HG-65403, RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535]; VA Connecticut and Philadelphia VA MIRECCs; NIH Genes, Environment and Health Initiative [GEI] [U01 HG004422]; Gene Environment Association Studies (GENEVA) under GEI; GENEVA Coordinating Center [U01 HG004446]; Collaborative Study on the Genetics of Alcoholism (COGA) [U10 AA008401]; Collaborative Genetic Study of Nicotine Dependence (COGEND) [P01 CA089392]; Family Study of Cocaine Dependence (FSCD) [R01 DA013423]; NIH GEI [U01HG004438]; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse; NIH [HHSN268200782096C] FX We appreciate the work in recruitment and assessment provided at Yale University School of Medicine and the APT Foundation by James Poling, PhD; at McLean Hospital by Roger Weiss, M. D., at the Medical University of South Carolina by Kathleen Brady, MD, Ph.D. and at the University of Pennsylvania by David Oslin, MD. Genotyping services for a part of our GWAS study were provided by the Center for Inherited Disease Research (CIDR) and Yale University (Center for Genome Analysis). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University (contract number N01-HG-65403). We are grateful to Ann Marie Lacobelle, Catherine Aldi and Christa Robinson for their excellent technical assistance, to the SSADDA interviewers, led by Yari Nunez and Michelle Slivinsky, who devoted substantial time and effort to phenotype the study sample and to John Farrell and Alexan Mardigan for database management assistance. This study was supported by National Institutes of Health grants RC2 DA028909, R01 DA12690, R01 DA12849, R01 DA18432, R01 AA11330, R01 AA017535 and the VA Connecticut and Philadelphia VA MIRECCs. The publicly available data sets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs0 00092.v1.p1 through dbGaP accession number phs000092.v1.p. Funding support for the Study of Addiction: Genetics and Environment (SAGE) was provided through the NIH Genes, Environment and Health Initiative [GEI] (U01 HG004422). SAGE is one of the genome-wide association studies funded as part of the Gene Environment Association Studies (GENEVA) under GEI. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by the GENEVA Coordinating Center (U01 HG004446). Assistance with data cleaning was provided by the National Center for Biotechnology Information. Support for collection of data sets and samples was provided by the Collaborative Study on the Genetics of Alcoholism (COGA; U10 AA008401), the Collaborative Genetic Study of Nicotine Dependence (COGEND; P01 CA089392) and the Family Study of Cocaine Dependence (FSCD; R01 DA013423). Funding support for genotyping, which was performed at the Johns Hopkins University Center for Inherited Disease Research, was provided by the NIH GEI (U01HG004438), the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse and the NIH contract 'High throughput genotyping for studying the genetic contributions to human disease' (HHSN268200782096C). NR 39 TC 86 Z9 87 U1 1 U2 18 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1359-4184 EI 1476-5578 J9 MOL PSYCHIATR JI Mol. Psychiatr. PD JAN PY 2014 VL 19 IS 1 BP 41 EP 49 DI 10.1038/mp.2013.145 PG 9 WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry GA 279MS UT WOS:000328964700011 PM 24166409 ER PT J AU Mori, T Ishii, S Greendale, GA Cauley, JA Sternfeld, B Crandall, CJ Han, W Karlamangla, AS AF Mori, T. Ishii, S. Greendale, G. A. Cauley, J. A. Sternfeld, B. Crandall, C. J. Han, W. Karlamangla, A. S. TI Physical activity as determinant of femoral neck strength relative to load in adult women: findings from the hip strength across the menopause transition study SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Active living; Composite strength indices; Femoral neck strength relative to load; Peak bone strength; Physical activity ID BONE-MINERAL DENSITY; FRACTURE RISK-ASSESSMENT; FINAL MENSTRUAL PERIOD; BODY-MASS INDEX; OSTEOPOROTIC FRACTURES; MULTIETHNIC COHORT; RANCHO-BERNARDO; CALCIUM INTAKE; HEALTH; PREMENOPAUSAL AB Our objective was to examine associations of physical activity in different life domains with peak femoral neck strength relative to load in adult women. Greater physical activity in each of the domains of sport, active living, home, and work was associated with higher peak femoral neck strength relative to load. Our objective was to examine the associations of physical activity in different life domains with peak femoral neck strength relative to load in adult women. Composite indices of femoral neck strength integrate body size with femoral neck size and bone mineral density to gauge bone strength relative to load during a fall, and are inversely associated with incident fracture risk. Participants were 1,919 pre- and early perimenopausal women from the Study of Women's Health Across the Nation. Composite indices of femoral neck strength relative to load in three failure modes (compression, bending, and impact) were created from hip dual-energy X-ray absorption scans and body size. Usual physical activity within the past year was assessed with the Kaiser Physical Activity Survey in four domains: sport, home, active living, and work. We used multiple linear regression to examine the associations. Greater physical activity in each of the four domains was independently associated with higher composite indices, adjusted for age, menopausal transition stage, race/ethnicity, Study of Women's Health Across the Nation study site, smoking status, smoking pack-years, alcohol consumption level, current use of supplementary calcium, current use of supplementary vitamin D, current use of bone-adverse medications, prior use of any sex steroid hormone pills or patch, prior use of depo-provera injections, history of hyperthyroidism, history of previous adult fracture, and employment status: standardized effect sizes ranged from 0.04 (p < 0.05) to 0.20 (p < 0.0001). Physical activity in each domain examined was associated with higher peak femoral neck strength relative to load in pre- and early perimenopausal women. C1 [Mori, T.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA 90073 USA. [Mori, T.; Greendale, G. A.; Han, W.; Karlamangla, A. S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Ishii, S.] Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan. [Cauley, J. A.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Sternfeld, B.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA. [Crandall, C. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA. RP Mori, T (reprint author), VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, 11301 Wilshire Blvd,Bldg B220 11 G, Los Angeles, CA 90073 USA. EM takahiromori@outlook.com RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA); National Institute of Nursing Research (NINR); NIH Office of Research on Women's Health (ORWH) [NR004061, AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495]; NIA [AG026463]; VA Advanced Fellowship Program in Geriatrics; VA Greater Los Angeles Geriatric Research Education and Clinical Center FX The Study of Women's Health Across the Nation (SWAN) has grant support from the National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR), and the NIH Office of Research on Women's Health (ORWH) (grants NR004061; AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, and AG012495). The Hip Strength Through the Menopausal Transition has grant support from the NIA (AG026463). Takahiro Mori was supported by the VA Advanced Fellowship Program in Geriatrics and the VA Greater Los Angeles Geriatric Research Education and Clinical Center. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIA, NINR, ORWH, VA, or the NIH. We thank the study staff at each site and all the women who participated in SWAN. NR 43 TC 7 Z9 7 U1 0 U2 7 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD JAN PY 2014 VL 25 IS 1 BP 265 EP 272 DI 10.1007/s00198-013-2429-z PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 281MP UT WOS:000329106000025 PM 23812598 ER PT J AU Bonn-Miller, MO Boden, MT Bucossi, MM Babson, KA AF Bonn-Miller, Marcel O. Boden, Matthew Tyler Bucossi, Meggan M. Babson, Kimberly A. TI Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE Cannabis; marijuana; medical marijuana; strain; symptoms ID MARIJUANA USE MOTIVES; NATIONALLY REPRESENTATIVE SAMPLE; POSTTRAUMATIC-STRESS-DISORDER; USE COPING MOTIVES; CHRONIC PAIN; ANXIETY SENSITIVITY; SOCIAL ANXIETY; PANIC-ATTACKS; YOUNG-ADULTS; DEPENDENCE AB Objectives: Little research has investigated the demographic and symptom profile of medical cannabis users in states in the USA that have legalized cannabis use. Methods: In the present cross-sectional study, we investigated the demographic profile of 217 adults currently receiving medical cannabis, as well as differences in problematic use and perceived helpfulness in terms of (i) symptoms of psychological disorders and pain, and (ii) motives for use. Results: Findings indicated that medical cannabis users (i) use and perceive cannabis to be beneficial for multiple conditions, some for which cannabis is not specifically prescribed or allowed at the state level; and (ii) report similar rates of disordered use as compared with population estimates among regular users. Furthermore, problematic cannabis use was predicted by several symptoms of psychological disorders (e.g. depression) and a variety of use motives (e.g. coping), while cannabis was reported as particularly helpful among those with several psychological symptoms (e.g. traumatic intrusions), as well as those reporting use for social anxiety reasons. Conclusions: Results are discussed in terms of future directions for research given the current debates regarding legalization of cannabis for medical purposes and, more generally, the lack of empirical data to inform such debates. C1 [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA. [Bonn-Miller, Marcel O.; Bucossi, Meggan M.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.; Boden, Matthew Tyler; Babson, Kimberly A.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Babson, Kimberly A.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. RP Bonn-Miller, MO (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. EM marcel.bonn-miller@va.gov NR 67 TC 32 Z9 32 U1 3 U2 20 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD JAN PY 2014 VL 40 IS 1 BP 23 EP 30 DI 10.3109/00952990.2013.821477 PG 8 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 279HL UT WOS:000328950900004 PM 24205805 ER PT J AU Bohnert, KM Walton, MA Resko, S Barry, KT Chermack, ST Zucker, RA Zimmerman, MA Booth, BM Blow, FC AF Bohnert, Kipling M. Walton, Maureen A. Resko, Stella Barry, Kristen T. Chermack, Stephen T. Zucker, Robert A. Zimmerman, Marc A. Booth, Brenda M. Blow, Frederic C. TI Latent class analysis of substance use among adolescents presenting to urban primary care clinics SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE Adolescent health; latent class analysis; primary care; polysubstance use ID ALCOHOL-USE DISORDERS; DRUG-USE; CANNABIS USE; YOUNG ADULTHOOD; PREVENTION PROGRAM; PROTECTIVE FACTORS; POLYSUBSTANCE USE; ABUSE PREVENTION; UNITED-STATES; SELF-REPORT AB Background: Polysubstance use during adolescence is a significant public health concern. However, few studies have investigated patterns of substance use during this developmental window within the primary care setting. Objectives: This study used an empirical method to classify adolescents into substance use groups, and examines correlates of the empirically defined groups. Methods: Data came from patients, ages 12-18 years, presenting to an urban, primary care community health clinics (Federally Qualified Health Centers) in two cities in the Midwestern United States (n = 1664). Latent class analysis (LCA) was used to identify classes of substance users. Multinomial logistic regression was used to examine variables associated with class membership. Results: LCA identified three classes: class 1 (64.5%) exhibited low probabilities of all types of substance use; class 2 (24.6%) was characterized by high probabilities of cannabis use and consequences; and class 3 (10.9%) had the highest probabilities of substance use, including heavy episodic drinking and misuse of prescription drugs. Those in class 2 and class 3 were more likely to be older and have poorer grades, poorer health, higher levels of psychological distress and more sexual partners than those in class 1. Individuals in class 3 were also less likely to be African-American than those in class 1. Conclusion: Findings provide novel insight into the patterns of substance use among adolescents presenting to low-income urban primary care clinics. Future research should examine the efficacy of interventions that address the complex patterns of substance use and concomitant health concerns among adolescents. C1 [Bohnert, Kipling M.; Barry, Kristen T.; Chermack, Stephen T.; Blow, Frederic C.] US Dept Vet Affairs, Natl Serious Mental Illness Treatment Resource &, Ann Arbor, MI USA. [Bohnert, Kipling M.; Walton, Maureen A.; Barry, Kristen T.; Chermack, Stephen T.; Zucker, Robert A.; Blow, Frederic C.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Resko, Stella] Wayne State Univ, Sch Social Work, Detroit, MI USA. [Resko, Stella] Wayne State Univ, Merrill Palmer Skillman Inst, Detroit, MI USA. [Zimmerman, Marc A.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Booth, Brenda M.] US Dept Vet Affairs, Ctr Mental Hlth Outcomes & Res, Little Rock, AR USA. [Booth, Brenda M.] Univ Arkansas Med Sci, Dept Psychiat, Little Rock, AR 72205 USA. RP Bohnert, KM (reprint author), NCRC, 2800 Plymouth Rd Bldg 16,Rm 243E, Ann Arbor, MI 48109 USA. EM kiplingb@med.umich.edu FU NIDA NIH HHS [DA020075, R01 DA020075] NR 58 TC 9 Z9 9 U1 4 U2 17 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PD JAN PY 2014 VL 40 IS 1 BP 44 EP 50 DI 10.3109/00952990.2013.844821 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 279HL UT WOS:000328950900007 PM 24219231 ER PT J AU Mojta, C Falconier, MK Huebner, AJ AF Mojta, Carl Falconier, Mariana K. Huebner, Angela J. TI Fostering Self-Awareness in Novice Therapists Using Internal Family Systems Therapy SO AMERICAN JOURNAL OF FAMILY THERAPY LA English DT Article AB This qualitative study used a phenomenological approach to understand: (a) whether and how the Internal Family Systems (IFS) model helps beginning therapists gain awareness of their internal processes and (b) whether and how such awareness influences their clinical work. Semi-structured individual interviews were conducted with seven beginning therapists and data were analyzed using thematic coding. Findings suggest that IFS helped therapists identify, understand, and manage their internal processes, which seemed to benefit the therapeutic relationship, identify therapists' personal agendas, model work with the internal system, and foster a better understanding of the client's internal system. Clinical training implications are discussed. C1 [Mojta, Carl] US Dept Vet Affairs, Readjustment Counseling Serv, DC Vet Ctr, Washington, DC USA. [Falconier, Mariana K.; Huebner, Angela J.] Virginia Polytech Inst & State Univ, Dept Human Dev, Falls Church, VA 22043 USA. RP Falconier, MK (reprint author), Virginia Polytech Inst & State Univ, Dept Human Dev, 7054 Haycock Rd,Suite 202C, Falls Church, VA 22043 USA. EM marianak@vt.edu NR 22 TC 1 Z9 1 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0192-6187 EI 1521-0383 J9 AM J FAM THER JI Am. J. Fam. Ther. PD JAN 1 PY 2014 VL 42 IS 1 BP 67 EP 78 DI 10.1080/01926187.2013.772870 PG 12 WC Psychology, Clinical; Family Studies SC Psychology; Family Studies GA 281ZC UT WOS:000329138800006 ER PT J AU Evans, ME Kralovic, SM Simbartl, LA Freyberg, RW Obrosky, DS Roselle, GA Jain, R AF Evans, Martin E. Kralovic, Stephen M. Simbartl, Loretta A. Freyberg, Ron W. Obrosky, D. Scott Roselle, Gary A. Jain, Rajiv TI Nationwide reduction of health careeassociated methicillin-resistant Staphylococcus aureus infections in Veterans Affairs long-term care facilities SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Methicillin-resistant Staphylococcus aureus; Long-term care; Nursing home; Health care-associated infection ID NURSING-HOMES; COLONIZATION; PREVENTION; RESIDENTS; CARRIAGE AB The Veterans Affairs methicillin-resistant Staphylococcus aureus (MRSA) Prevention Initiative was implemented in its 133 long-term care facilities in January 2009. Between July 2009 and December 2012, there were similar to 12.9 million resident-days in these facilities nationwide. During this period, the mean quarterly MRSA admission prevalence increased from 23.3% to 28.7% (P < .0001, Poisson regression for trend), but the overall rate of MRSA health care-associated infections decreased by 36%, from 0.25 to 0.16/1,000 resident-days (P < .0001, Poisson regression for trend). Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Evans, Martin E.] Vet Hlth Adm MRSA, MDRO Program Off, Vet Affairs Cent Off, Natl Infect Dis Serv,Patient Care Serv, Lexington, KY USA. [Evans, Martin E.] Lexington Vet Affairs Med Ctr, Lexington, KY USA. [Evans, Martin E.] Univ Kentucky, Sch Med, Dept Internal Med, Lexington, KY 40536 USA. [Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] Vet Affairs Cent Off, Patient Care Serv, Natl Infect Dis Serv, Cincinnati, OH USA. [Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA. [Kralovic, Stephen M.; Roselle, Gary A.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA. [Freyberg, Ron W.] Vet Affairs Inpatient Evaluat Ctr, Cincinnati, OH USA. [Obrosky, D. Scott] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. Vet Affairs Cent Off, Patient Care Serv, Washington, DC USA. RP Evans, ME (reprint author), 1101 Vet Dr, Lexington, KY 40502 USA. EM Martin.Evans@va.gov NR 13 TC 13 Z9 13 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD JAN PY 2014 VL 42 IS 1 BP 60 EP 62 DI 10.1016/j.ajic.2013.06.004 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 282IT UT WOS:000329165200015 PM 24388470 ER PT J AU Sullivan, DR Ganzini, L Duckart, JP Lopez-Chavez, A Deffebach, ME Thielke, SM Slatore, CG AF Sullivan, D. R. Ganzini, L. Duckart, J. P. Lopez-Chavez, A. Deffebach, M. E. Thielke, S. M. Slatore, C. G. TI Treatment Receipt and Outcomes among Lung Cancer Patients with Depression SO CLINICAL ONCOLOGY LA English DT Article DE Depression; epidemiology; lung cancer; lung cancer treatment; patient outcomes ID EARLY PALLIATIVE CARE; QUALITY-OF-LIFE; SMALL-CELL; SMOKING-CESSATION; PROGNOSTIC VALUE; OLDER-ADULTS; SURVIVAL; COMORBIDITY; PREDICTORS; CHEMOTHERAPY AB Aims: Among lung cancer patients, depression has been associated with increased mortality, although the mechanisms are unknown. We evaluated the association of depression with mortality and receipt of cancer therapies among depressed veterans with lung cancer. Materials and methods: A retrospective, cohort study of lung cancer patients in the Veterans Affairs-Northwest Health Network from 1995 to 2010. Depression was defined by ICD-9 coding within 24 months before lung cancer diagnosis. Multivariable Cox proportional analysis and logistic regression were used. Results: In total, 3869 lung cancer patients were evaluated; 14% had a diagnosis of depression. A diagnosis of depressionwas associated with increased mortality among all stage lung cancer patients (hazard ratio 1.14, 95% confidence interval: 1.03-1.27, P = 0.01). Among early-stage (I and II) non-small cell lung cancer (NSCLC) patients, the hazard ratio was 1.37 (95% confidence interval: 1.12-1.68, P = 0.003). There was no association of depression diagnosis with surgery (odds ratio 0.83, 95% confidence interval: 0.56-1.22, P = 0.34) among early-stage NSCLC patients. A depression diagnosis was not associated with mortality (hazard ratio 1.02, 95% confidence interval: 0.89-1.16, P = 0.78) or chemotherapy (odds ratio 1.07, 95% confidence interval: 0.83-1.39, P = 0.59) or radiation (odds ratio 1.04, 95% confidence interval: 0.81-1.34, P = 0.75) receipt among advanced-stage (III and IV) NSCLC patients. Increased utilisation of health services for depression was associated with increased mortality among depressed patients. Conclusions: Depression is associated with increased mortality in lung cancer patients and this association is higher among those with increased measures of depression care utilisation. Differences in lung cancer treatment receipt are probably not responsible for the observed mortality differences between depressed and non-depressed patients. Clinicians should recognise the significant effect of depression on lung cancer survival. (c) 2013 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved. C1 [Sullivan, D. R.; Ganzini, L.; Duckart, J. P.; Slatore, C. G.] Portland VA Med Ctr, Portland, OR USA. [Sullivan, D. R.; Deffebach, M. E.; Slatore, C. G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. [Lopez-Chavez, A.] Oregon Hlth & Sci Univ, Dept Med, Div Hematol & Med Oncol, Portland, OR 97201 USA. [Deffebach, M. E.; Slatore, C. G.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, OR USA. [Thielke, S. M.] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. [Thielke, S. M.] Univ Washington, Dept Behav Sci, Seattle, WA 98195 USA. [Thielke, S. M.] Puget Sound Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Seattle, WA USA. RP Sullivan, DR (reprint author), 3710 SW US Vet Hosp Rd,R&D 66, Portland, OR 97239 USA. EM sullivad@ohsu.edu OI Sullivan, Donald/0000-0003-3266-3389; Slatore, Christopher/0000-0003-0958-8122 FU NIH [5 T32 HL083808-05-32]; VA HSR&D Career Development Award; NIMH Beeson Career Development Award [K23MH093591]; Portland Veterans Affairs Medical Center, Portland, Oregon; Veterans Affairs Puget Sound Healthcare System, Seattle, Washington FX Dr Sullivan takes responsibility for the content of the manuscript, including the data and analysis. All authors have participated sufficiently in the conception and design of this work or the analysis and interpretation of the data, as well as the writing of the manuscript, to take public responsibility for it. All authors believe the manuscript represents valid work. All authors have reviewed the final version, and approve it for publication. Dr Sullivan is supported by a NIH T-32 (5 T32 HL083808-05-32). Dr Slatore is supported by a VA HSR&D Career Development Award. Dr Thielke is supported by an NIMH Beeson Career Development Award (K23MH093591). This study is the result of work supported by resources from the Portland Veterans Affairs Medical Center, Portland, Oregon and the Veterans Affairs Puget Sound Healthcare System, Seattle, Washington. The Department of Veterans Affairs did not have a role in the conduct of the study, in the collection, management, analysis or interpretation of data, or in the preparation of the manuscript. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 46 TC 5 Z9 5 U1 4 U2 8 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0936-6555 EI 1433-2981 J9 CLIN ONCOL-UK JI Clin. Oncol. PD JAN PY 2014 VL 26 IS 1 BP 25 EP 31 DI 10.1016/j.clon.2013.09.001 PG 7 WC Oncology SC Oncology GA 281RJ UT WOS:000329118400005 PM 24080122 ER PT J AU Saxon, AJ Browne, KC AF Saxon, Andrew J. Browne, Kendall C. TI Marijuana not ready for prime time as an analgesic SO GENERAL HOSPITAL PSYCHIATRY LA English DT Editorial Material ID CANNABIS USE; ENDOCANNABINOID SYSTEM; ANXIETY DISORDERS; DOPAMINE RELEASE; NEUROPATHIC PAIN; DOUBLE-BLIND; DELTA-9-TETRAHYDROCANNABINOL; SCHIZOPHRENIA; PERFORMANCE; SYMPTOMS C1 [Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. [Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Browne, Kendall C.] Univ Calif San Diego, San Diego State Univ, San Diego Joint Doctoral Program Clin Psychol, San Diego, CA 92103 USA. [Browne, Kendall C.] VA Puget Sound Hlth Care Syst, Psychol Serv, Seattle, WA 98108 USA. RP Saxon, AJ (reprint author), VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA 98108 USA. EM Andrew.Saxon@va.gov NR 43 TC 1 Z9 1 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 EI 1873-7714 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD JAN-FEB PY 2014 VL 36 IS 1 BP 4 EP 6 DI 10.1016/j.genhosppsych.2013.08.005 PG 3 WC Psychiatry SC Psychiatry GA 281OY UT WOS:000329112100005 PM 24176513 ER PT J AU Ganzini, L AF Ganzini, Linda TI Psychiatric evaluations for individuals requesting assisted death in Washington and Oregon should not be mandatory SO GENERAL HOSPITAL PSYCHIATRY LA English DT Editorial Material ID DEPRESSION; SUICIDE; VIEWS; AID C1 [Ganzini, Linda] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Psychiat, Res Serv,Mental Hlth Div, Portland, OR 97201 USA. [Ganzini, Linda] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Psychiat, Res Serv,Hlth Serv Res & Dev Sect, Portland, OR 97201 USA. RP Ganzini, L (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Psychiat, Res Serv,Mental Hlth Div, Portland, OR 97201 USA. EM linda.ganzini@va.gov NR 10 TC 2 Z9 2 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0163-8343 EI 1873-7714 J9 GEN HOSP PSYCHIAT JI Gen. Hosp. Psych. PD JAN-FEB PY 2014 VL 36 IS 1 BP 10 EP 12 DI 10.1016/j.genhosppsych.2013.08.006 PG 3 WC Psychiatry SC Psychiatry GA 281OY UT WOS:000329112100007 PM 24091255 ER PT J AU Shen, Q Du, F Huang, SL Duong, TQ AF Shen, Qiang Du, Fang Huang, Shiliang Duong, Timothy Q. TI Effects of cerebral ischemic and reperfusion on T-2*-weighted MRI responses to brief oxygen challenge SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE CBF; diffusion; middle cerebral artery occlusion; mismatch; perfusion ID BLOOD-FLOW; NORMOBARIC HYPEROXIA; FUNCTIONAL MRI; QUANTITATIVE PERFUSION; ANESTHETIZED RATS; FOCAL ISCHEMIA; TISSUE FATE; BOLD FMRI; STROKE; DIFFUSION AB This study characterized the effects of cerebral ischemia and reperfusion on T-2*-weighted magnetic resonance image (MRI) responses to brief oxygen challenge (OC) in transient (60 minutes) cerebral ischemia in rats. During occlusion, the ischemic core tissue showed no significant OC response, whereas the perfusion-diffusion mismatch tissue showed markedly higher percent changes relative to normal tissue. After reperfusion, much of the pixels with initial exaggerated OC responses showed normal OC responses, and the majority of these tissues were salvaged as defined by endpoint T-2 MRI. The initial core pixels showed exaggerated OC responses after reperfusion, but the majority of the core pixels eventually became infarct, suggesting exaggerated OC responses do not necessarily reflect salvageable tissue. Twenty-four hours after stroke, basal T-1 increased in the ischemic core. Oxygen challenge decreased T-1 significantly in the core, indicative of the substantial increases in dissolved oxygen in the core as the result of hyperperfusion. We concluded that exaggerated T-2*-weighted MRI responses to OC offer useful insight in ischemic tissue fates. However, exaggerated OC pixels are not all salvageable, and they exhibited complex dynamics depending on reperfusion status, hyperperfusion, and edema effects. C1 [Shen, Qiang; Du, Fang; Huang, Shiliang; Duong, Timothy Q.] Dept Res Imaging Inst, San Antonio, TX USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas San Antonio, Hlth Sci Ctr, Dept Ophthalmol, San Antonio, TX 78284 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Shen, Qiang/B-8784-2008 OI Shen, Qiang/0000-0002-4287-3403 FU NIH [R01-NS45879]; American Heart Association [EIA 0940104N, 12BGIA 9300047]; Clinical Translational Science Award Pilot Grant; Translational Technology Resource grant [UL1TR000149] FX This work was supported by the NIH (R01-NS45879), the American Heart Association (EIA 0940104N and 12BGIA 9300047), a Clinical Translational Science Award Pilot Grant, and a Translational Technology Resource grant (parent grant UL1TR000149). NR 31 TC 7 Z9 8 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD JAN PY 2014 VL 34 IS 1 BP 169 EP 175 DI 10.1038/jcbfm.2013.179 PG 7 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 282YK UT WOS:000329210700020 PM 24129750 ER PT J AU Wong, SPY Kreuter, W O'Hare, AM AF Wong, Susan P. Y. Kreuter, William O'Hare, Ann M. TI Healthcare Intensity at Initiation of Chronic Dialysis among Older Adults SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; OF-LIFE CARE; ADVANCE CARE; DECISION-MAKING; STARTING DIALYSIS; END; INDEPENDENCE; NEPHROLOGY; SURVIVAL AB Little is known about the circumstances under which older adults initiate chronic dialysis and subsequent outcomes. Using national registry data, we conducted a retrospective analysis of 416,657 Medicare beneficiaries aged 67 years who initiated chronic dialysis between January 1995 and December 2008. Our goal was to define the relationship between health care intensity around the time of dialysis initiation and subsequent survival and patterns of hospitalization, use of intensive procedures (mechanical ventilation, feeding tube placement, and cardiopulmonary resuscitation), and discontinuation of dialysis before death. We found that most patients (64.5%) initiated dialysis in the hospital, including 36.6% who were hospitalized for 2 weeks and 7.4% who underwent one or more intensive procedures. Compared with patients who initiated dialysis in the outpatient setting, those who received the highest intensity of care at dialysis initiation (those hospitalized 2 weeks and receiving at least one intensive procedure) had a shorter median survival (0.7 versus 2.1 years; P<0.001), spent a greater percentage of remaining follow-up time in the hospital (median, 22.9% versus 3.1%; P<0.001), were more likely to undergo subsequent intensive procedures (44.9% versus 26.0%; adjusted hazard ratio, 2.33; 95% confidence interval [CI], 2.27 to 2.39), and were less likely to have discontinued dialysis before death (19.1% versus 26.2%; adjusted odds ratio, 0.68; 95% CI, 0.65 to 0.72). In conclusion, most older adults initiate chronic dialysis in the hospital. Those who have a prolonged hospital stay and receive other forms of life support around the time of dialysis initiation have limited survival and more intensive patterns of subsequent healthcare utilization. C1 [Wong, Susan P. Y.; O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Kreuter, William] Univ Washington, Ctr Cost & Outcomes Res, Seattle, WA 98195 USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Healthcare Syst, Seattle, WA USA. RP Wong, SPY (reprint author), Univ Washington, Dept Med, 1959 NE Pacific St,Box 356521, Seattle, WA 98195 USA. EM spywong@uw.edu FU Veterans Affairs Puget Sound Healthcare System; Centers for Disease Control and Prevention; National Institute on Aging; Veterans Affairs Health Services Research and Development Service FX A.M.O. receives research funding from an interagency agreement between the Veterans Affairs Puget Sound Healthcare System and the Centers for Disease Control and Prevention and from grants from the National Institute on Aging and the Veterans Affairs Health Services Research and Development Service. She also receives royalties from UpToDate. NR 29 TC 23 Z9 23 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD JAN PY 2014 VL 25 IS 1 BP 143 EP 149 DI 10.1681/ASN.2013050491 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 282FN UT WOS:000329155800016 PM 24262795 ER PT J AU Pittman, CB Davis, LA Zeringue, AL Caplan, L Wehmeier, KR Scherrer, JF Xian, H Cunningham, FE McDonald, JR Arnold, A Eisen, SA AF Pittman, Cory B. Davis, Lisa A. Zeringue, Angelique L. Caplan, Liron Wehmeier, Kent R. Scherrer, Jeffrey F. Xian, Hong Cunningham, Francesca E. McDonald, Jay R. Arnold, Alexis Eisen, Seth A. TI Myocardial Infarction Risk Among Patients With Fractures Receiving Bisphosphonates SO MAYO CLINIC PROCEEDINGS LA English DT Article ID POSITIVE PREDICTIVE-VALUE; CORONARY-ARTERY; CARDIOVASCULAR-DISEASE; ETHANE-1-HYDROXY-1,1-DIPHOSPHONATE EHDP; AORTIC CALCIFICATION; ATRIAL-FIBRILLATION; BONE-DENSITY; OSTEOPOROSIS; PREVALENCE; DIAGNOSIS AB Objective: To determine if bisphosphonates are associated with reduced risk of acute myocardial infarction (AMI). Patients and Methods: A cohort of 14,256 veterans 65 years or older with femoral or vertebral fractures was selected from national administrative databases operated by the US Department of Veterans Affairs and was derived from encounters at Veterans Affairs facilities between October 1, 1998, and September 30, 2006. The time to first AMI was assessed in relationship to bisphosphonate exposure as determined by records from the Pharmacy Benefits Management Database. Time to event analysis was performed using multivariate Cox proportional hazards regression. An adjusted survival analysis curve and a Kaplan-Meier survival curve were analyzed. Results: After controlling for atherosclerotic cardiovascular disease risk factors and medications, bisphosphonate use was associated with an increased risk of incident AMI (hazard ratio, 1.38; 95% CI, 1.08-1.77; P=.01). The timing of AMI correlated closely with the timing of bisphosphonate therapy initiation. Conclusion: Our observations in this study conflict with our hypothesis that bisphosphonates have antiatherogenic effects. These findings may alter the risk-benefit ratio of bisphosphonate use for treatment of osteoporosis, especially in elderly men. However, further analysis and confirmation of these findings by prospective clinical trials is required. (C) 2014 Mayo Foundation for Medical Education and Research C1 [Pittman, Cory B.] Mercy Arthrit & Osteoporosis Ctr, Urbandale, IA 50322 USA. [Davis, Lisa A.] Denver Hlth & Hosp Author, Denver, CO USA. [Davis, Lisa A.; Caplan, Liron] Denver Vet Affairs Med Ctr, Denver, CO USA. [Davis, Lisa A.; Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO USA. [Zeringue, Angelique L.; McDonald, Jay R.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Scherrer, Jeffrey F.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Wehmeier, Kent R.; Arnold, Alexis] Univ Florida, Coll Med Jacksonville, Dept Med, Div Endocrinol Diabet & Metab, Jacksonville, FL USA. [Xian, Hong] St Louis Univ, Coll Publ Hlth & Social Justice, Dept Biostat, St Louis, MO 63103 USA. [Cunningham, Francesca E.] Vet Affairs Pharm Benefits Management, Hines, IL USA. [Arnold, Alexis] St Olaf Coll, Northfield, MN 55057 USA. [Eisen, Seth A.] Vet Affairs Hlth Serv Res & Dev, Washington, DC USA. RP Pittman, CB (reprint author), Mercy Arthrit & Osteoporosis Ctr, 8421 Plum Dr, Urbandale, IA 50322 USA. EM cpittman@mercydesmoines.org FU National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases [NIH/NIAMS T32 5T32 AR007279, NIH/NIAMS T32 AR007534-24]; National Institutes of Health Loan Repayment Award; Rheumatology Research Foundation Rheumatology Scientist Development Award; Denver Health and Hospital Authority; University of Colorado; Department of Veterans Affairs Health Services Research & Development Career Development Award [CDA 07-221] FX This work was supported in part by National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases grants NIH/NIAMS T32 5T32 AR007279 (C. B. P.) and NIH/NIAMS T32 AR007534-24 (L. A. D.); a National Institutes of Health Loan Repayment Award, the Rheumatology Research Foundation Rheumatology Scientist Development Award, the Denver Health and Hospital Authority, and the University of Colorado (L. A. D.); and Department of Veterans Affairs Health Services Research & Development Career Development Award CDA 07-221 (L.C.). NR 50 TC 6 Z9 7 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JAN PY 2014 VL 89 IS 1 BP 43 EP 51 DI 10.1016/j.mayocp.2013.08.021 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 282IE UT WOS:000329163600011 PM 24388021 ER PT J AU Corrales-Medina, VF Taljaard, M Fine, MJ Dwivedi, G Perry, JJ Musher, DM Chirinos, JA AF Corrales-Medina, Vicente F. Taljaard, Monica Fine, Michael J. Dwivedi, Girish Perry, Jeffrey J. Musher, Daniel M. Chirinos, Julio A. TI Risk Stratification for Cardiac Complications in Patients Hospitalized for Community-Acquired Pneumonia SO MAYO CLINIC PROCEEDINGS LA English DT Article ID SEVERITY INDEX; ADULTS; VALIDATION; MORTALITY; BURDEN; MODELS; SYSTEM AB Objective: To derive and validate a clinical rule that stratifies the risk of cardiac complications in patients hospitalized for community-acquired pneumonia (CAP) and compare its performance to the pneumonia severity index (PSI) score. Patients and Methods: Two cohorts of patients hospitalized for CAP were selected for the study. We used regression techniques in the derivation cohort (1343 patients enrolled in the Pneumonia Patient Outcomes Research Team study between October 1991 and March 1994) to generate a prediction rule that we validated in the validation cohort (608 patients enrolled in the Dissemination of Guidelines for Length of Stay study between February 1998 and March 1999). Discrimination and reclassification analyses compared its performance against the PSI score. Results: A prediction model for cardiac complications in the derivation cohort included age, 3 preexisting conditions, 2 vital signs, and 7 common laboratory or radiographic parameters. Discrimination (C statistic, 0.81; 95% CI, 0.78-0.84) and calibration (Hosmer-Lemeshow goodness-of-fit test, chi(2) = 13.0; P = .11) were good. We derived a point score system from this model that when applied to the validation cohort also had good discrimination (C statistic, 0.78; 95% CI, 0.74-0.83) and calibration (Hosmer-Lemeshow, chi(2) = 9.0; P = .34). On the basis of this score, we defined 4 categories of incremental risk of cardiac complications. The incidence of cardiac complications across risk categories increased linearly (from lowest to highest) in both the derivation (3.0%, 17.8%, 35.2%, and 72.2%) and validation (5.0%, 8.2%, 28.3%, and 48.9%) cohorts (Cochran-Armitage linear trend test, P<.01). The new score outperformed the PSI score in predicting cardiac complications in the validation cohort (C statistic, 0.78 vs 0.74; P = .03; proportion of patients correctly reclassified by the new score, 44%). Conclusion: We derived and validated a clinical rule that accurately stratifies the risk of cardiac complications in patients hospitalized for CAP. (C) 2014 Mayo Foundation for Medical Education and Research C1 [Corrales-Medina, Vicente F.; Dwivedi, Girish] Univ Ottawa, Dept Med, Ottawa Hosp Res Inst, Ottawa, ON K1N 6N5, Canada. [Taljaard, Monica] Univ Ottawa, Ottawa Hosp Res Inst, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada. [Perry, Jeffrey J.] Univ Ottawa, Ottawa Hosp Res Inst, Dept Emergency Med, Ottawa, ON K1N 6N5, Canada. [Dwivedi, Girish] Univ Ottawa, Inst Heart, Ottawa, ON, Canada. [Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA. [Fine, Michael J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Musher, Daniel M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Musher, Daniel M.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Musher, Daniel M.] Michael E DeBakey VA Med Ctr, Med Care Line Infect Dis Sect, Houston, TX USA. [Chirinos, Julio A.] Univ Penn, Div Cardiol, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Corrales-Medina, VF (reprint author), Ottawa Hosp, Dept Med, ASB 2-003,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada. EM vcorrales@toh.on.ca OI Corrales-Medina, Vicente/0000-0002-9691-491X; Perry, Jeffrey/0000-0003-2134-9597 FU Agency for Healthcare Research and Quality, Rockville, MD; Department of Medicine of the the Ottawa Hospital, Ottawa, Ontario, Canada FX The Pneumonia Patient Outcomes Research Team (PORT) study was funded by the Agency for Healthcare Research and Quality, Rockville, MD. Dr Corrales-Medina is supported by a Research Priority Grant from the Department of Medicine of the the Ottawa Hospital, Ottawa, Ontario, Canada. NR 25 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD JAN PY 2014 VL 89 IS 1 BP 60 EP 68 DI 10.1016/j.mayocp.2013.09.015 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 282IE UT WOS:000329163600013 PM 24388023 ER PT J AU Mills, KA Starr, PA Ostrem, JL AF Mills, Kelly A. Starr, Philip A. Ostrem, Jill L. TI Neuromodulation for Dystonia: Target and Patient Selection SO NEUROSURGERY CLINICS OF NORTH AMERICA LA English DT Article DE Deep brain stimulation; Globus pallidus; Subthalamic nucleus; Brain target; Outcomes; Predictive factors ID DEEP-BRAIN-STIMULATION; GLOBUS-PALLIDUS INTERNUS; PRIMARY GENERALIZED DYSTONIA; PRIMARY CERVICAL DYSTONIA; TERM-FOLLOW-UP; QUALITY-OF-LIFE; KINASE-ASSOCIATED NEURODEGENERATION; PRIMARY TORSION DYSTONIA; FOCAL HAND DYSTONIA; MEIGE-SYNDROME AB Treatment of dystonia refractory to oral medications or botulinum toxin injections includes the use of deep brain stimulation (DBS). Expectations should be established based on patient-related factors, including type of dystonia, genetic cause, target symptoms, age at the time of surgery, disease duration, or the presence of fixed skeletal deformities. Premorbid conditions such as psychiatric illness and cognitive impairment should be considered. Target selection is an emerging issue in DBS for dystonia. Although efficacy has been established for targeting the globus pallidus internus for dystonia, other brain targets such as the subthalamic nucleus, thalamus, or cortex may be promising alternatives. C1 [Mills, Kelly A.; Ostrem, Jill L.] San Francisco VA Med Ctr, UCSF Dept Neurol, PADRECC, San Francisco, CA 94143 USA. [Starr, Philip A.] San Francisco VA Med Ctr, UCSF Dept Neurosurg, PADRECC, San Francisco, CA 94143 USA. RP Starr, PA (reprint author), San Francisco VA Med Ctr, UCSF Dept Neurosurg, PADRECC, Box 1838,1635 Divisadero St,Suite 520, San Francisco, CA 94143 USA. EM StarrP@neurosurg.ucsf.edu NR 127 TC 11 Z9 11 U1 0 U2 4 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1042-3680 EI 1558-1349 J9 NEUROSURG CLIN N AM JI Neurosurg. Clin. N. Am. PD JAN PY 2014 VL 25 IS 1 BP 59 EP + DI 10.1016/j.nec.2013.08.014 PG 18 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA 278VS UT WOS:000328918600009 PM 24262900 ER PT J AU Robles, TF Slatcher, RB Trombello, JM McGinn, MM AF Robles, Theodore F. Slatcher, Richard B. Trombello, Joseph M. McGinn, Meghan M. TI Marital Quality and Health: A Meta-Analytic Review SO PSYCHOLOGICAL BULLETIN LA English DT Review DE marriage; marital quality; health; mortality; meta-analysis ID AMBULATORY BLOOD-PRESSURE; CORONARY-HEART-DISEASE; LESBIAN COHABITING COUPLES; AFRICAN-AMERICAN COUPLES; LEFT-VENTRICULAR MASS; TRAIT NEGATIVE AFFECT; SURROGATE END-POINTS; SELF-RATED HEALTH; MIDDLE-AGED WOMEN; PHYSICAL HEALTH AB This meta-analysis reviewed 126 published empirical articles over the past 50 years describing associations between marital relationship quality and physical health in more than 72,000 individuals. Health outcomes included clinical endpoints (objective assessments of function, disease severity, and mortality; subjective health assessments) and surrogate endpoints (biological markers that substitute for clinical endpoints, such as blood pressure). Biological mediators included cardiovascular reactivity and hypothalamic-pituitary-adrenal axis activity. Greater marital quality was related to better health, with mean effect sizes from r = .07 to.21, including lower risk of mortality (r = .11) and lower cardiovascular reactivity during marital conflict (r = -.13), but not daily cortisol slopes or cortisol reactivity during conflict. The small effect sizes were similar in magnitude to previously found associations between health behaviors (e. g., diet) and health outcomes. Effect sizes for a small subset of clinical outcomes were susceptible to publication bias. In some studies, effect sizes remained significant after accounting for confounds such as age and socioeconomic status. Studies with a higher proportion of women in the sample demonstrated larger effect sizes, but we found little evidence for gender differences in studies that explicitly tested gender moderation, with the exception of surrogate endpoint studies. Our conclusions are limited by small numbers of studies for specific health outcomes, unexplained heterogeneity, and designs that limit causal inferences. These findings highlight the need to explicitly test affective, health behavior, and biological mechanisms in future research, and focus on moderating factors that may alter the relationship between marital quality and health. C1 [Robles, Theodore F.; Trombello, Joseph M.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Slatcher, Richard B.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA. [McGinn, Meghan M.] Vet Affairs Puget Sound Healthcare Syst, Mental Illness Res Educ & Clin Care, Seattle, WA USA. RP Robles, TF (reprint author), Univ Calif Los Angeles, Dept Psychol, Box 951563,1285 Franz Hall, Los Angeles, CA 90095 USA. EM robles@psych.ucla.edu FU William T. Grant Foundation [9333]; National Institutes of Health [R21 AG032494, T32 MH015750, R01 HL114097, F31 AG034718]; Department of Veterans Affairs Office of Academic Affiliations; Advanced Fellowship Program in Mental Illness Research and Treatment; Veterans Affairs Puget Sound Healthcare System, Seattle, Washington FX This research was supported by William T. Grant Foundation Research Grant 9333 and National Institutes of Health Grants R21 AG032494 (to Theodore F. Robles), T32 MH015750 and R01 HL114097 (to Richard B. Slatcher), and F31 AG034718 (to Meghan M. McGinn). The work of Meghan M. McGinn was also supported by resources from the Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, and the Veterans Affairs Puget Sound Healthcare System, Seattle, Washington. We thank the article authors who sent us additional statistics to allow us to compute effect sizes; Blair Ibarra, Emily Kelleher, Jennifer Linchey, and Meera Parbhakar for collecting citations; Julianne Holt-Lunstad and Annemarie Cano for supportive consultation; and graduate students and postdoctoral trainees in the UCLA Relationships and Health Laboratory and Tom Bradbury for comments on drafts of this article. NR 321 TC 97 Z9 100 U1 7 U2 76 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0033-2909 EI 1939-1455 J9 PSYCHOL BULL JI Psychol. Bull. PD JAN PY 2014 VL 140 IS 1 BP 140 EP 187 DI 10.1037/a0031859 PG 48 WC Psychology; Psychology, Multidisciplinary SC Psychology GA 280QB UT WOS:000329044700008 PM 23527470 ER PT J AU Zhang, XY Chen, DC Tan, YL Xiu, MH Cui, JY Hui, L Yang, FD Kosten, TR AF Zhang, Xiang Yang Chen, Da Chun Tan, Yun Long Xiu, Mei Hong Cui, Jingyi Hui, Li Yang, Fu De Kosten, Thomas R. TI Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population SO PSYCHOPHARMACOLOGY LA English DT Article DE Schizophrenia; Smoking; Cigarettes; Heavy; Psychopathology; Side effects ID CIGARETTE-SMOKING; NICOTINE DEPENDENCE; MENTAL-ILLNESS; ANTIPSYCHOTIC MEDICATIONS; NONPSYCHIATRIC CONTROLS; CARDIOVASCULAR-DISEASE; TOBACCO SMOKING; USE DISORDERS; SUBSTANCE USE; SEVERITY AB Despite higher smoking rates in schizophrenia, few studies have explored the clinical-demographic correlates of different amounts of smoking exposure. Little is known about the association between smoking severity and clinical phenotypes in Chinese patients with schizophrenia. We investigated differences between heavy (a parts per thousand yen1 pack/day) and non-heavy (< 1 pack/day) smoking in 550 male inpatients with schizophrenia using clinician-administered questionnaires and the Fagerstrom Test for Nicotine Dependence. They also were rated on the Positive and Negative Symptom Scale (PANSS), the Simpson and Angus Extrapyramidal Symptom Rating Scale (SAES), and the Abnormal Involuntary Movement Scale (AIMS), as well as were assayed with laboratory tests and an electrocardiogram. Heavy smoking prevalence was approximately 31 %. Compared to the non-heavy smokers, the heavy smokers were younger, more with paranoid subtype but less with disorganized subtype schizophrenia, smoked at an earlier age, fewer getting clozapine or all atypical antipsychotics together, and were taking larger doses of antipsychotic drugs. The heavy smokers scored significantly lower on the PANSS negative symptom subscore and total score, and also on the SAES and AIMS scores than the non-heavy smokers. In addition, heavy smokers displayed longer rate-corrected electrocardiographic QT intervals, but without any significant differences in other laboratory tests. Our results suggest several clinical or demographic differences between the heavy and non-heavy smoking patients with schizophrenia in a Chinese population. Heavy smoking remains a general health risk for schizophrenia. C1 [Zhang, Xiang Yang; Chen, Da Chun; Tan, Yun Long; Xiu, Mei Hong; Cui, Jingyi; Hui, Li; Yang, Fu De] Beijing HuiLongGuan Hosp, Beijing 100096, Peoples R China. [Zhang, Xiang Yang; Kosten, Thomas R.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA. [Zhang, Xiang Yang] VA Med Ctr, Houston, TX 77030 USA. RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA. EM xyzhang@bcm.edu FU Beijing Municipal Natural Science Foundation [7132063]; Stanley Medical Research Institute [03T-459, 05T-726]; United States National Institute of Health [K05-DA0454, P50-DA18827, U01-MH79639] FX This study was funded by the Beijing Municipal Natural Science Foundation, 7132063, the Stanley Medical Research Institute (03T-459 and 05T-726), and the United States National Institute of Health K05-DA0454, P50-DA18827, and U01-MH79639. NR 67 TC 4 Z9 5 U1 2 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0033-3158 EI 1432-2072 J9 PSYCHOPHARMACOLOGY JI Psychopharmacology PD JAN PY 2014 VL 231 IS 1 BP 305 EP 314 DI 10.1007/s00213-013-3239-x PG 10 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 281NI UT WOS:000329107900029 PM 23963531 ER PT J AU Hser, YI Saxon, AJ Huang, D Hasson, A Thomas, C Hillhouse, M Jacobs, P Teruya, C McLaughlin, P Wiest, K Cohen, A Ling, W AF Hser, Yih-Ing Saxon, Andrew J. Huang, David Hasson, Al Thomas, Christie Hillhouse, Maureen Jacobs, Petra Teruya, Cheryl McLaughlin, Paul Wiest, Katharina Cohen, Allan Ling, Walter TI Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial SO ADDICTION LA English DT Article DE Buprenorphine; methadone; opiate dependence; treatment outcomes ID OPIOID RECEPTOR AVAILABILITY; HEROIN-DEPENDENT VOLUNTEERS; MAINTENANCE TREATMENT; ABUSE; PHARMACOLOGY; ABSTINENCE; DIVERSION; HEALTH AB AimsTo examine patient and medication characteristics associated with retention and continued illicit opioid use in methadone (MET) versus buprenorphine/naloxone (BUP) treatment for opioid dependence. Design, settings and participantsThis secondary analysis included 1267 opioid-dependent individuals participating in nine opioid treatment programs between 2006 and 2009 and randomized to receive open-label BUP or MET for 24 weeks. MeasurementsThe analyses included measures of patient characteristics at baseline (demographics; use of alcohol, cigarettes and illicit drugs; self-rated mental and physical health), medication dose and urine drug screens during treatment, and treatment completion and days in treatment during the 24-week trial. FindingsThe treatment completion rate was 74% for MET versus 46% for BUP (P<0.01); the rate among MET participants increased to 80% when the maximum MET dose reached or exceeded 60mg/day. With BUP, the completion rate increased linearly with higher doses, reaching 60% with doses of 30-32mg/day. Of those remaining in treatment, positive opioid urine results were significantly lower [odds ratio (OR)=0.63, 95% confidence interval (CI)=0.52-0.76, P<0.01] among BUP relative to MET participants during the first 9 weeks of treatment. Higher medication dose was related to lower opiate use, more so among BUP patients. A Cox proportional hazards model revealed factors associated with dropout: (i) BUP [versus MET, hazard ratio (HR)=1.61, CI=1.20-2.15], (ii) lower medication dose (<16mg for BUP, <60mg for MET; HR=3.09, CI=2.19-4.37), (iii) the interaction of dose and treatment condition (those with higher BUP dose were 1.04 times more likely to drop out than those with lower MET dose, and (iv) being younger, Hispanic and using heroin or other substances during treatment. ConclusionsProvision of methadone appears to be associated with better retention in treatment for opioid dependence than buprenorphine, as does use of provision of higher doses of both medications. Provision of buprenorphine is associated with lower continued use of illicit opioids. C1 [Hser, Yih-Ing; Huang, David; Hasson, Al; Thomas, Christie; Hillhouse, Maureen; Teruya, Cheryl; Ling, Walter] Univ Calif Los Angeles, Los Angeles, CA USA. [Saxon, Andrew J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Jacobs, Petra] Natl Inst Drug Abuse, Bethesda, MD USA. [McLaughlin, Paul] Hartford Dispensary, Hartford, CT USA. [Cohen, Allan] Bay Area Addict Res & Treatment, Hayward, CA USA. RP Hser, YI (reprint author), UCLA Integrated Substance Abuse Programs, 11075 Santa Monica Blvd,Suite 200, Los Angeles, CA 90025 USA. EM yhser@ucla.edu FU National Institute on Drug Abuse [U10 U10DA13045, K05DA017648] FX Funding was provided by the National Institute on Drug Abuse through grants U10 U10DA13045 and K05DA017648. The corresponding author, Yih-Ing Hser, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Author contributions to the manuscript are as follows. Study concept and design: Y.-I.H., A.J.S., C.T., P.J. and W.L. Acquisition of data: A.J.S., C.T., A.H., M.H., K.W., A.C. and W.L. Analysis and interpretation of data: Y.-I.H., A.J.S., D.H., C.T., P.McL., A.C. and W.L. Drafting of the manuscript: Y.-I.H., A.J.S., D.H. and W.L. Critical revision of the manuscript for important intellectual content: Y.-I.H., A.J.S., A.H., C.T., M.H., P.J., C.T., P.McL., K.W., A.C. and W.L. Statistical analysis: D.H. and M.H. Obtaining funding: Y.-I.H., A.J.S., A.H. and W.L. Administrative, technical or material support: A.J.S., A.H., C.T., M.H. and C.T. Study supervision: Y.-I.H., A.J.S., C.T., P.J. and W.L. NR 35 TC 38 Z9 39 U1 5 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD JAN PY 2014 VL 109 IS 1 BP 79 EP 87 DI 10.1111/add.12333 PG 9 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 268GD UT WOS:000328157300012 PM 23961726 ER PT J AU Durazzo, TC Mon, A Pennington, D Abe, C Gazdzinski, S Meyerhoff, DJ AF Durazzo, Timothy C. Mon, Anderson Pennington, David Abe, Christoph Gazdzinski, Stefan Meyerhoff, Dieter J. TI Interactive effects of chronic cigarette smoking and age on brain volumes in controls and alcohol-dependent individuals in early abstinence SO ADDICTION BIOLOGY LA English DT Article DE Alcohol dependence; brain reward system; brain volume; cigarette smoking; magnetic resonance imaging ID SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; CORTICAL THICKNESS; DRUG-USE; ALZHEIMERS-DISEASE; REWARD SYSTEM; MATTER VOLUME; USE DISORDERS; GRAY; ADDICTION AB Chronic alcohol-use disorders (AUDs) have been shown to interact with normal age-related volume loss to exacerbate brain atrophy with increasing age. However, chronic cigarette smoking, a highly co-morbid condition in AUD and its influence on age-related brain atrophy have not been evaluated. We performed 1.5T quantitative magnetic resonance imaging in non-smoking controls [non-smoking light drinking controls (nsCONs); n=54], smoking light drinking controls (sCONs, n=34), and one-week abstinent, treatment-seeking alcohol-dependent (ALC) non-smokers (nsALCs, n=35) and smokers (sALCs, n=43), to evaluate the independent and interactive effects of alcohol dependence and chronic smoking on regional cortical and subcortical brain volumes, emphasizing the brain reward/executive oversight system (BREOS). The nsCONs and sALCs showed greater age-related volume losses than the nsALCs in the dorsal prefrontal cortex (DPFC), total cortical BREOS, superior parietal lobule and putamen. The nsALCs and sALCs demonstrated smaller volumes than the nsCONs in most cortical region of interests (ROIs). The sCONs had smaller volumes than the nsCONs in the DPFC, insula, inferior parietal lobule, temporal pole/parahippocampal region and all global cortical measures. The nsALCs and sALCs had smaller volumes than the sCONs in the DPFC, superior temporal gyrus, inferior and superior parietal lobules, precuneus and all global cortical measures. Volume differences between the nsALCs and sALCs were observed only in the putamen. Alcohol consumption measures were not related to volumes in any ROI for ALC; smoking severity measures were related to corpus callosum volume in the sCONs and sALCs. The findings indicate that consideration of smoking status is necessary for a better understanding of the factors contributing to regional brain atrophy in AUD. C1 [Durazzo, Timothy C.; Mon, Anderson; Pennington, David; Abe, Christoph; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. [Durazzo, Timothy C.; Pennington, David; Abe, Christoph; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu OI Abe, Christoph/0000-0002-1680-8480 FU National Institutes of Health [NIDA DA24136, NIAAA AA10788] FX This work was supported by the National Institutes of Health (NIDA DA24136 to TCD and NIAAA AA10788 to DJM) and by the use of resources and facilities at the San Francisco Veterans Administration Medical Center. The authors have no disclosures or conflicts of interest to report. We thank Mary Rebecca Young, Kathleen Altieri, Ricky Chen and Drs. Peter Banys and Ellen Herbst of the Veterans Administration Substance Abuse Day Hospital and Dr. David Pating, Karen Moise and their colleagues at the Kaiser Permanente Chemical Dependency Recovery Program in San Francisco for their valuable assistance in recruiting participants. We also wish to extend our gratitude to the study participants, who made this research possible. NR 52 TC 21 Z9 21 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1369-1600 J9 ADDICT BIOL JI Addict. Biol. PD JAN PY 2014 VL 19 IS 1 BP 132 EP 143 DI 10.1111/j.1369-1600.2012.00492.x PG 12 WC Biochemistry & Molecular Biology; Substance Abuse SC Biochemistry & Molecular Biology; Substance Abuse GA 274MJ UT WOS:000328610300013 PM 22943795 ER PT J AU Guenechea-Sola, M Hariri, SR Galoosian, A Yusin, JS AF Guenechea-Sola, Miren Hariri, Sherwin R. Galoosian, Artin Yusin, Joseph S. TI A retrospective review of veterans' adherence to allergen immunotherapy over 10 years SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Letter C1 [Guenechea-Sola, Miren] Cedars Sinai Med Ctr, Dept Internal Med, Los Angeles, CA 90048 USA. [Hariri, Sherwin R.; Galoosian, Artin; Yusin, Joseph S.] W Los Angeles Vet Affairs Med Ctr, Dept Allergy Immunol, Los Angeles, CA 90073 USA. [Galoosian, Artin] George Washington Univ, Sch Med, Washington, DC USA. RP Guenechea-Sola, M (reprint author), Cedars Sinai Med Ctr, Dept Internal Med, Los Angeles, CA 90048 USA. EM miren.guenechea-sola@cshs.org NR 7 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 EI 1534-4436 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD JAN PY 2014 VL 112 IS 1 BP 79 EP 81 PG 4 WC Allergy; Immunology SC Allergy; Immunology GA 274ZF UT WOS:000328644000023 PM 24331403 ER PT J AU Barshes, NR Kougias, P Ozaki, CK Pisimisis, G Bechara, CF Henson, HK Belkin, M AF Barshes, Neal R. Kougias, Panos Ozaki, C. Keith Pisimisis, George Bechara, Carlos F. Henson, Helene K. Belkin, Michael TI Cost-effectiveness of Revascularization for Limb Preservation in Patients with Marginal Functional Status SO ANNALS OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 23rd Annual Winter Meeting of the Peripheral-Vascular-Surgery-Society CY JAN 31-FEB 03, 2013 CL Park City, UT SP Peripheral Vasc Surg Soc ID INFRAINGUINAL ARTERIAL RECONSTRUCTION; LOWER-EXTREMITY BYPASS; CONTEMPORARY MANAGEMENT; ISCHEMIA; SALVAGE; OCTOGENARIANS; AMPUTATION; DISEASE; TRIAL; GRAFT AB Background: Revascularization and limb salvage attempts are often offered to patients with foot wounds and chronic limb ischemia who are thought to be good-risk candidates, but some skepticism remains about the utility of these efforts for elderly patients with marginal functional status. We sought to determine whether limb preservation efforts in this population could be justified from a patient-centered, cost-effectiveness perspective. Methods: A probabilistic Markov model was used to simulate the clinical outcomes, health utilities, and costs over a 10-year period with various management strategies. Clinical parameter estimates were obtained from previous clinical trials and large observational series. Cost estimates were obtained from cost literature and also a single-center study that reviewed total costs accumulated (including secondary amputations, wound care, outpatient nursing care, and nursing home costs). Cost (in 2011 U. S. dollars) per year of ambulation (with limb preservation or with a prosthesis after amputation) was the primary measure of cost-effectiveness. Results: The total 10-year costs of revascularization-either endovascular or surgical-were lower than the costs of either local wound care alone or primary amputation. Revascularization strategies also produced more health benefits as measured in terms of years of ambulatory ability, years of limb salvage, or quality-adjusted life-years. In none of the scenarios modeled in deterministic sensitivity analyses did primary amputation prove to be cost-effective. Conclusions: Revascularization and limb preservation attempts appear less costly and provide more health benefits than wound care alone or primary amputation, even among patients with marginal functional status at baseline. C1 [Barshes, Neal R.; Kougias, Panos; Pisimisis, George; Bechara, Carlos F.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Therapy, Houston, TX 77030 USA. [Ozaki, C. Keith; Belkin, Michael] Brigham & Womens Hosp, Dept Surg, Div Vasc & Endovasc Surg, Boston, MA 02115 USA. [Henson, Helene K.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Div Phys Med & Rehabil, Houston, TX 77030 USA. RP Barshes, NR (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc & Endovasc Surg, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA. EM nbarshes@bcm.edu NR 22 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-5096 EI 1615-5947 J9 ANN VASC SURG JI Ann. Vasc. Surg. PD JAN PY 2014 VL 28 IS 1 BP 10 EP 17 DI 10.1016/j.avsg.2013.08.004 PG 8 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 275AD UT WOS:000328646400002 PM 24332257 ER PT J AU Barshes, NR Bechara, CF Pisimisis, G Kougias, P AF Barshes, Neal R. Bechara, Carlos F. Pisimisis, George Kougias, Panos TI Preliminary Experiences with Early Primary Closure of Foot Wounds after Lower Extremity Revascularization SO ANNALS OF VASCULAR SURGERY LA English DT Article; Proceedings Paper CT 23rd Annual Winter Meeting of the Peripheral-Vascular-Surgery-Society CY JAN 31-FEB 03, 2013 CL Park City, UT SP Peripheral Vasc Surg Soc ID CRITICAL LIMB ISCHEMIA; INFRAINGUINAL BYPASS; COST-EFFECTIVENESS; AMPUTATION; OUTCOMES; SURGERY; PREVENTION; MANAGEMENT; TRIAL; GRAFT AB Background: The costs associated with local wound care after revascularization can be significant, and it has been suggested that early closure or healing of foot wounds can be a source of cost savings. We sought to determine the safety and effectiveness of attempts to primarily close chronic foot wounds early after revascularization. Methods: We performed a single-center 1-year review of patients who underwent primary wound closure during the same hospitalization as revascularization. Results: Seven patients underwent an attempt at early primary wound closure. Most (71%) were diabetic. The wounds were primarily closed at a median of 6 days after revascularization (range 3-8 days). The limb-salvage rate at 6 months was 86%. Four patients remained completely healed with primary closure. One healed secondarily with wound care, and 2 required major amputation. Wound-closure techniques included the use of toe/forefoot amputations, skin grafting, and local flaps. Conclusions: Early primary closure after revascularization may be a safe technique to consider for carefully selected foot wounds without ongoing soft tissue infection. C1 [Barshes, Neal R.; Bechara, Carlos F.; Pisimisis, George; Kougias, Panos] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc Surg & Endovasc Surg, Houston, TX 77030 USA. RP Barshes, NR (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc & Endovasc Surg, 2002 Holcombe Blvd OCL 112, Houston, TX 77030 USA. EM nbarshes@bcm.tmc.edu NR 18 TC 2 Z9 2 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-5096 EI 1615-5947 J9 ANN VASC SURG JI Ann. Vasc. Surg. PD JAN PY 2014 VL 28 IS 1 BP 48 EP 52 DI 10.1016/j.avsg.2013.06.012 PG 5 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA 275AD UT WOS:000328646400006 PM 24189006 ER PT J AU Leutwyler, H Hubbard, EM Jeste, DV Miller, B Vinogradov, S AF Leutwyler, Heather Hubbard, Erin M. Jeste, Dilip V. Miller, Bruce Vinogradov, Sophia TI Associations of Schizophrenia Symptoms and Neurocognition With Physical Activity in Older Adults With Schizophrenia SO BIOLOGICAL RESEARCH FOR NURSING LA English DT Article DE schizophrenia; physical activity; symptomatology; neurocognition ID MEDICAL COMORBIDITY; FUNCTIONAL STATUS; MENTAL-ILLNESS; HEALTH; TRIAL; PANSS AB Background: Low levels of physical activity contribute to the generally poor physical health of older adults with schizophrenia. The associations linking schizophrenia symptoms, neurocognition, and physical activity are not known. Research is needed to identify the reasons for this population's lack of adequate physical activity before appropriate interventions can be designed and tested. Design and Methods: In this cross-sectional study, 30 adults aged 55 years with schizophrenia were assessed on symptoms (Positive and Negative Syndrome Scale), neurocognition (MATRICS Consensus Cognitive Battery), and physical activity (Sensewear ProArmband). Pearson's bivariate correlations (two-tailed) and univariate linear regression models were used to test the following hypotheses: (1) more severe schizophrenia symptoms are associated with lower levels of physical activity and (2) more severe neurocognitive deficits are associated with lower levels of physical activity. Results: Higher scores on a speed-of-processing test were associated with more average daily steps (p = .002) and more average daily minutes of moderate physical activity (p = .009). Higher scores on a verbal working memory task were associated with more average daily minutes of moderate physical activity (p = .05). More severe depressive symptoms were associated with more average daily minutes of sedentary activity (p = .03). Conclusion: Physical activity interventions for this population are imperative. In order for a physical activity intervention to be successful, it must include components to enhance cognition and diminish psychiatric symptoms. C1 [Leutwyler, Heather; Hubbard, Erin M.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA. [Jeste, Dilip V.] Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, Dept Psychiat & Neurosci, San Diego, CA 92103 USA. [Miller, Bruce] Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA 94143 USA. [Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA. [Vinogradov, Sophia] San Francisco VA Med Ctr, San Francisco, CA USA. RP Leutwyler, H (reprint author), Univ Calif San Francisco, Dept Physiol Nursing, 2 Koret Way,N631A,Box 0610, San Francisco, CA 94143 USA. EM heather.leutwyler@nursing.ucsf.edu FU UCSF Academic Senate; National Center for Research Resources [KL2R024130, UCSF-CTSI UL1 RR024131]; National Institute of Nursing Research [P30-NR011934-0] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the UCSF Academic Senate (Individual Investigator Grant), National Center for Research Resources (KL2R024130 to H. L. & UCSF-CTSI UL1 RR024131), and the National Institute of Nursing Research (P30-NR011934-0). NR 33 TC 16 Z9 16 U1 3 U2 12 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1099-8004 EI 1552-4175 J9 BIOL RES NURS JI Biol. Res. Nurs. PD JAN PY 2014 VL 16 IS 1 BP 23 EP 30 DI 10.1177/1099800413500845 PG 8 WC Nursing SC Nursing GA 274CE UT WOS:000328581900004 PM 24057223 ER PT J AU Sherry, D Knight, BP Casey, C Larson, J Hacker, ED Quinn, LT Wang, E Collins, EG AF Sherry, Daisy Knight, Bradley P. Casey, Cash Larson, Janet Hacker, Eileen D. Quinn, Lauretta T. Wang, Edward Collins, Eileen G. TI A Pilot Study Evaluating Daily Physical Activity Before and After Cardiac Resynchronization Therapy SO BIOLOGICAL RESEARCH FOR NURSING LA English DT Article DE cardiac resynchronization therapy; physical activity; heart failure ID CHRONIC HEART-FAILURE; QUESTIONNAIRE CHINESE VERSION; RANDOMIZED CONTROLLED-TRIAL; VALIDATION AB Benefits of daily physical activity are well known, but there are limited data to describe physical activity in heart failure patients who receive cardiac resynchronization therapy devices. The purpose of this pilot study was to evaluate changes in physical activity (PA) levels before and 3 months after Cardiac Resynchronization Therapy (CRT) and determine relationships of PA to physical function and comorbidities, as well as describe changes in heart failure symptoms. This was a prospective pre-/post- design that included a convenience sample of 21 subjects using self- report questionnaires and 6-minute walk test (6MWT). In this sample, there was a 2.6 hour increase in high level PA (p = 0.024). 6MW distance improved 27% (p < .0001). Subjects experienced a 25% reduction in dyspnea (p = 0.015). Knowledge gained from this study adds to the understanding of the patient response to CRT. Further study is recommended to generalize findings and explore whether an intervention (cardiac rehabilitation) is indicated. C1 [Sherry, Daisy] US Dept Vet Affairs, Edward Hines Jr VA Hosp, Hines, IL 60141 USA. [Knight, Bradley P.] NW Mem Hosp, Bluhm Cardiovasc Inst, Chicago, IL 60611 USA. [Casey, Cash] Midwest Heart Specialists, Elmhurst, IL USA. [Larson, Janet; Hacker, Eileen D.; Quinn, Lauretta T.; Wang, Edward; Collins, Eileen G.] Univ Illinois, Coll Nursing, Dept Biobehav Hlth Sci, Chicago, IL USA. [Larson, Janet] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA. [Collins, Eileen G.] Edward Hines Jr VA Hosp, Dept Rehabil, Hines, IL USA. RP Sherry, D (reprint author), US Dept Vet Affairs, Edward Hines Jr VA Hosp, 5000 S 5th Ave, Hines, IL 60141 USA. EM daisyc6@juno.com FU National Institute of Nursing Research's Ruth L. Kirchstein National Research Service Award [5F31NR009901] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Sherry received funding for this study through the National Institute of Nursing Research's Ruth L. Kirchstein National Research Service Award, #5F31NR009901. NR 22 TC 0 Z9 0 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1099-8004 EI 1552-4175 J9 BIOL RES NURS JI Biol. Res. Nurs. PD JAN PY 2014 VL 16 IS 1 BP 31 EP 37 DI 10.1177/1099800413481619 PG 7 WC Nursing SC Nursing GA 274CE UT WOS:000328581900005 PM 23539670 ER PT J AU El-Serag, HB Xu, F Biyani, P Cooper, GS AF El-Serag, Hashem B. Xu, Fang Biyani, Prachi Cooper, Gregory S. TI Bundling in Medicare Patients Undergoing Bidirectional Endoscopy: How Often Does It Happen? SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Medicare; Insurance; Colonoscopy; Health Services Research. ID UPPER GASTROINTESTINAL ENDOSCOPY; OCCULT BLOOD-TEST; NEGATIVE COLONOSCOPY; ASYMPTOMATIC PATIENTS; POSITIVE STOOL; CLAIMS; YIELD AB BACKGROUND & AIMS: In patients with appropriate indications, performance of both colonoscopy and esophagogastroduodenoscopy (EGD) at the same time (bundling) is convenient for patients, efficient for providers, and cost saving for the health care system. However, Medicare reimbursement for bundled procedures is at a rate that is less than the sum of the 2 procedures when charged separately, and this may create a disincentive to bundle. The practice patterns of bundling are unknown at a US population-based level. METHODS: We examined Medicare claims from 2007 to 2009 from the Carrier file in a national, random sample of fee-for-service beneficiaries aged 66 and older. We identified patients who had both a colonoscopy and EGD performed within 180 days of each other and calculated the proportions of patients with both procedures bundled on the same date, within 1 to 30 days, and within 31 to 180 days of each other. We compared patients in these 3 groups for demographics and clinical indications for the procedures (bleeding, lower or upper gastrointestinal symptoms, surveillance, and screening). RESULTS: We identified 12,982 Medicare-enrolled individuals who had a colonoscopy and an EGD performed within 180 days of each other. Approximately 35% of procedures were not bundled on the same day, and, of these, 2359 (18%) were performed within 30 days of each other, and 2219 (17%) were performed within 31 to 180 days of each other. There were marked geographic differences in the percentage of bundling, with the lowest occurrence in the Northeast and the highest in the West. Patients with bundled procedures were more likely to have gastrointestinal bleeding and less likely to have screening or surveillance indications. CONCLUSIONS: Although same-day bundling of endoscopic procedures offers a number of advantages, it is not practiced in more than one-third of cases in a national sample of Medicare beneficiaries. C1 [El-Serag, Hashem B.] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Xu, Fang; Biyani, Prachi; Cooper, Gregory S.] Case Western Reserve Univ, Div Gastroenterol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA. [Xu, Fang; Biyani, Prachi; Cooper, Gregory S.] Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA. RP El-Serag, HB (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hasheme@bcm.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [K24-04-107]; National Institutes of Health/National Cancer Institute [R01 116845]; Houston VA Health Services Research & Development Center of Excellence [HFP90-020]; Texas Digestive Disease Center National Institutes of Health [DK58338]; NCI [R01 132862]; National Center for Advancing Translational Sciences [UL1TR000439] FX Supported by the National Institute of Diabetes and Digestive and Kidney Diseases grant K24-04-107 (H.E.-S.). This work was funded in part by a grant from the National Institutes of Health/National Cancer Institute (R01 116845), the Houston VA Health Services Research & Development Center of Excellence (HFP90-020), and the Texas Digestive Disease Center National Institutes of Health (DK58338). Also supported by grant NCI R01 132862 and by the National Center for Advancing Translational Sciences (UL1TR000439) (G.C.). NR 11 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD JAN PY 2014 VL 12 IS 1 BP 58 EP 63 DI 10.1016/j.cgh.2013.07.021 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 276FQ UT WOS:000328734300012 PM 23911874 ER PT J AU Bielawska, B Day, AG Lieberman, DA Hookey, LC AF Bielawska, Barbara Day, Andrew G. Lieberman, David A. Hookey, Lawrence C. TI Risk Factors for Early Colonoscopic Perforation Include Non-Gastroenterologist Endoscopists: A Multivariable Analysis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE ASA Classification; GI; Intestine; Quality Control; Endoscopy Training ID NURSE-ADMINISTERED PROPOFOL; GENERAL-SURGERY RESIDENTS; POPULATION-BASED-ANALYSIS; SURGICAL-MANAGEMENT; COLORECTAL CANCERS; ANESTHESIA; SEDATION; OUTCOMES; COMPLICATIONS; PERFORMANCE AB BACKGROUND & AIMS: Bowel perforation is a rare but serious complication of colonoscopy. Its prevalence is increasing with the rapidly growing volume of procedures performed. Although colonoscopies have been performed for decades, the risk factors for perforation are not completely understood. We investigated risk factors for perforation during colonoscopy by assessing variables that included sedation type and endoscopist specialty and level of training. METHODS: We performed a retrospective multivariate analysis of risk factors for early perforation (occurring at any point during the colonoscopy but recognized during or immediately after the procedure) in adult patients by using the Clinical Outcomes Research Initiative National Endoscopic Database. Risk factors were determined from published articles. Additional variables assessed included endoscopist specialty and years of experience, trainee involvement, and sedation with propofol. RESULTS: We identified 192 perforation events during 1,144,900 colonoscopies from 85 centers entered into the database from January 2000-March 2011. On multivariate analysis, increasing age, American Society of Anesthesia class, female sex, hospital setting, any therapy, and polyps >10 mm were significantly associated with increased risk of early perforation. Colonoscopies performed by surgeons and endoscopists of unknown specialty had higher rates of perforation than those performed by gastroenterologists (odds ratio, 2.00; 95% confidence interval, 1.30-3.08). Propofol sedation did not significantly affect risk for perforation. CONCLUSIONS: In addition to previously established risk factors, non-gastroenterologist specialty was found to affect risk for perforations detected during or immediately after colonoscopy. This finding could result from differences in volume and style of endoscopy training. Further investigation into these observed associations is warranted. C1 [Bielawska, Barbara; Hookey, Lawrence C.] Queens Univ, Gastrointestinal Dis Res Unit, Kingston, ON K7L 5G2, Canada. [Day, Andrew G.] Kingston Gen Hosp, Clin Res Ctr, Kingston, ON K7L 2V7, Canada. [Lieberman, David A.] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland Vet Affairs Med Ctr, Portland, OR USA. RP Hookey, LC (reprint author), Queens Univ, Div Gastroenterol, Dept Med, Hotel Dieu Hosp, Kingston, ON K7L 5G2, Canada. EM hookeyl@hdh.kari.net FU NIDDK [U01DK57132, R33-DK61778-01, R21-CA131626] FX This project was supported with funding from NIDDK U01DK57132, R33-DK61778-01, and R21-CA131626. In addition, the practice network (Clinical Outcomes Research Initiative) has received support from the following entities to support the infrastructure of the practice-based network: AstraZeneca, Novartis, Bard International, Pentax USA, ProVation, Endosoft, GIVEN Imaging, and Ethicon. The commercial entities had no involvement in this research. NR 32 TC 23 Z9 25 U1 0 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD JAN PY 2014 VL 12 IS 1 BP 85 EP 92 DI 10.1016/j.cgh.2013.06.030 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 276FQ UT WOS:000328734300016 PM 23891916 ER PT J AU Liu, XD Luo, H Zhang, L Leung, FW Liu, ZG Wang, XP Huang, R Hui, N Wu, KC Fan, DM Pan, YL Guo, XG AF Liu, Xiaodong Luo, Hui Zhang, Lin Leung, Felix W. Liu, Zhiguo Wang, Xiangping Huang, Rui Hui, Na Wu, Kaichun Fan, Daiming Pan, Yanglin Guo, Xuegang TI Telephone-based re-education on the day before colonoscopy improves the quality of bowel preparation and the polyp detection rate: a prospective, colonoscopist-blinded, randomised, controlled study SO GUT LA English DT Article DE COLONOSCOPY ID SCREENING COLONOSCOPY; PATIENT EDUCATION; COLORECTAL-CANCER; DIAGNOSTIC YIELD; IMPACT; TRIAL; COLON; DETERMINES; VALIDATION; COST AB Background Despite advances in bowel preparation methods, the quality of bowel preparation in some patients undergoing colonoscopy remains unsatisfactory. The effect of telephone re-education (TRE) on the day before colonoscopy on the quality of bowel preparation and other outcome measures had not been studied. Methods A prospective colonoscopist-blinded study was conducted. All patients received regular instructions during a visit to discuss colonoscopy. Those scheduled for colonoscopy were randomly assigned to receive TRE on the day before colonoscopy (TRE group) for bowel preparation or no TRE (control group). The primary outcome was the rate of adequate bowel preparation. The secondary outcomes included polyp detection rate (PDR), non-compliance with instructions, and willingness to repeat bowel preparation. Results A total of 605 patients were randomised, 305 to the TRE group and 300 to the control group. In an intention-to-treat analysis of the primary outcome, adequate preparation was found in 81.6% vs 70.3% of TRE and control patients, respectively (p=0.001). PDR was 38.0% vs 24.7% in the TRE and control group, respectively (p<0.001). Among patients with successful colonoscopy, the Ottawa scores were 3.02.3 in the TRE group and 4.9 +/- 3.2 in the control group (p<0.001). Fewer patients who showed non-compliance with instructions were found in the TRE group (9.4% vs 32.6%, p<0.001). No significant differences were observed between the two groups with regard to willingness to have a repeat bowel preparation (p=0.409). Conclusions TRE about the details of bowel preparation on the day before colonoscopy significantly improved the quality of bowel preparation and PDR. C1 [Liu, Xiaodong; Luo, Hui; Zhang, Lin; Liu, Zhiguo; Wang, Xiangping; Huang, Rui; Hui, Na; Wu, Kaichun; Fan, Daiming; Pan, Yanglin; Guo, Xuegang] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shannxi, Peoples R China. [Leung, Felix W.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hill, CA USA. [Leung, Felix W.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Guo, XG (reprint author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, 169 Changle West Rd, Xian 710032, Shannxi, Peoples R China. EM xuegangguo@gmail.com FU National Natural Science Foundation of China [81172288]; Science Foundation of the Ministry of Education FX We thank the nurse, Jing Li, for patient education on bowel preparation, and Subesh Kumar Dahal for preparation of the manuscript. This work was supported in part by the National Natural Science Foundation of China (81172288). Support was also received by YP from the Science Foundation of the Ministry of Education. NR 30 TC 32 Z9 35 U1 1 U2 20 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD JAN PY 2014 VL 63 IS 1 BP 125 EP 130 DI 10.1136/gutjnl-2012-304292 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 263VB UT WOS:000327835000015 PM 23503044 ER PT J AU Boyd, JD Lee-Armandt, JP Feiler, MS Zaarur, N Liu, M Kraemer, B Concannon, JB Ebata, A Wolozin, B Glicksman, MA AF Boyd, Justin D. Lee-Armandt, J. Peter Feiler, Marisa S. Zaarur, Nava Liu, Min Kraemer, Brian Concannon, John B. Ebata, Atsushi Wolozin, Benjamin Glicksman, Marcie A. TI A High-Content Screen Identifies Novel Compounds That Inhibit Stress-Induced TDP-43 Cellular Aggregation and Associated Cytotoxicity SO JOURNAL OF BIOMOLECULAR SCREENING LA English DT Article DE amyotrophic lateral sclerosis; RNA granule; RNA binding protein; aggregation; high-throughput screen; protein synthesis ID AMYOTROPHIC-LATERAL-SCLEROSIS; CAENORHABDITIS-ELEGANS; OXIDATIVE STRESS; RNA TRIAGE; GRANULES; PROTEIN; NEURODEGENERATION; PROTEINOPATHIES; DEGENERATION; MUTATION AB TDP-43 is an RNA binding protein found to accumulate in the cytoplasm of brain and spinal cord from patients affected with amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Nuclear TDP-43 protein regulates transcription through several mechanisms, and under stressed conditions, it forms cytoplasmic aggregates that co-localize with stress granule (SG) proteins in cell culture. These granules are also found in the brain and spinal cord of patients affected with ALS and FTLD. The mechanism through which TDP-43 might contribute to neurodegenerative diseases is poorly understood. To investigate the pathophysiology of TDP-43 aggregation and to isolate potential therapeutic targets, we screened a chemical library of 75,000 compounds using high-content analysis with PC12 cells that inducibly express human TDP-43 tagged with green fluorescent protein (GFP). The screen identified 16 compounds that dose-dependently decreased the TDP-43 inclusions without significant cellular toxicity or changes in total TDP-43 expression levels. To validate the effect, we tested compounds by Western blot analysis and in a Caenorhabditis elegans model that replicates some of the relevant disease phenotypes. The hits from this assay will be useful for elucidating regulation of TDP-43, stress granule response, and possible ALS therapeutics. C1 [Boyd, Justin D.; Liu, Min; Concannon, John B.; Glicksman, Marcie A.] Brigham & Womens Hosp, Harvard NeuroDiscovery Ctr, Lab Drug Discovery Neurodegenerat, Cambridge, MA USA. [Boyd, Justin D.; Liu, Min; Concannon, John B.; Glicksman, Marcie A.] Harvard Univ, Sch Med, Cambridge, MA 02139 USA. [Lee-Armandt, J. Peter; Feiler, Marisa S.; Zaarur, Nava; Ebata, Atsushi; Wolozin, Benjamin] Boston Univ, Dept Pharmacol & Expt Therapeut, Boston, MA 02215 USA. [Kraemer, Brian] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Kraemer, Brian] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98104 USA. [Ebata, Atsushi] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA. [Wolozin, Benjamin] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. RP Glicksman, MA (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol, 65 Landsdowne St, Cambridge, MA 02139 USA. EM bwolozin@bu.edu; mglicksman@rics.bwh.harvard.edu OI Ebata, Atsushi/0000-0001-9051-2971 FU National Institutes of Health [NIH] [ES020395, NS066108, NS073679, NS060872]; BrightFocus Foundation; NIH [NS073679]; ALS Therapy Alliance; Harvard NeuroDiscovery Center; Department of Veterans Affairs [1147891]; National Institutes of Health [R01NS064131] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grant awards to BW (National Institutes of Health [NIH] grants ES020395, NS066108, NS073679, NS060872, and BrightFocus Foundation) and to MAG (NIH NS073679, ALS Therapy Alliance and the Harvard NeuroDiscovery Center). This work was supported by grants from the Department of Veterans Affairs to BK (Merit Review Grant #1147891) and National Institutes of Health (R01NS064131). NR 28 TC 10 Z9 11 U1 0 U2 10 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1087-0571 EI 1552-454X J9 J BIOMOL SCREEN JI J. Biomol. Screen PD JAN PY 2014 VL 19 IS 1 SI SI BP 44 EP 56 DI 10.1177/1087057113501553 PG 13 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Chemistry, Analytical SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry GA 272GC UT WOS:000328447300004 PM 24019256 ER PT J AU Johnson, HM Thorpe, CT Bartels, CM Schumacher, JR Palta, M Pandhi, N Sheehy, AM Smith, MA AF Johnson, Heather M. Thorpe, Carolyn T. Bartels, Christie M. Schumacher, Jessica R. Palta, Mari Pandhi, Nancy Sheehy, Ann M. Smith, Maureen A. TI Undiagnosed hypertension among young adults with regular primary care use SO JOURNAL OF HYPERTENSION LA English DT Article DE delayed diagnosis; hypertension; young adults ID AMERICAN-HEART-ASSOCIATION; CHRONIC KIDNEY-DISEASE; HIGH BLOOD-PRESSURE; UNITED-STATES; CARDIOVASCULAR-DISEASE; DIABETES CARE; TRENDS; POPULATION; PREVALENCE; IMPACT AB Objective:Young adults meeting hypertension diagnostic criteria have a lower prevalence of a hypertension diagnosis than middle-aged and older adults. The purpose of this study was to compare the rates of a new hypertension diagnosis for different age groups and identify predictors of delays in the initial diagnosis among young adults who regularly use primary care.Methods:A 4-year retrospective analysis included 14970 patients, at least 18 years old, who met clinical criteria for an initial hypertension diagnosis in a large, Midwestern, academic practice from 2008 to 2011. Patients with a previous hypertension diagnosis or prior antihypertensive medication prescription were excluded. The probability of diagnosis at specific time points was estimated by Kaplan-Meier analysis. Cox proportional hazard models (hazard ratio; 95% confidence interval) were fit to identify predictors of delays to an initial diagnosis, with a subsequent subset analysis for young adults (18-39 years old).Results:After 4 years, 56% of 18-24-year-olds received a diagnosis compared with 62% (25-31-year-olds), 68% (32-39-year-olds), and more than 70% (40-year-olds). After adjustment, 18-31-year-olds had a 33% slower rate of receiving a diagnosis (18-24 years hazard ratio 0.66, 0.53-0.83; 25-31 years hazard ratio 0.68, 0.58-0.79) compared with adults at least 60 years. Other predictors of a slower diagnosis rate among young adults were current tobacco use, white ethnicity, and non-English primary language. Young adults with diabetes, higher blood pressures, or a female provider had a faster diagnosis rate.Conclusion:Provider and patient factors are critical determinants of poor hypertension diagnosis rates among young adults with regular primary care use. C1 [Johnson, Heather M.; Bartels, Christie M.; Sheehy, Ann M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA. [Johnson, Heather M.; Bartels, Christie M.; Schumacher, Jessica R.; Pandhi, Nancy; Sheehy, Ann M.; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Hlth Innovat Program, Madison, WI USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Vet Affairs Pittsburgh Healthcare Syst, Hlth Serv Res & Dev, Pittsburgh, PA USA. [Thorpe, Carolyn T.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Schumacher, Jessica R.; Palta, Mari; Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA. [Palta, Mari] Univ Wisconsin, Sch Med & Publ Hlth, Dept Biostat & Med Informat, Madison, WI USA. [Pandhi, Nancy; Smith, Maureen A.] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI USA. [Smith, Maureen A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. RP Johnson, HM (reprint author), Div Cardiovasc Med, H4-512 CSC,MC 3248,600 Highland Ave, Madison, WI 53792 USA. EM hm2@medicine.wisc.edu OI Johnson, Heather/0000-0002-4916-3519 FU Clinical and Translational Science Award (CTSA) program; National Center for Research Resources (NCRR) [UL1RR025011]; National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health [U54TR000021]; National Heart, Lung, and Blood Institute of the National Institutes of Health [K23HL112907]; University of Wisconsin Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [K23AR062381]; National Institute on Aging of the National Institutes of Health [K08AG029527]; University of Wisconsin Health Innovation Program; University of Wisconsin School of Medicine and Public Health from The Wisconsin Partnership Program FX Research reported in this study was supported by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR) under award number UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health under award number U54TR000021. H.J. is supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under award number K23HL112907, and also by the University of Wisconsin Centennial Scholars Program of the University of Wisconsin School of Medicine and Public Health. C.B. is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number K23AR062381. N.P. is supported by the National Institute on Aging of the National Institutes of Health under award number K08AG029527. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Additional funding for this project was provided by the University of Wisconsin Health Innovation Program and the University of Wisconsin School of Medicine and Public Health from The Wisconsin Partnership Program.; Additional funding for this project was provided by the University of Wisconsin Health Innovation Program and the University of Wisconsin School of Medicine and Public Health from The Wisconsin Partnership Program. NR 42 TC 18 Z9 18 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0263-6352 EI 1473-5598 J9 J HYPERTENS JI J. Hypertens. PD JAN PY 2014 VL 32 IS 1 BP 65 EP 74 DI 10.1097/HJH.0000000000000008 PG 10 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 276IK UT WOS:000328743500010 PM 24126711 ER PT J AU Johnson, PJ Schmidt, DE Duvvuri, U AF Johnson, Paul J. Schmidt, David E. Duvvuri, Umamaheswar TI Output control of da Vinci surgical system's surgical graspers SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Robotic surgery; da Vinci; User interface; Usability ID ASSISTED LAPAROSCOPIC SURGERY; MINIMALLY INVASIVE SURGERY; ROBOTIC SURGERY; HAPTIC FEEDBACK; PERFORMANCE; DAMAGE; STANDARD AB Introduction: The number of robot-assisted surgeries performed with the da Vinci surgical system has increased significantly over the past decade. The articulating movements of the robotic surgical grasper are controlled by grip controls at the master console. The user interface has been implicated as one contributing factor in surgical grasping errors. The goal of our study was to characterize and evaluate the user interface of the da Vinci surgical system in controlling surgical graspers. Materials and methods: An angular manipulator with force sensors was used to increment the grip control angle as grasper output angles were measured. Input force at the grip control was simultaneously measured throughout the range of motion. Pressure film was used to assess the maximum grasping force achievable with the endoscopic grasping tool. Results: The da Vinci robot's grip control angular input has a nonproportional relationship with the grasper instrument output. The grip control mechanism presents an intrinsic resistant force to the surgeon's fingertips and provides no haptic feedback. The da Vinci Maryland graspers are capable of applying up to 5.1 MPa of local pressure. Conclusions: The angular and force input at the grip control of the da Vinci robot's surgical graspers is nonproportional to the grasper instrument's output. Understanding the true relationship of the grip control input to grasper instrument output may help surgeons understand how to better control the surgical graspers and promote fewer grasping errors. (C) 2014 Elsevier Inc. All rights reserved. C1 [Johnson, Paul J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Schmidt, David E.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA. [Duvvuri, Umamaheswar] Univ Pittsburgh, Sch Med, Dept Otolaryngol, VA Pittsburgh Hlth Syst, Pittsburgh, PA 15213 USA. RP Johnson, PJ (reprint author), Univ Pittsburgh, Inst Eye & Ear, Dept Otolaryngol, Sch Med, Suite 500,203 Lothrop St, Pittsburgh, PA 15213 USA. EM pjohnsonj@gmail.com FU PNC Foundation; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX Departmental Startup Funds, and the PNC Foundation (Dr. Duvvuri, Department of Otolaryngology, University of Pittsburgh). This material is based on the work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. This work does not represent the views of the United States Government or the Department of Veterans Affairs. NR 29 TC 2 Z9 2 U1 2 U2 21 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD JAN PY 2014 VL 186 IS 1 BP 56 EP 62 DI 10.1016/j.jss.2013.07.032 PG 7 WC Surgery SC Surgery GA 274TJ UT WOS:000328628800008 PM 23968806 ER PT J AU Whelan, SP Carchman, EH Kautza, B Nassour, I Mollen, K Escobar, D Gomez, H Rosengart, MA Shiva, S Zuckerbraun, BS AF Whelan, Sean P. Carchman, Evie H. Kautza, Benjamin Nassour, Ibrahim Mollen, Kevin Escobar, Daniel Gomez, Hernando Rosengart, Matthew A. Shiva, Sruti Zuckerbraun, Brian S. TI Polymicrobial sepsis is associated with decreased hepatic oxidative phosphorylation and an altered metabolic profile SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Metabolomic; Carbohydrate; Amino Acid; fatty acid; Lipopolysaccharide ID ORGAN FAILURE; MITOCHONDRIAL DYSFUNCTION; ENERGY SENSOR; INJURY; MECHANISM; HYPOXIA AB Background: Organ failure in sepsis accounts for significant mortality worldwide. Mitochondrial and metabolic responses are central to the overall response of the cell, and thus of the organ and organism. Adaptive responses in metabolism are critical to the recovery at the cellular level. The purpose of these investigations was to test the hypothesis that sepsis is associated with decreased aerobic respiration and significant metabolic changes in the liver. Methods: C57BL/6 mice underwent cecal ligation and puncture (CLP) with a 21 gauge needle or an operation without CLP. Mice were euthanized from 0e24 h after the procedure and liver tissue was harvested. Tissue oxygen consumption and mitochondrial complex activity were measured. Global biochemical profiles of 311 metabolites were performed at the 8-h time point (n = 8/group) and analyzed by gas chromatographye-mass spectrometry and liquid chromatography tandem mass spectrometry platforms by Metabolon (Durham, North Carolina). The influence of lipopolysaccharide (LPS) on aerobic and anaerobic respiration in primary mouse hepatocytes was also investigated. Results: CLP in vivo or LPS in vitro resulted in a significant decrease in hepatic oxygen consumption. There was a significant decrease in oxidative phosphorylation measured at 12 h. LPS also resulted in a significant increase in anaerobic respiration in hepatocytes. Interestingly, the metabolomic analysis resulted in a metabolic shift in the liver from carbohydrate-based energy to utilization of fatty acids and amino acids. This included an increase in every tricarboxylic acid cycle intermediate and derivative, suggesting an increased flux into the cycle from fatty acid beta-oxidation and anaplerotic contributions from amino acids. Conclusions: Sepsis results in a metabolic response and profile consistent with increased anaerobic respiration, which occurs prior to significant changes in hemodynamics. The metabolic responses of cells and organs may be important adaptive responses to prevent organ failure and death. (C) 2014 Published by Elsevier Inc. C1 [Whelan, Sean P.; Carchman, Evie H.; Kautza, Benjamin; Nassour, Ibrahim; Mollen, Kevin; Escobar, Daniel; Rosengart, Matthew A.; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA. [Gomez, Hernando; Rosengart, Matthew A.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA. [Shiva, Sruti] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA. [Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Surg Serv Line, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), Univ Pittsburgh, Dept Surg, F1271 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu OI Nassour, Ibrahim/0000-0002-9845-1074 FU NHLBI NIH HHS [T32 HL098036]; NIGMS NIH HHS [R01 GM082830] NR 25 TC 7 Z9 8 U1 0 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD JAN PY 2014 VL 186 IS 1 BP 297 EP 303 DI 10.1016/j.jss.2013.08.007 PG 7 WC Surgery SC Surgery GA 274TJ UT WOS:000328628800053 PM 24054495 ER PT J AU Reddy, LF Lee, J Davis, MC Altshuler, L Glahn, DC Miklowitz, DJ Green, MF AF Reddy, L. Felice Lee, Junghee Davis, Michael C. Altshuler, Lori Glahn, David C. Miklowitz, David J. Green, Michael F. TI Impulsivity and Risk Taking in Bipolar Disorder and Schizophrenia SO NEUROPSYCHOPHARMACOLOGY LA English DT Article DE schizophrenia; psychopharmacology; behavioral sciences; dopamine ID DECISION-MAKING; TRAIT IMPULSIVITY; RATING-SCALE; TASK BART; DOPAMINERGIC MODULATION; RESPONSE-INHIBITION; REWARD; BEHAVIOR; SENSITIVITY; DEPRESSION AB Impulsive risk taking contributes to deleterious outcomes among clinical populations. Indeed, pathological impulsivity and risk taking are common in patients with serious mental illness, and have severe clinical repercussions including novelty seeking, response disinhibition, aggression, and substance abuse. Thus, the current study seeks to examine self-reported impulsivity (Barratt Impulsivity Scale) and performance-based behavioral risk taking (Balloon Analogue Risk Task) in bipolar disorder and schizophrenia. Participants included 68 individuals with bipolar disorder, 38 with schizophrenia, and 36 healthy controls. Self-reported impulsivity was elevated in the bipolar group compared with schizophrenia patients and healthy controls, who did not differ from each other. On the risk-taking task, schizophrenia patients were significantly more risk averse than the bipolar patients and controls. Aside from the diagnostic group differences, there was a significant effect of antipsychotic (AP) medication within the bipolar group: bipolar patients taking AP medications were more risk averse than those not taking AP medications. This difference in risk taking because of AP medications was not explained by history of psychosis. Similarly, the differences in risk taking between schizophrenia and bipolar disorder were not fully explained by AP effects. Implications for clinical practice and future research are discussed. C1 [Reddy, L. Felice; Lee, Junghee; Davis, Michael C.; Altshuler, Lori; Green, Michael F.] MIRECC, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Lee, Junghee; Davis, Michael C.; Altshuler, Lori; Miklowitz, David J.; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Glahn, David C.] Inst Living, Olin Neuropsychiat Res Ctr, Hartford, CT USA. [Glahn, David C.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. RP Reddy, LF (reprint author), MIRECC, VA Greater Los Angeles Healthcare Syst, Bldg 210,11301 Wilshire Blvd Room 117, Los Angeles, CA 90073 USA. EM lena.reddy@va.gov RI Lee, Junghee/C-5226-2014; Davis, Michael/L-8920-2013 OI Lee, Junghee/0000-0001-9567-8700; Davis, Michael/0000-0003-2293-5694; Miklowitz, David/0000-0002-9647-6147 FU Amgen; Sepracor; Eli Lilly; Takeda Pharmaceuticals North America; H. Lundbeck A/S; Sunovion Pharmaceuticals Inc.; National Institute of Mental Health (NIMH); National Association for Research on Schizophrenia and Depression (NARSAD); Danny Alberts Foundation; Attias Family Foundation; Robert L Sutherland Foundation FX Dr Green has served as a consultant for Abbott Laboratories, Amgen, Biogen, Mnemosyne, Roche, and Shire. He has received research support from Amgen. Dr Altshuler has received past funding from Sepracor (advisory board honoraria, January 2010), Eli Lilly (consultant, September 2010), and Takeda Pharmaceuticals North America, and H. Lundbeck A/S (advisory board honoraria, October 2012); and past and potential future funding from Sunovion Pharmaceuticals Inc. (advisory board honoraria, Jan 2013). Dr Miklowitz has received research funding from the National Institute of Mental Health (NIMH), the National Association for Research on Schizophrenia and Depression (NARSAD), the Danny Alberts Foundation, the Attias Family Foundation, and the Robert L Sutherland Foundation; and book royalties from Guilford Press and John Wiley & Sons. Dr Davis is named as a co-inventor on a University of California provisional patent application entitled 'Methods of using (S)-Hydroxyzine and (R)-Hydroxyzine.' Dr Reddy, Dr Glahn, and Dr Lee have no conflicts of interests or disclosures. NR 50 TC 21 Z9 22 U1 5 U2 25 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD JAN PY 2014 VL 39 IS 2 BP 456 EP 463 DI 10.1038/npp.2013.218 PG 8 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA 274DM UT WOS:000328585400022 PM 23963117 ER PT J AU Duarte, VM Liu, YF Rafizadeh, S Tajima, T Nabili, V Wang, MB AF Duarte, Victor M. Liu, Yuan F. Rafizadeh, Sassan Tajima, Tracey Nabili, Vishad Wang, Marilene B. TI Comparison of Dental Health of Patients with Head and Neck Cancer Receiving IMRT vs Conventional Radiation SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY LA English DT Article DE dental health; radiation and dental health; IMRT and dental ID INTENSITY-MODULATED RADIOTHERAPY; THERAPY; XEROSTOMIA; DISEASE AB Objective To analyze the dental health of patients with head and neck cancer who received comprehensive dental care after intensity-modulated radiation therapy (IMRT) compared with radiation therapy (RT). Study Design Historical cohort study. Setting Veteran Affairs (VA) hospital. Subjects and Methods In total, 158 patients at a single VA hospital who were treated with RT or IMRT between 2003 and 2011 were identified. A complete dental evaluation was performed prior to radiation treatment, including periodontal probing, tooth profile, cavity check, and mobility. The dental treatment plan was formulated to eliminate current and potential dental disease. The rates of dental extractions, infections, caries, mucositis, xerostomia, and osteoradionecrosis (ORN) were analyzed, and a comparison was made between patients treated with IMRT and those treated with RT. Results Of the 158 patients, 99 were treated with RT and 59 were treated with IMRT. Compared with those treated with IMRT, significantly more patients treated with RT exhibited xerostomia (46.5% vs 16.9%; P < .001; odds ratio [OR], 0.24; 95% confidence interval [CI], 0.11-0.52), mucositis (46.5% vs 16.9%; P < .001; OR, 0.24; 95% CI, 0.11-0.52), and ORN (10.1% vs 0%; P = .014; OR, 0.07; 95% CI, 0.00-1.21). However, significantly more patients treated with IMRT were edentulous by the conclusion of radiation treatment (32.2% vs 11.1%; P = .002; OR, 3.8; 95% CI, 1.65-8.73). Conclusion Patients who were treated with IMRT had fewer instances of dental disease, more salivary flow, and fewer requisite posttreatment extractions compared with those treated with RT. The number of posttreatment extractions has been reduced with the advent of IMRT and more so with a complete dental evaluation prior to treatment. C1 [Duarte, Victor M.; Liu, Yuan F.; Rafizadeh, Sassan; Nabili, Vishad; Wang, Marilene B.] Univ Calif Los Angeles, David E Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Duarte, Victor M.; Tajima, Tracey; Nabili, Vishad; Wang, Marilene B.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Tajima, Tracey] Univ Calif Los Angeles, Sch Dent, Dept Oral Med, Los Angeles, CA 90095 USA. RP Duarte, VM (reprint author), Univ Calif Los Angeles, David E Geffen Sch Med, Dept Head & Neck Surg, Ctr Hlth Sci 62 132, Los Angeles, CA 90095 USA. EM vduarte@mednet.ucla.edu OI Liu, Yuan/0000-0002-8637-661X NR 12 TC 17 Z9 18 U1 1 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0194-5998 EI 1097-6817 J9 OTOLARYNG HEAD NECK JI Otolaryngol. Head Neck Surg. PD JAN PY 2014 VL 150 IS 1 BP 81 EP 86 DI 10.1177/0194599813509586 PG 6 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA 275QB UT WOS:000328690800013 PM 24145147 ER PT J AU Rasmussen, A Ice, JA Li, H Grundahl, K Kelly, JA Radfar, L Stone, DU Hefner, KS Anaya, JM Rohrer, M Gopalakrishnan, R Houston, GD Lewis, DM Chodosh, J Harley, JB Hughes, P Maier-Moore, JS Montgomery, CG Rhodus, NL Farris, AD Segal, BM Jonsson, R Lessard, CJ Scofield, RH Sivils, KLM AF Rasmussen, Astrid Ice, John A. Li, He Grundahl, Kiely Kelly, Jennifer A. Radfar, Lida Stone, Donald U. Hefner, Kimberly S. Anaya, Juan-Manuel Rohrer, Michael Gopalakrishnan, Rajaram Houston, Glen D. Lewis, David M. Chodosh, James Harley, John B. Hughes, Pamela Maier-Moore, Jacen S. Montgomery, Courtney G. Rhodus, Nelson L. Farris, A. Darise Segal, Barbara M. Jonsson, Roland Lessard, Christopher J. Scofield, R. Hal Sivils, Kathy L. Moser TI Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article DE Sjogren's syndrome; Classification; Diagnosis ID PREVALENCE; COMMUNITY; REGISTRY; TESTS AB Objective To compare the performance of the American-European Consensus Group (AECG) and the newly proposed American College of Rheumatology (ACR) classification criteria for Sjogren's Syndrome (SS) in a well-characterised sicca cohort, given ongoing efforts to resolve discrepancies and weaknesses in the systems. Methods In a multidisciplinary clinic for the evaluation of sicca, we assessed features of salivary and lacrimal gland dysfunction and autoimmunity as defined by tests of both AECG and ACR criteria in 646 participants. Global gene expression profiles were compared in a subset of 180 participants. Results Application of the AECG and ACR criteria resulted in classification of 279 and 268 participants with SS, respectively. Both criteria were met by 244 participants (81%). In 26 of the 35 AECG+/ACR participants, the minor salivary gland biopsy focal score was 1 (74%), while nine had positive anti-Ro/La (26%). There were 24 AECG-/ACR+ who met ACR criteria mainly due to differences in the scoring of corneal staining. All patients with SS, regardless of classification, had similar gene expression profiles, which were distinct from the healthy controls. Conclusions The two sets of classification criteria yield concordant results in the majority of cases and gene expression profiling suggests that patients meeting either set of criteria are more similar to other SS participants than to healthy controls. Thus, there is no clear evidence for increased value of the new ACR criteria over the old AECG criteria from the clinical or biological perspective. It is our contention, supported by this report, that improvements in diagnostic acumen will require a more fundamental understanding of the pathogenic mechanisms than is at present available. C1 [Rasmussen, Astrid; Ice, John A.; Li, He; Grundahl, Kiely; Kelly, Jennifer A.; Maier-Moore, Jacen S.; Montgomery, Courtney G.; Farris, A. Darise; Lessard, Christopher J.; Scofield, R. Hal; Sivils, Kathy L. Moser] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, Oklahoma City, OK 73104 USA. [Li, He; Houston, Glen D.; Lewis, David M.; Lessard, Christopher J.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA. [Radfar, Lida] Univ Oklahoma, Coll Dent, Dept Oral Diag & Radiol, Oklahoma City, OK USA. [Stone, Donald U.] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK USA. [Hefner, Kimberly S.] Hefner Eye Care & Opt Ctr, Oklahoma City, OK USA. [Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res CREA, Bogota, Colombia. [Rohrer, Michael] Univ Minnesota, Sch Dent, Hard Tissue Res Lab, Minneapolis, MN 55455 USA. [Gopalakrishnan, Rajaram] Univ Minnesota, Sch Dent, Dept Dev & Surg Sci, Div Oral Pathol, Minneapolis, MN 55455 USA. [Chodosh, James] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA. [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, Cincinnati, OH 45229 USA. [Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA. [Hughes, Pamela] Univ Minnesota, Sch Dent, Dept Dev & Surg Sci, Div Oral & Maxillofacial Surg, Minneapolis, MN 55455 USA. [Rhodus, Nelson L.] Univ Minnesota, Sch Dent, Dept Oral Surg, Minneapolis, MN 55455 USA. [Segal, Barbara M.] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA. [Jonsson, Roland] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway. [Jonsson, Roland] Haukeland Hosp, Dept Rheumatol, N-5021 Bergen, Norway. [Scofield, R. Hal] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA. [Scofield, R. Hal] Dept Vet Affairs Med Ctr, Oklahoma City, OK USA. RP Sivils, KLM (reprint author), Oklahoma Med Res Fdn, Arthrit & Clin Immunol Res Program, 825 NE 13th St,MS57, Oklahoma City, OK 73104 USA. EM sivilsk@omrf.org RI Anaya, Juan-Manuel/J-1960-2016 OI Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario, Biblioteca/0000-0003-3491-9392; Houston, Graeme/0000-0002-9786-7975 FU Phileona Foundation; Oklahoma Medical Research Foundation; [5R01 AR50782]; [P50 AR0608040]; [5U19 AI 082714]; [5R01 DE018209]; [5R37AI024717-22S1] FX This publication was made possible by grants 5R01 AR50782 (KLS), P50 AR0608040 (KLS, CJL, RHS, and ADF), 5U19 AI 082714 (KLS, CJL), 5R01 DE018209 (KLS, JBH), 5R37AI024717-22S1 (JBH, AR). The contents are the sole responsibility of the authors and do not necessarily represent the official views of the NIH. Additional funding was obtained from the Phileona Foundation (KLS) and the Oklahoma Medical Research Foundation (CJL and KLS). DUS received funding from an unrestricted grant from Research to Prevent Blindness to the University of Oklahoma Department of Ophthalmology. NR 30 TC 48 Z9 50 U1 1 U2 6 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD JAN PY 2014 VL 73 IS 1 BP 31 EP 38 DI 10.1136/annrheumdis-2013-203845 PG 8 WC Rheumatology SC Rheumatology GA 263VC UT WOS:000327835100011 PM 23968620 ER PT J AU Soulimane, S Simon, D Herman, WH Lange, C Lee, CMY Colagiuri, S Shaw, JE Zimmet, PZ Magliano, D Ferreira, SRG Dong, YH Zhang, L Jorgensen, T Tuomilehto, J Mohan, V Christensen, DL Kaduka, L Dekker, JM Nijpels, G Stehouwer, CDA Lantieri, O Fujimoto, WY Leonetti, DL McNeely, MJ Borch-Johnsen, K Boyko, EJ Vistisen, D Balkau, B AF Soulimane, Soraya Simon, Dominique Herman, William H. Lange, Celine Lee, Crystal M. Y. Colagiuri, Stephen Shaw, Jonathan E. Zimmet, Paul Z. Magliano, Dianna Ferreira, Sandra R. G. Dong, Yanghu Zhang, Lei Jorgensen, Torben Tuomilehto, Jaakko Mohan, Viswanathan Christensen, Dirk L. Kaduka, Lydia Dekker, Jacqueline M. Nijpels, Giel Stehouwer, Coen D. A. Lantieri, Olivier Fujimoto, Wilfred Y. Leonetti, Donna L. McNeely, Marguerite J. Borch-Johnsen, Knut Boyko, Edward J. Vistisen, Dorte Balkau, Beverley CA DETECT-2 Study Grp DESIR Study Grp TI HbA(1c), fasting and 2 h plasma glucose in current, ex- and never-smokers: a meta-analysis SO DIABETOLOGIA LA English DT Article DE FPG; HbA(1c); 2H-PG; Meta-analysis; Smoking ID CIGARETTE-SMOKING; INSULIN-RESISTANCE; DIABETES-MELLITUS; METABOLIC SYNDROME; HEMOGLOBIN A(1C); RISK-FACTORS; POPULATION; PREVALENCE; TOLERANCE; AUSDIAB AB Aims/Hypothesis The relationships between smoking and glycaemic variables have not been well explored. We compared HbA(1c), fasting plasma glucose (FPG) and 2 h plasma glucose (2H-PG) in current, ex-and never-smokers. Methods This meta-analysis used individual data from 16,886 men and 18,539 women without known diabetes in 12 DETECT-2 consortium studies and in the French Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) and Telecom studies. Means of three glycaemic variables in current, ex-and never-smokers were modelled by linear regression, with study as a random factor. The I 2 statistic was used to evaluate heterogeneity among studies. Results HbA(1c) was 0.10% (95% CI 0.08, 0.12) (1.1 mmol/mol [0.9, 1.3]) higher in current smokers and 0.03% (0.01, 0.05) (0.3 mmol/mol [0.1, 0.5]) higher in ex-smokers, compared with never-smokers. For FPG, there was no significant difference between current and never-smokers (-0.004 mmol/l [-0.03, 0.02]) but FPG was higher in ex-smokers (0.12 mmol/l [ 0.09, 0.14]). In comparison with never-smokers, 2H-PG was lower (-0.44 mmol/l [-0.52, -0.37]) in current smokers, with no difference for ex-smokers (0.02 mmol/l [-0.06, 0.09]). There was a large and unexplained heterogeneity among studies, with I-2 always above 50%; I-2 was little changed after stratification by sex and adjustment for age and BMI. In this study population, current smokers had a prevalence of diabetes that was 1.30% higher as screened by HbA(1c) and 0.52% lower as screened by 2H-PG, in comparison with never-smokers. Conclusion/interpretation Across this heterogeneous group of studies, current smokers had a higher HbA1c and lower 2H-PG than never-smokers. This will affect the chances of smokers being diagnosed with diabetes. C1 [Soulimane, Soraya; Simon, Dominique; Lange, Celine; Balkau, Beverley] INSERM, CESP U1018, F-94807 Villejuif, France. [Soulimane, Soraya; Lange, Celine; Balkau, Beverley] Univ Paris 11, UMRS 1018, Villejuif, France. [Simon, Dominique] Grp Hosp Pitie Salpetriere, Dept Diabet, F-75634 Paris, France. [Simon, Dominique] Univ Paris 06, Paris, France. [Herman, William H.] Univ Michigan, Ann Arbor, MI 48109 USA. [Lee, Crystal M. Y.; Colagiuri, Stephen; DETECT-2 Study Grp] Univ Sydney, Boden Inst Obes Nutr Exercise & Eating Disorders, Sydney, NSW 2006, Australia. [Shaw, Jonathan E.; Zimmet, Paul Z.; Magliano, Dianna] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia. [Ferreira, Sandra R. G.] Univ Sao Paulo, Sch Publ Hlth, Dept Nutr, Sao Paulo, Brazil. [Dong, Yanghu; Zhang, Lei] Qingdao Endocrine & Diabet Hosp, Dept Endocrinol & Metab, Qingdao, Peoples R China. [Dong, Yanghu; Zhang, Lei] Weifang Med Univ, Weifang, Peoples R China. [Jorgensen, Torben] Capital Reg Denmark, Res Ctr Prevent & Hlth, Glostrup, Denmark. [Tuomilehto, Jaakko] Danube Univ Krems, Krems, Austria. [Tuomilehto, Jaakko] Hosp Univ La Paz, Ctr Vasc Prevent Red RECAVA Grp, Madrid, Spain. [Tuomilehto, Jaakko] King Abdulaziz Univ, Jeddah 21413, Saudi Arabia. [Mohan, Viswanathan] Dr Mohans Diabet Special Ctr, Madras, Tamil Nadu, India. [Mohan, Viswanathan] Madras Diabet Res Fdn, Madras, Tamil Nadu, India. [Christensen, Dirk L.] Univ Copenhagen, Unit Int Hlth, Copenhagen, Denmark. [Kaduka, Lydia] KEMRI, Ctr Publ Hlth Res, Nairobi, Kenya. [Dekker, Jacqueline M.] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands. [Dekker, Jacqueline M.; Nijpels, Giel] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. [Nijpels, Giel] Vrije Univ Amsterdam Med Ctr, Dept Gen Practice & Elderly Care Med, Amsterdam, Netherlands. [Stehouwer, Coen D. A.] Maastricht Univ Med Ctr, Dept Internal Med, Maastricht, Netherlands. [Stehouwer, Coen D. A.] Maastricht Univ Med Ctr, Cardiovasc Res Inst Maastricht CARIM, Maastricht, Netherlands. [Lantieri, Olivier; DESIR Study Grp] IRSA, La Riche, France. [Fujimoto, Wilfred Y.; McNeely, Marguerite J.; Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA. [Leonetti, Donna L.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. [Borch-Johnsen, Knut] Holbaek Cent Hosp, Holbaek, Denmark. [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Vistisen, Dorte] Steno Diabet Ctr AS, Gentofte, Denmark. RP Balkau, B (reprint author), INSERM, CESP U1018, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France. EM beverley.balkau@inserm.fr RI Shaw, Jonathan/E-7388-2010 OI Shaw, Jonathan/0000-0002-6187-2203; Jorgensen, Torben/0000-0001-9453-2830; Boyko, Edward/0000-0002-3695-192X FU Australian National Health and Medical Research Council Training Fellowship; Paris-Sud University, France; Australian National Health and Medical Research Council Senior Research Fellowship; DANIDA; Cluster of International Health, University of Copenhagen FX The DETECT-2 project was undertaken on the initiative of the World Health Organization and the International Diabetes Federation. DETECT-2: Task Group. Stephen Colagiuri and Crystal M. Y. Lee (Australia), Knut Borch-Johnsen and Dorte Vistisen (Denmark), Beverley Balkau (France), Jacqueline M. Dekker (the Netherlands). Crystal M. Y. Lee was supported by an Australian National Health and Medical Research Council Training Fellowship. Soraya Soulimane was supported by a PhD grant from Paris-Sud University, France. Jonathan E. Shaw was supported by an Australian National Health and Medical Research Council Senior Research Fellowship. Dirk L. Christensen was supported by a DANIDA grant and by a grant from the Cluster of International Health, University of Copenhagen. NR 42 TC 15 Z9 16 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD JAN PY 2014 VL 57 IS 1 BP 30 EP 39 DI 10.1007/s00125-013-3058-y PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 270QG UT WOS:000328332900004 PM 24065153 ER PT J AU Sonnenberg, A AF Sonnenberg, Amnon TI Birth-cohort patterns in Crohn's disease and ulcerative colitis SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Article DE birth-cohort study; death rates; environmental risk factors; inflammatory bowel disease; time trends ID INFLAMMATORY-BOWEL-DISEASE; TIME TRENDS; PEPTIC-ULCER; MORTALITY; PERIOD; RATES; AGE AB AimTo test the long-term time trends of mortality from inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), for the presence of birth-cohort phenomena.MethodsWe analyzed mortality data from the national statistical offices of Canada, England and Wales, Italy, the Netherlands, Switzerland, and the USA for the past 60-80 years. Age-specific rates of death were plotted against the period of death, as period-age contours, and against the period of birth, as cohort-age contours.ResultsIn all six countries alike, the general time trends of IBD have been shaped by an underlying birth-cohort pattern. This pattern was also observed in the data of CD and UC analyzed separately. UC mortality increased in all generations born during the 19th century. It peaked among generations born shortly before the turn of the century and then decreased in all subsequent generations born throughout the 20th century. Compared with UC, the birth-cohort pattern of CD was delayed by 30-50 years.ConclusionIn addition to one risk factor responsible for the general occurrence of IBD and possibly UC alone, there exists at least one additional risk factor responsible for CD. Exposure to both separate risk factors must occur during early life. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins. C1 [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr, Portland, OR 97239 USA. RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol, Portland VA Med Ctr GI P3, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 12 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0954-691X EI 1473-5687 J9 EUR J GASTROEN HEPAT JI Eur. J. Gastroenterol. Hepatol. PD JAN PY 2014 VL 26 IS 1 BP 19 EP 25 DI 10.1097/01.meg.0000435547.11908.97 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 262UR UT WOS:000327763900004 PM 24216571 ER PT J AU Al Hazzouri, AZ Haan, MN Deng, YZ Neuhaus, J Yaffe, K AF Al Hazzouri, Adina Zeki Haan, Mary N. Deng, Yingzi Neuhaus, John Yaffe, Kristine TI Reduced Heart Rate Variability Is Associated With Worse Cognitive Performance in Elderly Mexican Americans SO HYPERTENSION LA English DT Article DE aging; autonomic nervous system diseases; cognition; epidemiology ID BLOOD-PRESSURE VARIABILITY; CARDIAC AUTONOMIC CONTROL; CARDIOVASCULAR RISK-FACTORS; SACRAMENTO-AREA-LATINO; MIDDLE-AGED MEN; MYOCARDIAL-INFARCTION; DIABETES-MELLITUS; ENGLISH-SPEAKING; NHANES-III; DISEASE AB Reduced heart rate variability is a strong predictor of cardiovascular risk factors, cardiovascular events, and mortality and thus may be associated with cognitive neurodegeneration. Yet, this has been relatively unexplored, particularly in minority populations with high cardiovascular burden. We used data from the Sacramento Area Latino Study on Aging to examine the cross-sectional association of reduced heart rate variability with cognitive function among elderly Mexican Americans. A total of 869 participants (mean age, 75 years; 59% women) had their 6-minute heart rate variability measured using an ECG monitor and respiration pacer in response to deep breathing. We used the mean circular resultant, known as R bar, as a measure of heart rate variability and categorized it into quartiles (Q1 to Q4 of R bar: reduced to high heart rate variability). Cognitive function was assessed using the modified Mini-Mental State Examination, a 100-point test of global cognitive function, and the Spanish and English verbal learning test, a 15-point test of verbal memory recall. In fully adjusted linear regression models, participants in quartile 1 had a 4-point lower modified Mini-Mental State Examination score (P<0.01), those in quartile 2 had a 2-point lower score (P=0.04), and those in quartile 3 had a 1-point lower score (P=0.35) compared with those in the highest quartile of R bar. Reduced R bar was not associated with verbal memory. Our results suggest that reduced heart rate variability is associated with worse performance on the test of global cognitive function, above and beyond traditional cardiovascular risk factors. C1 [Al Hazzouri, Adina Zeki; Haan, Mary N.; Neuhaus, John; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94107 USA. [Al Hazzouri, Adina Zeki; Haan, Mary N.; Neuhaus, John; Yaffe, Kristine] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94107 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94107 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94107 USA. [Deng, Yingzi] Univ Med & Dent New Jersey, Cardiovasc Inst, Newark, NJ 07103 USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. RP Al Hazzouri, AZ (reprint author), Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA. EM Adina.zekialhazzouri@ucsf.edu FU National Institute on Aging [AG12975, AG033751]; National Institute of Diabetes and Digestive and Kidney Diseases [DK60753]; American Heart Association/American Stroke Association/American Brain Foundation FX This work is supported by grants from the National Institute on Aging (AG12975, AG033751) and National Institute of Diabetes and Digestive and Kidney Diseases (DK60753). Dr Zeki Al Hazzouri is supported by the American Heart Association/American Stroke Association/American Brain Foundation Lawrence M. Brass, MD, Stroke Research Postdoctoral Fellowship. NR 44 TC 8 Z9 9 U1 2 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0194-911X EI 1524-4563 J9 HYPERTENSION JI Hypertension PD JAN PY 2014 VL 63 IS 1 BP 181 EP 187 DI 10.1161/HYPERTENSIONAHA.113.01888 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 268YM UT WOS:000328206800033 ER PT J AU Horning, SM Melrose, R Sultzer, D AF Horning, Sheena M. Melrose, Rebecca Sultzer, David TI Insight in Alzheimer's disease and its relation to psychiatric and behavioral disturbances SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE insight; Alzheimer's disease; dementia; apathy; depression ID NEUROBEHAVIORAL RATING-SCALE; NURSING-HOME PLACEMENT; IMPAIRED INSIGHT; DEPRESSIVE SYMPTOMS; COGNITIVE DEFICITS; APATHY; DEMENTIA; ANOSOGNOSIA; AWARENESS; RELIABILITY AB ObjectiveIndividuals suffering from Alzheimer's disease (AD) often have impaired awareness or a lack of insight into their cognitive deficits and functional abilities, especially in the later stages of the disease. Previous research has documented a relationship between depression and insight in AD, such that greater awareness of one's disease has been associated with a higher degree of depression. However, little is known about the relationship between insight, cognitive decline, and other psychiatric or behavioral problems associated with AD. MethodsThis study included 107 outpatients who met criteria for probable AD. Instruments included the Neurobehavioral Rating Scale, the Apathy Evaluation Scale, and the mini mental state exam. A series of hierarchical regression analyses were conducted to determine the relationship between insight and depressed mood, anxiety, psychosis, apathy, agitation, and behavioral retardation in AD patients after controlling for cognitive skills. ResultsInsight was found to significantly predict depressed mood, anxiety, and apathy even after controlling for global cognition. Greater insight was found to be associated with depressed mood and anxiety. However, impaired insight was associated with higher levels of apathy. ConclusionInsight may be differentially related to mood symptoms and apathy within AD, such that patients with intact insight are more depressed, whereas patients with impaired insight are more apathetic. This suggests that assessment of insight in AD may complement the clinical evaluation of depression and apathy in AD and help guide the most appropriate interventions. Published 2013. This article is a U.S. Government work and is in the public domain in the USA. C1 [Horning, Sheena M.; Melrose, Rebecca; Sultzer, David] VA Greater Los Angeles Healthcare Syst, Brain Behav & Aging Res Ctr, Los Angeles, CA USA. [Melrose, Rebecca; Sultzer, David] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Horning, SM (reprint author), VA Greater Los Angeles Healthcare Syst, Brain Behav & Aging Res Ctr, Los Angeles, CA USA. EM Sheena.Horning@va.gov OI Horning, Sheena/0000-0002-9704-0070 FU Department of Veterans Affairs (Office of Academic Affiliation); National Institute of Mental Health [MH56031] FX This project was supported in part by the Department of Veterans Affairs (Office of Academic Affiliation, Psychology Postdoctoral Training Program to Dr. Horning, Research Career Development Award to Dr. Melrose, and Merit Review Award to Dr. Sultzer) and the National Institute of Mental Health (#MH56031). NR 43 TC 12 Z9 14 U1 1 U2 17 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD JAN PY 2014 VL 29 IS 1 BP 77 EP 84 DI 10.1002/gps.3972 PG 8 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 263QP UT WOS:000327823400008 PM 23671016 ER PT J AU Nomura, Y Lambertini, L Rialdi, A Lee, M Mystal, EY Grabie, M Manaster, I Huynh, N Finik, J Davey, M Davey, K Ly, J Stone, J Loudon, H Eglinton, G Hurd, Y Newcorn, JH Chen, J AF Nomura, Yoko Lambertini, Luca Rialdi, Alexander Lee, MenJean Mystal, Elana Ying Grabie, Mordy Manaster, Isaac Huynh, Nancy Finik, Jackie Davey, Mia Davey, Kei Ly, Jenny Stone, Joanne Loudon, Holly Eglinton, Gary Hurd, Yasmin Newcorn, Jeffrey H. Chen, Jia TI Global Methylation in the Placenta and Umbilical Cord Blood From Pregnancies With Maternal Gestational Diabetes, Preeclampsia, and Obesity SO REPRODUCTIVE SCIENCES LA English DT Article DE global methylation; fetal programming; placenta; umbilical cord blood; gestational diabetes mellitus; preeclampsia; obesity; birth outcomes ID DNA METHYLATION; DEVELOPMENTAL ORIGINS; IN-UTERO; MELLITUS; EXPOSURE; MOTHERS; RISK; CHILDREN; MAMMALS; DISEASE AB Emerging evidence indicates that maternal medical risk during pregnancy, such as gestational diabetes mellitus (GDM), preeclampsia, and obesity, predisposes the offspring to suboptimal development. However, the underlying biological/epigenetic mechanism in utero is still unknown. The current pilot study (N = 50) compared the levels of global methylation in the placenta and umbilical cord blood among women with and without each risk condition (GDM, preeclampsia, and obesity) and explored whether the levels of global methylation were associated with fetal/infant growth. Results show that global methylation levels in the placenta were lower in patients with gestational diabetes (P = .003) and preeclampsia (P = .05) but higher with obesity (P = .01). Suggestive negative associations were found between global methylation level in the placenta and infant body length and head circumference. While preliminary, it is possible that the placenta tissue, but not umbilical cord blood, may be epigenetically programmed by maternal GDM, preeclampsia, and obesity to carry out its own specific functions that influence fetal growth. C1 [Nomura, Yoko; Mystal, Elana Ying; Grabie, Mordy; Huynh, Nancy; Finik, Jackie; Ly, Jenny] CUNY, Queens Coll, Dept Psychol, Flushing, NY 11376 USA. [Nomura, Yoko; Mystal, Elana Ying; Grabie, Mordy; Manaster, Isaac; Huynh, Nancy; Finik, Jackie; Davey, Mia; Davey, Kei; Ly, Jenny; Hurd, Yasmin; Newcorn, Jeffrey H.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Lambertini, Luca; Rialdi, Alexander; Chen, Jia] Mt Sinai Sch Med, Dept Prevent Med, New York, NY USA. [Lambertini, Luca; Lee, MenJean] Indiana Univ, Dept Obstet & Gynecol, Indianapolis, IN 46204 USA. [Stone, Joanne; Loudon, Holly] Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY USA. [Eglinton, Gary] Cornell Univ, Weill Med Coll, Dept Obstet & Gynecol, Flushing, NY USA. [Hurd, Yasmin] James J Peters VA Med Ctr, Bronx, NY USA. [Newcorn, Jeffrey H.; Chen, Jia] Mt Sinai Sch Med, Dept Pediat, New York, NY USA. [Chen, Jia] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY USA. RP Nomura, Y (reprint author), CUNY, Queens Coll, Dept Psychol, 65-30 Kissena Blvd, Flushing, NY 11376 USA. EM Yoko.Nomura@qc.cuny.edu OI Newcorn, Jeffrey /0000-0001-8993-9337 FU National Institutes of Health (NIH) from NIMH [K01 MH080062]; NCRR [P20 RR018728]; Queens College; CUNY Research Enhancement Grant; Venture Capital Research Funding Program of the Mount Sinai Children's Environmental Health Center FX The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: the National Institutes of Health (NIH) grants from the NIMH (K01 MH080062), the NCRR (P20 RR018728), Queens College, CUNY Research Enhancement Grant, and the Venture Capital Research Funding Program of the Mount Sinai Children's Environmental Health Center. NR 33 TC 23 Z9 27 U1 1 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 EI 1933-7205 J9 REPROD SCI JI Reprod. Sci. PD JAN PY 2014 VL 21 IS 1 BP 131 EP 137 DI 10.1177/1933719113492206 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 265CL UT WOS:000327927200014 PM 23765376 ER PT J AU Cerulli, C Bossarte, RM Dichter, ME AF Cerulli, Catherine Bossarte, Robert M. Dichter, Melissa E. TI Exploring Intimate Partner Violence Status Among Male Veterans and Associated Health Outcomes SO AMERICAN JOURNAL OF MENS HEALTH LA English DT Article DE intimate partner violence; veterans; mental health; physical health ID DOMESTIC VIOLENCE; MEN; PREVALENCE; EMERGENCY; COMPUTER; VICTIMS; WOMEN AB The World Health Organization has identified intimate partner violence (IPV) as a public health issue affecting both men and women, though significantly more information is available regarding female victimization. This study examines IPV through the lens of male victimization, focusing on a comparison of physical and mental health consequences among men who are and are not military veterans. Results from a secondary analysis of data from the Behavior Risk Factor Survey taken by 13,765 males indicated that all males, regardless of veteran status, should be screened for IPV victimization given the prevalence reported in this sample (9.5% to 12.5%). Furthermore, it was found that veteran status did affect prevalence of particular health consequences, such as depression, smoking, and binge drinking. Based on the specific comparisons examined in this study, implications for Veteran's Administration Health Services are discussed, as is the need for more research on IPV victimization rates for men and the particular health consequences that they suffer. C1 [Cerulli, Catherine; Bossarte, Robert M.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Bossarte, Robert M.] Canandaigua VA Med Ctr, Canandaigua, NY USA. [Dichter, Melissa E.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Cerulli, C (reprint author), Univ Rochester, Med Ctr, Dept Psychiat, 300 Crittenden Blvd, Rochester, NY 14642 USA. EM catherine_cerulli@urmc.rochester.edu NR 25 TC 5 Z9 5 U1 3 U2 15 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1557-9883 EI 1557-9891 J9 AM J MENS HEALTH JI Am. J. Mens Health PD JAN PY 2014 VL 8 IS 1 BP 66 EP 73 DI 10.1177/1557988313492558 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 266AB UT WOS:000327992900008 PM 23832953 ER PT J AU Abedi, A Velez, MI Echevarria, KL Restrepo, MI Anzueto, A Adams, SG AF Abedi, A. Velez, M. I. Echevarria, K. L. Restrepo, M. I. Anzueto, A. Adams, S. G. TI Severe Acute Respiratory Distress Syndrome (ards) Secondary To Sirolimus-Induced Pneumonitis In A Non-Transplant Patient SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Abedi, A.; Velez, M. I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Echevarria, K. L.; Restrepo, M. I.; Anzueto, A.; Adams, S. G.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A2285 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838201444 ER PT J AU Akgun, KM Tate, J Pisani, MA Butt, AA Gibert, CL Fried, T Huang, L Rodriguez-Barradas, MC Rimland, D Justice, AC Crothers, KA AF Akgun, K. M. Tate, J. Pisani, M. A. Butt, A. A. Gibert, C. L. Fried, T. Huang, L. Rodriguez-Barradas, M. C. Rimland, D. Justice, A. C. Crothers, K. A. TI Hospital Readmission And Incident Skilled Nursing Facility Placement In MICU Survivors From A Nationally Representative Cohort Of Hiv-Infected And Uninfected Veterans: 1996-2010 SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Akgun, K. M.; Tate, J.; Fried, T.; Justice, A. C.] Yale Univ, VA Connecticut West Haven, West Haven, CT USA. [Pisani, M. A.] Yale Univ, Sch Med, New Haven, CT USA. [Butt, A. A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Butt, A. A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Butt, A. A.] Sheikh Khalifa Med City, Abu Dhabi, U Arab Emirates. [Gibert, C. L.] VAMC, Washington, DC USA. [Gibert, C. L.] George Washington Univ, Washington, DC USA. [Huang, L.] UCSF, Div Pulm & Crit Care Med, San Francisco, CA USA. [Rodriguez-Barradas, M. C.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Rodriguez-Barradas, M. C.] Baylor Coll Med, Houston, TX 77030 USA. [Rimland, D.] Atlanta VA, Decatur, GA USA. [Rimland, D.] Emory Univ, Decatur, GA USA. [Crothers, K. A.] Univ Washington, Sch Med, Seattle, WA USA. EM kathleen.akgun@yale.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A4518 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838204012 ER PT J AU Atwood, CW Kuna, ST Little, KC Hin, S Gupta, R Gurubhagavatula, I Glick, H AF Atwood, C. W. Kuna, S. T. Little, K. C. Hin, S. Gupta, R. Gurubhagavatula, I. Glick, H. TI Cost-Effectiveness Of Home Management Of Obstructive Sleep Apnea: The Veterans Sleep Apnea Treatment Trial SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Atwood, C. W.; Little, K. C.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kuna, S. T.; Hin, S.; Gupta, R.; Gurubhagavatula, I.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Glick, H.] Univ Penn, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A3672 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838203044 ER PT J AU Betancourt, J Kafi, A Bonet, A Shapiro, S Oh, SS Zeidler, MR AF Betancourt, J. Kafi, A. Bonet, A. Shapiro, S. Oh, S. S. Zeidler, M. R. TI Resolution Of A Mobile Right Atrial Thrombus Complicating Acute Pulmonary Embolism With Low-Dose Tissue Plasminogen Activator In A Patient With Recent Craniotomy SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Betancourt, J.; Kafi, A.; Bonet, A.; Shapiro, S.; Oh, S. S.; Zeidler, M. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Betancourt, J.; Kafi, A.; Bonet, A.; Shapiro, S.; Oh, S. S.; Zeidler, M. R.] West Los Angeles VA Med Ctr, Los Angeles, CA USA. EM jaimebetancourt@yahoo.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A6462 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838206261 ER PT J AU Chen, Z Fan, V Belza, B Lee, J Borson, S Adams, SG Herting, J Kohen, R Matute-Bello, G Nguyen, HQ AF Chen, Z. Fan, V. Belza, B. Lee, J. Borson, S. Adams, S. G. Herting, J. Kohen, R. Matute-Bello, G. Nguyen, H. Q. TI Association Between Social Support And Physical Activity In Patients With COPD SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Chen, Z.; Belza, B.; Lee, J.; Borson, S.; Herting, J.; Kohen, R.] Univ Washington, Seatlle, WA USA. [Fan, V.; Matute-Bello, G.] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA. [Chen, Z.; Fan, V.; Matute-Bello, G.] Univ Washington, Seattle, WA 98195 USA. [Adams, S. G.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Nguyen, H. Q.] Kaiser Permanente Southern Calif, Pasadena, CA USA. EM Huong.Q2.Nguyen@kp.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A2451 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838201610 ER PT J AU Clark, BJ Ho, PJM Au, DH Bradley, KA Burnham, EL Moss, M AF Clark, B. J. Ho, P. -J. M. Au, D. H. Bradley, K. A. Burnham, E. L. Moss, M. CA NIH NHLBI ARDS Network TI Brief Versus Full Alcohol Use Disorders Identification Test For The Identification Of Alcohol Misuse In Critical Illness SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Clark, B. J.; Burnham, E. L.; Moss, M.] Univ Colorado Denver, Aurora, CO USA. [Ho, P. -J. M.] Denver VA Med Ctr, Denver, CO USA. [Au, D. H.] Univ Washington, VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98195 USA. [Bradley, K. A.] Grp Hlth Res Inst, Seattle, WA USA. EM brendan.clark@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A5144 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838204628 ER PT J AU Clark, BJ Rubinsky, AD Ho, P Au, DH Moss, M Bradley, KA AF Clark, B. J. Rubinsky, A. D. Ho, P. Au, D. H. Moss, M. Bradley, K. A. TI Alcohol Screening Scores And Risk Of Intensive Care Unit Admission In The Veterans Affairs Health System SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Clark, B. J.; Moss, M.] Univ Colorado Denver, Aurora, CO USA. [Rubinsky, A. D.] Hlth Serv Res Dev Northwest Ctr Exellence, Seattle, WA USA. [Ho, P.] Denver VA Med Ctr, Denver, CO USA. [Au, D. H.] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA. [Au, D. H.] Univ Washington, Seattle, WA 98195 USA. [Bradley, K. A.] Grp Hlth Res Inst, Seattle, WA USA. EM brendan.clark@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A2179 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838201338 ER PT J AU Collins, BF Feemster, LC Uman, J Au, DH AF Collins, B. F. Feemster, L. C. Uman, J. Au, D. H. TI Obesity And Smoking Status: COPD Patient Ratings Of Quality Of Care SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Collins, B. F.; Feemster, L. C.; Uman, J.; Au, D. H.] Univ Washington, Div Pulm & Crit Care, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Uman, J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM bfc3@uw.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A1085 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838200077 ER PT J AU Dada, L Sun, H Deiss-Yehiely, N Tokhtaeva, E Angulo, M Ardila, NG Garty, H Sznajder, JI Vagin, O AF Dada, L. Sun, H. Deiss-Yehiely, N. Tokhtaeva, E. Angulo, M. Ardila, N. Gabrieli Garty, H. Sznajder, J. I. Vagin, O. TI Fxyd5 Impairs Epithelial Barrier Function By Disrupting The Intercellular Interaction Between The Na,k-Atpase beta 1 Subunits SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Dada, L.; Sun, H.; Deiss-Yehiely, N.; Angulo, M.; Ardila, N. Gabrieli; Sznajder, J. I.] Northwestern Univ, Chicago, IL 60611 USA. [Tokhtaeva, E.; Vagin, O.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Dada, L.; Tokhtaeva, E.; Vagin, O.] Vet Adm Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Garty, H.] Weizmann Inst Sci, Rehovo, Israel. EM lauradada@northwestern.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A3438 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838202714 ER PT J AU De Cruz, SJ Dzierzewski, J Martin, JL Zeidler, MR AF De Cruz, S. J. Dzierzewski, J. Martin, J. L. Zeidler, M. R. TI Improved Continuous Positive Airway Pressure Adherence Following Cognitive Behavioral Therapy SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [De Cruz, S. J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dzierzewski, J.; Martin, J. L.] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, North Hills, CA USA. [Zeidler, M. R.] Univ Calif Los Angeles, WLA VA, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A5620 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838205240 ER PT J AU Joo, MJ Au, DH Fitzgibbon, M Bunyan, A Vinicky, M Lee, TA AF Joo, M. J. Au, D. H. Fitzgibbon, M. Bunyan, A. Vinicky, M. Lee, T. A. TI Comparative Effectiveness Of A COPD Assessment And Management Bundle Versus Usual Care: Baseline Characteristics SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Joo, M. J.; Fitzgibbon, M.; Bunyan, A.; Vinicky, M.; Lee, T. A.] Univ Illinois, Chicago, IL USA. [Au, D. H.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM joo@uic.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A3030 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838202307 ER PT J AU Martires, JS Girgis, GM Chen, J Hoo, GWS AF Martires, J. S. Girgis, G. M. Chen, J. Hoo, G. W. Soo TI Mycobacterium Xenopi Pleural Infection: Role Of Fdg-Pet Scan In Diagnosis SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract CT 108th International Congress of the American-Thoracic-Society CY MAY 16-21, 2014 CL San Diego, CA SP Amer Thorac Soc C1 [Martires, J. S.; Girgis, G. M.; Chen, J.; Hoo, G. W. Soo] VA Greater Los Angeles Healthcare Syst, West Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A1742 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838200730 ER PT J AU Melzer, AC Uman, J Au, DH AF Melzer, A. C. Uman, J. Au, D. H. TI Predictors Of Decreased Medication Adherence For Hypertensive Patients SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Uman, J.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Au, D. H.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM acmelzer@u.washington.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A1410 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838200399 ER PT J AU Mortensen, EM Murphy, J Bollinger, M Anzueto, A Fine, M AF Mortensen, E. M. Murphy, J. Bollinger, M. Anzueto, A. Fine, M. TI Electronic Medical Record Based Intervention To Reduce Length Of Stay For Veterans Hospitalized With Pneumonia SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Mortensen, E. M.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Murphy, J.; Bollinger, M.; Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Fine, M.] VA Pittsburgh Healthcare Syst 151 C, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A6237 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838206036 ER PT J AU Moseson, EM Slatore, CG Golden, SE AF Moseson, E. M. Slatore, C. G. Golden, S. E. TI Adherence To Fleischner Society Guidelines Among Veterans With Pulmonary Nodules In A Clinical Registry SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Moseson, E. M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Moseson, E. M.; Slatore, C. G.; Golden, S. E.] Portland VA Med Ctr, Portland, OR USA. EM emoseson@stanfordalumni.org NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A2251 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838201410 ER PT J AU Nguyen, HQ Lee, J Chen, Z Borson, S Adams, SG Herting, J Kohen, R Matute-Bello, G Fan, V AF Nguyen, H. Q. Lee, J. Chen, Z. Borson, S. Adams, S. G. Herting, J. Kohen, R. Matute-Bello, G. Fan, V. TI Associations Between Cognitive Functioning And Functional Status In COPD SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Nguyen, H. Q.] Kaiser Permanente Southern Calif, Pasadena, CA USA. [Lee, J.; Chen, Z.; Borson, S.; Herting, J.; Kohen, R.; Matute-Bello, G.] Univ Washington, Seattle, WA 98195 USA. [Adams, S. G.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Fan, V.] Univ Washington, VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A2447 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838201606 ER PT J AU Polverino, E Torres, A Sibila, O Ferrer, M Menendez, R Mensa, J Gabarrus, A Sellares, J Restrepo, MI Anzueto, A Niederman, M Agusti, C AF Polverino, E. Torres, A. Sibila, O. Ferrer, M. Menendez, R. Mensa, J. Gabarrus, A. Sellares, J. Restrepo, M. I. Anzueto, A. Niederman, M. Agusti, C. TI Corticosteroids In Severe Community-Acquired Pneumonia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Polverino, E.; Torres, A.; Ferrer, M.; Gabarrus, A.; Sellares, J.; Agusti, C.] CIBERES, Hosp Clin IDIBAPS, Barcelona, Spain. [Sibila, O.] Hosp Santa Creu & Sant Pau, Barcelona, Spain. [Menendez, R.] CIBERES, Hosp Univ Politecn La Fe, Valencia, Spain. [Mensa, J.] Hosp Clin Barcelona, Barcelona, Spain. [Restrepo, M. I.] Univ Texas Hlth Sci Ctr San Antonio, STVHCS, San Antonio, TX 78229 USA. [Anzueto, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. Winthrop Univ Hosp, Mineola, NY 11501 USA. EM epolveri@clinic.ub.es NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A5226 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838204710 ER PT J AU Rinne, ST Collins, BF Perkins, M Au, DH Liu, CF AF Rinne, S. T. Collins, B. F. Perkins, M. Au, D. H. Liu, C-F TI Weekend Discharges After COPD Hospitalizations Are Not Associated With A Higher Risk Of Readmission SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Rinne, S. T.; Au, D. H.] Univ Washington, Seattle, WA 98195 USA. [Rinne, S. T.; Collins, B. F.; Perkins, M.; Liu, C-F] VA Puget Sound Hlth Care Syst, Seattle, WA USA. EM srinne@uw.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A3717 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838203089 ER PT J AU Shahrir, S Rimlamd, D Brown, S Akgun, KM Wongtrakool, C Rodgriguez-Barradas, M Hoo, GS Sharafkhaneh, A Crothers, KA AF Shahrir, S. Rimlamd, D. Brown, S. Akgun, K. M. Wongtrakool, C. Rodgriguez-Barradas, M. Hoo, G. Soo Sharafkhaneh, A. Crothers, K. A. TI Abnormal Pulmonary Findings On CT Scan And Subsequent Smoking Behavior SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Shahrir, S.; Crothers, K. A.] Univ Washington, Seattle, WA 98195 USA. [Rimlamd, D.; Wongtrakool, C.] Atlanta VA Med Ctr, Atlanta, GA USA. [Brown, S.] James J Peters VA Med Ctr, New York, NY USA. [Akgun, K. M.] Yale Univ, VA Connecticut West Haven, West Haven, CT USA. [Wongtrakool, C.] Emory Univ, Atlanta, GA 30322 USA. [Rodgriguez-Barradas, M.; Sharafkhaneh, A.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Hoo, G. Soo] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Sharafkhaneh, A.] Baylor Coll Med, Houston, TX 77030 USA. EM sshahrir@uw.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A1078 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838200070 ER PT J AU Sheth, CT Hoo, GS AF Sheth, C. T. Hoo, G. Soo TI Catheter Related Bloodstream Infections: Differences Between Central Line And Picc Line Infections SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Sheth, C. T.; Hoo, G. Soo] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A3119 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838202396 ER PT J AU Slatore, CG Au, DH Golden, SE Ganzini, L AF Slatore, C. G. Au, D. H. Golden, S. E. Ganzini, L. TI Pulmonary Nodule Detection: Association Of Patient-Clinician Communication With Distress SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Slatore, C. G.; Au, D. H.; Golden, S. E.; Ganzini, L.] Portland VA Med Ctr, Portland, OR USA. EM christopher.slatore@va.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A1088 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838200080 ER PT J AU Sullivan, DR Pappas, M Humphrey, LL Slatore, CG AF Sullivan, D. R. Pappas, M. Humphrey, L. L. Slatore, C. G. TI Populations And Individuals: A Systematic Review Of The Psychosocial Impact Of Lung Cancer Screening With Computed Tomography On Patients SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Sullivan, D. R.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Pappas, M.; Humphrey, L. L.] Pacific Northwest Evidence Based Practice Ctr, Portland, OR USA. [Slatore, C. G.] Portland VA Med Ctr, Portland, OR USA. EM sullivad@ohsu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A6309 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838206108 ER PT J AU Wiener, RS Slatore, CG Bolton, R Koppelman, E Au, DH Clark, JA AF Wiener, R. S. Slatore, C. G. Bolton, R. Koppelman, E. Au, D. H. Clark, J. A. TI Attitudes Of Va Pulmonologists Towards Implementation Of Low Dose CT Screening For Lung Cancer: Results Of A National Survey SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Wiener, R. S.; Bolton, R.; Koppelman, E.; Clark, J. A.] Edith Nourse Rogers Mem VA Hosp, Bedford, MA USA. [Wiener, R. S.; Slatore, C. G.] Portland VA Med Ctr, Portland, OR USA. [Au, D. H.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. EM rwiener@bu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2014 VL 189 MA A2254 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V45TF UT WOS:000209838201413 ER PT J AU Waldrop, AE Cohen, BE AF Waldrop, Angela E. Cohen, Beth E. TI Trauma Exposure Predicts Alcohol, Nicotine, and Drug Problems Beyond the Contribution of PTSD and Depression in Patients with Cardiovascular Disease: Data from the Heart and Soul Study SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; SUBSTANCE USE DISORDERS; RISK-FACTORS; PSYCHOLOGICAL TRAUMA; YOUNG-ADULTS; HEALTH; ABUSE; COMORBIDITY; PREVALENCE; VETERANS AB Background and ObjectivesThis study examined the role of lifetime trauma exposure in a longitudinal study of adults with cardiovascular disease to determine the unique contribution of trauma exposure to risk for drug and alcohol problems and smoking. MethodsData were drawn from the Heart and Soul Study, a prospective cohort study designed to determine the mechanisms of associations between psychological factors and increased risk of cardiovascular events in high-risk patients (n=1,022). ResultsLifetime exposure to a higher number of trauma types predicted substance use outcomes beyond risk explained by PTSD and depression. In addition, across trauma types, interpersonal traumas were most strongly associated with substance use problems. ConclusionsOur results suggest that, though PTSD and depression play a role in the association between trauma exposure and substance use, many other factors also contribute; therefore focusing on these psychological comorbidities alone is not sufficient. Scientific SignificanceThe integration of mental health care and/or case management support with primary and specialty medical care may improve detection and treatment for patients with substance use and comorbid mental and physical health problems. Screening for trauma exposure is an important part of good clinical care. (Am J Addict 2014;23:53-61) C1 [Waldrop, Angela E.; Cohen, Beth E.] San Francisco VA Med Ctr, San Francisco, CA USA. [Waldrop, Angela E.; Cohen, Beth E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Waldrop, AE (reprint author), 4150 Clement St,116P, San Francisco, CA 94121 USA. EM angela.waldrop@ucsf.edu FU NHLBI NIH HHS [K23 HL 094765‐01, K23 HL094765, L30 HL104707, R01 HL079235]; NIDA NIH HHS [5K23DA018718‐05, K23 DA018718] NR 32 TC 3 Z9 3 U1 3 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD JAN PY 2014 VL 23 IS 1 BP 53 EP 61 DI 10.1111/j.1521-0391.2013.12053.x PG 9 WC Substance Abuse SC Substance Abuse GA 264RC UT WOS:000327897000009 PM 24313242 ER PT J AU Mehan, MR Williams, SA Siegfried, JM Bigbee, WL Weissfeld, JL Wilson, DO Pass, HI Rom, WN Muley, T Meister, M Franklin, W Miller, YE Brody, EN Ostroff, RM AF Mehan, Michael R. Williams, Stephen A. Siegfried, Jill M. Bigbee, William L. Weissfeld, Joel L. Wilson, David O. Pass, Harvey I. Rom, William N. Muley, Thomas Meister, Michael Franklin, Wilbur Miller, York E. Brody, Edward N. Ostroff, Rachel M. TI Validation of a blood protein signature for non-small cell lung cancer SO CLINICAL PROTEOMICS LA English DT Article DE Lung cancer; Biomarker; SOMAmer; Proteomic; Squamous cell carcinoma; Diagnosis; Preanalytic variability; Sample bias AB Background: CT screening for lung cancer is effective in reducing mortality, but there are areas of concern, including a positive predictive value of 4% and development of interval cancers. A blood test that could manage these limitations would be useful, but development of such tests has been impaired by variations in blood collection that may lead to poor reproducibility across populations. Results: Blood-based proteomic profiles were generated with SOMAscan technology, which measured 1033 proteins. First, preanalytic variability was evaluated with Sample Mapping Vectors (SMV), which are panels of proteins that detect confounders in protein levels related to sample collection. A subset of well collected serum samples not influenced by preanalytic variability was selected for discovery of lung cancer biomarkers. The impact of sample collection variation on these candidate markers was tested in the subset of samples with higher SMV scores so that the most robust markers could be used to create disease classifiers. The discovery sample set (n = 363) was from a multi-center study of 94 non-small cell lung cancer (NSCLC) cases and 269 long-term smokers and benign pulmonary nodule controls. The analysis resulted in a 7-marker panel with an AUC of 0.85 for all cases (68% adenocarcinoma, 32% squamous) and an AUC of 0.93 for squamous cell carcinoma in particular. This panel was validated by making blinded predictions in two independent cohorts (n = 138 in the first validation and n = 135 in the second). The model was recalibrated for a panel format prior to unblinding the second cohort. The AUCs overall were 0.81 and 0.77, and for squamous cell tumors alone were 0.89 and 0.87. The estimated negative predictive value for a 15% disease prevalence was 93% overall and 99% for squamous lung tumors. The proteins in the classifier function in destruction of the extracellular matrix, metabolic homeostasis and inflammation. Conclusions: Selecting biomarkers resistant to sample processing variation led to robust lung cancer biomarkers that performed consistently in independent validations. They form a sensitive signature for detection of lung cancer, especially squamous cell histology. This non-invasive test could be used to improve the positive predictive value of CT screening, with the potential to avoid invasive evaluation of nonmalignant pulmonary nodules. C1 [Mehan, Michael R.; Williams, Stephen A.; Brody, Edward N.; Ostroff, Rachel M.] SomaLogic Inc, Boulder, CO USA. [Siegfried, Jill M.] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA USA. [Weissfeld, Joel L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Pass, Harvey I.] NYU, Sch Med, Langone Med Ctr, New York, NY USA. [Pass, Harvey I.] NYU, Sch Med, Ctr Canc, New York, NY USA. [Rom, William N.] NYU, Sch Med, New York, NY USA. [Muley, Thomas; Meister, Michael] Univ Heidelberg Hosp, Thoraxklin, Heidelberg, Germany. [Muley, Thomas; Meister, Michael] TLRC H, Heidelberg, Germany. [Franklin, Wilbur; Miller, York E.] Univ Colorado, Sch Med, Ctr Canc, Aurora, CO USA. [Miller, York E.] Denver Vet Affairs Med Ctr, Denver, CO USA. RP Ostroff, RM (reprint author), SomaLogic Inc, Boulder, CO USA. EM rostroff@somalogic.com FU SPORE in Lung Cancer [P50 090440, U01CA86137, U01CA84968]; NCI Cancer Center Support Grant [5P30CA016056, 5P30CA047904, P30 CA46934]; NCI SPORE in Lung Cancer [P50 CA58187]; LUNGevity Foundation; SomaLogic FX SPORE in Lung Cancer P50 090440 (JMS, JWL, DOW, WLB), U01CA86137 (WR, HP), U01CA84968 (WLB), NCI Cancer Center Support Grant 5P30CA016056 (RPCI), and 5P30CA047904 (PITT), NCI SPORE in Lung Cancer P50 CA58187 (WF and YEM), NCI Cancer Center Support Grant, P30 CA46934 (WF and YEM) and an Early Detection Award from the LUNGevity Foundation (YEM).; SomaLogic funded the proteomic analysis. NR 54 TC 21 Z9 21 U1 2 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1542-6416 EI 1559-0275 J9 CLIN PROTEOM JI Clin. Proteom. PY 2014 VL 11 AR 32 DI 10.1186/1559-0275-11-32 PG 12 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA V42YR UT WOS:000209649600026 PM 25114662 ER PT J AU Hoggatt, KJ Greenland, S AF Hoggatt, Katherine J. Greenland, Sander TI Extending Organizational Schema for Causal Effects SO EPIDEMIOLOGY LA English DT Editorial Material ID MARGINAL STRUCTURAL MODELS; LOGISTIC-REGRESSION; INFERENCE; INTERFERENCE; COLLAPSIBILITY; LOST; BIAS; TOOL C1 [Hoggatt, Katherine J.] VA Greater Los Angeles Hlth Serv Res & Dev, Ctr Excellence, Sepulveda, CA USA. [Hoggatt, Katherine J.; Greenland, Sander] UCLA Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA. [Greenland, Sander] UCLA Coll Letters & Sci, Dept Stat, Los Angeles, CA USA. RP Hoggatt, KJ (reprint author), VA HSR&D Ctr Excellence Study Healthcare Provider, 16111 Plummer St 152, Sepulveda, CA 91343 USA. EM khoggatt@ucla.edu NR 42 TC 6 Z9 6 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2014 VL 25 IS 1 BP 98 EP 102 DI 10.1097/EDE.0000000000000023 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 268XW UT WOS:000328205200016 PM 24296927 ER PT J AU Bergman, J Litwin, MS AF Bergman, Jonathan Litwin, Mark S. TI The Henderson-Hasselbalch Equation for Urologists SO EUROPEAN UROLOGY LA English DT Editorial Material ID QUALITY-OF-LIFE; RADICAL PROSTATECTOMY; FOLLOW-UP; MORTALITY; TRIAL C1 [Bergman, Jonathan; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. [Bergman, Jonathan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bergman, Jonathan] Univ Calif Los Angeles, Robert Wood Johnson Fdn Clin Scholars Program, Los Angeles, CA 90095 USA. [Litwin, Mark S.] Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90095 USA. [Litwin, Mark S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. RP Litwin, MS (reprint author), Univ Calif Los Angeles, Dept Urol, Box 951738, Los Angeles, CA 90095 USA. EM mlitwin@mednet.ucla.edu NR 10 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 EI 1873-7560 J9 EUR UROL JI Eur. Urol. PD JAN PY 2014 VL 65 IS 1 BP 48 EP 49 DI 10.1016/j.eururo.2012.12.021 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 262VR UT WOS:000327766500015 PM 23291297 ER PT J AU Bader, HN Bierer, LM Lehrner, A Makotkine, I Daskalakis, NP Yehuda, R AF Bader, Heather N. Bierer, Linda M. Lehrner, Amy Makotkine, Iouri Daskalakis, Nikolaos P. Yehuda, Rachel TI Maternal age at Holocaust exposure and maternal PTSD independently influence urinary cortisol levels in adult offspring SO FRONTIERS IN ENDOCRINOLOGY LA English DT Article DE maternal; PTSD; risk; cortisol; intergenerational; Holocaust; offspring; trauma AB Background: Parental traumatization has been associated with increased risk for the expression of psychopathology in offspring, and maternal posttraumatic stress disorder (PTSD) appears to increase the risk for the development of offspring PTSD. In this study, Holocaust-related maternal age of exposure and PTSD were evaluated for their association with offspring ambient cortisol and PTSD-associated symptom expression. Method: Ninety-five Holocaust offspring and Jewish comparison subjects received diagnostic and psychological evaluations, and 24 h urinary cortisol was assayed by RIA. Offspring completed the parental PTSD questionnaire to assess maternal PTSD status. Maternal Holocaust exposure was identified as having occurred in childhood, adolescence, or adulthood and examined in relation to offspring psychobiology. Results: Urinary cortisol levels did not differ for Holocaust offspring and comparison subjects but differed significantly in offspring based on maternal age of exposure and maternal PTSD status. Increased maternal age of exposure and maternal PTSD were each associated with lower urinary cortisol in offspring, but did not exhibit a significant interaction. In addition, offspring PTSD-associated symptom severity increased with maternal age at exposure and PTSD diagnosis. A regression analysis of correlates of offspring cortisol indicated that both maternal age of exposure and maternal PTSD were significant predictors of lower offspring urinary cortisol, whereas childhood adversity and offspring PTSD symptoms were not. Conclusion: Offspring low cortisol and PTSD-associated symptom expression are related to maternal age of exposure, with the greatest effects associated with increased age at exposure. These effects are relatively independent of the negative consequences of being raised by a trauma survivor. These observations highlight the importance of maternal age of exposure in determining a psychobiology in offspring that is consistent with increased risk for stress-related pathology. C1 [Bader, Heather N.; Bierer, Linda M.; Lehrner, Amy; Makotkine, Iouri; Daskalakis, Nikolaos P.; Yehuda, Rachel] James J Peters VA Med Ctr, Bronx, NY USA. [Bader, Heather N.; Bierer, Linda M.; Lehrner, Amy; Makotkine, Iouri; Daskalakis, Nikolaos P.; Yehuda, Rachel] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. RP Yehuda, R (reprint author), Icahn Sch Med Mt Sinai, James J Peters Vet Affairs Med Ctr, Traumat Stress Studies Div, Dept Psychiat,Mental Hlth Care Ctr, 526 OOMH PTSD 116-A,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM rachel.yehuda@va.gov RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 FU National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1TR000067]; NIMH [R01 MH 64675-01]; [1RC1MH088101-01] FX This work was supported by 1RC1MH088101-01 "identification of an epigenetic risk marker for PTSD" and NIMH R01 MH 64675-01 "biology of risk and PTSD in Holocaust survivor offspring" and in part by the Grant Number #UL1TR000067 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The NIMH and NIH had no further role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the paper for publication. NR 34 TC 3 Z9 3 U1 1 U2 6 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2392 J9 FRONT ENDOCRINOL JI Front. Endocrinol. PY 2014 VL 5 AR 103 DI 10.3389/fendo.2014.00103 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA V44LF UT WOS:000209749800103 PM 25071719 ER PT J AU Daskalakis, NP Enthoven, L Schoonheere, E de Kloet, ER Oitzl, MS AF Daskalakis, Nikolaos P. Enthoven, Leo Schoonheere, Edwige de Kloet, Edo Ronald Oitzl, Melly S. TI Immediate Effects of Maternal Deprivation on the (Re)Activity of the HPA-Axis Differ in CD1 and C57B1/6J Mouse Pups SO FRONTIERS IN ENDOCRINOLOGY LA English DT Article DE hypothalamic pituitary adrenal axis; corticosterone; ACTH; CRH; GR; neonate; maternal deprivation; genetic AB The postnatal development of the mouse is characterized by a period of hypo responsiveness of the hypothalamic pituitary adrenal (HPA) axis to mild stressors. Maternal deprivation (MD) during this period can disrupt the quiescence of the HPA-axis. The present study examined the influence of strain (outbred CD1 vs. inbred C57BL/6J mice) on some central and peripheral components of the HPA-axis in neonatal mice (5-day-old) in the presence of their mother or after 24 h MD (on postnatal day 4) under basal or mild stressful conditions. In the presence of the dam, adrenal corticosterone (CORT) secretion was low in both mouse strains. Compared to CD1 mice, C57BL/6J had lower CORT levels associated with higher ACTH levels and ACTH/CORT ratio (i.e., lower adrenal sensitivity to ACTH), and higher glucocorticoid receptor (GR) mRNA expression in the paraventricular nucleus. Although MD disinhibited the HPA-axis in both strains as reflected by increased basal CORT and ACTH, we found a strain-dependent pattern. MD increased CORT more in C57BL/6J compared to CD1 mice together with a lower ACTH/CORT ratio (i.e., higher adrenal sensitivity to ACTH), while GR mRNA was no longer different in the two strains. However, this increased adrenal sensitivity in maternally deprived C57BL/6J mice was not reflected in their CORT response to a subsequent novelty stressor, possibly due to an MD-induced ceiling effect in their steroidogenic capacity. In conclusion, the immediate outcome of MD depends on the genetic background of the mother infant dyad, suggesting that maybe also the outcome in later-life cannot be generalized. C1 [Daskalakis, Nikolaos P.; Enthoven, Leo; Schoonheere, Edwige; de Kloet, Edo Ronald; Oitzl, Melly S.] Leiden Univ, Div Med Pharmacol, Leiden Acad Ctr Drug Res, Leiden, Netherlands. [Daskalakis, Nikolaos P.; de Kloet, Edo Ronald] Leiden Univ, Dept Endocrinol & Metab, Med Ctr, Leiden, Netherlands. [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, Traumat Stress Studies Div, New York, NY 10029 USA. [Daskalakis, Nikolaos P.] Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, One Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. [Daskalakis, Nikolaos P.] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, PTSD Res Program, Bronx, NY USA. [Oitzl, Melly S.] Univ Amsterdam, Swammerdam Inst Life Sci, Ctr Neurosci, Amsterdam, Netherlands. RP Daskalakis, NP (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Lab Mol Neuropsychiat, One Gustave L Levy Pl,Box 1668, New York, NY 10029 USA. EM nikolaos.daskalakis@mssm.edu RI Daskalakis, Nikolaos/B-7930-2014 OI Daskalakis, Nikolaos/0000-0003-1660-9112 FU Top Institute of Pharmaceutical Sciences [209]; NWO-NDRF/STIGON; Royal Netherlands Academy of Arts and Sciences; NWO-Aspasia; NWO-IRTG [95-420] FX This work was supported by the Top Institute of Pharmaceutical Sciences T5#209 (Edo Ronald de Kloet, Nikolaos P. Daskalakis), NWO-NDRF/STIGON (Leo Enthoven), Royal Netherlands Academy of Arts and Sciences (Edo Ronald de Kloet), NWO-Aspasia (Melly S. Oitzl), NWO-IRTG 95-420 (Melly S. Oitzl). NR 45 TC 3 Z9 3 U1 0 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2392 J9 FRONT ENDOCRINOL JI Front. Endocrinol. PY 2014 VL 5 AR 190 DI 10.3389/fendo.2014.00190 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA V44LF UT WOS:000209749800188 PM 25414695 ER PT J AU Ma, RS Bonnefond, S Morshed, SA Latif, R Davies, TF AF Ma, Risheng Bonnefond, Simon Morshed, Syed A. Latif, Rauf Davies, Terry F. TI Stemness is derived from thyroid cancer cells SO FRONTIERS IN ENDOCRINOLOGY LA English DT Article DE epithelial-mesenchymal transition; cancer stem cells; thyroid papillary carcinoma; celastrol; thyroid peroxidase; thyroglobulin; Braf AB Background: One hypothesis for thyroid cancer development is its derivation from thyroid cancer stem cells (CSCs). Such cells could arise via different paths including from mutated resident stem cells within the thyroid gland or via epithelial to mesenchymal transition (EMT) from malignant cells since EMT is known to confer stem-like characteristics. Furthermore, EMT is a critical process for epithelial tumor progression, local invasion, and metastasis formation. In addition, stemness provides cells with therapeutic resistance and is the likely cause of tumor recurrence. However, the relevance of EMT and stemness in thyroid cancer progression has not been extensively studied. Methods: To examine the status of stemness in thyroid papillary cancer, we employed a murine model of thyroid papillary carcinoma and examined the expression of stemness and EMT using qPCR and histochemistry in mice with a thyroid-specific knock-in of oncogenic Braf (LSI-Braf((v6ocE))/TPO-Cre). This construct is only activated at the time of thyroid peroxidase (TPO) expression in differentiating thyroid cells and cannot be activated by undifferentiated stem cells, which do not express TPO. Results:There was decreased expression of thyroid-specific genes such as Tg and NIS and increased expression of stemness markers, such as Oct4, Rex1, CD15, and Sox2 in the thyroid carcinoma tissue from 6-week-old BRAF(V600E) mice indicating the dedifferentiated status of the cells and the fact that stemness was derived in this model from differentiated thyroid cells. The decreased expression of the epithelial marker E-cadherin and increased EMT regulators including Snail, Slug, and TGF-beta 1 and TGF-beta 3, and the mesenchymal marker vimentin demonstrated the simultaneous progression of EMT and the CSC-like phenotype. Stemness was also found in a cancer thyroid cell line (named Marca cells) derived from one of the murine tumors. In this cell line, we also found that overexpression of Snail caused up-regulation of vimentin expression and up-regulation of stemness markers Oct4, Rex1, and CD15, with enhanced migration ability of the cells. We also showed that TGF-beta 1 was able to induce Snail and vimentin expression in the Marca cell thyroid cancer line, indicating the induction of EMT in these cells, and this induction of EMT and stemness was significantly inhibited by celastro a natural inhibitor of neoplastic cells. Conclusion: Our findings support our earlier hypothesis that stemness in thyroid cancer is derived via EMT rather than from resident thyroid stem cells. In mice with a thyroid-specific knock-in of oncogenic Braf (LSL-Braf(v(600E))/TPO-Cre), the neoplastic changes were dependent on thyroid cell differentiation and the onset of stemness must have been derived from differentiated thyroid epithelial cells. Furthermore, celastrol suppressed TGF-beta 1 induced EMT in thyroid cancer cells and may have therapeutic potential. C1 [Ma, Risheng; Morshed, Syed A.; Latif, Rauf; Davies, Terry F.] Icahn Sch Med Mt Sinai, Dept Med, Thyroid Res Unit, Room 2F-28,130 West Kingsbridge Rd, New York, NY 10468 USA. [Ma, Risheng; Morshed, Syed A.; Latif, Rauf; Davies, Terry F.] James J Peters VA Med Ctr, New York, NY 10468 USA. [Bonnefond, Simon] Reims Univ Med, Reims, France. RP Ma, RS (reprint author), Icahn Sch Med Mt Sinai, Dept Med, Thyroid Res Unit, Room 2F-28,130 West Kingsbridge Rd, New York, NY 10468 USA. EM risheng.ma@mssm.edu OI latif, rauf/0000-0002-4226-3728 FU National Institutes of Health [DK080459, DK069713, DK052464]; VA Merit Review Program; David Owen Segal Endowment Fund FX This work was supported in part by DK080459, DK069713, and DK052464 from the National Institutes of Health, the VA Merit Review Program and the David Owen Segal Endowment Fund. We thank all of our colleagues including Xiaoming Yin, Ramkumarie Baliram and Rejwan Ali for their help. NR 46 TC 7 Z9 7 U1 0 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2392 J9 FRONT ENDOCRINOL JI Front. Endocrinol. PY 2014 VL 5 AR 114 DI 10.3389/fendo.2014.00114 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA V44LF UT WOS:000209749800114 PM 25076938 ER PT J AU Elder, GA Stone, JR Ahlers, ST AF Elder, Gregory A. Stone, James R. Ahlers, Stephen T. TI Effects of low-level east exposure on the nervous system: is there really a controversy? SO FRONTIERS IN NEUROLOGY LA English DT Review DE animal models; blast; human studies; post-traumatic stress disorder; traumatic brain injury AB High-pressure blast waves can cause extensive CNS injury in human beings. However, in combat settings, such as Iraq and Afghanistan, lower level exposures associated with mild traumatic brain injury (mTBI) or subclinical exposure have been much more common. Yet controversy exists concerning what traits can be attributed to low-level blast, in large part due to the difficulty of distinguishing blast-related mTBI from post-traumatic stress disorder (PTSD). We describe how TBI is defined in human beings and the problems posed in using current definitions to recognize blast-related mTBI. We next consider the problem of applying definitions of human mTBI to animal models, in particular that TBI severity in human beings is defined in relation to alteration of consciousness at the time of injury, which typically cannot be assessed in animals. However, based on outcome assessments, a condition of "low-level" blast exposure can be defined in animals that likely approximates human mTBI or subclinical exposure. We review blast injury modeling in animals noting that inconsistencies in experimental approach have contributed to uncertainty over the effects of low-level blast. Yet, animal studies show that low-level blast pressure waves are transmitted to the brain. In brain, low-level blast exposures cause behavioral, biochemical, pathological, and physiological effects on the nervous system including the induction of PTSD-related behavioral traits in the absence of a psychological stressor. We review the relationship of blast exposure to chronic neurodegenerative diseases noting the paradoxical lowering of Abeta by blast, which along with other observations suggest that blast-related TBI is pathophysiologically distinct from non-blast TBI. Human neuroimaging studies show that blast-related mTBI is associated with a variety of chronic effects that are unlikely to be explained by co-morbid PTSD. We conclude that abundant evidence supports low-level blast as having long-term effects on the nervous system. C1 [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY 10468 USA. [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Stone, James R.] Univ Virginia, Dept Radiol, Charlottesville, VA USA. [Stone, James R.] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA. [Ahlers, Stephen T.] Naval Med Res Ctr, Dept Neurotrauma, Operat & Undersea Med Directorate, Silver Spring, MD USA. RP Elder, GA (reprint author), James J Peters Dept Vet Affairs Med Ctr, Neurol Serv 3E16, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM gregory.elder@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service [1I01RX000179-01, 1I01RX000996-01] FX The authors have received research support from the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Awards 1I01RX000179-01 and 1I01RX000996-01. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. Stephen T. Ahlers: I am a military service member (or employee of the U.S. Government). This work was prepared as part of my official duties. Title 17 U.S.C. 105 provides that copyright protection under this title is not available for any work of the United States Government. Title 17 U.S.C. 101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties. NR 212 TC 15 Z9 15 U1 0 U2 2 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2295 J9 FRONT NEUROL JI Front. Neurol. PY 2014 VL 5 AR 269 DI 10.3389/fneur.2014.00269 PG 22 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V42QW UT WOS:000209629300252 PM 25566175 ER PT J AU Stapleton-Kotloski, JR Kotloski, RJ Boggs, JA Popli, G O'Donovan, CA Couture, DE Cornell, C Godwin, DW AF Stapleton-Kotloski, Jennifer R. Kotloski, Robert J. Boggs, Jane A. Popli, Gautam O'Donovan, Cormac A. Couture, Daniel E. Cornell, Cassandra Godwin, Dwayne W. TI Localization of interictal epileptiorm activity using magnetoencephalography with synthetic aperture magnetometry in patients with a vagus nerve stimulator SO FRONTIERS IN NEUROLOGY LA English DT Article DE magnetoencephalography; synthetic aperture magnetometry; vagus nerve stimulator; epilepsy; epilepsy surgical evaluation AB Magnetoencephalography (MEG) provides useful and non-redundant information in the evaluation of patients with epilepsy, and in particular, during the pre-surgical evaluation of pharmaco-resistant epilepsy. Vagus nerve stimulation (VNS) is a common treatment for pharmaco-resistant epilepsy. However, interpretation of MEG recordings from patients with a VNS is challenging due to the severe magnetic artifacts produced by the VNS. We used synthetic aperture magnetometry (g2) [SAM(g2)], an adaptive beamformer that maps the excessive kurtosis, to map interictal spikes to the coregistered MRI image, despite the presence of contaminating VNS artifact. We present a series of eight patients with a VNS who underwent MEG recording. Localization of interictal epileptiform activity by SAM(g2) is compared to invasive electrophysiologic monitoring and other localizing approaches. While the raw MEG recordings were uninterpretable, analysis of the recordings with SAM(g2) identified foci of peak kurtosis and source signal activity that was unaffected by the VNS artifact. SAM(g2) analysis of MEG recordings in patients with a VNS produces interpretable results and expands the use of MEG for the pre-surgical evaluation of epilepsy. C1 [Stapleton-Kotloski, Jennifer R.; Boggs, Jane A.; Popli, Gautam; O'Donovan, Cormac A.; Cornell, Cassandra; Godwin, Dwayne W.] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, 1 Med Ctr Blvd, Winston Salem, NC 27103 USA. [Kotloski, Robert J.] William S Middleton Mem Vet Adm Med Ctr, Dept Neurol, Madison, WI USA. [Kotloski, Robert J.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI USA. [Couture, Daniel E.] Wake Forest Univ, Sch Med, Dept Neurosurg, Winston Salem, NC USA. [Godwin, Dwayne W.] Wake Forest Univ, Sch Med, Dept Neurobiol & Anat, Winston Salem, NC USA. RP Stapleton-Kotloski, JR (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, 1 Med Ctr Blvd, Winston Salem, NC 27103 USA. EM jstaplet@wakehealth.edu FU NIAAA [T32 AA-007565, RO1AA016852]; Wake Forest University School of Medicine Translational Science Institute Salisbury Veterans Administration Joint Pilot Award FX We would like to thank Valerie Woodard, Tanya Lassila, Scott Kuhn, Melissa Brown, and Sandra Griffin for their help and assistance. We would also like to thank the Epilepsy Center of Excellence for their support of this project. This work was funded by NIAAA T32 AA-007565 (Jennifer Rebecca Stapleton-Kotloski), Wake Forest University School of Medicine Translational Science Institute Salisbury Veterans Administration Joint Pilot Award (Jennifer Rebecca Stapleton-Kotloski, Dwayne W. Godwin), and NIAAA RO1AA016852 (Dwayne W. Godwin). NR 53 TC 0 Z9 0 U1 1 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 1664-2295 J9 FRONT NEUROL JI Front. Neurol. PY 2014 VL 5 AR 244 DI 10.3389/fneur.2014.00244 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA V42QW UT WOS:000209629300230 PM 25505894 ER PT J AU Guizzetti, M Zhang, XL Goeke, C Gavin, DP AF Guizzetti, Marina Zhang, Xiaolu Goeke, Calla Gavin, David P. TI Glia and neurodevelopment: focus on fetal alcohol spectrum disorders SO FRONTIERS IN PEDIATRICS LA English DT Review DE glia; astrocytes; oligodendrocytes; microglia; fetal alcohol spectrum disorders; neurodevelopment AB During the last 20 years, new and exciting roles for glial cells in brain development have been described. Moreover, several recent studies implicated glial cells in the pathogenesis of neurodevelopmental disorders including Down syndrome, Fragile X syndrome, Rett Syndrome, Autism Spectrum Disorders, and Fetal Alcohol Spectrum Disorders (FASD). Abnormalities in glial cell development and proliferation and increased glial cell apoptosis contribute to the adverse effects of ethanol on the developing brain and it is becoming apparent that the effects of fetal alcohol are due, at least in part, to effects on glial cells affecting their ability to modulate neuronal development and function. The three major classes of glial cells, astrocytes, oligodendrocytes, and microglia as well as their precursors are affected by ethanol during brain development. Alterations in glial cell functions by ethanol dramatically affect neuronal development, survival, and function and ultimately impair the development of the proper brain architecture and connectivity. For instance, ethanol inhibits astrocyte-mediated neuritogenesis and oligodendrocyte development, survival and myelination; furthermore, ethanol induces microglia activation and oxidative stress leading to the exacerbation of ethanol-induced neuronal cell death. This review article describes the most significant recent findings pertaining the effects of ethanol on glial cells and their significance in the pathophysiology of FASD and other neurodevelopmental disorders. C1 [Guizzetti, Marina; Zhang, Xiaolu; Goeke, Calla; Gavin, David P.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA. [Guizzetti, Marina; Zhang, Xiaolu; Goeke, Calla; Gavin, David P.] US Dept Vet Affairs, Jesse Brown VA Med Ctr, Chicago, IL USA. [Guizzetti, Marina] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. RP Guizzetti, M (reprint author), Jesse Brown VA Med Ctr, Res & Dev Sect, M-C 151,820 South Damen Ave, Chicago, IL 60612 USA. EM mguizzetti@psych.uic.edu FU National Institute of Alcoholism and Alcohol Abuse [AA021876] FX This study was supported in part by grant AA021876 from the National Institute of Alcoholism and Alcohol Abuse. The authors are extremely grateful to Mr. Jeff Frkonja for the graphic design of Figures 1, 3, and 4. NR 171 TC 22 Z9 23 U1 0 U2 1 PU FRONTIERS MEDIA SA PI LAUSANNE PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND SN 2296-2360 J9 FRONT PEDIATR JI Front. Pediatr. PY 2014 VL 2 AR 123 DI 10.3389/fped.2014.00123 PG 12 WC Pediatrics SC Pediatrics GA V46PX UT WOS:000209897200122 PM 25426477 ER PT J AU Nott, CR Neptune, RR Kautz, SA AF Nott, C. R. Neptune, R. R. Kautz, S. A. TI Relationships between frontal-plane angular momentum and clinical balance measures during post-stroke hemiparetic walking SO GAIT & POSTURE LA English DT Article DE Stability; Gait; Dynamic balance; Hemiparesis; Clinical measures ID DYNAMIC GAIT INDEX; ASSESSMENT TOOLS; OLDER-ADULTS; COMMUNITY; STROKE; INDIVIDUALS; FALLS; RELIABILITY; TREADMILL; VALIDITY AB Stroke has significant impact on dynamic balance during locomotion, with a 73% incidence rate for falls post-stroke. Current clinical assessments often rely on tasks and/or questionnaires that relate to the statistical probability of falls and provide little insight into the mechanisms that impair dynamic balance. Current quantitative measures that assess medial-lateral balance performance do not consider the angular motion of the body, which can be particularly impaired after stroke. Current control methods in bipedal robotics rely on the regulation of angular momentum (H) to maintain dynamic balance during locomotion. This study tests whether frontal-plane H is significantly correlated to clinical balance tests that could be used to provide a detailed assessment of medial-lateral balance impairments in hemiparetic gait. H was measured in post-stroke (n = 48) and control (n = 20) subjects. Post-stroke there were significant negative relationships between the change in frontal-plane H during paretic single-leg stance and two clinical tests: the Dynamic Gait Index (DGI) (r = -0.57, p < 0.001) and the Berg Balance Scale (BBS) (r = -0.54, p < 0.001). Control subjects showed timely regulation of frontal-plane H during the first half of single-leg stance, with the level of regulation depending on the initial magnitude. In contrast, the post-stroke subjects who made poorer adjustments to frontal-plane H during initial paretic leg single stance exhibited lower DGI and BBS scores (r = 0.45, p = 0.003). We conclude that H is a promising balance indicator during steady-state hemiparetic walking and that paretic single-leg stance is a period with higher instability for stroke patients. Published by Elsevier B.V. C1 [Nott, C. R.; Kautz, S. A.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29403 USA. [Neptune, R. R.] Univ Texas Austin, Dept Mech Engn, Austin, TX 78712 USA. [Kautz, S. A.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Kautz, SA (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St, Charleston, SC 29403 USA. EM kautz@musc.edu OI Kautz, Steven/0000-0003-3151-8235 FU NIH [R01 HD46820] FX Supported by NIH Grant R01 HD46820. NR 32 TC 10 Z9 10 U1 4 U2 18 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 EI 1879-2219 J9 GAIT POSTURE JI Gait Posture PD JAN PY 2014 VL 39 IS 1 BP 129 EP 134 DI 10.1016/j.gaitpost.2013.06.008 PG 6 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 259QS UT WOS:000327542000023 PM 23820449 ER PT J AU Cameron, M Mazumder, R Murchison, C King, L AF Cameron, Michelle Mazumder, Rajarshi Murchison, Charles King, Laurie TI Mini Balance Evaluation Systems Test in people with multiple sclerosis: Reflects imbalance but may not predict falls SO GAIT & POSTURE LA English DT Letter C1 [Cameron, Michelle] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Cameron, Michelle] Portland VA Med Ctr, Portland, OR USA. [Cameron, Michelle; Mazumder, Rajarshi; Murchison, Charles; King, Laurie] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Cameron, M (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L226, Portland, OR 97201 USA. EM cameromi@ohsu.edu NR 2 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0966-6362 EI 1879-2219 J9 GAIT POSTURE JI Gait Posture PD JAN PY 2014 VL 39 IS 1 BP 669 EP 669 DI 10.1016/j.gaitpost.2013.08.009 PG 1 WC Neurosciences; Orthopedics; Sport Sciences SC Neurosciences & Neurology; Orthopedics; Sport Sciences GA 259QS UT WOS:000327542000120 PM 24184138 ER PT J AU Ovretveit, J Hempel, S Magnabosco, JL Mittman, BS Rubenstein, LV Ganz, DA AF Ovretveit, John Hempel, Susanne Magnabosco, Jennifer L. Mittman, Brian S. Rubenstein, Lisa V. Ganz, David A. TI Guidance for research-practice partnerships (R-PPs) and collaborative research SO JOURNAL OF HEALTH ORGANIZATION AND MANAGEMENT LA English DT Article DE Knowledge sharing; Action research; Evidence-based practice; Research methods; Implementation; Research methodology AB Purpose - The purpose of this paper is to provide evidence based guidance to researchers and practice personnel about forming and carrying out effective research partnerships. Design/methodology/approach - A review of the literature, interviews and discussions with colleagues in both research and practice roles, and a review of the authors' personal experiences as researchers in partnership research. Findings - Partnership research is, in some respects, a distinct "approach" to research, but there are many different versions. An analysis of research publications and of their research experience led the authors to develop a framework for planning and assessing the partnership research process, which includes defining expected outcomes for the partners, their roles, and steps in the research process. Practical implications - This review and analysis provides guidance that may reduce commonly-reported misunderstandings and help to plan more successful partnerships and projects. It also identifies future research which is needed to define more precisely the questions and purposes for which partnership research is most appropriate, and methods and designs for specific types of partnership research. Originality/value - As more research moves towards increased participation of practitioners and patients in the research process, more precise and differentiated understanding of the different partnership approaches is required, and when each is most suitable. This article describes research approaches that have the potential to reduce "the research-practice gap". It gives evidence- and experience-based guidance for choosing and establishing a partnership research process, so as to improve partnership relationship-building and more actionable research. C1 [Ovretveit, John] Karolinska Inst, MMC, Stockholm, Sweden. [Hempel, Susanne; Rubenstein, Lisa V.; Ganz, David A.] RAND Corp, Santa Monica, CA USA. [Magnabosco, Jennifer L.] VA QUERI Calif Mental Hlth Serv Author, Los Angeles, CA USA. [Magnabosco, Jennifer L.] Yo San Univ Tradit Chinese Med, Los Angeles, CA USA. [Mittman, Brian S.; Rubenstein, Lisa V.; Ganz, David A.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Mittman, Brian S.; Rubenstein, Lisa V.] VA QUERI Ctr Implementat Practice & Res Support, Sepulveda, CA USA. [Mittman, Brian S.] Kaiser Permanente Southern Calif Dept Res & Evalu, Oakland, CA USA. [Rubenstein, Lisa V.; Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Ovretveit, J (reprint author), Karolinska Inst, MMC, Stockholm, Sweden. EM jovret@aol.com FU US Department of Veterans Affairs, Veterans Health Administration Quality Enhancement Research Initiative [TRA 08-379]; US Department of Veterans Affairs, Health Services Research and Development (HSRD) Service [VA CD2 08-012-1] FX This project was funded by the US Department of Veterans Affairs, Veterans Health Administration Quality Enhancement Research Initiative through core funding to the Center for Implementation Practice and Research Support (Project # TRA 08-379). Additional support for investigator time and visiting professorship was provided from the Medical Management Center, Karolinska Institutet, Stockholm, and by a Career Development Award to David Ganz from the US Department of Veterans Affairs, Health Services Research and Development (HSR&D) Service (Project #VA CD2 08-012-1). NR 34 TC 8 Z9 8 U1 0 U2 0 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND SN 1477-7266 EI 1758-7247 J9 J HEALTH ORGAN MANAG JI J. Health Organ. Manag. PY 2014 VL 28 IS 1 BP 115 EP 126 DI 10.1108/JHOM-08-2013-0164 PG 12 WC Health Policy & Services SC Health Care Sciences & Services GA V46NN UT WOS:000209891000007 PM 24783669 ER PT J AU Dzierzewski, JM AF Dzierzewski, Joseph M. TI Diversity in Late Life: Definitions, Implications, and Considerations INTRODUCTION SO CLINICAL GERONTOLOGIST LA English DT Editorial Material ID PSYCHOLOGY C1 [Dzierzewski, Joseph M.] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Dzierzewski, Joseph M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Dzierzewski, JM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 16111 Plummer St 11E, North Hills, CA 91343 USA. EM Joseph.Dzierzewski@va.gov NR 4 TC 0 Z9 0 U1 0 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0731-7115 EI 1545-2301 J9 CLIN GERONTOLOGIST JI Clin. Gerontol. PD JAN 1 PY 2014 VL 37 IS 1 SI SI BP 1 EP 3 DI 10.1080/07317115.2014.847308 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA 259FK UT WOS:000327512600001 ER PT J AU Hebert, EA Dugas, MJ Tulloch, TG Holowka, DW AF Hebert, Elizabeth A. Dugas, Michel J. Tulloch, Tyler G. Holowka, Darren W. TI Positive beliefs about worry: A psychometric evaluation of the Why Worry-II SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Generalized anxiety disorder; Worry; Positive beliefs about worry; Confirmatory factor analysis; Psychometrics ID GENERALIZED ANXIETY DISORDER; COGNITIVE MODEL; QUESTIONNAIRE; INVENTORY AB Positive beliefs about worry are theorized to maintain excessive and uncontrollable worry, the hallmark of generalized anxiety disorder (GAD; American Psychiatric Association, 2013). The Why Worry-II (WW-II) is a 25-item revised questionnaire designed to measure five positive beliefs about worry. These five beliefs are that worry: (1) facilitates problem solving; (2) enhances motivation; (3) protects against negative emotions; (4) prevents negative outcomes; and (5) reflects a positive personality trait. The main goal of this study was to assess the WW-II's psychometric properties, including its factor structure. Undergraduate participants (N = 309) completed the WW-II, and measures of worry, depression, anxiety, and positive and negative beliefs about worry. Overall, the results suggest that the five-factor model is a good fit to the data. The WW-II demonstrated excellent internal consistency, good test-retest reliability at six weeks, and evidence of convergent and divergent validity. The WW-II also uniquely predicted worry severity. Overall, our findings suggest that the WW-II has a five-factor structure congruent with theoretical predictions, sound psychometric properties, and a unique relationship to excessive worry. The theoretical and clinical implications of these findings are discussed. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Hebert, Elizabeth A.; Dugas, Michel J.] Concordia Univ, Dept Psychol, Montreal, PQ, Canada. [Dugas, Michel J.] Hop Sacre Coeur Montreal, Clin Troubles Anxieux, Montreal, PQ, Canada. [Tulloch, Tyler G.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada. [Holowka, Darren W.] US Dept Vet Affairs, Natl Ctr PTSD, Washington, DC USA. [Holowka, Darren W.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA. RP Dugas, MJ (reprint author), Univ Quebec Outaouais, Dept Psychoeduc & Psychol, POB 1250,Stn Hull, Gatineau, PQ J8X 3X7, Canada. EM michel.dugas@uqo.ca OI Dugas, Michel/0000-0003-2615-1782 NR 29 TC 4 Z9 4 U1 1 U2 21 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD JAN PY 2014 VL 56 BP 3 EP 8 DI 10.1016/j.paid.2013.08.009 PG 6 WC Psychology, Social SC Psychology GA 244VV UT WOS:000326419200001 ER PT B AU McNamee, S AF McNamee, Shane BE Murphy, D TI History of Amputation: From the Past to the Present SO FUNDAMENTALS OF AMPUTATION CARE AND PROSTHETICS LA English DT Article; Book Chapter C1 [McNamee, Shane] US Dept Vet Affairs, Hunter Holmes McGuire VA Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA. [McNamee, Shane] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA. RP McNamee, S (reprint author), US Dept Vet Affairs, Hunter Holmes McGuire VA Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-9362-8770-3 PY 2014 BP 1 EP 6 PG 6 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA BGT29 UT WOS:000324075500001 ER PT B AU McNamee, S AF McNamee, Shane BE Murphy, D TI Physical Exam SO FUNDAMENTALS OF AMPUTATION CARE AND PROSTHETICS LA English DT Article; Book Chapter C1 [McNamee, Shane] US Dept Vet Affairs, Hunter Holmes McGuire VA Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA. [McNamee, Shane] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA. RP McNamee, S (reprint author), US Dept Vet Affairs, Hunter Holmes McGuire VA Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU DEMOS MEDICAL PUBLICATIONS PI NEW YORK PA 11 WEST 42ND STREET, 15TH FLOOR, NEW YORK, NY 10036 USA BN 978-1-9362-8770-3 PY 2014 BP 7 EP 14 PG 8 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA BGT29 UT WOS:000324075500002 ER PT J AU Storage, S Mandelkern, MA Phuong, J Kozman, M Neary, MK Brody, AL AF Storage, Steven Mandelkern, Mark A. Phuong, Jonathan Kozman, Maggie Neary, Meaghan K. Brody, Arthur L. TI A positive relationship between harm avoidance and brain nicotinic acetylcholine receptor availability SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Harm avoidance; Temperament and Character Inventory; Tobacco; Nicotine dependence; Positron emission tomography; Nicotinic acetylcholine receptor ID POSITRON-EMISSION-TOMOGRAPHY; INDUCED DOPAMINE RELEASE; ANXIETY-LIKE BEHAVIOR; PERSONALITY-TRAITS; (S)-3-METHYL-5-(1-METHYL-2-PYRROLIDINYL)ISOXAZOLE ABT-418; PSYCHOBIOLOGICAL APPROACH; ANXIOLYTIC ACTIVITIES; CHARACTER INVENTORY; DORSAL HIPPOCAMPUS; CHOLINERGIC LIGAND AB Prior research indicates that disturbance of cholinergic neurotransmission reduces anxiety, leading to the hypothesis that people with heightened cholinergic function have a greater tendency toward anxiety-like and/or harm-avoidant behavior. We sought to determine if people with elevated levels of harm avoidance (HA), a dimension of temperament from the Temperament and Character Inventory (TCI), have high alpha 4 beta 2* nicotinic acetylcholine receptor (nAChR) availability. Healthy adults (n = 10 5; 47 non-smokers and 58 smokers) underwent bolus-plus-continuous infusion positron emission tomography (PET) scanning using the radiotracer 2-[8F]fluoro-3-(2(S)azetidinylmethoxy) pyridine (abbreviated as 2-FA). During the uptake period of 2-FA, participants completed the TCI The central study analysis revealed a significant association between total HA and mean nAChR availability, with higher total HA scores being linked with greater nAChR availability. In examining HA subscales, both 'Fear of Uncertainty' and 'Fatigability' were significant, based on higher levels of these characteristics being associated with greater nAChR availabilities. This study adds to a growing body of knowledge concerning the biological basis of personality and may prove useful in understanding the pathophysiology of psychiatric disorders (such as anxiety disorders) that have similar characteristics to HA. Study findings may indicate that heightened cholinergic neurotransmission is associated with increased anxiety-like traits. Published by Elsevier Ireland Ltd. C1 [Storage, Steven; Brody, Arthur L.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA. [Storage, Steven; Mandelkern, Mark A.; Phuong, Jonathan; Kozman, Maggie; Neary, Meaghan K.; Brody, Arthur L.] VA Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA. [Mandelkern, Mark A.] Univ Calif Irvine, Dept Phys, Irvine, CA 92717 USA. [Brody, Arthur L.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. RP Brody, AL (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 300 UCLA Med Plaza,Suite 2200, Los Angeles, CA 90095 USA. EM abrody@ucla.edu FU Tobacco Related Disease Research Program [19XT-0135]; National Institute on Drug Abuse [R01 DA20872]; Department of Veterans Affairs FX This study was supported by the Tobacco Related Disease Research Program (ALB. [19XT-0135]), the National Institute on Drug Abuse (A.L.B. [R01 DA20872]), and the Department of Veterans Affairs (Merit Review Award [A.L.B.I]). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The authors report no biomedical financial disclosures or potential conflicts of interest. NR 88 TC 4 Z9 4 U1 3 U2 82 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 EI 1872-7506 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD DEC 30 PY 2013 VL 214 IS 3 BP 415 EP 421 DI 10.1016/j.pscychresns.2013.07.010 PG 7 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 259MS UT WOS:000327531600031 PM 24148908 ER PT J AU Pavlin, JA Burkom, HS Elbert, Y Lucero-Obusan, C Winston, CA Cox, KL Oda, G Lombardo, JS Holodniy, M AF Pavlin, Julie A. Burkom, Howard S. Elbert, Yevgeniy Lucero-Obusan, Cynthia Winston, Carla A. Cox, Kenneth L. Oda, Gina Lombardo, Joseph S. Holodniy, Mark TI Combining Surveillance Systems: Effective Merging of US Veteran and Military Health Data SO PLOS ONE LA English DT Article ID INFLUENZA AB Background: The U. S. Department of Veterans Affairs (VA) and Department of Defense (DoD) had more than 18 million healthcare beneficiaries in 2011. Both Departments conduct individual surveillance for disease events and health threats. Methods: We performed joint and separate analyses of VA and DoD outpatient visit data from October 2006 through September 2010 to demonstrate geographic and demographic coverage, timeliness of influenza epidemic awareness, and impact on spatial cluster detection achieved from a joint VA and DoD biosurveillance platform. Results: Although VA coverage is greater, DoD visit volume is comparable or greater. Detection of outbreaks was better in DoD data for 58% and 75% of geographic areas surveyed for seasonal and pandemic influenza, respectively, and better in VA data for 34% and 15%. The VA system tended to alert earlier with a typical H3N2 seasonal influenza affecting older patients, and the DoD performed better during the H1N1 pandemic which affected younger patients more than normal influenza seasons. Retrospective analysis of known outbreaks demonstrated clustering evidence found in separate DoD and VA runs, which persisted with combined data sets. Conclusion: The analyses demonstrate two complementary surveillance systems with evident benefits for the national health picture. Relative timeliness of reporting could be improved in 92% of geographic areas with access to both systems, and more information provided in areas where only one type of facility exists. Combining DoD and VA data enhances geographic cluster detection capability without loss of sensitivity to events isolated in either population and has a manageable effect on customary alert rates. C1 [Pavlin, Julie A.] US Dept Def, Armed Forces Hlth Surveillance Ctr, Silver Spring, MD 20910 USA. [Burkom, Howard S.; Elbert, Yevgeniy; Lombardo, Joseph S.] Johns Hopkins Univ, Appl Phys Lab, Laurel, MD USA. [Lucero-Obusan, Cynthia; Winston, Carla A.; Oda, Gina] US Dept Vet Affairs, Off Publ Hlth, Washington, DC USA. [Cox, Kenneth L.] US Dept Def, US Army Inst Publ Hlth, Aberdeen Proving Ground, MD USA. RP Pavlin, JA (reprint author), US Dept Def, Armed Forces Hlth Surveillance Ctr, Silver Spring, MD 20910 USA. EM julie.a.pavlin.civ@mail.mil OI burkom, howard/0000-0003-0667-9467 FU Department of Veterans Affairs; Department of Defense FX This work was financially supported by intramural funding from the Departments of Veterans Affairs and Defense through the Joint Incentive Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 12 TC 5 Z9 5 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 26 PY 2013 VL 8 IS 12 AR e84077 DI 10.1371/journal.pone.0084077 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 281QS UT WOS:000329116700096 PM 24386335 ER PT J AU Smith, AK Lo, B Aronson, L AF Smith, Alexander K. Lo, Bernard Aronson, Louise TI Elder Self-Neglect - How Can a Physician Help? SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID ABUSE; RISK AB Clinicians often expend considerable effort caring for elderly patients who neglect their own needs. But there are some practical approaches to the clinical care of self-neglecting patients. Mr. L. is a 96-year-old widower with critical aortic stenosis and mild cognitive impairment who had become increasingly short of breath and exhausted over the course of several weeks and needed 3 hours to get dressed on the day of admission. A concerned neighbor brought him to the hospital. He is not a candidate for aortic-valve replacement owing to poor functional status and coexisting conditions, and after several days of gentle diuresis, he can barely walk across the room. At the request of the primary care physician, Mr. L.'s son flies in for a family meeting to discuss discharge options. ... C1 [Smith, Alexander K.; Aronson, Louise] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Lo, Bernard] Greenwall Fdn Bioeth, New York, NY USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. FU NIA NIH HHS [K23 AG040772, P30 AG044281] NR 10 TC 3 Z9 3 U1 0 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 26 PY 2013 VL 369 IS 26 BP 2476 EP 2479 DI 10.1056/NEJMp1310684 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 278BT UT WOS:000328863700005 PM 24369074 ER PT J AU Wheeler, SE Borenstein, JT Clark, AM Ebrahimkhani, M Fox, IJ Griffith, L Inman, W Lauffenburger, D Nguyen, T Pillai, VC Prantil-Baun, R Stolz, DB Taylor, D Ulrich, T Venkataramanan, R Wells, A Young, C AF Wheeler, Sarah E. Borenstein, Jeffrey T. Clark, Amanda M. Ebrahimkhani, Mohammed Fox, Ira J. Griffith, Linda Inman, Walker Lauffenburger, Douglas Transon Nguyen Pillai, Venkateswaran C. Prantil-Baun, Rachelle Stolz, Donna B. Taylor, Donald Ulrich, Theresa Venkataramanan, Raman Wells, Alan Young, Carissa TI All-human microphysical model of metastasis therapy SO STEM CELL RESEARCH & THERAPY LA English DT Review DE liver; mammary carcinoma; microenvironment; tumor dissemination ID SYSTEMS BIOLOGY; CIRCADIAN CLOCK; DORMANCY; CANCER; MORPHOGENESIS; INEFFICIENCY; PROGRESSION; SURVIVAL; CULTURES; RHYTHMS AB The vast majority of cancer mortalities result from distant metastases. The metastatic microenvironment provides unique protection to ectopic tumors as the primary tumors often respond to specific agents. Although significant interventional progress has been made on primary tumors, the lack of relevant accessible model in vitro systems in which to study metastases has plagued metastatic therapeutic development - particularly among micrometastases. A real-time, all-human model of metastatic seeding and cancer cells that recapitulate metastatic growth and can be probed in real time by a variety of measures and challenges would provide a critical window into the pathophysiology of metastasis and pharmacology of metastatic tumor resistance. To achieve this we are advancing our microscale bioreactor that incorporates human hepatocytes, human nonparenchymal liver cells, and human breast cancer cells to mimic the hepatic niche in three dimensions with functional tissue. This bioreactor is instrumented with oxygen sensors, micropumps capable of generating diurnally varying profiles of nutrients and hormones, while enabling real-time sampling. Since the liver is a major metastatic site for a wide variety of carcinomas and other tumors, this bioreactor uniquely allows us to more accurately recreate the human metastatic microenvironment and probe the paracrine effects between the liver parenchyma and metastatic cells. Further, as the liver is the principal site of xenobiotic metabolism, this reactor will help us investigate the chemotherapeutic response within a metabolically challenged liver microenvironment. This model is anticipated to yield markers of metastatic behavior and pharmacologic metabolism that will enable better clinical monitoring, and will guide the design of clinical studies to understand drug efficacy and safety in cancer therapeutics. This highly instrumented bioreactor format, hosting a growing tumor within a microenvironment and monitoring its responses, is readily transferable to other organs, giving this work impact beyond the liver. C1 [Wheeler, Sarah E.; Clark, Amanda M.; Taylor, Donald; Wells, Alan] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA. [Borenstein, Jeffrey T.; Transon Nguyen; Prantil-Baun, Rachelle] Charles Stark Draper Lab, Cambridge, MA 02139 USA. [Ebrahimkhani, Mohammed; Griffith, Linda; Inman, Walker; Lauffenburger, Douglas; Ulrich, Theresa; Young, Carissa] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. [Fox, Ira J.; Wells, Alan] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15203 USA. [Pillai, Venkateswaran C.; Venkataramanan, Raman] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Stolz, Donna B.] Univ Pittsburgh, Dept Surg, Dept Cell Biol, Pittsburgh, PA 15261 USA. [Taylor, Donald; Wells, Alan] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15219 USA. [Wells, Alan] VA Pittsburgh Healthcare Syst, Pittsburg VA Med Ctr, Pittsburgh, PA 15240 USA. RP Wells, A (reprint author), Univ Pittsburgh, Dept Pathol, 3550 Terrace St,S713 Scaife Hall, Pittsburgh, PA 15261 USA. EM wellsa@upmc.edu OI Clark, Amanda/0000-0003-1590-2560; Wells, Alan/0000-0002-1637-8150 FU NIH [1UH2TR000496-01, DARPA-BAA-11-73] FX Funding for publication of this article came from grants NIH 1UH2TR000496-01 (All-human Microphysical Model of Metastasis Therapy) and DARPA-BAA-11-73 (Microphysiological Systems: W911NF-12-2-0039 Barrier-Immune-Organ: Microphysiology, Microenvironment Engineered Tissue Construct Systems (BIO-MIMETICS)). NR 30 TC 10 Z9 10 U1 2 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1757-6512 J9 STEM CELL RES THER JI Stem Cell Res. Ther. PD DEC 20 PY 2013 VL 4 SU 1 AR S11 DI 10.1186/scrt372 PG 5 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 286DG UT WOS:000329444700012 PM 24565274 ER PT J AU Ranayhossaini, DJ Rodriguez, AI Sahoo, S Chen, BB Mallampalli, RK Kelley, EE Csanyi, G Gladwin, MT Romero, G Pagano, PJ AF Ranayhossaini, Daniel J. Rodriguez, Andres I. Sahoo, Sanghamitra Chen, Beibei B. Mallampalli, Rama K. Kelley, Eric E. Csanyi, Gabor Gladwin, Mark T. Romero, Guillermo Pagano, Patrick J. TI Selective Recapitulation of Conserved and Nonconserved Regions of Putative NOXA1 Protein Activation Domain Confers Isoform-specific Inhibition of Nox1 Oxidase and Attenuation of Endothelial Cell Migration SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Enzyme Inhibitors; Enzyme Mechanisms; NADPH Oxidase; Peptides; Reactive Oxygen Species (ROS); Nox1 ID NADPH OXIDASE; HYDROGEN-PEROXIDE; SUPEROXIDE GENERATION; NITRIC-OXIDE; OXYGEN; PEPTIDE; PEROXYNITRITE; HYPERTENSION; P67(PHOX); DIPHENYLENEIODONIUM AB Background: Nox1, an oxidant source in colon carcinoma and vascular disease, is activated by NOXA1. Results: A NOXA1 peptide blocked NOXA1-Nox1 binding and inhibited colon carcinoma and endothelial oxidants and migration. Conclusion: The findings identify a NOXA1-activating domain and an isoform-specific Nox1 inhibitor. Significance: The data provide insight into Nox1 regulation and present a potential therapy for suppressing oxidative stress-related disease. Excessive vascular and colon epithelial reactive oxygen species production by NADPH oxidase isoform 1 (Nox1) has been implicated in a number of disease states, including hypertension, atherosclerosis, and neoplasia. A peptide that mimics a putative activation domain of the Nox1 activator subunit NOXA1 (NOXA1 docking sequence, also known as NoxA1ds) potently inhibited Nox1-derived superoxide anion (O-radical anion) production in a reconstituted Nox1 cell-free system, with no effect on Nox2-, Nox4-, Nox5-, or xanthine oxidase-derived reactive oxygen species production as measured by cytochrome c reduction, Amplex Red fluorescence, and electron paramagnetic resonance. The ability of NoxA1ds to cross the plasma membrane was tested by confocal microscopy in a human colon cancer cell line exclusively expressing Nox1 (HT-29) using FITC-labeled NoxA1ds. NoxA1ds significantly inhibited whole HT-29 carcinoma cell-derived O-radical anion generation. ELISA and fluorescence recovery after photobleaching experiments indicate that NoxA1ds, but not its scrambled control, binds Nox1. FRET experiments conducted using Nox1-YFP and NOXA1-CFP illustrate that NoxA1ds disrupts the binding interaction between Nox1 and NOXA1, whereas a control peptide did not. Moreover, hypoxia-induced human pulmonary artery endothelial cell O-radical anion production was completely inhibited by NoxA1ds. Human pulmonary artery endothelial cell migration under hypoxic conditions was also reduced by pretreatment with NoxA1ds. Our data indicate that a peptide recapitulating a putative activation subdomain of NOXA1 (NoxA1ds) is a highly efficacious and selective inhibitor of Nox1 activity and establishes a critical interaction site for Nox1-NOXA1 binding required for enzyme activation. C1 [Ranayhossaini, Daniel J.; Rodriguez, Andres I.; Kelley, Eric E.; Csanyi, Gabor; Gladwin, Mark T.; Pagano, Patrick J.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA 15261 USA. [Ranayhossaini, Daniel J.; Rodriguez, Andres I.; Sahoo, Sanghamitra; Kelley, Eric E.; Csanyi, Gabor; Romero, Guillermo; Pagano, Patrick J.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA. [Chen, Beibei B.; Mallampalli, Rama K.; Gladwin, Mark T.] Univ Pittsburgh, Dept Pulm Allergy & Crit Care Med, Pittsburgh, PA 15261 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15240 USA. RP Pagano, PJ (reprint author), Univ Pittsburgh, BST E1247,200 Lothrop St, Pittsburgh, PA 15261 USA. EM pagano@pitt.edu FU National Institutes of Health [HL079207, HL096376, HL097376, HL098174, HL116472]; United States Department of Veterans Affairs FX This work was supported, in whole or in part, by National Institutes of Health Grant HL079207; Grants HL096376, HL097376, and HL098174 (to R. K. M.); and Grant HL116472 (to B. B. C.). This work was also supported by a merit review award from the United States Department of Veterans Affairs. This work is the subject of a pending United States patent application No. 61/560,075 titled "Novel Inhibitors of Nox1," on which D. J. R. and P. J. P. are listed as inventors. NR 57 TC 15 Z9 16 U1 0 U2 4 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD DEC 20 PY 2013 VL 288 IS 51 BP 36437 EP 36450 DI 10.1074/jbc.M113.521344 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 278IQ UT WOS:000328883400025 PM 24187133 ER PT J AU Wong, CA Davis, JC Asch, DA Shugerman, RP AF Wong, Charlene A. Davis, Jeremiah C. Asch, David A. Shugerman, Richard P. TI Political Tug-of-War and Pediatric Residency Funding SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID GRADUATE MEDICAL-EDUCATION AB The recent government shutdown led to effective defunding of the Children's Hospitals Graduate Medical Education (CHGME) Payment Program. The funding lapse highlights the danger of subjecting GME funding to a politicized process. On October 1, 2013, without a continuing resolution in place to support its budget, the U.S. federal government partially closed. One of many effects of the government shutdown was the defunding of the Children's Hospitals Graduate Medical Education (CHGME) Payment Program. Fifty-five freestanding children's hospitals currently receive CHGME funds. These hospitals train almost 30% of the general pediatricians, 44% of the pediatric medical and surgical subspecialists, and the majority of the pediatric physician-researchers in the United States.(1),(2) Capable of providing highly specialized care for pediatric patients with complex and acute conditions, freestanding children's hospitals are at the apex of ... C1 [Wong, Charlene A.; Asch, David A.] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Davis, Jeremiah C.; Shugerman, Richard P.] Seattle Childrens Hosp, Pediat Residency Program, Seattle, WA USA. [Davis, Jeremiah C.; Shugerman, Richard P.] Univ Washington, Sch Med, Seattle, WA USA. RP Wong, CA (reprint author), Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA. OI Asch, David/0000-0002-7970-286X NR 5 TC 1 Z9 1 U1 0 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 19 PY 2013 VL 369 IS 25 BP 2372 EP 2374 DI 10.1056/NEJMp1312898 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 274DQ UT WOS:000328586000004 PM 24171507 ER PT J AU Shlipak, MG Coresh, J Gansevoort, RT AF Shlipak, Michael G. Coresh, Josef Gansevoort, Ron T. TI Cystatin C versus Creatinine for Kidney Function-Based Risk SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Gansevoort, Ron T.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands. RP Shlipak, MG (reprint author), San Francisco VA Med Ctr, San Francisco, CA USA. EM ckdpc@jhmi.edu NR 0 TC 10 Z9 10 U1 0 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD DEC 19 PY 2013 VL 369 IS 25 BP 2459 EP 2459 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 274DQ UT WOS:000328586000023 PM 24350959 ER PT J AU Kostin, A McGinty, D Szymusiak, R Alam, MN AF Kostin, A. McGinty, D. Szymusiak, R. Alam, M. N. TI SLEEP-WAKE AND DIURNAL MODULATION OF NITRIC OXIDE IN THE PERIFORNICAL-LATERAL HYPOTHALAMIC AREA: REAL-TIME DETECTION IN FREELY BEHAVING RATS SO NEUROSCIENCE LA English DT Article DE perifornical-lateral hypothalamus; nitric oxide; sleep-wakefulness; sleep deprivation; NO sensor; Nafion (R)-modified Platinum electrode ID EYE-MOVEMENT SLEEP; MEDIAL PREFRONTAL CORTEX; BASAL FOREBRAIN NEURONS; EXTRACELLULAR LEVELS; S-NITROSYLATION; CEREBRAL-CORTEX; NERVOUS-SYSTEM; OREXIN NEURONS; MOVING RATS; CYCLE AB Nitric oxide (NO) has been implicated in the regulation of sleep. The perifornical-lateral hypothalamic area (PF-LHA) is a key wake-promoting region and contains neurons that are active during behavioral or cortical activation. Recently, we found higher levels of NO metabolites (NO.), an indirect measure of NO levels, in the PF-LHA during prolonged waking (SD). However, NO is highly reactive and diffuses rapidly and the NO assay is not sensitive enough to detect rapid-changes in NO levels across spontaneous sleep-waking states. We used a novel Nafion -modified Platinum (NF-PT) electrode for real-time detection of NO levels in the PF-LHA across sleep-wake cycles, dark-light phases, and during SD. Sprague-Dawley male rats were surgically prepared for chronic sleep-wake recording and implantation of NF-PT electrode into the PF-LHA. Electroencephalogram (EEG), electromyogram (EMG), and electrochemical current generated by NF-PT electrode were continuously acquired for 5-7 days including one day with 3 h of SD. In the PF-LHA, NO levels exhibited -. waking > rapid eye movement (REM) > non-rapid eye movement (nonREM) sleep pattern (0.56 0.03 AM > 0.47 0.02 j.i.M 0.02 ELM; p < 0.01). NO levels were also higher during the darkas compared to the light-phase (0.53 0.03 RM vs. 0.44 0.02 p.M; p < 0.01). NO levels increased during 3 h of SD as compared to undisturbed control (0.58 0.04 ELM vs. 0.47 0.01 p.M; p < 0.05). The findings indicate that in the PF-LHA, NO is produced during behavioral or cortical activation. Since elevated levels of NO inhibits most of the PF-LHA neurons that are active during cortical activation, these findings support a hypothesis that NO produced in conjunction with the activation of PF-LHA neurons during waking/SD, inhibits the same neuronal population to promote sleep. Published by Elsevier Ltd. on behalf of IBRO. C1 [Kostin, A.; McGinty, D.; Szymusiak, R.; Alam, M. N.] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Sepulveda, CA 91343 USA. [McGinty, D.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA. [Szymusiak, R.; Alam, M. N.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. RP Alam, MN (reprint author), VAGLAHS, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM noor@ucla.edu FU Medical Research Service; US Department of Veterans Affairs FX This work was supported by the Medical Research Service, US Department of Veterans Affairs. NR 60 TC 2 Z9 2 U1 0 U2 12 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD DEC 19 PY 2013 VL 254 BP 275 EP 284 DI 10.1016/j.neuroscience.2013.09.022 PG 10 WC Neurosciences SC Neurosciences & Neurology GA 255ZN UT WOS:000327279400024 PM 24056193 ER PT J AU Hoge, CW LeardMann, CA Boyko, EJ AF Hoge, Charles W. LeardMann, Cynthia A. Boyko, Edward J. TI Suicides Among Military Personnel Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID MILLENNIUM COHORT; US; COMBAT C1 [Hoge, Charles W.] Walter Reed Army Inst Res, Silver Spring, MD USA. [LeardMann, Cynthia A.] Naval Hlth Res Ctr, Deployment Hlth Res Dept, San Diego, CA 92106 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. RP LeardMann, CA (reprint author), Naval Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA. EM cynthia.leardmann@med.navy.mil OI Boyko, Edward/0000-0002-3695-192X NR 6 TC 2 Z9 2 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 18 PY 2013 VL 310 IS 23 BP 2565 EP 2566 DI 10.1001/jama.2013.282701 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 272ZZ UT WOS:000328503600031 PM 24346997 ER PT J AU Wylie, KP Tanabe, J Martin, LF Wongngamnit, N Tregellas, JR AF Wylie, Korey P. Tanabe, Jody Martin, Laura F. Wongngamnit, Narin Tregellas, Jason R. TI Nicotine Increases Cerebellar Activity during Finger Tapping SO PLOS ONE LA English DT Article ID ACETYLCHOLINE-RECEPTOR; SCHIZOPHRENIC-PATIENTS; NONSMOKERS; ATTENTION; BRAIN; ACTIVATION; FMRI; METAANALYSIS; MOVEMENTS; SLICES AB Nicotine improves performance on several cognitive and sensorimotor tasks. The neuronal mechanisms associated with these changes in performance are, however, largely unknown. Functional magnetic resonance imaging (fMRI) was used to examine the effect of nicotine on neuronal response in nineteen healthy subjects while they performed an auditory-paced finger tapping task. Subjects performed the task, after receiving either a nicotine patch or placebo treatment, in a single blind, crossover design. Compared to placebo, nicotine treatment increased response in the cerebellar vermis. Increased vermal activity, in the absence of changes in other task-related regions suggests specificity in nicotine's effects. C1 [Wylie, Korey P.; Tanabe, Jody; Martin, Laura F.; Wongngamnit, Narin; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80309 USA. [Tanabe, Jody] Univ Colorado, Dept Radiol, Aurora, CO 80309 USA. [Tregellas, Jason R.] Denver Vet Affairs Med Ctr, Eastern Colorado Hlth Syst, Res Serv, Res Serv 151, Denver, CO USA. RP Tregellas, JR (reprint author), Univ Colorado, Dept Psychiat, Anschutz Med Campus, Aurora, CO 80309 USA. EM Jason.Tregellas@UCDenver.edu RI Tregellas, Jason/J-3637-2015 FU Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service; National Institutes of Mental Health [MH-086383]; Brain and Behavior Research Foundation; Blowitz-Ridgeway Foundation FX This work was supported by the Veterans Administration Biomedical Laboratory and Clinical Science Research and Development Service, the National Institutes of Mental Health grant MH-086383, the Brain and Behavior Research Foundation, and the Blowitz-Ridgeway Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 31 TC 4 Z9 6 U1 0 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 17 PY 2013 VL 8 IS 12 AR e84581 DI 10.1371/journal.pone.0084581 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 276GT UT WOS:000328737700102 PM 24358367 ER PT J AU Nallamothu, BK Spertus, JA Lansky, AJ Cohen, DJ Jones, PG Kureshi, F Dehmer, GJ Drozda, JP Walsh, MN Brush, JE Koenig, GC Waites, TF Gantt, DS Kichura, G Chazal, RA O'Brien, PK Valentine, CM Rumsfeld, JS Reiber, JHC Elmore, JG Krumholz, RA Weaver, WD Krumholz, HM AF Nallamothu, Brahmajee K. Spertus, John A. Lansky, Alexandra J. Cohen, David J. Jones, Philip G. Kureshi, Faraz Dehmer, Gregory J. Drozda, Joseph P., Jr. Walsh, Mary Norine Brush, John E., Jr. Koenig, Gerald C. Waites, Thad F. Gantt, D. Scott Kichura, George Chazal, Richard A. O'Brien, Peter K. Valentine, C. Michael Rumsfeld, John S. Reiber, Johan H. C. Elmore, Joann G. Krumholz, Richard A. Weaver, W. Douglas Krumholz, Harlan M. TI Response to Letters Regarding Article, "Comparison of Clinical Interpretation With Visual Assessment and Quantitative Coronary Angiography in Patients Undergoing Percutaneous Coronary Intervention in Contemporary Practice: The Assessing Angiography (A2) Project" SO CIRCULATION LA English DT Letter ID FLOW RESERVE C1 [Nallamothu, Brahmajee K.] Ann Arbor VA Ctr Clin Management & Res, Ann Arbor, MI USA. [Spertus, John A.; Cohen, David J.; Jones, Philip G.; Kureshi, Faraz] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Lansky, Alexandra J.] Yale Univ, Sch Med, New Haven, CT USA. [Dehmer, Gregory J.; Gantt, D. Scott] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Temple, TX 76508 USA. [Drozda, Joseph P., Jr.] Mercy Hlth, St Louis, MO USA. [Walsh, Mary Norine] St Vincent Heart Ctr Indiana, Indianapolis, IN USA. [Brush, John E., Jr.] Sentara Cardiovasc Res Inst, Norfolk, VA USA. [Koenig, Gerald C.; Weaver, W. Douglas] Henry Ford Hlth Syst, Detroit, MI USA. [Waites, Thad F.] Forrest Gen, Hattiesburg, MS USA. [Kichura, George] Mercy Hlth Syst, St Louis, MO USA. [Chazal, Richard A.] Lee Mem Hlth Syst, Ft Myers, FL USA. [O'Brien, Peter K.; Valentine, C. Michael] Centra Lynchburg Gen Hosp, Lynchburg, VA USA. [Rumsfeld, John S.] Denver VA Med Ctr, Denver, CO USA. [Reiber, Johan H. C.] Leiden Univ, Med Ctr, Dept Radiol, Leiden, Netherlands. [Elmore, Joann G.] Univ Washington, Dept Med, Seattle, WA USA. [Krumholz, Richard A.] ImageCor, Bradenton, FL USA. [Krumholz, Harlan M.] Ctr Outcomes Res & Evaluat, New Haven, CT USA. RP Nallamothu, BK (reprint author), Ann Arbor VA Ctr Clin Management & Res, Ann Arbor, MI USA. NR 5 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD DEC 17 PY 2013 VL 128 IS 24 BP E463 EP E464 DI 10.1161/CIRCULATIONAHA.113.005507 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 271SB UT WOS:000328410800008 PM 24344070 ER PT J AU Dasgupta, SK Le, A Haudek, SB Entman, ML Rumbaut, RE Thiagarajan, P AF Dasgupta, Swapan K. Anhquyen Le Haudek, Sandra B. Entman, Mark L. Rumbaut, Rolando E. Thiagarajan, Perumal TI Rho Associated Coiled-Coil Kinase-1 Regulates Collagen-Induced Phosphatidylserine Exposure in Platelets SO PLOS ONE LA English DT Article ID BCL-X(L)-INHIBITORY BH3 MIMETICS; ACTIN STRESS FIBERS; PROTEIN-KINASE; SHAPE CHANGE; PROCOAGULANT RESPONSE; SIGNALING PATHWAYS; THROMBUS FORMATION; ROCK-II; PHOSPHORYLATION; CYTOSKELETON AB Background: The transbilayer movement of phosphatidylserine mediates the platelet procoagulant activity during collagen stimulation. The Rho-associated coiled-coil kinase (ROCK) inhibitor Y-27632 inhibits senescence induced but not activation induced phosphatidylserine exposure. To investigate further the specific mechanisms, we now utilized mice with genetic deletion of the ROCK1 isoform. Methods and Results: ROCK1-deficient mouse platelets expose significantly more phosphatidylserine and generate more thrombin upon activation with collagen compared to wild-type platelets. There were no significant defects in platelet shape change, aggregation, or calcium response compared to wild-type platelets. Collagen-stimulated ROCK1-deficient platelets also displayed decreased phosphorylation levels of Lim Kinase-1 and cofilin-1. However, there was no reduction in phosphorylation levels of myosin phosphatase subunit-1 (MYPT1) or myosin light chain (MLC). In an in vivo light/dye-induced endothelial injury/thrombosis model, ROCK1-deficient mice presented a shorter occlusion time in cremasteric venules when compared to wild-type littermates (3.16 +/- 1.33 min versus 6.6 +/- 2.6 min; p = 0.01). Conclusions: These studies define ROCK1 as a new regulator for collagen-induced phosphatidylserine exposure in platelets with functional consequences on thrombosis. This effect was downstream of calcium signaling and was mediated by Lim Kinase-1 / cofilin-1-induced cytoskeletal changes. C1 [Dasgupta, Swapan K.; Anhquyen Le; Rumbaut, Rolando E.; Thiagarajan, Perumal] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX 77030 USA. [Dasgupta, Swapan K.; Anhquyen Le; Thiagarajan, Perumal] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Haudek, Sandra B.; Entman, Mark L.; Rumbaut, Rolando E.; Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Rumbaut, Rolando E.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. RP Dasgupta, SK (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Ctr Translat Res Inflammatory Dis, Houston, TX 77030 USA. EM swapand@bcm.edu OI Thiagarajan, Perumal/0000-0003-2186-7036 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; National Institutes of Health [HL116524, HL089792]; National Blood Foundation FX This study was supported by grants from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development (to PT and RR), grants from National Institutes of Health (HL116524 to RR and PT; HL089792 to MLE and SBH) and by a grant from the National Blood Foundation (to SKD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 2 Z9 2 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 16 PY 2013 VL 8 IS 12 AR e84649 DI 10.1371/journal.pone.0084649 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 276GD UT WOS:000328735700164 PM 24358370 ER PT J AU Kluenemann, HH Nutt, JG Davis, MY Thomas, D AF Kluenemann, Hans H. Nutt, John G. Davis, Marie Y. Bird, Thomas D. TI Parkinsonism syndrome in heterozygotes for Niemann-Pick C1 SO JOURNAL OF THE NEUROLOGICAL SCIENCES LA English DT Article DE Parkinson disease; Niemann-Pick C disease; Parkinsonism; Genetics; Lysosomal storage; Gaucher disease ID DISEASE; GENE AB Niemann-Pick C (NPC) disease is a rare autosomal recessive lipid storage disorder. We report here the unique occurrence of three adult heterozygous carriers of mutations in the NPC1 gene who also have a parkinsonism syndrome. This suggests the possibility that mutations in NPC1 could be a risk factor for Parkinson's disease similar to the phenomenon that is now recognized with Gaucher disease and the glucocerebrosidase (GBA) gene. This report should be a stimulus for larger more detailed epidemiological studies. (c) 2013 Elsevier B.V. All rights reserved. C1 [Kluenemann, Hans H.] Univ Regensburg, Dept Psychiat, D-93053 Regensburg, Germany. [Nutt, John G.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Davis, Marie Y.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Bird, Thomas D.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. RP Thomas, D (reprint author), 1660 S Columbian Way,S-182-GRECC, Seattle, WA 98108 USA. EM tomnroz@uw.edu FU Veterans Affairs research and fellowship funds; National Parkinson Foundation; NIH; Michael J. Fox Foundation; Ceregene FX The authors acknowledge Veterans Affairs research and fellowship funds, National Parkinson Foundation, NIH, Michael J. Fox Foundation, and Ceregene. NR 7 TC 10 Z9 10 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0022-510X EI 1878-5883 J9 J NEUROL SCI JI J. Neurol. Sci. PD DEC 15 PY 2013 VL 335 IS 1-2 BP 219 EP 220 DI 10.1016/j.jns.2013.08.033 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 274HH UT WOS:000328596900040 PM 24035292 ER PT J AU Burk, M Moore, V Glassman, P Good, CB Emmendorfer, T Leadholm, TC Cunningham, F AF Burk, Muriel Moore, Von Glassman, Peter Good, Chester B. Emmendorfer, Thomas Leadholm, Thomas C. Cunningham, Francesca TI Medication-use evaluation with a Web application SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Article ID DRUG-USE EVALUATION; INTERVENTIONS; SYSTEM; TRIAL AB Purpose. A Web-based application for coordinating medication-use evaluation (MUE) initiatives within the Veterans Affairs (VA) health care system is described. Summary. The MUE Tracker (MUET) software program was created to improve VA's ability to conduct national medication-related interventions throughout its network of 147 medical centers. MUET initiatives are centrally coordinated by the VA Center for Medication Safety (VAMedSAFE), which monitors the agency's integrated databases for indications of suboptimal prescribing or drug therapy monitoring and adverse treatment outcomes. When a pharmacovigilance signal is detected,. VAMedSAFE identifies "trigger groups" of at-risk veterans and uploads patient lists to the secure MUET application, where locally designated personnel (typically pharmacists) can access and use the data to target risk-reduction efforts. Local data on patient-specific interventions are stored in a centralized database and regularly updated to enable tracking and reporting for surveillance and quality-improvement purposes; aggregated data can be further analyzed for provider education and benchmarking. In a three-year pilot project, the MUET program was found effective in promoting improved prescribing of erythropoiesis-stimulating agents (ESAs) and enhanced laboratory monitoring of ESA-treated patients in all specified trigger groups. The MUET initiative has since been expanded to target other high-risk drugs, and efforts are underway to refine the tool for broader utility. Conclusion. The MUET application has enabled the increased standardization of medication safety initiatives across the VA system and may serve as a useful model for the development of pharmacovigilance tools by other large integrated health care systems. C1 [Burk, Muriel; Cunningham, Francesca] VA Ctr Medicat Safety, Hines, IL 60141 USA. [Moore, Von] VA Northern Indiana Hlth Care Syst, VA Ctr Medicat Safety, Marion, IN USA. [Glassman, Peter] VA Greater Los Angeles Healthcare Syst, Div Gen Internal Med, VA Ctr Medicat Safety, West Los Angeles, CA USA. [Good, Chester B.] VA Pittsburgh Healthcare Syst, Div Gen Internal Med, VA Ctr Medicat Safety, Pittsburgh, PA USA. [Emmendorfer, Thomas] VA Pharm Benefits Management Serv, Hines, IL USA. [Leadholm, Thomas C.] VA Ctr Medicat Safety, VA Consolidated Mail Outpatient Pharm, Dexter, MI USA. RP Burk, M (reprint author), VA Ctr Medicat Safety, 1st Ave 1 Block North Cermak Rd,Bldg 37,Room 139, Hines, IL 60141 USA. EM muriel.burk@va.gov NR 16 TC 1 Z9 2 U1 0 U2 5 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 EI 1535-2900 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD DEC 15 PY 2013 VL 70 IS 24 BP 2226 EP 2234 DI 10.2146/ajhp130252 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 274ER UT WOS:000328589500011 PM 24296845 ER PT J AU Yu, CE Cudaback, E Foraker, J Thomson, Z Leong, L Lutz, F Gill, JA Saxton, A Kraemer, B Navas, P Keene, CD Montine, T Bekris, LM AF Yu, Chang-En Cudaback, Eiron Foraker, Jessica Thomson, Zachary Leong, Lesley Lutz, Franziska Gill, James Anthony Saxton, Aleen Kraemer, Brian Navas, Patrick Keene, C. Dirk Montine, Thomas Bekris, Lynn M. TI Epigenetic signature and enhancer activity of the human APOE gene SO HUMAN MOLECULAR GENETICS LA English DT Article ID ONSET ALZHEIMERS-DISEASE; HUMAN APOLIPOPROTEIN-E; CENTRAL-NERVOUS-SYSTEM; DNA METHYLATION; CPG-ISLANDS; COMPREHENSIVE ANALYSIS; TARGETED REPLACEMENT; TRANSGENIC MICE; E POLYMORPHISM; BRAIN AB The human apolipoprotein E (APOE) gene plays an important role in lipid metabolism. It has three common genetic variants, alleles epsilon 2/epsilon 3/epsilon 4, which translate into three protein isoforms of apoE2, E3 and epsilon 4. These isoforms can differentially influence total serum cholesterol levels; therefore, APOE has been linked with cardiovascular disease. Additionally, its 14 allele is strongly associated with the risk of Alzheimer's disease (AD), whereas the 12 allele appears to have a modest protective effect for AD. Despite decades of research having illuminated multiple functional differences among the three apoE isoforms, the precise mechanisms through which different APOE alleles modify diseases risk remain incompletely understood. In this study, we examined the genomic structure of APOE in search for properties that may contribute novel biological consequences to the risk of disease. We identify one such element in the epsilon 2/epsilon 3/epsilon 4 allele-carrying 3'-exon of APOE. We show that this exon is imbedded in a well-defined CpG island (CGI) that is highly methylated in the human postmortem brain. We demonstrate that this APOE CGI exhibits transcriptional enhancer/silencer activity. We provide evidence that this APOE CGI differentially modulates expression of genes at the APOE locus in a cell type-, DNA methylation-and epsilon 2/epsilon 3/epsilon 4 allele-specific manner. These findings implicate a novel functional role for a 3'-exon CGI and support a modified mechanism of action for APOE in disease risk, involving not only the protein isoforms but also an epigenetically regulated transcriptional program at the APOE locus driven by the APOE CGI. C1 [Yu, Chang-En; Foraker, Jessica; Thomson, Zachary; Leong, Lesley; Gill, James Anthony; Saxton, Aleen; Kraemer, Brian; Bekris, Lynn M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Yu, Chang-En; Foraker, Jessica; Lutz, Franziska; Kraemer, Brian; Bekris, Lynn M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Navas, Patrick] Univ Washington, Div Med Genet, Seattle, WA 98195 USA. [Cudaback, Eiron; Keene, C. Dirk; Montine, Thomas] Univ Washington, Dept Pathol, Div Neuropathol, Seattle, WA 98195 USA. RP Yu, CE (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. EM changeyu@uw.edu RI Keene, Christopher/N-1806-2015 FU US Department of Veterans Affairs Office of Research and Development Biomedical Laboratory Research Program; National Institute of Health/NIH [P50 AG05136, K99 AG34214, T32 AG000258]; Nancy and Buster Alvord Endowment FX This work was supported in part by the US Department of Veterans Affairs Office of Research and Development Biomedical Laboratory Research Program; the National Institute of Health/NIH grants (P50 AG05136, K99 AG34214, T32 AG000258); and the Nancy and Buster Alvord Endowment. NR 70 TC 21 Z9 22 U1 1 U2 19 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0964-6906 EI 1460-2083 J9 HUM MOL GENET JI Hum. Mol. Genet. PD DEC 15 PY 2013 VL 22 IS 24 BP 5036 EP 5047 DI 10.1093/hmg/ddt354 PG 12 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 259QY UT WOS:000327542600014 PM 23892237 ER PT J AU Perez, SE Raghanti, MA Hof, PR Kramer, L Ikonomovic, MD Lacor, PN Erwin, JM Sherwood, CC Mufson, EJ AF Perez, Sylvia E. Raghanti, Mary Ann Hof, Patrick R. Kramer, Lynn Ikonomovic, Milos D. Lacor, Pascale N. Erwin, Joseph M. Sherwood, Chet C. Mufson, Elliott J. TI Alzheimer's Disease Pathology in the Neocortex and Hippocampus of the Western Lowland Gorilla (Gorilla gorilla gorilla) SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE aging; amyloid; brain; evolution; great ape; mammals; pathology; tau ID CEREBRAL AMYLOID ANGIOPATHY; AGED SQUIRREL-MONKEYS; PROGRESSIVE SUPRANUCLEAR PALSY; MILD COGNITIVE IMPAIRMENT; PAIRED HELICAL FILAMENTS; CENTRAL-NERVOUS-SYSTEM; SENILE PLAQUES; NEUROFIBRILLARY TANGLES; A-BETA; BASAL FOREBRAIN AB The two major histopathologic hallmarks of Alzheimer's disease (AD) are amyloid beta protein (A) plaques and neurofibrillary tangles (NFT). A pathology is a common feature in the aged nonhuman primate brain, whereas NFT are found almost exclusively in humans. Few studies have examined AD-related pathology in great apes, which are the closest phylogenetic relatives of humans. In the present study, we examined A and tau-like lesions in the neocortex and hippocampus of aged male and female western lowland gorillas using immunohistochemistry and histochemistry. Analysis revealed an age-related increase in A-immunoreactive plaques and vasculature in the gorilla brain. A plaques were more abundant in the neocortex and hippocampus of females, whereas A-positive blood vessels were more widespread in male gorillas. Plaques were also A40-, A42-, and A oligomer-immunoreactive, but only weakly thioflavine S- or 6-CN-PiB-positive in both sexes, indicative of the less fibrillar (diffuse) nature of A plaques in gorillas. Although phosphorylated neurofilament immunostaining revealed a few dystrophic neurites and neurons, choline acetyltransferase-immunoreactive fibers were not dystrophic. Neurons stained for the tau marker Alz50 were found in the neocortex and hippocampus of gorillas at all ages. Occasional Alz50-, MC1-, and AT8-immunoreactive astrocyte and oligodendrocyte coiled bodies and neuritic clusters were seen in the neocortex and hippocampus of the oldest gorillas. This study demonstrates the spontaneous presence of both A plaques and tau-like lesions in the neocortex and hippocampus in old male and female western lowland gorillas, placing this species at relevance in the context of AD research. J. Comp. Neurol. 521:4318-4338, 2013. (c) 2013 Wiley Periodicals, Inc. C1 [Perez, Sylvia E.; Mufson, Elliott J.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Raghanti, Mary Ann] Kent State Univ, Dept Anthropol, Kent, OH 44242 USA. [Raghanti, Mary Ann] Kent State Univ, Sch Biomed Sci, Kent, OH 44242 USA. [Raghanti, Mary Ann] Cleveland Metroparks Zoo, Cleveland, OH 44109 USA. [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA. [Hof, Patrick R.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA. [Kramer, Lynn] Dallas Zoo Management, Dallas, TX 75203 USA. [Ikonomovic, Milos D.] Carnegie Mellon Univ, VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. [Ikonomovic, Milos D.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15213 USA. [Lacor, Pascale N.] Northwestern Univ, Dept Neurobiol, Evanston, IL 60208 USA. [Lacor, Pascale N.] Northwestern Univ, Cognit Neurol & Alzheimers Dis Ctr, Evanston, IL 60208 USA. [Erwin, Joseph M.; Sherwood, Chet C.] George Washington Univ, Dept Anthropol, Washington, DC 20052 USA. RP Mufson, EJ (reprint author), Rush Univ, Med Ctr, Chicago, IL 60612 USA. EM emufson@rush.edu FU National Science Foundation [BCS-0921079, BCS-0827531]; James S. McDonnell Foundation [22002078, 22002029]; National Institute of Aging [AG14308] FX Grant sponsor: National Science Foundation; Grant numbers: BCS-0921079 (to M. A. R.) and BCS-0827531 (to C. C. S.); Grant sponsor: James S. McDonnell Foundation; Grant numbers: 22002078 (to C. C. S., P. R. H) and 22002029 (to C. C. S.); Grant sponsor: National Institute of Aging; Grant number: AG14308 (to J.M.E.). NR 117 TC 17 Z9 17 U1 0 U2 31 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9967 EI 1096-9861 J9 J COMP NEUROL JI J. Comp. Neurol. PD DEC 15 PY 2013 VL 521 IS 18 BP 4318 EP 4338 DI 10.1002/cne.23428 PG 21 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA 240RI UT WOS:000326114300016 PM 23881733 ER PT J AU Sitek, KR Mathalon, DH Roach, BJ Houde, JF Niziolek, CA Ford, JM AF Sitek, Kevin R. Mathalon, Daniel H. Roach, Brian J. Houde, John F. Niziolek, Caroline A. Ford, Judith M. TI Auditory Cortex Processes Variation in Our Own Speech SO PLOS ONE LA English DT Article ID EVENT-RELATED POTENTIALS; COROLLARY DISCHARGE DYSFUNCTION; FEEDBACK-CONTROL; SENSORIMOTOR ADAPTATION; EVOKED-POTENTIALS; VOICE; PITCH; SCHIZOPHRENIA; RESPONSES; MANIPULATION AB As we talk, we unconsciously adjust our speech to ensure it sounds the way we intend it to sound. However, because speech production involves complex motor planning and execution, no two utterances of the same sound will be exactly the same. Here, we show that auditory cortex is sensitive to natural variations in self-produced speech from utterance to utterance. We recorded event-related potentials (ERPs) from ninety-nine subjects while they uttered "ah'' and while they listened to those speech sounds played back. Subjects' utterances were sorted based on their formant deviations from the previous utterance. Typically, the N1 ERP component is suppressed during talking compared to listening. By comparing ERPs to the least and most variable utterances, we found that N1 was less suppressed to utterances that differed greatly from their preceding neighbors. In contrast, an utterance's difference from the median formant values did not affect N1. Trial-to-trial pitch (f0) deviation and pitch difference from the median similarly did not affect N1. We discuss mechanisms that may underlie the change in N1 suppression resulting from trial-to-trial formant change. Deviant utterances require additional auditory cortical processing, suggesting that speaking-induced suppression mechanisms are optimally tuned for a specific production. C1 [Sitek, Kevin R.; Mathalon, Daniel H.; Roach, Brian J.; Ford, Judith M.] San Francisco VA Med Ctr, Mental Hlth Serv, San Francisco, CA USA. [Mathalon, Daniel H.; Niziolek, Caroline A.; Ford, Judith M.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Houde, John F.; Niziolek, Caroline A.] Univ Calif San Francisco, Dept Otolaryngol, San Francisco, CA 94143 USA. RP Sitek, KR (reprint author), Harvard Univ, Program Speech & Hearing Biosci & Technol, Div Med Sci, Boston, MA 02115 USA. EM sitek@fas.harvard.edu OI Roach, Brian/0000-0002-3264-1465; Niziolek, Caroline/0000-0002-6085-1371 FU University of California, San Francisco's Resource Allocation Program; Department of Veterans Affairs; National Institute of Mental Health [MH-58262, MH-076989]; National Institute on Deafness and Other Communication Disorders [R01-DC010145]; National Science Foundation [BCS-0926196]; National Institutes of Health [NRSA 1F32DC011249]; National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI [UL1 TR000004] FX This work was supported by a grant from the University of California, San Francisco's Resource Allocation Program, the Department of Veterans Affairs (Merit Review, Research Career Scientist: JF), the National Institute of Mental Health (MH-58262: JF, BR, DM, KS; MH-076989: JF, BR, DM, KS), the National Institute on Deafness and Other Communication Disorders (R01-DC010145: JH, CN), the National Science Foundation (BCS-0926196: JH, CN), the National Institutes of Health (NRSA 1F32DC011249: CN), and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR000004 (JF, DM). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 51 TC 9 Z9 9 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 13 PY 2013 VL 8 IS 12 AR e82925 DI 10.1371/journal.pone.0082925 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 276FP UT WOS:000328734200060 PM 24349399 ER PT J AU Valentim, CLL Cioli, D Chevalier, FD Cao, XH Taylor, AB Holloway, SP Pica-Mattoccia, L Guidi, A Basso, A Tsai, IJ Berriman, M Carvalho-Queiroz, C Almeida, M Aguilar, H Frantz, DE Hart, PJ LoVerde, PT Anderson, TJC AF Valentim, Claudia L. L. Cioli, Donato Chevalier, Frederic D. Cao, Xiaohang Taylor, Alexander B. Holloway, Stephen P. Pica-Mattoccia, Livia Guidi, Alessandra Basso, Annalisa Tsai, Isheng J. Berriman, Matthew Carvalho-Queiroz, Claudia Almeida, Marcio Aguilar, Hector Frantz, Doug E. Hart, P. John LoVerde, Philip T. Anderson, Timothy J. C. TI Genetic and Molecular Basis of Drug Resistance and Species-Specific Drug Action in Schistosome Parasites SO SCIENCE LA English DT Article ID HYCANTHONE RESISTANCE; PLASMODIUM-FALCIPARUM; MANSONI; OXAMNIQUINE; SULFOTRANSFERASE; MECHANISMS; LINKAGE; GENOME AB Oxamniquine resistance evolved in the human blood fluke (Schistosoma mansoni) in Brazil in the 1970s. We crossed parental parasites differing similar to 500-fold in drug response, determined drug sensitivity and marker segregation in clonally derived second-generation progeny, and identified a single quantitative trait locus (logarithm of odds = 31) on chromosome 6. A sulfotransferase was identified as the causative gene by using RNA interference knockdown and biochemical complementation assays, and we subsequently demonstrated independent origins of loss-of-function mutations in field-derived and laboratory-selected resistant parasites. These results demonstrate the utility of linkage mapping in a human helminth parasite, while crystallographic analyses of protein-drug interactions illuminate the mode of drug action and provide a framework for rational design of oxamniquine derivatives that kill both S. mansoni and S. haematobium, the two species responsible for >99% of schistosomiasis cases worldwide. C1 [Valentim, Claudia L. L.; Cao, Xiaohang; Taylor, Alexander B.; Holloway, Stephen P.; Carvalho-Queiroz, Claudia; Hart, P. John; LoVerde, Philip T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. [Valentim, Claudia L. L.; Cao, Xiaohang; Taylor, Alexander B.; Holloway, Stephen P.; Carvalho-Queiroz, Claudia; Hart, P. John; Anderson, Timothy J. C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Valentim, Claudia L. L.; Chevalier, Frederic D.; Almeida, Marcio; Anderson, Timothy J. C.] Texas Biomed Res Inst, San Antonio, TX 78245 USA. [Cioli, Donato; Pica-Mattoccia, Livia; Guidi, Alessandra; Basso, Annalisa] CNR, Inst Cell Biol & Neurobiol, Rome, Italy. [Tsai, Isheng J.; Berriman, Matthew] Wellcome Trust Sanger Inst, Hinxton, England. [Aguilar, Hector; Frantz, Doug E.] Univ Texas San Antonio, Dept Chem, San Antonio, TX 78249 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA. EM pjhart@biochem.uthscsa.edu; loverde@uthscsa.edu; tanderso@txbiomedgenetics.org RI CHEVALIER, Frederic/E-6852-2010; Tsai, Isheng/H-6606-2014 OI CHEVALIER, Frederic/0000-0003-2611-8106; Tsai, Isheng Jason/0000-0002-2123-5058 FU NIH [5R21-AI096277, 5R21-AI072704, R01-AI097576]; World Health Organization [HQNTD1206356]; Research Facilities Improvement Program Grant from National Center for Research Resources (NIH) [C06 RR013556]; Wellcome Trust [098051]; Robert A. Welch Foundation [AQ-1399]; NIH-National Institute of Allergy and Infectious Diseases [HHSN272201000005I]; University of Texas Health Science Center, San Antonio, Office of the Vice President for Research FX Funded by NIH (5R21-AI096277, 5R21-AI072704, R01-AI097576) and World Health Organization (HQNTD1206356) in facilities constructed with support from Research Facilities Improvement Program Grant (C06 RR013556) from National Center for Research Resources (NIH). Work at Wellcome Trust Sanger Institute was supported by the Wellcome Trust (grant 098051). P.J.H. was funded by the Robert A. Welch Foundation (AQ-1399). B. glabrata snails were supplied by Fred Lewis (Biomedical Research Institute, Rockville, MD) under NIH-National Institute of Allergy and Infectious Diseases contract no. HHSN272201000005I. We thank W. Le Clec'h and C. Valle (capillary sequencing), Z. Lai (RNA sequencing), N. Holroyd (coordinated genome sequencing), Q. Bickle (RNAi support), and G. Anderson (movie compilation). The X-ray Crystallography Core Laboratory is supported by the University of Texas Health Science Center, San Antonio, Office of the Vice President for Research. The authors declare no competing financial interests. Data deposition: Illumina sequence reads (www.ebi.ac.uk/ena/accession#ERP000160); GenBank accessions (KF733459-61), RNAseq data (www.ncbi.nlm.nih.gov/geo/, GSE51847), structural data (www.wwpdb.org/, accession 4MUA, 4MUB) NR 30 TC 31 Z9 32 U1 2 U2 44 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD DEC 13 PY 2013 VL 342 IS 6164 BP 1385 EP 1389 DI 10.1126/science.1243106 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 268UL UT WOS:000328196000055 PM 24263136 ER PT J AU Clark, KB AF Clark, Kevin B. TI Biotic activity of Ca2+-modulating non-traditional antimicrobial and -viral agents SO FRONTIERS IN MICROBIOLOGY LA English DT Editorial Material DE antiifective; bacteria; calcium channel blockers; drug design and development; pathogen toxins; probiotic; protozoa; viruses ID IMMUNODEFICIENCY-VIRUS TYPE-1; POLYAMINE-SENSITIVE-SITE; D-ASPARTATE RECEPTOR; TRYPANOSOMA-CRUZI; X-PROTEIN; ESCHERICHIA-COLI; REQUIRE FUNCTION; MAMMALIAN-CELLS; INFECTED-CELLS; CA2+ C1 [Clark, Kevin B.] Vet Affairs Greater Los Angeles Healthcare Syst, Res & Dev Serv, Los Angeles, CA USA. RP Clark, KB (reprint author), 4229 SE Harney St, Portland, OR USA. EM kbclarkphd@yahoo.com NR 51 TC 3 Z9 3 U1 2 U2 3 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-302X J9 FRONT MICROBIOL JI Front. Microbiol. PD DEC 12 PY 2013 VL 4 AR 381 DI 10.3389/fmicb.2013.00381 PG 4 WC Microbiology SC Microbiology GA AB1KO UT WOS:000331550600001 PM 24376441 ER PT J AU Lim, MM Elkind, J Xiong, GX Galante, R Zhu, JX Zhang, L Lian, J Rodin, J Kuzma, NN Pack, AI Cohen, AS AF Lim, Miranda M. Elkind, Jaclynn Xiong, Guoxiang Galante, Ray Zhu, Jingxu Zhang, Lin Lian, Jie Rodin, Julianna Kuzma, Nicholas N. Pack, Allan I. Cohen, Akiva S. TI Dietary Therapy Mitigates Persistent Wake Deficits Caused by Mild Traumatic Brain Injury SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID CHAIN AMINO-ACIDS; FLUID-PERCUSSION MODEL; SLEEP-DEPRIVATION; SUSTAINED ATTENTION; ALZHEIMERS-DISEASE; RATS; MICE; METABOLISM; WAKEFULNESS; PREVALENCE AB Sleep disorders are highly prevalent in patients with traumatic brain injury (TBI) and can significantly impair cognitive rehabilitation. No proven therapies exist to mitigate the neurocognitive consequences of TBI. We show that mild brain injury in mice causes a persistent inability to maintain wakefulness and decreases orexin neuron activation during wakefulness. We gave mice a dietary supplement of branched-chain amino acids (BCAAs), precursors for de novo glutamate synthesis in the brain. BCAA therapy reinstated activation of orexin neurons and improved wake deficits in mice with mild brain injury. Our data suggest that dietary BCAA intervention, acting in part through orexin, can ameliorate injury-induced sleep disturbances and may facilitate cognitive rehabilitation after brain injury. C1 [Lim, Miranda M.; Pack, Allan I.] Univ Penn, Perelman Sch Med, Dept Med, Div Sleep Med, Philadelphia, PA 19104 USA. [Lim, Miranda M.] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Lim, Miranda M.; Galante, Ray; Zhu, Jingxu; Zhang, Lin; Lian, Jie; Rodin, Julianna; Pack, Allan I.] Univ Penn, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Elkind, Jaclynn; Xiong, Guoxiang; Cohen, Akiva S.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA. [Kuzma, Nicholas N.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. [Cohen, Akiva S.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Lim, MM (reprint author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Div Hosp & Specialty Med, Sleep Disorders Lab, Portland, OR 92739 USA. EM lmir@ohsu.edu FU NIH [T32 HL007713, R01HL111725-01A1, R01NS069629, R01HD059288]; University of Pennsylvania Department of Medicine/Measey Research Fellowship FX Supported by NIH T32 HL007713 and University of Pennsylvania Department of Medicine/Measey Research Fellowship to M. M. L., NIH R01HL111725-01A1 to A.I P., and NIH R01NS069629 and R01HD059288 to A.S.C. NR 51 TC 15 Z9 15 U1 2 U2 12 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD DEC 11 PY 2013 VL 5 IS 215 AR 215ra173 DI 10.1126/scitranslmed.3007092 PG 12 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 275OA UT WOS:000328685500004 PM 24337480 ER PT J AU Lawson, KA Teteak, CJ Gao, JD Li, N Hacquebord, J Ghatan, A Zielinska-Kwiatkowska, A Song, GC Chansky, HA Yang, L AF Lawson, Kevin A. Teteak, Colin J. Gao, Jidi Li, Ning Hacquebord, Jacques Ghatan, Andrew Zielinska-Kwiatkowska, Anna Song, Guangchun Chansky, Howard A. Yang, Liu TI ESET histone methyltransferase regulates osteoblastic differentiation of mesenchymal stem cells during postnatal bone development SO FEBS LETTERS LA English DT Article DE Epigenetic regulation; Osteoblast differentiation; Mesenchymal stem cell; Bone development ID GROWTH-PLATE; INTERACTS; CHONDROCYTES; EXPRESSION; MATURATION; H3-K9; RUNX2 AB To investigate the effects of histone methyltransferase ESET (also known as SETDB1) on bone metabolism, we analyzed osteoblasts and osteoclasts in ESET knockout animals, and performed osteogenesis assays using ESET-null mesenchymal stem cells. We found that ESET deletion severely impairs osteoblast differentiation but has no effect on osteoclastogenesis, that co-transfection of ESET represses Runx2-mediated luciferase reporter while siRNA knockdown of ESET activates the luciferase reporter in mesenchymal cells, and that ESET is required for postnatal expression of Indian hedgehog protein in the growth plate. As the bone phenotype in ESET-null mice is 100% penetrant, these results support ESET as a critical regulator of osteoblast differentiation during bone development. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. C1 [Lawson, Kevin A.; Teteak, Colin J.; Gao, Jidi; Hacquebord, Jacques; Ghatan, Andrew; Zielinska-Kwiatkowska, Anna; Chansky, Howard A.; Yang, Liu] Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98195 USA. [Li, Ning; Chansky, Howard A.; Yang, Liu] VA Puget Sound Hlth Care Syst, Res & Dev, Seattle, WA 98108 USA. [Song, Guangchun] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. RP Yang, L (reprint author), Univ Washington, Dept Orthoped & Sports Med, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA. EM lyang@u.washington.edu FU NIH [RO1 AR051455]; VA Merit Review Award from the U.S. Department of Veterans Affairs, Office of Research and Development Biomedical Laboratory Research Program FX We thank Dr. Y. Shinkai for frozen mouse embryos harboring (exon 15 & 16)-floxed ESET allele, Dr. J.J. Westendorf for pOG2-Luc, Dr. G. Karsenty for pCMV-HA-Runx2 plasmid, S.L. Carey for assistance in mouse breeding, and Dr. Roberto Nicosia's lab for assistance in image acquisition. This work is supported in part by NIH grant RO1 AR051455 (to L.Y.), and by a VA Merit Review Award from the U.S. Department of Veterans Affairs, Office of Research and Development Biomedical Laboratory Research Program (to H.A.C.). NR 17 TC 10 Z9 10 U1 1 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-5793 EI 1873-3468 J9 FEBS LETT JI FEBS Lett. PD DEC 11 PY 2013 VL 587 IS 24 BP 3961 EP 3967 DI 10.1016/j.febslet.2013.10.028 PG 7 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 257QI UT WOS:000327400100012 PM 24188826 ER PT J AU Sherwood, B Wang, L Zhou, XH AF Sherwood, Ben Wang, Lan Zhou, Xiao-Hua TI Weighted quantile regression for analyzing health care cost data with missing covariates SO STATISTICS IN MEDICINE LA English DT Article DE health care cost data; missing data; inverse probability weighting; quantile regression ID LONGITUDINAL DATA; MODELS; FIT AB Analysis of health care cost data is often complicated by a high level of skewness, heteroscedastic variances and the presence of missing data. Most of the existing literature on cost data analysis have been focused on modeling the conditional mean. In this paper, we study a weighted quantile regression approach for estimating the conditional quantiles health care cost data with missing covariates. The weighted quantile regression estimator is consistent, unlike the naive estimator, and asymptotically normal. Furthermore, we propose a modified BIC for variable selection in quantile regression when the covariates are missing at random. The quantile regression framework allows us to obtain a more complete picture of the effects of the covariates on the health care cost and is naturally adapted to the skewness and heterogeneity of the cost data. The method is semiparametric in the sense that it does not require to specify the likelihood function for the random error or the covariates. We investigate the weighted quantile regression procedure and the modified BIC via extensive simulations. We illustrate the application by analyzing a real data set from a health care cost study. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Sherwood, Ben; Wang, Lan] Univ Minnesota, Sch Stat, Minneapolis, MN 55455 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA 98101 USA. [Zhou, Xiao-Hua] Univ Washington, Dept Biostat, HSB, Seattle, WA 98198 USA. [Zhou, Xiao-Hua] Renmin Univ China, Sch Stat, Beijing, Peoples R China. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, HSB, F600,Box 357232, Seattle, WA 98198 USA. EM azhou@u.washington.edu FU National Science Foundation [DMS-1007603]; US Department of Veterans Affairs, Veterans Affairs Health Administration, HSRD grants [RCS 05-196] FX The authors are grateful for the comments from the Associate Editor and the two referees, which help us significantly improve the paper. Wang and Zhou are joint correspondence authors for this paper. National Science Foundation grant DMS-1007603 supported the work of Sherwood and Wang. Xiao-Hua Zhou, PhD, is presently a Core Investigator and Biostatistics Unit Director at the Northwest HSR&D Center of Excellence, Department of Veterans Affairs Medical Center, Seattle, WA, USA. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Zhou's work was supported in part by US Department of Veterans Affairs, Veterans Affairs Health Administration, HSR&D grants (RCS 05-196). NR 15 TC 10 Z9 12 U1 0 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD DEC 10 PY 2013 VL 32 IS 28 BP 4967 EP 4979 DI 10.1002/sim.5883 PG 13 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 248UH UT WOS:000326729100008 PM 23836597 ER PT J AU Walling, AM Tisnado, D Asch, SM Malin, JM Pantoja, P Dy, SM Ettner, SL Zisser, AP Schreibeis-Baum, H Lee, M Lorenz, KA AF Walling, Anne M. Tisnado, Diana Asch, Steven M. Malin, Jennifer M. Pantoja, Philip Dy, Sydney M. Ettner, Susan L. Zisser, Ann P. Schreibeis-Baum, Hannah Lee, Martin Lorenz, Karl A. TI The Quality of Supportive Cancer Care in the Veterans Affairs Health System and Targets for Improvement SO JAMA INTERNAL MEDICINE LA English DT Article ID OF-LIFE CARE; EVIDENCE-BASED RECOMMENDATIONS; PALLIATIVE CARE; SYMPTOM MANAGEMENT; MENTAL-HEALTH; END; INTERVENTIONS; DISCUSSIONS; FAMILIES; MEDICARE AB IMPORTANCE Characterizing the quality of supportive cancer care can guide quality improvement. OBJECTIVE To evaluate nonhospice supportive cancer care comprehensively in a national sample of veterans. DESIGN, SETTING, AND PARTICIPANTS Using a retrospective cohort study design, we measured evidence-based cancer care processes using previously validated indicators of care quality in patients with advanced cancer, addressing pain, nonpain symptoms, and information and care planning among 719 veterans with a 2008 Veterans Affairs Central Cancer Registry diagnosis of stage IV colorectal (37.0%), pancreatic (29.8%), or lung (33.2%) cancer. MAIN OUTCOMES AND MEASURES We abstracted medical records from diagnosis for 3 years or until death among eligible veterans (lived >= 30 days following diagnosis with >= 1 Veterans Affairs hospitalization or >= 2 Veterans Affairs outpatient visits). Each indicator identified a clinical scenario and an appropriate action. For each indicator for which a veteran was eligible, we determined whether appropriate care was provided. We also determined patient-level quality overall and by pain, nonpain symptoms, and information and care planning domains. RESULTS Most veterans were older (mean age, 66.2 years), male (97.2%), and white (74.3%). Eighty-five percent received both inpatient and outpatient care, and 92.5% died. Overall, the 719 veterans triggered a mean of 11.7 quality indicators (range, 1-22) and received a mean 49.5% of appropriate care. Notable gaps in care were that inpatient pain screening was common (96.5%) but lacking for outpatients (58.1%). With opioids, bowel prophylaxis occurred for only 52.2% of outpatients and 70.5% of inpatients. Few patients had a timely dyspnea evaluation (15.8%) or treatment (10.8%). Outpatient assessment of fatigue occurred for 31.3%. Of patients at high risk for diarrhea from chemotherapy, 24.2% were offered appropriate antidiarrheals. Only 17.7% of veterans had goals of care addressed in the month after a diagnosis of advanced cancer, and 63.7% had timely discussion of goals following intensive care unit admission. Most decedents (86.4%) were referred to palliative care or hospice before death. Single- vs multiple-fraction radiotherapy should have been considered in 28 veterans with bone metastasis, but none were offered this option. CONCLUSIONS AND RELEVANCE These care gaps reflect important targets for improving the patient and family experience of cancer care. C1 [Walling, Anne M.; Tisnado, Diana; Malin, Jennifer M.; Pantoja, Philip; Ettner, Susan L.; Zisser, Ann P.; Schreibeis-Baum, Hannah; Lee, Martin; Lorenz, Karl A.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Walling, Anne M.; Tisnado, Diana; Lorenz, Karl A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Walling, Anne M.; Lorenz, Karl A.] RAND Hlth, Santa Monica, CA USA. [Asch, Steven M.] VA Palo Alto Healthcare Syst, Palo Alto, CA USA. [Asch, Steven M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Malin, Jennifer M.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. [Dy, Sydney M.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA. [Ettner, Susan L.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90095 USA. RP Walling, AM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 911 Broxton Ave, Los Angeles, CA 90095 USA. EM awalling@mednet.ucla.edu OI Schreibeis-Baum, Hannah/0000-0001-7798-9804 FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research & Development Service [IIR 09-097] FX This study is based on work supported by the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research & Development Service (project IIR 09-097). NR 44 TC 17 Z9 17 U1 1 U2 6 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD DEC 9 PY 2013 VL 173 IS 22 BP 2071 EP 2079 DI 10.1001/jamainternmed.2013.10797 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA AA2WL UT WOS:000330954800015 PM 24126685 ER PT J AU Mishra, RK Dubin, RF AF Mishra, Rakesh K. Dubin, Ruth F. TI The Effects of Frequent Hemodialysis on Left Ventricular Mass, Volumes, and Geometry SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Editorial Material ID STAGE RENAL-DISEASE; BLOOD-PRESSURE; NOCTURNAL HEMODIALYSIS; HYPERTROPHY; SURVIVAL; DIALYSIS; DETERMINANTS; REDUCTION; MECHANICS; FAILURE C1 Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mishra, Rakesh K.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Mishra, RK (reprint author), San Francisco VA Med Ctr, 4150 Clement St,Box 111C, San Francisco, CA 94121 USA. EM rakesh.mishra@ucsf.edu FU NIDDK NIH HHS [K23 DK092354, T32 DK007219] NR 28 TC 0 Z9 0 U1 0 U2 3 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD DEC 6 PY 2013 VL 8 IS 12 BP 2025 EP 2027 DI 10.2215/CJN.10611013 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA 265KT UT WOS:000327951100001 PM 24235288 ER PT J AU Alge, JL Karakala, N Neely, BA Janech, MG Tumlin, JA Chawla, LS Shaw, AD Arthur, JM AF Alge, Joseph L. Karakala, Nithin Neely, Benjamin A. Janech, Michael G. Tumlin, James A. Chawla, Lakhmir S. Shaw, Andrew D. Arthur, John M. CA SAKInet Investigator TI Association of Elevated Urinary Concentration of Renin-Angiotensin System Components and Severe AKI SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID ACUTE KIDNEY INJURY; ACUTE-RENAL-FAILURE; GELATINASE-ASSOCIATED LIPOCALIN; FACTOR-KAPPA-B; CARDIAC-SURGERY; HOSPITALIZED-PATIENTS; AT(2) RECEPTORS; RIFLE CRITERIA; BIOMARKER; RISK AB BackgroundPrognostic biomarkers that predict the severity of AKI at an early time point are needed. Urinary angiotensinogen was recently identified as a prognostic AKI biomarker. The study hypothesis is that urinary renin could also predict AKI severity and that in combination angiotensinogen and renin would be a strong predictor of prognosis at the time of AKI diagnosis.Design, setting, participants, & measurementsIn this multicenter, retrospective cohort study, urine was obtained from 204 patients who developed AKI after cardiac surgery from August 2008 to June 1, 2012. All patients were classified as having Acute Kidney Injury Network (AKIN) stage 1 disease by serum creatinine criteria at the time of sample collection. Urine output was not used for staging. Urinary angiotensinogen and renin were measured, and the area under the receiver-operating characteristic curve (AUC) was used to test for prediction of progression to AKIN stage 3 or in-hospital 30-day mortality. These biomarkers were added stepwise to a clinical model, and improvement in prognostic predictive performance was evaluated by category free net reclassification improvement (cfNRI) and chi-squared automatic interaction detection (CHAID).ResultsBoth the urinary angiotensinogen-to-creatinine ratio (uAnCR; AUC, 0.75; 95% confidence interval [CI], 0.65 to 0.85) and the urinary renin-to-creatinine ratio (uRenCR; AUC, 0.70; 95% CI, 0.57 to 0.83) predicted AKIN stage 3 or death. Addition of uAnCR to a clinical model substantially improved prediction of the outcome (AUC, 0.85; cfNRI, 0.673), augmenting sensitivity and specificity. Further addition of uRenCR increased the sensitivity of the model (cfNRI(events), 0.44). CHAID produced a highly accurate model (AUC, 0.91) and identified the combination of uAnCR >337.89 ng/mg and uRenCR >893.41 pg/mg as the strongest predictors (positive predictive value, 80.4%; negative predictive value, 90.7%; accuracy, 90.2%).ConclusionThe combination of urinary angiotensinogen and renin predicts progression to very severe disease in patients with early AKI after cardiac surgery. C1 [Alge, Joseph L.; Karakala, Nithin; Neely, Benjamin A.; Janech, Michael G.; Arthur, John M.] Med Univ S Carolina, Charleston, SC 29425 USA. [Tumlin, James A.] Univ Tennessee, Coll Med Chattanooga, Chattanooga, TN USA. [Chawla, Lakhmir S.] George Washington Univ, Washington, DC USA. [Shaw, Andrew D.] Duke Univ, Durham, NC USA. [Shaw, Andrew D.] Durham Vet Affairs Med Ctr, Durham, NC USA. [Arthur, John M.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Arthur, JM (reprint author), Med Univ S Carolina, Dept Med, Div Nephrol, 96 Jonathan Lucas St,POB 250623, Charleston, SC 29425 USA. EM arthurj@musc.edu RI Velez, Juan Carlos/N-3782-2016 OI Neely, Benjamin/0000-0001-6120-7695; Alge, Joseph/0000-0002-2491-1066; Janech, Michael/0000-0002-3202-4811 FU National Institutes of Health [R01 DK080234]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs FX This study was supported by National Institutes of Health grant R01 DK080234 and by a Merit Review award from the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs. The contents do not necessarily represent the views of the Department of Veterans Affairs or the United States government. NR 39 TC 13 Z9 14 U1 0 U2 2 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD DEC 6 PY 2013 VL 8 IS 12 BP 2043 EP 2052 DI 10.2215/CJN.03510413 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 265KT UT WOS:000327951100005 PM 24009222 ER PT J AU Bera, A Zhao, SJ Cao, L Chiao, PJ Freeman, JW AF Bera, Alakesh Zhao, Shujie Cao, Lin Chiao, Paul J. Freeman, James W. TI Oncogenic K-Ras and Loss of Smad4 Mediate Invasion by Activating an EGFR/NF-kappa B Axis That Induces Expression of MMP9 and uPA in Human Pancreas Progenitor Cells SO PLOS ONE LA English DT Article ID EPIDERMAL-GROWTH-FACTOR; UROKINASE PLASMINOGEN-ACTIVATOR; FACTOR RECEPTOR; BREAST-CANCER; MATRIX METALLOPROTEINASES; NUCLEAR TRANSLOCATION; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; PROSTATE-CANCER; OVARIAN-CANCER AB Activating K-Ras mutations and inactivating mutations of Smad4 are two common genetic alterations that occur in the development and progression of pancreatic ductal adenocarcinomas (PDAC). To further study the individual and combinatorial roles of these two mutations in the pathogenesis of PDAC, immortalized human pancreas nestin postive cells (HPNE) were genetically modified by either expressing oncogenic K-Ras (HPNE/K-Ras), by shRNA knock down of Smad4 (HPNE/ShSmad4) or by creating both alterations in the same cell line (HPNE/K-Ras/ShSmad4). We previously found that expression of oncogenic K-Ras caused an increase in expression of EGFR and loss of Smad4 further enhanced the up regulation in expression of EGFR and that this increase in EGFR was sufficient to induce invasion. Here we further investigated the mechanism that links mutational alterations and EGFR expression with invasion. The increase in EGFR signaling was associated with up regulation of MMP9 and uPA protein and activity. Moreover, the increase in EGFR signaling promoted a nuclear translocation and binding of RelA (p65), a subunit of NF-kappa B, to the promoters of both MMP-9 and uPA. Treatment of HPNE/K-Ras/ShSmad4 cells with an inhibitor of EGFR reduced EGF-mediated NF-kappa B nuclear translocation and inhibitors of either EGFR or NF-kappa B reduced the increase in MMP-9 or uPA expression. In conclusion, this study provides the mechanism of how a combination of oncogenic K-Ras and loss of Smad4 causes invasion and provides the basis for new strategies to inhibit metastases. C1 [Bera, Alakesh; Zhao, Shujie; Cao, Lin; Freeman, James W.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA. [Freeman, James W.] Canc Therapy & Res Ctr S Texas, Expt & Dev Therapeut Program, San Antonio, TX 78229 USA. [Freeman, James W.] Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX USA. [Chiao, Paul J.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA. RP Freeman, JW (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA. EM freemanjw@uthscsa.edu FU VA merit award; Cancer Center; CPRIT; [NIH-RO1CA069122]; [NIH-P30CA054174] FX This work was supported by Grants to JWF, VA merit award, and NIH-RO1CA069122, and Cancer Center Grant to CTRC, NIH-P30CA054174 provided support for the use of Flow Cytometry Core Facility, UTHSCSA and the Optical Imaging Core, UTHSCSA. The work was also supported by CPRIT postdoctoral fellowship to Dr. AB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 63 TC 13 Z9 14 U1 0 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 5 PY 2013 VL 8 IS 12 AR e82282 DI 10.1371/journal.pone.0082282 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 273WD UT WOS:000328566100095 PM 24340014 ER PT J AU Nyendak, MR Park, B Null, MD Baseke, J Swarbrick, G Mayanja-Kizza, H Nsereko, M Johnson, DF Gitta, P Okwera, A Goldberg, S Bozeman, L Johnson, JL Boom, WH Lewinsohn, DA Lewinsohn, DM AF Nyendak, Melissa R. Park, Byung Null, Megan D. Baseke, Joy Swarbrick, Gwendolyn Mayanja-Kizza, Harriet Nsereko, Mary Johnson, Denise F. Gitta, Phineas Okwera, Alphonse Goldberg, Stefan Bozeman, Lorna Johnson, John L. Boom, W. Henry Lewinsohn, Deborah A. Lewinsohn, David M. CA TB Res Unit TB Trials Consortium TI Mycobacterium tuberculosis Specific CD8(+) T Cells Rapidly Decline with Antituberculosis Treatment SO PLOS ONE LA English DT Article ID INTERFERON-GAMMA RESPONSES; PULMONARY TUBERCULOSIS; IFN-GAMMA; ANTIGEN; INFECTION; MALNUTRITION; INDIVIDUALS; BIOMARKERS; SIGNATURE; REVERSION AB Rationale: Biomarkers associated with response to therapy in tuberculosis could have broad clinical utility. We postulated that the frequency of Mycobacterium tuberculosis (Mtb) specific CD8(+) T cells, by virtue of detecting intracellular infection, could be a surrogate marker of response to therapy and would decrease during effective antituberculosis treatment. Objectives: We sought to determine the relationship of Mtb specific CD4(+) T cells and CD8(+) T cells with duration of antituberculosis treatment. Materials and Methods: We performed a prospective cohort study, enrolling between June 2008 and August 2010, of HIV-uninfected Ugandan adults (n = 50) with acid-fast bacillus smear-positive, culture confirmed pulmonary TB at the onset of antituberculosis treatment and the Mtb specific CD4(+) and CD8(+) T cell responses to ESAT-6 and CFP-10 were measured by IFN-gamma ELISPOT at enrollment, week 8 and 24. Results: There was a significant difference in the Mtb specific CD8(+) T response, but not the CD4(+) T cell response, over 24 weeks of antituberculosis treatment (p<0.0001), with an early difference observed at 8 weeks of therapy (p = 0.023). At 24 weeks, the estimated Mtb specific CD8(+) T cell response decreased by 58%. In contrast, there was no significant difference in the Mtb specific CD4(+) T cell during the treatment. The Mtb specific CD4(+) T cell response, but not the CD8(+) response, was negatively impacted by the body mass index. Conclusions: Our data provide evidence that the Mtb specific CD8(+) T cell response declines with antituberculosis treatment and could be a surrogate marker of response to therapy. Additional research is needed to determine if the Mtb specific CD8(+) T cell response can detect early treatment failure, relapse, or to predict disease progression. C1 [Nyendak, Melissa R.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Park, Byung] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Null, Megan D.; Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA. [Baseke, Joy; Mayanja-Kizza, Harriet; Nsereko, Mary; Gitta, Phineas; Okwera, Alphonse; Johnson, John L.; Boom, W. Henry] Uganda Case Western Reserve Univ, Res Collaborat, Kampala, Uganda. [Swarbrick, Gwendolyn; Lewinsohn, David M.] Portland VA Med Ctr, Dept Med, Portland, OR USA. [Mayanja-Kizza, Harriet] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Johnson, Denise F.; Johnson, John L.; Boom, W. Henry] Case Western Reserve Univ, TB Res Unit, Cleveland, OH 44106 USA. [Goldberg, Stefan; Bozeman, Lorna] Ctr Dis Control & Prevent, TB Trials Consortium, Natl Ctr HIV AIDS Viral Hepatitis & TB Prevent, Div TB Eliminat, Atlanta, GA USA. RP Nyendak, MR (reprint author), Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. EM nyendakm@ohsu.edu; lewinsod@ohsu.edu RI ; Lewinsohn, David/I-4936-2013 OI Mayanja-Kizza, Harriet/0000-0002-9297-6208; Lewinsohn, David/0000-0001-9906-9494 FU NIH [HHSN266200400081C, HHSN272200900053C]; National Center for Research Resources [KL2RR024141]; VA Merit Review Grant; Portland VA Medical Center; Tuberculosis Research Unit at Case Western Reserve University; United States National Institute of Allergy and Infectious Diseases, National Institutes of Health and Human Services [HHSN266200700022C/NO1-AI-70022]; US Government Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC) [200-2009-32598] FX This work was supported in part by the following agency and institutes: NIH grants HHSN266200400081C and HHSN272200900053C, The National Center for Research Resources KL2RR024141, VA Merit Review Grant and the Portland VA Medical Center. This work was also supported by the Tuberculosis Research Unit at Case Western Reserve University, established with funds from the United States National Institute of Allergy and Infectious Diseases, National Institutes of Health and Human Services, under contract number HHSN266200700022C/NO1-AI-70022 and the Tuberculosis Trials Consortium sponsored by the US Government Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC), contract number 200-2009-32598. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC or the Agency for Toxic Substances and Disease Registry. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 44 TC 15 Z9 15 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD DEC 4 PY 2013 VL 8 IS 12 AR e81564 DI 10.1371/journal.pone.0081564 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 265KD UT WOS:000327949300095 PM 24324704 ER PT J AU Dhaliwal, G Hauer, KE AF Dhaliwal, Gurpreet Hauer, Karen E. TI The Oral Patient Presentation in the Era of Night Float Admissions Credit and Critique SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Dhaliwal, Gurpreet; Hauer, Karen E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Dhaliwal, G (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111, San Francisco, CA 94121 USA. EM gurpreet.dhaliwal@ucsf.edu NR 5 TC 5 Z9 5 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 4 PY 2013 VL 310 IS 21 BP 2247 EP 2248 DI 10.1001/jama.2013.282322 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 262OV UT WOS:000327746300004 PM 24302082 ER PT J AU Curtis, JR Back, AL Ford, DW Downey, L Shannon, SE Doorenbos, AZ Kross, EK Reinke, LF Feemster, LC Edlund, B Arnold, RW O'Connor, K Engelberg, RA AF Curtis, J. Randall Back, Anthony L. Ford, Dee W. Downey, Lois Shannon, Sarah E. Doorenbos, Ardith Z. Kross, Erin K. Reinke, Lynn F. Feemster, Laura C. Edlund, Barbara Arnold, Richard W. O'Connor, Kim Engelberg, Ruth A. TI Effect of Communication Skills Training for Residents and Nurse Practitioners on Quality of Communication With Patients With Serious Illness A Randomized Trial SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID OF-LIFE CARE; EARLY PALLIATIVE CARE; CELL LUNG-CANCER; DYING PATIENTS; PHYSICIAN COMMUNICATION; CHRONIC DISEASE; MENTAL-HEALTH; MEDICAL-CARE; END; PERSPECTIVES AB IMPORTANCE Communication about end-of-life care is a core clinical skill. Simulation-based training improves skill acquisition, but effects on patient-reported outcomes are unknown. OBJECTIVE To assess the effects of a communication skills intervention for internal medicine and nurse practitioner trainees on patient- and family-reported outcomes. DESIGN, SETTING, AND PARTICIPANTS Randomized trial conducted with 391 internal medicine and 81 nurse practitioner trainees between 2007 and 2013 at the University of Washington and Medical University of South Carolina. INTERVENTION Participants were randomized to an 8-session, simulation-based, communication skills intervention (N = 232) or usual education (N = 240). MAIN OUTCOMES AND MEASURES Primary outcome was patient- reported quality of communication (QOC; mean rating of 17 items rated from 0-10, with 0 = poor and 10 = perfect). Secondary outcomes were patient- reported quality of end-of-life care (QEOLC; mean rating of 26 items rated from 0-10) and depressive symptoms (assessed using the 8-item Personal Health Questionnaire [PHQ-8]; range, 0-24, higher scores worse) and family-reported QOC and QEOLC. Analyses were clustered by trainee. RESULTS There were 1866 patient ratings (44% response) and 936 family ratings (68% response). The intervention was not associated with significant changes in QOC or QEOLC. Mean values for postintervention patient QOC and QEOLC were 6.5 (95% CI, 6.2 to 6.8) and 8.3 (95% CI, 8.1 to 8.5) respectively, compared with 6.3 (95% CI, 6.2 to 6.5) and 8.3 (95% CI, 8.1 to 8.4) for control conditions. After adjustment, comparing intervention with control, there was no significant difference in the QOC score for patients (difference, 0.4 points [95% CI, -0.1 to 0.9]; P = .15) or families (difference, 0.1 [95% CI, -0.8 to 1.0]; P = .81). There was no significant difference in QEOLC score for patients (difference, 0.3 points [95% CI, -0.3 to 0.8]; P = .34) or families (difference, 0.1 [95% CI, -0.7 to 0.8]; P = .88). The intervention was associated with significantly increased depression scores among patients of postintervention trainees (mean score, 10.0 [95% CI, 9.1 to 10.8], compared with 8.8 [95% CI, 8.4 to 9.2]) for control conditions; adjusted model showed an intervention effect of 2.2 (95% CI, 0.6 to 3.8; P = .006). CONCLUSIONS AND RELEVANCE Among internal medicine and nurse practitioner trainees, simulation-based communication training compared with usual education did not improve quality of communication about end-of-life care or quality of end-of-life care but was associated with a small increase in patients' depressive symptoms. These findings raise questions about skills transfer from simulation training to actual patient care and the adequacy of communication skills assessment. C1 [Curtis, J. Randall; Downey, Lois; Kross, Erin K.; Feemster, Laura C.; Engelberg, Ruth A.] Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care, Dept Med, Seattle, WA 98104 USA. [Curtis, J. Randall; Shannon, Sarah E.; Doorenbos, Ardith Z.; Reinke, Lynn F.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98104 USA. [Back, Anthony L.] Univ Washington, Dept Med, Div Med Oncol, Seattle Canc Care Alliance, Seattle, WA 98104 USA. [Back, Anthony L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Ford, Dee W.] Med Univ S Carolina, Dept Med, Div Pulm & Crit Care, Charleston, SC USA. [Reinke, Lynn F.; Feemster, Laura C.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Edlund, Barbara] Med Univ S Carolina, Coll Nursing, Charleston, SC USA. [Arnold, Richard W.; O'Connor, Kim] Univ Washington, Dept Med, Seattle, WA 98104 USA. RP Curtis, JR (reprint author), Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care, Box 359762, Seattle, WA 98104 USA. EM jrc@u.washington.edu FU National Institute of Nursing Research of the National Institutes of Health [R01NR009987] FX This study was supported by the National Institute of Nursing Research of the National Institutes of Health (R01NR009987). NR 41 TC 90 Z9 90 U1 5 U2 49 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD DEC 4 PY 2013 VL 310 IS 21 BP 2271 EP 2281 DI 10.1001/jama.2013.282081 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 262OV UT WOS:000327746300012 PM 24302090 ER PT J AU Nation, DA Edland, SD Bondi, MW Salmon, DP Delano-Wood, L Peskind, ER Quinn, JF Galasko, DR AF Nation, Daniel A. Edland, Steven D. Bondi, Mark W. Salmon, David P. Delano-Wood, Lisa Peskind, Elaine R. Quinn, Joseph F. Galasko, Douglas R. TI Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults SO NEUROLOGY LA English DT Article ID BLOOD-PRESSURE; DISEASE; AGE AB Objective: The current study examined the association between pulse pressure (PP) and CSF-based biomarkers for Alzheimer disease, including beta-amyloid 1-42 (A beta(1-42)) and phosphorylated tau (P-tau) protein, in cognitively normal older adults. Methods: One hundred seventy-seven cognitively normal, stroke-free older adult participants (aged 55-100 years) underwent blood pressure assessment for determination of PP (systolic - diastolic blood pressure) and lumbar puncture for measurement of CSF A beta(1-42) and P-tau. Pearson correlations and multiple linear regression, controlling for age, sex, APOE genotype, and body mass index, evaluated the relationship between PP and Alzheimer disease biomarkers. Results: PP elevation was associated with increased P-tau (r = 0.23, p = 0.002), reduced A beta(1-42) (r=-20.19, p = 0.01), and increased P-tau to A beta(1-42) ratio (r = 0.27, p < 0.001). After controlling for covariates, PP remained associated with P-tau (beta = 0.18, p = 0.0196) and P-tau to A beta(1-42) ratio (beta = 0.0016, p < 0.001) but was no longer associated with A beta(1-42) (beta = -0.1, p = 0.35). Post hoc multivariate analyses indicated that increased PP was associated with all biomarkers in younger participants (aged 55-70 years) (A beta(1-42): p = 0.050; P-tau: p = 0.003; P-tau to A beta ratio: p = 0.0007) but not older participants (aged 70-100 years). Conclusions: PP elevation is associated with increased CSF P-tau and decreased Ab1-42 in cognitively normal older adults, suggesting that pulsatile hemodynamics may be related to amyloidosis and tau-related neurodegeneration. The relationship between PP and CSF biomarkers is age-dependent and observed only in participants in the fifth and sixth decades of life. C1 [Nation, Daniel A.; Bondi, Mark W.; Delano-Wood, Lisa] Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA. [Edland, Steven D.; Salmon, David P.; Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Bondi, Mark W.; Delano-Wood, Lisa] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA. [Peskind, Elaine R.] Mental Illness Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA. [Peskind, Elaine R.] Univ Washington, Sch Med, Dept Behav Sci, Seattle, WA USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR USA. RP Nation, DA (reprint author), Vet Affairs San Diego Healthcare Syst, San Diego, CA 92161 USA. EM dnation@ucsd.edu FU Alzheimer's Association [IIRG 07-59343]; NIH [R01 AG012674, K24 AG026431, P50 AG05131, AG05131, AB005136, AG010129] FX The current study was supported by the Alzheimer's Association (grant IIRG 07-59343 to M. W. B.), and the NIH (grants R01 AG012674 to M. W. B., K24 AG026431 to M. W. B., and P50 AG05131). CSF sample collection was supported by NIH grants AG05131 (UCSD), AB005136 (University of Washington), and AG010129 (Oregon Health Sciences University). NR 10 TC 18 Z9 18 U1 1 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 EI 1526-632X J9 NEUROLOGY JI Neurology PD DEC 3 PY 2013 VL 81 IS 23 BP 2024 EP 2027 PG 4 WC Clinical Neurology SC Neurosciences & Neurology GA AA0FT UT WOS:000330771700013 PM 24225352 ER PT J AU Fenton-May, AE Dibben, O Emmerich, T Ding, HT Pfafferott, K Aasa-Chapman, MM Pellegrino, P Williams, I Cohen, MS Gao, F Shaw, GM Hahn, BH Ochsenbauer, C Kappes, JC Borrow, P AF Fenton-May, Angharad E. Dibben, Oliver Emmerich, Tanja Ding, Haitao Pfafferott, Katja Aasa-Chapman, Marlen M. Pellegrino, Pierre Williams, Ian Cohen, Myron S. Gao, Feng Shaw, George M. Hahn, Beatrice H. Ochsenbauer, Christina Kappes, John C. Borrow, Persephone TI Relative resistance of HIV-1 founder viruses to control by interferon-alpha SO RETROVIROLOGY LA English DT Article DE Human immunodeficiency virus type 1; Type 1 interferon; Viral inhibition; Founder virus; Acute infection ID SIMIAN IMMUNODEFICIENCY VIRUS; PERSISTENT LCMV INFECTION; I INTERFERON; GENE-EXPRESSION; REPLICATION CAPACITY; T-CELLS; MUCOSAL TRANSMISSION; REGULATORY FACTOR-3; DISEASE PROGRESSION; VIRAL REPLICATION AB Background: Following mucosal human immunodeficiency virus type 1 (HIV-1) transmission, type 1 interferons (IFNs) are rapidly induced at sites of initial virus replication in the mucosa and draining lymph nodes. However, the role played by IFN-stimulated antiviral activity in restricting HIV-1 replication during the initial stages of infection is not clear. We hypothesized that if type 1 IFNs exert selective pressure on HIV-1 replication in the earliest stages of infection, the founder viruses that succeed in establishing systemic infection would be more IFN-resistant than viruses replicating during chronic infection, when type 1 IFNs are produced at much lower levels. To address this hypothesis, the relative resistance of virus isolates derived from HIV-1-infected individuals during acute and chronic infection to control by type 1 IFNs was analysed. Results: The replication of plasma virus isolates generated from subjects acutely infected with HIV-1 and molecularly cloned founder HIV-1 strains could be reduced but not fully suppressed by type 1 IFNs in vitro. The mean IC50 value for IFNa2 (22 U/ml) was lower than that for IFN beta (346 U/ml), although at maximally-inhibitory concentrations both IFN subtypes inhibited virus replication to similar extents. Individual virus isolates exhibited differential susceptibility to inhibition by IFNa2 and IFN beta, likely reflecting variation in resistance to differentially up-regulated IFN-stimulated genes. Virus isolates from subjects acutely infected with HIV-1 were significantly more resistant to in vitro control by IFNa than virus isolates generated from the same individuals during chronic, asymptomatic infection. Viral IFN resistance declined rapidly after the acute phase of infection: in five subjects, viruses derived from six-month consensus molecular clones were significantly more sensitive to the antiviral effects of IFNs than the corresponding founder viruses. Conclusions: The establishment of systemic HIV-1 infection by relatively IFNa-resistant founder viruses lends strong support to the hypothesis that IFNa plays an important role in the control of HIV-1 replication during the earliest stages of infection, prior to systemic viral spread. These findings suggest that it may be possible to harness the antiviral activity of type 1 IFNs in prophylactic and potentially also therapeutic strategies to combat HIV-1 infection. C1 [Fenton-May, Angharad E.; Dibben, Oliver; Emmerich, Tanja; Pfafferott, Katja; Borrow, Persephone] Univ Oxford, Nuffield Dept Med, Oxford OX3 7FZ, England. [Ding, Haitao; Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Aasa-Chapman, Marlen M.] Fac Med, Div Infect & Immun, London, England. [Aasa-Chapman, Marlen M.] Ctr Sexual Hlth & HIV Res, London, England. [Pellegrino, Pierre; Williams, Ian] UCL, Mortimer Market Ctr, Ctr Sexual Hlth & HIV Res, London, England. [Cohen, Myron S.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Gao, Feng] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC USA. [Gao, Feng] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Shaw, George M.; Hahn, Beatrice H.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Shaw, George M.; Hahn, Beatrice H.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. RP Borrow, P (reprint author), Univ Oxford, Nuffield Dept Med, NDM Res Bldg,Old Rd Campus, Oxford OX3 7FZ, England. EM persephone.borrow@ndm.ox.ac.uk OI Fenton-May, Angharad/0000-0002-6267-1315 FU NIH NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI) [U19 AI067854]; NIH NIAID Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) [UM1 AI100645]; UAB CFAR [AI27767]; Edward Jenner Institute for Vaccine Research (PB); Senior Jenner Fellowship; Jenner Institute Investigator FX We are extremely grateful to the patients who provided samples for this study. We would also like to thank Julie Lewis and Elizabeth Marshall for expert technical assistance. This work was supported by funding from the NIH NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI) (U19 AI067854) (FG, GMS, BHH, JCK, PB); the NIH NIAID Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) (UM1 AI100645) (FG, GMS, BHH, JCK, PB); core facilities of the UAB CFAR (AI27767) (JCK); and core funding from The Edward Jenner Institute for Vaccine Research (PB). PB received salary support from a Senior Jenner Fellowship and is a Jenner Institute Investigator. NR 102 TC 67 Z9 68 U1 1 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD DEC 3 PY 2013 VL 10 AR 146 DI 10.1186/1742-4690-10-146 PG 18 WC Virology SC Virology GA 280RH UT WOS:000329048000001 PM 24299076 ER PT J AU Kansagara, D Dyer, E Englander, H Fu, RW Freeman, M Kagen, D AF Kansagara, Devan Dyer, Edward Englander, Honora Fu, Rongwei Freeman, Michele Kagen, David TI Treatment of Anemia in Patients With Heart Disease A Systematic Review SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; BLOOD-CELL TRANSFUSION; CHRONIC KIDNEY-DISEASE; INTRAVENOUS FERRIC CARBOXYMALTOSE; CLINICAL-PRACTICE GUIDELINE; IRON-DEFICIENCY ANEMIA; QUALITY-OF-LIFE; FAIR-HF TRIAL; DARBEPOETIN-ALPHA AB Background: The benefits of anemia treatment in patients with heart disease are uncertain. Purpose: To evaluate the benefits and harms of treatments for anemia in adults with heart disease. Data Sources: MEDLINE, EMBASE, and Cochrane databases; clinical trial registries; reference lists; and technical advisors. Study Selection: English-language trials of blood transfusions, iron, or erythropoiesis-stimulating agents in adults with anemia and congestive heart failure or coronary heart disease and observational studies of transfusion. Data Extraction: Data on study design, population characteristics, hemoglobin levels, and health outcomes were extracted. Trials were assessed for quality. Data Synthesis: Low-strength evidence from 6 trials and 26 observational studies suggests that liberal transfusion protocols do not improve short-term mortality rates compared with less aggressive protocols (combined relative risk among trials, 0.94 [95% CI, 0.61 to 1.42]; I-2 = 16.8%), although decreased mortality rates occurred in a small trial of patients with the acute coronary syndrome (1.8% vs. 13.0%; P = 0.032). Moderate-strength evidence from 3 trials of intravenous iron found improved short-term exercise tolerance and quality of life in patients with heart failure. Moderate- to high-strength evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consistent benefits, but their use may be associated with harms, such as venous thromboembolism. Limitations: Few trials have examined transfusions in patients with heart disease, and observational studies are potentially confounded by indication. Data supporting iron use come mainly from 1 large trial, and long-term effects are unknown. Conclusion: Higher transfusion thresholds do not consistently improve mortality rates, but large trials are needed. Intravenous iron may help to alleviate symptoms in patients with heart failure and iron deficiency and also warrants further study. Erythropoiesis-stimulating agents do not seem to benefit patients with mild to moderate anemia and heart disease and may be associated with serious harms. C1 [Kansagara, Devan] Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Kansagara, D (reprint author), Portland VA Med Ctr, Mailcode RD71,3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA. EM kansagar@ohsu.edu FU U.S. Department of Veterans Affairs FX U.S. Department of Veterans Affairs. NR 81 TC 21 Z9 21 U1 0 U2 4 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 3 PY 2013 VL 159 IS 11 BP 746 EP + DI 10.7326/0003-4819-159-11-201312030-00007 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA 276EN UT WOS:000328731000004 PM 24297191 ER PT J AU Qaseem, A Humphrey, LL Fitterman, N Starkey, M Shekelle, P AF Qaseem, Amir Humphrey, Linda L. Fitterman, Nick Starkey, Melissa Shekelle, Paul CA Amer Coll Phys TI Treatment of Anemia in Patients With Heart Disease: A Clinical Practice Guideline From the American College of Physicians SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID PERCUTANEOUS CORONARY INTERVENTION; ACUTE MYOCARDIAL-INFARCTION; BLOOD-CELL TRANSFUSIONS; DARBEPOETIN-ALPHA; INTRAVENOUS IRON; DOUBLE-BLIND; SUBCUTANEOUS ERYTHROPOIETIN; RESTRICTIVE TRANSFUSION; RENAL-INSUFFICIENCY; EXERCISE TOLERANCE AB Description: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease. Methods: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library. Literature was reassessed in April 2013, and additional studies were included. Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events. The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease. This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system. Recommendation 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease. (Grade: weak recommendation; low-quality evidence) Recommendation 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease. (Grade: strong recommendation; moderate-quality evidence) C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. Huntington Hosp, Pasadena, CA USA. W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA. RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA. EM aqaseem@acponline.org FU ACP FX Financial support for the development of this guideline comes exclusively from the ACP operating budget. NR 66 TC 32 Z9 33 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD DEC 3 PY 2013 VL 159 IS 11 BP 770 EP + DI 10.7326/0003-4819-159-11-201312030-00009 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 276EN UT WOS:000328731000006 PM 24297193 ER PT J AU Reber, CAS Boden, MT Mitragotri, N Alvarez, J Gross, JJ Bonn-Miller, MO AF Reber, Cecily A. S. Boden, Matthew Tyler Mitragotri, Neha Alvarez, Jennifer Gross, James J. Bonn-Miller, Marcel O. TI A Prospective Investigation of Mindfulness Skills and Changes in Emotion Regulation Among Military Veterans in Posttraumatic Stress Disorder Treatment SO MINDFULNESS LA English DT Article DE Mindfulness; Acceptance; Emotion regulation; Posttraumatic stress disorder ID COGNITIVE PROCESSING THERAPY; EXPERIENTIAL AVOIDANCE; EMPIRICAL LITERATURE; COMMITMENT THERAPY; SELF-REPORT; ACCEPTANCE; DYSREGULATION; DEPRESSION; ANXIETY; PTSD AB We prospectively investigated associations between mindfulness and changes in the use of expressive suppression and cognitive reappraisal occurring during a residential treatment program for posttraumatic stress disorder (PTSD). The sample consisted of 50 male veterans who were assessed with the Kentucky Inventory of Mindfulness Skills at treatment intake, and the Emotion Regulation Questionnaire (ERQ) and PTSD Checklist-Military Version at treatment intake and discharge. Hierarchical multiple regressions indicated that greater nonjudgmental acceptance at intake predicted greater reductions in expressive suppression (p<.05) and less improvement in cognitive reappraisal (p<.05) between treatment intake and discharge. Additionally, greater ability to observe thoughts, emotions, and sensations at intake was associated with less improvement in cognitive reappraisal between treatment intake and discharge (p<.05). Findings remained significant after statistically adjusting for treatment-related changes in PTSD symptoms. C1 [Reber, Cecily A. S.] VA Palo Alto Hlth Care Syst, PGSP Stanford Psy D Consortium, Menlo Pk, CA 94025 USA. [Boden, Matthew Tyler] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care, Ctr Hlth Care Evaluat, Natl Ctr PTSD, Menlo Pk, CA USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA USA. [Mitragotri, Neha; Alvarez, Jennifer] VA Palo Alto Hlth Care Syst, Menlo Pk, CA 94025 USA. [Gross, James J.] Stanford Univ, Dept Psychol, Stanford, CA 94305 USA. RP Boden, MT (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd 152 MPD, Menlo Pk, CA 94025 USA. EM matthew.t.boden@gmail.com NR 34 TC 4 Z9 5 U1 6 U2 27 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1868-8527 EI 1868-8535 J9 MINDFULNESS JI Mindfulness PD DEC PY 2013 VL 4 IS 4 BP 311 EP 317 DI 10.1007/s12671-012-0131-4 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA AM1OR UT WOS:000339617300004 ER PT J AU La Hoz, RM Baddley, JW AF La Hoz, Ricardo M. Baddley, John W. TI Infectious Complications of Immune Modulatory Agents SO CURRENT INFECTIOUS DISEASE REPORTS LA English DT Article DE Alemtuzumab; Belatacept; Rituximab; Solid organ transplant; Opportunistic infection ID KIDNEY-TRANSPLANT RECIPIENTS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CHRONIC LYMPHOCYTIC-LEUKEMIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; DOSE MAINTENANCE IMMUNOSUPPRESSION; SOLID-ORGAN TRANSPLANTATION; RITUXIMAB INDUCTION THERAPY; ANTIBODY-MEDIATED REJECTION; B-CELL LYMPHOMA; PHASE-II TRIAL AB Immune modulatory agents used in solid organ transplantation and other disciplines have various mechanisms of action and differences in the duration and intensity of immunosuppression. While newer agents have improved patient outcomes, an important result of these immune modulatory agents is associated infections, caused by organisms such as cytomegalovirus, BK polyomavirus, Epstein-Barr virus and tuberculosis. Herein, we review the infectious complications of several newer immune modulatory drugs-belatacept, alemtuzumab, and rituximab-and focus on their use in solid organ transplantation. New immune modulatory agents can potentially modify the landscape of allograft rejection and noninfectious and infectious complications. Health-care practitioners should remain familiar with these agents and their potential infectious complications to help ensure optimal patient outcomes. C1 [La Hoz, Ricardo M.] Wake Forest Univ, Infect Dis Sect, Dept Med, Winston Salem, NC USA. [Baddley, John W.] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Baddley, JW (reprint author), Univ Alabama Birmingham, Div Infect Dis, Dept Med, 1900 Univ Blvd,Tinsley Harrison Tower 229, Birmingham, AL 35294 USA. EM jbaddley@uab.edu FU BMS FX John Baddley has done consulting for Merck, Astellas and Pfizer and has a pending research grant from BMS. NR 86 TC 2 Z9 2 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3847 EI 1534-3146 J9 CURR INFECT DIS REP JI Curr. Infect. Dis. Rep. PD DEC PY 2013 VL 15 IS 6 BP 465 EP 471 DI 10.1007/s11908-013-0365-x PG 7 WC Infectious Diseases SC Infectious Diseases GA AK2YU UT WOS:000338287300004 PM 24072569 ER PT J AU Sosenko, JM Skyler, JS Beam, CA Krischer, JP Greenbaum, CJ Mahon, J Rafkin, LE Matheson, D Herold, KC Palmer, JP AF Sosenko, Jay M. Skyler, Jay S. Beam, Craig A. Krischer, Jeffrey P. Greenbaum, Carla J. Mahon, Jeffrey Rafkin, Lisa E. Matheson, Della Herold, Kevan C. Palmer, Jerry P. CA Type 1 Diabet TrialNet Grp Diabet Prevention Trial-Type 1 Stu TI Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants SO DIABETES LA English DT Article ID RELATIVES; MELLITUS; SECRETION; MARKERS; ONSET AB We studied the change in the first-phase insulin response (FPIR) during the progression to type 1 diabetes (T1D). Seventy-four oral insulin trial progressors to T1D from the Diabetes Prevention Trial-Type 1 with at least one FPIR measurement after baseline and before diagnosis were studied. The FPIR was examined longitudinally in 26 progressors who had FPIR measurements during each of the 3 years before diagnosis. The association between the change from the baseline FPIR to the last FPIR and time to diagnosis was studied in the remainder (n = 48). The 74 progressors had lower baseline FPIR values than nonprogressors (n = 270), with adjustments made for age and BMI. In the longitudinal analysis of the 26 progressors, there was a greater decline in the FPIR from 1.5 to 0.5 years before diagnosis than from 2.5 to 1.5 years before diagnosis. This accelerated decline was also evident in a regression analysis of the 48 remaining progressors in whom the rate of decline became more marked with the approaching diagnosis. The patterns of decline were similar between the longitudinal and regression analyses. There is an acceleration of decline in the FPIR during the progression to T1D, which becomes especially marked between 1.5 and 0.5 years before diagnosis. C1 [Sosenko, Jay M.; Skyler, Jay S.; Rafkin, Lisa E.; Matheson, Della] Univ Miami, Div Endocrinol, Miami, FL 33136 USA. [Beam, Craig A.; Krischer, Jeffrey P.] Univ S Florida, Div Informat & Biostat, Tampa, FL USA. [Greenbaum, Carla J.] Virginia Mason, Benaroya Res Inst, Seattle, WA USA. [Mahon, Jeffrey] Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada. [Herold, Kevan C.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA. [Palmer, Jerry P.] Univ Washington, VA Puget Sound Hlth Care Syst, Div Endocrinol Metab & Nutr, Seattle, WA 98195 USA. RP Sosenko, JM (reprint author), Univ Miami, Div Endocrinol, Miami, FL 33136 USA. EM jsosenko@med.miami.edu RI Skyler, Jay/F-4211-2016 OI Gallagher, Mary/0000-0002-5844-2309 FU National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health through the National Institute of Allergy and Infectious Diseases; National Institutes of Health through the Eunice Kennedy Shriver National Institute of Child Health and Human Development [U01-DK-061010, U01-DK-061016, U01-DK-061034, U01-DK-061036, U01-DK-061040, U01-DK-061041, U01-DK-061042, U01-DK-061055, U01-DK-061058, U01-DK-084565, U01-DK-085453, U01-DK-085461, U01-DK-085463, U01-DK-085466, U01-DK-085499, U01-DK-085505, U01-DK-085509, HHSN267200800019C]; National Center for Research Resources through Clinical Translational Science Awards [UL1-RR-024131, UL1-RR-024139, UL1-RR-024153, UL1-RR-024975, UL1-RR-024982, UL1-RR-025744, UL1-RR-025761, UL1-RR-025780, UL1-RR-029890, UL1-RR-031986, P30-DK-017047]; General Clinical Research Center [M01-RR-00400]; JDRF; American Diabetes Association FX The sponsor of the trial was the Type 1 Diabetes TrialNet Study Group, which is a clinical trials network funded by the National Institutes of Health through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development through cooperative agreements U01-DK-061010, U01-DK-061016, U01-DK-061034, U01-DK-061036, U01-DK-061040, U01-DK-061041, U01-DK-061042, U01-DK-061055, U01-DK-061058, U01-DK-084565, U01-DK-085453, U01-DK-085461, U01-DK-085463, U01-DK-085466, U01-DK-085499, U01-DK-085505, and U01-DK-085509 and contract HHSN267200800019C; the National Center for Research Resources through Clinical Translational Science Awards UL1-RR-024131, UL1-RR-024139, UL1-RR-024153, UL1-RR-024975, UL1-RR-024982, UL1-RR-025744, UL1-RR-025761, UL1-RR-025780, UL1-RR-029890, UL1-RR-031986, and P30-DK-017047 and General Clinical Research Center Award M01-RR-00400; JDRF; and the American Diabetes Association. NR 15 TC 18 Z9 18 U1 0 U2 16 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD DEC PY 2013 VL 62 IS 12 BP 4179 EP 4183 DI 10.2337/db13-0656 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AE1OJ UT WOS:000333738500034 PM 23863814 ER PT J AU Zhang, W Liu, JR Tian, L Liu, QL Fu, YC Garvey, WT AF Zhang, Wei Liu, Jiarong Tian, Ling Liu, Qinglan Fu, Yuchang Garvey, W. Timothy TI TRIB3 Mediates Glucose-Induced Insulin Resistance via a Mechanism That Requires the Hexosamine Biosynthetic Pathway SO DIABETES LA English DT Article ID LINKED N-ACETYLGLUCOSAMINE; HUMAN SKELETAL-MUSCLE; II DIABETES-MELLITUS; O-GLCNAC; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; TRIBBLES HOMOLOG; TRANSPORT SYSTEM; NUCLEOCYTOPLASMIC PROTEINS; INDUCED DESENSITIZATION; BIOCHEMICAL PATHWAYS AB In the current study, we investigated the role of tribbles homolog 3 (TRIB3) in glucose-induced insulin resistance and whether the induction of TRIB3 by glucose is dependent on the nutrient-sensing hexosamine biosynthetic pathway (HBP) known to mediate glucose toxicity in diabetes. In diabetic rats, TRIB3 expression in skeletal muscle was increased after 10 days of hyperglycemia, and glycemia and muscle TRIB3 were both restored toward normal by insulin therapy. In L6 myocytes, the induction of TRIB3 by high glucose or glucosamine was reversible upon removal of these substrates. To assess the role of HBP in the induction of TRIB3, we demonstrated that the ability of high glucose to augment TRIB3 expression was prevented by azaserine, an inhibitor of glutamine: fructose-6-phosphate amidotransferase (GFAT), which is the rate-limiting enzyme in the HBP pathway. TRIB3 expression was also substantially stimulated by glucosamine, which bypasses GFAT, accompanied by a decrease in the insulin-stimulated glucose transport rate, and neither response was affected by azaserine. Further, knockdown of TRIB3 inhibited, and TRIB3 overexpression enhanced, the ability of both high glucose and glucosamine to induce insulin resistance. These data provide the mechanistic link between the HBP flux and insulin resistance and point to TRIB3 as a novel target for treatment of glucose-induced insulin resistance. C1 [Zhang, Wei; Tian, Ling; Fu, Yuchang; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Liu, Jiarong; Liu, Qinglan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Zhang, W (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. EM siweizh@uab.edu FU National Institutes of Health [DK-038765, DK-083562]; Merit Review program of the Department of Veterans Affairs; Amylin; Merck; Weight Watchers FX This work was supported by grants from the National Institutes of Health (DK-038765 and DK-083562) and by the Merit Review program of the Department of Veterans Affairs. We also acknowledge support from core facilities of the University of Alabama (UAB) Diabetes Research Center (P60 DK-079626).; W.T.G. has served on advisory boards for Novo Nordisk, Eisai, Daiichi Sankyo, Liposcience, Vivus, Janssen, Boehringer Ingelheim, and Bristol-Myers Squibb/AstraZeneca; speaker's list for Merck, Eisai, and Amylin; sponsored research funded by Amylin, Merck, and Weight Watchers. No other potential conflicts of interest relevant to this article were reported. NR 50 TC 10 Z9 10 U1 0 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD DEC PY 2013 VL 62 IS 12 BP 4192 EP 4200 DI 10.2337/db13-0312 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA AE1OJ UT WOS:000333738500036 PM 23990361 ER PT J AU Bray, JR AF Bray, Janice R. TI Genitourinary Trauma: A Battle Cry for Integrated Collaborative Veteran-Centric Care SO JOURNAL OF MENS HEALTH LA English DT Editorial Material ID SEXUAL DYSFUNCTION; COMBAT VETERANS; AFGHANISTAN; IRAQ C1 US Dept Vet Affairs, Temple Mental Hlth & Behav Med, Cent Texas Vet Hlth Care Syst, Temple, TX 76504 USA. RP Bray, JR (reprint author), US Dept Vet Affairs, Temple Mental Hlth & Behav Med, Cent Texas Vet Hlth Care Syst, 1901 Vet Mem Dr, Temple, TX 76504 USA. EM janice.bray@va.gov NR 20 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1875-6867 EI 1875-6859 J9 J MENS HEALTH JI J. Mens Health PD DEC PY 2013 VL 10 IS 4 BP 121 EP 123 DI 10.1089/jomh.2013.0028 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AD2AA UT WOS:000333033600002 ER PT J AU Allison, TA AF Allison, Theresa A. TI The Culture of AIDS in Africa: Hope and Healing Through Music and the Arts SO ETHNOMUSICOLOGY LA English DT Book Review ID TRANSMISSION C1 [Allison, Theresa A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Allison, Theresa A.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Allison, TA (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 8 TC 0 Z9 0 U1 1 U2 2 PU SOC ETHNOMUSICOLOGY INC PI BLOOMINGTON PA MORRISON HALL, ROOM 005 INDIANA UNIVERSITY, BLOOMINGTON, IN 47405 USA SN 0014-1836 EI 2156-7417 J9 ETHNOMUSICOLOGY JI Ethnomusicology PD WIN PY 2013 VL 57 IS 1 BP 138 EP 142 PG 5 WC Music SC Music GA AC0LT UT WOS:000332187500014 ER PT J AU Mikesell, L Bromley, E Khodyakov, D AF Mikesell, Lisa Bromley, Elizabeth Khodyakov, Dmitry TI Ethical Community-Engaged Research: A Literature Review SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Review ID PARTICIPATORY ACTION RESEARCH; HEALTH RESEARCH; INTERVENTION RESEARCH; CONDUCTING RESEARCH; GENETIC RESEARCH; NORTH-CAROLINA; PUBLIC-HEALTH; CHALLENGES; BOARD; PARTNERSHIP AB Health research has relied on ethical principles, such as those of the Belmont Report, to protect the rights and well-being of research participants. Community-based participatory research (CBPR), however, must also consider the rights and wellbeing of communities. This requires additional ethical considerations that have been extensively discussed but not synthesized in the CBPR literature. We conducted a comprehensive thematic literature review and summarized empirically grounded discussions of ethics in CBPR, with a focus on the value of the Belmont principles in CBPR, additional essential components of ethical CBPR, the ethical challenges CBPR practitioners face, and strategies to ensure that CBPR meets ethical standards. Our study provides a foundation for developing a working definition and a conceptual model of ethical CBPR. C1 [Mikesell, Lisa] Rutgers State Univ, Sch Commun & Informat, Dept Commun, New Brunswick, NJ 08901 USA. [Bromley, Elizabeth] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Ctr Hlth Serv & Soc, Los Angeles, CA 90024 USA. [Bromley, Elizabeth] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. [Khodyakov, Dmitry] RAND Corp, Santa Monica, CA USA. RP Mikesell, L (reprint author), Rutgers State Univ, Sch Commun & Informat, Dept Commun, 4 Huntington St, New Brunswick, NJ 08901 USA. EM lisa.mikesell@rutgers.edu FU Office of Research Integrity; National Institute of Environmental Health Sciences [R21ES022093] FX This research was supported by the Office of Research Integrity and the National Institute of Environmental Health Sciences (grant R21ES022093). NR 71 TC 25 Z9 25 U1 3 U2 25 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 IS 12 BP E7 EP E14 DI 10.2105/AJPH.2013.301605 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4CV UT WOS:000331043200008 PM 24134352 ER PT J AU Casey, R Clark, C Smits, P Peters, R AF Casey, Roger Clark, Colleen Smits, Paul Peters, Roger TI Application of Implementation Science for Homeless Interventions SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID INTERACTIVE SYSTEMS FRAMEWORK C1 [Casey, Roger] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Tampa, FL USA. [Clark, Colleen; Peters, Roger] Univ S Florida, Dept Mental Hlth, Law & Policy Inst, Tampa, FL USA. [Smits, Paul] Univ S Florida, Natl Ctr Homelessness Vet, Tampa, FL USA. RP Casey, R (reprint author), Natl Ctr Homelessness Vet, 8900 Grand Oak Circle 116H, Tampa, FL 33617 USA. EM roger.casey@va.gov NR 7 TC 1 Z9 1 U1 1 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 SU 2 BP S183 EP S185 DI 10.2105/AJPH.2013.301729 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NP UT WOS:000331073100007 PM 24148045 ER PT J AU Culhane, DP Kane, V Johnston, M AF Culhane, Dennis P. Kane, Vincent Johnston, Mark TI Homelessness Research: Shaping Policy and Practice, Now and Into the Future SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID MENTAL-ILLNESS C1 [Culhane, Dennis P.; Kane, Vincent] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Washington, DC USA. [Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Johnston, Mark] US Dept Housing & Urban Dev, Off Community Planning & Dev, Washington, DC USA. RP Kane, V (reprint author), Vet Affiars Dept Homelessness, VA Ctr Homelessness Vet, 4100 Chester Ave, Philadelphia, PA 19106 USA. EM Vincent.kane@va.gov NR 9 TC 0 Z9 0 U1 3 U2 10 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 SU 2 BP S181 EP S183 DI 10.2105/AJPH.2013.301728 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NP UT WOS:000331073100006 PM 24148044 ER PT J AU Doran, KM Vashi, AA Platis, S Curry, LA Rowe, M Gang, M Vaca, FE AF Doran, Kelly M. Vashi, Anita A. Platis, Stephanie Curry, Leslie A. Rowe, Michael Gang, Maureen Vaca, Federico E. TI Navigating the Boundaries of Emergency Department Care: Addressing the Medical and Social Needs of Patients Who Are Homeless SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HEALTH-SERVICES RESEARCH; SAFETY-NET EMERGENCY; NEW-YORK-CITY; PEOPLE; ADULTS; URBAN; INSTABILITY; POPULATION; PATTERNS; ALCOHOL AB Objectives. We sought to understand interpersonal and systems-level factors relevant to delivering health care to emergency department (ED) patients who are homeless. Methods. We conducted semistructured interviews with emergency medicine residents from 2 residency programs, 1 in New York City and 1 in a medium-sized northeastern city, from February to September 2012. A team of researchers reviewed transcripts independently and coded text segments using a grounded theory approach. They reconciled differences in code interpretations and generated themes inductively. Data collection and analysis occurred iteratively, and interviews continued until theoretical saturation was achieved. Results. From 23 interviews, 3 key themes emerged: (1) use of pattern recognition in identifying and treating patients who are homeless, (2) variations from standard ED care for patients who are homeless, and (3) tensions in navigating the boundaries of ED social care. Conclusions. Our study revealed practical and philosophical tensions in providing social care to patients in the ED who are homeless. Screening for homelessness in the ED and admission practices for patients who are homeless are important areas for future research and intervention with implications for health care costs and patient outcomes. C1 [Doran, Kelly M.; Vashi, Anita A.] Yale Univ, Sch Med, US Dept Vet Affairs, Robert Wood Johnson Fdn,Clin Scholars Program, New Haven, CT USA. [Doran, Kelly M.; Vashi, Anita A.; Vaca, Federico E.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA. [Platis, Stephanie; Curry, Leslie A.] Yale Univ, Sch Publ Hlth, New Haven, CT USA. [Curry, Leslie A.] Yale Univ, Sch Med, Robert Wood Johnson Fdn, Clin Scholars Program, New Haven, CT USA. [Rowe, Michael] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Doran, Kelly M.; Gang, Maureen] NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, New York, NY 10016 USA. RP Doran, KM (reprint author), NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, First Ave & 27th St,Room A345, New York, NY 10016 USA. EM kelly.doran@nyumc.org OI Gang, Maureen/0000-0003-1747-2410 FU Robert Wood Johnson Foundation; US Department of Veterans Affairs through Clinical Scholars Program FX The study was funded by the Robert Wood Johnson Foundation and US Department of Veterans Affairs through the Clinical Scholars Program. NR 52 TC 9 Z9 9 U1 1 U2 7 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 SU 2 BP S355 EP S360 DI 10.2105/AJPH.2013.301540 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NP UT WOS:000331073100037 PM 24148054 ER PT J AU Fargo, JD Munley, EA Byrne, TH Montgomery, E Culhane, DP AF Fargo, Jamison D. Munley, Ellen A. Byrne, Thomas H. Montgomery, Elizabeth Culhane, Dennis P. TI Community-Level Characteristics Associated With Variation in Rates of Homelessness Among Families and Single Adults SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NEW-YORK-CITY; RENT CONTROL; DETERMINANTS AB Objectives. We modeled rates of family and single-adult homelessness in the United States in metropolitan and nonmetropolitan regions and as a function of community-level demographic, behavioral, health, economic, and safety net characteristics. Methods. We entered community-level characteristics and US Department of Housing and Urban Development point-in-time counts for a single night in January 2009 into separate mixed-effects statistical analyses that modeled homelessness rates for 4 subpopulations: families and single adults inmetropolitan and nonmetropolitan regions. Results. Community-level factors accounted for 25% to 50% of the variance in homelessness rates across models. In metropolitan regions, alcohol consumption, social support, and several economic indicators were uniquely associated with family homelessness, and drug use and homicide were uniquely associated with single-adult homelessness. In nonmetropolitan regions, life expectancy, religious adherence, unemployment, and rent burden were uniquely associated with family homelessness, and health care access, crime, several economic indicators, and receipt of Supplemental Security Income were uniquely associated with single-adult homelessness. Conclusions. Considering homeless families and single adults separately enabled more precise modeling of associations between homelessness rates and community-level characteristics, indicating targets for interventions to reduce homelessness among these subpopulations. C1 [Fargo, Jamison D.; Munley, Ellen A.; Byrne, Thomas H.; Montgomery, Elizabeth; Culhane, Dennis P.] US Dept Vet Affairs, Natl Ctr Homelessness Among Vet, Philadelphia, PA USA. [Fargo, Jamison D.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. [Byrne, Thomas H.; Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Fargo, JD (reprint author), Utah State Univ, Dept Psychol, 2810 Old Main Hill, Logan, UT 84322 USA. EM jamison.fargo@usu.edu FU US Department of Veterans Affairs FX We are grateful to the US Department of Veterans Affairs for the support provided to conduct this research. NR 38 TC 5 Z9 5 U1 1 U2 15 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 SU 2 BP S340 EP S347 DI 10.2105/AJPH.2013.301619 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NP UT WOS:000331073100035 PM 24148057 ER PT J AU Kertesz, SG Holt, CL Steward, JL Jones, RN Roth, DL Stringfellow, E Gordon, AJ Kim, TW Austin, EL Henry, SR Johnson, NK Granstaff, US O'Connell, JJ Golden, JF Young, AS Davis, LL Pollio, DE AF Kertesz, Stefan G. Holt, Cheryl L. Steward, Jocelyn L. Jones, Richard N. Roth, David L. Stringfellow, Erin Gordon, Adam J. Kim, Theresa W. Austin, Erika L. Henry, Stephen Randal Johnson, N. Kay Granstaff, U. Shanette O'Connell, James J. Golden, Joya F. Young, Alexander S. Davis, Lori L. Pollio, David E. TI Comparing Homeless Persons' Care Experiences in Tailored Versus Nontailored Primary Care Programs SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID HEALTH-CARE; PATIENT EXPERIENCE; PROSPECTIVE COHORT; LOS-ANGELES; QUALITY; PERCEPTIONS; VETERANS; PEOPLE; ADULTS; PREDICTORS AB Objectives. We compared homeless patients' experiences of care in health care organizations that differed in their degree of primary care design service tailoring. Methods. We surveyed homeless-experienced patients (either recently or currently homeless) at 3 Veterans Affairs (VA) mainstream primary care settings in Pennsylvania and Alabama, a homeless-tailored VA clinic in California, and a highly tailored non-VA Health Care for the Homeless Program in Massachusetts (January 2011-March 2012). We developed a survey, the "Primary Care Quality-Homeless Survey," to reflect the concerns and aspirations of homeless patients. Results. Mean scores at the tailored non-VA site were superior to those from the 3 mainstream VA sites (P < .001). Adjusting for patient characteristics, these differences remained significant for subscales assessing the patient-clinician relationship (P < .001) and perceptions of cooperation among providers (P = .004). There were 1.5- to 3-fold increased odds of an unfavorable experience in the domains of the patient-clinician relationship, cooperation, and access or coordination for the mainstream VA sites compared with the tailored non-VA site; the tailored VA site attained intermediate results. Conclusions. Tailored primary care service design was associated with a superior service experience for patients who experienced homelessness. C1 [Kertesz, Stefan G.; Austin, Erika L.; Johnson, N. Kay; Granstaff, U. Shanette] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Holt, Cheryl L.] Univ Maryland, Baltimore, MD 21201 USA. [Steward, Jocelyn L.] Univ Alabama Birmingham, Birmingham, AL USA. [Jones, Richard N.] Brown Univ, Providence, RI 02912 USA. [Roth, David L.] Johns Hopkins Univ, Baltimore, MD USA. [Stringfellow, Erin] Washington Univ, St Louis, MO USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Kim, Theresa W.] Boston Med Ctr, Boston, MA USA. [Kim, Theresa W.; O'Connell, James J.] Boston Healthcare Homeless Program, Boston, MA USA. [Henry, Stephen Randal; Golden, Joya F.; Young, Alexander S.] VA Med Ctr, Los Angeles, CA USA. [Davis, Lori L.] Tuscaloosa VA Med Ctr, Tuscaloosa, AL USA. [Pollio, David E.] Univ Alabama, Tuscaloosa, AL USA. RP Kertesz, SG (reprint author), Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Stop Code 151,700 South 19th St, Birmingham, AL 35233 USA. EM Stefan.Kertesz@va.gov RI Jones, Richard/J-3488-2013 OI Jones, Richard/0000-0002-1049-218X; Kim, Theresa/0000-0001-6043-0721; Kertesz, Stefan/0000-0001-6101-8421 FU Department of Veterans Affairs, Health Services Research & Development Branch [IAA-07-069-2]; National Institute on Drug Abuse [T32DA01035] FX Research was funded by the Department of Veterans Affairs, Health Services Research & Development Branch (Grant IAA-07-069-2). E. Stringfellow received additional support from the National Institute on Drug Abuse (T32DA01035). NR 66 TC 7 Z9 7 U1 0 U2 13 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 SU 2 BP S331 EP S339 DI 10.2105/AJPH.2013.301481 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NP UT WOS:000331073100034 PM 24148052 ER PT J AU Metraux, S Clegg, LX Daigh, JD Culhane, DP Kane, V AF Metraux, Stephen Clegg, Limin X. Daigh, John D. Culhane, Dennis P. Kane, Vincent TI Risk Factors for Becoming Homeless Among a Cohort of Veterans Who Served in the Era of the Iraq and Afghanistan Conflicts SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID MENTAL-HEALTH PROBLEMS; PAST HOMELESSNESS; AFFAIRS; CARE; ASSOCIATION; DISORDERS; ATTRITION; SERVICES; ILLNESS; FEMALE AB Objectives. In this population-based cohort study, we assessed baseline risk factors for homelessness, including the role of service in the Iraq or Afghanistan conflicts, among a large cohort of recent veterans. Methods. Data for this study came from administrative records for 310 685 veterans who separated from active military duty from July 1, 2005, to September 30, 2006. We used survival analysis methods to determine incidence rates and risk factors for homelessness, based on baseline data for military factors, demographic characteristics, and diagnoses of behavioral health disorders and traumatic brain injury. Results. Service in Iraq or Afghanistan and, more specifically, posttraumatic stress disorder among veterans deployed there, were significant risk factors of modest magnitude for homelessness, and socioeconomic and behavioral health factors provided stronger indicators of risk. Gender was not a significant indicator of differential risk. Conclusions. Although service in Iraq and Afghanistan was significant, socioeconomic and behavioral health indicators show more promise in efforts to use administrative data to inform prevention efforts by identifying veterans who are at elevated risk for becoming homeless upon their return to civilian life. C1 [Metraux, Stephen; Culhane, Dennis P.; Kane, Vincent] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA 19104 USA. [Metraux, Stephen] Univ Sci, Dept Hlth Policy & Publ Hlth, Philadelphia, PA USA. [Culhane, Dennis P.] Univ Penn, Sch Social Welf Policy & Practice, Philadelphia, PA 19104 USA. [Clegg, Limin X.; Daigh, John D.] US Dept Vet Affairs, Off Inspector Gen, Washington, DC USA. RP Metraux, S (reprint author), US Dept Vet Affairs, Ctr Homelessness Vet, 4200 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. EM stephen.metraux@va.gov FU US Department of Veterans Affairs, National Center on Homelessness Among Veterans FX This project was funded by the US Department of Veterans Affairs, National Center on Homelessness Among Veterans. NR 36 TC 10 Z9 10 U1 2 U2 16 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 SU 2 BP S255 EP S261 DI 10.2105/AJPH.2013.301432 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NP UT WOS:000331073100023 PM 24148066 ER PT J AU Montgomery, AE Fargo, JD Byrne, TH Kane, V Culhane, DP AF Montgomery, Ann Elizabeth Fargo, Jamison D. Byrne, Thomas H. Kane, Vincent Culhane, Dennis P. TI Universal Screening for Homelessness and Risk for Homelessness in the Veterans Health Administration SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article AB We examined data for all veterans who completed the Veterans Health Administration's national homelessness screening instrument between October 1, 2012, and January 10, 2013. Among veterans who were not engaged with the US Department of Veterans Affairs homeless system and presented for primary care services, the prevalence of recent housing instability or homelessness was 0.9% and homelessness risk was 1.2%. Future research will refine out-reach strategies, targeting of prevention resources, and development of novel interventions. C1 [Montgomery, Ann Elizabeth; Fargo, Jamison D.; Byrne, Thomas H.; Kane, Vincent; Culhane, Dennis P.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Fargo, Jamison D.] Utah State Univ, Dept Psychol, Logan, UT 84322 USA. [Byrne, Thomas H.; Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. RP Montgomery, AE (reprint author), 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. EM ann.montgomery2@va.gov FU US Department of Veterans Affairs, National Center on Homelessness Among Veterans FX This project was funded by the US Department of Veterans Affairs, National Center on Homelessness Among Veterans. NR 3 TC 8 Z9 8 U1 0 U2 6 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 SU 2 BP S210 EP S211 DI 10.2105/AJPH.2013.301398 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NP UT WOS:000331073100013 PM 24148032 ER PT J AU Russell, LM Devore, MD Barnes, SM Forster, JE Hostetter, TA Montgomery, AE Casey, R Kane, V Brenner, LA AF Russell, Leah M. Devore, Maria D. Barnes, Sean M. Forster, Jeri E. Hostetter, Trisha A. Montgomery, Ann Elizabeth Casey, Roger Kane, Vincent Brenner, Lisa A. TI Challenges Associated With Screening for Traumatic Brain Injury Among US Veterans Seeking Homeless Services SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID PREVALENCE; METAANALYSIS; HEALTH AB We identified the prevalence of traumatic brain injury (TBI) among homeless veterans and assessed the TBI-4, a screening tool created to identify TBI history. Between May 2010 and October 2011, 800 US veterans from 2 hospitals, one eastern (n = 122) and one western (n = 678) completed some or all measures. Findings suggested that 47% of veterans seeking homeless services had a probable history of TBI (data for prevalence obtained only at the western hospital). However, psychometric results from the screening measure suggested that this may be an underestimate and supported comprehensive assessment of TBI in this population. C1 [Russell, Leah M.; Devore, Maria D.; Barnes, Sean M.; Forster, Jeri E.; Hostetter, Trisha A.; Brenner, Lisa A.] 19 Mental Illness Res Educ & Clin Ctr MIRECC, VISN, Denver, CO USA. [Montgomery, Ann Elizabeth; Kane, Vincent] Vet Affairs Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Casey, Roger] Vet Affairs Natl Ctr Homelessness Vet, Tampa, FL USA. RP Brenner, LA (reprint author), MIRECC, Denver VA Med Ctr, 1055 Clermont St, Denver, CO 80203 USA. EM lisa.brenner@va.gov FU National Center on Homelessness Among Veterans; VISN 19 MIRECC FX This project was funded by the National Center on Homelessness Among Veterans. Additional support was provided by the VISN 19 MIRECC. NR 12 TC 6 Z9 6 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 SU 2 BP S211 EP S213 DI 10.2105/AJPH.2013.301485 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NP UT WOS:000331073100014 PM 24148060 ER PT J AU van den Berk-Clark, C McGuire, J AF van den Berk-Clark, Carissa McGuire, James TI Elderly Homeless Veterans in Los Angeles: Chronicity and Precipitants of Homelessness SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID MINI-MENTAL-STATE; OLDER; PREDICTORS; ILLNESS; ADULTS; ABUSE; WOMEN AB Objectives. We compared the characteristics of chronically homeless and acutely homeless elderly veterans to better understand precipitants of homelessness. Methods. We conducted interviews with 33 chronically and 26 acutely homeless veterans aged 65 years and older receiving transitional housing services in Los Angeles, California, between 2003 and 2005. We asked questions regarding their sociodemographic characteristics and other social status measures. Other precipitants of homelessness were acquired via observation and open-ended and structured questions. Results. Both veterans groups weremore similar than different, with substantial levels of physical, psychiatric, and social impairment. They differed significantly in homelessness history, with chronically homeless veterans having more homelessness episodes and more total time homeless. They were also less educated and had smaller social networks. In response to open-ended questioning, elderly homeless veterans revealed how health and substance use issues interacted with loss of social support and eviction to exacerbate homelessness. Conclusions. Assessment of a range of factors is needed to address risk factors and events leading to homelessness. Further research with larger samples is needed to confirm the characteristics and needs of the elderly homeless veteran population. C1 [van den Berk-Clark, Carissa] US Dept Vet Affairs, St Louis Healthcare Ctr, Washington, DC USA. [McGuire, James] US Dept Vet Affairs, West Los Angles Healthcare Ctr, Washington, DC USA. [van den Berk-Clark, Carissa] Washington Univ, Dept Psychiat, Sch Med, St Louis, MO 63110 USA. RP van den Berk-Clark, C (reprint author), Washington Univ, Dept Psychiat, Sch Med, Med Box 8134, St Louis, MO 63110 USA. EM vandenbc@psychiatry.wustl.edu OI van den Berk-Clark, Carissa/0000-0001-7712-3787 FU Veterans Affairs Greater Los Angeles Healthcare System; National Institute on Drug Abuse Training Grant [T32DA007313] FX The study was supported by the Veterans Affairs Greater Los Angeles Healthcare System; completion of the article was funded by a National Institute on Drug Abuse Training Grant (T32DA007313). NR 35 TC 4 Z9 4 U1 2 U2 14 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD DEC PY 2013 VL 103 SU 2 BP S232 EP S238 DI 10.2105/AJPH.2013.301309 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA AA4NP UT WOS:000331073100020 PM 24148059 ER PT J AU Byrne, T Munley, EA Fargo, JD Montgomery, AE Culhane, DP AF Byrne, Thomas Munley, Ellen A. Fargo, Jamison D. Montgomery, Ann E. Culhane, Dennis P. TI NEW PERSPECTIVES ON COMMUNITY-LEVEL DETERMINANTS OF HOMELESSNESS SO JOURNAL OF URBAN AFFAIRS LA English DT Article ID NEW-YORK-CITY; RENT CONTROL; RISK-FACTORS; PHILADELPHIA; PREDICTORS; FAMILIES; HEALTH; POLICY AB Understanding the root causes of homelessness is important for developing effective solutions to the problem. This fact has not gone unnoticed by researchers, who have made numerous attempts to identify the underlying structural determinants of homelessness by modeling inter-community variation in the rate of homelessness as a function of community-level variables. Yet, prior studies in this area have a number of serious limitations, principally their reliance on methodologically flawed estimates of the size of the homeless population. The present study addresses this and other limitations by using newly available and more reliable estimates from the U. S. Department of Housing and Urban Development to model variation in the rate of homelessness across a large and diverse sample of communities throughout the United States. In doing so, this study builds on the analysis conducted by Lee, Price-Spratlen, and Kanan (2003), and its findings have implications for policy and future research. C1 [Byrne, Thomas; Munley, Ellen A.; Fargo, Jamison D.; Montgomery, Ann E.; Culhane, Dennis P.] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Washington, DC USA. [Byrne, Thomas; Munley, Ellen A.; Montgomery, Ann E.; Culhane, Dennis P.] Univ Penn, Philadelphia, PA 19104 USA. [Fargo, Jamison D.] Utah State Univ, Logan, UT 84322 USA. RP Byrne, T (reprint author), Natl Ctr Homelessness Vet, 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. EM byrnet@sp2.upenn.edu NR 60 TC 4 Z9 4 U1 5 U2 31 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0735-2166 EI 1467-9906 J9 J URBAN AFF JI J. Urban Aff. PD DEC PY 2013 VL 35 IS 5 BP 607 EP 625 DI 10.1111/j.1467-9906.2012.00643.x PG 19 WC Urban Studies SC Urban Studies GA AA2UT UT WOS:000330950400006 ER PT J AU Rahimy, E Beardsley, RM Gomez, J Hung, C Sarraf, D AF Rahimy, Ehsan Beardsley, Robert M. Gomez, Jessica Hung, Crystal Sarraf, David TI Grading of posterior staphyloma with spectral-domain optical coherence tomography and correlation with macular disease SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE LA English DT Article ID HIGHLY MYOPIC EYES; RETINAL-DETACHMENT; REFRACTIVE ERRORS; TRACTION MACULOPATHY; VITREORETINAL INTERFACE; ADULT-POPULATION; NATURAL COURSE; UNITED-STATES; AXIAL LENGTH; RISK-FACTORS AB Objective: To develop a novel grading system for posterior staphyloma imaged by spectral-domain optical coherence tomography (SD-OCT) and to correlate the incidence of macular disease (vitreomacular traction, epiretinal membrane, macular schisis, lamellar macular hole, and full-thickness macular hole) with each grade. Design: Retrospective chart review. Participants: A total of 150 eyes from 89 patients with posterior staphylomas were examined at Jules Stein Eye Institute, University of California Los Angeles. Methods: Retrospective analysis of the Cirrus SD-OCT (Carl Zeiss Meditec, Dublin, Calif.) database at a large institution (Jules Stein Eye Institute) was performed and eyes with a posterior staphyloma involving the macula were evaluated for the presence of macular pathology. The radius of each circle was measured and graded, and the incidence of macular pathology was correlated with each staphyloma grade. Statistical analysis was done using Fisher exact and Kruskal-Wallis tests. Results: The overall incidence rate of macular disease was 50.6% (76/150 eyes). The incidence rate of macular schisis was 17.3% (26/150) and was significantly greater with steeper (grade 3 [25.0%] and grade 4 [30.3%] staphyloma) versus shallower grade (grade 1 [5.6%]) staphyloma (p = 0.016). Conclusions: Imaging of staphyloma via SD-OCT is a valuable tool for determining the severity of posterior staphyloma and for determining risk stratification for various macular diseases. C1 [Rahimy, Ehsan; Beardsley, Robert M.; Gomez, Jessica; Hung, Crystal; Sarraf, David] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu FU Karl Kirchgessner Foundation at the Jules Stein Eye Institute FX This study was supported by a grant from the Karl Kirchgessner Foundation at the Jules Stein Eye Institute. NR 36 TC 2 Z9 2 U1 0 U2 1 PU CANADIAN OPHTHAL SOC PI OTTAWA PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA SN 0008-4182 EI 1715-3360 J9 CAN J OPHTHALMOL JI Can. J. Opthalmol.-J. Can. Opthalmol. PD DEC PY 2013 VL 48 IS 6 BP 539 EP 545 DI 10.1016/j.jcio.2013.07.006 PG 7 WC Ophthalmology SC Ophthalmology GA AA5OQ UT WOS:000331149800033 PM 24314419 ER PT J AU Rapuano, BE MacDonald, DE AF Rapuano, Bruce E. MacDonald, Daniel E. TI Structure-activity relationship of human bone sialoprotein peptides SO EUROPEAN JOURNAL OF ORAL SCIENCES LA English DT Article DE biomimetic; extracellular matrix; integrins; osteoblasts; RGD peptide ID PLASMA GLOW-DISCHARGE; OXIDE NET CHARGE; CELL-ADHESION; TITANIUM-ALLOY; DENTAL IMPLANTS; HUMAN FIBRONECTIN; CRYSTAL-STRUCTURE; INTEGRIN-BINDING; I-TASSER; ATTACHMENT AB In the current study, the relationship between the structure of the RGD-containing human bone sialoprotein (hBSP) peptide 278-293 and its attachment activity toward osteoblast-like (MC3T3) cells was investigated. This goal was accomplished by examining the comparative cell-attachment activities of several truncated forms of peptide 278-293. Computer modeling of the various peptides was also performed to assess the role of secondary structure in peptide bioactivity. Elimination of tyrosine-278 at the N-terminus resulted in a more dramatic loss of cell-attachment activity compared with the removal of either tyrosine-293 or the arg-ala-tyr (291-293) tripeptide. Although replacement of the RGD (arg-gly-asp) peptide moiety with peptide KAE (lys-ala-glu) resulted in a dramatic loss of cell-attachment activity, a peptide containing RGE (arg-gly-glu) in place of RGD retained 70-85% of the parental peptide's attachment activity. These results suggest that the N-terminal RGD-flanking region of hBSP peptide 278-293, in particular the tyrosine-278 residue, represents a second cell-attachment site that stabilizes the RGD-integrin receptor complex. Computer modeling also suggested that a beta-turn encompassing RGD or RGE in some of the hBSP peptides may facilitate its binding to integrins by increasing the exposure of the tripeptide. This knowledge may be useful in the future design of biomimetic peptides which are more effective in promoting the attachment of osteogenic cells to implant surfaces in vivo. C1 [Rapuano, Bruce E.; MacDonald, Daniel E.] Cornell Univ, Weill Med Coll, Hosp Special Surg, New York, NY 10021 USA. [MacDonald, Daniel E.] James J Peters VA Med Ctr, Bronx, NY USA. [MacDonald, Daniel E.] Columbia Univ, Langmuir Ctr Colloids & Interfaces, New York, NY USA. RP MacDonald, DE (reprint author), Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA. EM dem14@columbia.edu FU VA Merit Grant [2894-005]; National Center for Research Resources, NIH [C06-RR12538-01]; [NIH RO1 DE017695] FX This work was supported by VA Merit Grant # 2894-005 and by Grant Number NIH RO1 DE017695 (both awarded to D. E. M.). This material is also the result of work supported with resources and the use of facilities at the James J. Peters VA Medical Center, Bronx, New York. This investigation was also conducted at the HSS research facility constructed with support of Grant C06-RR12538-01 from the National Center for Research Resources, NIH. The authors wish to acknowledge the technical assistance of Christina Silva, Keith Tachibana and Kyle Hackshaw. NR 56 TC 1 Z9 1 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0909-8836 EI 1600-0722 J9 EUR J ORAL SCI JI Eur. J. Oral Sci. PD DEC PY 2013 VL 121 IS 6 BP 600 EP 609 DI 10.1111/eos.12081 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA AA3DO UT WOS:000330973300013 PM 24103036 ER PT J AU Hill, MN Bierer, LM Makotkine, I Golier, JA Galea, S McEwen, BS Hillard, CJ Yehuda, R AF Hill, Matthew N. Bierer, Linda M. Makotkine, Iouri Golier, Julia A. Galea, Sandro McEwen, Bruce S. Hillard, Cecilia J. Yehuda, Rachel TI Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks SO PSYCHONEUROENDOCRINOLOGY LA English DT Article DE Stress; PTSD; Trauma; Endocannabinoid; HPA axis; Cortisol; N-arachidonylethanolamine; Anandamide; 2-Arachidonoylglycerol; Anxiety ID PITUITARY-ADRENAL AXIS; NEUROPEPTIDE-Y CONCENTRATIONS; CONDITIONED FEAR; NERVOUS-SYSTEM; PTSD; INHIBITION; EXTINCTION; ACTIVATION; PLASMA; GLUCOCORTICOIDS AB Endocannabinoid (eCB) signaling has been identified as a modulator of adaptation to stress, and is integral to basal and stress-induced glucocorticoid regulation. Furthermore, interactions between eCBs and glucocorticoids have been shown to be necessary for the regulation of emotional memories, suggesting that eCB function may relate to the development of post-traumatic stress disorder (PTSD). To examine this, plasma eCBs were measured in a sample (n = 46) drawn from a population-based cohort selected for physical proximity to the World Trade Center (WTC) at the time of the 9/11 attacks. Participants received a structured diagnostic interview and were grouped according to whether they met diagnostic criteria for PTSD (no PTSD, n = 22; lifetime diagnosis of PTSD = 24). eCB content (2-arachidonoylglycerol (2-AG) and anandamide (AEA)) and cortisol were measured from 8 a.m. plasma samples. Circulating 2-AG content was significantly reduced among individuals meeting diagnostic criteria for PTSD. The effect of reduced 2-AG content in PTSD remained significant after controlling for the stress of exposure to the WTC collapse, gender, depression and alcohol abuse. There were no significant group differences for AEA or cortisol levels; however, across the whole sample AEA levels positively correlated with circulating cortisol, and AEA levels exhibited a negative relationship with the degree of intrusive symptoms within the PTSD sample. This report shows that PTSD is associated with a reduction in circulating levels of the eCB 2-AG. Given the role of 2-AG in the regulation of the stress response, these data support the hypothesis that deficient eCB signaling may be a component of the glucocorticoid dysregulation associated with PTSD. The negative association between AEA levels and intrusive symptoms is consistent with animal data indicating that reductions in AEA promote retention of aversive emotional memories. Future work will aim to replicate these findings and extend their relevance to clinical pathophysiology, as well as to neuroendocrine and molecular markers of PTSD. (C) 2013 Elsevier Ltd. All rights reserved. C1 [Hill, Matthew N.] Univ Calgary, Hotchkiss Brain Inst, Dept Cell Biol & Anat & Psychiat, Calgary, AB T2N 4N1, Canada. [Hill, Matthew N.; McEwen, Bruce S.] Rockefeller Univ, Neuroendocrinol Lab, New York, NY 10021 USA. [Bierer, Linda M.; Makotkine, Iouri; Golier, Julia A.; Yehuda, Rachel] Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY USA. [Bierer, Linda M.; Makotkine, Iouri; Golier, Julia A.; Yehuda, Rachel] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Galea, Sandro] Columbia Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Hillard, Cecilia J.] Med Coll Wisconsin, Neurosci Res Ctr, Milwaukee, WI 53226 USA. [Hillard, Cecilia J.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA. RP Hill, MN (reprint author), Univ Calgary, Hotchkiss Brain Inst, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada. EM mnhill@ucalgary.ca FU National Institute of Mental Health (NIMH) [1R56MH077321-01]; NIH [DA026996, MH41256]; Lightfighter Foundation; Canadian Institutes of Health Research; Research and Education Initiative Fund, a component of the Advancing a Healtheir Wisconsin endowment at the Medical College of Wisconsin; National Center for Research Resources [5MO1 RR00071]; Department of Veterans Affairs FX This research was supported by National Institute of Mental Health (NIMH) Innovation Award 1R56MH077321-01 (R.Y.) and NIH Grants DA026996 (C.J.H.) and MH41256 (B.S.M.), operating grants from the Lightfighter Foundation (R.Y. and B.S.M.) and the Canadian Institutes of Health Research (M.N.H.). Partial funding for this study came from the Research and Education Initiative Fund, a component of the Advancing a Healtheir Wisconsin endowment at the Medical College of Wisconsin. Funding was also supported, in part, by 5MO1 RR00071 for the Mount Sinai General Clinical Research Center from the National Center for Research Resources. Support for Dr. Yehuda and Dr. Golier is provided by the Department of Veterans Affairs. The funding bodies had no role in the design of this study, the analysis or interpretation of the data or the composition of this manuscript. NR 57 TC 32 Z9 33 U1 1 U2 25 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4530 J9 PSYCHONEUROENDOCRINO JI Psychoneuroendocrinology PD DEC PY 2013 VL 38 IS 12 BP 2952 EP 2961 DI 10.1016/j.psyneuen.2013.08.004 PG 10 WC Endocrinology & Metabolism; Neurosciences; Psychiatry SC Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry GA AA0YX UT WOS:000330824400014 PM 24035186 ER PT J AU Carbone, L Chin, AS Lee, TA Burns, SP Svircev, JN Hoenig, H Akhigbe, T Thomas, F Bailey, L Weaver, F AF Carbone, Laura Chin, Amy S. Lee, Todd A. Burns, Stephen P. Svircev, Jelena N. Hoenig, Helen Akhigbe, Titilola Thomas, Fridtjof Bailey, Lauren Weaver, Frances TI The Association of Anticonvulsant Use with Fractures in Spinal Cord Injury SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Spinal Cord Injury; Anticonvulsants; Fractures; Cox Regression; Survival Analysis ID BONE-MINERAL DENSITY; RANDOMIZED CONTROLLED-TRIAL; ANTIEPILEPTIC DRUGS; HIP-FRACTURES; OLDER MEN; VITAMIN-D; CALCIUM SUPPLEMENTATION; RISK-FACTORS; HEALTH; VETERANS AB Objective: The aim of this study was to determine whether anticonvulsants, including the benzodiazepine subclass, are associated with an increased risk for lower extremity fractures in male patients with spinal cord injury. Design: All male patients with a history of a traumatic spinal cord injury of 2 yrs' duration or longer in the Veterans Affairs Spinal Cord Disease Registry from 2002 to 2007 were included. Incident lower extremity fractures during this period and anticonvulsant use were identified. The association of anticonvulsant use, overall, by type (enzyme inducing, non-enzyme inducing), by number (monotherapy vs. polytherapy), by benzodiazepine subclass, and by individual medication used was determined. Results: In this cohort, 892 veterans sustained a fracture, and 6555 did not. Compared with nonusers of anticonvulsants, there was a significant positive relationship with fractures by overall use of anticonvulsants (HR, 1.17 [95% CI, 1.01-1.36]), by users of the benzodiazepine subclass (HR, 1.28 [95% CI, 1.11-1.47]), and by polytherapy compared with monotherapy (HR, 1.20 [95% CI, 1.00-1.42]) but not by anticonvulsant type (HR, 0.92 [95% CI, 0.58-1.47]). Temazepam (HR, 1.28 [95% CI, 1.01-1.62]), alprazolam (HR, 1.54 [95% CI, 1.04-2.29]), and diazepam (HR, 1.23 [95% CI, 1.06-1.41]) were significantly positively associated with fractures. Conclusions: Attention to fracture prevention is important when anticonvulsants are prescribed in spinal cord injury, particularly when more than one anticonvulsant is used. C1 [Carbone, Laura; Akhigbe, Titilola] Dept Vet Affairs Med Ctr, Memphis, TN USA. [Carbone, Laura; Akhigbe, Titilola] Univ Tennessee, Dept Med, Hlth Sci Ctr, Memphis, TN 38104 USA. [Chin, Amy S.; Lee, Todd A.; Bailey, Lauren; Weaver, Frances] Edward J Hines Jr VA Hosp, Hines, IL USA. [Lee, Todd A.] Univ Illinois, Chicago, IL USA. [Burns, Stephen P.; Svircev, Jelena N.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Burns, Stephen P.; Svircev, Jelena N.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA. [Hoenig, Helen] Durham VAMC, Durham, NC USA. [Thomas, Fridtjof] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA. [Weaver, Frances] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA. RP Carbone, L (reprint author), Georgia Regents Univ, Dept Med, Rheumatol Sect, 1120 15th St,BI 5086, Augusta, GA 30912 USA. FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development [IIR 08-033] FX Supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development IIR 08-033. NR 61 TC 3 Z9 3 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD DEC PY 2013 VL 92 IS 12 BP 1037 EP 1046 DI 10.1097/PHM.0000000000000014 PG 10 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 299DN UT WOS:000330375500001 PM 24252933 ER PT J AU Merkow, RP Bentrem, DJ Mulcahy, MF Chung, JW Abbott, DE Kmiecik, TE Stewart, AK Winchester, DP Ko, CY Bilimoria, KY AF Merkow, Ryan P. Bentrem, David J. Mulcahy, Mary F. Chung, Jeanette W. Abbott, Daniel E. Kmiecik, Thomas E. Stewart, Andrew K. Winchester, David P. Ko, Clifford Y. Bilimoria, Karl Y. TI Effect of Postoperative Complications on Adjuvant Chemotherapy Use for Stage III Colon Cancer SO ANNALS OF SURGERY LA English DT Article DE ACS NSQIP; adjuvant chemotherapy; colon cancer; complications; NCDB ID SURGICAL QUALITY IMPROVEMENT; COLORECTAL-CANCER; UNITED-STATES; THERAPY; FLUOROURACIL; LEVAMISOLE; CARCINOMA; SURGERY; PROGRAM; AGE AB Objective: The National Quality Forum has endorsed a quality metric concerning the use of adjuvant chemotherapy administration in stage III colon cancer, yet a substantial treatment gap exists. Our objective was to evaluate the association of postoperative complications on the use of adjuvant therapy after colectomy for cancer. Patients and Methods: Data from the American College of Surgeons National Surgical Quality Improvement Program and National Cancer Data Base were linked to augment cancer registry information with robust clinical data on comorbidities and postoperative complications (2006-2008). The association of complications on adjuvant chemotherapy use was assessed using hierarchical multivariable regression models. Results: From 126 hospitals, 2368 patients underwent resection for stage III colon adenocarcinoma. Overall utilization of adjuvant chemotherapy was 63.2% (1497/2368). Of the 871 patients who did not receive chemotherapy, 652 met National Quality Forum exclusion criteria: death, severe comorbidity, refusal of care, advanced age (>= 80 years), or prior malignancy. Of the remaining 219 patients, 19.1% (42/219) had 1 or more serious postoperative complications (eg, pneumonia, pulmonary failure). After accounting for the aforementioned potential explanations, the utilization rate was 87.2% (1497/1716). The strongest predictors of adjuvant chemotherapy omission were prolonged postoperative ventilation, renal failure, reintubation, and pneumonia (all Ps < 0.05). Superficial surgical site infection did not decrease adjuvant therapy receipt but delayed the time to its use by 3-fold. Serious complications increased time to chemotherapy by 65%. Abscess/anastomotic leak increased time to adjuvant chemotherapy by more than 5-fold. Conclusions: Serious postoperative complications explained nearly 20% of the adjuvant chemotherapy treatment gap for patients with stage III colon cancer. The use of clinical data remains important when judging provider performance. C1 [Merkow, Ryan P.; Stewart, Andrew K.; Winchester, David P.; Ko, Clifford Y.; Bilimoria, Karl Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA. [Merkow, Ryan P.; Bentrem, David J.; Mulcahy, Mary F.; Chung, Jeanette W.; Kmiecik, Thomas E.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Surg Outcomes & Qual Improvement Ctr, Northwestern Inst Comparat Effectiveness Res Onco, Chicago, IL 60611 USA. [Merkow, Ryan P.; Bentrem, David J.; Mulcahy, Mary F.; Chung, Jeanette W.; Kmiecik, Thomas E.; Bilimoria, Karl Y.] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA. [Merkow, Ryan P.] Univ Chicago, Pritzker Sch Med, Dept Surg, Chicago, IL 60637 USA. [Bentrem, David J.] Jesse Brown VAMC, Dept Surg, Chicago, IL USA. [Abbott, Daniel E.] Univ Cincinnati, Dept Surg, Sch Med, Cincinnati, OH 45267 USA. [Ko, Clifford Y.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Merkow, RP (reprint author), Amer Coll Surg, Div Res & Optimal Patient Care, 633 N St Clair St,22nd Floor, Chicago, IL 60611 USA. EM RMerkow@facs.org FU American Cancer Society [280521]; Northwestern Institute for Comparative Effectiveness Research in Oncology FX Supported in part by the American Cancer Society (#280521) to R.P.M. and K.Y.B. and the Northwestern Institute for Comparative Effectiveness Research in Oncology to R.P.M., K.Y.B., and D.J.B. The authors declare no conflicts of interest. NR 32 TC 29 Z9 29 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD DEC PY 2013 VL 258 IS 6 BP 847 EP 853 DI 10.1097/SLA.0000000000000312 PG 7 WC Surgery SC Surgery GA 300MF UT WOS:000330467300002 PM 24169157 ER PT J AU Lawson, EH Ko, CY Adams, JL Chow, WB Hall, BL AF Lawson, Elise H. Ko, Clifford Y. Adams, John L. Chow, Warren B. Hall, Bruce Lee TI Reliability of Evaluating Hospital Quality by Colorectal Surgical Site Infection Type SO ANNALS OF SURGERY LA English DT Article DE colorectal; quality measure; reliability; surgical site infection ID COMPOSITE END-POINTS; RANDOMIZED-TRIALS; WOUND-INFECTION; RISK-FACTORS; MORTALITY; SURGERY; SURVEILLANCE; RESECTION; COLON; CARE AB Objective: To determine whether risk-adjusted colorectal SSI rates are statistically reliable as hospital quality measures. Background: Policymakers use surgical site infections (SSI) for public reporting of hospital quality and pay-for-performance because they are a relatively common and costly cause of patient morbidity. Methods: Patients who underwent a colorectal procedure in 2009 were identified from the American College of Surgeons National Surgical Quality Improvement Program. We developed hierarchical multivariate logistic models for (1) superficial SSI, (2) deep/organ-space SSI, and (3) "any SSI" and compared how each model ranked hospital-level risk-adjusted performance. Statistical reliability of hospital quality measurements was estimated on a scale from 0 to 1; with 0 indicating that apparent variation between a hospital's quality measurement and the average hospital is statistically unreliable, and 1 indicating that any observed variation is due to a real difference in performance. Results: Mean reliability of hospital-level quality measurements was 0.650 for superficial, 0.404 for deep/organ-space, and 0.586 for "any SSI." Lower reliability was accounted for by relatively little variation in risk-adjusted SSI rates between hospitals and insufficient numbers of colorectal cases submitted by individual hospitals. In 2009, we estimate that 22.1% of all US hospitals performed a sufficient number of colorectal cases to report superficial SSI rates at a high standard of statistical reliability and 1.0% did for deep/organ-space SSI. Conclusions: As currently constructed, colorectal SSI quality measures might not meet a high standard of statistical reliability for most hospitals, limiting their ability to confidently differentiate high and low performance. Despite an expectation of improving statistical power, combining superficial and deep/organ-space SSI into an "any SSI" measure worsens reliability. C1 [Lawson, Elise H.; Ko, Clifford Y.; Chow, Warren B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Lawson, Elise H.; Ko, Clifford Y.; Chow, Warren B.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Adams, John L.] RAND Corp, Santa Monica, CA USA. [Hall, Bruce Lee] Washington Univ, Sch Med, Dept Surg, Barnes Jewish Hosp,St Louis Vet Affairs Med Ctr, St Louis, MO 63110 USA. [Hall, Bruce Lee] Washington Univ, Ctr Hlth Policy, St Louis, MO USA. [Hall, Bruce Lee] Olin Business Sch, St Louis, MO USA. RP Lawson, EH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 10833 Le Conte Ave,72-215 CHS, Los Angeles, CA 90095 USA. EM elawson@mednet.ucla.edu FU VA Health Services Research and Development program [RWJ 65-020]; American College of Surgeons (ACS) through the Robert Wood Johnson Foundation Clinical Scholars Program (RWJF CSP) FX E.H.L.'s time was supported by the VA Health Services Research and Development program (RWJ 65-020) and the American College of Surgeons (ACS) through the Robert Wood Johnson Foundation Clinical Scholars Program (RWJF CSP). J.L.A. and B.L.H. are each consultants for the ACS, W.B.C. is a Scholar in Residence at the ACS, and C.Y.K. is staff at the ACS. This study received no outside funding. The authors declare no conflicts of interest. NR 26 TC 16 Z9 16 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD DEC PY 2013 VL 258 IS 6 BP 994 EP 1000 DI 10.1097/SLA.0b013e3182929178 PG 7 WC Surgery SC Surgery GA 300MF UT WOS:000330467300021 PM 23657082 ER PT J AU Heneghan, AF Pierre, JF Kudsk, KA AF Heneghan, Aaron F. Pierre, Joseph F. Kudsk, Kenneth A. TI IL-25 Improves IgA Levels During Parenteral Nutrition Through the JAK-STAT Pathway SO ANNALS OF SURGERY LA English DT Article DE adaptive immunity; IgA; JAK-STAT; parenteral nutrition; pIgR; small intestine ID POLYMERIC IMMUNOGLOBULIN RECEPTOR; UPPER RESPIRATORY-TRACT; MAJOR ABDOMINAL-TRAUMA; SMOOTH-MUSCLE CELLS; LYMPHOID-TISSUE; SEPTIC MORBIDITY; MUCOSAL IMMUNITY; EOTAXIN RELEASE; RESPONSES; INTERLEUKIN-13 AB Introduction: Parenteral nutrition (PN) impairs mucosal immunity and increases the risk of infection in part via lower IgA levels at mucosal surfaces. Transport of immunoglobulin A (IgA) across the mucosa to the gut lumen depends on the epithelial transport protein, polymeric immunoglobulin receptor (pIgR), which is reduced during PN. In vitro, studies demonstrate that IL-4 up-regulates pIgR production via Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling. Because IL-4 stimulates IgA and is reduced during PN, we hypothesized that the suppressed pIgR is a result of decreased JAK-1 and STAT-6 phosphorylation. Because IL-4 is mediated by IL-25, we also hypothesized that PN + IL-25 would restore luminal IgA by increasing phosphorylated JAK-1 and STAT-6, resulting in increased tissue pIgR and luminal IgA. Method: Experiment 1: 2 days after intravenous cannulation, male Institute of Cancer Research mice were randomized to chow (n = 11) or PN (n = 9). Experiment 2: 2 days after intravenous cannulation, male Institute of Cancer Research mice were randomized to chow (n = 12), PN (n = 10), or PN + 0.7 mu g of exogenous IL-25 (n = 11) per day. After 5 days, distal ileum tissue was collected, homogenized, and protein extracted for JAK-STAT expression levels using a phospho-specific antibody microarray. Tissue was homogenized to measure pIgR expression via Western blot or fixed in 4% paraformaldehyde to measure pIgR expression via immunohistochemistry. Small intestinal wash fluid was collected and IgA was quantified using enzyme-linked immunosorbent assay. Results: Experiment 1: PN significantly reduced phosphorylated JAK-1 and STAT-6 compared with chow. PN also decreased the tissue levels of the Th2 cytokines, IL-4 and IL-13, as well as pIgR, and luminal IgA compared with chow. Experiment 2: Exogenous administration of PN + IL-25 increased the phosphorylated JAK-1 and STAT-6 compared with PN alone. IL-25 completely restored expression of IL-13 to chow levels. IL-4, pIgR, IgA, and phosphorylated JAK-1 were significantly increased with IL-25 treatment compared with PN but failed to reach levels measured in chow. STAT-6 was significantly increased with IL-25 treatment compared with chow and PN. Conclusions: PN significantly decreases the JAK-STAT pathway by reducing levels of phosphorylated STAT-6 and JAK-1. Consistent with our previous work, sIgA, pIgR, and IL-4 decreased with PN, whereas the addition of IL-25 to PN reversed these decreases and demonstrated the role of the JAK-STAT pathway in vivo during PN. C1 [Heneghan, Aaron F.; Pierre, Joseph F.; Kudsk, Kenneth A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Veteran Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), 600 Highland Ave,H4-736, Madison, WI 53792 USA. EM Kudsk@surgery.wisc.edu FU Biomedical Laboratory Research and Development Service of the VA Office of Research and Development [I01BX001672]; National Institute of Health (NIH) [R01 GM53439] FX This project was supported by Award Number I01BX001672 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development. This research is supported by National Institute of Health (NIH) Grant R01 GM53439. The contents of this article do not represent the views of the Veterans Affairs or the United States Government. The authors declare no conflicts of interest. NR 47 TC 5 Z9 6 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD DEC PY 2013 VL 258 IS 6 BP 1065 EP 1071 DI 10.1097/SLA.0b013e318277ea9e PG 7 WC Surgery SC Surgery GA 300MF UT WOS:000330467300031 PM 23160152 ER PT J AU Gupta, PK Sundaram, A MacTaggart, JN Johanning, JM Gupta, H Fang, X Forse, RA Balters, M Longo, GM Sugimoto, JT Lynch, TG Pipinos, II AF Gupta, Prateek K. Sundaram, Abhishek MacTaggart, Jason N. Johanning, Jason M. Gupta, Himani Fang, Xiang Forse, Robert Armour Balters, Marcus Longo, Gernon Matthew Sugimoto, Jeffrey T. Lynch, Thomas G. Pipinos, Iraklis I. TI Preoperative Anemia Is an Independent Predictor of Postoperative Mortality and Adverse Cardiac Events in Elderly Patients Undergoing Elective Vascular Operations SO ANNALS OF SURGERY LA English DT Article DE anemia; endovascular; hemoglobin; outcomes; vascular ID NONCARDIAC SURGERY; BLOOD-TRANSFUSION; EPOETIN-ALPHA; RISK; COHORT; SURVIVAL; OUTCOMES; DISEASE; REPAIR AB Objective: The objective of this study was to assess the impact of preoperative anemia (hematocrit <39%) on postoperative 30-day mortality and adverse cardiac events in patients 65 years or older undergoing elective vascular procedures. Background: Preoperative anemia is associated with adverse outcomes after cardiac surgery, but its association with postoperative outcomes after open and endovascular procedures is not well established. Elderly patients have a decreased tolerance to anemia and are at high risk for complications after vascular procedures. Methods: Patients (N = 31,857) were identified from the American College of Surgeons' 2007-2009 National Surgical Quality Improvement Program-a prospective, multicenter (>250) database maintained across the United States. The primary and secondary outcomes of interest were 30-day mortality and a composite end point of death or cardiac event (cardiac arrest or myocardial infarction), respectively. Results: Forty-seven percent of the study population was anemic. Anemic patients had a postoperative mortality and cardiac event rate of 2.4% and 2.3% in contrast to the 1.2% and 1.2%, respectively, in patients with hematocrit within the normal range (P < 0.0001). On multivariate analysis, we found a 4.2% (95% confidence interval, 1.9-6.5) increase in the adjusted risk of 30-day postoperative mortality for every percentage point of hematocrit decrease from the normal range. Conclusions: The presence and degree of preoperative anemia are independently associated with 30-day death and adverse cardiac events in patients 65 years or older undergoing elective open and endovascular procedures. Identification and treatment of anemia should be important components of preoperative care for patients undergoing vascular operations. C1 [Gupta, Prateek K.] Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA. [Sundaram, Abhishek; Forse, Robert Armour; Balters, Marcus; Sugimoto, Jeffrey T.] Creighton Univ, Dept Surg, Omaha, NE 68178 USA. [MacTaggart, Jason N.; Johanning, Jason M.; Longo, Gernon Matthew; Lynch, Thomas G.; Pipinos, Iraklis I.] Univ Nebraska Med Ctr, Dept Surg, Omaha, NE 68154 USA. [MacTaggart, Jason N.; Johanning, Jason M.; Longo, Gernon Matthew; Lynch, Thomas G.; Pipinos, Iraklis I.] VA Nebraska & Western Iowa Hlth Care Syst, Omaha, NE USA. [MacTaggart, Jason N.; Johanning, Jason M.; Longo, Gernon Matthew; Lynch, Thomas G.; Pipinos, Iraklis I.] Western Iowa Hlth Care Syst, Omaha, NE USA. [Gupta, Himani] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Fang, Xiang] Creighton Univ, Biostat Core, Omaha, NE 68178 USA. RP Pipinos, II (reprint author), Univ Nebraska Med Ctr, Dept Surg, Omaha, NE 68154 USA. EM ipipinos@unmc.edu FU NIH [R01AG034995]; American Vascular Association; Charles and Mary Heider Fund for Excellence in Vascular Surgery FX Supported in part by the NIH grant R01AG034995, the William J. von Liebig Award by the American Vascular Association, and the Charles and Mary Heider Fund for Excellence in Vascular Surgery. NR 31 TC 22 Z9 22 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD DEC PY 2013 VL 258 IS 6 BP 1096 EP 1102 DI 10.1097/SLA.0b013e318288e957 PG 7 WC Surgery SC Surgery GA 300MF UT WOS:000330467300035 PM 23511839 ER PT J AU Navara, CS Hornecker, J Grow, D Chaudhari, S Hornsby, PJ Ichida, JK Eggan, K McCarrey, JR AF Navara, Christopher S. Hornecker, Jacey Grow, Douglas Chaudhari, Shital Hornsby, Peter J. Ichida, Justin K. Eggan, Kevin McCarrey, John R. TI Derivation of Induced Pluripotent Stem Cells from the Baboon: A Nonhuman Primate Model for Preclinical Testing of Stem Cell Therapies SO CELLULAR REPROGRAMMING LA English DT Article ID MARMOSET CALLITHRIX-JACCHUS; LINES; ESTABLISHMENT; BLASTOCYSTS; GENERATION; FIBROBLASTS; MACAQUES; NEURONS; HUMANS; VOLUME AB Development of effective pluripotent stem cell-based therapies will require safety and efficacy testing in a clinically relevant preclinical model such as nonhuman primates (NHPs). Baboons and macaques are equally similar to humans genetically and both have been extensively used for biomedical research. Macaques are preferred for human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) research whereas baboons are preferred for transplantation studies because of the greater similarity of their anatomy and immunogenetic system to those of humans. We generated four induced pluripotent stem cell (iPSC) lines from skin cells of the olive baboon (Papio anubis). Each line shows the distinct morphology of primate pluripotent stem cells, including flat colonies with well-defined borders and a high nuclear/cytoplasm ratio. Each is positive for the pluripotency markers OCT4, SOX2, NANOG, and SSEA4. Pluripotency was confirmed in two lines by teratoma formation with representative tissues from each germ layer, whereas a third produced cells from all three germ layers following embryoid body differentiation. Three lines have a normal male karyotype and the fourth is missing the short arm of one copy of chromosome 18. This may serve as an in vitro model for the human developmental disorder 18p-, which impacts 1 in 50,000 births/year. These iPSC lines represent the first step toward establishing the baboon as a NHP model for developing stem cell-based therapies. C1 [Navara, Christopher S.; Hornecker, Jacey; Grow, Douglas; Chaudhari, Shital; McCarrey, John R.] Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA. [Hornsby, Peter J.] South Texas Vet Hlth Care Syst, San Antonio, TX 78245 USA. [Hornsby, Peter J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78245 USA. [Ichida, Justin K.; Eggan, Kevin] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. [Eggan, Kevin] Howard Hughes Med Inst, Cambridge, MA 02138 USA. RP Navara, CS (reprint author), Univ Texas San Antonio, Dept Biol, San Antonio, TX 78249 USA. EM Christopher.Navara@utsa.edu RI Navara, Christopher/C-2813-2011 FU National Institutes of Health (NIH) [RR022865, HD046732, GM099117] FX This work was partially supported by National Institutes of Health (NIH) grants RR022865 to J.R.M. and HD046732 and GM099117 to K.E. NR 48 TC 1 Z9 1 U1 0 U2 8 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2152-4971 EI 2152-4998 J9 CELL REPROGRAM JI Cell. Reprogramm. PD DEC PY 2013 VL 15 IS 6 BP 495 EP 502 DI 10.1089/cell.2012.0093 PG 8 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Genetics & Heredity SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA 300HC UT WOS:000330454000004 PM 24182315 ER PT J AU Buttenheim, AM Asch, DA AF Buttenheim, Alison M. Asch, David A. TI Making vaccine refusal less of a free ride SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE vaccine hesitancy; immunization; decision-making; free rider; public good AB Herd immunity against vaccine-preventable diseases is a public good because it is both non-excludable (meaning that there is no way to exclude people from using it) and non-rivalrous (meaning that one person's use does not limit or restrict others' use). Like other public goods, such as lighthouses, street lights and national defense, herd immunity is vulnerable to the "free rider" problem. We discuss four conventional responses to the free rider problem (participation mandates, exclusion, incentives, and social norms) and highlight how a public good perspective can inform the design of interventions to increase vaccine acceptance. C1 [Buttenheim, Alison M.] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA. [Buttenheim, Alison M.] Univ Penn, LDI Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA. [Asch, David A.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Asch, David A.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA. RP Buttenheim, AM (reprint author), Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA. EM abutt@nursing.upenn.edu FU NICHD NIH HHS [T32 HD007545] NR 7 TC 3 Z9 3 U1 0 U2 11 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PD DEC PY 2013 VL 9 IS 12 BP 2674 EP 2675 PG 2 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 299GE UT WOS:000330383200036 PM 24088616 ER PT J AU Separovic, D Breen, P Boppana, NB Van Buren, E Joseph, N Kraveka, JM Rahmaniyan, M Li, L Gudz, TI Bielawska, A Bai, A Bielawski, J Pierce, JS Korbelik, M AF Separovic, Duska Breen, Paul Boppana, Nithin B. Van Buren, Eric Joseph, Nicholas Kraveka, Jacqueline M. Rahmaniyan, Mehrdad Li, Li Gudz, Tatyana I. Bielawska, Alicja Bai, Aiping Bielawski, Jacek Pierce, Jason S. Korbelik, Mladen TI Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE apoptosis; ceramide; ceramide synthase; ceramidase; dasatinib; PDT; sphingolipids; sphingosine ID APOPTOTIC PHOTOSENSITIZED CELLS; CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; DE-NOVO SPHINGOLIPIDS; BREAST-CANCER CELLS; HUMAN HEAD; INHIBITOR DASATINIB; OXIDATIVE STRESS; DEATH; KINASE AB Photodynamic therapy (PDT) is not always effective as an anticancer treatment, therefore, PDT is combined with other anticancer agents for improved efficacy. The combination of dasatinib and PDT with the silicone phthalocyanine photosensitizer Pc 4 was assessed for increased killing of SCCVII mouse squamous cell carcinoma cells, a preclinical model of head and neck squamous cell carcinoma, using apoptotic markers and colony formation as experimental end-points. Because each of these treatments regulates the metabolism of the sphingolipid ceramide, their effects on mRNA levels of ceramide synthase, a ceramide-producing enzyme, and the sphingolipid profile were determined. PDT + dasatinib induced an additive loss of clonogenicity. Unlike PDT alone or PDT + dasatinib, dasatinib induced zVAD-fmk-dependent cell killing. PDT or dasatinib-induced caspase-3 activation was potentiated after the combination. PDT alone induced mitochondrial depolarization, and the effect was inhibited after the combination. Annexin V+ and propidium iodide+ cells remained at control levels after treatments. In contrast to PDT alone, dasatinib induced upregulation of ceramide synthase 1 mRNA, and the effect was enhanced after the combination. Dasatinib induced a modest increase in C20:1-and C22-ceramide but had no effect on total ceramide levels. PDT increased the levels of 12 individual ceramides and total ceramides, and the addition of dasatinib did not affect these increases. PDT alone decreased substantially sphingosine levels and inhibited the activity of acid ceramidase, an enzyme that converts ceramide to sphingosine. The data suggest that PDT-induced increases in ceramide levels do not correlate with ceramide synthase mRNA levels but rather with inhibition of ceramidase. Cell killing was zVAD-fmk-sensitive after dasatinib but not after either PDT or the combination and enhanced cell killing after the combination correlated with potentiated caspase-3 activation and upregulation of ceramide synthase 1 mRNA but not the production of ceramide. The data imply potential significance of the combination for cancer treatment. C1 [Separovic, Duska; Breen, Paul; Boppana, Nithin B.; Joseph, Nicholas] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Detroit, MI 48201 USA. [Separovic, Duska; Van Buren, Eric] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48201 USA. [Kraveka, Jacqueline M.; Rahmaniyan, Mehrdad; Li, Li] Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, Charles Darby Childrens Res Inst, Charleston, SC 29425 USA. [Kraveka, Jacqueline M.; Rahmaniyan, Mehrdad; Li, Li] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA. [Gudz, Tatyana I.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Gudz, Tatyana I.] Med Univ S Carolina, Dept Neurosci, Charleston, SC 29425 USA. [Bielawska, Alicja; Bai, Aiping; Bielawski, Jacek; Pierce, Jason S.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Korbelik, Mladen] British Columbia Canc Agcy, Vancouver, BC V5Z 1L3, Canada. RP Separovic, D (reprint author), Wayne State Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, 259 Mack Ave, Detroit, MI 48201 USA. EM dseparovic@wayne.edu FU U.S. Public Health Service from the National Cancer Institute (NCI), National Institutes of Health (NIH) [R01 CA77475]; NIH [P20-RR17677]; Rally Foundation for Childhood Cancer Research; Hyundai Hope on Wheels; Monica Kreber Golf Tournament; Chase after a Cure Foundation; Veterans Administration Merit Awards from RRD program; Veterans Administration Merit Awards from BLRD program; (Karmanos Cancer Institute, Wayne State University), NCI [P30 CA22453]; (Medical University of South Carolina), NCI [IPO1CA097132, P30 CA 138313]; NIH/NCRR SC COBRE from the Extramural Research Facilities Program of the National Center for Research Resources [P20 RR017677, C06 RR018823] FX This study was supported by U.S. Public Health Service Grants: to D. S., R01 CA77475 from the National Cancer Institute (NCI), National Institutes of Health (NIH); to J.M.K., P20-RR17677 (NIH), grants from the Rally Foundation for Childhood Cancer Research, Hyundai Hope on Wheels, Monica Kreber Golf Tournament, and Chase after a Cure Foundation; to T. I. G., the Veterans Administration Merit Awards from RR&D and BLRD programs; to the flow cytometry-related work at the Microscopy, Imaging, and Cytometry Resources Core (Karmanos Cancer Institute, Wayne State University), NCI Grant P30 CA22453; to the MS-related work at the Lipidomics Shared Resource (Medical University of South Carolina), NCI Grants IPO1CA097132 and P30 CA 138313, NIH/NCRR SC COBRE Grant P20 RR017677, C06 RR018823 from the Extramural Research Facilities Program of the National Center for Research Resources. NR 37 TC 6 Z9 6 U1 2 U2 10 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1019-6439 EI 1791-2423 J9 INT J ONCOL JI Int. J. Oncol. PD DEC PY 2013 VL 43 IS 6 BP 2064 EP 2072 DI 10.3892/ijo.2013.2132 PG 9 WC Oncology SC Oncology GA 297AA UT WOS:000330225800039 PM 24126464 ER PT J AU Bayoumi, AM Barnett, PG Joyce, VR Griffin, SC Sun, HY Bansback, NJ Holodniy, M Sanders, G Brown, ST Kyriakides, TC Angus, B Cameron, DW Anis, AH Sculpher, M Owens, DK AF Bayoumi, Ahmed M. Barnett, Paul G. Joyce, Vilija R. Griffin, Susan C. Sun, Huiying Bansback, Nick J. Holodniy, Mark Sanders, Gillian Brown, Sheldon T. Kyriakides, Tassos C. Angus, Brian Cameron, D. William Anis, Aslam H. Sculpher, Mark Owens, Douglas K. TI Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE novel antiretroviral drugs; multidrug-resistant HIV infection; cost-effectiveness analysis; quality of life; health economics ID PLACEBO-CONTROLLED TRIAL; OPTIMIZED BACKGROUND THERAPY; QUALITY-OF-LIFE; PREVIOUSLY TREATED PATIENTS; LONG-TERM EFFICACY; HIV-1-INFECTED PATIENTS; INFECTED PATIENTS; DOUBLE-BLIND; TIPRANAVIR-RITONAVIR; PROTEASE INHIBITORS AB Objective: Newer antiretroviral drugs provide substantial benefits but are expensive. The cost-effectiveness of using antiretroviral drugs in combination for patients with multidrug-resistant HIV disease was determined. Design: A cohort state-transition model was built representing treatment-experienced patients with low CD4 counts, high viral load levels, and multidrug-resistant virus. The effectiveness of newer drugs (those approved in 2005 or later) was estimated from published randomized trials. Other parameters were estimated from a randomized trial and from the literature. The model had a lifetime time horizon and used the perspective of an ideal insurer in the United States. The interventions were combination antiretroviral therapy, consisting of 2 newer drugs and 1 conventional drug, compared with 3 conventional drugs. Outcome measures were life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness. Results: Substituting newer antiretroviral drugs increased expected survival by 3.9 years in advanced HIV disease. The incremental cost-effectiveness ratio of newer, compared with conventional, antiretroviral drugs was $75,556/QALY gained. Sensitivity analyses showed that substituting only one newer antiretroviral drug cost $54,559 to $68,732/QALY, depending on assumptions about efficacy. Substituting 3 newer drugs cost $105,956 to $117,477/QALY. Cost-effectiveness ratios were higher if conventional drugs were not discontinued. Conclusions: In treatment-experienced patients with advanced HIV disease, use of newer antiretroviral agents can be cost-effective, given a cost-effectiveness threshold in the range of $50,000 to $75,000 per QALY gained. Newer antiretroviral agents should be used in carefully selected patients for whom less expensive options are clearly inferior. C1 [Bayoumi, Ahmed M.] St Michaels Hosp, Ctr Res Inner City Hlth, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada. [Bayoumi, Ahmed M.] Univ Toronto, Dept Med, Toronto, ON, Canada. [Bayoumi, Ahmed M.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Bayoumi, Ahmed M.] St Michaels Hosp, Div Gen Internal Med, Toronto, ON M5B 1W8, Canada. [Barnett, Paul G.; Joyce, Vilija R.] VA Palo Alto Hlth Care Syst, VA HSR&D Hlth Econ Resource Ctr, VA Cooperat Studies Program Coordinating Ctr, Menlo Pk, CA USA. [Griffin, Susan C.; Sculpher, Mark] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England. [Sun, Huiying] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada. [Sun, Huiying] CIHR Canadian HIV Trials Network, Vancouver, BC, Canada. [Bansback, Nick J.; Anis, Aslam H.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada. [Holodniy, Mark; Owens, Douglas K.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Holodniy, Mark; Owens, Douglas K.] Stanford Univ, Dept Med, Stanford, CA 94305 USA. [Sanders, Gillian] Duke Univ, Duke Clin Res Inst, Durham, NC USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA. [Brown, Sheldon T.] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Kyriakides, Tassos C.] VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA. [Angus, Brian] MRC Clin Trials Unit, London, England. [Angus, Brian] Univ Oxford, Nuffield Dept Med, Oxford, England. [Cameron, D. William] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada. [Owens, Douglas K.] Stanford Univ, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA. [Owens, Douglas K.] Stanford Univ, Ctr Hlth Policy, Stanford, CA 94305 USA. RP Bayoumi, AM (reprint author), St Michaels Hosp, Ctr Res Inner City Hlth, 30 Bond St, Toronto, ON M5B 1W8, Canada. EM ahmed.bayoumi@utoronto.ca OI Cameron, Bill/0000-0002-0090-3539 FU Canadian Institutes of Health Research/Ontario Ministry of Health & Long-Term Care Applied Chair in Health Services and Policy Research; Ontario Ministry of Health and Long-Term Care; US Department of Veterans Affairs Cooperative Studies Program; UK Medical Research Council; Canadian Institutes of Health Research; National Institutes of Health [1RC1AI086927-01, 2 R01 DA15612-016]; Department of Veterans Affairs FX A.M.B is supported by a Canadian Institutes of Health Research/Ontario Ministry of Health & Long-Term Care Applied Chair in Health Services and Policy Research. The Center for Research on Inner City Health is supported in part by a grant from the Ontario Ministry of Health and Long-Term Care. The US Department of Veterans Affairs Cooperative Studies Program, the UK Medical Research Council, and the Canadian Institutes of Health Research funded the OPTIMA trial for Health Research. This work was supported in part by Grants 1RC1AI086927-01 and 2 R01 DA15612-016 from the National Institutes of Health. D.K.O., P. G. B., M. H., S. T. B., and T. C. K. are supported by the Department of Veterans Affairs. NR 50 TC 2 Z9 2 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD DEC 1 PY 2013 VL 64 IS 4 BP 382 EP 391 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300HE UT WOS:000330454200009 PM 24129369 ER PT J AU De Genna, NM Feske, U AF De Genna, Natacha M. Feske, Ulrike TI Phenomenology of Borderline Personality Disorder The Role of Race and Socioeconomic Status SO JOURNAL OF NERVOUS AND MENTAL DISEASE LA English DT Article DE Borderline personality disorder; health disparities; women; race; suicide ID AFRICAN-AMERICAN SUICIDE; SUBSTANCE USE-DISORDERS; HISPANIC MEN; SELF-INJURY; DRUG-USE; PREVALENCE; BEHAVIOR; CRITERIA; VIOLENCE; COMORBIDITY AB Little is known about racial differences in borderline personality disorder (BPD) that may influence etiology, phenomenology, and treatment of women with BPD. A total of 83 women with BPD participated in this cross-sectional study: n = 41 white and n = 42 African-American women. Structured interviews were used to assess Axis I and II disorders, and a series of interviews and questionnaires captured internalizing and externalizing symptoms. The white women with BPD reported more severe internalizing symptoms, whereas the African-American women reported more severe externalizing symptoms. Except for the association between race and number of suicide attempts, the relationship between race and internalizing/ externalizing symptoms was mediated by socioeconomic status. In conclusion, African-American women with BPD may present with more severe symptoms of lack of anger control and fewer suicidal behaviors than those of white women with BPD, raising the possibility that they are misdiagnosed and receive treatments that are not optimal for BPD. C1 [De Genna, Natacha M.] Univ Pittsburgh, Dept Psychiat, Sch Med, WPIC, Pittsburgh, PA 15213 USA. [Feske, Ulrike] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. RP De Genna, NM (reprint author), Univ Pittsburgh, Dept Psychiat, Sch Med, WPIC, 3811 OHara St, Pittsburgh, PA 15213 USA. EM degennan@pitt.edu FU NIH [DA025734, DA020130]; Borderline Personality Disorder Research Foundation FX This work was funded by the NIH (DA025734, PI: De Genna; DA020130, PI: Feske) and the Borderline Personality Disorder Research Foundation (Young Investigator Award, PI: Feske). The authors have no other financial disclosures to report. NR 71 TC 2 Z9 2 U1 4 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0022-3018 EI 1539-736X J9 J NERV MENT DIS JI J. Nerv. Ment. Dis. PD DEC PY 2013 VL 201 IS 12 BP 1027 EP 1034 DI 10.1097/NMD.0000000000000053 PG 8 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 299EP UT WOS:000330378700003 PM 24284636 ER PT J AU Nakamoto, BK Shikuma, CM Ogata-Arakaki, D Umaki, T Neuwelt, EA Shiramizu, BT Chow, DC Parikh, NI Kallianpur, KJ Hamilton, BE AF Nakamoto, Beau K. Shikuma, Cecilia M. Ogata-Arakaki, Debra Umaki, Tracie Neuwelt, Edward A. Shiramizu, Bruce T. Chow, Dominic C. Parikh, Nisha I. Kallianpur, Kalpana J. Hamilton, Bronwyn E. TI Feasibility and potential role of ferumoxytol-enhanced neuroimaging in HIV-associated neurocognitive disorder SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE HIV; HIV dementia; MRI; Ferumoxytol ID CENTRAL-NERVOUS-SYSTEM; ANTIRETROVIRAL THERAPY; IMPAIRMENT; INFECTION; AIDS; ERA AB We assessed ferumoxytol-enhanced brain MRI to identify monocyte/macrophage accumulation in HIV-associated neurocognitive disorder (HAND). Four HIV-infected subjects with undetectable HIV RNA levels on antiretroviral therapy, HIV DNA level in CD14+ cells >= 10 copies/10(6) cells, and cognitive impairment underwent ferumoxytol-enhanced brain MRI. On post-ferumoxytol susceptibility-weighted images, all HIV-infected subjects demonstrated a diffuse "tram track" appearance in the perivascular regions of cortical and deep white matter vessels suggesting ferumoxytol uptake in monocytes/macrophages. This finding was not present in an HIV-seronegative control. While ferumoxytol may have potential as an imaging biomarker for monocyte/macrophage accumulation in patients with HAND, future study is needed. C1 [Nakamoto, Beau K.; Shikuma, Cecilia M.; Ogata-Arakaki, Debra; Umaki, Tracie; Shiramizu, Bruce T.; Chow, Dominic C.; Parikh, Nisha I.; Kallianpur, Kalpana J.] Univ Hawaii, Hawaii Ctr AIDS, Honolulu, HI 96822 USA. [Nakamoto, Beau K.] Straub Clin & Hosp, Honolulu, HI USA. [Hamilton, Bronwyn E.] Oregon Hlth & Sci Univ, Dept Radiol, Portland, OR 97201 USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Neuwelt, Edward A.] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA. [Neuwelt, Edward A.] Portland VA Med Ctr, Portland, OR USA. [Parikh, Nisha I.] Queens Med Ctr, Dept Cardiol, Honolulu, HI USA. [Nakamoto, Beau K.] Univ Hawaii Manoa, John A Burns Sch Med, Hawaii Ctr AIDS, Honolulu, HI 96816 USA. RP Nakamoto, BK (reprint author), Univ Hawaii Manoa, John A Burns Sch Med, Hawaii Ctr AIDS, 3675 Kilauea Ave,Young Bldg,5th Floor, Honolulu, HI 96816 USA. EM beau_nakamoto@yahoo.com; shikuma@hawaii.edu; ogataara@hawaii.edu; tracieu2@hawaii.edu; neuwelte@ohsu.edu; bshirami@hawaii.edu; dominicc@hawaii.edu; parikh.nisha@gmail.com; kalpana@hawaii.edu; hamiltob@ohsu.edu FU NIH [U54MD007584, U54NS43049, P20RR011091, R01HL095135, R01 CA137488, R01 NS044687, R01 NS053468, R01NS053345, K23 HL088981, U19MH081835]; Pfizer; Merck; Gilead Pharmaceuticals FX Dr. Nakamoto has received research support from NIH (U54MD007584). Dr. Nakamoto declares that there are no conflicts of interest.; Dr. Shikuma has received research support from NIH (U54MD007584, U54NS43049, P20RR011091, and R01HL095135) Pfizer, Merck, and Gilead Pharmaceuticals, and has served on an advisory board for Glaxo Smith Kline. Dr. Shikuma declares that there are no conflicts of interest.; Dr. Neuwelt has received research support from NIH (R01 CA137488, R01 NS044687, R01 NS053468). Dr. Neuwelt declares that there are no conflicts of interest.; Dr. Shiramizu has received research support from NIH (R01NS053345, U54MD007584, U54NS43049). Dr. Shiramizu declares that there are no conflicts of interest.; Dr. Chow has received research support from NIH (K23 HL088981). Dr. Chow declares that there are no conflicts of interest.; Dr. Kallianpur has received research support from NIH (U54MD007584, U19MH081835, U54MD007584). Dr. Kallianpur declares that there are no conflicts of interest. NR 15 TC 2 Z9 2 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD DEC PY 2013 VL 19 IS 6 BP 601 EP 605 DI 10.1007/s13365-013-0213-7 PG 5 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 296WU UT WOS:000330216900011 PM 24129909 ER PT J AU Tuomela, J Sandholm, J Kauppila, JH Lehenkari, P Harris, KW Selander, KS AF Tuomela, Johanna Sandholm, Jouko Kauppila, Joonas H. Lehenkari, Petri Harris, Kevin W. Selander, Katri S. TI Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer SO ONCOLOGY LETTERS LA English DT Article DE chloroquine; hypoxia; toll-like receptor-9; triple-negative breast cancer ID POTENTIAL MEDIATORS; CELLULAR INVASION; CELLS; ACTIVATION; GROWTH; LINES; AKT; P53 AB Toll-like receptor-9 (TLR9) is an intracellular DNA receptor that is widely expressed in breast and other cancers. We previously demonstrated that low tumor TLR9 expression upon diagnosis is associated with significantly shortened disease-specific survival times in patients with triple-negative breast cancer (TNBC). There are no targeted therapies for this subgroup of patients whose prognosis is among the worst in breast cancer. Due to the previously detected in vitro anti-invasive effects of chloroquine in these cell lines, the present study aimed to investigate the in vivo effects of chloroquine against two clinical subtypes of TNBC that differ in TLR9 expression. Chloroquine suppressed matrix metalloproteinase (MMP)-2 and MMP-9 mRNA expression and protein activity, whereas MMP-13 mRNA expression and proteolytic activity were increased. Despite enhancing TLR9 mRNA expression, chloroquine suppressed TLR9 protein expression in vitro. Daily treatment of mice with intraperitoneal (i.p.) chloroquine (80 mg/kg/day) for 22 days, did not inhibit the growth of control siRNA or TLR9 siRNA MDA-MB-231 breast cancer cells. In conclusion, despite the favorable in vitro effects on TNBC invasion and viability, particularly in hypoxic conditions, chloroquine does not prevent the growth of the triple-negative MDA-MB-231 cells with high or low TLR9 expression levels in vivo. This may be explained by the activating effects of chloroquine on MMP-13 expression or by the fact that chloroquine, by suppressing TLR9 expression, permits the activation of currently unknown molecular pathways, which allow the aggressive behavior of TNBC cells with low TLR9 expression in hypoxia. C1 [Tuomela, Johanna; Sandholm, Jouko; Harris, Kevin W.; Selander, Katri S.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Tuomela, Johanna] Univ Turku, MediC PET Preclin Imaging, Turku PET Ctr, Turku 20521, Finland. [Sandholm, Jouko] Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland. [Sandholm, Jouko] Abo Akad Univ, FIN-20520 Turku, Finland. [Kauppila, Joonas H.; Lehenkari, Petri] Univ Oulu, Dept Anat & Cell Biol, Oulu 90014, Finland. [Kauppila, Joonas H.; Lehenkari, Petri] Univ Hosp Oulu, Dept Surg, Oulu 90020, Finland. [Kauppila, Joonas H.] Univ Hosp Oulu, Dept Pathol, Oulu 90020, Finland. [Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Selander, KS (reprint author), Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, SHEL 514,1825 Univ Blvd, Birmingham, AL 35294 USA. EM Katriselander@uabmc.edu RI Kauppila, Joonas/P-1363-2015; Lehenkari, Petri/O-3009-2016 OI Kauppila, Joonas/0000-0001-6740-3726; Lehenkari, Petri/0000-0002-0055-5183; Tuomela, Johanna/0000-0003-4390-4563 FU Department of Defense [W81XWH-10-1-0308]; Lapland Cultural Foundation; Elsa U. Pardee Foundation; Maud Kuistila Memorial Foundation; Finnish Cultural Foundation; Emil Aaltonen Foundation; Cancer Foundation of Northern Ostrobotnia; Oulu University Research Foundation; Georg C. and Mary Ehrnroot Foundation; Orion-Farmos Research Foundation; Finnish Medical Foundation FX This study was funded by grants from the Department of Defense (W81XWH-10-1-0308, K.S.S.), Lapland Cultural Foundation (K.S.S.), Elsa U. Pardee Foundation (K.S.S.), Maud Kuistila Memorial Foundation (J.T.), Finnish Cultural Foundation (J.S.), Emil Aaltonen Foundation (J.H.K.), Cancer Foundation of Northern Ostrobotnia (J.H.K.), Oulu University Research Foundation (J.H.K.), Georg C. and Mary Ehrnroot Foundation (J.H.K.), Orion-Farmos Research Foundation (J.H.K.) and the Finnish Medical Foundation (J.H.K.). Christine Pressey is acknowledged for providing assistance with the qPCR assays. NR 25 TC 3 Z9 4 U1 0 U2 3 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1792-1074 EI 1792-1082 J9 ONCOL LETT JI Oncol. Lett. PD DEC PY 2013 VL 6 IS 6 BP 1665 EP 1672 DI 10.3892/ol.2013.1602 PG 8 WC Oncology SC Oncology GA AA0LQ UT WOS:000330787000023 ER PT J AU Nguyen, JT Nguyen, JL Wheatley, MJ Nguyen, TA AF Nguyen, Jesse T. Nguyen, Jenny L. Wheatley, Michael J. Nguyen, Tuan A. TI Muscle hernias of the leg: A case report and comprehensive review of the literature SO CANADIAN JOURNAL OF PLASTIC SURGERY LA English DT Review DE Leg; Muscle hernia; Peroneus brevis; Review ID ANTERIOR TIBIALIS MUSCLE; PERONEAL COMPARTMENT SYNDROME; GASTROCNEMIUS-MUSCLE; FASCIAL DEFECT; LONGUS MUSCLE; DONOR-SITE; REPAIR; NERVE; MESH; COMPLICATION AB A case involving a retired, elderly male war veteran with a symptomatic peroneus brevis muscle hernia causing superficial peroneal nerve compression with chosen surgical management is presented. Symptomatic muscle hernias of the extremities occur most commonly in the leg and are a rare cause of chronic leg pain. Historically, treating military surgeons pioneered the early documentation of leg hernias observed in active military recruits. A focal fascial defect can cause a muscle to herniate, forming a variable palpable subcutaneous mass, and causing pain and potentially neuropathic symptoms with nerve involvement. While the true incidence is not known, the etiology has been classified as secondary to a congenital (or constitutional) fascial weakness, or acquired fascial defect, usually secondary to direct or indirect trauma. The highest occurrence is believed to be in young, physically active males. Involvement of the tibialis anterior is most common, although other muscles have been reported. Dynamic ultrasonography or magnetic resonance imaging is often used to confirm diagnosis and guide treatment. Most symptomatic cases respond successfully to conservative treatment, with surgery reserved for refractory cases. A variety of surgical techniques have been described, ranging from fasciotomy to anatomical repair of the fascial defect, with no consensus on optimal treatment. Clinicians must remember to consider muscle hernias in their repertoire of differential diagnoses for chronic leg pain or neuropathy. A comprehensive review of muscle hernias of the leg is presented to highlight their history, occurrence, presentation, diagnosis and treatment. C1 [Nguyen, Jesse T.] Mayo Clin, Dept Gen Surg, Rochester, MN USA. [Nguyen, Jenny L.] Michigan State Univ, Grand Rapids Med Educ Partners, Dept Plast Surg, Grand Rapids, MI USA. [Wheatley, Michael J.; Nguyen, Tuan A.] Portland VA Med Ctr, Div Plast Surg, Portland, OR USA. RP Nguyen, TA (reprint author), Portland Veteran Affairs Med Ctr, Div Plast Surg, 3710 Southwest,US Vet Hosp Rd, Portland, OR 97239 USA. EM tuan.nguyen6@VA.gov NR 68 TC 6 Z9 7 U1 0 U2 2 PU PULSUS GROUP INC PI OAKVILLE PA 2902 S SHERIDAN WAY, OAKVILLE, ONTARIO L6J 7L6, CANADA SN 1195-2199 J9 CAN J PLAST SURG JI Can. J. Plast. Surg. PD WIN PY 2013 VL 21 IS 4 BP 243 EP 247 PG 5 WC Surgery SC Surgery GA 296NN UT WOS:000330191900009 PM 24497767 ER PT J AU Omer, S Kar, B Cornwell, LD Blaustein, A Levine, GN Ali, N Jneid, H Paniagua, D Atluri, PV Bechara, CF Kougias, P Ruma, M Preventza, O Bozkurt, B Carabello, BA Bakaeen, FG AF Omer, Shuab Kar, Biswajit Cornwell, Lorraine D. Blaustein, Alvin Levine, Glen N. Ali, Nadir Jneid, Hani Paniagua, David Atluri, Prasad V. Bechara, Carlos F. Kougias, Panos Ruma, Maryrose Preventza, Ourania Bozkurt, Biykem Carabello, Blase A. Bakaeen, Faisal G. TI Early Experience of a Transcatheter Aortic Valve Program at a Veterans Affairs Facility SO JAMA SURGERY LA English DT Article ID HIGH-RISK PATIENTS; INOPERABLE PATIENTS; COST-EFFECTIVENESS; EDWARDS-SAPIEN; TRIAL COHORT; HEART-VALVE; REPLACEMENT; IMPLANTATION; STENOSIS; OUTCOMES AB IMPORTANCE The US Food and Drug Administration recently approved the use of a transcatheter aortic valve in patients for whom traditional valve replacement surgery poses a high or prohibitive risk. Our hospital was one of the first Veterans Affairs facilities to launch a transcatheter aortic valve replacement (TAVR) program. OBJECTIVE To evaluate our early experience with transfemoral TAVR. DESIGN AND SETTING We retrospectively reviewed the records of all patients who underwent TAVR during the first year of our program at the Department of Cardiothoracic Surgery, Michael E. DeBakey Veterans Affairs Medical Center. PARTICIPANTS The mean (SD) age of the patients was 77 (9) years, and their mean (SD) Society of Thoracic Surgeons predicted risk of mortality score was 8.8 (10.7). INTERVENTIONS All patients underwent TAVR with the SAPIEN transcutaneous valve. MAIN OUTCOME MEASURES We evaluated operative mortality and major operative morbidity (stroke, myocardial infarction, renal failure necessitating dialysis, and requirement for mechanical circulatory support, as well as vascular complications and requirement for permanent pacemaker), in addition to length of hospital stay and discharge status. RESULTS Between December 21, 2011, and December 13, 2012, a total of 19 transfemoral TAVR procedures were performed at our center. Implantation was successful in all cases. There were no reports of operative (30-day) mortality, prosthetic valve endocarditis, renal failure necessitating dialysis, perioperative myocardial infarction or stroke, or conversion to surgical aortic valve replacement. Seven patients (37%) had mild paravalvular leak, 3 patients (16%) had moderate paravalvular leak, 2 patients (11%) had groin wound complications, 2 patients (11%) required a permanent pacemaker, 1 patient (5%) had a vascular access complication requiring endovascular repair, and 1 patient (5%) required temporary circulatory support (with extracorporeal membrane oxygenation). The mean (SD) length of hospital stay after TAVR was 8.0 (5.9) days. All patients were discharged home. CONCLUSIONS AND RELEVANCE Transcatheter aortic valve replacement can be performed safely and with good outcomes at a Veterans Affairs facility with a committed multidisciplinary team and substantial experience in heart valve and endovascular therapies. C1 [Omer, Shuab; Cornwell, Lorraine D.; Preventza, Ourania] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Cardiothorac Surg, Houston, TX USA. [Omer, Shuab; Kar, Biswajit; Cornwell, Lorraine D.; Blaustein, Alvin; Levine, Glen N.; Ali, Nadir; Jneid, Hani; Paniagua, David; Atluri, Prasad V.; Bechara, Carlos F.; Kougias, Panos; Ruma, Maryrose; Bozkurt, Biykem; Carabello, Blase A.; Bakaeen, Faisal G.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Kar, Biswajit; Blaustein, Alvin; Levine, Glen N.; Ali, Nadir; Jneid, Hani; Paniagua, David; Bozkurt, Biykem; Carabello, Blase A.] Baylor Coll Med, Dept Cardiol, Houston, TX 77030 USA. [Atluri, Prasad V.] Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA. [Bechara, Carlos F.; Kougias, Panos] Baylor Coll Med, Div Vasc Surg, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Preventza, Ourania; Carabello, Blase A.; Bakaeen, Faisal G.] Texas Heart Inst, Houston, TX 77025 USA. RP Omer, S (reprint author), DeBakey Vet Affairs Med Ctr, Mail Code 112,Operat Care Line,2002 Holcombe Blvd, Houston, TX 77030 USA. EM shuab.omer@bcm.edu NR 29 TC 5 Z9 5 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD DEC PY 2013 VL 148 IS 12 BP 1087 EP 1093 DI 10.1001/jamasurg.2013.3743 PG 7 WC Surgery SC Surgery GA 295LD UT WOS:000330116700006 PM 24048246 ER PT J AU Jones, TS Dunn, CL Wu, DS Cleveland, JC Kile, D Robinson, TN AF Jones, Teresa S. Dunn, Christina L. Wu, Daniel S. Cleveland, Joseph C., Jr. Kile, Deidre Robinson, Thomas N. TI Relationship Between Asking an Older Adult About Falls and Surgical Outcomes SO JAMA SURGERY LA English DT Article ID GERIATRIC SYNDROMES; ELDERLY-PATIENTS; CARDIAC-SURGERY; FRAILTY; COMPLICATIONS; PREDICTOR; MORBIDITY; MORTALITY; RISK; CARE AB IMPORTANCE More than one-third of all US inpatient operations are performed on patients aged 65 years and older. Existing preoperative risk assessment strategies are not adequate to meet the needs of the aging population. OBJECTIVES To evaluate the relationship of a history of falls (a geriatric syndrome) to postoperative outcomes in older adults undergoing major elective operations. DESIGN, SETTING, AND PARTICIPANTS This prospective, cohort study was conducted at a referral medical center. Persons aged 65 years and older undergoing elective colorectal and cardiac operations were enrolled. The predictor variable was having fallen in the 6 months prior to the operation. MAIN OUTCOMES AND MEASURES Postoperative outcomes measured included 30-day complications, the need for discharge institutionalization, and 30-day readmission. RESULTS There were 235 subjects with a mean (SD) age of 74 (6) years. Preoperative falls occurred in 33%. One or more postoperative complications occurred more frequently in the group with prior falls compared with the nonfallers following both colorectal (59% vs 25%; P = .004) and cardiac (39% vs 15%; P = .002) operations. These findings were independent of advancing chronologic age. The need for discharge to an institutional care facility occurred more frequently in the group that had fallen in comparison with the nonfallers in both the colorectal (52% vs 6%; P < .001) and cardiac (62% vs 32%; P = .001) groups. Similarly, 30-day readmission was higher in the group with prior falls following both colorectal (P = .04) and cardiac (P = .02) operations. CONCLUSIONS AND RELEVANCE A history of 1 or more falls in the 6 months prior to an operation forecasts increased postoperative complications, the need for discharge institutionalization, and 30-day readmission across surgical specialties. Using a history of prior falls in preoperative risk assessment for an older adult represents a shift from current preoperative assessment strategies. C1 [Jones, Teresa S.; Dunn, Christina L.; Wu, Daniel S.; Cleveland, Joseph C., Jr.; Robinson, Thomas N.] Univ Colorado, Sch Med, Dept Surg, Aurora, CO 80045 USA. [Cleveland, Joseph C., Jr.; Robinson, Thomas N.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Kile, Deidre] Univ Colorado, Colorado Hlth Outcomes Program, Aurora, CO 80045 USA. RP Robinson, TN (reprint author), Univ Colorado, Sch Med, MS C313,12631 E 17th Ave, Aurora, CO 80045 USA. EM thomas.robinson@ucdenver.edu FU NHLBI NIH HHS [K24 HL089223]; NIA NIH HHS [K23 AG034632] NR 20 TC 21 Z9 21 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD DEC PY 2013 VL 148 IS 12 BP 1132 EP 1138 DI 10.1001/jamasurg.2013.2741 PG 7 WC Surgery SC Surgery GA 295LD UT WOS:000330116700015 PM 24108317 ER PT J AU Redmond, N Richman, J Gamboa, CM Albert, MA Sims, M Durant, RW Glasser, SP Safford, MM AF Redmond, Nicole Richman, Joshua Gamboa, Christopher M. Albert, Michelle A. Sims, Mario Durant, Raegan W. Glasser, Stephen P. Safford, Monika M. TI Perceived Stress Is Associated With Incident Coronary Heart Disease and All-Cause Mortality in Low- but Not High-Income Participants in the Reasons for Geographic And Racial Differences in Stroke Study SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE epidemiology; mortality; myocardial infarction; stress ID MAJOR RISK-FACTORS; SOCIOECONOMIC-STATUS; CARDIOVASCULAR-DISEASE; UNITED-STATES; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY; PSYCHOLOGICAL DISTRESS; ATHEROSCLEROSIS RISK; MULTIPLE IMPUTATION; HEALTH AB Background-Perceived stress may increase risk for coronary heart disease (CHD) and death, but few studies have examined these relationships longitudinally. We sought to determine the association of perceived stress with incident CHD and all-cause mortality. Methods and Results-Data were from a prospective study of 24 443 participants without CHD at baseline from the national Reasons for Geographic And Racial Differences in Stroke (REGARDS) study cohort. Outcomes were expert-adjudicated acute CHD and all-cause mortality. Over a mean follow-up of 4.2 (maximum 6.9) years, there were 659 incident CHD events and 1320 deaths. Analyses were stratified by income level because of significant interactions with stress. For individuals with low income, 3529 (35.4%) reported high stress, and for those with high income, 2524 (22.1%) did so. Compared with reporting no stress, those reporting the highest stress had higher risk for incident CHD if they reported low income (sociodemographic-adjusted HR 1.36, 95% CI: 1.04, 1.78) but not high income (sociodemographic-adjusted HR 0.82, 95% CI: 0.57, 1.16); the finding in low income individuals attenuated with adjustment for clinical and behavioral factors (HR 1.29, 95% CI: 0.99, 1.69, P=0.06). After full adjustment, the highest stress category was associated with higher risk for death among those with low income (HR 1.55, 95% CI: 1.31, 1.82) but not high income (HR 1.13, 95% CI: 0.88, 1.46). Conclusions-High stress was associated with greater risks of CHD and death for individuals with low but not high income. C1 [Redmond, Nicole; Gamboa, Christopher M.; Durant, Raegan W.; Glasser, Stephen P.; Safford, Monika M.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL 35294 USA. [Richman, Joshua] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Gamboa, Christopher M.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA. [Albert, Michelle A.] Howard Univ, Coll Med, Div Cardiovasc Med, Washington, DC USA. [Sims, Mario] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA. [Durant, Raegan W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Redmond, N (reprint author), Univ Alabama Birmingham, Div Prevent Med, 1717 11th Ave South,Med Towers 610, Birmingham, AL 35294 USA. EM nredmond@uabmc.edu OI Glasser, Stephen/0000-0001-9620-6406 FU National Institute of Neurological Disorders and Stroke (NINDS) [U01NS041588]; National Heart, Lung, and Blood Institute (NHLBI) [R01HL080477, K24HL111154]; NHLBI [R01HL080477-07S1]; Centers for Medicare & Medicaid Services [1CMS331071-01-00, 1CMS331300-01-00]; Amgen Corporation FX REGARDS is supported by cooperative agreement U01NS041588 from the National Institute of Neurological Disorders and Stroke (NINDS, Dr G. Howard, PI). Dr Safford is supported by grants R01HL080477 and K24HL111154 from the National Heart, Lung, and Blood Institute (NHLBI). Dr Redmond is supported by Minority Investigator Research Supplement R01HL080477-07S1 from NHLBI and grants 1CMS331071-01-00 and 1CMS331300-01-00 from the Centers for Medicare & Medicaid Services. Both Drs Safford and Glasser are supported by investigator-initiated grant-in-aid from Amgen Corporation. NR 56 TC 23 Z9 23 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD DEC PY 2013 VL 2 IS 6 AR e000447 DI 10.1161/JAHA.113.000447 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 296IG UT WOS:000330177900040 PM 24356528 ER PT J AU Zhang, XC Xu, C Mitchell, RM Zhang, B Zhao, D Li, Y Huang, X Fan, WH Wang, HW Lerma, LA Upton, MP Hay, A Mendez, E Zhao, LP AF Zhang, Xinyi Cindy Xu, Chang Mitchell, Ryan M. Zhang, Bo Zhao, Derek Li, Yao Huang, Xin Fan, Wenhong Wang, Hongwei Lerma, Luisa Angelica Upton, Melissa P. Hay, Ashley Mendez, Eduardo Zhao, Lue Ping TI Tumor Evolution and Intratumor Heterogeneity of an Oropharyngeal Squamous Cell Carcinoma Revealed by Whole-Genome Sequencing SO NEOPLASIA LA English DT Article ID INTRONIC VARIANTS; NECK-CANCER; HEAD; MUTATIONS; METASTASIS; EXPRESSION; THERAPY; PATHWAY; GENE; DNA AB Head and neck squamous cell carcinoma (HNSCC) is characterized by significant genomic instability that could lead to clonal diversity. Intratumor clonal heterogeneity has been proposed as a major attribute underlying tumor evolution, progression, and resistance to chemotherapy and radiation. Understanding genetic heterogeneity could lead to treatments specific to resistant and metastatic tumor cells. To characterize the degree of intratumor genetic heterogeneity within a single tumor, we performed whole-genome sequencing on three separate regions of an human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma and two separate regions from one corresponding cervical lymph node metastasis. This approach achieved coverage of approximately 97.9% of the genome across all samples. In total, 5701 somatic point mutations (SPMs) and 4347 small somatic insertions and deletions (indels) were detected in at least one sample. Ninety-two percent of SPMs and 77% of indels were validated in a second set of samples adjacent to the discovery set. All five tumor samples shared 41% of SPMs, 57% of the 1805 genes with SPMs, and 34 of 55 cancer genes. The distribution of SPMs allowed phylogenetic reconstruction of this tumor's evolutionary pathway and showed that the metastatic samples arose as a late event. The degree of intratumor heterogeneity showed that a single biopsy may not represent the entire mutational landscape of HNSCC tumors. This approach may be used to further characterize intratumor heterogeneity in more patients, and their sample-to-sample variations could reveal the evolutionary process of cancer cells, facilitate our understanding of tumorigenesis, and enable the development of novel targeted therapies. C1 [Zhang, Xinyi Cindy; Zhang, Bo; Zhao, Derek; Li, Yao; Huang, Xin; Fan, Wenhong; Wang, Hongwei; Hay, Ashley; Zhao, Lue Ping] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [Xu, Chang; Mitchell, Ryan M.; Lerma, Luisa Angelica; Mendez, Eduardo] Univ Washington, Sch Med, Dept Otolaryngol Head & Neck Surg, Seattle, WA USA. [Xu, Chang; Mendez, Eduardo] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA. [Upton, Melissa P.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA. [Mendez, Eduardo] VA Puget Sound Hlth Care Syst, Surg & Perioperat Care Serv, Seattle, WA USA. [Zhao, Lue Ping] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA. RP Mendez, E (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,POB 19024,Mailstop D5-390, Seattle, WA 98109 USA. EM edmendez@u.washington.edu; lzhao@fhcrc.org FU National Institutes of Health, Early Physician-Scientist Career Development Award from the Howard Hughes Medical Institute [CA119225, MH084621, R01MH084621-03S2, R01CA124574-01, 5T32DC000018-29]; American Cancer Society [RSG TBG-123653]; center funds from the Department of Otolaryngology-Head and Neck Surgery, University of Washington and VA Puget Sound Health Care System, Seattle, WA FX This work was supported in part by grants CA119225, MH084621, R01MH084621-03S2, R01CA124574-01, and 5T32DC000018-29 from National Institutes of Health, Early Physician-Scientist Career Development Award from the Howard Hughes Medical Institute, grant RSG TBG-123653 from the American Cancer Society, and center funds from the Department of Otolaryngology-Head and Neck Surgery, University of Washington and VA Puget Sound Health Care System, Seattle, WA. NR 27 TC 26 Z9 27 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1522-8002 EI 1476-5586 J9 NEOPLASIA JI Neoplasia PD DEC PY 2013 VL 15 IS 12 BP 1371 EP + DI 10.1593/neo.131400 PG 10 WC Oncology SC Oncology GA 295PO UT WOS:000330128200006 PM 24403859 ER PT J AU Brennan, MA Gallun, FJ Souza, PE Stecker, GC AF Brennan, Marc A. Gallun, Frederick J. Souza, Pamela E. Stecker, G. Christopher TI Temporal Resolution With a Prescriptive Fitting Formula SO AMERICAN JOURNAL OF AUDIOLOGY LA English DT Article DE amplification or hearing aids; psychoacoustics; adults with hearing loss ID FAST-ACTING COMPRESSION; SPEECH RECOGNITION; HEARING; AMPLIFICATION; LISTENERS; LOUDNESS AB Purpose: Authors of previous work using laboratory-based paradigms documented that wide dynamic range compression (WDRC) may improve gap detection compared to linear amplification. The purpose of this study was to measure temporal resolution using WDRC fit with compression ratios set for each listener's hearing loss. Method: Nineteen adults with mild-to-moderate hearing loss fitted with WDRC or linear amplification set to a prescriptive fitting method participated in this study. Subjects detected amplitude modulations and gaps. Two types of noise carrier were used: narrowband (1995-2005 Hz) and broadband (100-8000 Hz). Results: Small differences between WDRC and linear amplification were observed in the measures of temporal resolution. Modulation detection thresholds worsened by a mean of 0.7 dB with WDRC compared to linear amplification. This reduction was observed for both carrier types. Gap detection thresholds did not differ between the 2 amplification conditions. Conclusions: WDRC set using a prescriptive fitting method with individualized compression ratios had a small but statistically significant effect on measures of modulation thresholds. Differences were not observed between the two amplification conditions for the measures of gap detection. These findings contrast with previous work using fixed compression ratios, suggesting that the effect of the fitting method on the compression ratio should be considered when attempting to generalize the effect of WDRC on temporal resolution to the clinical setting. C1 [Brennan, Marc A.; Stecker, G. Christopher] Univ Washington, Seattle, WA 98195 USA. [Gallun, Frederick J.] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR USA. [Souza, Pamela E.] Northwestern Univ, Evanston, IL USA. RP Brennan, MA (reprint author), Univ Washington, Seattle, WA 98195 USA. EM Marc.Brennan@boystown.org FU National Institutes of Health [F31 DC010978-01, P30 DC 04661, T32 DC000033, R01 DC011548, R01 DC006014, I01 RX000536, VA-RRD CD2 C4963W] FX The authors wish to thank Ryan McCreery for assistance with the statistical analysis. This work was supported by National Institutes of Health Grants F31 DC010978-01, P30 DC 04661, T32 DC000033, R01 DC011548, R01 DC006014, I01 RX000536, and VA-RR&D CD2 C4963W. A portion of these data were presented at the 2010 American Auditory Society Annual Meeting and at the 2010 International Hearing Aid Research Conference. NR 35 TC 3 Z9 3 U1 0 U2 3 PU AMER SPEECH-LANGUAGE-HEARING ASSOC PI ROCKVILLE PA 10801 ROCKVILLE PIKE, ROCKVILLE, MD 20852-3279 USA SN 1059-0889 EI 1558-9137 J9 AM J AUDIOL JI Am. J. Audiol. PD DEC PY 2013 VL 22 IS 2 BP 216 EP 225 DI 10.1044/1059-0889(2013/13-0001) PG 10 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 294EF UT WOS:000330024500003 PM 23824436 ER PT J AU John, J Thannickal, TC McGregor, R Ramanathan, L Ohtsu, H Nishino, S Sakai, N Yamanaka, A Stone, C Cornford, M Siegel, JM AF John, Joshi Thannickal, Thomas C. McGregor, Ronald Ramanathan, Lalini Ohtsu, Hiroshi Nishino, Seiji Sakai, Noriaki Yamanaka, Akhiro Stone, Carly Cornford, Marcia Siegel, Jerome M. TI Greatly Increased Numbers of Histamine Cells in Human Narcolepsy with Cataplexy SO ANNALS OF NEUROLOGY LA English DT Article ID CEREBROSPINAL-FLUID HISTAMINE; HYPOCRETIN OREXIN; PARKINSONS-DISEASE; TUBEROMAMMILLARY NUCLEUS; HISTIDINE-DECARBOXYLASE; NEURONS; SYSTEM; RECEPTOR; MICE; SLEEP AB ObjectiveTo determine whether histamine cells are altered in human narcolepsy with cataplexy and in animal models of this disease. MethodsImmunohistochemistry for histidine decarboxylase (HDC) and quantitative microscopy were used to detect histamine cells in human narcoleptics, hypocretin (Hcrt) receptor-2 mutant dogs, and 3 mouse narcolepsy models: Hcrt (orexin) knockouts, ataxin-3-orexin, and doxycycline-controlled-diphtheria-toxin-A-orexin. ResultsWe found an average 64% increase in the number of histamine neurons in human narcolepsy with cataplexy, with no overlap between narcoleptics and controls. However, we did not see altered numbers of HDC cells in any of the animal models of narcolepsy. InterpretationChanges in histamine cell numbers are not required for the major symptoms of narcolepsy, because all animal models have these symptoms. The histamine cell changes we saw in humans did not occur in the 4 animal models of Hcrt dysfunction we examined. Therefore, the loss of Hcrt receptor-2, of the Hcrt peptide, or of Hcrt cells is not sufficient to produce these changes. We speculate that the increased histamine cell numbers we see in human narcolepsy may instead be related to the process causing the human disorder. Although research has focused on possible antigens within the Hcrt cells that might trigger their autoimmune destruction, the present findings suggest that the triggering events of human narcolepsy may involve a proliferation of histamine-containing cells. We discuss this and other explanations of the difference between human narcoleptics and animal models of narcolepsy, including therapeutic drug use and species differences. Ann Neurol 2013;74:786-793 C1 [John, Joshi; Thannickal, Thomas C.; McGregor, Ronald; Ramanathan, Lalini; Stone, Carly; Siegel, Jerome M.] Univ Calif Los Angeles, Inst Neuropsychiat, Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [John, Joshi; Thannickal, Thomas C.; McGregor, Ronald; Ramanathan, Lalini; Stone, Carly; Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA. [Ohtsu, Hiroshi] Tohoku Univ, Grad Sch Engn, Sendai, Miyagi 980, Japan. [Nishino, Seiji; Sakai, Noriaki] Stanford Univ, Sch Med, Stanford Sleep Res Ctr, Palo Alto, CA 94304 USA. [Yamanaka, Akhiro] Nagoya Univ, Environm Med Res Inst, Dept Neurosci 2, Nagoya, Aichi 464, Japan. [Cornford, Marcia] Harbor Univ Calif, Los Angeles Med Ctr, Dept Pathol, Torrance, CA USA. RP John, J (reprint author), Univ Calif Los Angeles, VA GLAHS, 16111 Plummer St, North Hills, CA 91343 USA. EM jjohn@ucla.edu; thomastc@ucla.edu; JSiegel@ucla.edu FU Medical Research Service of the Department of Veterans Affairs; NIH [NS14610, MH064109] FX This study was supported by the Medical Research Service of the Department of Veterans Affairs and NIH grants NS14610 and MH064109 to J.M.S. NR 47 TC 32 Z9 32 U1 1 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0364-5134 EI 1531-8249 J9 ANN NEUROL JI Ann. Neurol. PD DEC PY 2013 VL 74 IS 6 BP 786 EP 793 DI 10.1002/ana.23968 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 292GV UT WOS:000329891100009 PM 23821583 ER PT J AU Carchman, EH Whelan, S Loughran, P Mollen, K Stratamirovic, S Shiva, S Rosengart, MR Zuckerbraun, BS AF Carchman, Evie H. Whelan, Sean Loughran, Patricia Mollen, Kevin Stratamirovic, Sladjana Shiva, Sruti Rosengart, Matthew R. Zuckerbraun, Brian S. TI Experimental sepsis-induced mitochondrial biogenesis is dependent on autophagy, TLR4, and TLR9 signaling in liver SO FASEB JOURNAL LA English DT Article DE lipopolysaccharide; Toll-like receptor 4; VPS34; peroxisome proliferator-activated receptor-gamma coactivator; PGC-1 alpha ID NITRIC-OXIDE; IN-VITRO; INFLAMMATORY RESPONSES; ADAPTIVE IMMUNITY; INNATE; DNA; FAILURE; MICE; HEPATOCYTES; ACTIVATION AB Organ injury in sepsis is initially characterized by dysfunction without cell death and structural damage, and thus with the ability to recover organ function. Adaptive metabolic responses to sepsis can prevent bioenergetic failure and death. These studies were aimed at investigating the influence of sepsis on mitochondrial homeostasis, focusing on removal of dysfunctional mitochondria and restitution of a healthy mitochondrial population. These data demonstrate decreased hepatic oxidative phosphorylation by 31 +/- 11% following murine cecal ligation and puncture (CLP) at 8 h and 34 +/- 9% following LPS treatment in vitro at 12 h (P<0.05). In addition, there was a loss of mitochondrial membrane potential. Mitochondrial density and number initially decreased (relative area per micrograph of 64 +/- 10% at baseline vs. 39 +/- 13% at 8 h following LPS; P<0.05) and was associated with an increase in autophagy and mitophagy. CLP-induced markers of mitochondrial biogenesis and mitochondrial number and density recovered over time. Furthermore, these data suggest that mitochondrial biogenesis was dependent on an autophagy and mitochondrial DNA/Toll-like receptor 9 (TLR9) signaling pathway. These results suggest that hepatocyte survival and maintenance of function in sepsis is dependent on a mitochondrial homeostasis pathway marked by mitophagy and biogenesis. C1 [Carchman, Evie H.; Whelan, Sean; Loughran, Patricia; Mollen, Kevin; Stratamirovic, Sladjana; Rosengart, Matthew R.; Zuckerbraun, Brian S.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Shiva, Sruti] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA. [Shiva, Sruti; Zuckerbraun, Brian S.] Univ Pittsburgh, Vasc Med Inst, Pittsburgh, PA USA. [Carchman, Evie H.; Loughran, Patricia; Stratamirovic, Sladjana; Zuckerbraun, Brian S.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Zuckerbraun, BS (reprint author), F1200PUH,200 Lothrop St, Pittsburgh, PA 15213 USA. EM zuckerbraunbs@upmc.edu FU U.S. National Institutes of Health [R01 GM082830, GM082852]; U.S. Veterans Affairs Merit Award [1I01BX000566]; U.S. Department of Defense grant [DM102439] FX This work is supported by U.S. National Institutes of Health grants R01 GM082830 (B.S.Z.) and GM082852 (M. R. R.), U.S. Veterans Affairs Merit Award 1I01BX000566 (B.S.Z.), and U.S. Department of Defense grant DM102439 (B.S.Z.). Author contributions: E. H. C. and B.S.Z., study concept and design; E. H. C., S. P. W., and P. L., acquisition of data; E. H. C., M. R. R., S.Sh., K. P. M., and B.S.Z., analysis and interpretation of data; E. H. C., S. P. M., and B.S.Z., drafting of the manuscript; E. H. C. and B.S.Z., critical revision of the manuscript for important intellectual content and statistical analysis; B.S.Z., acquisition of funding; S.St., technical support. The authors declare no conflicts of interest. NR 36 TC 23 Z9 30 U1 0 U2 17 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD DEC PY 2013 VL 27 IS 12 BP 4703 EP 4711 DI 10.1096/fj.13-229476 PG 9 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 293UK UT WOS:000329999000006 PM 23982147 ER PT J AU Lee, RJ Chen, B Doghramji, L Adappa, ND Palmer, JN Kennedy, DW Cohen, NA AF Lee, Robert J. Chen, Bei Doghramji, Laurel Adappa, Nithin D. Palmer, James N. Kennedy, David W. Cohen, Noam A. TI Vasoactive intestinal peptide regulates sinonasal mucociliary clearance and synergizes with histamine in stimulating sinonasal fluid secretion SO FASEB JOURNAL LA English DT Article DE allergic rhinitis; chronic rhinosinusitis; ciliary beat frequency; cystic fibrosis transmembrane conductance regulator; CFTR ID CILIARY BEAT FREQUENCY; HUMAN NASAL-MUCOSA; PERENNIAL ALLERGIC RHINITIS; SEROUS ACINAR-CELLS; CHRONIC RHINOSINUSITIS; CYSTIC-FIBROSIS; NITRIC-OXIDE; RECEPTOR PHARMACOLOGY; NEUTRAL ENDOPEPTIDASE; MESSENGER-RNA AB Mucociliary clearance (MCC) is the primary physical airway defense against inhaled pathogens and particulates. MCC depends on both proper fluid/mucus homeostasis and epithelial ciliary beating. Vasoactive intestinal peptide (VIP) is a neurotransmitter expressed in the sinonasal epithelium that is up-regulated in allergy. However, the effects of VIP on human sinonasal physiology are unknown, as are VIP's interactions with histamine, a major regulator of allergic disease. We imaged ciliary beat frequency, mucociliary transport, apical Cl- permeability, and airway surface liquid (ASL) height in primary human sinonasal air-liquid-interface cultures to investigate the effects of VIP and histamine. VIP stimulated an increase in ciliary beat frequency (EC50 0.5 mu M; maximal increase similar to 40% compared with control) and cystic fibrosis transmembrane conductance regulator (CFTR)-dependent and Na(+)K(+)2Cl(-) cotransporter-dependent fluid secretion, all requiring cAMP/PKA signaling. Histamine activated Ca2+ signaling that increased ASL height but not ciliary beating. Low concentrations of VIP and histamine had synergistic effects on CFTR-dependent fluid secretion, revealed by increased ASL heights. An up-regulation of VIP in histamine-driven allergic rhinitis would likely enhance mucosal fluid secretion and contribute to allergic rhinorrhea. Conversely, a loss of VIP-activated secretion in patients with CF may impair mucociliary transport, contributing to increased incidences of sinonasal infections and rhinosinusitis. C1 [Lee, Robert J.; Chen, Bei; Doghramji, Laurel; Adappa, Nithin D.; Palmer, James N.; Kennedy, David W.; Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Cohen, NA (reprint author), Hosp Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Ravdin Bldg,5th Floor,3400 Spruce St, Philadelphia, PA 19104 USA. EM cohenn@uphs.upenn.edu OI Cohen, Noam/0000-0002-9462-3932; Lee, Robert/0000-0001-5826-6686 FU Flight Attendants Medical Research Institute FX This work was supported by a grant from The Flight Attendants Medical Research Institute and a philanthropic contribution from the RLG Foundation, Inc. (to N.A.C.). NR 69 TC 18 Z9 18 U1 0 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD DEC PY 2013 VL 27 IS 12 BP 5094 EP 5103 DI 10.1096/fj.13-234476 PG 10 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA 293UK UT WOS:000329999000041 PM 23934280 ER PT J AU Wang, J Tang, C Ferruzzi, MG Gong, B Song, BJ Janle, EM Chen, TY Cooper, B Varghese, M Cheng, A Freire, D Bilski, A Roman, J Nguyen, T Ho, L Talcott, ST Simon, JE Wu, QL Pasinetti, GM AF Wang, Jun Tang, Cheuk Ferruzzi, Mario G. Gong, Bing Song, Brian J. Janle, Elsa M. Chen, Tzu-Ying Cooper, Bruce Varghese, Merina Cheng, Alice Freire, Daniel Bilski, Amanda Roman, Jessica Tuyen Nguyen Ho, Lap Talcott, Stephen T. Simon, James E. Wu, Qingli Pasinetti, Giulio M. TI Role of standardized grape polyphenol preparation as a novel treatment to improve synaptic plasticity through attenuation of features of metabolic syndrome in a mouse model SO MOLECULAR NUTRITION & FOOD RESEARCH LA English DT Article DE Metabolic syndrome; Polyphenols; Standardized grape polyphenol preparation; Synaptic plasticity ID INDEPENDENT COMPONENT ANALYSIS; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE; COGNITIVE DETERIORATION; DIETARY POLYPHENOLS; RATS; RESVERATROL; NEUROPATHOLOGY; MEMORY; SUPPLEMENTATION AB ScopeMetabolic syndrome has become an epidemic and poses tremendous burden on the health system. People with metabolic syndrome are more likely to experience cognitive decline. As obesity and sedentary lifestyles become more common, the development of early prevention strategies is critical. In this study, we explore the potential beneficial effects of a combinatory polyphenol preparation composed of grape seed extract, Concord purple grape juice extract, and resveratrol, referred to as standardized grape polyphenol preparation (SGP), on peripheral as well as brain dysfunction induced by metabolic syndrome. Methods and resultsWe found dietary fat content had minimal effect on absorption of metabolites of major polyphenols derived from SGP. Using a diet-induced animal model of metabolic syndrome (DIM), we found that brain functional connectivity and synaptic plasticity are compromised in the DIM mice. Treatment with SGP not only prevented peripheral metabolic abnormality but also improved brain synaptic plasticity. ConclusionOur study demonstrated that SGP, comprised of multiple bioavailable and bioactive components targeting a wide range of metabolic syndrome related pathological features, provides greater global protection against peripheral and central nervous system dysfunctions and can be potentially developed as a novel prevention/treatment for improving brain connectivity and synaptic plasticity important for learning and memory. C1 [Wang, Jun; Gong, Bing; Varghese, Merina; Cheng, Alice; Freire, Daniel; Bilski, Amanda; Ho, Lap; Pasinetti, Giulio M.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Tang, Cheuk; Roman, Jessica; Tuyen Nguyen] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA. [Ferruzzi, Mario G.; Song, Brian J.; Janle, Elsa M.; Chen, Tzu-Ying; Cooper, Bruce] Purdue Univ, Dept Food Sci, W Lafayette, IN 47907 USA. [Talcott, Stephen T.] Purdue Univ, Dept Foods & Nutr, W Lafayette, IN 47907 USA. [Talcott, Stephen T.] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX USA. [Wang, Jun; Simon, James E.; Wu, Qingli] Rutgers State Univ, Dept Plant Biol & Pathol, New Use Agr & Nat Plant Prod Program, New Brunswick, NJ 08903 USA. [Ho, Lap; Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Pasinetti, GM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 FU NIH [AT004511] FX This study was supported by NIH grant AT004511. NR 48 TC 10 Z9 10 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1613-4125 EI 1613-4133 J9 MOL NUTR FOOD RES JI Mol. Nutr. Food Res. PD DEC PY 2013 VL 57 IS 12 BP 2091 EP 2102 DI 10.1002/mnfr.201300230 PG 12 WC Food Science & Technology SC Food Science & Technology GA 293AZ UT WOS:000329945100001 PM 23963661 ER PT J AU Walker, RH Fink, JK AF Walker, Ruth H. Fink, John K. TI Morphea and Parry-Romberg syndrome associated with a mixed movement disorder SO PARKINSONISM & RELATED DISORDERS LA English DT Letter DE Parry-Romberg; Morphea; Scleroderma; Dystonia; Hemiparkinsonism ID LOCALIZED SCLERODERMA; FOCAL DYSTONIA C1 [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY 10468 USA. [Walker, Ruth H.] Mt Sinai Sch Med, New York, NY USA. [Fink, John K.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [Fink, John K.] Ann Arbor Vet Med Ctr, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA. RP Walker, RH (reprint author), James J Peters Vet Affairs Med Ctr, Dept Neurol, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM ruth.walker@mssm.edu FU NINDS NIH HHS [R01 NS069700, R01NS069700] NR 5 TC 1 Z9 2 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8020 EI 1873-5126 J9 PARKINSONISM RELAT D JI Parkinsonism Relat. Disord. PD DEC PY 2013 VL 19 IS 12 BP 1169 EP 1170 DI 10.1016/j.parkreldis.2013.07.025 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 295AV UT WOS:000330089900021 PM 23968650 ER PT J AU Wei, JX Mialki, RK Dong, S Khoo, A Mallampalli, RK Zhao, YT Zhao, J AF Wei, Jianxin Mialki, Rachel K. Dong, Su Khoo, Andrew Mallampalli, Rama K. Zhao, Yutong Zhao, Jing TI A new mechanism of RhoA ubiquitination and degradation: Roles of SCFFBXL19 E3 ligase and Erk2 SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH LA English DT Article DE Small GTPase protein; Protein stability; Ubiquitin-proteasome system; Phosphorylation; Cell proliferation; Stress fiber ID SIGNAL-INDUCED UBIQUITINATION; KAPPA-B-ALPHA; F-BOX; DEPENDENT PROTEOLYSIS; ACTIN CYTOSKELETON; CELL-CYCLE; PROTEASOME PATHWAY; C-MYC; PROTEIN; PHOSPHORYLATION AB RhoA is a small GTPase multifunctional protein that regulates cell proliferation and cytoskeletal reorganization. Regulation of its protein stability plays an important role in its biological functions. We have shown that a Skp1-Cul1-F-box (SCF) FBXL19 E3 ubiquitin ligase targets Rac1, a related member of the Rho family for ubiquitination and degradation. Here, SCFFBXL19:19 mediates RhoA ubiquitination and proteasomal degradation in lung epithelial cells. Ectopically expressed FBXL19 decreased RhoA wild type, active, and inactive forms. Cellular depletion of FBXL19 increased RhoA protein levels and extended its half-life. FBXL19 bound the small GTPase in the cytoplasm leading to RhoA ubiquitination at Lys(135). A RhoA(K135R) mutant protein was resistant to SCFFBXL19-mediated ubiquitination and degradation and exhibited a longer lifespan. Protein kinase Erk2-mediated phosphorylation of RhoA was both sufficient and required for SCFFBXL19-mediated RhoA ubiquitination and degradation. Thus, SCFFBXL19 targets RhoA for its disposal, a process regulated by Erk2. Ectopically expressed FBXL19 reduced phosphorylation of p27 and cell proliferation, a process mediated by RhoA. Further, FBXL19 cellular expression diminished lysophosphatidic acid (LPA)-induced phosphorylation of myosin light chain (MLC) and stress fiber formation. Hence, SCFFBXL19 functions as a RhoA antagonist during cell proliferation and cytoskeleton rearrangement These results provide the first evidence of an F-box protein targeting RhoA thereby modulating its cellular lifespan that impacts cell proliferation and cytoskeleton rearrangement. (c) 2013 Elsevier B.V. All rights reserved. C1 [Wei, Jianxin; Mialki, Rachel K.; Dong, Su; Khoo, Andrew; Mallampalli, Rama K.; Zhao, Yutong; Zhao, Jing] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA. [Wei, Jianxin; Mialki, Rachel K.; Dong, Su; Khoo, Andrew; Mallampalli, Rama K.; Zhao, Yutong; Zhao, Jing] Univ Pittsburgh, Sch Med, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA. [Dong, Su] Jilin Univ, Hosp 1, Dept Anesthesia, Changchun 130023, Jilin, Peoples R China. RP Zhao, J (reprint author), Univ Pittsburgh, Sch Med, Dept Med, 3459 5th Ave NW,628 MUH, Pittsburgh, PA 15213 USA. EM zhaoj@upmc.edu RI Wei, Jianxin/P-5431-2016 FU US National Institutes of Health [RO1 HL01916, HL112791, HL096376, HL097376, HL098174]; American Heart Association [12SDG9050005]; US Department of Veterans Affairs FX This study was supported by the US National Institutes of Health RO1 HL01916 and HL112791 (to Y.Z.), HL096376, HL097376 and HL098174 (to R.K.M.), American Heart Association awards 12SDG9050005 (J.Z.), and a Merit Review Award from the US Department of Veterans Affairs (to R.K.M.). NR 43 TC 14 Z9 15 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0167-4889 EI 0006-3002 J9 BBA-MOL CELL RES JI Biochim. Biophys. Acta-Mol. Cell Res. PD DEC PY 2013 VL 1833 IS 12 BP 2757 EP 2764 DI 10.1016/j.bbamcr2013.07.005 PG 8 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 288FA UT WOS:000329596200019 PM 23871831 ER PT J AU Tai, B Saxon, AJ Ling, W AF Tai, Betty Saxon, Andrew J. Ling, Walter TI Medication-assisted therapy for opioid addiction SO JOURNAL OF FOOD AND DRUG ANALYSIS LA English DT Article; Proceedings Paper CT International Conference on Global Health (ICGH) CY APR 17-19, 2013 CL Taipei, TAIWAN DE Buprenorphine; Chronic care model; Methadone; Opioid addiction ID BUPRENORPHINE-NALOXONE; CARE AB The "Medication-Assisted Therapy for Opioid Addiction" session was chaired by Dr Betty Tai and had three presenters. The presenters (and their topics) were: Dr Andrew J. Saxon (methadone and buprenorphine for treatment of opioid addiction and human immunodeficiency virus risk reduction); Dr Walter Ling (opioid antagonist treatment for opioid addiction); and Dr Betty Tai (chronic care model for substance use disorder). Copyright (C) 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan LLC. All rights reserved. C1 [Tai, Betty] Natl Inst Drug Abuse, Ctr Clin Trials Network, Bethesda, MD 20892 USA. [Saxon, Andrew J.] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Ling, Walter] Univ Calif Los Angeles, David Geffen Sch Med, Integrated Subst Abuse Programs, Los Angeles, CA 90095 USA. RP Tai, B (reprint author), Natl Inst Drug Abuse, Ctr Clin Trials Network, 6001 Execut Blvd, Bethesda, MD 20892 USA. EM btai@nida.nih.gov FU NIDA NIH HHS [P30 DA016383, R13 DA035084] NR 11 TC 4 Z9 4 U1 0 U2 4 PU FOOD & DRUG ADMINSTRATION PI TAIPEI PA 161-2 KUNYANG STREET, NANGANG, TAIPEI, 00000, TAIWAN SN 1021-9498 J9 J FOOD DRUG ANAL JI J. Food Drug Anal. PD DEC PY 2013 VL 21 SU 4 BP S13 EP S15 DI 10.1016/j.jfda.2013.09.023 PG 3 WC Food Science & Technology; Pharmacology & Pharmacy SC Food Science & Technology; Pharmacology & Pharmacy GA 285VJ UT WOS:000329422800007 PM 25264415 ER PT J AU Fachko, MJ Xiao, CH Bowles, KH Robinson, KM Libonati, JR AF Fachko, Michael J. Xiao, Canhau Bowles, Kathryn H. Robinson, Keith M. Libonati, Joseph R. TI Cardiovascular Effects and Enjoyment of Exercise Gaming in Older Adults SO JOURNAL OF GERONTOLOGICAL NURSING LA English DT Article ID HEART-RATE RECOVERY; ACTIVE VIDEO GAMES; SUDDEN CARDIAC DEATH; PHYSICAL-ACTIVITY; VIRTUAL-REALITY; ENERGY-EXPENDITURE; BARRIERS; CHILDREN; REHABILITATION; TECHNOLOGY AB The purpose of this study was to quantify the cardiovascular responses and enjoyment of one trial of electronic exercise gaming (EG) (Nintendo (R) Wii (TM) Tennis) in healthy, older adults (mean age = 81 [SD = 4 years]). Findings indicate that 15 minutes of EG moderately increased heart rate (p < 0.001), blood pressure (p < 0001), and perceived exertion (p < 00001) compared to resting levels. This corresponded to achieving 64% of age-predicted maximum heart rate. No differences were observed for the cardiovascular responses to EG between genders, but participants taking beta-blocker drugs showed an attenuated response (p < 0.05). All participants completed EG tennis without excessive fatigue, with 86% of participants enjoying the experience. There were only a few cases of EG-related arrhythmias (n = 2) and post-exercise muscle soreness (n = 3). These results suggest that Nintendo Wii Tennis EG technology represents an enjoyable, moderate intensity physical activity for healthy, older adults. C1 [Fachko, Michael J.] Univ Penn, Perelman Sch Med, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Bowles, Kathryn H.] Univ Penn, Sch Nursing, Ctr Integrat Sci Aging, Philadelphia, PA 19104 USA. [Robinson, Keith M.] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Robinson, Keith M.] Univ Penn, Perelman Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA. [Libonati, Joseph R.] Univ Penn, Sch Nursing, Lab Innovat & Translat Nursing Res, Philadelphia, PA 19104 USA. [Xiao, Canhau] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Atlanta, GA 30322 USA. RP Libonati, JR (reprint author), Univ Penn, Sch Nursing, Lab Innovat & Translat Nursing Res, 135 Claire M Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA. EM jlibonat@nursing.upenn.edu NR 57 TC 4 Z9 4 U1 2 U2 14 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0098-9134 EI 1938-243X J9 J GERONTOL NURS JI J. Gerontol. Nurs. PD DEC PY 2013 VL 39 IS 12 BP 43 EP 54 PG 12 WC Geriatrics & Gerontology; Gerontology; Nursing SC Geriatrics & Gerontology; Nursing GA 282RG UT WOS:000329189600007 PM 23855328 ER PT J AU Brooks-Worrell, B Palmer, JP AF Brooks-Worrell, Barbara Palmer, Jerry P. TI Prevention versus intervention of type 1 diabetes SO CLINICAL IMMUNOLOGY LA English DT Review DE Type 1 diabetes; Type 2 diabetes; Islet autoimmunity; Prediction; Intervention; Prevention ID STEM-CELL TRANSPLANTATION; PLACEBO-CONTROLLED TRIAL; RECENT-ONSET; DOUBLE-BLIND; DIETARY INTERVENTION; CD3-ANTIBODY THERAPY; NATURAL-HISTORY; MELLITUS; INSULIN; AUTOIMMUNITY AB Type 1 diabetes (T1D) is a cell-mediated autoimmune disease. New cases of T1D are on the increase and exogenous insulin therapy is the only intervention regularly initiated for T1D patients. Though tremendous strides have been made in prediction of T1D, prevention and intervention strategies have not experienced the same success. In this review, we will discuss some possible reasons why new intervention therapies for T1D have not been implemented into the mainstream treatment regimen for T1D patients. We will also discuss potential caveats for why prevention and intervention trials in T1D may not have experienced the same success as prediction trials. (C) 2013 Elsevier Inc. All rights reserved. C1 [Brooks-Worrell, Barbara] Univ Washington, Dept Med, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA 98108 USA. RP Brooks-Worrell, B (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM bbrooks@u.washington.edu NR 53 TC 5 Z9 5 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1521-6616 EI 1521-7035 J9 CLIN IMMUNOL JI Clin. Immunol. PD DEC PY 2013 VL 149 IS 3 SI SI BP 332 EP 338 DI 10.1016/j.clim.2013.05.018 PN A PG 7 WC Immunology SC Immunology GA 278FN UT WOS:000328874700009 PM 23803322 ER PT J AU Benavides, GA Liang, QL Dodson, M Darley-Usmar, V Zhang, JH AF Benavides, Gloria A. Liang, Qiuli Dodson, Matthew Darley-Usmar, Victor Zhang, Jianhua TI Inhibition of autophagy and glycolysis by nitric oxide during hypoxia-reoxygenation impairs cellular bioenergetics and promotes cell death in primary neurons SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE DetaNONOate; LC3; 3-MA; Mitochondria; Glucose; 2-DG; Free radicals ID ISCHEMIC BRAIN-INJURY; CYTOCHROME-C-OXIDASE; OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION; NEUROTRANSMITTER RELEASE; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; SYNTHASE GENE; PEROXYNITRITE; PATHWAY AB Excessive nitric oxide (NO) production is known to damage mitochondrial proteins and the autophagy repair pathway and so can potentially contribute to neurotoxicity. Accordingly, we hypothesized that protection against protein damage from reactive oxygen and nitrogen species under conditions of low oxygen by the autophagy pathway in neurons would be impaired by NO and enhance bioenergetic dysfunction. Rat primary cortical neurons had the same basal cellular respiration in hypoxia as in normoxia, whereas NO-exposed cells exhibited a gradual decrease in mitochondrial respiration in hypoxia. Upon reoxygenation, the respiration in NO-treated cells did not recover to prehypoxic levels. Hypoxia-reoxygenation in the presence of NO was associated with inhibition of autophagy, and the inability to recover during reoxygenation was exacerbated by an inhibitor of autophagy, 3-methyladenine. The effects of hypoxia could be recapitulated by inhibiting glycolytic flux under normoxic conditions. Under both normoxic and hypoxic conditions NO exposure induced immediate stimulation of glycolysis, but prolonged NO exposure, associated with irreversible inhibition of mitochondrial respiration in hypoxia, inhibited glycolysis. Importantly, we found that NO inhibited basal respiration under normoxic conditions only when glucose was absent from the medium or glycolysis was inhibited by 2-deoxy-oglucose, revealing a novel NO-dependent mechanism for the inhibition of mitochondrial respiration that is modulated by glycolysis. Taken together these data suggest an oxygen-dependent interaction between mitochondrial respiration, glycolysis, and autophagy in protecting neuronal cells exposed to NO. Importantly, they indicate that mitochondrial dysfunction is intimately linked to a failure of glycolytic flux induced by exposure to NO. In addition, these studies provide new insights into the understanding of how autophagy and NO may play interactive roles in neuroinflammation-induced cellular damage, which is pertinent to our understanding of the pathology of neurodegenerative diseases in which excessive NO is generated. (C) 2013 Elsevier Inc. All rights reserved. C1 [Benavides, Gloria A.; Liang, Qiuli; Dodson, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Benavides, Gloria A.; Liang, Qiuli; Dodson, Matthew; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL 35233 USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. EM zhanja@uab.edu FU VA merit award; [NIHR01-NS064090] FX We thank IDDEC Core B for primary neuron cultures and members of the Dr. Zhang and Dr. Darley-Usmar laboratories for technical help and discussions. This work was supported by NIHR01-NS064090 and a VA merit award (to J.Z.). V.D.U. is a member of the Seahorse Biosciences Scientific Advisory Board. NR 56 TC 20 Z9 22 U1 1 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 EI 1873-4596 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD DEC PY 2013 VL 65 BP 1215 EP 1228 DI 10.1016/j.freeradbiomed.2013.09.006 PG 14 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 278DI UT WOS:000328868900115 PM 24056030 ER PT J AU Stengel, A Tache, Y AF Stengel, A. Tache, Y. TI Role of NUCB2/Nesfatin-1 in the Hypothalamic Control of Energy Homeostasis SO HORMONE AND METABOLIC RESEARCH LA English DT Review DE body weight; food intake; hypothalamus; NUCB2; nesfatin-1; obesity; satiation ID INTER-MEAL INTERVALS; BODY-MASS INDEX; FOOD-INTAKE; NESFATIN-1 INFLUENCES; ARCUATE NUCLEUS; RAT-BRAIN; NEURONS; MICE; IMMUNOREACTIVITY; NEUROPEPTIDE AB Hunger and satiety are regulated in a complex fashion by a few food intake stimulatory (orexigenic) and a multitude of inhibitory (anorexigenic) factors produced in the periphery (mainly in the gastrointestinal tract) or directly in the brain. Within the brain, the hypothalamus plays a pivotal role as a production site of food intake regulatory factors. Importantly, this site integrates peripheral and central signaling factors to orchestrate food intake and in the long term body weight. Our knowledge on these regulatory pathways is not static but rather rapidly changing as new factors as well as up- and downstream signaling pathways of already known transmitters are uncovered. Hypothalamic nucleobindin2 (NUCB2), the precursor of nesfatin-1, was first described in 2006 and nesfatin-1 found to be a novel anorexigenic modulator of food intake and body weight. The initial report stimulated several groups to investigate the biological actions of nesfatin-1 and subsequent studies delineated the underlying brain mechanisms involved in its food reducing effect. Of interest was the demonstration that NUCB2 also exerts its anorexigenic action in the paraventricular nucleus of the hypothalamus and is regulated at this site by changes in metabolic status with a diurnal rhythm inversely related to that of feeding in rats. The present review describes the current state-of-knowledge on central nesfatin-1's effects on food intake and body weight and highlights important missing links regarding cellular signaling mechanisms involved in nesfatin-1's action. C1 [Stengel, A.] Charite, Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, D-13353 Berlin, Germany. [Tache, Y.] Univ Calif Los Angeles, Dept Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Tache, Y.] Univ Calif Los Angeles, Div Digest Dis, Ctr Neurobiol Stress, Los Angeles, CA USA. [Tache, Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Tache, Y (reprint author), VA GLA Healthcare Syst, Ctr Neurobiol Stress, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU German Research Foundation [STE 1765/3-1]; Charite University [UFF 89-441-176]; NIH [R01 DK-33061]; NIH Center Grant [DK-41301]; VA Research Career Scientist FX This work was supported by German Research Foundation STE 1765/3-1 (A. S.) and Charite University Funding UFF 89-441-176 (A. S.), NIH R01 DK-33061, NIH Center Grant DK-41301 (Animal Core), and VA Research Career Scientist (Y.T.). NR 51 TC 9 Z9 9 U1 0 U2 11 PU GEORG THIEME VERLAG KG PI STUTTGART PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY SN 0018-5043 EI 1439-4286 J9 HORM METAB RES JI Horm. Metab. Res. PD DEC PY 2013 VL 45 IS 13 BP 975 EP 979 DI 10.1055/s-0033-1351324 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 269KW UT WOS:000328241200009 PM 24048879 ER PT J AU Lane, HY Lin, CH Green, MF Hellemann, G Huang, CC Chen, PW Tun, R Chang, YC Tsai, GCE AF Lane, Hsien-Yuan Lin, Ching-Hua Green, Michael F. Hellemann, Gerhard Huang, Chih-Chia Chen, Po-Wei Tun, Rene Chang, Yue-Cung Tsai, Guochuan E. TI Add-on Treatment of Benzoate for Schizophrenia A Randomized, Double-blind, Placebo-Controlled Trial of D-Amino Acid Oxidase Inhibitor SO JAMA PSYCHIATRY LA English DT Article ID CONSENSUS COGNITIVE BATTERY; SARCOSINE N-METHYLGLYCINE; TRANSPORTER-I INHIBITOR; D-SERINE; EMOTIONAL INTELLIGENCE; ANTIPSYCHOTIC-DRUGS; NEGATIVE SYMPTOMS; EFFICACY; DEFICITS; SCALE AB IMPORTANCE In addition to dopaminergic hyperactivity, hypofunction of the N-methyl-D-aspartate receptor (NMDAR) has an important role in the pathophysiology of schizophrenia. Enhancing NMDAR-mediated neurotransmission is considered a novel treatment approach. To date, several trials on adjuvant NMDA-enhancing agents have revealed beneficial, but limited, efficacy for positive and negative symptoms and cognition. Another method to enhance NMDA function is to raise the levels of D-amino acids by blocking their metabolism. Sodium benzoate is a D-amino acid oxidase inhibitor. OBJECTIVE To examine the clinical and cognitive efficacy and safety of add-on treatment of sodium benzoate for schizophrenia. DESIGN, SETTING, AND PARTICIPANTS A randomized, double-blind, placebo-controlled trial in 2 major medical centers in Taiwan composed of 52 patients with chronic schizophrenia who had been stabilized with antipsychotic medications for 3 months or longer. INTERVENTIONS Six weeks of add-on treatment of 1 g/d of sodium benzoate or placebo. MAIN OUTCOMES AND MEASURES The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS) total score. Clinical efficacy and adverse effects were assessed biweekly. Cognitive functions were measured before and after the add-on treatment. RESULTS Benzoate produced a 21% improvement in PANSS total score and large effect sizes (range, 1.16-1.69) in the PANSS total and subscales, Scales for the Assessment of Negative Symptoms-20 items, Global Assessment of Function, Quality of Life Scale and Clinical Global Impression and improvement in the neurocognition subtests as recommended by the National Institute of Mental Health's Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative, including the domains of processing speed and visual learning. Benzoate was well tolerated without significant adverse effects. CONCLUSIONS AND RELEVANCE Benzoate adjunctive therapy significantly improved a variety of symptom domains and neurocognition in patients with chronic schizophrenia. The preliminary results show promise for D-amino acid oxidase inhibition as a novel approach for new drug development for schizophrenia. C1 [Lane, Hsien-Yuan; Huang, Chih-Chia] China Med Univ Hosp, Dept Psychiat, Taichung, Taiwan. [Lane, Hsien-Yuan; Huang, Chih-Chia] China Med Univ, Inst Clin Med Sci, Taichung, Taiwan. [Lin, Ching-Hua] Kaohsiung Municipal Kai Syuan Psychiat Hosp, Dept Adult Psychiat, Kaohsiung, Taiwan. [Green, Michael F.; Hellemann, Gerhard] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Green, Michael F.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chen, Po-Wei] Taichung Chin Ho Hosp, Dept Psychiat, Taichung, Taiwan. [Tun, Rene; Tsai, Guochuan E.] Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA. [Chang, Yue-Cung] Tamkang Univ, Dept Math, Taipei, Taiwan. RP Tsai, GCE (reprint author), Harbor UCLA Med Ctr, Dept Psychiat, 1000 W Carson St, Torrance, CA 90509 USA. EM etsai@labiomed.org FU National Science Council of Taiwan [NSC-97-2314-B-039-006-MY3, NSC-99-2314-B-280-001-MY3, NSC-99-2811-B-039-005, NSC-100-2627-B-039-001, NSC-101-2314-B-039-030-MY3, NSC-101-2627-B-039-001]; National Health Research Institutes of Taiwan [NHRI-EX-101-9904NI]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH102-TD-B-111-004]; China Medical University Hospital [CMU 101-AWARD-13, DMR-99-153, DMR-99-117] FX This work was supported in part by grants NSC-97-2314-B-039-006-MY3, NSC-99-2314-B-280-001-MY3, NSC-99-2811-B-039-005, NSC-100-2627-B-039-001, NSC-101-2314-B-039-030-MY3, and NSC-101-2627-B-039-001 from the National Science Council of Taiwan, grant NHRI-EX-101-9904NI from the National Health Research Institutes of Taiwan, grant DOH102-TD-B-111-004 from the Taiwan Department of Health Clinical Trial and Research Center of Excellence, and grants CMU 101-AWARD-13, DMR-99-153, and DMR-99-117 from the China Medical University Hospital. NR 72 TC 41 Z9 44 U1 1 U2 9 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD DEC PY 2013 VL 70 IS 12 BP 1267 EP 1275 DI 10.1001/jamapsychiatry.2013.2159 PG 9 WC Psychiatry SC Psychiatry GA 279HK UT WOS:000328950800005 PM 24089054 ER PT J AU Iltis, AS Misra, S Dunn, LB Brown, GK Campbell, A Earll, SA Glowinski, A Hadley, WB Pies, R DuBois, JM AF Iltis, Ana S. Misra, Sahana Dunn, Laura B. Brown, Gregory K. Campbell, Amy Earll, Sarah A. Glowinski, Anne Hadley, Whitney B. Pies, Ronald DuBois, James M. TI Addressing Risks to Advance Mental Health Research SO JAMA PSYCHIATRY LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; INTERVENTION EFFECTIVENESS CATIE; SCHIZOPHRENIA RESEARCH PROTOCOLS; CLINICAL ANTIPSYCHOTIC TRIALS; ASSESSING DECISIONAL CAPACITY; INFORMED-CONSENT; BIPOLAR DISORDER; RESEARCH ETHICS; RESEARCH PARTICIPANTS; PEDIATRIC RESEARCH AB IMPORTANCE Risk communication and management are essential to the ethical conduct of research, yet addressing risks may be time consuming for investigators and institutional review boards may reject study designs that seem too risky. This can discourage needed research, particularly in higher-risk protocols or those enrolling potentially vulnerable individuals, such as those with some level of suicidality. Improved mechanisms for addressing research risks may facilitate much needed psychiatric research. OBJECTIVE To provide mental health researchers with practical approaches to (1) identify and define various intrinsic research risks, (2) communicate these risks to others (eg, potential participants, regulatory bodies, and society), (3) manage these risks during the course of a study, and (4) justify the risks. EVIDENCE REVIEW As part of a National Institute of Mental Health-funded scientific meeting series, a public conference and a closed-session expert panel meeting were held on managing and disclosing risks in mental health clinical trials. The expert panel reviewed the literature with a focus on empirical studies and developed recommendations for best practices and further research on managing and disclosing risks in mental health clinical trials. No institutional review board-review was required because there were no human subjects. FINDINGS Challenges, current data, practical strategies, and topics for future research are addressed for each of 4 key areas pertaining to management and disclosure of risks in clinical trials: identifying and defining risks, communicating risks, managing risks during studies, and justifying research risks. CONCLUSIONS AND RELEVANCE Empirical data on risk communication, managing risks, and the benefits of research can support the ethical conduct of mental health research and may help investigators better conceptualize and confront risks and to gain institutional review board-approval. C1 [Iltis, Ana S.] Wake Forest Univ, Ctr Bioeth Hlth & Soc, Winston Salem, NC 27109 USA. [Iltis, Ana S.] Wake Forest Univ, Dept Philosophy, Winston Salem, NC 27109 USA. [Misra, Sahana] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Misra, Sahana] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Dunn, Laura B.] Univ Calif San Francisco, Dept Psychiat, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Dunn, Laura B.] Univ Calif San Francisco, Dept Psychooncol, UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Brown, Gregory K.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Campbell, Amy] SUNY Upstate Med Univ, Ctr Bioeth & Humanities, Syracuse, NY 13210 USA. [Earll, Sarah A.] St Louis Empowerment, St Louis, MO USA. [Glowinski, Anne] Washington Univ, Sch Med, Dept Psychiat Child, St Louis, MO USA. [Hadley, Whitney B.] Syracuse Univ, Falk Coll Sports & Human Dynam, Syracuse, NY USA. [Pies, Ronald] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [DuBois, James M.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [DuBois, James M.] St Louis Univ, Ctr Hlth Care Eth, St Louis, MO 63104 USA. RP DuBois, JM (reprint author), St Louis Univ, Albert Gnaegi Ctr Hlth Care Eth, Salus Ctr, 3545 Lafayette,5th Floor, St Louis, MO 63104 USA. EM jdubois@wustl.edu FU National Institute of Mental Health [1R13MH079690]; National Center for Advancing Translational Science, National Institutes of Health [UL1 TR000448] FX This work was supported by the National Institute of Mental Health (grant 1R13MH079690) and the National Center for Advancing Translational Science (grant UL1 TR000448), National Institutes of Health. NR 101 TC 6 Z9 6 U1 4 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD DEC PY 2013 VL 70 IS 12 BP 1363 EP 1371 DI 10.1001/jamapsychiatry.2013.2105 PG 9 WC Psychiatry SC Psychiatry GA 279HK UT WOS:000328950800016 PM 24173618 ER PT J AU Winges, KM Werner, JS Harvey, DJ Cello, KE Durbin, MK Balcer, LJ Calabresi, PA Keltner, JL AF Winges, Kimberly M. Werner, John S. Harvey, Danielle J. Cello, Kimberly E. Durbin, Mary K. Balcer, Laura J. Calabresi, Peter A. Keltner, John L. TI Baseline Retinal Nerve Fiber Layer Thickness and Macular Volume Quantified by OCT in the North American Phase 3 Fingolimod Trial for Relapsing-Remitting Multiple Sclerosis SO JOURNAL OF NEURO-OPHTHALMOLOGY LA English DT Article ID OPTICAL COHERENCE TOMOGRAPHY; ORAL FINGOLIMOD; AXONAL LOSS; ATROPHY; PATHOLOGY; NEURITIS; NEUROPATHIES; DISABILITY; VISION AB Background:Patients with multiple sclerosis (MS) demonstrate thinning of peripapillary retinal nerve fiber layer (RNFL) and decreased macular volume as measured by optical coherence tomography (OCT). To our knowledge, there are no previous reports from a large MS OCT database with strict quality control measures that quantitate RNFL and macula in patients with relapsing-remitting multiple sclerosis.Methods:The University of California Davis OCT Reading Center gathered OCT data at baseline as part of the North American phase 3 trial of fingolimod (Gilenya). Average RNFL thickness (RNFLT) and macular volume (TMV) were measured using time domain OCT (TD-OCT). RNFL quadrants, clock hours, and macular subfields were included. With strict quality control and accounting for signal strength differences, scans were categorized as reduced or not reduced for each field, based on being less than 5th percentile for age-matched controls derived from the normative database in the scanner software. Patients were deemed abnormal if at least 1 eye had reduced values for a given parameter. Patients with abnormalities in corresponding RNFL and macular subfields were compared by cross-tabulation.Results:The TD-OCT data were prospectively collected from 939 of the 1,083 trial patients, 712 of whom met all final quality and data inclusion criteria. Of the final cohort, 242 (34.0%) demonstrated reduced (less than 5th percentile) average RNFLT in at least 1 eye. One hundred seventy-eight (25.0%) patients had reduced TMV. One hundred twenty-eight (18.0%) demonstrated both reduced TMV and RNFLT in the same eye, whereas 42 (5.8%) had reduced TMV and RNFLT in both eyes. Of the 242 patients with reduced average RNFL thickness, 128 (52.9%) also had reduced TMV. Fifty patients had reduced TMV in the absence of reduced RNFLT in at least 1 eye, a cohort prevalence of 7.0%. Quadrant and subfield analysis showed a predominance of temporal and inferior RNFL thinning, with inferior macular thinning corresponding best to RNFL thinning.Conclusion:RNFL and macular thinning/volume loss is common at baseline in relapsing-remitting multiple sclerosis, as measured by TD-OCT. When the RNFL is thin, the macular volume is reduced in more than half of the patients. There is a population of reduced TMV without any reduction in RNFLT. Documenting the prevalence and distribution of these structural abnormalities supports recent reports and suggests new retinal areas to probe for functional vision changes in MS. C1 [Winges, Kimberly M.] Vet Adm Med Ctr, Dept Ophthalmol, Portland, OR USA. [Winges, Kimberly M.; Werner, John S.; Cello, Kimberly E.; Keltner, John L.] Univ Calif Davis, Sch Med, Dept Ophthalmol & Vis Sci, Davis, CA 95616 USA. [Harvey, Danielle J.] Univ Calif Davis, Sch Med, Div Biostat, Davis, CA 95616 USA. Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Keltner, John L.] Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA. [Keltner, John L.] Univ Calif Davis, Sch Med, Dept Neurosurg, Davis, CA 95616 USA. [Durbin, Mary K.] Carl Zeiss Meditec Inc, Dublin, CA USA. [Balcer, Laura J.] NYU, Dept Neurol, Langone Med Ctr, New York, NY 10016 USA. [Calabresi, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. RP Winges, KM (reprint author), Portland VA Med Ctr, Dept Ophthalmol, Mail Code P3EYE,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM kim.winges@gmail.com FU Novartis Pharmaceuticals Corporation; Research to Prevent Blindness; Department of Veterans Affairs FX Novartis Pharmaceuticals Corporation funded OCT data collection as part of the fingolimod phase 3 clinical trial NCT00355134. Partial support was also provided by an unrestricted grant from Research to Prevent Blindness to University of California Davis, CA. KMW received support from the Department of Veterans Affairs. NR 32 TC 1 Z9 1 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1070-8022 EI 1536-5166 J9 J NEURO-OPHTHALMOL JI J. Neuro-Ophthal. PD DEC PY 2013 VL 33 IS 4 BP 341 EP 348 DI 10.1097/WNO.0b013e31829c51f7 PG 8 WC Clinical Neurology; Ophthalmology SC Neurosciences & Neurology; Ophthalmology GA 277KW UT WOS:000328819100009 ER PT J AU Nawaz, H Mounzer, R Yadav, D Yabes, JG Slivka, A Whitcomb, DC Papachristou, GI AF Nawaz, Haq Mounzer, Rawad Yadav, Dhiraj Yabes, Jonathan G. Slivka, Adam Whitcomb, David C. Papachristou, Georgios I. TI Revised Atlanta and Determinant-Based Classification: Application in a Prospective Cohort of Acute Pancreatitis Patients SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID PERSISTENT ORGAN FAILURE; PROSPECTIVE-VALIDATION; SEVERITY; SCORE; MORTALITY; DISEASE AB OBJECTIVES: Atlanta classification (Atlanta 1992) of acute pancreatitis (AP) has several limitations. Two new classification systems were recently proposed: the Atlanta reclassification (Atlanta 2012) and the determinant-based classification (DBC). The aim of our study was to: (i) determine the association between different severity categories and clinical outcomes and (ii) perform a head-to-head comparison between Atlanta 1992, Atlanta 2012, and DBC in predicting these clinical outcomes. METHODS: A total of 256 prospectively enrolled patients were assigned a severity category for all three classifications. Five clinical outcomes were evaluated: mortality, intensive care unit (ICU) admission and length of stay (LOS), need for interventions, and hospital LOS. Pairwise testing between severity grades within a classification system was performed using Fisher's exact and Kruskal-Wallis tests. Predictive accuracies were evaluated using area under the ROC curve (AUC) and Somer's D co-efficient. RESULTS: Overall, higher grades of severity were associated with worse clinical outcomes for all three classification systems. Atlanta 2012 and DBC performed better than Atlanta 1992 and were comparable in predicting mortality (AUC 0.89 for both vs. 0.76, P < 0.001), ICU admission (AUC 0.91 for both vs. 0.80, P < 0.001), and ICU LOS (Somer's D 0.21 and 0.28 vs. 0.07, P < 0.05). DBC performed better in predicting need for interventions (AUC 0.93 vs. 0.85, P < 0.001), whereas Atlanta 2012 performed better in predicting hospital LOS (Somer's D 0.43 vs. 0.37, P = 0.04). CONCLUSIONS: Atlanta 2012 and DBC severity categories accurately reflected clinical outcomes in our cohort and were superior to Atlanta 1992. These novel classification systems can guide the selection of homogeneous patient populations for clinical research and provide an accurate spectrum of disease severity categories in the clinical setting. C1 [Nawaz, Haq; Mounzer, Rawad; Yadav, Dhiraj; Slivka, Adam; Whitcomb, David C.; Papachristou, Georgios I.] Univ Pittsburgh, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. [Yabes, Jonathan G.] Univ Pittsburgh, Sch Med, Hlth Care Data Ctr, Res Ctr, Pittsburgh, PA USA. [Papachristou, Georgios I.] Vet Affairs Pittsburgh Hlth Syst, Dept Med, Div Gastroenterol, Pittsburgh, PA USA. RP Papachristou, GI (reprint author), Univ Pittsburgh, Med Ctr, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. EM papachri@pitt.edu FU Veterans Affairs VA Merit Review [PR000000496] FX Veterans Affairs VA Merit Review (PR000000496). NR 24 TC 40 Z9 43 U1 1 U2 8 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 2013 VL 108 IS 12 BP 1911 EP 1917 DI 10.1038/ajg.2013.348 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 272KM UT WOS:000328459300013 PM 24126632 ER PT J AU Welzel, TM Graubard, BI Quraishi, S Zeuzem, S Davila, JA El-Serag, HB McGlynn, KA AF Welzel, Tania M. Graubard, Barry I. Quraishi, Sabah Zeuzem, Stefan Davila, Jessica A. El-Serag, Hashem B. McGlynn, Katherine A. TI Hepatocellular Carcinoma and Smoking: Oblivion or Contempt? Response SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Letter C1 [Welzel, Tania M.; Zeuzem, Stefan] Johann Wolfgang Goethe Univ Hosp, Frankfurt, Germany. [Graubard, Barry I.; Quraishi, Sabah; McGlynn, Katherine A.] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Bethesda, MD 20892 USA. [Davila, Jessica A.; El-Serag, Hashem B.] Houston Vet Affairs Med Ctr, Houston, TX USA. [Davila, Jessica A.; El-Serag, Hashem B.] Baylor Coll Med, Houston, TX 77030 USA. RP McGlynn, KA (reprint author), NCI, DCEG, EPS 5022 6120 Execut Blvd, Rockville, MD 20852 USA. EM mcglynnk@mail.nih.gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD DEC PY 2013 VL 108 IS 12 BP 1931 EP 1931 DI 10.1038/ajg.2013.342 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 272KM UT WOS:000328459300020 PM 24300871 ER PT J AU Wang, JM Isenberg, JS Billiar, TR Chen, AF AF Wang, Jie-Mei Isenberg, Jeffery S. Billiar, Timothy R. Chen, Alex F. TI Thrombospondin-1/CD36 pathway contributes to bone marrow-derived angiogenic cell dysfunction in type 1 diabetes via Sonic hedgehog pathway suppression SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE bone marrow-derived angiogenic cells; Sonic hedgehog; thrombospondin-1; type 1 diabetes ID ENDOTHELIAL PROGENITOR CELLS; NITRIC-OXIDE; GENE-THERAPY; PROTEIN THROMBOSPONDIN-1; OXIDATIVE STRESS; TISSUE SURVIVAL; CD36; EXPRESSION; ACTIVATION; CD47 AB Refractory wounds in diabetic patients present a significant clinical problem. Sonic hedgehog (SHH), a morphogenic protein central to wound repair, is deficient in diabetes. Regulation of SHH in wound healing is poorly understood. We hypothesize that thrombospondin-1 (TSP-1), through its receptor CD36, contributes to the SHH signaling defect in bone marrow-derived angiogenic cells (BMACs) in type 1 diabetic mice. Isolated BMACs from TSP-1-knockout mice demonstrated improved tube formation, migration, and adhesion in parallel with active SHH signaling. BMACs from STZ-induced type 1 diabetic mice showed significantly impaired Matrigel tube formation (n = 5; P < 0.05 vs. control), which was rescued by TSP-1 depletion (n = 5; P < 0.05 STZ-TSP-1(-/-) vs. STZ-WT) or exogenous SHH (20 mg/l, 24 h, n = 4; P < 0.05 vs. STZ-control). The expression of CD36 was elevated in BMACs from STZ mice (n = 4; P < 0.05). SHH signaling was significantly higher in BMACs from TSP-1(-/-) mice and TSP-1 receptor CD36-knockout mice (n = 6; P < 0.05 vs. WT) but not CD47-knockout mice (n = 3; P > 0.05 vs. WT). The impairment of recombinant human TSP-1 (2.2 nM, 24 h) on BMAC Matrigel tube formation was delayed significantly by CD36 deletion (n = 5; P < 0.05). CD36(-/-) BMACs demonstrated better tube formation under both normal and diabetic conditions with active SHH signaling (n = 4; P < 0.05 vs. WT BMACs). In conclusion, The TSP-1/CD36 pathway contributes to the SHH signaling defect, resulting in BMAC dysfunction in type 1 diabetic mice. C1 [Wang, Jie-Mei; Billiar, Timothy R.; Chen, Alex F.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Wang, Jie-Mei; Chen, Alex F.] Vet Affairs Pittsburgh Healthcare Syst, Vasc Surg Res, Pittsburgh, PA USA. [Wang, Jie-Mei; Chen, Alex F.] Cent S Univ, Dept Cardiol, Changsha 410013, Hunan, Peoples R China. [Wang, Jie-Mei; Chen, Alex F.] Cent S Univ, Ctr Clin Pharmacol, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China. [Isenberg, Jeffery S.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA. RP Chen, AF (reprint author), Cent S Univ, Xiangya Hosp 3, 138 Tong Zi Bo Rd, Changsha 410013, Hunan, Peoples R China. EM afychen@yahoo.com RI WANG, JIEMEI/G-9805-2017 OI WANG, JIEMEI/0000-0002-8723-4410 FU National Institute of General Medical Sciences [R01-GM-077352]; Veterans Affairs Rehabilitation Research & Development Merit Awards [I01RX000244, 1I01RX000652]; American Diabetes Association Research Award; National Science Foundation of China (NSFC) [81130004]; NSFC for Distinguished Young Scholars of China Award [81300240]; American Heart Association Scientist Development Grant [13SDG16930098] FX This work was supported in part by National Institute of General Medical Sciences Grant R01-GM-077352 (to A. F. Chen), Veterans Affairs Rehabilitation Research & Development Merit Awards I01RX000244 and 1I01RX000652 (to A. F. Chen), American Diabetes Association Research Award 7-11-BS-23 (to A. F. Chen), National Science Foundation of China (NSFC) Key Research Project no. 81130004 (to A. F. Chen), NSFC for Distinguished Young Scholars of China Award no. 81300240 (to J. M. Wang), and American Heart Association Scientist Development Grant 13SDG16930098 (to J. M. Wang). NR 48 TC 7 Z9 7 U1 1 U2 6 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD DEC PY 2013 VL 305 IS 12 BP E1464 EP E1472 DI 10.1152/ajpendo.00516.2013 PG 9 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 276LR UT WOS:000328752300005 PM 24148348 ER PT J AU Dodson, M Liang, QL Johnson, MS Redmann, M Fineberg, N Darley-Usmar, VM Zhang, JH AF Dodson, Matthew Liang, Qiuli Johnson, Michelle S. Redmann, Matthew Fineberg, Naomi Darley-Usmar, Victor M. Zhang, Jianhua TI Inhibition of glycolysis attenuates 4-hydroxynonenal-dependent autophagy and exacerbates apoptosis in differentiated SH-SY5Y neuroblastoma cells SO AUTOPHAGY LA English DT Article DE autophagy; oxidative stress; 4-hydroxynonenal; glycolysis; apoptosis; ATP; glutathione; Z-VAD; 3-MA ID CEREBRAL GLUCOSE-METABOLISM; AMYLOID BETA-PEPTIDE; LIPID-PEROXIDATION; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASES; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; PROTEIN OXIDATION; REDOX PROTEOMICS; STROKE PATIENTS AB How cellular metabolic activities regulate autophagy and determine the susceptibility to oxidative stress and ultimately cell death in neuronal cells is not well understood. An important example of oxidative stress is 4-hydroxynonenal (HNE), which is a lipid peroxidation product that is formed during oxidative stress, and accumulates in neurodegenerative diseases causing damage. The accumulation of toxic oxidation products such as HNE, is a prevalent feature of neurodegenerative diseases, and can promote organelle and protein damage leading to induction of autophagy. In this study, we used differentiated SH-SY5Y neuroblastoma cells to investigate the mechanisms and regulation of cellular susceptibility to HNE toxicity and the relationship to cellular metabolism. We found that autophagy is immediately stimulated by HNE at a sublethal concentration. Within the same time frame, HNE induces concentration dependent CASP3/caspase 3 activation and cell death. Interestingly, both basal and HNE-activated autophagy, were regulated by glucose metabolism. Inhibition of glucose metabolism by 2-deoxyglucose (2DG), at a concentration that inhibited autophagic flux, further exacerbated CASP3 activation and cell death in response to HNE. Cell death was attenuated by the pan-caspase inhibitor Z-VAD-FMK. Specific inhibition of glycolysis using koningic acid, a GAPDH inhibitor, inhibited autophagic flux and exacerbated HNE-induced cell death similarly to 2DG. The effects of 2DG on autophagy and HNE-induced cell death could not be reversed by addition of mannose, suggesting an ER stress-independent mechanism. 2DG decreased LAMP1 and increased BCL2 levels suggesting that its effects on autophagy may be mediated by more than one mechanism. Furthermore, 2DG decreased cellular ATP, and 2DG and HNE combined treatment decreased mitochondrial membrane potential. We conclude that glucose-dependent autophagy serves as a protective mechanism in response to HNE. C1 [Dodson, Matthew; Liang, Qiuli; Johnson, Michelle S.; Redmann, Matthew; Darley-Usmar, Victor M.; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Ctr Free Rad Biol, Birmingham, AL 35294 USA. [Liang, Qiuli; Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA. [Fineberg, Naomi] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, Ctr Free Rad Biol, Birmingham, AL 35294 USA. EM zhanja@uab.edu OI Zhang, Jianhua/0000-0002-2128-9574 FU VA merit award; [NIHR01-NS064090] FX We thank members of the laboratories of Dr Zhang and Dr Darley-Usmar for technical help and discussions. This work was supported by NIHR01-NS064090 and a VA merit award (to JZ). NR 57 TC 20 Z9 21 U1 1 U2 12 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8627 EI 1554-8635 J9 AUTOPHAGY JI Autophagy PD DEC 1 PY 2013 VL 9 IS 12 BP 1996 EP 2008 DI 10.4161/auto.26094 PG 13 WC Cell Biology SC Cell Biology GA 270DT UT WOS:000328299800007 PM 24145463 ER PT J AU Jang, HS Han, SJ Kim, JI Lee, S Lipschutz, JH Park, KM AF Jang, Hee-Seong Han, Sang Jun Kim, Jee In Lee, Sanggyu Lipschutz, Joshua H. Park, Kwon Moo TI Activation of ERK accelerates repair of renal tubular epithelial cells, whereas it inhibits progression of fibrosis following ischemia/reperfusion injury SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE LA English DT Article DE Ischemia; Mitogen-activated protein kinase; Regeneration; Proliferation; Primary cilium; Exocyst ID ACUTE KIDNEY INJURY; INDUCED FUNCTIONAL INJURY; MAPK KINASE ACTIVATION; MARROW-DERIVED CELLS; OXIDATIVE STRESS; TUBULOINTERSTITIAL FIBROSIS; MESENCHYMAL TRANSITION; PRIMARY CILIOGENESIS; REPERFUSION INJURY; PROXIMAL TUBULE AB Extracellular signal-regulated kinase (ERR) signals play important roles in cell death and survival. However, the role of ERR in the repair process after injury remains to be defined in the kidney. Here, we investigated the role of ERR in proliferation and differentiation of tubular epithelial cells, and proliferation of interstitial cells following ischemia/reperfusion (I/R) injury in the mouse kidney. Mice were subjected to 30 min of renal ischemia. Some mice were administered with U0126, a specific upstream inhibitor of ERK, daily during the recovery phase, beginning at I day after ischemia until sacrifice. I/R caused severe tubular cell damage and functional loss in the kidney. Nine days after ischemia, the kidney was restored functionally with a partial restoration of damaged tubules and expansion of fibrotic lesions. ERR was activated by I/R and the activated ERK was sustained for 9 days. U0126 inhibited the proliferation, basolateral relocalization of Na,K-ATPase and lengthening of primary cilia in tubular epithelial cells, whereas it enhanced the proliferation of interstitial cells and accumulation of extracellular matrix. Furthermore, U0126 elevated the expression of cell cycle arrest-related proteins, p21 and phospholylated-chk2 in the post-ischemic kidney. U0126 mitigated the post-I/R increase of Sec10 which is a crucial component of exocyst complex and an important factor in ciliogenesis and tubulogenesis. U0126 also enhanced the expression of fibrosis-related proteins, TGF-beta 1 and phosphorylated NF-kappa B after ischemia. Our findings demonstrate that activation of ERK is required for both the restoration of damaged tubular epithelial cells and the inhibition of fibrosis progression following injury. (C) 2013 Elsevier B.V. All rights reserved. C1 [Jang, Hee-Seong; Han, Sang Jun; Kim, Jee In; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Dept Anat, Taegu 700422, South Korea. [Jang, Hee-Seong; Kim, Jee In; Park, Kwon Moo] Kyungpook Natl Univ, Sch Med, Cardiovasc Res Inst, Taegu 700422, South Korea. [Lee, Sanggyu] Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Taegu 702701, South Korea. [Lipschutz, Joshua H.] Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA. [Lipschutz, Joshua H.] Univ Penn, Philadelphia, PA 19104 USA. RP Park, KM (reprint author), Kyungpook Natl Univ, Sch Med, Dept Anat, 101 Dongindong, Taegu 700422, South Korea. EM kmpark@knu.ac.kr OI Jang, Hee-Seong/0000-0002-9620-351X FU Korea Health Technology RD Project; Ministry of Health & Welfare, Republic of Korea [A111366]; National Research Foundation; Korean Government [NRF-2011-220-E00001] FX This study was supported by a grant of the Korea Health Technology R&D Project, the Ministry of Health & Welfare, Republic of Korea (A111366 to KMP) and by the National Research Foundation Grant funded by the Korean Government (NRF-2011-220-E00001 to KMP). NR 57 TC 26 Z9 26 U1 0 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0925-4439 EI 0006-3002 J9 BBA-MOL BASIS DIS JI Biochim. Biophys. Acta-Mol. Basis Dis. PD DEC PY 2013 VL 1832 IS 12 BP 1998 EP 2008 DI 10.1016/j.bbadis.2013.07.001 PG 11 WC Biochemistry & Molecular Biology; Biophysics; Cell Biology SC Biochemistry & Molecular Biology; Biophysics; Cell Biology GA 260AO UT WOS:000327567600010 PM 23851027 ER PT J AU Smith, MW Giardina, TD Murphy, DR Laxmisan, A Singh, H AF Smith, Michael W. Giardina, Traber Davis Murphy, Daniel R. Laxmisan, Archana Singh, Hardeep TI Resilient actions in the diagnostic process and system performance SO BMJ QUALITY & SAFETY LA English DT Article DE Patient safety; Diagnostic errors; Medical error; measurement; epidemiology; Primary care; Quality measurement ID HEALTH-CARE; PATIENT SAFETY; CANCER-DIAGNOSIS; MISSED OPPORTUNITIES; COLORECTAL-CANCER; ADVERSE EVENTS; FOLLOW-UP; ERRORS; QUALITY; FRAMEWORK AB Objectives Systemic issues can adversely affect the diagnostic process. Many system-related barriers can be masked by resilient' actions of frontline providers (ie, actions supporting the safe delivery of care in the presence of pressures that the system cannot readily adapt to). We explored system barriers and resilient actions of primary care providers (PCPs) in the diagnostic evaluation of cancer. Methods We conducted a secondary data analysis of interviews of PCPs involved in diagnostic evaluation of 29 lung and colorectal cancer cases. Cases covered a range of diagnostic timeliness and were analysed to identify barriers for rapid diagnostic evaluation, and PCPs' actions involving elements of resilience addressing those barriers. We rated these actions according to whether they were usual or extraordinary for typical PCP work. Results Resilient actions and associated barriers were found in 59% of the cases, in all ranges of timeliness, with 40% involving actions rated as beyond typical. Most of the barriers were related to access to specialty services and coordination with patients. Many of the resilient actions involved using additional communication channels to solicit cooperation from other participants in the diagnostic process. Discussion Diagnostic evaluation of cancer involves several resilient actions by PCPs targeted at system deficiencies. PCPs' actions can sometimes mitigate system barriers to diagnosis, and thereby impact the sensitivity of downstream' measures (eg, delays) in detecting barriers. While resilient actions might enable providers to mitigate system deficiencies in the short run, they can be resource intensive and potentially unsustainable. They complement, rather than substitute for, structural remedies to improve system performance. Measures to detect and fix system performance issues targeted by these resilient actions could facilitate diagnostic safety. C1 [Smith, Michael W.; Giardina, Traber Davis; Murphy, Daniel R.; Laxmisan, Archana; Singh, Hardeep] Houston VA HSR&D Ctr Excellence, Houston, TX USA. [Smith, Michael W.; Giardina, Traber Davis; Murphy, Daniel R.; Laxmisan, Archana; Singh, Hardeep] Ctr Inquiry Improve Outpatient Safety Effect Elec, Houston, TX USA. [Smith, Michael W.; Giardina, Traber Davis; Murphy, Daniel R.; Laxmisan, Archana; Singh, Hardeep] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA. [Smith, Michael W.; Giardina, Traber Davis; Murphy, Daniel R.; Laxmisan, Archana; Singh, Hardeep] Sect Hlth Serv Res, Houston, TX USA. RP Smith, MW (reprint author), Houston VA Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM ms6@bcm.edu RI McLean, Laurence /C-7367-2014 OI Davis Giardina, Traber/0000-0002-9184-6524 FU Federal Funding Agency FX This paper was funded by the Federal Funding Agency, sponsor of K23 award. NR 61 TC 5 Z9 5 U1 4 U2 13 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD DEC PY 2013 VL 22 IS 12 BP 1006 EP 1013 DI 10.1136/bmjqs-2012-001661 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 269NA UT WOS:000328246800009 PM 23813210 ER PT J AU Pomykala, KL Ganz, PA Bower, JE Kwan, L Castellon, SA Mallam, S Cheng, I Ahn, R Breen, EC Irwin, MR Silverman, DHS AF Pomykala, K. L. Ganz, P. A. Bower, J. E. Kwan, L. Castellon, S. A. Mallam, S. Cheng, I. Ahn, R. Breen, E. C. Irwin, M. R. Silverman, D. H. S. TI The association between pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Positron emission tomography; Brain imaging; Breast cancer; Cognitive complaints; Chemotherapy; Pro-inflammatory cytokines ID LONGITUDINAL ASSESSMENT; CHEMORADIATION THERAPY; SYSTEMIC CHEMOTHERAPY; SURVIVORS; FATIGUE; DYSFUNCTION; WOMEN; DEPRESSION; SYMPTOMS; PERFORMANCE AB To examine relationships following adjuvant chemotherapy between circulating pro-inflammatory cytokines, regional cerebral metabolism, and cognitive complaints in early stage breast cancer patients. 33 breast cancer patients who had completed initial treatment (surgery, +/- radiation, 23 chemotherapy, 10 no chemotherapy) obtained resting (18)F-FDG PET/CT brain imaging at baseline and 1 year later. Pro-inflammatory cytokine markers (IL-1ra, sTNF-RII, CRP, and IL-6) and cognitive complaints were also assessed at both time points. At baseline, consistent correlations were seen between the left medial frontal and right inferior lateral anterior temporal cortices and inflammatory markers within the chemotherapy group, and not in the no chemotherapy group. After 1 year, correlations persisted in the medial frontal cortex and the temporal cortex, the latter shifting superiorly. Both of these regional correlations demonstrated the highest levels of significance when looking across the 1 year time frame (IL-1ra: peak voxel p < 0.0005; cluster size p < 0.0005, p = 0.001 after correction (medial prefrontal), p < 0.0005; cluster size p = 0.001, p = 0.029 corr. (anterior temporal), sTNF-RII: p < 0.0005; cluster size p = 0.001, p = 0.040 corr. (medial prefrontal)). Positive correlations were also seen within the chemotherapy group between baseline memory complaints and the medial frontal (p < 0.0005; cluster size p < 0.0005, p < 0.0005 corr.) and anterior temporal (p < 0.0005; cluster size p < 0.0005, p = 0.002 corr.) cortices at baseline and 1 year later. Metabolism in the medial prefrontal cortex and anterior temporal cortex was found to correlate with both memory complaints and cytokine marker levels in chemotherapy patients. C1 [Pomykala, K. L.; Mallam, S.; Cheng, I.; Ahn, R.; Silverman, D. H. S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Ganz, P. A.] UCLA Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA. [Ganz, P. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Ganz, P. A.; Bower, J. E.; Kwan, L.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Div Canc Prevent & Control Res, Los Angeles, CA 90024 USA. [Bower, J. E.; Irwin, M. R.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Bower, J. E.; Breen, E. C.; Irwin, M. R.] Semel Inst Neurosci, Cousins Ctr Psychoneuroimmunol, Los Angeles, CA USA. [Castellon, S. A.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Castellon, S. A.; Breen, E. C.; Irwin, M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. RP Silverman, DHS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, 200 Med Plaza,Suite B114,Mail Code 737024, Los Angeles, CA 90095 USA. EM dsilver@ucla.edu RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431 FU NIH/NCI [R01 CA 109650]; Breast Cancer Research Foundation [R01-AG034588, R01-AG026364, R01CA160245-01, R01-CA119159, R01HL095799, R01 DA032922-01, P30-AG028748]; UCLA CTSI [UL1TR000124]; Cousins Center for Psychoneuroimmunology FX Supported by grant NIH/NCI R01 CA 109650 and the Breast Cancer Research Foundation (PAG); R01-AG034588; R01-AG026364; R01CA160245-01; R01-CA119159; R01HL095799; R01 DA032922-01; P30-AG028748 to MRI; and UCLA CTSI UL1TR000124, the Cousins Center for Psychoneuroimmunology (MRI). NR 56 TC 23 Z9 24 U1 2 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 EI 1931-7565 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD DEC PY 2013 VL 7 IS 4 SI SI BP 511 EP 523 DI 10.1007/s11682-013-9243-2 PG 13 WC Neuroimaging SC Neurosciences & Neurology GA 277XY UT WOS:000328853800011 PM 23835929 ER PT J AU Ercoli, LM Castellon, SA Hunter, AM Kwan, L Kahn-Mills, BA Cernin, PA Leuchter, AF Ganz, PA AF Ercoli, Linda M. Castellon, Steven A. Hunter, Aimee M. Kwan, Lorna Kahn-Mills, Barbara A. Cernin, Paul A. Leuchter, Andrew F. Ganz, Patricia A. TI Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints SO BRAIN IMAGING AND BEHAVIOR LA English DT Article DE Breast cancer; Chemotherapy; Cognitive; qEEG; Rehabilitation; Intervention ID ADJUVANT CHEMOTHERAPY; DOSE CHEMOTHERAPY; MEMORY; DYSFUNCTION; PERFORMANCE; TRIAL; MANAGEMENT; TAMOXIFEN; WORKSHOP; WOMEN AB To assess the feasibility of a cognitive rehabilitation program in breast cancer survivors (BCS) with persistent post-treatment cognitive complaints. BCS with cognitive complaints, 18-months to 5-years post-treatment, were recruited for a once-weekly, five-week, group cognitive training intervention. Outcome measures included self-reported mood and cognitive function, and neurocognitive tests administered at pre-intervention, immediate-, two-month and four-month post-intervention. A sub-study in eight participants evaluated resting state quantitative electroencephalography (qEEG) changes from pre- to immediate post-intervention in relationship to post-intervention changes in cognitive complaints. Twenty-seven BCS completed the protocol and tolerated the intervention well. We observed significant reductions in total and memory-specific cognitive complaints from pre-intervention to immediate post-intervention (p = 0.031 and p = 0.009, respectively) and at four-months post-intervention (p < 0.0001 and p < 0.001, respectively). Significant improvement in neurocognitive tests were found for Symbol Digit, Stroop, and Trails A tests (df = 26, all p's < 0.05). Effect sizes for changes from pre-intervention to immediate and to four-month post intervention ranged from 0.429 to 0.607, and from 0.439 to 0.741, respectively. Increase in qEEG absolute alpha power over the course of the intervention was associated with reduced complaints at immediate post-intervention (r = -0.78, p = 0.021), two-months (r range = -0.76 to -0.82, p-value range 0.004 to 0.03), and four-months (r = -0.71, p = 0.048). A five-week group cognitive training intervention is feasible and well tolerated. Cognitive complaints and neurocognitive test performances showed positive changes. qEEG may serve as a potential biomarker for improvement in self-reported complaints. A randomized clinical trial is underway to test the efficacy of the intervention. C1 [Ercoli, Linda M.; Hunter, Aimee M.; Cernin, Paul A.; Leuchter, Andrew F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Ercoli, Linda M.; Hunter, Aimee M.; Cernin, Paul A.; Leuchter, Andrew F.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Castellon, Steven A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychol, Los Angeles, CA 90095 USA. [Castellon, Steven A.] VA Greater Los Angeles Hlth Care Syst, Dept Psychiat & Mental Hlth, Los Angeles, CA USA. [Hunter, Aimee M.; Leuchter, Andrew F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Lab Brain Behav & Pharmacol, Los Angeles, CA 90024 USA. [Hunter, Aimee M.; Leuchter, Andrew F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Depress Res & Clin Program, Los Angeles, CA 90024 USA. [Kwan, Lorna; Kahn-Mills, Barbara A.; Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Ganz, Patricia A.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA. [Ganz, Patricia A.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA. RP Ercoli, LM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. EM lercoli@mednet.ucla.edu FU Breast Cancer Research Foundation; Jonsson Cancer Center Foundation FX Funding for this research was provided by the Breast Cancer Research Foundation and the Jonsson Cancer Center Foundation. We thank the participants for their contribution to this research. NR 55 TC 19 Z9 19 U1 3 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1931-7557 EI 1931-7565 J9 BRAIN IMAGING BEHAV JI Brain Imaging Behav. PD DEC PY 2013 VL 7 IS 4 SI SI BP 543 EP 553 DI 10.1007/s11682-013-9237-0 PG 11 WC Neuroimaging SC Neurosciences & Neurology GA 277XY UT WOS:000328853800014 PM 23955490 ER PT J AU Wiener, RS Slatore, CG AF Wiener, Renda Soylemez Slatore, Christopher G. TI Framing Discussions About CT Scan Screening for Lung Cancer So That Patients See the Whole Picture SO CHEST LA English DT Editorial Material ID WORKS C1 [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA. [Wiener, Renda Soylemez] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Wiener, Renda Soylemez] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA. [Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA. [Slatore, Christopher G.] Portland VA Med Ctr, Sect Pulm & Crit Care Med, Portland, OR USA. [Slatore, Christopher G.] Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA. RP Wiener, RS (reprint author), Boston Univ, Sch Med, Ctr Pulm, 72 E Concord St,R-304, Boston, MA 02118 USA. EM rwiener@bu.edu OI Wiener, Renda/0000-0001-7712-2135; Slatore, Christopher/0000-0003-0958-8122 FU NCI NIH HHS [K07 CA138772] NR 12 TC 1 Z9 1 U1 0 U2 1 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2013 VL 144 IS 6 BP 1749 EP 1750 DI 10.1378/chest.13-1521 PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 272IU UT WOS:000328454500004 PM 24297116 ER PT J AU Almeida, FA Casal, RF Jimenez, CA Eapen, GA Uzbeck, M Sarkiss, M Rice, D Morice, RC Ost, DE AF Almeida, Francisco A. Casal, Roberto F. Jimenez, Carlos A. Eapen, George A. Uzbeck, Mateen Sarkiss, Mona Rice, David Morice, Rodolfo C. Ost, David E. TI Quality Gaps and Comparative Effectiveness in Lung Cancer Staging The Impact of Test Sequencing on Outcomes SO CHEST LA English DT Article ID TRANSBRONCHIAL NEEDLE ASPIRATION; POSITRON-EMISSION-TOMOGRAPHY; CLINICAL-PRACTICE GUIDELINES; SOLITARY PULMONARY NODULE; ENDOSCOPIC ULTRASOUND; CONTROLLED-TRIAL; MEDIASTINOSCOPY; BRONCHOSCOPY; DIAGNOSIS; REGISTRY AB Background: Evidence-based guidelines recommend mediastinal sampling as the first invasive test in patients with suspected lung cancer and mediastinal adenopathy. The goal of this study was to assess practice patterns and outcomes of diagnostic strategies in this patient population. Methods: We conducted a retrospective analysis of all patients in 2009 who had mediastinal adenopathy without distant metastatic disease to determine whether guideline-consistent care was delivered. Guideline-consistent care was defined as mediastinal lymph node sampling being performed as part of the first invasive procedure. Results: One hundred thirty-seven patients were included. Guideline-consistent care was provided in 30 cases (22%). Patients receiving guideline-consistent care had fewer invasive tests than patients with guideline-inconsistent care (1.3 +/- 0.5 tests/patient vs 2.3 +/- 0.5 tests/patient, respectively; P<.0001) and fewer complications (0 of 30, 0% vs 18 of 108, 17%; P=.01). Most of the complications (16 of 18) were related to CT image-guided needle biopsy. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) was sufficient to guide treatment decisions without any other invasive tests in 88 patients (64%). Although not all the complications and costs due to CT image-guided biopsies could have been avoided, roughly two-thirds could have been eliminated by just changing the testing sequence. Conclusion: Quality gaps in lung cancer staging in patients with mediastinal adenopathy are common and lead to unnecessary testing and increased complications. In patients with suspected lung cancer without distant metastatic disease with mediastinal adenopathy, EBUS-TBNA should be the first test. C1 [Almeida, Francisco A.] Cleveland Clin, Dept Pulm Allergy & Crit Care Med, Cleveland, OH 44106 USA. [Casal, Roberto F.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Dept Pulm & Crit Care Med, Houston, TX 77030 USA. [Jimenez, Carlos A.; Eapen, George A.; Morice, Rodolfo C.; Ost, David E.] Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA. [Sarkiss, Mona] Univ Texas MD Anderson Canc Ctr, Dept Anesthesia, Houston, TX 77030 USA. [Rice, David] Univ Texas MD Anderson Canc Ctr, Dept Thorac Surg, Houston, TX 77030 USA. [Uzbeck, Mateen] Our Lady Lourdes & Beaumont Hosp, Dept Pulm Med, Dublin, Ireland. RP Ost, DE (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Unit 1462,1515 Holcombe Blvd, Houston, TX 77030 USA. EM dost@mdanderson.org OI Ost, David/0000-0001-6351-5552 FU Olympus Corporation FX The authors have reported to CHEST the following conflicts of interest: In the last 3 years, Dr Eapen has received unrestricted educational grants from the Olympus Corporation and has provided consulting services to the Pentax Ricoch Imaging Co, Ltd. Dr Rice is a consultant to Olympus Corporation and teaches courses on EBUS. Drs Almeida, Casal, Jimenez, Uzbeck, Sarkiss, Morice, and Ost have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. NR 34 TC 17 Z9 17 U1 0 U2 13 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2013 VL 144 IS 6 BP 1776 EP 1782 DI 10.1378/chest.12-3046 PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 272IU UT WOS:000328454500011 PM 23703671 ER PT J AU Tanner, NT Egede, LE Shamblin, C Gebregziabher, M Silvestri, GA AF Tanner, Nichole T. Egede, Leonard E. Shamblin, Clayton Gebregziabher, Mulugeta Silvestri, Gerard A. TI Attitudes and Beliefs Toward Lung Cancer Screening Among US Veterans SO CHEST LA English DT Article ID SMOKERS; SYSTEM; TRIAL AB Background: Lung cancer (LC) is the leading cause of cancer-related death for veterans cared for by the US Veterans Health Administration. The LC burden among veterans is almost double that of the general population. Before implementation of an LC screening program, we set out to assess the role of beliefs and attitudes toward LC screening among veterans. Methods: Veterans presenting to the Ralph H. Johnson VA Medical Center were invited to complete a self-administered survey. The survey comprised questions about demographics, smoking status, health status, and knowledge about LC and willingness to be screened. Responses from veteran ever and never smokers were compared. Results: A total of 209 veterans completed the survey. Smokers were significantly (P<.05) more likely than never smokers to be less educated, have a lower income, and report poorer health. Smokers were more likely than never smokers to have two or more comorbidities, which trended toward significance (P=.062). Smokers were more likely to have been told by a physician that they were at high risk for LC and to believe that they were at risk. Nearly all veterans surveyed (92.8%) would have a CT scan for LC screening, and 92.4% would have surgery for a screen-detected LC. Conclusions: Veterans are overwhelmingly willing to undergo screening for LC, and it seems that participation will not be a barrier to implementation of an LC screening program. The mortality benefit of LC screening, however, may not be generalizable to the veteran population because of a higher number of comorbid conditions. C1 [Tanner, Nichole T.; Shamblin, Clayton; Silvestri, Gerard A.] Med Univ S Carolina, Div Pulm & Crit Care Allergy & Sleep Med, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Dept Internal Med, Div Internal Med & Geriatr, Charleston, SC 29425 USA. [Egede, Leonard E.] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA. [Gebregziabher, Mulugeta] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Tanner, Nichole T.; Egede, Leonard E.] Ralph H Johnson VA Med Ctr, Charleston VA Res Enhancement Award Program, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. RP Tanner, NT (reprint author), Med Univ S Carolina, Div Pulm & Crit Care Allergy & Sleep Med, 96 Jonathan Lucas St,Ste 812 CSB, Charleston, SC 29425 USA. EM tripici@musc.edu OI Gebregziabher, Mulugeta/0000-0002-4826-481X FU National Institutes of Health (NIH) [1K24CA12049-01A1]; South Carolina Clinical and Translational Research Institute Bio-medical Informatics Services [NIH 1UL1RR029882] FX This study was supported by grants from the National Institutes of Health (NIH) [1K24CA12049-01A1] and South Carolina Clinical and Translational Research Institute Bio-medical Informatics Services [NIH 1UL1RR029882]. NR 17 TC 10 Z9 10 U1 0 U2 6 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2013 VL 144 IS 6 BP 1783 EP 1787 DI 10.1378/chest.13-0056 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 272IU UT WOS:000328454500012 PM 23764896 ER PT J AU Chan, MM Chan, MM Mengshol, JA Fish, DN Chan, ED AF Chan, Mallory M. Chan, Michael M. Mengshol, John Andrew Fish, Douglas N. Chan, Edward D. TI Octreotide A Drug Often Used in the Critical Care Setting but Not Well Understood SO CHEST LA English DT Review ID TYPE-1 HEPATORENAL-SYNDROME; SULFONYLUREA-INDUCED HYPOGLYCEMIA; PLACEBO-CONTROLLED TRIAL; CIRRHOTIC-PATIENTS; SOMATOSTATIN RECEPTORS; NEUROENDOCRINE TUMORS; VARICEAL HEMORRHAGE; DOUBLE-BLIND; POSTOPERATIVE CHYLOTHORAX; ENDOSCOPIC TREATMENT AB While the canonical function of somatostatin (SST) is to inhibit the secretion of growth hormone, it has a number of other physiologic effects that are less widely appreciated. Octreotide, an analog of SST, is not uncommonly used in the critical care setting, particularly for the treatment of variceal hemorrhage. Herein, we discuss the biology and pharmacology of SST, octreotide, and other SST analogs. We also review the evidence behind their use in esophageal variceal bleeds, hepatorenal syndrome, hypoglycemia due to sulfonylurea poisoning, and chylous pleural effusions. C1 Univ Colorado, Sch Med, Denver, CO USA. [Fish, Douglas N.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA. [Mengshol, John Andrew] Univ Colorado Anschutz Med Campus, Div Gastroenterol, Aurora, CO USA. Univ Colorado Anschutz Med Campus, Div Pulm Sci & Crit Care Med, Aurora, CO USA. [Mengshol, John Andrew] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA. Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA. Natl Jewish Hlth, Dept Acad Affairs, Denver, CO 80206 USA. RP Chan, ED (reprint author), Natl Jewish Hlth, D509 Neustadt Bldg,1400 Jackson St, Denver, CO 80206 USA. EM chane@njhealth.org NR 75 TC 3 Z9 4 U1 1 U2 5 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD DEC PY 2013 VL 144 IS 6 BP 1937 EP 1945 DI 10.1378/chest.13-0382 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 272IU UT WOS:000328454500032 PM 24297127 ER PT J AU Moore, JG Ross, SM Williams, BA AF Moore, Jeffrey G. Ross, Scott M. Williams, Brian A. TI Regional anesthesia and ambulatory surgery SO CURRENT OPINION IN ANESTHESIOLOGY LA English DT Article DE ambulatory anesthesia; healthcare economics; nerve block; postoperative nausea and vomiting; regional anesthesia ID PERIPHERAL-NERVE BLOCKS; RANDOMIZED CONTROLLED-TRIAL; ABDOMINIS PLANE BLOCK; OUTPATIENT KNEE ARTHROSCOPY; ELIMINATING POSTOPERATIVE NAUSEA; CRUCIATE LIGAMENT RECONSTRUCTION; THORACIC PARAVERTEBRAL BLOCK; MINIDOSE LIDOCAINE-FENTANYL; OFF-PATENT ANTIEMETICS; RECTUS SHEATH BLOCK AB Purpose of reviewAdvances in surgery and anesthesia have allowed for more surgeries to be done on an outpatient basis. A recent important advance entails availability of suitable recovery criteria to capitalize on the benefits of regional anesthesia for ambulatory surgery. With ever-escalating healthcare costs and expectations for faster recovery, anesthesiologists are now challenged to design anesthesia plans focused on Phase I postanesthesia care unit bypass and early facility discharge. Satisfying the recently published WAKE Score criteria upon operating room exit is associated with hospital cost reductions. This review highlights regional anesthesia techniques with focus on outpatient orthopedics. We also discuss multimodalities' addressing postoperative nausea and vomiting prophylaxis, perioperative analgesia (including perineural analgesia), and sedation-hypnosis, which are all central to timely recovery using now-available suitable recovery criteria.Recent findingsUltrasound-guided regional anesthesia has increased the comfort level for many anesthesiologists performing blocks. Other advances include better monitoring of anesthetic depth for titration of sedatives, en route to avoiding emetogenic and hyperalgesic volatile anesthetics.SummaryRoutine regional anesthesia use, multimodal postoperative nausea and vomiting prophylaxis, multimodal sedation-hypnosis, and multimodal analgesia, along with avoiding volatile agents and short-duration opioids, can lead to both routine Phase 1 postanesthesia care unit bypass and expedited same-day discharge, when using suitable recovery criteria. C1 [Moore, Jeffrey G.; Ross, Scott M.; Williams, Brian A.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15240 USA. RP Williams, BA (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, VA Pittsburgh Hlth Syst, Pittsburgh, PA 15240 USA. EM williamsba@anes.upmc.edu FU National Institutes of Health [K01DA025146]; Department of Defense [PRORP OR090012] FX Departmental resources were used for the underwriting of professional effort in the preparation of this article. Drs. J.G.M. and S.M.R. have no potential conflicts of interest to disclose. Dr B.A.W. was funded by the National Institutes of Health (2008-2010 K01DA025146, 'Peripheral Nerve Blocks with Multimodal Analgesics'). At the time of article submission, Dr B.A.W. was funded by the Department of Defense (2010-2013 PRORP OR090012, 'Enhancing Post-Traumatic Pain Relief with Alternative Perineural Drugs'). NR 86 TC 4 Z9 5 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0952-7907 EI 1473-6500 J9 CURR OPIN ANESTHESIO JI Curr. Opin. Anesthesiol. PD DEC PY 2013 VL 26 IS 6 BP 652 EP 660 DI 10.1097/ACO.0000000000000011 PG 9 WC Anesthesiology SC Anesthesiology GA 268EW UT WOS:000328153000003 PM 24113264 ER PT J AU McCaffery, JM Papandonatos, GD Huggins, GS Peter, I Kahn, SE Knowler, WC Hudnall, GE Lipkin, EW Kitabchi, AE Wagenknecht, LE Wing, RR AF McCaffery, J. M. Papandonatos, G. D. Huggins, G. S. Peter, I. Kahn, S. E. Knowler, W. C. Hudnall, G. E. Lipkin, E. W. Kitabchi, A. E. Wagenknecht, L. E. Wing, R. R. CA Genetic Subgrp Look AHEAD Look AHEAD Res Grp TI FTO predicts weight regain in the Look AHEAD clinical trial SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Article DE type 2 diabetes; weight loss; diet; genetics ID GENOME-WIDE ASSOCIATION; DIABETES PREVENTION PROGRAM; LIFE-STYLE INTERVENTION; OBESITY-RELATED TRAITS; REDUCES ENERGY-INTAKE; BODY-MASS INDEX; NEUROTROPHIC FACTOR; ADULT OBESITY; CHILDHOOD OBESITY; RISK-FACTORS AB BACKGROUND: Genome-wide association studies have provided new insights into the genetic factors that contribute to the development of obesity. We hypothesized that these genetic markers would also predict magnitude of weight loss and weight regain after initial weight loss. METHODS: Established obesity risk alleles available on the Illumina CARe iSelect (IBC) chip were characterized in 3899 overweight or obese participants with type 2 diabetes from the Look AHEAD (Action for Health in Diabetes), a randomized trial to determine the effects of intensive lifestyle intervention (ILI) and diabetes support and education (DSE) on cardiovascular morbidity and mortality. Primary analyses examined the interaction between 13 obesity risk polymorphisms in eight genes and randomized treatment arm in predicting weight change at year 1, and weight regain at year 4 among individuals who lost 3% or more of their baseline weight by year 1. RESULTS: No single-nucleotide polymorphisms (SNPs) were significantly associated with magnitude of weight loss or interacted with treatment arm at year 1. However, fat mass and obesity associated gene (FTO) rs3751812 predicted weight regain within DSE (1.56 kg per risk allele, P = 0.005), but not ILI (P = 0.761), resulting in SNP x treatment arm interaction (P = 0.009). In a partial replication of prior research, the obesity risk (G) allele at BDNF rs6265 was associated with greater weight regain across treatment arms (0.773 kg per risk allele), although results were of borderline statistical significance (P = 0.051). CONCLUSIONS: Variations in the FTO and BDNF loci may contribute risk of weight regain after weight loss. C1 [McCaffery, J. M.; Wing, R. R.] Miriam Hosp, Dept Psychiat & Human Behav, Weight Control & Diabet Res Ctr, Providence, RI 02903 USA. [McCaffery, J. M.; Wing, R. R.] Brown Med Sch, Providence, RI USA. [Papandonatos, G. D.] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA. [Huggins, G. S.] Tufts Med Ctr, Mol Cardiol Res Inst, MCRI Ctr Translat Genom, Boston, MA USA. [Peter, I.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA. [Kahn, S. E.; Kitabchi, A. E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Knowler, W. C.] Natl Inst Diabet & Digest & Kidney Dis, Phoenix, AZ USA. [Hudnall, G. E.] Baylor Coll Med, Houston, TX 77030 USA. [Hudnall, G. E.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Lipkin, E. W.] Univ Tennessee, Ctr Hlth Sci, Div Endocrinol Diabet & Metab, Memphis, TN 38163 USA. [Wagenknecht, L. E.] Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA. RP McCaffery, JM (reprint author), Miriam Hosp, Dept Psychiat & Human Behav, Weight Control & Diabet Res Ctr, 196 Richmond St, Providence, RI 02903 USA. EM jeanne_mccaffery@brown.edu RI Papandonatos, George/J-2328-2014 OI Papandonatos, George/0000-0001-6770-932X; Kahn, Steven/0000-0001-7307-9002 FU Department of Health and Human Services through National Institutes of Health [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992]; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women's Health; Centers for Disease Control and Prevention; Johns Hopkins Medical Institutions Bayview General Clinical Research Center [M01RR02719]; Massachusetts General Hospital Mallinckrodt General Clinical Research Center [M01RR01066]; University of Colorado Health Sciences Center General Clinical Research Center [M01RR00051]; Clinical and Nutrition Research Unit [P30 DK48520]; University of Tennessee at Memphis General Clinical Research Center [M01RR0021140]; University of Pittsburgh General Clinical Research Center [M01RR000056 44]; NIH [DK 046204, DK072497]; VA Puget Sound Health Care System and Department of Veterans Affairs; Frederic C Bartter General Clinical Research Center [M01RR01346]; Training Program in Cardiovascular Research (NIH) [5T32HL069770] FX We acknowledge the Look AHEAD sites that participated in this ancillary study. This study is supported by the Department of Health and Human Services through the following cooperative agreements from the National Institutes of Health: DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135 and DK56992. The following federal agencies have contributed support: National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; Office of Research on Women's Health; and the Centers for Disease Control and Prevention. Additional support was received from The Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) Clinical and Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center (M01RR000056 44) and NIH grants (DK 046204 and DK072497); and VA Puget Sound Health Care System and Department of Veterans Affairs; Frederic C Bartter General Clinical Research Center (M01RR01346). AKH was supported by the Training Program in Cardiovascular Research (NIH, 5T32HL069770). The following organizations have committed to make major contributions to Look AHEAD: Federal Express; Health Management Resources; Johnson & Johnson, LifeScan Inc.; Optifast-Novartis Nutrition; Roche Pharmaceuticals; Ross Product Division of Abbott Laboratories; Slim-Fast Foods Company; and Unilever. NR 38 TC 12 Z9 12 U1 0 U2 14 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 EI 1476-5497 J9 INT J OBESITY JI Int. J. Obes. PD DEC PY 2013 VL 37 IS 12 BP 1545 EP 1552 DI 10.1038/ijo.2013.54 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 272JJ UT WOS:000328456200005 PM 23628854 ER PT J AU Morshed, SA Ma, R Latif, R Davies, TE AF Morshed, Syed A. Ma, Risheng Latif, Rauf Davies, Terry E. TI How one TSH receptor antibody induces thyrocyte proliferation while another induces apoptosis SO JOURNAL OF AUTOIMMUNITY LA English DT Article DE Thyrocyte; TSH receptor; Antibodies; ROS-signaling; Apoptosis; Proliferation ID HUMAN THYROTROPIN RECEPTOR; GRAVES-DISEASE; SYNTHETIC PEPTIDES; SIGNALING CASCADES; OXIDATIVE STRESS; GENE-EXPRESSION; MITOCHONDRIA; CREB; IDENTIFICATION; RESPONSES AB Thyroid stimulating hormone (TSH) activates two major G-protein arms, Gs alpha and Gq leading to initiation of down-stream signaling cascades for survival, proliferation and production of thyroid hormones. Antibodies to the TSH receptor (TSHR-Abs), found in patients with Graves' disease, may have stimulating, blocking, or neutral actions on the thyroid cell. We have shown previously that such TSHR-Abs are distinct signaling imprints after binding to the TSHR and that such events can have variable functional consequences for the cell. In particular, there is a great contrast between stimulating (S) TSHR-Abs, which induce thyroid hormone synthesis and secretion as well as thyroid cell proliferation, compared to so called "neutral" (N) TSHR-Abs which may induce thyroid cell apoptosis via reactive oxygen species (ROS) generation. In the present study, using a rat thyrocyte (FRTL-5) ex vivo model system, our hypothesis was that while N-TSHR-Abs can induce apoptosis via activation of mitochondrial ROS (mR0S), the S-TSHR-Abs are able to stimulate cell survival and avoid apoptosis by actively suppressing mR0S. Using fluorescent microscopy, fluorometry, live cell imaging, immunohistochemistry and immunoblot assays, we have observed that S-TSHR-Abs do indeed suppress mROS and cellular stress and this suppression is exerted via activation of the PKA/CREB and AKT/mTOR/S6K signaling cascades. Activation of these signaling cascades, with the suppression of mR0S, initiated cell proliferation. In sharp contrast, a failure to activate these signaling cascades with increased activation of mROS induced by N-TSHR-Abs resulted in thyroid cell apoptosis. Our current findings indicated that signaling diversity induced by different TSHR-Abs regulated thyroid cell fate. While S-TSHR-Abs may rescue cells from apoptosis and induce thyrocyte proliferation, N-TSHR-Abs aggravate the local inflammatory infiltrate within the thyroid gland, or in the retro-orbit, by inducing cellular apoptosis; a phenomenon known to activate innate and by-stander immune-reactivity via DNA release from the apoptotic cells. Published by Elsevier Ltd. C1 [Morshed, Syed A.] Icahn Sch Med Mt Sinai, Thyroid Res Unit, New York, NY USA. James J Peters VA Med Ctr, New York, NY USA. RP Morshed, SA (reprint author), Vet Adm Med Ctr, Room 2F-26,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM syed.morshed@mssm.edu FU NIH [DK069713, DK052464]; VA Merit Award Program FX Supported in part by NIH grants DK069713, DK052464 and the VA Merit Award Program. NR 34 TC 11 Z9 11 U1 1 U2 5 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0896-8411 EI 1095-9157 J9 J AUTOIMMUN JI J. Autoimmun. PD DEC PY 2013 VL 47 BP 17 EP 24 DI 10.1016/j.jaut.2013.07.009 PG 8 WC Immunology SC Immunology GA 273HY UT WOS:000328527100002 PM 23958398 ER PT J AU Dachman, AH Yee, J AF Dachman, Abraham H. Yee, Judy TI The Challenges of CT Colonography Reimbursement SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Article DE CT colonography; colorectal cancer; technology adoption ID COMPUTED TOMOGRAPHIC COLONOGRAPHY; EXTRACOLONIC FINDINGS; COLORECTAL-CANCER; VIRTUAL COLONOSCOPY; ASYMPTOMATIC ADULTS; SCREENING POPULATION; ADENOMATOUS POLYPS; ECONOMIC-IMPACT; TASK-FORCE; ACCURACY AB CT colonography has been shown to be an effective method to screen for colorectal cancer. However, at present, full endorsement and reimbursement for screening CT colonography, particularly by the US Preventive Services Task Force and CMS, respectively, are absent, so this screening option is infrequently used, and optical colonoscopy remains the de facto standard screening option. The authors summarize the past accomplishments that led to the current state of reimbursement and outline the remaining challenges and road to full acceptance and reimbursement of screening CT colonography nationally. C1 [Dachman, Abraham H.] Univ Chicago, Med Ctr, Chicago, IL 60637 USA. [Yee, Judy] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Yee, Judy] San Francisco VA Med Ctr, San Francisco, CA USA. RP Dachman, AH (reprint author), Univ Chicago, Med Ctr, 5841 S Maryland Ave,MC 2026, Chicago, IL 60637 USA. EM andachma@uchicago.edu FU Hologic (Bedford, Massachusetts); UC Tech (Chicago, Illinois); Bracco (Milan, Italy); EchoPixel (Sunnyvale, California) FX Dr Dachman is an instructor of virtual colonoscopy courses for GE Healthcare (Milwaukee, Wisconsin) and receives royalties from Hologic (Bedford, Massachusetts) and UC Tech (Chicago, Illinois). Dr Yee has received research grants from Bracco (Milan, Italy) and EchoPixel (Sunnyvale, California) and is chair of the Colon Cancer Committee for the ACR (Reston, Virginia). NR 57 TC 5 Z9 6 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD DEC PY 2013 VL 10 IS 12 BP 937 EP 942 DI 10.1016/j.jacr.2013.09.014 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 277DX UT WOS:000328800300016 PM 24295944 ER PT J AU Dimopoulos, G Koulenti, D Blot, S Sakr, Y Anzueto, A Spies, C Violan, JS Kett, D Armaganidis, A Martin, C Vincent, JL AF Dimopoulos, George Koulenti, Despoina Blot, Stijn Sakr, Yasser Anzueto, Antonio Spies, Claudia Sole Violan, Jordi Kett, Daniel Armaganidis, Apostolos Martin, Claude Vincent, Jean Louis CA Extended Prevalence Infection TI Critically Ill Elderly Adults with Infection: Analysis of the Extended Prevalence of Infection in Intensive Care Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE critically ill; age; infections ID REQUIRING VENTILATORY SUPPORT; BLOOD-STREAM INFECTIONS; MECHANICAL VENTILATION; NOSOCOMIAL INFECTIONS; RISK-FACTORS; OLD PATIENTS; UNIT; MORTALITY; AGE; EPIDEMIOLOGY AB ObjectivesTo determine the effect of age on patterns of infection and on outcomes in individuals with infection. DesignAnalysis of data from an international, observational, point-prevalence study: Extended Prevalence of Infection in Intensive Care (EPIC II). SettingIntensive care units (ICUs; N=1,265) in 75 countries. ParticipantsAll adults present in a participating ICU on May 8, 2007. Individuals with an infection were included and classified according to age (18-44, 45-64, 65-74, 75-84, 85). MeasurementsDemographic, physiological, bacteriological, and therapeutic data were collected on the day of the study. Outcome data were collected until hospital discharge or for 60days. ResultsOf the 13,796 adults enrolled in EPIC II, 7,087 (51.4%) had an infection. Of these, 330 (4.7%) were aged 85 and older, 1,405 (19.8%) were 75 to 84, 1,713 (24.2%) were 65 to 74, 2,358 (33.3%) were 45 to 64, and 1,281 (18.1%) were 18 to 44. Severity of illness did not differ between groups. Those aged 85 and older had fewer bloodstream infections than those younger than 75, fewer central nervous system infections than those who were younger than 65, and more abdominal infections than those who were younger than 45. A microbiological diagnosis was established less frequently in participants aged 85 and older than in younger participants. Gram-negative microorganisms were more frequently isolated in those aged 85 and older than in other groups. ICU and hospital mortality were significantly higher in participants aged 85 and older than in those who were younger than 65. ConclusionA large proportion of individuals in the ICU with infection are aged 65 and older. Patterns of infection, including site and type of microorganism, vary according to age. Being aged 85 and older was an independent risk factor for mortality in individuals in the ICU with infection. C1 [Dimopoulos, George; Koulenti, Despoina; Armaganidis, Apostolos] Attikon Univ Hosp, Dept Crit Care Med, Athens, Greece. [Blot, Stijn] Ghent Univ Hosp, Dept Internal Med, Ghent, Belgium. [Sakr, Yasser] Univ Jena, Dept Anesthesiol & Intens Care, Jena, Germany. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Pulm & Crit Care, San Antonio, TX 78229 USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Spies, Claudia] Charite, Campus Virchow Klinikum, Dept Anesthesiol & Intens Care, D-13353 Berlin, Germany. [Spies, Claudia] Charite, Campus Charite Mitte, D-13353 Berlin, Germany. [Sole Violan, Jordi] Hosp Dr Negrin, Intens Care Unit, Las Palmas Gran Canaria, Spain. [Kett, Daniel] Univ Miami, Miller Sch Med, Dept Med, Div Pulm & Crit Care, Miami, FL 33136 USA. [Kett, Daniel] Jackson Mem Hosp, Miami, FL 33136 USA. [Martin, Claude] Hosp Nord, Dept Anesthesiol & Intens Care, Marseille, France. [Vincent, Jean Louis] Univ Libre Brussels, Erasme Hosp, Dept Intens Care, Brussels, Belgium. RP Dimopoulos, G (reprint author), Univ Athens, Sch Med, Univ Hosp Attikon, Dept Crit Care, 1 Rimini Str, Athens 12462, Greece. EM gdimop@med.uoa.gr RI Sakr, Yasser/D-9802-2013; Koulenti, Despoina/D-4851-2010 OI Koulenti, Despoina/0000-0003-4364-2612 NR 35 TC 6 Z9 8 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2013 VL 61 IS 12 BP 2065 EP 2071 DI 10.1111/jgs.12544 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 271UB UT WOS:000328416000001 PM 24479140 ER PT J AU Shega, JW Andrew, M Kotwal, A Lau, DT Herr, K Ersek, M Weiner, DK Chin, MH Dale, W AF Shega, Joseph W. Andrew, Melissa Kotwal, Ashwin Lau, Denys T. Herr, Keela Ersek, Mary Weiner, Debra K. Chin, Marshall H. Dale, William TI Relationship Between Persistent Pain and 5-Year Mortality: A Population-Based Prospective Cohort Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE pain; mortality; older adult ID DWELLING OLDER-ADULTS; LOW-BACK-PAIN; HEALTH-CARE UTILIZATION; COGNITIVE IMPAIRMENT; PHYSICAL FUNCTION; MANAGEMENT; PREVALENCE; FRAILTY; PEOPLE; OSTEOARTHRITIS AB ObjectivesTo assess the association between self-reported noncancer pain and 5-year mortality. DesignCohort. SettingCommunity-dwelling older adults. ParticipantsCanadian Study of Health and Aging 1996 wave. MeasurementsRegistrar of Vital Statistics-established 5-year mortality. Noncancer pain was assessed using the 5-point verbal descriptor scale, dichotomized into no or very mild versus moderate, severe, or very severe pain. Frailty was the accumulation of health deficits. Cognitive status (Modified Mini-Mental State Examination) and depressed mood (five-item mental health screening questionnaire) were also assessed. Multivariable logistic regression and Cox proportional hazards were used to analyze the relationship between pain and 5-year mortality. ResultsOf 5,703 participants, 4,694 (82.3%) had complete data for analysis; 1,663 of these (35.4%) reported moderate, severe, or very severe pain, and 1,343 (28.6%) had died at 5-year follow-up. Four hundred ninety-six of those who died (29.8%) reported moderate, severe, or very severe pain and 847 (27.9%) no or very mild pain. Multivariate logistic analysis found that individuals with moderate, severe, or very severe pain had lower odds of 5-year mortality than those with no or very mild pain (odds ratio=0.78, 95% confidence interval (CI)=0.66-0.92; P<.001). The risk of death was lower in persons reporting moderate or greater pain than in those with no or very mild pain (HR=0.85, 95% CI=0.75-0.96; P=.01). An interaction between pain and sex explained this effect. Men with pain were not significantly more likely than men without pain to die (HR=1.00, 95% CI=0.84-1.19; P=.99), whereas women without pain (HR=0.54, 95% CI=0.47-0.63; P<0.01) and women with pain (HR=0.40; CI=0.33-0.47; P<.01) had less risk of death than men without and with pain, respectively. ConclusionOlder women with pain were less likely to die within 5years than older women without pain, men in pain, or men without pain. C1 [Shega, Joseph W.; Kotwal, Ashwin; Dale, William] Univ Chicago, Sect Geriatr & Palliat Med, Chicago, IL 60637 USA. [Andrew, Melissa] Dalhousie Univ, Div Geriatr Med, Halifax, NS, Canada. [Lau, Denys T.] Ctr Dis Control & Prevent, Div Hlth Care Stat, Natl Ctr Hlth Stat, Atlanta, GA USA. [Lau, Denys T.] Univ Illinois, Coll Pharm, Dept Pharm Adm, Chicago, IL USA. [Herr, Keela] Univ Iowa, Coll Nursing, Iowa City, IA 52242 USA. [Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Weiner, Debra K.] Univ Pittsburgh, Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Chin, Marshall H.] Univ Chicago, Gen Internal Med Sect, Chicago, IL 60637 USA. [Dale, William] Univ Chicago, Sect Hematol & Oncol, Chicago, IL 60637 USA. RP Shega, JW (reprint author), Univ Chicago, Sect Geriatr & Palliat Med, MC 6098,5841 S Maryland Ave, Chicago, IL 60637 USA. EM jshega@gmail.com FU National Health Research Development Program [6606-3954-MC(S)]; National Institute on Aging [K23AG029815]; Canadian Institutes of Health Research [MOP-62823]; National Institute of Diabetes and Digestive and Kidney Diseases Midcareer Investigator Award in Patient-Oriented Research [K24 DK071933]; Chicago Center for Diabetes Translation Research [P30 DK092949] FX All the data reported here were gathered using public funding from the National Health Research Development Program, which administrated a grant from the Seniors' Independence Research program (6606-3954-MC(S)). Funding for these analyses came from a career development award from the National Institute on Aging (K23AG029815) and from the Canadian Institutes of Health Research through an operating grant (MOP-62823). Dr. Chin was supported by a National Institute of Diabetes and Digestive and Kidney Diseases Midcareer Investigator Award in Patient-Oriented Research (K24 DK071933) and the Chicago Center for Diabetes Translation Research (P30 DK092949). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the National Institute on Aging, the Centers for Disease Control and Prevention, or the National Center for Health Statistics. NR 41 TC 5 Z9 5 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2013 VL 61 IS 12 BP 2135 EP 2141 DI 10.1111/jgs.12554 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 271UB UT WOS:000328416000010 PM 24320761 ER PT J AU Reuben, DB Evertson, LC Wenger, NS Serrano, K Chodosh, J Ercoli, L Tan, ZS AF Reuben, David B. Evertson, Leslie C. Wenger, Neil S. Serrano, Katherine Chodosh, Joshua Ercoli, Linda Tan, Zaldy S. TI The University of California at Los Angeles Alzheimer's and Dementia Care Program for Comprehensive, Coordinated, Patient-Centered Care: Preliminary Data SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE Alzheimer's disease; dementia; care coordination; caregiver support ID MANAGEMENT INTERVENTION; COGNITIVE IMPAIRMENT; CONTROLLED-TRIAL; OLDER-ADULTS; QUALITY; DISEASE; DEPRESSION; COMMUNITY; IMPROVE; MODELS AB Dementia is a chronic disease that requires medical and social services to provide high-quality care and prevent complications. As a result of time constraints in practice, lack of systems-based approaches, and poor integration of community-based organizations (CBOs), the quality of care for dementia is poorer than that for other diseases that affect older persons. The University of California at Los Angeles (UCLA) Alzheimer's and Dementia Care (UCLA ADC) program partners with CBOs to provide comprehensive, coordinated, patient-centered care for individuals with Alzheimer's disease and other dementias. The goals of the program are to maximize function, independence, and dignity; minimize caregiver strain and burnout; and reduce unnecessary costs. The UCLA ADC program consists of five core components: recruitment and a dementia registry, structured needs assessments of individuals in the registry and their caregivers, creation and implementation of individualized dementia care plans based on needs assessments and input from the primary care physicians, monitoring and revising care plans as needed, and around-the-clock access for assistance and advice. The program uses a comanagement model with a nurse practitioner Dementia Care Manager working with primary care physicians and CBOs. Based on the first 150 individuals served, the most common recommendations in the initial care plans were referrals to support groups (73%) and Alzheimer's Association Safe Return (73%), caregiver training (45%), and medication adjustment (41%). The program will be evaluated on its ability to achieve the triple aim of better care for individuals, better health for populations, and lower costs. C1 [Reuben, David B.; Evertson, Leslie C.; Serrano, Katherine; Tan, Zaldy S.] Univ Calif Los Angeles, David Geffen Sch Med, Multicampus Program Geriatr Med & Gerontol, Los Angeles, CA 90095 USA. [Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Chodosh, Joshua] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Ercoli, Linda] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat, Div Geriatr Psychol, Los Angeles, CA 90095 USA. RP Reuben, DB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 10945 Le Conte Ave,Suite 2339, Los Angeles, CA 90095 USA. EM dreuben@mednet.ucla.edu OI Chodosh, Joshua/0000-0001-7784-4306 FU Centers for Medicare and Medicaid Services [CMS-1C1-12-0001]; Centers for Medicare and Medicaid Innovation [1C1CMS330982-01-00]; UCLA Claude Pepper Older Americans Independence Center; National Institute on Aging [5P30AG028748] FX The project described was supported by Funding Opportunity CMS-1C1-12-0001 from Centers for Medicare and Medicaid Services (1C1CMS330982-01-00) Centers for Medicare and Medicaid Innovation and by the UCLA Claude Pepper Older Americans Independence Center, funded by the National Institute on Aging (5P30AG028748). The contents are solely the responsibility of the authors and do not necessarily represent the official views of HHS or any of its agencies. NR 20 TC 16 Z9 16 U1 3 U2 19 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD DEC PY 2013 VL 61 IS 12 BP 2214 EP 2218 DI 10.1111/jgs.12562 PG 5 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 271UB UT WOS:000328416000021 PM 24329821 ER PT J AU Janzen, DM Paik, DY Rosales, MA Yep, B Cheng, DH Witte, ON Kayadibi, H Ryan, CM Jung, ME Faull, K Memarzadeh, S AF Janzen, Deanna M. Paik, Daniel Y. Rosales, Miguel A. Yep, Brian Cheng, Donghui Witte, Owen N. Kayadibi, Huseyin Ryan, Christopher M. Jung, Michael E. Faull, Kym Memarzadeh, Sanaz TI Low Levels of Circulating Estrogen Sensitize PTEN-Null Endometrial Tumors to PARP Inhibition In Vivo SO MOLECULAR CANCER THERAPEUTICS LA English DT Article ID BREAST-CANCER CELLS; POLY(ADP-RIBOSE) POLYMERASE; PHASE-I; HOMOLOGOUS RECOMBINATION; MUTANT-CELLS; CARCINOMA; RECURRENT; OLAPARIB; EXPRESSION; AROMATASE AB Earlier in vitro work demonstrated that PARP inhibition induces cell death in PTEN-null endometrial cancer cell lines, but the in vivo therapeutic efficacy of these agents against endometrial cancer remains unknown. Here, we test the efficacy of AZD2281 (olaparib), an oral PARP inhibitor, in the therapy of PTEN-null endometrial tumors in a preclinical endometrial cancer mouse model. Primary endometrial tumors were generated by epithelial loss of PTEN using an in vivo model. This model recapitulates epithelial-specific loss of PTEN seen in human tumors, and histologically resembles endometrioid carcinomas, the predominant subtype of human endometrial cancers. Olaparib was administered orally to tumor-bearing mice in two hormonal extremes: high or low estrogen. Olaparib treatment achieved a significant reduction in tumor size in a low estrogenic milieu. In striking contrast, no response to olaparib was seen in tumors exposed to high levels of estrogen. Two key observations were made when estrogen levels were dropped: (i) the serum concentration of olaparib was significantly increased, resulting in sustained PARP inhibition at the tumor bed; and (ii) the homologous recombination pathway was compromised, as evidenced by decreased Rad51 protein expression and function. These two mechanisms may account for the sensitization of PTEN-null tumors to olaparib with estrogen deprivation. Results of this preclinical trial suggest that orally administered PARP inhibitors in a low estrogenic hormonal milieu can effectively target PTEN-null endometrial tumors. Extension of this work to clinical trials could personalize the therapy of women afflicted with advanced endometrial cancer using well-tolerated orally administered therapeutic agents. (C)2013 AACR. C1 [Janzen, Deanna M.; Paik, Daniel Y.; Rosales, Miguel A.; Yep, Brian; Memarzadeh, Sanaz] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA. [Witte, Owen N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Kayadibi, Huseyin; Ryan, Christopher M.; Faull, Kym] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Witte, Owen N.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA. [Jung, Michael E.] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA. [Memarzadeh, Sanaz] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Witte, Owen N.; Memarzadeh, Sanaz] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA. [Cheng, Donghui; Witte, Owen N.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA. RP Memarzadeh, S (reprint author), Univ Calif Los Angeles, 555 Westwood Plaza,Level B,Box 957243,1015 Terasa, Los Angeles, CA 90095 USA. EM smemarzadeh@mednet.ucla.edu FU Concern foundation; CDU/UCLA NIH/NCI [U54-CA-143931]; VA CDA-2 Award; Scholars in Translational Medicine Program; Mary Kay Foundation Award; STOP Cancer Award; Broad Stem Cell Research Center Research Award; Sidney Kimmel Foundation award; National Center for Research Resources Grant [UL1TR000124]; University of California Cancer Research Coordinating Committee FX This work was financially supported by the Concern foundation, CDU/UCLA NIH/NCI Grant #U54-CA-143931, VA CDA-2 Award, Scholars in Translational Medicine Program, Mary Kay Foundation Award, STOP Cancer Award, Broad Stem Cell Research Center Research Award, Sidney Kimmel Foundation award, National Center for Research Resources Grant UL1TR000124, and the University of California Cancer Research Coordinating Committee grant to S. Memarzadeh. O.N. Witte is an Investigator of the Howard Hughes Medical Institute. NR 50 TC 9 Z9 10 U1 0 U2 4 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1535-7163 EI 1538-8514 J9 MOL CANCER THER JI Mol. Cancer Ther. PD DEC PY 2013 VL 12 IS 12 BP 2917 EP 2928 DI 10.1158/1535-7163.MCT-13-0572 PG 12 WC Oncology SC Oncology GA 272UK UT WOS:000328486600028 PM 24222661 ER PT J AU Okun, MS Weintraub, D AF Okun, Michael S. Weintraub, Daniel TI Should Impulse Control Disorders and Dopamine Dysregulation Syndrome Be Indications for Deep Brain Stimulation and Intestinal Levodopa? SO MOVEMENT DISORDERS LA English DT Article ID PARKINSONS-DISEASE; SUBTHALAMIC STIMULATION; COMPULSIVE BEHAVIORS; NUCLEUS-ACCUMBENS; MANAGEMENT; ADDICTION; MEDICATION; MECHANISMS; AMANTADINE; RELEASE C1 [Okun, Michael S.] Univ Florida, Ctr Movement Disorders & Neurorestorat, Dept Neurol, Gainesville, FL 32610 USA. [Okun, Michael S.] Univ Florida, Ctr Movement Disorders & Neurorestorat, Dept Neurosurg, Gainesville, FL 32610 USA. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. RP Okun, MS (reprint author), Univ Florida, J Hillis Miller Hlth Ctr, Dept Neurol, 100 S Newell Dr,Room L3-101, Gainesville, FL 32610 USA. EM okun@neurology.ufl.edu OI Okun, Michael/0000-0002-6247-9358 FU NINDS NIH HHS [K23 NS044997] NR 49 TC 7 Z9 8 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD DEC PY 2013 VL 28 IS 14 BP 1915 EP 1919 DI 10.1002/mds.25735 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA 264TB UT WOS:000327902400003 PM 24243803 ER PT J AU Weimer, MB Macey, TA Nicolaidis, C Dobscha, SK Duckart, JP Morasco, BJ AF Weimer, Melissa B. Macey, Tara A. Nicolaidis, Christina Dobscha, Steven K. Duckart, Jonathan P. Morasco, Benjamin J. TI Sex Differences in the Medical Care of VA Patients with Chronic Non-Cancer Pain SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Veteran Women; Sex Differences; Chronic Opioid Therapy ID HEALTH-CARE; MUSCULOSKELETAL PAIN; OPIOID THERAPY; WOMEN VETERANS; PREVALENCE; GENDER; POPULATION; FIBROMYALGIA; MANAGEMENT; MEN AB ObjectiveDespite a growing number of women seeking medical care in the veterans affairs (VA) system, little is known about the characteristics of their chronic pain or the pain care they receive. This study sought to determine if sex differences are present in the medical care veterans received for chronic pain. DesignRetrospective cohort study using VA administrative data. SubjectsThe subjects were 17,583 veteran patients with moderate to severe chronic non-cancer pain treated in the Pacific Northwest during 2008. MethodsMultivariate logistic regression assessed for sex differences in primary care utilization, prescription of chronic opioid therapy, visits to emergency departments for a pain-related diagnosis, and physical therapy referral. ResultsCompared with male veterans, female veterans were more often diagnosed with two or more pain conditions, and had more of the following pain-related diagnoses: fibromyalgia, low back pain, inflammatory bowel disease, migraine headache, neck or joint pain, and arthritis. After adjustment for demographic characteristics, pain diagnoses, mental health diagnoses, substance use disorders, and medical comorbidity, women had lower odds of being prescribed chronic opioid therapy (adjusted OR [AOR] 0.67, 95% CI 0.58-0.78), greater odds of visiting an emergency department for a pain-related complaint (AOR 1.40, 95% CI 1.18-1.65), and greater odds of receiving physical therapy (AOR 1.19, 95% CI 1.05-1.33). Primary care utilization was not significantly different between sexes. ConclusionsSex differences are present in the care female veterans receive for chronic pain. Further research is necessary to understand the etiology of the observed differences and their associations with clinical outcomes. C1 [Weimer, Melissa B.; Nicolaidis, Christina] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA. [Macey, Tara A.; Dobscha, Steven K.; Morasco, Benjamin J.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA. [Nicolaidis, Christina] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA. [Dobscha, Steven K.; Morasco, Benjamin J.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Dobscha, Steven K.; Duckart, Jonathan P.; Morasco, Benjamin J.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA. RP Weimer, MB (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,L-475, Portland, OR 97239 USA. EM weimerm@ohsu.edu FU National Institute of Drug Abuse [K23DA023467]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH) [UL1 RR024140] FX The authors wish to thank Michael R. Lasarev, MS, for help with statistical consultation. This study was supported in part by award K23DA023467 from the National Institute of Drug Abuse to Dr. Morasco. This publication was made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1 RR024140 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Dr. Weimer's time was supported by the Samuel F. Wise Trust. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, National Institute on Drug Abuse, or the Department of Veterans Affairs. NR 33 TC 8 Z9 8 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD DEC PY 2013 VL 14 IS 12 BP 1839 EP 1847 DI 10.1111/pme.12177 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 270WH UT WOS:000328349400008 PM 23802846 ER PT J AU Edelman, EJ Gordon, KS Lo Re, V Skanderson, M Fiellin, DA Justice, AC AF Edelman, E. Jennifer Gordon, Kirsha S. Lo Re, Vincent, III Skanderson, Melissa Fiellin, David A. Justice, Amy C. CA VACS Project Team TI Acetaminophen receipt among HIV-infected patients with advanced hepatic fibrosis SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE acetaminophen; HIV; hepatitis C; Veterans; medication; pharmacoepidemiology ID PRESCRIPTION PATTERNS; LIVER-DISEASE; OVERDOSE; COHORT; PAIN AB PurposeHIV-infected patients may be at particular risk for acetaminophen-induced hepatotoxicity, but acetaminophen use in the context of liver injury has been incompletely examined among HIV-infected patients. Among a sample of HIV-infected patients, we aimed to determine acetaminophen exposure, assess the cross-sectional association between acetaminophen exposure and advanced hepatic fibrosis, and determine whether factors associated with acetaminophen exposure varied by HCV status. MethodsWe conducted a cross-sectional analysis of the Veterans Aging Cohort Study. Advanced hepatic fibrosis was defined as a FIB-4>3.25, a composite score calculated based on age, alanine aminotransferase, aspartate aminotransferase, and platelet count. Multivariable ordered polytomous logistic regression was used to determine the association between FIB-4 status and acetaminophen exposure stratified by HCV status. ResultsAmong HIV-infected patients (n=14885), 31% received at least one acetaminophen prescription. Among those receiving acetaminophen, acetaminophen overuse was common among both HIV-monoinfected and HIV/HCV-coinfected patients (846 [31%] vs 596[32%], p=0.79). After stratifying by HCV status, those with evidence of advanced liver fibrosis were equally likely to be exposed to acetaminophen. Furthermore, HIV-monoinfected patients with an alcohol use disorder were more likely to have acetaminophen overuse (OR [95%CI]=1.56 [1.21-2.02]). ConclusionsStrategies to minimize acetaminophen exposure, especially for HIV-monoinfected patients, are warranted. Copyright (c) 2013 John Wiley & Sons, Ltd. C1 [Edelman, E. Jennifer; Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA. [Edelman, E. Jennifer; Fiellin, David A.; Justice, Amy C.] Yale Univ, Sch Publ Hlth, Ctr Interdisciplinary Res AIDS, New Haven, CT 06520 USA. [Gordon, Kirsha S.; Skanderson, Melissa; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Lo Re, Vincent, III] Univ Penn, Dept Med, Div Infect Dis, Perelman Sch Med, Philadelphia, PA 19104 USA. [Lo Re, Vincent, III] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Skanderson, Melissa] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Edelman, EJ (reprint author), Yale Univ, Sch Med, POB 208093, New Haven, CT 06520 USA. EM ejennifer.edelman@yale.edu RI Lo Re, Vincent/N-7817-2015 OI Fiellin, David/0000-0002-4006-010X FU Society of General Internal Medicine's Lawrence Linn Award; Robert Wood Johnson Foundation Clinical Scholars Program; Department of Veterans Affairs; Veterans Aging Cohort study; National Institute on Alcohol Abuse and Alcoholism [U10 AA 13566] FX This work was generously supported by the Society of General Internal Medicine's Lawrence Linn Award, the Robert Wood Johnson Foundation Clinical Scholars Program, the Department of Veterans Affairs, and the Veterans Aging Cohort study, funded by the National Institute on Alcohol Abuse and Alcoholism (U10 AA 13566). NR 19 TC 4 Z9 5 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-8569 EI 1099-1557 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD DEC PY 2013 VL 22 IS 12 BP 1352 EP 1356 DI 10.1002/pds.3517 PG 5 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 258GG UT WOS:000327446700014 PM 24285468 ER PT J AU Miller, LS Sandel, ME AF Miller, Lawrence S. Sandel, M. Elizabeth TI Dr. Rene Cailliet: Advancing the Field of Musculoskeletal Medicine by Making the Complicated Understandable SO PM&R LA English DT Editorial Material C1 [Miller, Lawrence S.] Univ Calif Los Angeles, Los Angeles, CA USA. [Miller, Lawrence S.] Vet Adm Greater Los Angeles Healthcare Syst, Vet Adm GLAHS UCLA PM&R Residency & Fellowship Pr, Los Angeles, CA USA. [Sandel, M. Elizabeth] Univ Calif Hlth Syst, Sacramento, CA USA. RP Miller, LS (reprint author), 1158 26th St,Suite 458, Santa Monica, CA USA. EM lsmillermd@gmail.com NR 15 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD DEC PY 2013 VL 5 IS 12 BP 991 EP 995 DI 10.1016/j.pmrj.2013.10.008 PG 5 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 277CJ UT WOS:000328795700001 PM 24332228 ER PT J AU Turner, AP Chapko, MK Yanez, D Leipertz, SL Sloan, AP Whitham, RH Haselkorn, JK AF Turner, Aaron P. Chapko, Michael K. Yanez, David Leipertz, Steve L. Sloan, Alicia P. Whitham, Ruth H. Haselkorn, Jodie K. TI Access to Multiple Sclerosis Specialty Care SO PM&R LA English DT Article ID QUALITY-OF-LIFE; HEALTH-CARE; REHABILITATION SERVICES; DISABLING CONDITIONS; MENTAL-HEALTH; PEOPLE; VETERANS; DISABILITIES; PATTERNS; REGISTRY AB Background: Health care providers recommend an annual visit to a multiple sclerosis specialty care provider. Objective: To examine potential barriers to the implementation of this recommendation in the Veterans Health Administration. Design: Observational cohort study. Setting: Veterans Health Administration. Participants: Participants were drawn from the Veterans Affairs Multiple Sclerosis National Data Repository and were included if they had an outpatient visit in 2007 and were alive in 2008 (N = 14,723). Main Outcome Measurements: Specialty care visit, receipt of medical services. Results: A total of 9643 (65.5%) participants had a specialty care visit in 2007. Veterans who were service connected, had greater medical comorbidity, and who lived in urban settings were more likely to have received a specialty care visit. Veterans who were older and had to travel greater distances to a center were less likely to have a specialty care visit. Conclusions: Access to care in rural areas and areas at a greater distance from a major medical center represent notable barriers to rehabilitation and other multiple sclerosis-related care. C1 [Turner, Aaron P.] Vet Affairs Puget Sound Hlth Care Syst, Dept Rehabil Med, Seattle, WA 98108 USA. [Turner, Aaron P.; Leipertz, Steve L.; Sloan, Alicia P.; Haselkorn, Jodie K.] Vet Affairs, Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. [Turner, Aaron P.; Haselkorn, Jodie K.] Univ Washington, Dept Phys Med & Rehabil, Seattle, WA 98195 USA. [Chapko, Michael K.; Yanez, David; Haselkorn, Jodie K.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Yanez, David] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Whitham, Ruth H.] Portland VA Med Ctr, Multiple Sclerosis Ctr Excellence West, Portland, OR USA. [Whitham, Ruth H.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Haselkorn, Jodie K.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. RP Turner, AP (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Rehabil Med, S-117-RCS,1660 S Columbian Way, Seattle, WA 98108 USA. EM Aaron.Turner@va.gov OI sloan, alicia/0000-0003-4891-3266; Turner, Aaron/0000-0001-6897-8003 FU U.S. Department of Veterans Affairs, Office of Research and Development Rehabilitation R&D Program, Health Services R&D Program Quality Enhancement Research Initiative QUERI Project [RRP 07-344]; Research and Development Rehabilitation R&D Program Career Development Award [B4927W]; Veterans Affairs Multiple Sclerosis Center of Excellence West FX This material is based upon work supported by the U.S. Department of Veterans Affairs, Office of Research and Development Rehabilitation R&D Program, Health Services R&D Program Quality Enhancement Research Initiative QUERI Project RRP 07-344 (Haselkom PI), Research and Development Rehabilitation R&D Program Career Development Award B4927W (Turner PI) and the Veterans Affairs Multiple Sclerosis Center of Excellence West. NR 20 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD DEC PY 2013 VL 5 IS 12 BP 1044 EP 1050 DI 10.1016/j.pmrj.2013.07.009 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 277CJ UT WOS:000328795700007 PM 23920332 ER PT J AU Elsaman, AM Radwan, AR Akmatov, MK Della Beffa, C Walker, A Mayer, CT Dai, L Nativ, S Rygg, M Atsali, E Saijo, K Ogdie, AR Srinivasulu, N Fathi, N Schumacher, HR Pessler, F AF Elsaman, Ahmed M. Radwan, Ahmed R. Akmatov, Manas K. Della Beffa, Cristina Walker, Alisha Mayer, Christian T. Dai, Lie Nativ, Simona Rygg, Marite Atsali, Erato Saijo, Kaoru Ogdie, Alexis R. Srinivasulu, Nagaraj Fathi, Nihal Schumacher, H. Ralph Pessler, Frank TI Amyloid arthropathy associated with multiple myeloma: A systematic analysis of 101 reported cases SO SEMINARS IN ARTHRITIS AND RHEUMATISM LA English DT Review DE Amyloid; Amyloid; Arthritis; Arthropathy; Multiple myeloma ID SIMULATING RHEUMATOID DISEASE; ARTHRITIS; DIAGNOSIS AB Objective: Amyloid deposition in multiple myeloma (MM) may lead to an arthropathy resembling rheumatoid arthritis (RA). Since a systematic description of its natural history is lacking, we have performed a systematic analysis of all published cases. Methods: Literature review featuring backward and forward database searches and direct inspection of reference lists. Inclusion criteria were as follows: publication between 1931 and 2012, diagnosis of multiple myeloma, and demonstration of light chain amyloid (AL) in any organ or in synovial fluid, arthritis, or synovitis. Results: Overall, 101 cases were identified. Median age was 59 years and the male-to-female ratio was 1:1. A systemic manifestation of MM was reported in 88 cases. In 53 of these, characteristic physical findings (carpal tunnel syndrome, macroglossia, shoulder pad, and soft tissue swelling/masses) were present. Arthritis manifested before the diagnosis of MM in 63 cases, with 33 cases initially misdiagnosed as RA. There were 72 cases of poly-, 17 of oligo-, and three of monoarthritis. The shoulder joint was most commonly affected, followed by knees and small hand joints. Median synovial fluid leukocyte count was 2460 cells/mm(3), and was normal in seven cases. Synovial histopathology often featured mild synovitis without plasma cell infiltration. Imaging revealed articular or periarticular inflammation in many cases and bone lesions near 22% of affected joints. Treatments varied but led to some improvement in the majority of cases. Conclusions: These results solidify previous experience that MM arthropathy tends to feature a symmetric RF-negative nonerosive polyarthritis. However, the results also highlight the diversity of its presentations and stress the importance of arthropathy as a potentially under-recognized presenting manifestation of MM. (C) 2013 Elsevier Inc. All rights reserved. C1 [Elsaman, Ahmed M.; Radwan, Ahmed R.] Sohag Univ, Dept Rheumatol & Rehabil, Sohag, Egypt. [Akmatov, Manas K.; Della Beffa, Cristina; Walker, Alisha] Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, Germany. [Dai, Lie] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Rheumatol, Guangzhou 510275, Guangdong, Peoples R China. [Nativ, Simona] Columbia Presbyterian Med Ctr, Div Rheumatol, New York, NY USA. [Rygg, Marite] Norwegian Univ Sci & Technol, Childrens & Womens Hlth, Dept Lab Med, N-7034 Trondheim, Norway. [Rygg, Marite] St Olavs Hosp, Dept Pediat, Trondheim, Norway. [Atsali, Erato] Attikon Univ Hosp, Rheumatol & Bone Metab Dept, Haidari, Greece. [Saijo, Kaoru] Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA. [Ogdie, Alexis R.; Schumacher, H. Ralph] Univ Penn, Div Rheumatol, Philadelphia, PA 19104 USA. [Srinivasulu, Nagaraj] PD Hinduja Natl Hosp, Dept Rheumatol, Bombay, Maharashtra, India. [Srinivasulu, Nagaraj] MRC, Bombay, Maharashtra, India. [Srinivasulu, Nagaraj] SPARSH Hosp, Bangalore, Karnataka, India. [Fathi, Nihal] Assiut Univ, Dept Rheumatol & Rehabil, Assiut, Egypt. [Schumacher, H. Ralph] Philadelphia VA Med Ctr, Div Rheumatol, Philadelphia, PA USA. [Della Beffa, Cristina; Pessler, Frank] TWINCORE Ctr Expt & Clin Infect Res, D-30625 Hannover, Germany. RP Pessler, F (reprint author), TWINCORE Ctr Expt & Clin Infect Res, Feodor Lynen Str 7-9, D-30625 Hannover, Germany. EM frank.pessler@twincore.de OI Ogdie, Alexis/0000-0002-4639-0775 FU German Academic Exchange Service (DAAD) [51309219]; Ministry of Higher Education and Scientific Research of the Arab Republic of Egypt; Helmholtz Association FX We thank Dr. Stefanie Castell (Helmholtz Centre for Infection Research) for helpful discussion and critical reading of the manuscript. The study was supported by the German-Egyptian Scientific Project (GESP) Grant no. 51309219 from the German Academic Exchange Service (DAAD) and the Ministry of Higher Education and Scientific Research of the Arab Republic of Egypt, and with intramural funds from the Helmholtz Association (program Infection and Immunity). NR 24 TC 6 Z9 6 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0049-0172 EI 1532-866X J9 SEMIN ARTHRITIS RHEU JI Semin. Arthritis Rheum. PD DEC PY 2013 VL 43 IS 3 BP 405 EP 412 DI 10.1016/j.semarthrit.2013.07.004 PG 8 WC Rheumatology SC Rheumatology GA 277DV UT WOS:000328800000014 PM 23992800 ER PT J AU Szymusiak, RS AF Szymusiak, Ronald S. TI New Insights into Melanin Concentrating Hormone and Sleep: A Critical Topics Forum INTRODUCTION SO SLEEP LA English DT Editorial Material ID PARADOXICAL SLEEP; NEURONS; OREXIN C1 [Szymusiak, Ronald S.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Szymusiak, Ronald S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Szymusiak, Ronald S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA. RP Szymusiak, RS (reprint author), UCLA VA Greater Los Angeles Healthcare Syst, Dept Med, David Geffen Sch Med, Sepulveda, CA 91343 USA. EM rszym@ucla.edu NR 20 TC 3 Z9 3 U1 0 U2 4 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD DEC 1 PY 2013 VL 36 IS 12 BP 1765 EP 1766 DI 10.5665/sleep.3184 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 262YH UT WOS:000327773300001 ER PT J AU McGinty, D Alam, N AF McGinty, Dennis Alam, Noor TI MCH Neurons: The End of the Beginning SO SLEEP LA English DT Editorial Material ID SLEEP; HYPOCRETIN; GABA C1 [McGinty, Dennis; Alam, Noor] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Sepulveda, CA USA. [McGinty, Dennis] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Alam, Noor] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. RP McGinty, D (reprint author), VAGLAHS, Res Serv 151A3, 16111 Plummer St, North Hills, CA 91343 USA. EM dmcginty@ucla.edu NR 12 TC 5 Z9 5 U1 0 U2 5 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD DEC 1 PY 2013 VL 36 IS 12 BP 1773 EP 1774 DI 10.5665/sleep.3190 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 262YH UT WOS:000327773300004 PM 24293747 ER PT J AU Blouin, AM Siegel, JM AF Blouin, Ashley M. Siegel, Jerome M. TI Relation of Melanin Concentrating Hormone Levels to Sleep, Emotion and Hypocretin Levels SO SLEEP LA English DT Editorial Material ID OREXIN; NEURONS; RELEASE C1 [Blouin, Ashley M.] Scripps Res Inst, Dept Metab & Aging, Jupiter, FL USA. [Blouin, Ashley M.] Scripps Res Inst, Dept Neurosci, Jupiter, FL USA. [Siegel, Jerome M.] Univ Calif Los Angeles, Neuropsychiat Inst, VA Greater Los Angeles Healthcare Syst, North Hills, CA 91343 USA. [Siegel, Jerome M.] Univ Calif Los Angeles, Brain Res Inst, North Hills, CA 91343 USA. RP Siegel, JM (reprint author), Univ Calif Los Angeles, Neuropsychiat Inst, VA Greater Los Angeles Healthcare Syst, 16111 Plummer St, North Hills, CA 91343 USA. NR 14 TC 4 Z9 4 U1 0 U2 4 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD DEC 1 PY 2013 VL 36 IS 12 BP 1777 EP 1777 DI 10.5665/sleep.3194 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 262YH UT WOS:000327773300006 PM 24293749 ER PT J AU Pelluru, D Konadhode, R Shiromani, PJ AF Pelluru, Dheeraj Konadhode, RodaRani Shiromani, Priyattam J. TI MCH Neurons Are the Primary Sleep-Promoting Group SO SLEEP LA English DT Editorial Material ID MELANIN-CONCENTRATING HORMONE; REPORTER GENE; HYPOCRETIN; HYPOTHALAMUS; STIMULATION; ACTIVATION; EXPRESSION; NUCLEUS C1 [Shiromani, Priyattam J.] Ralph H Johnson VA, Charleston, SC 29425 USA. [Shiromani, Priyattam J.] Med Univ S Carolina, Charleston, SC 29425 USA. RP Shiromani, PJ (reprint author), Ralph H Johnson VA, Charleston, SC 29425 USA. EM shiroman@musc.edu FU NIMH NIH HHS [R01 MH055772]; NINDS NIH HHS [R21 NS084477, R21 NS079940] NR 21 TC 10 Z9 10 U1 0 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD DEC 1 PY 2013 VL 36 IS 12 BP 1779 EP 1781 DI 10.5665/sleep.3196 PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 262YH UT WOS:000327773300007 PM 24293750 ER PT J AU Bjornsdottir, E Janson, C Sigurdsson, JF Gehrman, P Perlis, M Juliusson, S Arnardottir, ES Kuna, ST Pack, AI Gislason, T Benediktsdottir, B AF Bjornsdottir, Erla Janson, Christer Sigurdsson, Jon F. Gehrman, Philip Perlis, Michael Juliusson, Sigurdur Arnardottir, Erna S. Kuna, Samuel T. Pack, Allan I. Gislason, Thorarinn Benediktsdottir, Bryndis TI Symptoms of Insomnia among Patients with Obstructive Sleep Apnea Before and After Two Years of Positive Airway Pressure Treatment SO SLEEP LA English DT Article DE Adherence; CPAP; insomnia; obstructive sleep apnea ID BREATHING DISORDERS; COMORBID INSOMNIA; RELIABILITY AB Study Objectives: To assess the changes of insomnia symptoms among patients with obstructive sleep apnea (OSA) from starting treatment with positive airway pressure (PAP) to a 2-y follow-up. Design: Longitudinal cohort study. Setting: Landspitali-The National University Hospital of Iceland. Participants: There were 705 adults with OSA who were assessed prior to and 2 y after starting PAP treatment. Intervention: PAP treatment for OSA. Measurements and Results: All patients underwent a medical examination along with a type 3 sleep study and answered questionnaires on health and sleep before and 2 y after starting PAP treatment. The change in prevalence of insomnia symptoms by subtype was assessed by questionnaire and compared between individuals who were using or not using PAP at follow-up. Symptoms of middle insomnia were most common at baseline and improved significantly among patients using PAP (from 59.4% to 30.7%, P < 0.001). Symptoms of initial insomnia tended to persist regardless of PAP treatment, and symptoms of late insomnia were more likely to improve among patients not using PAP. Patients with symptoms of initial and late insomnia at baseline were less likely to adhere to PAP (odds ratio [OR] 0.56, P = 0.007, and OR 0.53, P < 0.001, respectively). Conclusion: Positive airway pressure treatment significantly reduced symptoms of middle insomnia. Symptoms of initial and late insomnia, however, tended to persist regardless of positive airway pressure treatment and had a negative effect on adherence. Targeted treatment for insomnia may be beneficial for patients with obstructive sleep apnea comorbid with insomnia and has the potential to positively affect adherence to positive airway pressure. C1 [Bjornsdottir, Erla; Sigurdsson, Jon F.; Arnardottir, Erna S.; Gislason, Thorarinn; Benediktsdottir, Bryndis] Univ Iceland, Fac Med, Reykjavik, Iceland. [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Med & Allergol, S-75105 Uppsala, Sweden. [Bjornsdottir, Erla; Arnardottir, Erna S.; Gislason, Thorarinn; Benediktsdottir, Bryndis] Landspitali Natl Univ Hosp Iceland, Dept Resp Med & Sleep, Reykjavik, Iceland. [Gehrman, Philip; Perlis, Michael; Kuna, Samuel T.; Pack, Allan I.] Univ Penn, Ctr Sleep & Circadian Neurobiol, Philadelphia, PA 19104 USA. [Gehrman, Philip; Perlis, Michael; Kuna, Samuel T.; Pack, Allan I.] Univ Penn, Dept Med, Div Sleep Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gehrman, Philip; Perlis, Michael] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Sigurdsson, Jon F.] Landspitali Natl Univ Hosp Iceland, Mental Hlth Serv, Reykjavik, Iceland. [Juliusson, Sigurdur] Landspitali Natl Univ Hosp Iceland, Dept Otolaryngol, Reykjavik, Iceland. [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Bjornsdottir, E (reprint author), Landspitali Univ Hosp Fossvogi, Dept Resp Med & Sleep E7, IS-108 Reykjavik, Iceland. EM erlabjo@gmail.com RI Sigurdsson, Jon Fridrik/M-1844-2015 OI Sigurdsson, Jon Fridrik/0000-0001-6873-8157 FU NIH [HL72067, HL94307]; Eimskip Fund of the University of Iceland; Landspitali University Hospital Research Fund; Philips Respironics FX This was not an industry supported study. Support for this study was provided by NIH grant HL72067 for "A Family Linkage Study of Obstructive Sleep Apnoea" and HL94307 for "Endophenotypes of Sleep Apnea and Role of Obesity," the Eimskip Fund of the University of Iceland and the Landspitali University Hospital Research Fund. Dr. Kuna has received grant support from Philips Respironics. Dr. Arnardottir is a consultant for Nox Medical and has received honorarium from ResMed and Pfizer, Iceland. Dr. Gehrman is a consultant for Design Interactive, Inc. The other authors have indicated no financial conflicts of interest. NR 24 TC 20 Z9 20 U1 0 U2 6 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD DEC 1 PY 2013 VL 36 IS 12 BP 1901 EP 1909 DI 10.5665/sleep.3226 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 262YH UT WOS:000327773300022 PM 24293765 ER PT J AU Bera, A Ghosh-Choudhury, N Dey, N Das, F Kasinath, BS Abboud, HE Choudhury, GG AF Bera, Amit Ghosh-Choudhury, Nandini Dey, Nirmalya Das, Falguni Kasinath, Balakuntalam S. Abboud, Hanna E. Choudhury, Goutam Ghosh TI NF kappa B-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation SO CELLULAR SIGNALLING LA English DT Article DE MicroRNA; Renal cancer; PTEN; NF kappa B ID TUMOR-SUPPRESSOR; MAMMALIAN TARGET; RETINOBLASTOMA PROTEIN; TRANSGENIC MICE; KIDNEY CANCER; PI3K PATHWAY; PTEN; CARCINOMA; MUTATION; GENE AB MicroRNAs regulate post-transcriptomic landscape in many tumors including renal cell carcinoma. We have recently shown significantly increased expression of miR-21 in renal tumors and that this miRNA contributes to the proliferation of renal cancer cells in culture. However, the mechanism by which nniR-21 regulates renal cancer cell proliferation is poorly understood. Addiction to constitutive NF kappa B activity is hallmark of many cancers including renal cancer. Using miR-21 Sponge in renal cancer cells to block endogenous function of miR-21, we show inhibition of phosphorylation of p65 subunit of NF kappa B, IKK beta and I kappa B, which results in attenuation of NF kappa B transcriptional activity. Subtle reduction in the tumor suppressor PTEN has been linked to various malignancies. We showed previously that miR-21 targeted PTEN in renal cancer cells. Inhibition of PTEN by siRNAs restored miR-21 Sponge-induced suppression of phosphorylation of p65, IKK beta, I kappa B and NF kappa B transcriptional activity along with reversal of miR-21 Sponge-reduced phosphorylation of Akt. Expression of constitutively active Akt protected against miR-21 Sponge- and PTEN-mediated decrease in p65/IKK beta/I kappa B phosphorylation and NF kappa B transcriptional activity. Furthermore, IKK beta and p65 were required for miR-21-induced renal cancer cell proliferation. Interestingly, miR-21 controlled the expression of cyclin D1 through NF kappa B-dependent transcription. Finally, we demonstrate that miR-21-regulated renal cancer cell proliferation is mediated by cyclin D1 and CDK4. Together, our results establish a molecular order of a phosphatase-kinase couple involving PTEN/Akt/IKK beta and NF kappa B-dependent cyclin D1 expression for renal carcinoma cell proliferation by increased miR-21 levels. (C)0 2013 Elsevier Inc. All rights reserved. C1 [Bera, Amit; Dey, Nirmalya; Das, Falguni; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, VA Res, San Antonio, TX USA. [Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA. RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. EM choudhuryg@uthscsa.edu FU VA Merit Review; NIH [RO1 DK50190, RC2A 036613, RO1 DK 78971]; VA Senior Research Career Scientist Award; VA Merit Review grant; Cancer Therapy and Research Center at San Antonio Pilot Project grant; VA Research Service; juvenile Diabetes Research Foundation FX This work was supported partly by the VA Merit Review and NIH RO1 DK50190 grants to GGC. GGC is a recipient of VA Senior Research Career Scientist Award. NGC is supported by VA Merit Review grant and Cancer Therapy and Research Center at San Antonio Pilot Project grant. BSK is supported by grants from NIH RC2A 036613 and VA Research Service. HEA is supported by NIH RO1 DK 78971, VA Merit Review and juvenile Diabetes Research Foundation grants. NR 68 TC 17 Z9 20 U1 0 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0898-6568 EI 1873-3913 J9 CELL SIGNAL JI Cell. Signal. PD DEC PY 2013 VL 25 IS 12 BP 2575 EP 2586 DI 10.1016/j.cellsig.2013.08.005 PG 12 WC Cell Biology SC Cell Biology GA 268OG UT WOS:000328179800024 PM 23981302 ER PT J AU Li, XB Malcolm, RJ Huebner, K Hanlon, CA Taylor, JJ Brady, KT George, MS See, RE AF Li, Xingbao Malcolm, Robert J. Huebner, Kristina Hanlon, Colleen A. Taylor, Joseph. J. Brady, Kathleen T. George, Mark S. See, Ronald E. TI Low frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex transiently increases cue-induced craving for methamphetamine: A preliminary study SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Methamphetamine; Craving; Transcranial magnetic stimulation; Dorsolateral prefrontal cortex ID LONG-TERM DEPRESSION; MOTOR CORTEX; ABSTINENT METHAMPHETAMINE; DEPENDENT SUBJECTS; DECISION-MAKING; DRUG-ADDICTION; BRAIN ACTIVITY; SELF-CONTROL; DOPAMINE; EXCITABILITY AB Background: Repetitive transcranial magnetic stimulation (rTMS) can temporarily interrupt or facilitate activity in a focal brain region. Several lines of evidence suggest that rTMS of the dorsolateral prefrontal cortex (DLPFC) can affect processes involved in drug addiction. We hypothesized that a single session of low-frequency rTMS of the left DLPFC would modulate cue-induced craving for methamphetamine (MA) when compared to a sham rTMS session. Methods: In this single-blind, sham-controlled crossover study, 10 non-treatment seeking MA-dependent users and 8 healthy controls were randomized to receive 15 min of sham and real (1 Hz) DLPFC rTMS in two experimental sessions separated by 1 h. During each rTMS session, participants were exposed to blocks of neutral cues and MA-associated cues. Participants rated their craving after each cue block. Results: In MA users, real rTMS over the left DLPFC increased self-reported craving as compared to sham stimulation (17.86 +/- 1.46 vs. 24.85 +/- 1.57, p = 0.001). rTMS had no effect on craving in healthy controls. One Hertz rTMS of the left DLPFC was safe and tolerable for all participants. Conclusions: Low frequency rTMS of the left DLPFC transiently increased cue-induced craving in MA participants. These preliminary results suggest that 1 Hz rTMS of the left DLPFC may increase craving by inhibiting the prefrontal cortex or indirectly activating subcortical regions involved in craving. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Li, Xingbao; Malcolm, Robert J.; Huebner, Kristina; Hanlon, Colleen A.; Taylor, Joseph. J.; Brady, Kathleen T.; George, Mark S.; See, Ronald E.] Med Univ S Carolina, Charleston, SC USA. [Brady, Kathleen T.; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Li, XB (reprint author), MUSC IOP, Brain Stimulat Lab, 502N,67 President St, Charleston, SC 29425 USA. EM lixi@musc.edu FU National Institutes of Health [P20 DA022658] FX The study was funded by a grant from the National Institutes of Health (Grant no. P20 DA022658 (RE SEE)). NR 64 TC 13 Z9 13 U1 5 U2 13 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD DEC 1 PY 2013 VL 133 IS 2 BP 641 EP 646 DI 10.1016/j.drugalcdep.2013.08.012 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 269KT UT WOS:000328240900047 PM 24028801 ER PT J AU Durazzo, TC Meyerhoff, DJ Nixon, SJ AF Durazzo, Timothy C. Meyerhoff, Dieter J. Nixon, Sara Jo TI Interactive effects of chronic cigarette smoking and age on hippocampal volumes SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Cigarette smoking; MRI; Hippocampus; Hippocampal subfields; Learning and memory; Aging ID MILD COGNITIVE IMPAIRMENT; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; ENTORHINAL CORTEX; AUTOMATED SEGMENTATION; NICOTINE ADDICTION; BACOSIDE-A; BRAIN AB Background: Previous cross-sectional MRI studies with healthy, young-to-middle-aged adults reported no significant differences between smokers and non-smokers on total hippocampal volume. However, these studies did not specifically test for greater age-related volume loss in the total hippocampus or hippocampal subregions in smokers, and did they did not examine relationships between hippocampal and subfield volumes and episodic learning and memory performance. Methods: Healthy, young-to-middle-aged (45 +/- 12 years of age) smokers (n = 39) and non-smokers (n = 43) were compared on total hippocampal and subfield volumes derived from high-resolution 4Tesla MRI, emphasizing testing for greater age-related volume losses in smokers. Associations between hippocampal volumes and measures of episodic learning and memory were examined. Results: Smokers showed significantly smaller volumes, as well as greater volume loss with increasing age than non-smokers in the bilateral total hippocampus and multiple subfields. In smokers, greater pack-years were associated with smaller volumes of the total hippocampus, presubiculum, and subiculum. In the entire cohort, performance on measures of learning and memory was related to larger total hippocampal and several subfield volumes, predominately in the left hemisphere. Conclusions: Chronic cigarette smoking in this young-to-middle aged cohort was associated with smaller total hippocampal and subfield volumes, which were exacerbated by advancing age. Findings also indicated an adverse smoking dose/duration response (i.e., pack-years) with total hippocampal and select subfield volumes. These hippocampal volume abnormalities in smokers may be related to the deficiencies in episodic learning and memory in young-to-middle-aged smokers reported in previous studies. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Durazzo, Timothy C.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA. [Durazzo, Timothy C.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Nixon, Sara Jo] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA. [Nixon, Sara Jo] Univ Florida, Dept Psychol, Gainesville, FL 32611 USA. RP Durazzo, TC (reprint author), San Francisco VA Med Ctr, CIND, 4150 Clement St 114M, San Francisco, CA 94121 USA. EM timothy.durazzo@ucsf.edu RI Nixon, Sara/L-1369-2014 OI Nixon, Sara/0000-0003-1179-2851 FU National Institute on Drug Abuse [DA24136]; Department of Defense [W81XWH-05-2-0094]; National Institute on Alcohol and Alcoholism [AA10788] FX This material is the result of work supported by the National Institute on Drug Abuse (DA24136 to TCD), Department of Defense (W81XWH-05-2-0094 to TCD), and National Institute on Alcohol and Alcoholism (AA10788 to Dieter J. Meyerhoff), and with resources and the use of facilities at the San Francisco Veterans Administration Medical Center, San Francisco CA. We thank Dr. Anderson Mon for assistance in MR data acquisition in early studied participants. We also wish to extend our gratitude to the study participants, who made this research possible. NR 83 TC 16 Z9 16 U1 1 U2 13 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD DEC 1 PY 2013 VL 133 IS 2 BP 704 EP 711 DI 10.1016/j.drugalcdep.2013.08.020 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA 269KT UT WOS:000328240900055 PM 24051060 ER PT J AU Anderson, SAR Michaelides, M Zarnegar, P Ren, YH Fagergren, P Thanos, PK Wang, GJ Bannon, M Neumaier, JF Keller, E Volkow, ND Hurd, YL AF Anderson, Sarah Ann R. Michaelides, Michael Zarnegar, Parisa Ren, Yanhua Fagergren, Pernilla Thanos, Panayotis K. Wang, Gene-Jack Bannon, Michael Neumaier, John F. Keller, Eva Volkow, Nora D. Hurd, Yasmin L. TI Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID MESSENGER-RNA EXPRESSION; GLUCOSE-METABOLISM; GENE-EXPRESSION; PARKINSONS-DISEASE; EXTENDED AMYGDALA; ANXIETY DISORDERS; DRUG-ADDICTION; HEROIN ABUSERS; OPIOID-SYSTEM; HUMAN BRAIN AB Negative affect is critical for conferring vulnerability to opiate addiction as reflected by the high comorbidity of opiate abuse with major depressive disorder (MDD). Rodent models implicate amygdala prodynorphin (Pdyn) as a mediator of negative affect; however, evidence of PDYN involvement in human negative affect is limited. Here, we found reduced PDYN mRNA expression in the postmortem human amygdala nucleus of the periamygdaloid. cortex (PAC) in both heroin abusers and MDD subjects. Similar to humans, rats that chronically self-administered heroin had reduced Pdyn mRNA expression in the PAC at a time point associated with a negative affective state. Using the in vivo functional imaging technology DREAMM (DREADD-assisted. metabolic mapping, where DREADD indicates designer receptors exclusively activated. by designer drugs), we found that selective inhibition of Pdyn-expressing neurons in the rat PAC increased metabolic activity in the extended amygdala, which is a key substrate of the extrahypothalamic brain stress system. In parallel, PAC-specific Pdyn inhibition provoked negative affect-related physiological and behavioral changes. Altogether, our translational study supports a functional role for impaired Pdyn in the PAC in opiate abuse through activation of the stress and negative affect neurocircuitry implicated in addiction vulnerability. C1 [Anderson, Sarah Ann R.; Michaelides, Michael; Ren, Yanhua; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. [Anderson, Sarah Ann R.; Michaelides, Michael; Ren, Yanhua; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY USA. [Anderson, Sarah Ann R.; Michaelides, Michael; Ren, Yanhua; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY USA. [Zarnegar, Parisa; Fagergren, Pernilla] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden. [Thanos, Panayotis K.; Volkow, Nora D.] NIAAA, Bethesda, MD USA. [Wang, Gene-Jack] SUNY Stony Brook, Dept Radiol, Upton, NY USA. [Bannon, Michael] Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA. [Neumaier, John F.] Univ Washington, Dept Psychiat, Seattle, WA 98195 USA. [Neumaier, John F.] Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA. [Keller, Eva] Semmelweis Univ, Dept Forens & Insurance Med, H-1085 Budapest, Hungary. [Hurd, Yasmin L.] James J Peters VA Med Ctr, New York, NY USA. RP Hurd, YL (reprint author), Hess Ctr Sci & Med, 1 Gustave L Levy Pl,Box 1065,1470 Madison Ave,Flo, New York, NY 10029 USA. EM Yasmin.hurd@mssm.edu FU UNCF-Merck Graduate Fellowship [DA015546, T32-GM007280-34S1-NHLBI/NIGMS]; NIDA Postdoctoral Training Program [DA007135]; [DA023214]; [DA030359]; [DA006470] FX This work was supported by DA015546, DA023214, DA030359, DA006470. S.A.R. Anderson was supported by the UNCF-Merck Graduate Fellowship, Diversity Supplement to DA015546 and T32-GM007280-34S1-NHLBI/NIGMS supplement to the Mount Sinai Medical Scientist Training Program. M. Michaelides was supported by NIDA Postdoctoral Training Program DA007135. NR 56 TC 12 Z9 12 U1 1 U2 9 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD DEC PY 2013 VL 123 IS 12 BP 5334 EP 5341 DI 10.1172/JCI70395 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 263RQ UT WOS:000327826100036 PM 24231353 ER PT J AU Michaelides, M Anderson, SAR Ananth, M Smirnov, D Thanos, PK Neumaier, JF Wang, GJ Volkow, ND Hurd, YL AF Michaelides, Michael Anderson, Sarah Ann R. Ananth, Mala Smirnov, Denis Thanos, Panayotis K. Neumaier, John F. Wang, Gene-Jack Volkow, Nora D. Hurd, Yasmin L. TI Whole-brain circuit dissection in free-moving animals reveals cell-specific mesocorticolimbic networks SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article ID STRIATOPALLIDAL NEURONS; RAT-BRAIN; PET; NORMALIZATION; ORGANIZATION; INHIBITION; MODULATION; TEMPLATE; PATHWAYS; F-18-FDG AB The ability to map the functional connectivity of discrete cell types in the intact mammalian brain during behavior is crucial for advancing our understanding of brain function in normal and disease states. We combined designer receptor exclusively activated by designer drug (DREADD) technology and behavioral imaging with mu PET and [F-18]fluorodeoxyglucose (FDG) to generate whole-brain metabolic maps of cell-specific functional circuits during the awake, freely moving state. We have termed this approach DREADD-assisted metabolic mapping (DREAMM) and documented its ability in rats to map whole-brain functional anatomy. We applied this strategy to evaluating changes in the brain associated with inhibition of prodynorphin-expressing (Pdyn-expressing) and of proenkephalin-expressing (Penk-expressing) medium spiny neurons (MSNs) of the nucleus accumbens shell (NAcSh), which have been implicated in neuropsychiatric disorders. DREAMM revealed discrete behavioral manifestations and concurrent engagement of distinct corticolimbic networks associated with dysregulation of Pdyn and Penk in MSNs of the NAcSh. Furthermore, distinct neuronal networks were recruited in awake versus anesthetized conditions. These data demonstrate that DREAMM is a highly sensitive, molecular, high-resolution quantitative imaging approach. C1 [Michaelides, Michael; Anderson, Sarah Ann R.; Wang, Gene-Jack; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Dept Psychiat, Friedman Brain Inst, New York, NY 10029 USA. [Michaelides, Michael; Anderson, Sarah Ann R.; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Dept Neurosci, Friedman Brain Inst, New York, NY 10029 USA. [Ananth, Mala; Thanos, Panayotis K.; Wang, Gene-Jack] Brookhaven Natl Lab, Dept Biosci, Upton, NY 11973 USA. [Smirnov, Denis; Neumaier, John F.] Univ Washington, Seattle, WA 98195 USA. [Thanos, Panayotis K.; Volkow, Nora D.] NIAAA, Lab Neuroimaging, Bethesda, MD USA. [Hurd, Yasmin L.] James J Peters VA Med Ctr, New York, NY USA. RP Hurd, YL (reprint author), Icahn Sch Med Mt Sinai, Hess Ctr Sci & Med, 10th Floor Room 105,1470 Madison Ave, New York, NY 10029 USA. EM yasmin.hurd@mssm.edu FU National Institute on Alcohol Abuse and Alcoholism (NIAAA) [AA11034, AA07574, AA07611]; National Institute on Drug Abuse (NIDA) [DA015446, DA023214, DA030359]; NIDA Postdoctoral Training Program at MSSM [DA007135] FX This work was supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) (AA11034, AA07574, and AA07611) and the National Institute on Drug Abuse (NIDA) (DA015446, DA023214, and DA030359). M. Michaelides was supported by the NIDA Postdoctoral Training Program at MSSM (DA007135). The authors thank the Mount Sinai Microscopy Shared Resource Facility and the microPET Facility (Wade Koba, Linda Jelicks) at the Albert Einstein College of Medicine of Yeshiva University. NR 30 TC 19 Z9 19 U1 1 U2 8 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA SN 0021-9738 EI 1558-8238 J9 J CLIN INVEST JI J. Clin. Invest. PD DEC PY 2013 VL 123 IS 12 BP 5342 EP 5350 DI 10.1172/JCI72117 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 263RQ UT WOS:000327826100037 PM 24231358 ER PT J AU Lee, SJ Karter, AJ Thai, JN Van Den Eeden, SK Huang, ES AF Lee, Sei J. Karter, Andrew J. Thai, Julie N. Van Den Eeden, Stephen K. Huang, Elbert S. TI Glycemic Control and Urinary Incontinence in Women with Diabetes Mellitus SO JOURNAL OF WOMENS HEALTH LA English DT Article ID QUALITY-OF-LIFE; RISK-FACTORS; POSTMENOPAUSAL WOMEN; OLDER-ADULTS; HEALTH; IMPACT; PREVALENCE; MANAGEMENT; SYMPTOMS; GLUCOSE AB Background: Although many studies have shown that diabetes increases the risk for urinary incontinence, it is unclear whether poor glycemic control in women with diabetes is associated with incontinence. This study aims to determine the relationship between the hemoglobin A1c (HbA1c) level and urinary incontinence in a large, diverse cohort of older women. Methods: We examined 6026 older women who responded to a survey (62% response rate) and were enrolled in the Diabetes and Aging Study, an ethnically stratified random sample of patients with diabetes enrolled in Kaiser Permanente Northern California. Our primary independent variable was the mean of all HbA1c measurements in the year preceding the survey. Outcomes included the presence/absence of incontinence and limitations in daily activities due to incontinence. We used modified Poisson regression and ordinal logistic regression models to account for age, race, body mass index, parity, diabetes treatment, duration of diabetes, and comorbidity. Results: Sixty-five percent of women reported incontinence (mean age 5910 years). After adjustment, HbA1c levels were not associated with the presence or absence of incontinence. However, among women reporting incontinence, HbA1c 9% was associated with more limitations due to incontinence than HbA1c <6% (adjusted odds ratio 1.67, 95% confidence interval: 1.09-2.57). Conclusion: In this cross-sectional analysis, HbA1c level is not associated with the presence or absence of incontinence. However, for women with incontinence, poor glycemic control (HbA1c 9%) is associated with more limitations in daily activities due to incontinence. Longitudinal studies are needed to determine whether improving glycemic control to HbA1c <9% leads to fewer limitations in daily activities due to incontinence. C1 [Lee, Sei J.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94121 USA. [Van Den Eeden, Stephen K.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94121 USA. [Lee, Sei J.] San Francisco VA Med Ctr, Res Enhancement Award Program, San Francisco, CA USA. [Karter, Andrew J.; Van Den Eeden, Stephen K.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Thai, Julie N.] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA. [Huang, Elbert S.] Univ Chicago, Med Ctr, Div Gen Internal Med, Chicago, IL 60637 USA. RP Lee, SJ (reprint author), Univ Calif San Francisco, Div Geriatr, 4150 Clement St Bldg 1,Room 220F, San Francisco, CA 94121 USA. EM Sei.lee@ucsf.edu FU Hellman Family Award for Early Career Faculty at University of California-San Francisco; National Center for Research Resources, a component of the U. S. National Institutes of Health [K23AG040779, KL2RR024130]; Diabetes and Aging Study [R01DK081796]; National Institute of Diabetes and Digestive and Kidney Disease [P30DK092949, P30DK092924] FX Dr. Sei J. Lee was supported by the Hellman Family Award for Early Career Faculty at University of California-San Francisco. Dr. Lee was also supported by K23AG040779 and KL2RR024130 from the National Center for Research Resources, a component of the U. S. National Institutes of Health. Drs. Andrew Karter and Elbert Huang were supported through the Diabetes and Aging Study (R01DK081796). Dr. Huang was also supported by P30DK092949 and Dr. Karter was also supported by P30DK092924 through the National Institute of Diabetes and Digestive and Kidney Disease. NR 25 TC 4 Z9 4 U1 0 U2 3 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD DEC 1 PY 2013 VL 22 IS 12 BP 1049 EP 1055 DI 10.1089/jwh.2012.4093 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 258CF UT WOS:000327435500010 PM 24032999 ER PT J AU Liu, H Li, WJ Rose, ME Pascoe, JL Miller, TM Ahmad, M Poloyac, SM Hickey, RW Graham, SH AF Liu, Hao Li, Wenjin Rose, Marie E. Pascoe, Jordan L. Miller, Tricia M. Ahmad, Muzamil Poloyac, Samuel M. Hickey, Robert W. Graham, Steven H. TI Prostaglandin D-2 toxicity in primary neurons is mediated through its bioactive cyclopentenone metabolites SO NEUROTOXICOLOGY LA English DT Article DE Cell death; Cyclopentenone prostaglandins; DP receptors; Primary neuron; Prostaglandin D-2; Ubiquitinated protein ID DP1 RECEPTOR; UBIQUITINATED PROTEINS; GENE-EXPRESSION; D SYNTHASE; RAT-BRAIN; APOPTOSIS; ISCHEMIA; CELLS; J2; CYCLOOXYGENASE-2 AB Prostaglandin D-2 (PGD(2)) is the most abundant prostaglandin in brain but its effect on neuronal cell death is complex and not completely understood. PGD(2) may modulate neuronal cell death via activation of DP receptors or its metabolism to the cyclopentenone prostaglandins (CyPGs) PGJ(2), Delta(12)-PGJ(2) and 15-deoxy-Delta(12,14)-PGJ(2), inducing cell death independently of prostaglandin receptors. This study aims to elucidate the effect of PGD(2) on neuronal cell death and its underlying mechanisms. PGD(2) dose-dependently induced cell death in rat primary neuron-enriched cultures in concentrations of >= 10 mu M, and this effect was not reversed by treatment with either DP1 or DP2 receptor antagonists. Antioxidants N-acetylcysteine (NAC) and glutathione which contain sulfhydryl groups that can bind to CyPGs, but not ascorbate or tocopherol, attenuated PGD(2)-induced cell death. Conversion of PGD(2) to CyPGs was detected in neuronal culture medium; treatment with these CyPG metabolites alone exhibited effects similar to those of PGD(2), including apoptotic neuronal cell death and accumulation of ubiquitinated proteins. Disruption of lipocalin-type prostaglandin D synthase (L-PGDS) protected neurons against hypoxia. These results support the hypothesis that PGD(2) elicits its cytotoxic effects through its bioactive CyPG metabolites rather than DP receptor activation in primary neuronal culture. Published by Elsevier Inc. C1 [Liu, Hao; Li, Wenjin; Rose, Marie E.; Pascoe, Jordan L.; Ahmad, Muzamil; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15205 USA. [Liu, Hao; Li, Wenjin; Rose, Marie E.; Pascoe, Jordan L.; Ahmad, Muzamil; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Miller, Tricia M.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Hickey, Robert W.] Univ Pittsburgh, Sch Med, Dept Pediat Emergency Med, Pittsburgh, PA 15224 USA. RP Graham, SH (reprint author), VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr 00 GR H, Highland Dr, Pittsburgh, PA 15205 USA. EM sgra@pitt.edu FU National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01NS37459]; Veteran's Administration Merit Review program FX This work was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke [grant number R01NS37459] and the Veteran's Administration Merit Review program [S.H.G.]. NR 45 TC 13 Z9 15 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0161-813X EI 1872-9711 J9 NEUROTOXICOLOGY JI Neurotoxicology PD DEC PY 2013 VL 39 BP 35 EP 44 DI 10.1016/j.neuro.2013.08.001 PG 10 WC Neurosciences; Pharmacology & Pharmacy; Toxicology SC Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology GA 270GK UT WOS:000328306700006 PM 23973622 ER PT J AU Dimitrov, DH Lee, S Yantis, J Valdez, C Paredes, RM Braida, N Velligan, D Walss-Bass, C AF Dimitrov, Dimitre H. Lee, Shuko Yantis, Jesse Valdez, Celina Paredes, R. Madelaine Braida, Nicole Velligan, Dawn Walss-Bass, Consuelo TI Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: Potential role for IL-17 pathway SO SCHIZOPHRENIA RESEARCH LA English DT Article DE Schizophrenia; Veterans; Inflammation; Cytokines; Psychosis ID AUTOIMMUNE-DISEASES; BIPOLAR DISORDER; SERUM-LEVELS; BRAIN; CELLS; INTERLEUKIN-6; HYPOTHESIS; SYSTEM; BLOOD; METAANALYSIS AB Pro-inflammatory cytokines have been consistently reported to be elevated in schizophrenia patients. However, it is not known whether cytokines influence the presentation of psychotic symptoms. To address this issue, we evaluated the relationship between levels of inflammatory molecules and psychopathological parameters in patients with schizophrenia. We hypothesized that severity of symptoms would correlate with increased levels of inflammatory cytokines. Serum samples from 47 veterans with a diagnosis of schizophrenia and 20 healthy controls were tested for levels of 33 cytokines/chemokines involved in regulation of immune /inflammatory reactions using a Millipore multiplex bead array in a Luminex 100 system. We found significantly increased levels of GRO, MCP-1, MDC, and 5CD40L, and significantly decreased levels of IFNI-gamma, IL-2, IL-12p70, and IL-17, in schizophrenia patients compared to controls. In addition, we observed positive correlations between levels of cytokines and the Positive and Negative Symptoms Scale (PANSS) scores in subjects with schizophrenia for GCSE, IL-1 beta, IL1ra, IL-3, IL-6, IL-9, IL-10, sCD40L and TNF-beta. Pathway analyses showed these cytokines to be part of the IL17 pathway. Using principal component analyses, we found the factor that included these cylokines and IL-17 to be associated with positive, general and total PANSS scores. These results suggest that alterations in this pathway may play a role in development of psychotic symptoms in schizophrenia. Published by Elsevier B.V. C1 [Dimitrov, Dimitre H.; Lee, Shuko; Yantis, Jesse; Braida, Nicole] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Dimitrov, Dimitre H.; Valdez, Celina; Paredes, R. Madelaine; Braida, Nicole; Velligan, Dawn; Walss-Bass, Consuelo] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. RP Dimitrov, DH (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM Dimitre.dimitrov@va.gov NR 39 TC 27 Z9 27 U1 5 U2 15 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2013 VL 151 IS 1-3 BP 29 EP 35 DI 10.1016/j.schres.2013.10.019 PG 7 WC Psychiatry SC Psychiatry GA 263GL UT WOS:000327795300004 PM 24210870 ER PT J AU Mamdani, M McMichael, GO Gadepalli, V Williamson, V Parker, EK Haroutunian, V Vladimirov, VI AF Mamdani, Mohammed McMichael, Gowon O. Gadepalli, Venkat Williamson, Vernell Parker, Erin K. Haroutunian, Vahram Vladimirov, Vladimir I. TI Differential regulation of schizophrenia-associated microRNA gene function by variable number tandem repeats (VNTR) polymorphism SO SCHIZOPHRENIA RESEARCH LA English DT Letter C1 [Mamdani, Mohammed; McMichael, Gowon O.; Gadepalli, Venkat; Williamson, Vernell; Parker, Erin K.; Vladimirov, Vladimir I.] Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychiat, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23298 USA. [Mamdani, Mohammed] Virginia Commonwealth Univ, Psychiat Behav Stat Genet Clin & Translat Sci Doc, Richmond, VA USA. [Haroutunian, Vahram] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Haroutunian, Vahram] MIRECC, James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Vladimirov, Vladimir I.] Virginia Commonwealth Univ, Med Coll Virginia, Sch Pharm, Ctr Biomarker Res & Personalized Med, Richmond, VA 23298 USA. RP Vladimirov, VI (reprint author), Virginia Commonwealth Univ, Med Coll Virginia Campus, Richmond, VA 23298 USA. EM vivladimirov@vcu.edu FU NCATS NIH HHS [UL1TR000058, KL2 TR000057, UL1 TR000058]; NIMH NIH HHS [5T32MH020030-14, T32 MH020030, MH066392] NR 9 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0920-9964 EI 1573-2509 J9 SCHIZOPHR RES JI Schizophr. Res. PD DEC PY 2013 VL 151 IS 1-3 BP 284 EP 286 DI 10.1016/j.schres.2013.10.024 PG 3 WC Psychiatry SC Psychiatry GA 263GL UT WOS:000327795300042 PM 24210531 ER PT J AU Shaik, JSB Ahmad, M Li, WJ Rose, ME Foley, LM Hitchens, TK Graham, SH Hwang, SH Hammock, BD Poloyac, SM AF Shaik, Jafar Sadik B. Ahmad, Muzamil Li, Wenjin Rose, Marie E. Foley, Lesley M. Hitchens, T. Kevin Graham, Steven H. Hwang, Sung Hee Hammock, Bruce D. Poloyac, Samuel M. TI Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE arachidonic acid; cerebral blood flow; cytochrome P-450; ischemic stroke; middle cerebral artery occlusion ID FREE FATTY-ACIDS; ARACHIDONIC-ACID; CEREBRAL-ISCHEMIA; EPOXYEICOSATRIENOIC ACIDS; ELECTROCONVULSIVE SHOCK; BRAIN; PERFUSION; HYPOXIA; TARGET; CYTOCHROME-P450 AB Soluble epoxide hydrolase (sEH) diminishes vasodilatory and neuroprotective effects of epoxyeicosatrienoic acids by hydrolyzing them to inactive dihydroxy metabolites. The primary goals of this study were to investigate the effects of acute sEH inhibition by trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB) on infarct volume, functional outcome, and changes in cerebral blood flow (CBF) in a rat model of ischemic stroke. Focal cerebral ischemia was induced in rats for 90 min followed by reperfusion. At the end of 24 h after reperfusion rats were euthanized for infarct volume assessment by triphenyltetrazolium chloride staining. Brain cortical sEH activity was assessed by ultra performance liquid chromatography-tandem mass spectrometry. Functional outcome at 24 and 48 h after reperfusion was evaluated by arm flexion and sticky-tape tests. Changes in CBF were assessed by arterial spin-labeled-MRI at baseline, during ischemia, and at 180 min after reperfusion. Neuroprotective effects of t-AUCB were evaluated in primary rat neuronal cultures by Cytotox-Flour kit and propidium iodide staining. t-AUCB significantly reduced cortical infarct volume by 35% (14.5 +/- 2.7% vs. 41.5 +/- 4.5%), elevated cumulative epoxyeicosatrienoic acids-to-dihydroxyeicosatrienoic acids ratio in brain cortex by twofold (4.40 +/- 1.89 vs. 1.97 +/- 0.85), and improved functional outcome in arm-flexion test (day 1: 3.28 +/- 0.5 s vs. 7.50 +/- 0.9 s; day 2: 1.71 +/- 0.4 s vs. 5.28 +/- 0.5 s) when compared with that of the vehicle-treated group. t-AUCB significantly reduced neuronal cell death in a dose-dependent manner (vehicle: 70.9 +/- 7.1% vs. t-AUCB(0.1 mu M): 58 +/- 5.11% vs. t-AUCB(0.5 mu M): 39.9 +/- 5.8%). These findings suggest that t-AUCB may exert its neuroprotective effects by affecting multiple components of neurovascular unit including neurons, astrocytes, and microvascular flow. C1 [Shaik, Jafar Sadik B.; Poloyac, Samuel M.] Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA. [Li, Wenjin; Rose, Marie E.; Graham, Steven H.] VA Pittsburgh Healthcare Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA. [Ahmad, Muzamil; Li, Wenjin; Rose, Marie E.; Graham, Steven H.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Foley, Lesley M.; Hitchens, T. Kevin] Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA. [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA. [Hwang, Sung Hee; Hammock, Bruce D.] Univ Calif Davis, Ctr Comprehens Canc, Davis, CA 95616 USA. RP Poloyac, SM (reprint author), Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, 807 Salk Hall, Pittsburgh, PA 15261 USA. EM poloyac@pitt.edu RI SHAIK, JAFAR SADIK/A-9638-2010 OI SHAIK, JAFAR SADIK/0000-0001-5776-3138 FU National Institutes of Health [NIEHS R01 ES002710, NIH/NIEHS R01 ES013933]; NIH Counter Act Program; [NINDS U54 NS079202]; [NINDS R01NS052315]; [NCRR S10RR023461] FX This research was supported by National Institutes of Health Grants NIEHS R01 ES002710 (to B. D. Hammock), NIH/NIEHS R01 ES013933 (to B. D. Hammock), the NIH Counter Act Program (to B. D. Hammock), NINDS U54 NS079202 (to B. D. Hammock), NINDS R01NS052315 (to S. M. Poloyac), and NCRR S10RR023461 (to S. M. Poloyac). NR 43 TC 11 Z9 11 U1 0 U2 11 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD DEC PY 2013 VL 305 IS 11 BP H1605 EP H1613 DI 10.1152/ajpheart.00471.2013 PG 9 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA 268JX UT WOS:000328167300006 PM 24043255 ER PT J AU Rochefort, MM Ankeny, JS Kadera, BE Donald, GW Isacoff, W Wainberg, ZA Hines, OJ Donahue, TR Reber, HA Tomlinson, JS AF Rochefort, Matthew M. Ankeny, Jacob S. Kadera, Brian E. Donald, Graham W. Isacoff, William Wainberg, Zev A. Hines, O. Joe Donahue, Timothy R. Reber, Howard A. Tomlinson, James S. TI Impact of Tumor Grade on Pancreatic Cancer Prognosis: Validation of a Novel TNMG Staging System SO ANNALS OF SURGICAL ONCOLOGY LA English DT Article ID RESECTION; ADENOCARCINOMA; SURVIVAL; CHEMOTHERAPY; NOMOGRAM; TRIAL AB Background. Pancreatic ductal adenocarcinoma (PDAC) patients demonstrate highly variable survival within each stage of the American Joint Committee on Cancer (AJCC) staging system. We hypothesize that tumor grade is partly responsible for this variation. Recently our group developed a novel tumor, node, metastasis, grade (TNMG) classification system utilizing Surveillance Epidemiology and End Results (SEER) data in which the presence of high tumor grade results in advancement to the next higher AJCC stage. This study's objective was to validate this TNMG staging system utilizing single-institution data. Methods. All patients with PDAC who underwent resection at UCLA between 1990 and 2009 were identified. Clinicopathologic data reviewed included age, sex, node status, tumor size, grade, and stage. Grade was redefined as a dichotomous variable. The impact of grade on survival was assessed by Cox regression analysis. Disease was restaged into the TNMG system and compared to the AJCC staging system. Results. We identified 256 patients who underwent resection for PDAC. Patients with low-grade tumors experienced a 13-month improvement in median survival compared to those with high-grade tumors. On multivariate analysis, tumor grade was the strongest predictor of survival with a hazard ratio of 2.02 (p = 0.0005). Restaging disease according to the novel TNMG staging system resulted in improved survival discrimination between stages compared to the current AJCC system. Conclusions. We were able to demonstrate that grade is one of the strongest independent prognostic factors in PDAC. Restaging with our novel TNMG system demonstrated improved prognostication. This system offers an effective and convenient way of adding grade to the current AJCC staging system. C1 [Rochefort, Matthew M.; Ankeny, Jacob S.; Tomlinson, James S.] Greater Los Angeles VA Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Rochefort, Matthew M.; Ankeny, Jacob S.; Kadera, Brian E.; Donald, Graham W.; Hines, O. Joe; Donahue, Timothy R.; Reber, Howard A.; Tomlinson, James S.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA. [Isacoff, William; Wainberg, Zev A.] Univ Calif Los Angeles, Dept Hematol & Oncol, Los Angeles, CA USA. RP Tomlinson, JS (reprint author), Greater Los Angeles VA Healthcare Syst, Dept Surg, Los Angeles, CA USA. EM jtomlinson@mednet.ucla.edu NR 16 TC 16 Z9 16 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9265 EI 1534-4681 J9 ANN SURG ONCOL JI Ann. Surg. Oncol. PD DEC PY 2013 VL 20 IS 13 BP 4322 EP 4329 DI 10.1245/s10434-013-3159-3 PG 8 WC Oncology; Surgery SC Oncology; Surgery GA 269QI UT WOS:000328256600041 PM 23943022 ER PT J AU Tsai, CY Rice, LA Hoelmer, C Boninger, ML Koontz, AM AF Tsai, Chung-Ying Rice, Laura A. Hoelmer, Claire Boninger, Michael L. Koontz, Alicia M. TI Basic Psychometric Properties of the Transfer Assessment Instrument (Version 3.0) SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Outcomes assessment; Rehabilitation; Reliability and validity; Wheelchairs ID SPINAL-CORD-INJURY; SITTING PIVOT TRANSFERS; MANUAL WHEELCHAIR USERS; SHOULDER PAIN; RELIABILITY; INDIVIDUALS; INTERRATER; KINEMATICS; AGREEMENT; VALIDITY AB Objectives: To refine the Transfer Assessment Instrument (TAI 2.0), develop a training program for the TAX, and analyze the basic psychometric properties of the TAI 3.0, including reliability, standard error of measurement (SEM), minimal detectable change (MDC), and construct validity. Design: Repeated measures. Setting: A winter sports clinic for disabled veterans. Participants: Wheelchair users (N=41) who perform sitting-pivot or standing-pivot transfers. Intervention: Not applicable. Main Outcome Measures: TAI version 3.0, intraclass correlation coefficients, SEMs, and MDCs for reliable measurement of raters' responses. Spearman correlation coefficient, 1-way analysis of variance, and independent t tests to evaluate construct validity. Results: TAI 3.0 had acceptable to high levels of reliability (range, .74.88). The SEMs for part 1, part 2, and final scores ranged from .45 to .75. The MDC was 1.5 points on the 10-point scale for the final score. There were weak correlations (p range, .13 to.25; P>.11) between TAI final scores and subjects' characteristics (eg, sex, body mass index, age, type of disability, length of wheelchair use, grip and elbow strength, sitting balance). Conclusions: With comprehensive training, the refined TAI 3.0 yields high reliability among raters of different clinical backgrounds and experience. TAI 3.0 was unbiased toward certain physical characteristics that may influence transfer. TAI fills a void in the field by providing a quantitative measurement of transfers and a tool that can be used to detect problems and guide transfer training. Archives of Physical Medicine and Rehabilitation 2013;94:2456-64 (C) 2013 by the American Congress of Rehabilitation Medicine C1 [Tsai, Chung-Ying; Boninger, Michael L.; Koontz, Alicia M.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Tsai, Chung-Ying; Boninger, Michael L.; Koontz, Alicia M.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Rice, Laura A.] Univ Illinois, Dept Kinesiol & Community Hlth, Champaign, IL 61820 USA. [Boninger, Michael L.; Koontz, Alicia M.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Hoelmer, Claire; Boninger, Michael L.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA. RP Koontz, AM (reprint author), VA Pittsburgh Healthcare Syst, 6425 Penn Ave,Ste 400, Pittsburgh, PA 15206 USA. EM akoontz@pitt.edu OI Boninger, Michael/0000-0001-6966-919X FU VA Rehabilitation Research & Development Services Merit Review Project [B6789C]; National Science Foundation [0849878]; National Institute on Disability and Rehabilitation Research [H133N060019, H133N110011] FX Supported by the VA Rehabilitation Research & Development Services Merit Review Project (grant no. B6789C), the National Science Foundation (grant no. 0849878), and the National Institute on Disability and Rehabilitation Research (grant nos. H133N060019, H133N110011). NR 34 TC 8 Z9 8 U1 1 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD DEC PY 2013 VL 94 IS 12 BP 2456 EP 2464 DI 10.1016/j.apmr.2013.05.001 PG 9 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA 264UD UT WOS:000327905600019 PM 23685096 ER PT J AU Ainslie, G AF Ainslie, George TI Monotonous tasks require self-control because they interfere with endogenous reward SO BEHAVIORAL AND BRAIN SCIENCES LA English DT Editorial Material AB Self-control is a necessary component of subjective effort, but it depends only on farsighted motivation, with no additional, depletable resource. The aversiveness of boring tasks probably comes from their interference with endogenous reward, a new and potentially controversial concept. The self-control needed to stick with any kind of aversive experience increases as the values of the competing motives draw closer together. C1 [Ainslie, George] Univ Cape Town, Sch Econ, ZA-7701 Rondebosch, South Africa. [Ainslie, George] US Dept Vet Affairs, Coatesville, PA 19320 USA. RP Ainslie, G (reprint author), Univ Cape Town, Sch Econ, ZA-7701 Rondebosch, South Africa. EM George.Ainslie@va.gov NR 0 TC 0 Z9 0 U1 1 U2 2 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0140-525X EI 1469-1825 J9 BEHAV BRAIN SCI JI Behav. Brain Sci. PD DEC PY 2013 VL 36 IS 6 BP 679 EP 680 DI 10.1017/S0140525X13000915 PG 2 WC Psychology, Biological; Behavioral Sciences; Neurosciences SC Psychology; Behavioral Sciences; Neurosciences & Neurology GA 265IJ UT WOS:000327943800032 PM 24304776 ER PT J AU Tuomela, J Sandholm, J Kaakinen, M Patel, A Kauppila, JH Ilvesaro, J Chen, DQ Harris, KW Graves, D Selander, KS AF Tuomela, Johanna Sandholm, Jouko Kaakinen, Mika Patel, Ankita Kauppila, Joonas H. Ilvesaro, Joanna Chen, Dongquan Harris, Kevin W. Graves, David Selander, Katri S. TI DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells SO BREAST CANCER RESEARCH AND TREATMENT LA English DT Article DE Triple-negative breast cancer; Toll-like receptor-9; Invasion; DNA; Inflammation ID TOLL-LIKE RECEPTOR-9; ANTIMICROBIAL PROTEIN HCAP18/LL-37; PUTATIVE GROWTH-FACTOR; BREAST-CANCER; RNA-SEQ; CELLULAR INVASION; PEPTIDE LL-37; WEIGHT-LOSS; IN-VITRO; EXPRESSION AB TLR9 is a cellular DNA-receptor, which is widely expressed in breast and other cancers. Although synthetic TLR9-ligands induce cancer cell invasion in vitro, the role of TLR9 in cancer pathophysiology has remained unclear. We show here that living cancer cells uptake DNA from chemotherapy-killed cancer cells. We discovered that such DNA induces TLR9- and cathepsin-mediated invasion in living cancer cells. To study whether this phenomenon contributes to treatment responses, triple-negative, human MDA-MB-231 breast cancer cells stably expressing control, or TLR9 siRNA were inoculated orthotopically into nude mice. The mice were treated with vehicle or doxorubicin. The tumor groups exhibited equal decreases in size in response to doxorubicin. However, while the weights of vehicle-treated mice were similar, mice bearing control siRNA tumors became significantly more cachectic in response to doxorubicin, as compared with similarly treated mice bearing TLR9 siRNA tumors, suggesting a TLR9-mediated inflammation at the site of the tumor. In conclusion, our findings propose that DNA released from chemotherapy-killed cancer cells has significant influence on TLR9-mediated biological effects in living cancer cells. Through these mechanisms, tumor TLR9 expression may affect treatment responses to chemotherapy. C1 [Tuomela, Johanna; Sandholm, Jouko; Ilvesaro, Joanna; Harris, Kevin W.; Selander, Katri S.] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. [Tuomela, Johanna; Sandholm, Jouko; Ilvesaro, Joanna; Harris, Kevin W.; Graves, David; Selander, Katri S.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Kaakinen, Mika; Kauppila, Joonas H.] Univ Oulu, Dept Anat & Cell Biol, Oulu, Finland. [Kaakinen, Mika] Univ Oulu, Bioctr Oulu, Oulu, Finland. [Patel, Ankita; Graves, David] Univ Alabama Birmingham, Dept Chem, Birmingham, AL 35294 USA. [Kauppila, Joonas H.] Oulu Univ Hosp, Dept Surg, Oulu, Finland. [Kauppila, Joonas H.] Univ Oulu, Dept Pathol, Oulu, Finland. [Chen, Dongquan] Univ Alabama Birmingham, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Harris, Kevin W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Selander, KS (reprint author), Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, SHEL 514,1825 Univ Blvd, Birmingham, AL 35294 USA. EM Katriselander@uabmc.edu RI Kauppila, Joonas/P-1363-2015 OI Kauppila, Joonas/0000-0001-6740-3726; Tuomela, Johanna/0000-0003-4390-4563 FU Department of Defense [W81XWH-10-1-0308]; Elsa U. Pardee Foundation; Cancer Foundation of Northern Ostrobotnia; Oulu University Scholarship Foundation; Finnish Medical Foundation; Maud Kuistila Memorial Foundation; Orion-Farmos Research Foundation; Finnish Cultural Foundation; Comprehensive Cancer Center Core [CA13148]; CCC [P30CA13148-38] FX Ms. Christine Pressey is acknowledged for skillful assistance with the qRT-PCR assays. This work was supported by a Grant from the Department of Defense (W81XWH-10-1-0308, K.S.S & D.G), Elsa U. Pardee Foundation (K.S.S), Cancer Foundation of Northern Ostrobotnia, Oulu University Scholarship Foundation, and Finnish Medical Foundation (J.H.K), Maud Kuistila Memorial Foundation (J.T), Orion-Farmos Research Foundation (J.T.), and Finnish Cultural Foundation (J.T). The body composition measurement services were provided by the UAB Small Animal Phenotyping Core supported by NIH P30AR046031, P30DK056336, and P60DK079626. The RNA-seq analyses were provided by the Heflin Genomics Core Facility and the Comprehensive Cancer Center Core Grant CA13148, the proteomics analysis was provided by the UAB proteomics shared facility, and the CCC Grant Number P30CA13148-38. NR 57 TC 12 Z9 12 U1 0 U2 10 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0167-6806 EI 1573-7217 J9 BREAST CANCER RES TR JI Breast Cancer Res. Treat. PD DEC PY 2013 VL 142 IS 3 BP 477 EP 487 DI 10.1007/s10549-013-2762-0 PG 11 WC Oncology SC Oncology GA 269CP UT WOS:000328218500002 PM 24212717 ER PT J AU Bonilha, HS Blair, J Carnes, B Huda, W Humphries, K McGrattan, K Michel, Y Martin-Harris, B AF Bonilha, Heather Shaw Blair, Julie Carnes, Brittni Huda, Walter Humphries, Kate McGrattan, Katlyn Michel, Yvonne Martin-Harris, Bonnie TI Preliminary Investigation of the Effect of Pulse Rate on Judgments of Swallowing Impairment and Treatment Recommendations SO DYSPHAGIA LA English DT Article DE Dysphagia; Modified barium swallow study; MBSImP (TM)(c); Pulse rate; Radiation exposure ID DYSPHAGIA; AUGMENTATION; FLUOROSCOPY; MANEUVERS AB Reducing fluoroscopic pulse rate, a method used to reduce radiation exposure from modified barium swallow studies (MBSSs), decreases the number of images available from which to judge swallowing impairment. It is necessary to understand the impact of pulse rate reduction on judgments of swallowing impairment and, consequentially, treatment recommendations. This preliminary study explored differences in standardized MBSS measurements [Modified Barium Swallow Impairment Profile (MBSImP (TM) A (c)) and Penetration Aspiration Scale (PAS) Scores] between two pulse rates: 30 and simulated 15 pulses per second (pps). Two reliable speech-language pathologists (SLPs) scored all five MBSSs. Five SLPs reported treatment recommendations based on those scores. Differences in judgments of swallowing impairment were found between 30 and simulated 15 pps in all five MBSSs. These differences were in six physiological swallowing components: initiation of pharyngeal swallow, anterior hyoid excursion, epiglottic movement, pharyngeal contraction, pharyngeal-esophageal segment opening, and tongue base retraction. Differences in treatment recommendations were found between 30 and simulated 15 pps in all five MBSSs. These findings suggest that there are differences in both judgment of swallowing impairment and treatment recommendations when pulse rates are reduced from 30 to 15 pps to minimize radiation exposure. C1 [Bonilha, Heather Shaw; McGrattan, Katlyn; Martin-Harris, Bonnie] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. [Bonilha, Heather Shaw; Martin-Harris, Bonnie] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Blair, Julie; Carnes, Brittni; Humphries, Kate; McGrattan, Katlyn; Martin-Harris, Bonnie] Med Univ S Carolina, Evelyn Trammell Inst Voice & Swallowing, Charleston, SC 29425 USA. [Huda, Walter] Med Univ S Carolina, Dept Radiol, Charleston, SC 29425 USA. [Michel, Yvonne] Med Univ S Carolina, Charleston, SC 29425 USA. [Martin-Harris, Bonnie] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Bonilha, HS (reprint author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St, Charleston, SC 29425 USA. EM bonilhah@musc.edu FU NIH/NIDCD [K23 DC005764-05]; NIH/NCRR [KL2 UL1 RR029880]; Bracco Diagnostics (NIH/NIDCD) [K24 DC012801]; Evelyn Trammell Voice and Swallowing Institute; Northern Speech Services FX This work was supported by the following grants: NIH/NIDCD Grant No. K23 DC005764-05, NIH/NCRR Grant No. KL2 UL1 RR029880, and Bracco Diagnostics (NIH/NIDCD No. K24 DC012801). Other financial or material support was provided by Evelyn Trammell Voice and Swallowing Institute and Northern Speech Services. NR 26 TC 7 Z9 7 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0179-051X EI 1432-0460 J9 DYSPHAGIA JI Dysphagia PD DEC PY 2013 VL 28 IS 4 BP 528 EP 538 DI 10.1007/s00455-013-9463-z PG 11 WC Otorhinolaryngology SC Otorhinolaryngology GA 269CK UT WOS:000328217900007 PM 23559454 ER PT J AU Funk, JA Schnellmann, RG AF Funk, Jason A. Schnellmann, Rick G. TI Accelerated recovery of renal mitochondrial and tubule homeostasis with SIRT1/PGC-1 alpha activation following ischemia-reperfusion injury SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE Mitochondrial biogenesis; Mitochondrial dysfunction; Acute kidney injury; SRT1720; Proximal tubule; Ischemia-reperfusion ID ACUTE KIDNEY INJURY; SMALL-MOLECULE ACTIVATORS; EPITHELIAL POLARITY; CALORIE RESTRICTION; HISTONE DEACETYLASE; ENERGY-EXPENDITURE; PROMOTES RECOVERY; OXIDANT INJURY; SIRT1; PGC-1-ALPHA AB Kidney ischemia-reperfusion (I/R) injury elicits cellular injury in the proximal tubule, and mitochondrial dysfunction is a pathological consequence of I/R. Promoting mitochondrial biogenesis (MB) as a repair mechanism after injury may offer (a) over dot unique strategy to restore both mitochondrial and organ function. Rats subjected to bilateral renal pedicle ligation for 22 min were treated once daily with the SIRT1 activator SRT1720 (5 mg/kg) starting 24 h after reperfusion until 72 h-144 h. SIRT1 expression was elevated in the renal cortex of rats after I/R + vehicle treatment (RV), but was associated with less nuclear localization. SIRT1 expression was even further augmented and nuclear localization was restored in the kidneys of rats after I/R + SRT1720 treatment (IRS). PGC-1 alpha was elevated at 72 h-144 h in IRV and IRS kidneys; however, SRT1720 treatment induced deacetylation of PGC-1 alpha, a marker of activation. Mitochondrial proteins ATP synthase beta, COX I, and NDUFB8, as well as mitochondrial respiration, were diminished 24 h-144 h in IRV rats, but were partially or fully restored in IRS rats. Urinary kidney injury molecule-1 (KIM-1) was persistently elevated in both IRV and IRS rats; however, KIM-1 tissue expression was attenuated in IRS rats. Additionally, sustained loss of Na+,K+-ATPase expression and basolateral localization and elevated vimentin in IRV rats was normalized in IRS rats, suggesting restoration of a differentiated, polarized tubule epithelium. The results suggest that SRT1720 treatment expedited recovery of mitochondrial protein expression and function by enhancing MB, which was associated with faster proximal tubule repair. Targeting MB may offer unique therapeutic strategy following ischemic injury. Published by Elsevier Inc. C1 [Funk, Jason A.; Schnellmann, Rick G.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA. [Schnellmann, Rick G.] Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Ctr Cell Death Injury & Regenerat, Charleston, SC 29425 USA. EM funkj@musc.edu; schnell@musc.edu FU NIH/NIGMS [084147]; Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs Merit [BX000851]; NIH [C06 RR-015455] FX This work was supported by NIH/NIGMS Grant 084147 and by the Biomedical Laboratory Research and Development Program of the Department of Veterans Affairs Merit grant BX000851. Animal facilities were funded by NIH grant C06 RR-015455. NR 43 TC 34 Z9 37 U1 1 U2 4 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X EI 1096-0333 J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD DEC 1 PY 2013 VL 273 IS 2 BP 345 EP 354 DI 10.1016/j.taap.2013.09.026 PG 10 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 267LP UT WOS:000328099500011 PM 24096033 ER PT J AU Singh, T Katiyar, SK AF Singh, Tripti Katiyar, Santosh K. TI Green tea polyphenol, (-)-epigallocatechin-3-gallate, induces toxicity in human skin cancer cells by targeting beta-catenin signaling SO TOXICOLOGY AND APPLIED PHARMACOLOGY LA English DT Article DE Cyclooxygenase-2; Prostaglandin; beta-Catenin; ()-Epigallocatechin-3-gallate; Green tea polyphenol; Skin cancer ID DNA-REPAIR; C-MYC; EXPRESSION; INHIBITION; MICE; PHOTOCARCINOGENESIS; ANGIOGENESIS; ACTIVATION; MECHANISMS; APOPTOSIS AB The green tea polyphenol, (-)-epigallocatechin-3-gallate (EGCG), has been shown to have anti-carcinogenic effects in several skin tumor models, and efforts are continued to investigate the molecular targets responsible for its cytotoxic effects to cancer cells. Our recent observation that beta-catenin is upregulated in skin tumors suggested the possibility that the anti-skin carcinogenic effects of EGCG are mediated, at least in part, through its effects on beta-catenin signaling. We have found that treatment of the A431 and SCC13 human skin cancer cell lines with EGCG resulted in reduced cell viability and increased cell death and that these cytotoxic effects were associated with inactivation of beta-catenin signaling. Evidence of EGCG-induced inactivation of beta-catenin included: (i) reduced accumulation of nuclear beta-catenin; (ii) enhanced levels of casein kinase1 alpha, reduced phosphorylation of glycogen synthase kinase-3 beta, and increased phosphorylation of beta-catenin on critical Serille(45,33137) residues; and (iii) reduced levels of matrix metalloproteinase (MMP)-2 and MMP-9, which are down-stream targets of beta-catenin. Treatment of cells with prostaglandin E2 (PGE(2)) enhanced the accumulation of beta-catenin and enhanced beta-catenin signaling. Treatment with either EGCG or an EP2 antagonist (AH6809) reduced the PGE(2)-enhanced levels of cAMP, an upstream regulator of beta-catenin. Inactivation of beta-catenin by EGCG resulted in suppression of cell-survival signaling proteins. siRNA knockdown of beta-catenin in A431 and SCC13 cells reduced cell viability. Collectively, these data suggest that induction of cytotoxicity in skin cancer cells by EGCG is mediated by targeting of beta-catenin signaling and that the beta-catenin signaling is upregulated by inflammatory mediators. (C) 2013 Elsevier Inc. All rights reserved. C1 [Singh, Tripti; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award [1I01BX001410]; National Institutes of Health [CA140197, CA166883] FX This work was partially supported by the Veterans Administration Merit Review Award (1I01BX001410, S.K.K.) and National Institutes of Health (CA140197, CA166883, S.K.K.). The funding agencies were not involved in study design, analysis and interpretation of data; the writing of the manuscript; and the decision to submit the manuscript for publication. We thank Dr. Fiona Hunter for editorial assistance. NR 25 TC 24 Z9 28 U1 1 U2 21 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0041-008X EI 1096-0333 J9 TOXICOL APPL PHARM JI Toxicol. Appl. Pharmacol. PD DEC 1 PY 2013 VL 273 IS 2 BP 418 EP 424 DI 10.1016/j.taap.2013.09.021 PG 7 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 267LP UT WOS:000328099500018 PM 24096034 ER PT J AU Fukuta, Y Muder, RR Agha, ME Clarke, LG Wagener, MM Hensler, AM Doi, Y AF Fukuta, Yuriko Muder, Robert R. Agha, Mounzer E. Clarke, Lloyd G. Wagener, Marilyn M. Hensler, Amelia M. Doi, Yohei TI Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Clinical outcome; Malignancy; Infection; Colonization; Case-control study ID CELL TRANSPLANT RECIPIENTS; BLOOD-STREAM INFECTIONS; HEMATOLOGICAL MALIGNANCIES; BACTEREMIA; EPIDEMIOLOGY; UPDATE; IMPACT; AGENTS AB Background: Data regarding multidrug-resistant (MDR) Acinetobacter baumannii infections among cancer patients are limited. Methods: We conducted a case-control study to investigate the risk factors for acquisition of MDR A baumannii and the outcomes among cancer patients. Cases were inpatients with malignancy who had MDR A baumannii from any cultures between 2008 and 2011. Controls were inpatients with malignancy but no MDR A baumannii. Results: A total of 31 case patients were matched with 62 control patients. Hematologic malignancy (P=.036), need for dialysis (P=.01), admission for other reasons except elective surgery (P=.03), transfer from other health care facilities (P=.02), prolonged intensive care unit stay (P=.004), mechanical ventilation (P<.001), pressor use (P=.001), tube feeding (P<.001), transfusion (P=.009), and prior antimicrobial use (P<.001) were identified as significant risk factors in univariate analysis. Need for dialysis (odds ratio [OR], 18.23; P=.04) and prolonged intensive care unit stay (OR, 19.28; P=.01) remained significant in multivariate analysis. Lengths of stay were 28 days for the case patients and 10 days for the control patients (P=.001). The 90-day mortality rates were 41.9% and 29.0%, respectively (P=.20). Conclusions: Acquisition of MDR A baumannii among cancer patients appears to be associated with general nosocomial infection risk factors rather than underlying malignancies. Copyright (C) 2013 by the Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Fukuta, Yuriko; Muder, Robert R.; Clarke, Lloyd G.; Doi, Yohei] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA 15261 USA. [Muder, Robert R.] VA Pittsburgh Healthcare Syst, Dept Infect Control, Pittsburgh, PA USA. [Agha, Mounzer E.] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Div Hematol, Pittsburgh, PA 15261 USA. [Clarke, Lloyd G.] Univ Pittsburgh, Med Ctr, Presbyterian Hosp, Dept Pharm,Antibiot Management Program, Pittsburgh, PA 15261 USA. [Wagener, Marilyn M.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15261 USA. [Hensler, Amelia M.] Univ Pittsburgh, Med Ctr, Shadyside Hosp, Dept Infect Prevent & Control, Pittsburgh, PA 15261 USA. RP Doi, Y (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Infect Dis, S829 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA. EM yod4@pitt.edu FU Thomas H. Nimick Jr. Competitive Research Fund; National Institutes of Health [K22AI80584]; Pennsylvania Department of Health [4100047864] FX This study was supported by the Thomas H. Nimick Jr. Competitive Research Fund. Y.D. was supported in part by the National Institutes of Health (grant No. K22AI80584) and the Pennsylvania Department of Health (grant No. 4100047864). NR 28 TC 17 Z9 17 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD DEC PY 2013 VL 41 IS 12 BP 1249 EP 1252 DI 10.1016/j.ajic.2013.04.003 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 259QA UT WOS:000327540200021 PM 23870296 ER PT J AU Anderson, M Ottum, A Zerbel, S Sethi, A Gaines, ME Safdar, N AF Anderson, Michael Ottum, Andy Zerbel, Sara Sethi, Ajay Gaines, Martha E. Safdar, Nasia TI A survey to examine patient awareness, knowledge, and perceptions regarding the risks and consequences of surgical site infections SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Hospital-acquired infection; Patient education; Prevention ID HEALTH; IMPACT AB We surveyed patients to determine awareness and knowledge regarding risks and consequences of and prevention of surgical site infection (SSI), and we found that 26% of respondents thought that education for SSI prevention could be improved and that 16% could not recall discussing SSI risks and prevention with a health care worker at all. Only 60% of patients recalled receiving an informational flyer in the hospital. Our results show that better educational and engagement interventions incorporating patient preferences are needed to promote awareness and patient engagement regarding SSI prevention. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Anderson, Michael; Safdar, Nasia] Univ Wisconsin, Dept Med, Madison, WI 53792 USA. [Ottum, Andy; Sethi, Ajay; Safdar, Nasia] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53792 USA. [Zerbel, Sara; Safdar, Nasia] Univ Wisconsin, Hosp & Clin, Madison, WI 53792 USA. [Gaines, Martha E.] Univ Wisconsin, Ctr Patient Partnerships, Madison, WI 53792 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin, Dept Med, MFCB 5221,1685 Highland Ave, Madison, WI 53792 USA. EM ns2@medicine.wisc.edu NR 8 TC 1 Z9 1 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD DEC PY 2013 VL 41 IS 12 BP 1293 EP 1295 DI 10.1016/j.ajic.2013.02.007 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 259QA UT WOS:000327540200033 PM 23680112 ER PT J AU Drake, RE Frey, W Bond, GR Goldman, HH Salkever, D Miller, A Moore, TA Riley, J Karakus, M Milfort, R AF Drake, Robert E. Frey, William Bond, Gary R. Goldman, Howard H. Salkever, David Miller, Alexander Moore, Troy A. Riley, Jarnee Karakus, Mustafa Milfort, Roline TI Assisting Social Security Disability Insurance Beneficiaries With Schizophrenia, Bipolar Disorder, or Major Depression in Returning to Work SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID SEVERE MENTAL-ILLNESS; SUPPORTED EMPLOYMENT; INDIVIDUAL PLACEMENT; CARE; PERFORMANCE; PEOPLE; SCALE; COSTS; MODEL; ILL AB Objective: People with psychiatric impairments (primarily schizophrenia or a mood disorder) are the largest and fastest-growing group of Social Security Disability Insurance (SSDI) beneficiaries. The authors investigated whether evidence-based supported employment and mental health treatments can improve vocational and mental health recovery for this population. Method: Using a randomized controlled trial design, the authors tested a multifaceted intervention: team-based supported employment, systematic medication management, and other behavioral health services, along with elimination of barriers by providing complete health insurance coverage (with no out-of-pocket expenses) and suspending disability reviews. The control group received usual services. Paid employment was the primary outcome measure, and overall mental health and quality of life were secondary outcome measures. Results: Overall, 2,059 SSDI beneficiaries with schizophrenia, bipolar disorder, or depression in 23 cities participated in the 2-year intervention. The teams implemented the intervention package with acceptable fidelity. The intervention group experienced more paid employment (60.3% compared with 40.2%) and reported better mental health and quality of life than the control group. Conclusions: Implementation of the complex intervention in routine mental health treatment settings was feasible, and the intervention was effective in assisting individuals disabled by schizophrenia or depression to return to work and improve their mental health and quality of life. C1 [Drake, Robert E.] Dartmouth Psychiat Res Ctr, Geisel Sch Med Dartmouth, Hanover, NH USA. Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. Univ Maryland, Dept Publ Policy, Baltimore, MD USA. Univ Texas San Antonio, Sch Med, Dept Psychiat, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Drake, RE (reprint author), Dartmouth Psychiat Res Ctr, Geisel Sch Med Dartmouth, Hanover, NH USA. EM robert.e.drake@dartmouth.edu FU Pfizer; SSA [SS00-05-60072]; Westat [SS00-05-60072] FX Dr. Miller has served on data monitoring committees for Otsuka and has received an investigator-initiated research grant from Pfizer. The other authors report no financial relationships with commercial interests.; The authors thank Susan Kalasunas and Tom Hale from the U.S. Social Security Administration (SSA) for their assistance. This study extends work that was conducted under contract SS00-05-60072 between the SSA and Westat. This analysis was conducted for the benefit of the SSA. The opinions expressed in this article are those of the authors and not necessarily those of the SSA. NR 30 TC 28 Z9 29 U1 2 U2 24 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD DEC PY 2013 VL 170 IS 12 BP 1433 EP 1441 DI 10.1176/appi.ajp.2013.13020214 PG 9 WC Psychiatry SC Psychiatry GA 263RE UT WOS:000327824900012 PM 23929355 ER PT J AU Olfson, M Marcus, SC Bridge, JA AF Olfson, Mark Marcus, Steven C. Bridge, Jeffrey A. TI Emergency Department Recognition of Mental Disorders and Short-Term Outcome of Deliberate Self-Harm SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID BORDERLINE PERSONALITY-DISORDER; SUICIDAL-BEHAVIOR; FOLLOW-UP; PSYCHIATRIC-ASSESSMENT; MANAGEMENT; ACCIDENT; CARE; ADOLESCENTS; POPULATION; THERAPY AB Objective: The authors sought to characterize the short-term risks of repeat self-harm and psychiatric hospital admission for deliberate self-harm patients discharged from emergency departments to the community, focusing on recognition of mental disorders in the emergency department. Method: A retrospective longitudinal cohort analysis of national Medicaid claims data was conducted of adults 21-64 years of age with deliberate self-harm who were discharged from emergency departments (N=5,567). Rates and adjusted risk ratios are presented of repeat self-harm visits and inpatient psychiatric admission during the 30 days following the initial emergency visit. Results: Approximately 9.7% of self-harm visits were followed by repeat self-harm visits and 13.6% by inpatient psychiatric admissions within 30 days after the initial emergency visit. The rate of repeat self-harm visits was inversely related to recognition of a mental disorder in the emergency department (adjusted risk ratio [ARR]=0.66, 95% CI=0.55-0.79) and directly related to recent diagnosis of anxiety disorders (ARR=1.56, 95% CI=1.30-1.86) or personality disorders (ARR=1.67, 95% CI=1.19-2.34). Recognition of a mental disorder in the emergency department was inversely related to repeat self-harm among patients with no recent mental disorder diagnosis (ARR=0.57, 95% CI=0.41-0.79); any recent mental disorder diagnosis (ARR=0.70, 95%=0.57-0.87); and depressive (ARR=0.71, 95% CI=0.54-0.94), bipolar (ARR=0.70, 95% CI=0.51-0.94), and substance use (ARR=0.71, 95% CI=0.53-0.96) disorder diagnoses. Recognition of a mental disorder was also inversely related to subsequent inpatient psychiatric admission (ARR=0.81, 95% CI=0.71-0.93). Conclusions: Adults who are discharged to the community after emergency visits for deliberate self-harm are at high short-term risk of repeat deliberate self-harm and hospital admission, although these risks may be attenuated by clinical recognition of a mental disorder in the emergency department. C1 [Olfson, Mark] Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA. Ctr Hlth Equ Res & Promot, Philedelphia Vet Affairs Med Ctr, Philadelphia, PA USA. Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. Nationwide Childrens Hosp, Ctr Innovat Pediat Practice, Res Inst, Columbus, OH USA. RP Olfson, M (reprint author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA. EM mo49@columbia.edu FU American Foundation for Suicide Prevention; NIMH [MH093552]; Centers for Disease Control and Prevention grant [CE002129] FX Supported by the American Foundation for Suicide Prevention (a Distinguished Investigator Award to Dr. Olfson); NIMH grant MH093552 (to Dr. Bridge); and Centers for Disease Control and Prevention grant CE002129 (to Dr. Bridge). NR 38 TC 11 Z9 11 U1 1 U2 11 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD DEC PY 2013 VL 170 IS 12 BP 1442 EP 1450 DI 10.1176/appi.ajp.2013.12121506 PG 9 WC Psychiatry SC Psychiatry GA 263RE UT WOS:000327824900013 PM 23897218 ER PT J AU Thaler, NS Linck, JF Heyanka, DJ Pastorek, NJ Miller, B Romesser, J Sim, A Allen, DN AF Thaler, Nicholas S. Linck, John F. Heyanka, Daniel J. Pastorek, Nicholas J. Miller, Brian Romesser, Jennifer Sim, Anita Allen, Daniel N. TI Heterogeneity in Trail Making Test Performance in OEF/OIF/OND Veterans with Mild Traumatic Brain Injury SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Mild cognitive impairment; Statistical methods; Assessment ID SERIAL-ADDITION TASK; METAANALYTIC METHODS; INSUFFICIENT EFFORT; MEMORY; LIMITATIONS; PROFILES; VALIDITY; SAMPLE; TBI AB This study used cluster analysis to examine variability in Trail Making Test (TMT) performance in a sample of Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) veterans referred for mild traumatic brain injury (mTBI). Three clusters were extracted, two of which were characterized by level of performance and the third with a unique performance pattern characterized by slow performance on the TMT B (Low B). Clusters did not differ on demographic or psychiatric variables. The Above Average cluster had better performance on measures of processing speed, working memory, and phonemic fluency compared with the Low B cluster. Results suggest that a subset of patients with mTBI perform poorly on TMT B, which subsequently predicts poorer cognitive functioning on several other neuropsychological measures. This subset may be vulnerable to cognitive changes in the context of mTBI and multiple comorbidities while a number of other patients remain cognitively unaffected under the same circumstances. C1 [Thaler, Nicholas S.; Linck, John F.; Heyanka, Daniel J.] Oklahoma City Dept Vet Affairs Med Ctr, Oklahoma City, OK USA. [Pastorek, Nicholas J.; Miller, Brian] Michael E DeBakey Dept Vet Affairs Med Ctr, Houston, TX USA. [Romesser, Jennifer] George E Wahlen Dept Vet Affairs Med Ctr, Salt Lake City, UT USA. [Sim, Anita] Minneapolis Dept Vet Affairs Med Ctr, Minneapolis, MN USA. [Allen, Daniel N.] Univ Nevada, Las Vegas, NV 89154 USA. RP Thaler, NS (reprint author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,C8-746, Los Angeles, CA 90095 USA. EM nick.thaler@gmail.com FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development [B6812C] FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; B6812C (PI- Levin HS) VA RR&D Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks. NR 50 TC 0 Z9 0 U1 1 U2 5 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD DEC PY 2013 VL 28 IS 8 BP 798 EP 807 DI 10.1093/arclin/act080 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA 262FC UT WOS:000327718700007 PM 24145667 ER PT J AU Hunt, KJ Baker, N Cleary, P Backlund, JY Lyons, T Jenkins, A Virella, G Lopes-Virella, MF AF Hunt, Kelly J. Baker, Nathaniel Cleary, Patricia Backlund, Jye-Yu Lyons, Timothy Jenkins, Alicia Virella, Gabriel Lopes-Virella, Maria F. CA DCCT EDIC Res Grp TI Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes SO ATHEROSCLEROSIS LA English DT Article DE Modified LDL; Subclinical atherosclerosis; Carotid artery intima-media thickness; Type 1 diabetes ID LOW-DENSITY-LIPOPROTEIN; INTIMA-MEDIA THICKNESS; ACUTE CORONARY SYNDROMES; COMPLICATIONS TRIAL; HUMAN MACROPHAGES; CARDIOVASCULAR HEALTH; WALL THICKNESS; HEART-DISEASE; END-PRODUCTS; RISK-FACTORS AB Objective: Over 90% of modified LDL in circulation is associated to specific antibodies circulating as part of immune complexes (IC); however, few studies have examined their relationship with cardiovascular disease. Methods: We report the relationship between circulating concentrations of IC of oxidized LDL (oxLDL-IC), malondialdehyde-LDL (MDA-LDL-IC) and advanced glycation end products-LDL (AGE-LDL-IC) and progression of atherosclerosis over a 12 year period in 467 individuals with type 1 diabetes who participated in the Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) study. OxLDL-IC, AGE-LDL-IC and MDA-LDL-IC levels were measured at DCCT closeout. Internal carotid intimaemedial thickness (IMT) was measured at EDIC follow-up years 1, 6 and 12. Results: OxLDL-IC, AGE-LDL-IC and MDA-LDL-IC levels were significantly correlated with age, lipid levels, blood pressure levels and albumin excretion rates. Levels of oxLDL, AGE-LDL and MDA-LDL in isolated LDL-IC were highly inter-correlated (r 0.66e0.84, P < 0.0001). After adjusting for cardiovascular risk factors individuals in the upper quartile of oxLDL-IC had a 2.98-fold increased odds (CI: 1.34, 6.62) of having IMT 1.00 mm and had a 5.13-fold increased odds (CI: 1.98, 13.3) of having significant IMT progression, relative to those in the lowest quartile. Parallel odds ratios for AGE-LDL-IC were 2.95 (CI: 1.37, 6.34) and 3.50 (CI: 1.38, 8.86), while results for MDA-LDL-IC were 1.76 (0.87, 3.56) and 2.86 (1.20, 6.81). Conclusion: Our study indicates that high levels of oxLDL-IC and AGE-LDL-IC are important predictors of carotid intimaemedial thickening in patients with type 1 diabetes. Published by Elsevier Ireland Ltd. C1 [Hunt, Kelly J.; Baker, Nathaniel] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Hunt, Kelly J.; Lopes-Virella, Maria F.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Cleary, Patricia; Backlund, Jye-Yu] George Washington Univ, Ctr Biostat, Washington, DC USA. [Lyons, Timothy; Jenkins, Alicia] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Clin & Translat Unit, Oklahoma City, OK USA. [Lyons, Timothy; Jenkins, Alicia] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73190 USA. [Virella, Gabriel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA. [Lyons, Timothy] Queens Univ Belfast, Inst Clin Sci, Ctr Vasc & Vis Res, Belfast, Antrim, North Ireland. RP Hunt, KJ (reprint author), Med Univ S Carolina, Dept Publ Hlth Sci, 135 Cannon St,Suite 302K,POB 250835, Charleston, SC 29425 USA. EM huntke@musc.edu FU National Institutes of Health/NHLBI [PO1 HL 55782]; NIH/NIDDK [R01 DK081352, R01 DK088778]; Juvenile Diabetes Foundation Grant; Research Service of the Ralph H. Johnson Department of Veterans Affairs Medical Center FX This work was supported by a Program Project funded by the National Institutes of Health/NHLBI (PO1 HL 55782), by two R01 Grants funded by NIH/NIDDK (R01 DK081352 and R01 DK088778) and by a Juvenile Diabetes Foundation Grant (2006-49). The work was also supported by the Research Service of the Ralph H. Johnson Department of Veterans Affairs Medical Center. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 46 TC 11 Z9 12 U1 0 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD DEC PY 2013 VL 231 IS 2 BP 315 EP 322 DI 10.1016/j.atherosclerosis.2013.09.027 PG 8 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 259PB UT WOS:000327537700024 PM 24267245 ER PT J AU Tache, Y Stengel, A AF Tache, Yvette Stengel, Andreas TI New Developments on NUCB2/Nesfatin-1 SO CURRENT PHARMACEUTICAL DESIGN LA English DT Editorial Material ID NESFATIN-1; IDENTIFICATION; GHRELIN; AXIS; RAT C1 [Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Tache, Yvette] CURE Digest Dis Res Ctr Anim Core, Los Angeles, CA 90073 USA. [Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Ctr Neurobiol Stress & Womens Hlth, Los Angeles, CA 90073 USA. [Stengel, Andreas] Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, D-10117 Berlin, Germany. RP Tache, Y (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, 11301 Wilshire Blvd,CURE Bldg 115,Room 117, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu; andreas.stengel@charite.de NR 30 TC 2 Z9 2 U1 1 U2 5 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 EI 1873-4286 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PD DEC PY 2013 VL 19 IS 39 BP 6919 EP 6920 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 262JL UT WOS:000327730800012 PM 24286377 ER PT J AU Goebel-Stengel, M Wang, LX AF Goebel-Stengel, Miriam Wang, Lixin TI Central and Peripheral Expression and Distribution of NUCB2/nesfatin-1 SO CURRENT PHARMACEUTICAL DESIGN LA English DT Article DE Central nervous system; homeostasis; hypothalamus; plasma ID AMPHETAMINE-REGULATED TRANSCRIPT; EDINGER-WESTPHAL NUCLEUS; PITUITARY-ADRENAL AXIS; PLASMA NESFATIN-1; RAT-BRAIN; NEURONS; HORMONE; PEPTIDE; IMMUNOREACTIVITY; NUCLEOBINDIN-2 AB Nesfatin-1 is the N-terminal fragment of nucleobindin-2 (NUCB2). The antibody against nesfatin-1 recognizes both full length of NUCB2 and nesfatin-1, thus the immunolabeling represents NUCB2/nesfatin-1. It has been found that NUCB2/nesfatin-1 is widely distributed in the rodent central nervous system. The immunoreactivity is more intensive in the brain autonomic centers that regulate feeding, neuroendocrine and cardiovascular functions, such as the hypothalamic paraventricular nucleus, supraoptic nucleus, lateral hypothalamic area, Edinger-Westphal nucleus, locus coeruleus, dorsal vagal complex and medullary raphe nuclei. In neurons, NUCB2/nesfatin-1 is located in the soma and primary dendrites, not in nerve fibers. NUCB2/nesfatin-1 is co-localized with several neurotransmitters involved in regulation of food intake, autonomic and neuroendocrine functions, including oxytocin, vasopressin, neuropeptide Y, cocaine-and amphetamine-regulated transcript, proopiomelanocortin, alpha-melanocyte-stimulating hormone, melanin-concentrating hormone, leptin, mammalian target of rapamycin, urocortin-1, corticotropin-releasing factor and serotonin. In the periphery, NUCB2/nesfatin-1 is located mainly in the pituitary, gastric mucosa where it coexists with ghrelin, and pancreatic endocrine cells containing insulin. Nesfatin-1 is detectable in the cerebrospinal fluid of rats. NUCB2/nesfatin-1 is measurable in the plasma, and altered under different conditions in rodents and humans, such as immune challenge, high fat diet and exercise, anorexia nervosa, anxiety and depression. Anatomical data suggest that nesfatin-1 is a unique neuroendocrine peptide that may be involved in regulation of homeostasis. C1 [Goebel-Stengel, Miriam] Charite, Dept Internal Med, Inst Neurogastroenterol & Motil, Martin Luther Hosp,Acad Teaching Inst, D-13353 Berlin, Germany. [Wang, Lixin] Univ Calif Los Angeles, CURE Digest Dis Res Ctr, Ctr Neurobiol Stress, Dept Med,Digest Dis Div, Los Angeles, CA 90073 USA. [Wang, Lixin] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA 90073 USA. RP Goebel-Stengel, M (reprint author), Martin Luther Hosp, Dept Internal Med, Caspar Theyss Str 27-31, D-14193 Berlin, Germany. EM miriam.goebel-stengel@gmx.de FU NIH [R01 DK-33061]; NIH Center [41301] FX This work was supported by NIH R01 DK-33061, NIH Center Grant DK-41301 (Animal Core). NR 50 TC 13 Z9 14 U1 1 U2 13 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 EI 1873-4286 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PD DEC PY 2013 VL 19 IS 39 BP 6935 EP 6940 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 262JL UT WOS:000327730800015 PM 23537079 ER PT J AU Stengela, A Tache, Y AF Stengela, Andreas Tache, Yvette TI Role of Brain NUCB2/nesfatin-1 in the Regulation of Food Intake SO CURRENT PHARMACEUTICAL DESIGN LA English DT Article DE Brainstem; CRF; hunger; hypothalamus; obesity; oxytocin; satiety ID CENTRAL-NERVOUS-SYSTEM; CORTICOTROPIN-RELEASING HORMONE; PITUITARY-ADRENAL AXIS; OREXIN MESSENGER-RNA; INTER-MEAL INTERVALS; PARAVENTRICULAR NUCLEUS; NESFATIN-1 INFLUENCES; SATIETY MOLECULE; ARCUATE NUCLEUS; RAT-BRAIN AB Nesfatin-1 was recently identified in the rat brain as a potential post-translational processing product derived from nucleobindin2 (NUCB2). The first biological action identified for nesfatin-1 was the reduction of nocturnal food intake in rats. The anorexigenic effect of nesfatin-1 was corroborated by several independent laboratories and is now established as a physiological action of this peptide based on the regulation of brain NUCB2/nesfatin-1 under different metabolic conditions and the stimulation of food intake and body weight when endogenous brain NUCB2/nesfatin-1 is blocked. Nesfatin-1 shows extensive co-localization with various other, predominantly food intake inhibitory, hypothalamic peptides including corticotropin-releasing factor (CRF), oxytocin, cholecystokinin, proopiomelanocortin, alpha-melanocyte stimulating hormone (alpha-MSH), thyrotropin-releasing hormone (TRH), the orexigenic neuropeptide Y and brain biogenic amines, histamine, serotonin, and catecholamines. The food intake suppressing effect of centrally injected nesfatin-1 has been established so far to involve several downstream mechanisms including H-1, CRF2, TRH, oxytocin as well as melanocortin-3/4 receptor signaling pathways. This intricate embedding of NUCB2/nesfatin-1 in central food intake regulatory pathways recruited during the dark phase corresponding to the eating period in rodents, unlike the orexigenic response to a fast, points towards a role for nesfatin-1 in modulating the nocturnal food intake. Although our knowledge on the regulation and effects of NUCB2/nesfatin-1 as a new anorexic peptide markedly increased during the past five years, several important gaps of knowledge remain to be filled in the near future such as the regulation of NUCB2 processing and nesfatin-1 release as well as the identification, localization and regulation of the nesfatin-1 receptor. C1 [Stengela, Andreas; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Stengela, Andreas; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Neurovisceral Sci & Womens Hlth, Div Digest Dis, Los Angeles, CA 90095 USA. [Stengela, Andreas; Tache, Yvette] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Stengela, Andreas] Charite, Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, D-13353 Berlin, Germany. RP Tache, Y (reprint author), VA Greater Los Angeles Healthcare Syst, CURE Digest Dis Res Ctr, Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU German Research Foundation [STE 1765/3-1]; Charite University [UFF 89-441-176]; Sonnenfeld foundation; VA Research Career Scientist Award; VA Merit Award; NIH [DK 33061, DK 57238] FX A.S. received funding of the German Research Foundation (STE 1765/3-1), Charite University Funding (UFF 89-441-176) and an equipment grant of the Sonnenfeld foundation. Y.T. is in receipt of the VA Research Career Scientist Award, VA Merit Award and NIH R01 grants DK 33061 and DK 57238. NR 57 TC 4 Z9 4 U1 1 U2 7 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1381-6128 EI 1873-4286 J9 CURR PHARM DESIGN JI Curr. Pharm. Design PD DEC PY 2013 VL 19 IS 39 BP 6955 EP 6959 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 262JL UT WOS:000327730800018 PM 23537088 ER PT J AU Gordon, AJ Conley, JW Gordon, JM AF Gordon, Adam J. Conley, James W. Gordon, Joanne M. TI Medical Consequences of Marijuana Use: A Review of Current Literature SO CURRENT PSYCHIATRY REPORTS LA English DT Review DE Marijuana; Medical consequences; Review; Substance use and related disorders; Psychiatry ID AMERICAN ADOLESCENT FEMALES; ACUTE MYOCARDIAL-INFARCTION; SQUAMOUS-CELL CARCINOMA; ILLICIT DRUG-USE; CANNABIS USE; LUNG-FUNCTION; YOUNG-ADULTS; MENINGOCOCCAL DISEASE; PULMONARY-FUNCTION; SUBSTANCE-ABUSE AB With the advent of legalization of marijuana for medicinal and recreational purposes, and the increase use of marijuana, healthcare providers will be increasingly confronted with marijuana users as patients in clinical environments. While there is vast literature regarding the societal and mental health harms associated with marijuana use, there is a paucity of reviews of the potential consequences of marijuana use on physical health or medical conditions. We examine the recent literature on the physical harms associated with illicit and legal marijuana administration. We surveyed the peer-reviewed medical literature from 1998 to 2013 of studies assessing the association of marijuana use and physical diseases. We conclude that healthcare providers should be cognizant that the existing literature suggests that marijuana use can cause physical harm. However, evidence is needed, and further research should be considered, to prove causal associations of marijuana with many physical health conditions. C1 [Gordon, Adam J.; Conley, James W.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA 15240 USA. [Gordon, Adam J.; Conley, James W.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA 15240 USA. [Gordon, Joanne M.] Missouri State Univ, Springfield, MO USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, CHERP, 151-C,Univ Dr C, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu FU National Institutes of Health; Department of Veterans Affairs; Substance Abuse and Mental Health Services Administration FX Adam J. Gordon has received research support from National Institutes of Health, Department of Veterans Affairs, and Substance Abuse and Mental Health Services Administration and royalties from Cambridge University Press and UpToDate. NR 127 TC 16 Z9 16 U1 4 U2 82 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 EI 1535-1645 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD DEC PY 2013 VL 15 IS 12 AR 419 DI 10.1007/s11920-013-0419-7 PG 11 WC Psychiatry SC Psychiatry GA 264NZ UT WOS:000327886400004 PM 24234874 ER PT J AU Meyer, S van der Meer, P Massie, BM O'Connor, CM Metra, M Ponikowski, P Teerlink, JR Cotter, G Davison, BA Cleland, JGF Givertz, MM Bloomfield, DM Fiuzat, M Dittrich, HC Hillege, HL Voors, AA AF Meyer, Sven van der Meer, Peter Massie, Barry M. O'Connor, Christopher M. Metra, Marco Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth A. Cleland, John G. F. Givertz, Michael M. Bloomfield, Daniel M. Fiuzat, Mona Dittrich, Howard C. Hillege, Hans L. Voors, Adriaan A. TI Sex-specific acute heart failure phenotypes and outcomes from PROTECT SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Acute heart failure; Sex; Biomarkers; Aetiology; Mortality ID PRESERVED EJECTION FRACTION; BLOOD UREA NITROGEN; GENDER-DIFFERENCES; DISEASE; PATHOPHYSIOLOGY; DYSFUNCTION; ANTAGONIST; MORTALITY; DIAGNOSIS; SURVIVAL AB Differences in manifestation, treatment, and outcomes of acute heart failure between men and women have not been well studied. The objective of this analysis was to characterize differences in clinical presentation, and in-hospital and post-discharge outcomes between sexes in acute heart failure patients. Clinical profiles, treatment characteristics, and outcomes were compared between sexes in 2033 patients hospitalized for acute heart failure and impaired renal function. Women comprised 33 of the study population and were older, had higher body mass index, LVEF, and systolic blood pressure, and a greater prevalence of diabetes. At baseline, women showed signs and symptoms of congestion comparable with men, but more often had rales, orthopnoea, and worse renal function. Women were less intensively diuresed, as indicated by lower oral and intravenous diuretic doses used, fewer dose increases, and less total weight loss during hospitalization. Furthermore, hospitalization was slightly but significantly prolonged in women (11.04 7.8 vs. 10.65 8.86 days; P 0.024). Age-adjusted 180-day mortality was lower in women (15.8 vs. 18.5, hazard ratio 0.74; 95 confidence interval 0.590.93, P 0.010), but multivariable risk-adjusted mortality was similar in both sexes, mainly attributable to lower blood urea nitrogen, higher LVEF, and higher systolic blood pressure in women compared with men. Women with acute heart failure present with a clinical profile different from that of men, with more hypertension, diabetes, and depression, and a preserved LVEF. During hospitalization, they were less intensively diuresed. Nevertheless, risk-adjusted 180-day outcome was similar between sexes. C1 [Meyer, Sven; van der Meer, Peter; Hillege, Hans L.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands. [Massie, Barry M.; Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry M.; Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [O'Connor, Christopher M.; Fiuzat, Mona] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Metra, Marco] Univ Brescia, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Cotter, Gad; Davison, Beth A.] Momentum Res, Durham, NC USA. [Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] NovaCardia, San Diego, CA USA. RP Voors, AA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1,POB 30-001, NL-9700 RB Groningen, Netherlands. EM a.a.voors@umcg.nl RI Ponikowski, Piotr/O-6454-2015 OI Ponikowski, Piotr/0000-0002-3391-7064; Metra, Marco/0000-0001-6691-8568; Davison, Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016 FU NovaCardia, a subsidiary of Merck FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. NR 22 TC 10 Z9 10 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD DEC PY 2013 VL 15 IS 12 BP 1374 EP 1381 DI 10.1093/eurjhf/hft115 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 259EM UT WOS:000327510200007 PM 24259042 ER PT J AU Labus, JS Hubbard, CS Bueller, J Ebrat, B Tillisch, K Chen, M Stains, J Dukes, GE Kelleher, DL Naliboff, BD Fanselow, M Mayer, EA AF Labus, Jennifer S. Hubbard, Catherine S. Bueller, Joshua Ebrat, Bahar Tillisch, Kirsten Chen, Michelle Stains, Jean Dukes, George E. Kelleher, Dennis L. Naliboff, Bruce D. Fanselow, Michael Mayer, Emeran A. TI Impaired Emotional Learning and Involvement of the Corticotropin-Releasing Factor Signaling System in Patients With Irritable Bowel Syndrome SO GASTROENTEROLOGY LA English DT Article DE Corticotropin-Releasing Factor Receptor 1 (CRF-R1) Antagonist; Fear Conditioning; Extinction ID POSTTRAUMATIC-STRESS-DISORDER; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PREFRONTAL CORTEX; ANIMAL-MODELS; ANTERIOR CINGULATE; NEURAL MECHANISMS; VISCERAL STIMULI; FEAR EXTINCTION; LOCUS-COERULEUS; ABDOMINAL-PAIN AB BACKGROUND & AIMS: Alterations in central corticotropin-releasing factor signaling pathways have been implicated in the pathophysiology of anxiety disorders and irritable bowel syndrome (IBS). We aimed to characterize the effects of the corticotropin-releasing factor receptor 1 (CRF-R1) antagonist, GW876008, on brain and skin conductance responses during acquisition and extinction of conditioned fear to the threat of abdominal pain in subjects with IBS and healthy individuals (controls). METHODS: We performed a single-center, randomized, double-blind, 3-period crossover study of 11 women with IBS (35.50 +/- 12.48 years old) and 15 healthy women (controls) given a single oral dose (20 mg or 200 mg) of the CRF-R1 antagonist or placebo. Blood-oxygen level-dependent responses were analyzed using functional magnetic resonance imaging in a tertiary care setting. RESULTS: Controls had greater skin conductance responses during acquisition than extinction, validating the fear-conditioning paradigm. In contrast, during extinction, women with IBS had greater skin conductance responses than controls-an effect normalized by administration of a CRF-R1 antagonist. Although the antagonist significantly reduced activity in the thalamus in patients with IBS and controls during acquisition, the drug produced greater suppression of blood-oxygen level-dependent activity in a wide range of brain regions in IBS patients during extinction, including the medial prefrontal cortex, pons, hippocampus, and anterior insula. CONCLUSIONS: Although CRF signaling via CRF-R1 is involved in fear acquisition and extinction learning related to expected abdominal pain in patients with IBS and controls, this system appears to be up-regulated in patients with IBS. This up-regulation might contribute to the previously reported abnormal brain responses to expected abdominal pain. C1 [Labus, Jennifer S.; Hubbard, Catherine S.; Bueller, Joshua; Ebrat, Bahar; Tillisch, Kirsten; Chen, Michelle; Stains, Jean; Naliboff, Bruce D.; Mayer, Emeran A.] Univ Calif Los Angeles, Gail & Gerald Oppenheimer Family Ctr Neurobiol St, Los Angeles, CA USA. [Labus, Jennifer S.; Hubbard, Catherine S.; Bueller, Joshua; Ebrat, Bahar; Tillisch, Kirsten; Chen, Michelle; Stains, Jean; Naliboff, Bruce D.; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Dept Physiol, Los Angeles, CA 90024 USA. [Labus, Jennifer S.; Fanselow, Michael; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA USA. [Fanselow, Michael; Mayer, Emeran A.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Mayer, Emeran A.] Univ Calif Los Angeles, Ahmanson Lovelace Brain Mapping Ctr, Los Angeles, CA USA. [Naliboff, Bruce D.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Dukes, George E.; Kelleher, Dennis L.] GlaxoSmithKline, Res Triangle Pk, NC USA. RP Mayer, EA (reprint author), Gail & Gerald Oppenheimer Family Ctr Neurobiol St, Div Digest Dis, UCLA CHS 42-210 MC737818,10833 Le Conte Ave, Los Angeles, CA 90095 USA. EM emayer@ucla.edu OI Hubbard, Catherine/0000-0002-9139-2198 FU GlaxoSmithKline; National Institutes of Health [R01 DK048351, P50 DK064539, K23 DK073451, K08 DK071626, T32 DK07180-34] FX Research supported by GlaxoSmithKline, National Institutes of Health grants R01 DK048351 (EAM), P50 DK064539 (EAM), K23 DK073451 (KT), K08 DK071626 (JSL), and National Institutes of Health GI Training Grant T32 DK07180-34. NR 60 TC 28 Z9 34 U1 2 U2 20 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD DEC PY 2013 VL 145 IS 6 BP 1253 EP + DI 10.1053/j.gastro.2013.08.016 PG 12 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 259PA UT WOS:000327537600028 PM 23954313 ER PT J AU Romo, RD Wallhagen, MI Yourman, L Yeung, CC Eng, C Micco, G Perez-Stable, EJ Smith, AK AF Romo, Rafael D. Wallhagen, Margaret I. Yourman, Lindsey Yeung, Christie C. Eng, Catherine Micco, Guy Perez-Stable, Eliseo J. Smith, Alexander K. TI Perceptions of Successful Aging Among Diverse Elders With Late-Life Disability SO GERONTOLOGIST LA English DT Article DE Attitudes and perception toward aging; aged; Diversity and ethnicity; Grounded theory; Qualitative research methods; Cross-cultural studies; Home and community; based care and services ID AFRICAN-AMERICAN; OLDER-ADULTS; HEALTH; SATISFACTION; DEFINITION; MODEL; WELL AB Purpose: Researchers often use the term successful aging to mean freedom from disability, yet the perspectives of elders living with late-life disability have not been well described. The purpose of this study was to explore the meaning of successful aging among a diverse sample of community-dwelling elders with late-life disability. Design and Methods: Using qualitative grounded theory methodology, we interviewed 56 African American, White, Cantonese-speaking Chinese, and Spanish-speaking Latino disabled elders who participate in On Lok Lifeways, a Program of All-inclusive Care for the Elderly. Through semi-structured interviews with open-ended questions, we explored the elders perceptions of what successful aging and being old meant to them. Results: Despite experiencing late-life disability, most participants felt they had aged successfully. An overarching theme was that aging results in Living in a New Reality, with two subthemes: Acknowledging the New Reality and Rejecting the New Reality. Participants achieved successful aging by using adaptation and coping strategies to align their perception of successful aging with their experiences. Themes were common across race/ethnic groups but certain strategies were more prominent among different groups. Implications: Across race and ethnic groups, most of these participants with late-life disability felt they had aged successfully. Thus, successful aging involves subjective criteria and has a cultural context that is not captured in objective measurements. Understanding elders perception will help establish common ground for communication between clinicians and elders and identify the most appropriate interventions to help elders achieve and maintain the experience of successful aging. C1 [Romo, Rafael D.; Wallhagen, Margaret I.] Univ Calif San Francisco, Sch Nursing, Dept Physiol Nursing, San Francisco, CA 94143 USA. [Yourman, Lindsey; Yeung, Christie C.; Eng, Catherine; Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Yourman, Lindsey] Scripps Mercy Med Educ, San Diego, CA USA. [Eng, Catherine] On Lok Lifeways, San Francisco, CA USA. [Micco, Guy] Univ Calif Berkeley, UC Berkeley UCSF Joint Med Program, Berkeley, CA 94720 USA. [Perez-Stable, Eliseo J.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Smith, Alexander K.] San Francisco Vet Adm Med Ctr, San Francisco, CA USA. RP Romo, RD (reprint author), UCSF Sch Nursing, Off Student Affairs N319X, 2 Koret Way, San Francisco, CA 94143 USA. EM Rafael.Romo@ucsf.edu FU NCRR NIH HHS [UL1 RR024131]; NIA NIH HHS [P30 AG015272, P30-AG15272] NR 34 TC 22 Z9 22 U1 5 U2 26 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD DEC PY 2013 VL 53 IS 6 BP 939 EP 949 DI 10.1093/geront/gns160 PG 11 WC Gerontology SC Geriatrics & Gerontology GA 258DV UT WOS:000327440300006 PM 23231944 ER PT J AU Wang, GH Zhang, J Hu, XM Zhang, LL Mao, LL Jiang, XY Liou, AKF Leak, RK Gao, YQ Chen, J AF Wang, Guohua Zhang, Jia Hu, Xiaoming Zhang, Lili Mao, Leilei Jiang, Xiaoyan Liou, Anthony Kian-Fong Leak, Rehana K. Gao, Yanqin Chen, Jun TI Microglia/macrophage polarization dynamics in white matter after traumatic brain injury SO JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM LA English DT Article DE inflammation; macrophage; microglia; polarization; white matter injury ID SPINAL-CORD; NEURODEGENERATIVE DISEASES; ACTIVATION PATTERNS; AXONAL INJURY; CELL-DEATH; MICROGLIA; INFLAMMATION; RAT; NEUROPROTECTION; IDENTIFICATION AB Mononuclear phagocytes are a population of multi-phenotypic cells and have dual roles in brain destruction/reconstruction. The phenotype-specific roles of microglia/macrophages in traumatic brain injury (TBI) are, however, poorly characterized. In the present study, TBI was induced in mice by a controlled cortical impact (CCI) and animals were killed at 1 to 14 days post injury. Real-time polymerase chain reaction (RT-PCR) and immunofluorescence staining for M1 and M2 markers were performed to characterize phenotypic changes of microglia/macrophages in both gray and white matter. We found that the number of M1-like phagocytes increased in cortex, striatum and corpus callosum (CC) during the first week and remained elevated until at least 14 days after TBI. In contrast, M2-like microglia/macrophages peaked at 5 days, but decreased rapidly thereafter. Notably, the severity of white matter injury (WMI), manifested by immunohistochemical staining for neurofilannent SMI-32, was strongly correlated with the number of M1-like phagocytes. In vitro experiments using a conditioned medium transfer system confirmed that M1 microglia-conditioned media exacerbated oxygen glucose deprivation-induced oligodendrocyte death. Our results indicate that microglia/macrophages respond dynamically to TBI, experiencing a transient M2 phenotype followed by a shift to the M1 phenotype. The M1 phenotypic shift may propel WMI progression and represents a rational target for TBI treatment. C1 [Wang, Guohua; Zhang, Jia; Mao, Leilei; Jiang, Xiaoyan; Gao, Yanqin; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. [Wang, Guohua; Zhang, Jia; Mao, Leilei; Jiang, Xiaoyan; Gao, Yanqin; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China. [Wang, Guohua; Hu, Xiaoming; Zhang, Lili; Mao, Leilei; Liou, Anthony Kian-Fong; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Dept Neurol, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15260 USA. [Wang, Guohua] Nantong Univ, Inst Naut Med, Dept Neuropharmacol, Nantong, Peoples R China. [Hu, Xiaoming; Zhang, Lili; Liou, Anthony Kian-Fong; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. RP Gao, YQ (reprint author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China. EM yqgao@shmu.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417 FU Chinese Ministry of Science and Technology; National Institutes of Health/NINDS grants [NS36736, NS43802, NS45048]; VA Career Scientist Award; Chinese Natural Science Foundation [30870794, 81020108021, 81171149, 81150110494, 81000497] FX This research is supported in part by the Special Research Funds from Chinese Ministry of Science and Technology to State Key laboratories (to GH Wang, Y Gao and J Chen), National Institutes of Health/NINDS grants NS36736, NS43802 and NS45048 (to J Chen), VA Career Scientist Award (J Chen), and Chinese Natural Science Foundation grants No 30870794, No 81020108021, No 81171149, and No 81150110494 (to YG), and No 81000497 (to GW). NR 43 TC 93 Z9 94 U1 6 U2 30 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0271-678X EI 1559-7016 J9 J CEREBR BLOOD F MET JI J. Cereb. Blood Flow Metab. PD DEC PY 2013 VL 33 IS 12 BP 1864 EP 1874 DI 10.1038/jcbfm.2013.146 PG 11 WC Endocrinology & Metabolism; Hematology; Neurosciences SC Endocrinology & Metabolism; Hematology; Neurosciences & Neurology GA 266DI UT WOS:000328002200007 PM 23942366 ER PT J AU Bloch, MJ Basile, JN AF Bloch, Michael J. Basile, Jan N. TI Review of Recent Literature in Hypertension: Updated Clinical Practice Guidelines for Chronic Kidney Disease Now Include Albuminuria in the Classification System SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article C1 [Bloch, Michael J.] Univ Nevada, Sch Med, Dept Internal Med, Reno, NV 89557 USA. [Basile, Jan N.] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Div Gen Internal Med Geriatr, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. RP Bloch, MJ (reprint author), Univ Hlth Syst, 1500 East 2nd St,Suite 302, Reno, NV 89502 USA. EM mbloch@aol.com NR 3 TC 0 Z9 1 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD DEC PY 2013 VL 15 IS 12 BP 865 EP 867 DI 10.1111/jch.12209 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 260YX UT WOS:000327631700002 PM 24119153 ER PT J AU McKay, JR Van Horn, DHA Lynch, KG Ivey, M Cary, MS Drapkin, ML Coviello, DM Plebani, JG AF McKay, James R. Van Horn, Deborah H. A. Lynch, Kevin G. Ivey, Megan Cary, Mark S. Drapkin, Michelle L. Coviello, Donna M. Plebani, Jennifer G. TI An Adaptive Approach for Identifying Cocaine Dependent Patients Who Benefit From Extended Continuing Care SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE cocaine dependence; continuing care; adaptive treatment; incentives; moderators ID ADDICTION SEVERITY INDEX; SUBSTANCE-ABUSE PATIENTS; TREATMENT ATTRITION; OUTPATIENT COCAINE; INITIAL ABSTINENCE; DRINKING BEHAVIOR; RANDOMIZED-TRIAL; SELF-REPORTS; ALCOHOL; OUTCOMES AB Objective: Study tested whether cocaine dependent patients using cocaine or alcohol at intake or in the first few weeks of intensive outpatient treatment would benefit more from extended continuing care than patients abstinent during this period. The effect of incentives for continuing care attendance was also examined. Method: Participants (N = 321) were randomized to treatment as usual (TAU), TAU and telephone monitoring and counseling (TMC), or TAU and TMC plus incentives (TMC+). The primary outcomes were (a) abstinence from all drugs and heavy alcohol use and (b) cocaine urine toxicology. Follow-ups were at 3, 6, 9, 12, 18, and 24 months. Results: Cocaine and alcohol use at intake or early in treatment predicted worse outcomes on both measures (ps <= .0002). Significant effects favoring TMC over TAU on the abstinence composite were obtained in participants who used cocaine (odds ratio [OR] = 1.95 [1.02, 3.73]) or alcohol (OR = 2.47 [1.28, 4.78]) at intake or early in treatment. A significant effect favoring TMC+ over TAU on cocaine urine toxicology was obtained in those using cocaine during that period (OR = 0.55 [0.31, 0.95]). Conversely, there were no treatment effects in participants abstinent at baseline and no overall treatment main effects. Incentives almost doubled the number of continuing care sessions received but did not further improve outcomes. Conclusion: An adaptive approach for cocaine dependence in which extended continuing care is provided only to patients who are using cocaine or alcohol at intake or early in treatment improves outcomes in this group while reducing burden and costs in lower risk patients. C1 [McKay, James R.; Van Horn, Deborah H. A.; Lynch, Kevin G.; Ivey, Megan; Drapkin, Michelle L.; Coviello, Donna M.; Plebani, Jennifer G.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [McKay, James R.; Van Horn, Deborah H. A.; Drapkin, Michelle L.] Philadelphia Vet Affairs Med Ctr, Dept Behav Hlth, Philadelphia, PA USA. [Cary, Mark S.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP McKay, JR (reprint author), Univ Penn, Ctr Continuum Care Addict, 3440 Market St,Suite 370, Philadelphia, PA 19104 USA. EM jimrache@mail.med.upenn.edu FU NIDA NIH HHS [K02 DA000361, K24 DA029062, R01 DA020623] NR 41 TC 13 Z9 13 U1 0 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD DEC PY 2013 VL 81 IS 6 BP 1063 EP 1073 DI 10.1037/a0034265 PG 11 WC Psychology, Clinical SC Psychology GA 264DE UT WOS:000327856400011 PM 24041231 ER PT J AU Kramer, EJ Bodendorfer, BM Laron, D Wong, J Kim, HT Liu, XH Feeley, BT AF Kramer, Erik J. Bodendorfer, Blake M. Laron, Dominique Wong, Jason Kim, Hubert T. Liu, Xuhui Feeley, Brian T. TI Evaluation of cartilage degeneration in a rat model of rotator cuff tear arthropathy SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE Massive rotator cuff tear; arthropathy; osteoarthritis; histology; articular cartilage ID SYNOVIAL-FLUID; BIOCHEMICAL MARKERS; SHOULDER JOINT AB Background and hypothesis: Rotator cuff tears are the most common injury seen by shoulder surgeons. Glenohumeral osteoarthritis develops in many late-stage rotator cuff tear patients as a result of torn cuff tendons, termed "cuff tear arthropathy." However, the mechanisms of cuff tear arthropathy have not been fully established. It has been hypothesized that a combination of synovial and mechanical factors contribute equally to the development of cuff tear arthropathy. The goal of this study was to assess the utility of this model in investigating cuff tear arthropathy. Materials and methods: We used a rat model that accurately reflects rotator cuff muscle degradation after massive rotator cuff tears through either infraspinatus and supraspinatus tenotomy or suprascapular nerve transection. Using a modified Mankin scoring system, we found significant glenohumeral cartilage damage after both rotator cuff tenotomy and suprascapular nerve transection after only 12 weeks. Results: Cartilage degeneration was similar between groups and was present on both the humeral head and the glenoid. Denervation of the supraspinatus and infraspinatus muscles without opening the joint capsule caused cartilage degeneration similar to that found in the tendon transection group. Conclusions: Our results suggest that altered mechanical loading after rotator cuff tears is the primary factor in cartilage degeneration after rotator cuff tears. Clinically, understanding the process of cartilage degeneration after rotator cuff injury will help guide treatment decisions in the setting of rotator cuff tears. (C) 2013 Journal of Shoulder and Elbow Surgery Board of Trustees. C1 [Kramer, Erik J.; Bodendorfer, Blake M.; Wong, Jason; Kim, Hubert T.; Liu, Xuhui] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA. [Kramer, Erik J.; Laron, Dominique; Kim, Hubert T.; Liu, Xuhui; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA. RP Feeley, BT (reprint author), Dept Orthopaed Surg, 1500 Owens Ave,Box 3004, San Francisco, CA 94158 USA. EM feeleyb@orthosurg.ucsf.edu FU Orthopaedic Research and Educational Foundation (Young Investigator Grant); National Institutes of Health [R03-AR060871-02] FX Funding was provided by grants from the Orthopaedic Research and Educational Foundation (Young Investigator Grant) and National Institutes of Health (R03-AR060871-02). NR 17 TC 4 Z9 4 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD DEC PY 2013 VL 22 IS 12 BP 1702 EP 1709 DI 10.1016/j.jse.2013.03.014 PG 8 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA 258VJ UT WOS:000327486500022 PM 23664745 ER PT J AU Gros, DF Milanak, ME Hershenberg, R AF Gros, Daniel F. Milanak, Melissa E. Hershenberg, Rachel TI CONVERGENCE OF DEPRESSION AND ANXIETY SYMPTOMS IN FRIENDSHIP DYADS SO JOURNAL OF SOCIAL AND CLINICAL PSYCHOLOGY LA English DT Article ID SOCIAL PHOBIA INVENTORY; STATE-TRAIT INVENTORY; SELF-OTHER AGREEMENT; PSYCHOMETRIC PROPERTIES; INFORMANT-REPORTS; CLINICAL-RESEARCH; PERSONALITY; VALIDATION; DISORDERS; RATINGS AB Despite psychometric rationale to include multiple informants, psychological assessment typically involves data collected from the patient (target) only, particularly with regard to depressive and anxious symptomatology. This study addressed this gap in the literature by assessing convergence between targets and their close friends (informants) in an ethnically diverse sample of young adults. One hundred and thirty-nine friendship dyads completed a packet of questionnaires including different versions administered to the targets and informants, with targets completing the standard questionnaire battery focused on their own symptoms and informants completing questionnaires on their view of the target participants' symptoms, rather than their own characteristics. Measures were included to assess a wide range of symptomatology, including behavioral, cognitive, and physiological symptoms of anxiety and depression. The target-informant correlations were largely significant and of small-to-medium magnitude. In addition, target-informant agreement was higher in more visible symptoms (e. g., behavioral) than in less visible symptoms (e. g., physiological) of anxiety and depression. Interestingly, level of closeness in the relationship did not influence the magnitude of correlations. Implications for future research and integration into clinical assessment practices are discussed. C1 Ralph H Johnson VA Med Ctr, Charleston, SC USA. Med Univ S Carolina, Charleston, SC USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU NIMH NIH HHS [T32 MH018869] NR 44 TC 3 Z9 3 U1 16 U2 18 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0736-7236 J9 J SOC CLIN PSYCHOL JI J. Soc. Clin. Psychol. PD DEC PY 2013 VL 32 IS 10 BP 1061 EP 1074 PG 14 WC Psychology, Clinical; Psychology, Social SC Psychology GA 263NJ UT WOS:000327815000003 PM 25089072 ER PT J AU Hage, FG Mansur, SJ Xing, DQ Oparil, S AF Hage, Fadi G. Mansur, Sulaf J. Xing, Dongqi Oparil, Suzanne TI Hypertension in women SO KIDNEY INTERNATIONAL SUPPLEMENTS LA English DT Article DE antihypertensive treatment; hypertension; oral contraceptives; preeclampsia; pregnancy-related hypertension; women ID AMERICAN-HEART-ASSOCIATION; LIPID-LOWERING TREATMENT; BLOOD-PRESSURE; MILD HYPERTENSION; OUTCOMES; TRIAL; DISEASE; MEN; PREVENTION; GUIDELINES AB Hypertension is the most common modifiable risk factor for cardiovascular disease, the leading cause of death in both men and women. The prevalence and severity of hypertension rise markedly with age, and blood pressure control becomes more difficult with aging in both genders, particularly in women. In addition, there are forms of hypertension that occur exclusively in women, e.g., hypertension related to menopause, oral contraceptive use, or pregnancy (e.g., chronic hypertension, gestational hypertension, pre-eclampsia or eclampsia). Randomized controlled trials show that antihypertensive therapy provides similar reductions in major cardiovascular events in men and women. Therefore, gender should not influence decisions on selection of blood pressure lowering therapies, except for consideration of gender-specific side effects or contraindications for use in women who are or may become pregnant. This article reviews the prevalence, awareness, treatment, and control of hypertension in women, as well as recent guidelines for management of hypertension in women. C1 [Hage, Fadi G.; Xing, Dongqi; Oparil, Suzanne] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, LA USA. [Mansur, Sulaf J.] Princeton Baptist Med Ctr, Birmingham, AL USA. RP Hage, FG (reprint author), Univ Alabama Birmingham, Div Cardiovasc Dis, Zeigler Res Bldg 1024,703 19th St South, Birmingham, AL 35294 USA. EM fadihage@uab.edu OI Hage, Fadi/0000-0002-1397-4942 FU American Heart Association; US Department Veterans Affairs Merit Award; Duke University (AstraZeneca AB); Daiichi Sankyo; Medtronic; Merck Co.; National Institutes of Health/National Heart, Lung, and Blood Institute (NHLBI); Novartis AG; Takeda Global Research Development; UAB Comprehensive Cardiovascular Center; Vivus; Turkish Society of Hypertension and Renal Diseases FX FGH has received grant support from the American Heart Association and a US Department Veterans Affairs Merit Award. SO has received research support from Duke University (Sponsor: AstraZeneca AB), Daiichi Sankyo, Medtronic, Merck & Co., National Institutes of Health/National Heart, Lung, and Blood Institute (NHLBI), Novartis AG, Takeda Global Research & Development, UAB Comprehensive Cardiovascular Center, and Vivus, and has served as PI or Co-PI for clinical trials with Duke University, Merck & Co., Novartis, and Takeda Global Research & Development. SO received honoraria in her capacity as Faculty Presenter for the American Society of Hypertension sponsored by Daiichi Sankyo, and served as advisor for Bayer, Daiichi Sankyo, Novartis, Pfizer, and Takeda. Publication costs for this article were supported by the Turkish Society of Hypertension and Renal Diseases, a nonprofit national organization in Turkey. NR 25 TC 5 Z9 5 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2157-1724 EI 2157-1716 J9 KIDNEY INT SUPPL JI Kidney Int. Suppl. PD DEC PY 2013 VL 3 IS 4 BP 352 EP 356 DI 10.1038/kisup.2013.76 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 264NI UT WOS:000327884500014 PM 25028640 ER PT J AU Bergman, J Neuhausen, K Chamie, K Scales, CD Carter, S Kwan, L Lerman, SE Aronson, W Litwin, MS AF Bergman, Jonathan Neuhausen, Katherine Chamie, Karim Scales, Charles D. Carter, Stacey Kwan, Lorna Lerman, Steven E. Aronson, William Litwin, Mark S. TI Building a Medical Neighborhood in the Safety Net: An Innovative Technology Improves Hematuria Workups SO UROLOGY LA English DT Article ID COMMUNITY-HEALTH CENTERS; INVASIVE BLADDER-CANCER; RADICAL CYSTECTOMY; CARE; MORTALITY; PROVIDERS; NATION; ACCESS AB OBJECTIVE To analyze whether ereferral is associated with decreased time to completion of hematuria workup. METHODS We included 100 individuals referred to Olive View-UCLA Medical Center for urologic consultation for hematuria. Half were referred before implementation of ereferral, and half were referred after the system was implemented. We performed bivariate analysis to assess correlations of baseline subject sociodemographic and clinical characteristics with ereferral status. We also created a multivariate linear regression model for log days to completion of hematuria workup, with ereferral as the main predictor and subject sociodemographic and clinical characteristics as covariates. RESULTS Excluding cases with an infectious cause, the mean number of days from urinalysis documenting hematuria to completed hematuria workup was 404 days before ereferral and 192 days after implementation of ereferral (median 239 vs 170; 2-sample median P=.0013). Upper tract imaging was obtained at a median of 76 days after initial positive urinalysis in the absence of infection, 122 days before ereferral, and 41 days after implementation of ereferral (2-sample median P=.1114). In all cases, lower tract evaluation was completed after upper tract imaging. Our multivariable model evaluating factors associated with time to hematuria workup demonstrated that ereferral use was independently associated with shorter time to hematuria workup (P=.006). CONCLUSION Electronic consultations can significantly shorten the time to work-up of hematuria in the safety net. (C) 2013 Elsevier Inc. C1 [Bergman, Jonathan] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Robert Wood Johnson Clin Scholars Program, Los Angeles, CA 90095 USA. RP Bergman, J (reprint author), Univ Calif Los Angeles, Dept Urol, Box 951738, Los Angeles, CA 90095 USA. EM jbergman@mednet.ucla.edu NR 23 TC 7 Z9 7 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0090-4295 EI 1527-9995 J9 UROLOGY JI Urology PD DEC PY 2013 VL 82 IS 6 BP 1277 EP 1282 DI 10.1016/j.urology.2013.08.015 PG 6 WC Urology & Nephrology SC Urology & Nephrology GA 259QB UT WOS:000327540300028 PM 24103564 ER PT J AU Zissen, MH Wang, ZJ Yee, J Aslam, R Monto, A Yeh, BM AF Zissen, Maurice H. Wang, Zhen Jane Yee, Judy Aslam, Rizwan Monto, Alexander Yeh, Benjamin M. TI Contrast-Enhanced CT Quantification of the Hepatic Fractional Extracellular Space: Correlation With Diffuse Liver Disease Severity SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE cirrhosis; CT; delayed enhancement; liver ID DELAYED ENHANCEMENT; HEPATOCELLULAR-CARCINOMA; HELICAL CT; FIBROSIS; CIRRHOSIS; BIOPSY; CHOLANGIOCARCINOMA; PROTOCOL; MASSES; APPEARANCE AB OBJECTIVE. The purpose of this study was to determine whether contrast-enhanced CT quantification of the hepatic fractional extracellular space (ECS) correlates with the severity of diffuse liver disease. MATERIALS AND METHODS. The cases of 70 patients without (46 men, 24 women; mean age, 59.1 years) and 36 patients with (23 men, 13 women; mean age, 63.1 years) cirrhosis who had undergone unenhanced and 10-minute delayed phase contrast-enhanced CT were retrospectively identified. By consensus one experienced radiologist and one trainee measured the CT attenuation of the liver and aorta to estimate the fractional ECS, defined as the ratio of the difference between the attenuation of the liver on 10-minute and unenhanced images to the difference between the attenuation of the aorta on 10-minute and unenhanced images multiplied by 1 minus the hematocrit. Findings were correlated with each patient's Model of End-Stage Liver Disease (MELD) score. RESULTS. The mean MELD score was higher in patients with than in those without cirrhosis (14.3 +/- 7.3 versus 7.20 +/- 2.4, p < 0.0001). The mean fractional ECS was significantly greater in patients with cirrhosis than in those without cirrhosis (41.0% +/- 9.0% versus 23.8% +/- 6.3%, p < 0.0001). The fractional ECS correlated with the MELD score (r = 0.572, p < 0.0001) and was predictive of cirrhosis with an area under the receiver operating characteristic curve of 0.953 (p < 0.0001). The sensitivity and specificity of an expanded fractional ECS greater than 30% for the prediction of cirrhosis were 92% and 83%. Multivariate linear regression revealed that the fractional ECS is complementary to the MELD score as a predictor of cirrhosis (p < 0.0001). CONCLUSION. Noninvasive contrast-enhanced CT quantification of the fractional ECS correlates with the MELD score, an indicator of the severity of liver disease, and merits further study. C1 [Zissen, Maurice H.; Wang, Zhen Jane; Yee, Judy; Aslam, Rizwan; Yeh, Benjamin M.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Monto, Alexander] San Francisco VA Med Ctr, Div Gastroenterol, Dept Internal Med, San Francisco, CA USA. RP Yeh, BM (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave,Box 0628,M-372, San Francisco, CA 94143 USA. EM ben.yeh@ucsf.edu FU GE Healthcare FX Supported by a grant from GE Healthcare. NR 34 TC 10 Z9 13 U1 0 U2 1 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD DEC PY 2013 VL 201 IS 6 BP 1204 EP 1210 DI 10.2214/AJR.12.10039 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 259BD UT WOS:000327501500028 PM 24261358 ER PT J AU Moshiri, M Mannelli, L Richardson, ML Bhargava, P Dubinsky, TJ AF Moshiri, Mariam Mannelli, Lorenzo Richardson, Michael L. Bhargava, Puneet Dubinsky, Theodore J. TI Fetal Lung Maturity Assessment With MRI Fetal Lung-to-Liver Signal-Intensity Ratio SO AMERICAN JOURNAL OF ROENTGENOLOGY LA English DT Article DE fetal lung; lung maturity; MRI ID CONGENITAL DIAPHRAGMATIC-HERNIA; PULMONARY HYPOPLASIA; IN-UTERO; VOLUME AB OBJECTIVE. The purpose of this study was to retrospectively determine whether the ratio of fetal lung-to-liver signal intensities at single-shot fast spin-echo MRI is associated with fetal gestational age. MATERIALS AND METHODS. All fetal MRI examinations over a 4-year period were reviewed. All MRI examinations were performed with a 1.5-T magnet for indications other than lung maturity. Only examinations performed with a single-shot fast spin-echo sequence of the fetal chest and abdomen were included in the study. Images from a total of 82 fetal MRI examinations were evaluated. Gestational age ranged from 20 weeks to 39 weeks 3 days. Two board-certified subspecialty-trained radiologists with 11 and 17 years of experience blinded to estimated gestational age (EGA) reviewed the images independently. The regions of interest (ROIs) of the fetal lung and liver were drawn in the same plane and on the same image in each case. Fetal EGA was determined either by first-trimester ultrasound when available or by last menstrual period. Linear regression analysis was used to analyze the relation between the lung-to-liver signal-intensity ratio (LLSIR) in the ROIs and fetal EGA for both readers. The association between the LLSIRs estimated by the two readers was assessed by Bland-Altman plot. RESULTS. Summary statistics for LLSIR showed a median value of 2.29 for reader 1 and 2.21 for reader 2. The mean value for reader 1 was 2.4 and for reader 2 was 2.5. The Pearson correlation coefficients between the LLSIR and EGA variables were 0.44 for reader 1 and 0.45 for reader 2. Linear regression analysis showed a statistically significant association between LLSIR and EGA for both readers (p < 0.0004). This ratio increased in a linear manner as EGA progressed. CONCLUSION. Fetal LLSIR at single-shot fast spin-echo MRI is associated with fetal gestational age. C1 [Moshiri, Mariam; Mannelli, Lorenzo; Richardson, Michael L.; Bhargava, Puneet; Dubinsky, Theodore J.] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA USA. RP Moshiri, M (reprint author), Univ Washington, Med Ctr, Dept Radiol, 1959 NE Pacific St,Box 357115, Seattle, WA 98195 USA. EM Moshiri@uw.edu OI Bhargava, Puneet/0000-0002-3849-9666; Mannelli, Lorenzo/0000-0002-9102-4176 NR 29 TC 3 Z9 3 U1 0 U2 3 PU AMER ROENTGEN RAY SOC PI RESTON PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA SN 0361-803X EI 1546-3141 J9 AM J ROENTGENOL JI Am. J. Roentgenol. PD DEC PY 2013 VL 201 IS 6 BP 1386 EP 1390 DI 10.2214/AJR.12.9679 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 259BD UT WOS:000327501500053 PM 24261381 ER PT J AU Sittig, DF Singh, H Longhurst, CA AF Sittig, Dean F. Singh, Hardeep Longhurst, Christopher A. TI Rights and responsibilities of electronic health records (EHR) users caring for children SO ARCHIVOS ARGENTINOS DE PEDIATRIA LA English DT Editorial Material ID SPECIAL REQUIREMENTS; SAFETY; CARE C1 [Sittig, Dean F.] Univ Texas Sch Biomed Informat, Houston, TX USA. [Sittig, Dean F.] UT Mem Hermann Ctr Healthcare Qual & Safety, Houston, TX USA. [Singh, Hardeep] Baylor Coll Med, Houston VA Hlth Sci Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Longhurst, Christopher A.] Stanford Univ, Dept Pediat, Sch Med, Div Syst Med, Stanford, CA 94305 USA. RP Sittig, DF (reprint author), Univ Texas Sch Biomed Informat, Houston, TX USA. NR 13 TC 2 Z9 3 U1 0 U2 0 PU SOC ARGENTINA PEDIATRIA PI CAP FED BUENO AIRES PA AV COLONEL DIAZ 1971-75-C1425DQF, CAP FED BUENO AIRES, 00000, ARGENTINA SN 0325-0075 EI 1668-3501 J9 ARCH ARGENT PEDIATR JI Arch. Argent. Pediatr. PD DEC PY 2013 VL 111 IS 6 BP 469 EP 471 DI 10.5546/aap.2013.469 PG 3 WC Pediatrics SC Pediatrics GA 258PL UT WOS:000327471100009 ER PT J AU Norman, RS Jaramillo, CA Amuan, M Wells, MA Eapen, BC Pugh, MJ AF Norman, Rocio S. Jaramillo, Carlos A. Amuan, Megan Wells, Margaret Ann Eapen, Blessen C. Pugh, Mary Jo TI Traumatic brain injury in veterans of the wars in Iraq and Afghanistan: Communication disorders stratified by severity of brain injury SO BRAIN INJURY LA English DT Article DE aphasia; epidemiology; fluency disorder; TBI severity; Veterans Health Administration; voice disorder ID POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; VOICE DISORDERS; MILD; LANGUAGE; SYMPTOMS; REHABILITATION; IMPAIRMENT; MANAGEMENT; ABILITIES AB Objective: To describe the prevalence of communication disorders in veterans of the wars in Iraq and Afghanistan with traumatic brain injury (TBI). Design: Retrospective study of the prevalence of aphasia, fluency and voice disorders among veterans with different severity levels of TBI. Data was obtained from the VA National repository for OEF/OIF/OND veterans who received VA care in Fiscal Years 2010 and 2011. Results: Among the 303 716 veterans in this study, 1848 were diagnosed with a communication disorder; 40% of these were also diagnosed with a TBI. Voice disorders were the most prevalent diagnosis (3.5 per 1000) followed by aphasia (1.9 per 1000) and fluency disorder (0.7 per 1000). Individuals with a TBI diagnosis were more likely to have a diagnosis of aphasia, followed by fluency and then voice disorder. The odds ratio (OR) of aphasia with TBI was 11.09-252.75 (95% CI = 8.78-441.52, p < 0.01). OR for fluency disorders with TBI was 3.58-10.41 (95% CI = 2.56-42.40, p < 0.01) and association of voice disorders with TBI was significant for all levels of TBI severity (OR = 1.5-6.61, 95% CI = 1.24-14.05, p < 0.01). Conclusions: Veterans who sustained a TBI were more likely to have a diagnosis of a communication disorder, regardless of TBI severity. Those with TBI, including mild TBI, should be screened and evaluated for communication disorders. C1 [Norman, Rocio S.; Jaramillo, Carlos A.] South Texas Vet Hlth Care Syst, Polytrauma Rehabil Ctr, San Antonio, TX USA. [Amuan, Megan] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA. [Wells, Margaret Ann] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Eapen, Blessen C.] South Texas Vet Hlth Care Syst, Polytrauma Transit Rehabil Program, San Antonio, TX USA. [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Norman, RS (reprint author), Univ Wisconsin, Dept Commun Sci & Disorders, 1975 Willow Dr, Madison, WI 53706 USA. EM rnorman2@wisc.edu OI Pugh, Mary Jo/0000-0003-4196-7763 FU South Texas Veterans Healthcare System/Audie L. Murphy Division; Edith Nourse Rogers VA Memorial Hospital FX The authors acknowledge and appreciate support from the South Texas Veterans Healthcare System/Audie L. Murphy Division and the Edith Nourse Rogers VA Memorial Hospital. We also acknowledge assistance with manuscript preparation by Barbara Elizondo and Kathleen Franklin as well as valuable input by Dr Juan Cabrera at the initial stages of the manuscript process. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 50 TC 6 Z9 6 U1 0 U2 9 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PD DEC PY 2013 VL 27 IS 13-14 BP 1623 EP 1630 DI 10.3109/02699052.2013.834380 PG 8 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA 259BW UT WOS:000327503400018 PM 24131337 ER PT J AU Shahedi, K Fuller, G Bolus, R Cohen, E Vu, M Shah, R Agarwal, N Kaneshiro, M Atia, M Sheen, V Kurzbard, N van Oijen, MGH Yen, L Hodgkins, P Erder, MH Spiegel, B AF Shahedi, Kamyar Fuller, Garth Bolus, Roger Cohen, Erica Vu, Michelle Shah, Rena Agarwal, Nikhil Kaneshiro, Marc Atia, Mary Sheen, Victoria Kurzbard, Nicole van Oijen, Martijn G. H. Yen, Linnette Hodgkins, Paul Erder, M. Haim Spiegel, Brennan TI Long-term Risk of Acute Diverticulitis Among Patients With Incidental Diverticulosis Found During Colonoscopy SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Colon; Pouch; Prognosis; Diverticular Disease ID UNITED-STATES; SIGMOID DIVERTICULITIS; PRACTICE PARAMETERS; NATURAL-HISTORY; YOUNG-PATIENTS; DISEASE; COLON; EPIDEMIOLOGY; POPULATION; MANAGEMENT AB BACKGROUND & AIMS: Colonic diverticulosis is the most common finding during routine colonoscopy, and patients often question the significance of these lesions. Guidelines state that these patients have a 10% to 25% lifetime risk of developing acute diverticulitis. However, this value was determined based on limited data, collected before population-based colonoscopy, so the true number of cases of diverticulosis was not known. We measured the long-term risk of acute diverticulitis among patients with confirmed diverticulosis discovered incidentally on colonoscopy. METHODS: We performed a retrospective study using administrative and clinical data from the Veterans Affairs Greater Los Angeles Healthcare System, collecting data on patients who underwent colonoscopies from January 1996 through January 2011. We identified patients diagnosed with diverticulosis, determined incidence rates per 1000 patient-years, and analyzed a subgroup of patients with rigorously defined events confirmed by imaging or surgery. We used a Cox proportional hazards model to identify factors associated with the development of diverticulitis. RESULTS: We identified 2222 patients with baseline diverticulosis. Over an 11-year follow-up period, 95 patients developed diverticulitis (4.3%; 6 per 1000 patient-years); of these, 23 met the rigorous definition of diverticulitis (1%; 1.5 per 1000 patient-years). The median time-to-event was 7.1 years. Each additional decade of age at time of diagnosis reduced the risk for diverticulitis by 24% (hazard ratio, 0.76; 95% confidence interval, 0.6-0.9). CONCLUSIONS: Based on a study of the Veterans Affairs Greater Los Angeles Healthcare System, only about 4% of patients with diverticulosis develop acute diverticulitis, contradicting the common belief that diverticulosis has a high rate of progression. We also found that younger patients have a higher risk of diverticulitis, with risk increasing per year of life. These results can help inform patients with diverticulosis about their risk of developing acute diverticulitis. C1 [Shahedi, Kamyar; Fuller, Garth; Bolus, Roger; Cohen, Erica; Vu, Michelle; Agarwal, Nikhil; van Oijen, Martijn G. H.; Spiegel, Brennan] Univ Calif Los Angeles, Vet Affairs Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Bolus, Roger; Shah, Rena; Agarwal, Nikhil; Kaneshiro, Marc; Kurzbard, Nicole; van Oijen, Martijn G. H.; Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Agarwal, Nikhil; Kaneshiro, Marc; Atia, Mary; Sheen, Victoria; Spiegel, Brennan] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Yen, Linnette; Hodgkins, Paul; Erder, M. Haim] Shire Dev LLC, Wayne, PA USA. [Spiegel, Brennan] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Spiegel, B (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU Shire Development, LLC FX This study was supported by a research grant from Shire Development, LLC. NR 37 TC 60 Z9 62 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2013 VL 11 IS 12 BP 1609 EP 1613 DI 10.1016/j.cgh.2013.06.020 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 258US UT WOS:000327484800019 PM 23856358 ER PT J AU Cohen, E Fuller, G Bolus, R Modi, R Vu, M Shahedi, K Shah, R Atia, M Kurzbard, N Sheen, V Agarwal, N Kaneshiro, M Yen, L Hodgkins, P Erder, MH Spiegel, B AF Cohen, Erica Fuller, Garth Bolus, Roger Modi, Rusha Vu, Michelle Shahedi, Kamyar Shah, Rena Atia, Mary Kurzbard, Nicole Sheen, Victoria Agarwal, Nikhil Kaneshiro, Marc Yen, Linnette Hodgkins, Paul Erder, M. Haim Spiegel, Brennan TI Increased Risk for Irritable Bowel Syndrome After Acute Diverticulitis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Outcome; Colon; Inflammatory Disorder; Functional Gastrointestinal Disease ID INTESTINAL BACTERIAL OVERGROWTH; DISEASE; COLON; DISORDERS; PATTERNS; INFLAMMATION; COMORBIDITY; MANAGEMENT; PERCEPTION; RIFAXIMIN AB BACKGROUND & AIMS: Individuals with diverticulosis frequently also have irritable bowel syndrome (IBS), but there are no longitudinal data to associate acute diverticulitis with subsequent IBS, functional bowel disorders, or related emotional distress. In patients with postinfectious IBS, gastrointestinal disorders cause long-term symptoms, so we investigated whether diverticulitis might lead to IBS. We compared the incidence of IBS and functional bowel and related affective disorders among patients with diverticulitis. METHODS: We performed a retrospective study of patients followed up for an average of 6.3 years at a Veteran's Administration medical center. Patients with diverticulitis were identified based on International Classification of Diseases, 9th revision codes, selected for the analysis based on chart review (cases, n = 1102), and matched with patients without diverticulosis (controls, n = 1102). We excluded patients with prior IBS, functional bowel, or mood disorders. We then identified patients who were diagnosed with IBS or functional bowel disorders after the diverticulitis attack, and controls who developed these disorders during the study period. We also collected information on mood disorders, analyzed survival times, and calculated adjusted hazard ratios. RESULTS: Cases were 4.7-fold more likely to be diagnosed later with IBS (95% confidence interval [CI], 1.6-14.0; P = .006), 2.4-fold more likely to be diagnosed later with a functional bowel disorder (95% CI, 1.6 -3.6; P < .001), and 2.2-fold more likely to develop a mood disorder (CI, 1.4-3.5; P < .001) than controls. CONCLUSIONS: Patients with diverticulitis could be at risk for later development of IBS and functional bowel disorders. We propose calling this disorder postdiverticulitis IBS. Diverticulitis appears to predispose patients to long-term gastrointestinal and emotional symptoms after resolution of inflammation; in this way, postdiverticulitis IBS is similar to postinfectious IBS. C1 [Cohen, Erica; Modi, Rusha; Vu, Michelle; Atia, Mary; Agarwal, Nikhil; Kaneshiro, Marc; Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Dept Gastroenterol, Los Angeles, CA USA. [Fuller, Garth; Bolus, Roger; Modi, Rusha; Shahedi, Kamyar; Agarwal, Nikhil; Spiegel, Brennan] UCLA VA Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Bolus, Roger; Shah, Rena; Kurzbard, Nicole; Sheen, Victoria; Agarwal, Nikhil; Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Spiegel, Brennan] UCLA Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA USA. [Yen, Linnette; Hodgkins, Paul; Erder, M. Haim] Shire Pharmaceut, Wayne, PA USA. RP Spiegel, B (reprint author), West Los Angeles VA Med Ctr, Dept Gastroenterol, 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU Shire Pharmaceuticals FX This study was supported by a research grant from Shire Pharmaceuticals. The principal investigators maintained all source data, SAS codes, and analytical files on site at the VA Medical Center. NR 34 TC 35 Z9 36 U1 0 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2013 VL 11 IS 12 BP 1614 EP 1619 DI 10.1016/j.cgh.2013.03.007 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 258US UT WOS:000327484800020 PM 23524129 ER PT J AU Peery, AF Sandler, RS Ahnen, DJ Galanko, JA Holm, AN Shaukat, A Mott, LA Barry, EL Fried, DA Baron, JA AF Peery, Anne F. Sandler, Robert S. Ahnen, Dennis J. Galanko, Joseph A. Holm, Adrian N. Shaukat, Aasma Mott, Leila A. Barry, Elizabeth L. Fried, David A. Baron, John A. TI Constipation and a Low-Fiber Diet Are Not Associated With Diverticulosis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Diverticular Disease; Risk Factors; Database Analysis ID PHYSICAL-ACTIVITY; GASTROINTESTINAL-DISEASE; COLONIC DIVERTICULOSIS; SIGMOID COLON; RISK; MEN; INCREASES; MOTILITY; PRESSURE; SMOKING AB BACKGROUND & AIMS: Asymptomatic diverticulosis is commonly attributed to constipation caused by a low-fiber diet, although evidence for this mechanism is limited. We examined the associations between constipation and low dietary fiber intake with risk of asymptomatic diverticulosis. METHODS: We performed a cross-sectional study that analyzed data from 539 individuals with diverticulosis and 1569 without (controls). Participants underwent colonoscopy and assessment of diet, physical activity, and bowel habits. Our analysis was limited to participants with no knowledge of their diverticular disease to reduce the risk of biased responses. RESULTS: Constipation was not associated with an increased risk of diverticulosis. Participants with less frequent bowel movements (<7/wk) had reduced odds of diverticulosis compared with those with regular bowel movements (7/wk) (odds ratio [OR], 0.56; 95% confidence interval [CI], 0.40-0.80). Those reporting hard stools also had reduced odds (OR, 0.75; 95% CI, 0.55-1.02). There was no association between diverticulosis and straining (OR, 0.85; 95% CI, 0.59-1.22) or incomplete bowel movement (OR, 0.85; 95% CI, 0.61-1.20). We found no association between dietary fiber intake and diverticulosis (OR, 0.96; 95% CI, 0.71-1.30) in comparing the highest quartile with the lowest (mean intake, 25 vs 8 g/day). CONCLUSIONS: In our cross-sectional, colonoscopy-based study, neither constipation nor a low-fiber diet was associated with an increased risk of diverticulosis. C1 [Peery, Anne F.; Sandler, Robert S.; Galanko, Joseph A.; Baron, John A.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA. [Ahnen, Dennis J.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Ahnen, Dennis J.] Univ Colorado Anschutz Med Campus, Denver, CO USA. [Holm, Adrian N.] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. [Shaukat, Aasma] Minneapolis Veteran Affairs Med Ctr, Minneapolis, MN USA. [Mott, Leila A.; Barry, Elizabeth L.; Fried, David A.; Baron, John A.] Geisel Sch Med Dartmouth, Hanover, NH USA. RP Peery, AF (reprint author), Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Bioinformat Bldg,CB 7080,130 Mason Farm Rd, Chapel Hill, NC 27599 USA. EM anne_peery@med.unc.edu FU National Institutes of Health [T32 DK07634, P30 DK034987, R01 DK094738, R01 CA098286] FX Supported in part by grants from the National Institutes of Health T32 DK07634, P30 DK034987, R01 DK094738, and R01 CA098286. NR 37 TC 25 Z9 26 U1 2 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2013 VL 11 IS 12 BP 1622 EP 1627 DI 10.1016/j.cgh.2013.06.033 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 258US UT WOS:000327484800022 PM 23891924 ER PT J AU Yu, L Morishima, C Ioannou, GN AF Yu, Lei Morishima, Chihiro Ioannou, George N. TI Dietary Cholesterol Intake Is Associated With Progression of Liver Disease in Patients With Chronic Hepatitis C: Analysis of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article DE Diet; Cholesterol; Hepatitis C; Cirrhosis ID TRIGLYCERIDE TRANSFER PROTEIN; INSULIN-RESISTANCE; DIABETES-MELLITUS; VIRUS-INFECTION; HCV INFECTION; UNITED-STATES; LOW-DENSITY; FIBROSIS; RISK; FAT AB BACKGROUND & AIMS: Little is known about whether dietary cholesterol affects disease progression in patients with chronic hepatitis C virus infection. METHODS: We analyzed data from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial, which included patients with advanced fibrosis and compensated cirrhosis. Cholesterol intake was determined for 608 participants on the basis of responses to food frequency questionnaires, administered at baseline and 1.8 years later. We investigated whether cholesterol intake was associated with clinical progression (death, variceal bleeding, encephalopathy, ascites, peritonitis, Child-Turcotte-Pugh score >= 7, or hepatocellular carcinoma) or histologic progression of disease (an increase in Ishak fibrosis score of 2 or more points in a second liver biopsy compared with the first). RESULTS: After adjustments for age, sex, race, presence of cirrhosis, body mass index, treatment with peginterferon, lifetime alcohol consumption, smoking, health status, and coffee and macronutrient intake, each higher quartile of cholesterol intake was associated with a 46% increase in the risk of clinical or histologic progression (adjusted hazard ratio [AHR], 1.46; 95% confidence interval [CI], 1.13-1.87; P for the trend = .004). Compared with patients in the lowest quartile of cholesterol intake (32-152 mg/day), those in the 3rd (224-310 mg/day; AHR, 2.83; 95% CI, 1.45-5.51) and 4th quartiles (>310 mg/day; AHR, 2.74; 95% CI, 1.22-6.16) had significantly increased risk of disease progression. CONCLUSIONS: On the basis of analysis of data from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis trial, higher dietary cholesterol intake is associated with higher risk of disease progression in HCV-infected patients with advanced fibrosis or compensated cirrhosis. C1 [Yu, Lei; Ioannou, George N.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. [Morishima, Chihiro] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA. [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Yu, L (reprint author), 1959 NE Pacific St,Box 356175, Seattle, WA 98195 USA. EM leiy@medicine.washington.edu FU Office of Research and Development, Veterans Affairs FX Supported by Research Enhancement Award Program (G.N.I.), Office of Research and Development, Veterans Affairs. NR 37 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD DEC PY 2013 VL 11 IS 12 BP 1661 EP U208 DI 10.1016/j.cgh.2013.05.018 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 258US UT WOS:000327484800029 PM 23707779 ER PT J AU Borrero, S Zite, N Potter, JE Trussell, J Smith, K AF Borrero, Sonya Zite, Nikki Potter, Joseph E. Trussell, James Smith, Kenneth TI Potential unintended pregnancies averted and cost savings associated with a revised Medicaid sterilization policy SO CONTRACEPTION LA English DT Article DE Tubal sterilization; Unfulfilled sterilization; Cost analysis ID POSTPARTUM TUBAL-STERILIZATION; REQUESTS; BARRIERS; TEXAS; FORM AB Objective: Medicaid sterilization policy, which includes a mandatory 30-day waiting period between consent and the sterilization procedure, poses significant logistical bathers for many women who desire publicly funded sterilization. Our goal was to estimate the number of unintended pregnancies and the associated costs resulting from unfulfilled sterilization requests due to Medicaid policy barriers. Study Design: We constructed a cost-effectiveness model from the health care payer perspective to determine the incremental cost over a 1-year time horizon of the current Medicaid sterilization policy compared to a hypothetical, revised policy in which women who desire a postpartum sterilization would face significantly reduced barriers. Probability estimates for potential outcomes in the model were based on published sources; costs of Medicaid-funded sterilizations and Medicaid-covered births were based on data from the Medicaid Statistical Information System and The Guttmacher Institute, respectively. Results: With the implementation of a revised Medicaid sterilization policy, we estimated that the number of fulfilled sterilization requests would increase by 45%, from 53.3% of all women having their sterilization requests fulfilled to 77.5%. Annually, this increase could potentially lead to over 29,000 unintended pregnancies averted and $215 million saved. Conclusion: A revised Medicaid sterilization policy could potentially honor women's reproductive decisions, reduce the number of unintended pregnancies and save a significant amount of public funds. Implication: Compared to the current federal Medicaid sterilization policy, a hypothetical, revised policy that reduces logistical barriers for women who desire publicly funded, postpartum sterilization could potentially avert over 29,000 unintended pregnancies annually and therefore lead to cost savings of $215 million each year. Published by Elsevier Inc. C1 [Borrero, Sonya; Smith, Kenneth] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Zite, Nikki] Univ Tennessee, Grad Sch Med, Dept Obstet & Gynecol, Knoxville, TN USA. [Potter, Joseph E.] Univ Texas Austin, Populat Res Ctr, Austin, TX 78712 USA. [Trussell, James] Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA. [Trussell, James] Hull York Med Sch, Kingston Upon Hull, N Humberside, England. RP Borrero, S (reprint author), Univ Pittsburgh, Ctr Res Hlth Care, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu OI Potter, Joseph/0000-0002-8960-813X FU National Center for Research Resources; National Center For Advancing Translational Sciences of the National Institutes of Health [2KL2 RR024154-06]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [R24HD047879] FX This work was supported by the National Center for Research Resources and the National Center For Advancing Translational Sciences of the National Institutes of Health through grant number 2KL2 RR024154-06. The funding agency had no role in the design and conduct of the study; in the collection, analysis and interpretation of the data; or in the preparation, review or approval of the manuscript. This work was also supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development grant for Infrastructure for Population Research at Princeton University (grant R24HD047879). NR 21 TC 9 Z9 9 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 EI 1879-0518 J9 CONTRACEPTION JI Contraception PD DEC PY 2013 VL 88 IS 6 BP 691 EP 696 DI 10.1016/j.contraception.2013.08.004 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 257VP UT WOS:000327416200004 PM 24028751 ER PT J AU Marsh, L AF Marsh, Laura TI Depression and Parkinson's Disease: Current Knowledge SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS LA English DT Review DE Depression; Parkinson's disease; Mood disorder; Psychiatric; Antidepressant; Cognitive behavioral therapy; Electroconvulsive therapy; Quality of life; Treatment; Suicide; Major depression: dysthymia; Minor depression; Subsyndromal depression; Epidemiology; Pathophysiology ID COGNITIVE-BEHAVIORAL THERAPY; TRANSCRANIAL MAGNETIC STIMULATION; RANDOMIZED CONTROLLED-TRIALS; SEROTONIN TRANSPORTER GENE; PLACEBO-CONTROLLED TRIAL; DEEP-BRAIN-STIMULATION; QUALITY-OF-LIFE; DOUBLE-BLIND; NONMOTOR SYMPTOMS; ANXIETY DISORDERS AB Depressive disturbances are common in patients with Parkinson's disease (PD) and influence many other clinical aspects of the disease. In addition to causing inherent emotional distress, depressive disorders negatively impact quality of life, motor and cognitive deficits, functional disability, and other psychiatric comorbidities in patients with PD. Knowledge of the pathophysiology of PD depression remains limited. However, clinical studies demonstrate the efficacy of medications and psychotherapies for PD depression, underscoring the importance of their timely detection and concerted management. C1 [Marsh, Laura] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA. [Marsh, Laura] Baylor Coll Med, Dept Neurol, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA. RP Marsh, L (reprint author), Baylor Coll Med, Dept Psychiat, Mental Hlth Care Line 116,2002 Holcombe Blvd, Houston, TX 77030 USA. EM laura.marsh2@va.gov FU NCATS NIH HHS [U54 TR001456]; NINDS NIH HHS [U54 NS065701] NR 103 TC 21 Z9 21 U1 4 U2 36 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1528-4042 EI 1534-6293 J9 CURR NEUROL NEUROSCI JI Curr. Neurol. Neurosci. Rep. PD DEC PY 2013 VL 13 IS 12 AR 409 DI 10.1007/s11910-013-0409-5 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 257RQ UT WOS:000327404200007 PM 24190780 ER PT J AU Brooks-Worrell, BM Iyer, D Coraza, I Hampe, CS Nalini, R Ozer, K Narla, R Palmer, JP Balasubramanyam, A AF Brooks-Worrell, Barbara M. Iyer, Dinakar Coraza, Ivonne Hampe, Christiane S. Nalini, Ramaswami Ozer, Kerem Narla, Radhika Palmer, Jerry P. Balasubramanyam, Ashok TI Islet-Specific T-Cell Responses and Proinflammatory Monocytes Define Subtypes of Autoantibody-Negative Ketosis-Prone Diabetes SO DIABETES CARE LA English DT Article ID CLASS-II ALLELES; MONONUCLEAR-CELLS; CLASSIFICATION; IDENTIFICATION; PROTEINS; MELLITUS; ASSAY AB OBJECTIVEKetosis-prone diabetes (KPD) is characterized by diabetic ketoacidosis (DKA) in patients lacking typical features of type 1 diabetes. A validated classification scheme for KPD includes two autoantibody-negative (A-) phenotypic forms: A-- (lean, early onset, lacking -cell functional reserve) and A-+ (obese, late onset, with substantial -cell functional reserve after the index episode of DKA). Recent longitudinal analysis of a large KPD cohort revealed that the A-+ phenotype includes two distinct subtypes distinguished by the index DKA episode having a defined precipitant (provoked, with progressive -cell function loss over time) or no precipitant (unprovoked, with sustained -cell functional reserve). These three A- KPD subtypes are characterized by absence of humoral islet autoimmune markers, but a role for cellular islet autoimmunity is unknown.RESEARCH DESIGN AND METHODSIslet-specific T-cell responses and the percentage of proinflammatory (CD14+CD16+) blood monocytes were measured in A-- (n = 7), provoked A-+ (n = 15), and unprovoked A-+ (n = 13) KPD patients. Genotyping was performed for type 1 diabetes-associated HLA class II alleles.RESULTSProvoked A-+ and A-- KPD patients manifested stronger islet-specific T-cell responses (P < 0.03) and higher percentages of proinflammatory CD14+CD16+ monocytes (P < 0.01) than unprovoked A-+ KPD patients. A significant relationship between type 1 diabetes HLA class II protective alleles and negative T-cell responses was observed.CONCLUSIONSProvoked A-+ KPD and A-- KPD are associated with a high frequency of cellular islet autoimmunity and proinflammatory monocyte populations. In contrast, unprovoked A-+ KPD lacks both humoral and cellular islet autoimmunity. C1 [Brooks-Worrell, Barbara M.; Hampe, Christiane S.; Narla, Radhika; Palmer, Jerry P.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Brooks-Worrell, Barbara M.; Narla, Radhika; Palmer, Jerry P.] VA Puget Sound Hlth Care Syst, Dept Med, Seattle, WA USA. [Iyer, Dinakar; Coraza, Ivonne; Nalini, Ramaswami; Ozer, Kerem; Balasubramanyam, Ashok] Baylor Coll Med, Translat Metab Unit, Diabet Res Ctr, Div Diabet Endocrinol & Metab, Houston, TX USA. [Nalini, Ramaswami; Balasubramanyam, Ashok] Ben Taub Gen Hosp, Endocrine Serv, Houston, TX 77030 USA. RP Brooks-Worrell, BM (reprint author), Univ Washington, Dept Med, Seattle, WA 98195 USA. EM bbrooks@u.washington.edu; ashokb@bcm.edu OI Hampe, Christiane/0000-0001-9111-6671 FU Diabetes Research Center at the University of Washington [P30-KD-017047]; National Institutes of Health [R21-DK-082827]; Diabetes Research Center at Baylor College of Medicine [P30-DK-079638]; [R01-DK-083471] FX This study was supported by R01-DK-083471, the Diabetes Research Center (P30-KD-017047) at the University of Washington, National Institutes of Health R21-DK-082827, and the Diabetes Research Center (P30-DK-079638) at Baylor College of Medicine. NR 22 TC 6 Z9 6 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD DEC PY 2013 VL 36 IS 12 BP 4098 EP 4103 DI 10.2337/dc12-2328 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 255AL UT WOS:000327211500063 PM 24130366 ER PT J AU Baliram, R Chow, A Huber, AK Collier, L Ali, MR Morshed, SA Latif, R Teixeira, A Merad, M Liu, L Sun, L Blair, HC Zaidi, M Davies, TF AF Baliram, R. Chow, A. Huber, A. K. Collier, L. Ali, M. R. Morshed, S. A. Latif, R. Teixeira, A. Merad, M. Liu, L. Sun, L. Blair, H. C. Zaidi, M. Davies, T. F. TI Thyroid and Bone: Macrophage-Derived TSH-beta Splice Variant Increases Murine Osteoblastogenesis SO ENDOCRINOLOGY LA English DT Article ID FOLLICLE-STIMULATING-HORMONE; 3-DIMENSIONAL STRUCTURE; THYROTROPIN; RECEPTOR; CELLS; OSTEOCLASTOGENESIS; INFLAMMATION; REGULATOR; COMPLEX; SYSTEM AB It is now firmly established that TSH may influence the physiology and patho-physiology of bone by activating osteoblasts and inhibiting osteoclast activity resulting in relative osteoprotection. Whether this influence is directly exerted by pituitary-derived TSH in vivo is less certain, because we have previously reported that the suppression of pituitary TSH does not remove such protection. Here, we have characterized the functional relevance of a novel form of the TSH-beta subunit, designated TSH-beta v, known to be produced by murine bone marrow cells. We found that fresh bone marrow-derived macrophages (Mempty sets) preferentially produced TSH-beta v and, when cocultured with CHO cells engineered to overexpress the full-length TSH receptor, were able to generate the production of intracellular cAMP; a phenomenon not seen in control CHO cells, such results confirmed the bioactivity of the TSH variant. Furthermore, cocultures of Mempty sets and osteoblasts were shown to enhance osteoblastogenesis, and this phenomenon was markedly reduced by antibody to TSH-beta, suggesting direct interaction between Mempty sets and osteoblasts as observed under the electron microscope. These data suggest a new paradigm of local modulation of bone biology by a Mempty set-derived TSH-like molecule and raise the question of the relative contribution of local vs pituitary-derived TSH in osteoprotection. C1 [Baliram, R.; Huber, A. K.; Collier, L.; Ali, M. R.; Morshed, S. A.; Latif, R.; Davies, T. F.] Mt Sinai Sch Med, Thyroid Res Unit, New York, NY 10468 USA. [Baliram, R.; Latif, R.; Sun, L.; Zaidi, M.; Davies, T. F.] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY 10468 USA. [Chow, A.; Teixeira, A.; Merad, M.; Davies, T. F.] Mt Sinai Sch Med, Dept Med, New York, NY 10468 USA. [Chow, A.; Teixeira, A.; Merad, M.; Davies, T. F.] Mt Sinai Sch Med, Inst Immunol, New York, NY 10468 USA. [Baliram, R.] James J Peters VA Med Ctr, New York, NY 10468 USA. [Liu, L.; Blair, H. C.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA. RP Baliram, R (reprint author), James J Peters VA Med Ctr, Room 2F-28,130 West Kingsbridge Rd, New York, NY 10468 USA. EM annie.baliram@mssm.edu FU National Institutes of Health [DK080459, DK069713, DK052464, DK80490, DK70526]; Veterans Administration Merit Review Program FX This work was supported in part by National Institutes of Health Grants DK080459 (to M. Z. and T. F. D.), DK069713 and DK052464 (to T. F. D.), and DK80490 and DK70526 (to M. Z.) and by the Veterans Administration Merit Review Program (T.F.D.). NR 34 TC 11 Z9 11 U1 0 U2 0 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD DEC PY 2013 VL 154 IS 12 BP 4919 EP 4926 DI 10.1210/en.2012-2234 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 259RY UT WOS:000327545200045 PM 24140716 ER PT J AU Morasco, BJ Cavanagh, R Gritzner, S Dobscha, SK AF Morasco, Benjamin J. Cavanagh, Renee Gritzner, Susan Dobscha, Steven K. TI Care management practices for chronic pain in veterans prescribed high doses of opioid medications SO FAMILY PRACTICE LA English DT Article DE Chronic pain; clinical treatment guidelines; high-dose opioids; opioids; primary care ID CHRONIC NONCANCER PAIN; CLINICAL GUIDELINES; BACK-PAIN; THERAPY; ADHERENCE; PATTERNS; OVERDOSE AB Background. There is growing interest in the primary care management of patients with chronic non-cancer pain (CNCP) who are prescribed long-term opioid therapy. Objective. The aim of this study was to examine the care management practices and medical utilization of patients prescribed high doses of opioids relative to patients prescribed traditional doses of opioids. Methods. We conducted a retrospective cohort study of veterans who had CNCP in 2008 and reviewed medical care for the prior 2 years. Patients with CNCP who were prescribed high-dose opioid therapy (>= 180 mg morphine equivalent per day for 90+ consecutive days; n = 60) were compared with patients prescribed traditional dose opioid therapy (5-179 mg morphine equivalent per day for 90+ consecutive days; n = 60). Results. Patients in the high-dose group had several aspects of documented care that differed from patients in the traditional dose group, including more medical visits, attempting an opioid taper, receiving a urine drug screen and developing a pain goal. The majority of variables that were assessed did not differ between groups, including documented assessments of functional status or co-morbid psychopathology, opioid rotation, discussion of treatment side effects, non-pharmacological treatments or collaboration with mental health or pain specialists. Conclusions. Further work is needed to identify mechanisms for optimizing care management for patients with CNCP who are prescribed high doses of opioid medications. C1 [Morasco, Benjamin J.; Dobscha, Steven K.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA. [Morasco, Benjamin J.; Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Med & Psychiat, Portland, OR 97239 USA. [Morasco, Benjamin J.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. [Cavanagh, Renee] Portland Vet Affairs Res Fdn, Portland, OR USA. [Cavanagh, Renee; Gritzner, Susan] Univ Pacific, Sch Profess Psychol, Portland, OR USA. RP Morasco, BJ (reprint author), Portland VA Med Ctr R&D99, Mental Hlth & Clin Neurosci Div, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA. EM benjamin.morasco@va.gov FU National Institute on Drug Abuse [K23DA023467]; Portland Veterans Affairs Medical Center FX Funding: National Institute on Drug Abuse (K23DA023467 to BJM); Portland Veterans Affairs Medical Center. NR 20 TC 11 Z9 11 U1 0 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0263-2136 EI 1460-2229 J9 FAM PRACT JI Fam. Pr. PD DEC PY 2013 VL 30 IS 6 BP 671 EP 678 DI 10.1093/fampra/cmt038 PG 8 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 259EW UT WOS:000327511200010 PM 23901065 ER PT J AU Zickmund, SL Yang, S Mulvey, EP Bost, JE Shinkunas, LA LaBrecque, DR AF Zickmund, Susan L. Yang, Suzanne Mulvey, Edward P. Bost, James E. Shinkunas, Laura A. LaBrecque, Douglas R. TI Predicting Cancer Mortality: Developing a New Cancer Care Variable Using Mixed Methods and the Quasi-Statistical Approach SO HEALTH SERVICES RESEARCH LA English DT Article DE Cancer; mixed methods; prognosis; quasi-statistical; view of self ID DEPRESSION; SURVIVAL; DESIGNS; IMPACT AB ObjectiveTo demonstrate the value of using a variable derived from qualitative analysis in subsequent quantitative analyses. Data Sources/Study SettingMixed methods data were combined with 10-year mortality outcomes. Participants with cancer were recruited from services at a large teaching hospital, and mortality data were from the Social Security Death Index. Study DesignAn observational concurrent or convergent mixed methods design was used to collect demographics and structured ratings along with qualitative data from 909 cancer patients at baseline. Data Collection/Extraction MethodsCoding rules for qualitative data were defined for open-ended responses from cancer participants speaking about their view of self, and a variable was numerically coded for each case. Mortality outcomes were matched to baseline data, including the view of self variable. Principal FindingsIndividuals with an improved view of self had a significantly lower mortality rate than those for whom it was worse or unchanged, even when adjusting for age, gender, and cancer stage. ConclusionsStatistical analysis of qualitative data is feasible and can identify new predictors with health services' implications associated with cancer mortality. Future studies should consider the value of testing coded qualitative variables in relation with key health care outcomes. C1 [Zickmund, Susan L.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Zickmund, Susan L.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15206 USA. [Yang, Suzanne] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Mulvey, Edward P.] Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USA. [Bost, James E.] Childrens Healthcare Atlanta, Atlanta, GA USA. [Shinkunas, Laura A.] Univ Iowa, Carver Coll Med, Program Bioeth & Humanities, Iowa City, IA USA. [LaBrecque, Douglas R.] Univ Iowa Healthcare, Dept Internal Med, Iowa City, IA USA. RP Zickmund, SL (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. EM susan.zickmund@va.gov FU Veterans Administration (VA) Health Services Research & Development (HSR&D) Merit Review Award FX This work was supported in part by a Veterans Administration (VA) Health Services Research & Development (HSR&D) Merit Review Award. Douglas LaBrecque is an Advisory Board member for HepQant LLC and has provided Continuing Medical Education presentations for the Chronic Liver Disease Foundation, Simply Speaking HBV, and Prova, Inc. These have not impacted the content of this manuscript. Dr. Susan Zickmund and Dr. Suzanne Yang are both affiliated with the VA Pittsburgh Healthcare System, which requires administrative review of manuscripts for the sole purpose of verifying correct assignment of the author's affiliation with the VA and the presence of a disclaimer stating that contents do not represent the views of the VA or the US Government. Publication is otherwise unconstrained. All remaining authors have no conflicts of interest (i.e., financial and personal relationships between themselves and others that might bias their work). NR 35 TC 3 Z9 3 U1 3 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD DEC PY 2013 VL 48 IS 6 BP 2208 EP 2223 DI 10.1111/1475-6773.12116 PN 2 PG 16 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 257NP UT WOS:000327391900005 PM 24138682 ER PT J AU Hamilton, AB Cohen, AN Glover, DL Whelan, F Chemerinski, E McNagny, KP Mullins, D Reist, C Schubert, M Young, AS AF Hamilton, Alison B. Cohen, Amy N. Glover, Dawn L. Whelan, Fiona Chemerinski, Eran McNagny, Kirk P. Mullins, Deborah Reist, Christopher Schubert, Max Young, Alexander S. TI Implementation of Evidence-Based Employment Services in Specialty Mental Health SO HEALTH SERVICES RESEARCH LA English DT Article DE Mixed methods; implementation research; schizophrenia; supported employment; health services ID SUPPORTED EMPLOYMENT; ORGANIZATIONAL READINESS; COMPETITIVE EMPLOYMENT; SCHIZOPHRENIA; QUALITY; CARE; MANAGEMENT; ILLNESS; DESIGNS AB ObjectiveStudy a quality improvement approach for implementing evidence-based employment services at specialty mental health clinics. Data Sources/Study SettingSemistructured interviews with clinicians and administrators before, during, and after implementation. Qualitative field notes, structured baseline and follow-up interviews with patients, semistructured interviews with patients after implementation, and administrative data. Study DesignSite-level controlled trial at four implementation and four control sites. Hybrid implementation-effectiveness study with mixed methods intervention evaluation design. Data Collection/Extraction MethodsSite visits, in-person and telephone interviews, patient surveys, patient self-assessment. A total of 801 patients completed baseline surveys and 53 clinicians and other clinical key stakeholders completed longitudinal qualitative interviews. Principal FindingsAt baseline, sites varied in the availability, utilization, and quality of supported employment. Each site needed quality improvement for this service, though for differing reasons, with some needing development of the service itself and others needing increased service capacity. Improvements in knowledge, attitudes, beliefs, and referral behaviors were evident in mid- and postimplementation interviews, though some barriers persisted. Half of patients expressed an interest in working at baseline. Patients at implementation sites were 2.3 times more likely to receive employment services during the study year. Those who had a service visit were more likely to be employed at follow-up than those who did not. ConclusionsStudies of implementation and effectiveness require mixed methods to both enhance implementation in real time and provide context for interpretation of complex results. In this study, a quality improvement approach resulted in superior patient-level outcomes and improved clinician knowledge, attitudes, and behaviors, in the context of substantial variation among sites. C1 [Hamilton, Alison B.; Cohen, Amy N.; Young, Alexander S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA. [Hamilton, Alison B.; Cohen, Amy N.; Glover, Dawn L.; Young, Alexander S.] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA. [Whelan, Fiona] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Biostat Core SIStat, Los Angeles, CA 90073 USA. [Chemerinski, Eran] James J Peters VA Med Ctr, Bronx, NY USA. [McNagny, Kirk P.; Reist, Christopher] Long Beach VA Healthcare Syst, Long Beach, CA USA. [Mullins, Deborah] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Schubert, Max] Cent Texas Vet Healthcare Syst, Waco, TX USA. RP Hamilton, AB (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 11301 Wilshire Blvd 210A, Los Angeles, CA 90073 USA. EM alisonh@ucla.edu FU Department of Veterans Affairs; Veterans Health Administration; Health Services Research and Development Service Quality Enhancement Research Initiative (QUERI) [MNT 03-213]; Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC); UCLA-RAND NIMH Partnered Research Center for Quality Care [P30 MH082760]; National Institute of Mental Health [R25 MH080916-01A2]; VA HSRD QUERI FX The research was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Quality Enhancement Research Initiative (QUERI; MNT 03-213), and Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC); and by the UCLA-RAND NIMH Partnered Research Center for Quality Care (P30 MH082760). At the time of manuscript preparation, Dr. Hamilton was an investigator with the Implementation Research Institute (IRI), at the George Warren Brown School of Social Work, Washington University, St. Louis, through an award from the National Institute of Mental Health (R25 MH080916-01A2) and VA HSR&D QUERI. The views expressed in this article are those of the authors and do not necessarily represent the views of affiliated institutions. NR 37 TC 4 Z9 4 U1 2 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD DEC PY 2013 VL 48 IS 6 BP 2224 EP 2244 DI 10.1111/1475-6773.12115 PN 2 PG 21 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 257NP UT WOS:000327391900006 PM 24138608 ER PT J AU Gelman, A Miller, E Schwarz, EB Akers, AY Jeong, K Borrero, S AF Gelman, Amanda Miller, Elizabeth Schwarz, Eleanor Bimla Akers, Aletha Y. Jeong, Kwonho Borrero, Sonya TI Racial Disparities in Human Papillomavirus Vaccination: Does Access Matter? SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Race/ethnicity; Human papillomavirus; National Survey of Family Growth; Disparities; Vaccination ID NATIONAL IMMUNIZATION SURVEY; YOUNG-ADULT WOMEN; CARE PROVIDER RECOMMENDATION; HEALTH INTERVIEW SURVEY; UNITED-STATES; ADOLESCENT FEMALES; HPV VACCINE; SERIES INITIATION; GIRLS; COMPLETION AB Purpose: To examine the association between race/ethnicity and human papillomavirus (HPV) vaccine initiation and to determine how access to health care influences this relationship. Methods: We used nationally representative data from the National Survey of Family Growth to assess HPV vaccine initiation in 2,168 females aged 15-24 years. A series of regression analyses were performed to determine the independent effect of race/ethnicity on HPV vaccine initiation after controlling for sociodemographic variables and health care access measures. Age-stratified regression analyses were also performed to assess whether the relationship between race/ethnicity and HPV vaccine initiation differed among females aged 15-18 and 19-24 years. Results: There were significant racial/ethnic disparities in HPV vaccination; United States (US)-born Hispanics, foreign-born Hispanics, and African-Americans were less likely to have initiated vaccination than were whites (p < .001). Adjusting for sociodemographic characteristics attenuated the disparity for both US-born and foreign-born Hispanics (adjusted odds ratio [AOR], .76; 95% confidence interval [CI], .50-1.16; and AOR, .67; 95% CI, .37-1.19) but not for African-Americans (AOR, .47, 95% CI, .33-.66). Adding health care access measures further attenuated the disparity for US-born and foreign-born Hispanics (AOR, .85, 95% CI, .54-1.34; and AOR, .84, 95% CI, .45-1.55). However, African-Americans remained less likely than whites to have initiated vaccination (AOR, .49, 95% CI, .36-.68). These racial/ethnic trends were similar for females aged 15-18 and 19-24 years. Conclusions: Lower rates of HPV vaccination among African-American females do not appear to be explained by differential access to health care. More research is necessary to elucidate factors contributing to HPV vaccination in this population. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Gelman, Amanda] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA. [Miller, Elizabeth] Univ Pittsburgh, Med Ctr, Div Adolescent Med, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA. [Schwarz, Eleanor Bimla; Borrero, Sonya] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Schwarz, Eleanor Bimla; Akers, Aletha Y.] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA. [Jeong, Kwonho] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15213 USA. [Borrero, Sonya] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. RP Borrero, S (reprint author), Univ Pittsburgh, Div Internal Med, 230 McKee Pl,Suite 600, Pittsburgh, PA 15213 USA. EM borrerosp@upmc.edu RI Miller, Elizabeth/E-7939-2012 OI Schwarz, Eleanor Bimla/0000-0002-9912-8236 FU University of Pittsburgh's Clinical and Translational Sciences Institute (National Institutes of Health) [UL1 RR024153, UL1TR000005] FX The project described was supported by the University of Pittsburgh's Clinical and Translational Sciences Institute (National Institutes of Health through Grants UL1 RR024153 and UL1TR000005). An abstract of this work was submitted to the 2013 Society of General Internal Medicine Meeting. NR 35 TC 14 Z9 14 U1 1 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD DEC PY 2013 VL 53 IS 6 BP 756 EP 762 DI 10.1016/j.jadohealth.2013.07.002 PG 7 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 258TJ UT WOS:000327481300014 PM 23992645 ER PT J AU Baca, CB Vickrey, BG Vassar, SD Cook, A Berg, AT AF Baca, Christine B. Vickrey, Barbara G. Vassar, Stefanie D. Cook, Aaron Berg, Anne T. TI Injuries in Adolescents with Childhood-Onset Epilepsy Compared with Sibling Controls SO JOURNAL OF PEDIATRICS LA English DT Article ID SEIZURE-RELATED INJURIES; EUROPEAN COHORT; CHILDREN; RISK; ACCIDENTS; PEOPLE; CIRCUMSTANCES AB Objective To compare the occurrence of injuries in adolescents with childhood-onset epilepsy and matched sibling controls. Study design Retrospective case-control lifetime injury assessments were obtained from a community-based cohort of adolescents with childhood-onset epilepsy diagnosed 9 years earlier and their siblings. The children with epilepsy (n = 501; mean age, 15.3 years) included those with complicated (abnormal neurologic examination or IQ <80; n = 133) and uncomplicated (normal neurologic examination and IQ >= 80; n = 368) epilepsy. Children with uncomplicated epilepsy were matched to sibling controls (n = 210 pairs). The children reported whether or not they had ever (before and after epilepsy diagnosis) experienced injuries "serious enough to require medical attention" and if so, the type of treatment required. Results Almost one-half (49.1%) of the children with epilepsy experienced injury, of whom 8.9% required surgery/hospitalization and 17.1% had injury related to a seizure. Fewer children with uncomplicated epilepsy had seizure-related injuries versus those with complicated epilepsy (13.6% vs 27.4%; P <= .01). The proportion of children with epilepsy with any injury by type (not mutually exclusive) were: 25.2% with fractures (n=126); 24.4% with head injuries (n = 122); 10.2% with other injuries (n = 51); 8.4% with dental injuries (n = 42); and 8% with burns/scalds (n = 40). A similar proportion of children with uncomplicated epilepsy experienced any injury (overall and by type) compared to matched sibling controls, with the exception that more children with uncomplicated epilepsy had head injuries (30.0% vs 19.5%; P < .02). Conclusion With the exception of head injuries, we found no evidence of an increased risk of injury in a representative cohort of children with epilepsy compared with matched sibling controls. This finding may reflect the fact that the sample was not biased to more severe cases, or that safety precautions to prevent injury were widely used. C1 [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.; Cook, Aaron] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA. [Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA. [Berg, Anne T.] Ann & Robert H Lurie Childrens Hosp Chicago, Epilepsy Ctr, Chicago, IL USA. [Berg, Anne T.] Northwestern Mem Feinberg Sch Med, Dept Pediat, Chicago, IL USA. RP Baca, CB (reprint author), Univ Calif Los Angeles, Box 951769,C-247 RNRC, Los Angeles, CA 90095 USA. EM cbower@mednet.ucla.edu FU National Institutes of Health (National Institute of Neurological Disorders and Stroke [NINDS] [R37-NS31146]; NINDS [R37-NS31146] FX Funded by the National Institutes of Health (National Institute of Neurological Disorders and Stroke [NINDS] R37-NS31146 [PI: A.B.]). All authors funded by NINDS (R37-NS31146). The study sponsor did not have a role in study design, collection, analysis, interpretation of data, writing of the report, or decision to submit the manuscript. NR 30 TC 2 Z9 2 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD DEC PY 2013 VL 163 IS 6 BP 1684 EP U232 DI 10.1016/j.jpeds.2013.07.046 PG 12 WC Pediatrics SC Pediatrics GA 259RE UT WOS:000327543200034 PM 24054432 ER PT J AU Whitaker, RM Wills, LP Stallons, LJ Schnellmann, RG AF Whitaker, Ryan M. Wills, Lauren P. Stallons, L. Jay Schnellmann, Rick G. TI cGMP-Selective Phosphodiesterase Inhibitors Stimulate Mitochondrial Biogenesis and Promote Recovery from Acute Kidney Injury SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PGC-1-ALPHA MESSENGER-RNA; RECEPTOR ACTIVATION; ENERGY-METABOLISM; OXIDANT INJURY; HEART-FAILURE; BRAIN-INJURY; COACTIVATOR; DYSFUNCTION; EXERCISE AB Recent studies demonstrate that mitochondrial dysfunction is a mediator of acute kidney injury (AKI). Consequently, restoration of mitochondrial function after AKI may be key to the recovery of renal function. Mitochondrial function can be restored through the generation of new, functional mitochondria in a process called mitochondrial biogenesis (MB). Despite its potential therapeutic significance, very few pharmacological agents have been identified to induce MB. To examine the efficacy of phosphodiesterase (PDE) inhibitors (PDE3: cAMP and cGMP activity; and PDE4: cAMP activity) in stimulating MB, primary cultures of renal proximal tubular cells (RPTCs) were treated with a panel of inhibitors for 24 hours. PDE3, but not PDE4, inhibitors increased the FCCP-uncoupled oxygen consumption rate (OCR), a marker of MB. Exposure of RPTCs to the PDE3 inhibitors, cilostamide and trequinsin, for 24 hours increased peroxisome proliferator-activated receptor gamma coactivator-1 alpha, and multiple mitochondrial electron transport chain genes. Cilostamide and trequinsin also increased mRNA expression of mitochondrial genes and mitochondrial DNA copy number in mice renal cortex. Consistent with these experiments, 8-Br-cGMP increased FCCP-uncoupled OCR and mitochondrial gene expression, whereas 8-Br-cAMP had no effect. The cGMP-specific PDE5 inhibitor sildenafil also induced MB in RPTCs and in vivo in mouse renal cortex. Treatment of mice with sildenafil after folic acid-induced AKI promoted restoration of MB and renal recovery. These data provide strong evidence that specific PDE inhibitors that increase cGMP are inducers of MB in vitro and in vivo, and suggest their potential efficacy in AKI and other diseases characterized by mitochondrial dysfunction and suppressed MB. C1 [Schnellmann, Rick G.] Med Univ S Carolina, Ctr Cell Death Injury & Regenerat, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Schnellmann, RG (reprint author), Med Univ S Carolina, Ctr Cell Death Injury & Regenerat, Dept Drug Discovery & Biomed Sci, 280 Calhoun St, Charleston, SC 29425 USA. EM schnell@musc.edu FU National Institutes of Health National Institute of General Medical Sciences [R01-GM084147, P20-GM103542-02]; National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [F30-DK096964, F32-DK098053]; National Institutes of Health National Heart, Lung, and Blood Institute [T32-HL007260]; National Institutes of Health National Center for Research Resources [C06-RR015455, UL1-RR029882]; Department of Veterans Affairs Biomedical Laboratory Research and Development Program [BX000851]; South Carolina Clinical and Translational Research Institute; academic home at the Medical University of South Carolina FX This study was supported by the National Institutes of Health National Institute of General Medical Sciences [Grants R01-GM084147 (to R. G. S.) and P20-GM103542-02 (to SC COBRE in Oxidants, Redox Balance, and Stress Signaling)]; the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grants F30-DK096964 (to R. M. W.) and F32-DK098053 (to L.J.S.)]; the National Institutes of Health National Heart, Lung, and Blood Institute [Grant T32-HL007260]; the National Institutes of Health National Center for Research Resources [Grant C06-RR015455]; and the Department of Veterans Affairs Biomedical Laboratory Research and Development Program [Grant BX000851]. This publication was supported, in part, by the South Carolina Clinical and Translational Research Institute, with an academic home at the Medical University of South Carolina, and funded by the National Institutes of Health National Center for Research Resources [Grant UL1-RR029882]. NR 51 TC 25 Z9 26 U1 1 U2 5 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD DEC PY 2013 VL 347 IS 3 BP 626 EP 634 DI 10.1124/jpet.113.208017 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 258IQ UT WOS:000327453200011 PM 24042162 ER PT J AU Kelz, RR Sellers, MM Reinke, CE Medbery, RL Morris, J Ko, C AF Kelz, Rachel R. Sellers, Morgan M. Reinke, Caroline E. Medbery, Rachel L. Morris, Jon Ko, Clifford TI Quality In-Training Initiatived-A Solution to the Need for Education in Quality Improvement: Results from a Survey of Program Directors SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Article ID SURGICAL OUTCOMES; AMERICAN-COLLEGE; HOSPITALS; NSQIP AB BACKGROUND: The Next Accreditation System and the Clinical Learning Environment Review Program will emphasize practice-based learning and improvement and systems-based practice. We present the results of a survey of general surgery program directors to characterize the current state of quality improvement in graduate surgical education and introduce the Quality In-Training Initiative (QITI). STUDY DESIGN: In 2012, a 20-item survey was distributed to 118 surgical residency program directors from ACS NSQIP-affiliated hospitals. The survey content was developed in collaboration with the QITI to identify program director opinions regarding education in practice-based learning and improvement and systems-based practice, to investigate the status of quality improvement education in their respective programs, and to quantify the extent of resident participation in quality improvement. RESULTS: There was a 57% response rate. Eighty-five percent of program directors (n = 57) reported that education in quality improvement is essential to future professional work in the field of surgery. Only 28% (n = 18) of programs reported that at least 50% of their residents track and analyze their patient outcomes, compare them with norms/benchmarks/published standards, and identify opportunities to make practice improvements. CONCLUSIONS: Program directors recognize the importance of quality improvement efforts in surgical practice. Subpar participation in basic practice-based learning and improvement activities at the resident level reflects the need for support of these educational goals. The QITI will facilitate programmatic compliance with goals for quality improvement education. ((C) 2013 by the American College of Surgeons) C1 [Kelz, Rachel R.; Sellers, Morgan M.; Reinke, Caroline E.; Morris, Jon] Univ Penn, Perelman Sch Med, Dept Surg, Philadelphia, PA 19104 USA. [Kelz, Rachel R.; Reinke, Caroline E.] Univ Penn, Leonard Davis Inst Healthcare Econ, Wharton Sch, Philadelphia, PA 19104 USA. [Sellers, Morgan M.; Ko, Clifford] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. [Ko, Clifford] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Ko, Clifford] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Medbery, Rachel L.] Emory Univ, Sch Med, Atlanta, GA USA. RP Kelz, RR (reprint author), Univ Penn, Perelman Sch Med, Dept Surg, 3400 Spruce St, Philadelphia, PA 19104 USA. EM Rachel.Kelz@uphs.upenn.edu NR 15 TC 8 Z9 8 U1 3 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD DEC PY 2013 VL 217 IS 6 BP 1126 EP + DI 10.1016/j.jamcollsurg.2013.07.395 PG 12 WC Surgery SC Surgery GA 258DT UT WOS:000327440100021 PM 24246623 ER PT J AU Dedhia, RC Shwaish, K Snyderman, CH Monte, R Eibling, DE AF Dedhia, Raj C. Shwaish, Kawa Snyderman, Carl H. Monte, Robert Eibling, David E. TI Perioperative Process Errors and Delays in Otolaryngology at a Veterans Hospital: Prospective Study SO LARYNGOSCOPE LA English DT Article DE Veterans Affairs; quality improvement; patient safety; otolaryngology; surgical workflow ID OPERATING-ROOM; SAFETY CLIMATE; COMMUNICATION; OUTCOMES; BRIEFINGS; THEATER; PROGRAM; IMPROVE; FLOW; CARE AB Objectives/HypothesisTo understand the leading causes for process errors and delays in the otolaryngology operating room and recognize the impact of process errors and delays on patient safety, operating room resources and hospital costs. Study DesignProspective, observational study. MethodsA 4-week study was conducted during 1 calendar month in 2012, evaluating 23 elective otolaryngology cases. A standardized data collection tool was developed and refined based on prestudy pilot observations. Two trained observers recorded relevant times and actions from patient check-in time in the preoperative holding area to the wheels out time. ResultsThe mean case observation time was 220.0167.8 minutes, with mean duration of operation length being 107.0146.2 minutes. The perioperative period was divided into six stages: patient holding, room preparation, preintubation, postintubation, intraoperative, and postextubation. One hundred process errors were recorded (average of 4.3 per case), 34% of which were due to communication failures. Forty delays were observed, resulting in 336 minutes of standstill delay. Again, communication failures represented the most common etiology, with 17 communication failures resulting in 146 minutes of standstill delay. The preintubation stage was most affected by delay, with 1 in 6 minutes comprising standstill delay. ConclusionProcess errors and significant delays were common in cases performed at our institution; communication errors were the most common etiology. There is opportunity for preoperative team discussion and the use of technology to minimize communication-related process errors and standstill delays. Further work is currently being undertaken to study this critical issue across specialties. Level of Evidence2c. Laryngoscope, 123:3010-3015, 2013 C1 [Dedhia, Raj C.; Snyderman, Carl H.; Eibling, David E.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA. [Shwaish, Kawa; Monte, Robert] Vet Affairs Pittsburgh Healthcare Syst, Vet Engn Resources Ctr, Pittsburgh, PA USA. RP Eibling, DE (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C, Pittsburgh, PA 15240 USA. EM david.eibling@va.gov NR 23 TC 0 Z9 1 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD DEC PY 2013 VL 123 IS 12 BP 3010 EP 3015 DI 10.1002/lary.24191 PG 6 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 256LA UT WOS:000327310500038 PM 23649943 ER PT J AU Lim, CM Mehta, V Chai, R Pinheiro, CND Rath, T Snyderman, C Duvvuri, U AF Lim, Chwee Ming Mehta, Vikas Chai, Raymond Pinheiro, Carlos-Neto D. Rath, Tanya Snyderman, Carl Duvvuri, Umamaheswar TI Transoral Anatomy of the Tonsillar Fossa and Lateral Pharyngeal Wall: Anatomic Dissection With Radiographic and Clinical Correlation SO LARYNGOSCOPE LA English DT Article DE Transoral robotic surgery; tonsillar fossa; lateral pharyngeal wall; anatomic dissection ID ROBOTIC SURGERY; ASSISTED SURGERY; NECK-CANCER; RECONSTRUCTION; CARCINOMA; TORS; HEAD AB Objectives/HypothesisTo evaluate the transoral anatomy of the tonsillar fossa and lateral pharyngeal wall and to correlate these findings with radiographic measurements and transoral robotic surgery (TORS) of patients with early tonsillar tumor. Study DesignPreclinical cadaveric study and patient cohort. MethodsSix complete cadaveric dissections were performed to identify key anatomic landmarks, and these landmarks were validated in two consecutive patients with T1 human papillomavirus-positive squamous cell carcinoma of the tonsil treated by TORS. For radiographic landmark analysis, 25 patients who underwent contrast-enhanced computed tomography (CT) of the neck for a variety of endoscopic skull base procedures were selected. Measurements were taken from the lateral pharyngeal wall at C2-C3 interspace and greater horn of hyoid (C6) to the external carotid artery (ECA). ResultsThe glossopharyngeal (IX) nerve was consistently identified deep to the superior constrictor musculature and at the intersection of the posterior tonsillar pillar with the base of tongue. The styloglossus muscle forms the deep plane medial to the ECA. The mean measurements for left C2-C3 interspace to the ECA and right C2-C3 interspace to ECA were 17.6 0.8 mm and 18.4 0.8 mm, respectively. Similarly, the mean measurements for left hyoid to ECA and right hyoid to ECA were 3.4 +/- 0.8 mm and 4.3 +/- 0.6 mm, respectively. ConclusionsA systematic approach to dissect the tonsillar fossa and lateral pharyngeal wall can be performed using key anatomic landmarks. CT measurements taken at the C2-C3 interspace and greater horn of hyoid bone (C6 level) to the ECA are consistently and reliably achieved. Level of EvidenceNA. Laryngoscope, 123:3021-3025, 2013 C1 [Lim, Chwee Ming; Mehta, Vikas; Chai, Raymond; Pinheiro, Carlos-Neto D.; Snyderman, Carl; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Inst Eye & Ear, Dept Otolaryngol Head & Neck Surg,Vet Affaris Pit, Pittsburgh, PA 15213 USA. [Rath, Tanya] Univ Pittsburgh, Med Ctr, Inst Eye & Ear, Dept Radiol, Pittsburgh, PA 15213 USA. [Lim, Chwee Ming] Natl Univ Singapore, Dept Otolaryngol, Singapore 117548, Singapore. RP Duvvuri, U (reprint author), Univ Pittsburgh, Inst Eye & Ear, Vet Affairs Pittsburgh HealthCare Syst, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA. EM duvuriu@upmc.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Biomedical Laboratory Research and Development; PNC Foundation FX This material is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Biomedical Laboratory Research and Development. The contents of this work do not represent the views of the Department of Veterans Affairs or the United States government. We acknowledge support from the PNC Foundation. The authors have no other funding, financial relationships, or conflicts of interest to disclose. NR 9 TC 5 Z9 5 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD DEC PY 2013 VL 123 IS 12 BP 3021 EP 3025 DI 10.1002/lary.23927 PG 5 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 256LA UT WOS:000327310500040 PM 24105605 ER PT J AU Oyer, SL Mulligan, JK Psaltis, AJ Henriquez, OA Schlosser, RJ AF Oyer, Samuel L. Mulligan, Jennifer K. Psaltis, Alkis J. Henriquez, Oswaldo A. Schlosser, Rodney J. TI Cytokine Correlation Between Sinus Tissue and Nasal Secretions Among Chronic Rhinosinusitis and Controls SO LARYNGOSCOPE LA English DT Article DE Chronic rhinosinusitis; cytokine; nasal secretion ID COLLECTION METHOD; POLYPS; CELLS; EOSINOPHILS; EXPRESSION; PROFILES; MARKERS; DISEASE; ASTHMA AB Objectives/HypothesisCompare cytokine levels in sinus tissue to sinus secretions from controls and chronic rhinosinusitis patients. Study DesignIn vitro. MethodsPolyurethane foam sponges were placed into middle meati of patients with chronic rhinosinusitis without nasal polyps (CRSsNP), with polyps (CRSwNP), and controls. Sinus biopsies were then taken from the same location. Protein levels of tumor necrosis factor-alpha (TNF-), interferon- (IFN-), and interleukins (IL) 2, 4, 6, 8, 10, and 17A were measured via cytometric bead assay for each sample. Protein values from sinus tissue and secretions were compared with Pearson's correlation between samples as well as one-way ANOVA with posthoc t test between groups. ResultsSamples from 43 patients in total were examined. Mucus was measured from 10 controls, 11 CRSsNP and 10 CRSwNP, and sinus tissue was measured from 10 controls, 15 CRSsNP and 10 CRSwNP. IL-8 and IFN- levels were outside of the detectable range of the assay. Levels of secreted IL-2, 4, 6, 10, and 17A correlated with tissue levels (P<0.05 for all, r>0.49) while TNF- did not (P=0.71). CRSsNP had elevated mucus levels of IL-2, 4, 6, 10, and 17A compared to controls. CRSwNP had elevated mucus levels of IL-4, 6, 10, 17A, and TNF- compared to controls. ConclusionsCytokine levels in sinus secretions correlate with levels in sinus tissue and are elevated in CRS versus control based on Th1/Th2 skewing. Level of EvidenceN/A (in vitro). Laryngoscope, 123:E72-E78, 2013 C1 [Oyer, Samuel L.; Mulligan, Jennifer K.; Henriquez, Oswaldo A.; Schlosser, Rodney J.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Div Rhinol & Sinus Surg, Charleston, SC 29425 USA. [Mulligan, Jennifer K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. [Mulligan, Jennifer K.; Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Psaltis, Alkis J.] Stanford Med Ctr, Rhinol Div, Dept Otolaryngol Head & Neck Surg, Stanford, CA USA. RP Schlosser, RJ (reprint author), MSC 550,135 Rutledge Ave, Charleston, SC 29425 USA. EM schlossr@musc.edu FU Flight Attendants Medical Research Institute [113039, 092401]; Department of Veterans Affairs; Medtronic; Arthrocare; NeilMed FX Funded in part by grants to R.J.S. (grant 113039) and J.K.M. (grant 092401) from the Flight Attendants Medical Research Institute, and to R.J.S. from the Department of Veterans Affairs. R.J.S. is a consultant for BrainLAB, Olympus, and Sunovion and received previous grant support from Medtronic, Arthrocare, NeilMed, and the speaker's bureau for NeilMed. The authors have no other funding, financial relationships, or conflicts of interest to disclose. NR 32 TC 25 Z9 25 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD DEC PY 2013 VL 123 IS 12 BP E72 EP E78 DI 10.1002/lary.24305 PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 256LA UT WOS:000327310500001 PM 23852962 ER PT J AU Lu, YT Zhao, LB Shen, QL Garcia, MA Wu, DX Hou, S Song, M Xu, XC OuYang, WH OuYang, WWL Lichterman, J Luo, Z Xuan, X Huang, JT Chung, LWK Rettig, M Tseng, HR Shao, C Posadas, EM AF Lu, Yi-Tsung Zhao, Libo Shen, Qinglin Garcia, Mitch A. Wu, Dongxia Hou, Shuang Song, Min Xu, Xiaochun OuYang, Wei-Han OuYang, William W. -L. Lichterman, Jake Luo, Zheng Xuan, Xuan Huang, Jiaoti Chung, Leland W. K. Rettig, Matthew Tseng, Hsian-Rong Shao, Chen Posadas, Edwin M. TI NanoVelcro Chip for CTC enumeration in prostate cancer patients SO METHODS LA English DT Article DE Nanomaterials; Microfluidics; Circulating tumor cell; Prostate cancer; Diagnostics ID CIRCULATING TUMOR-CELLS; METASTATIC BREAST-CANCER; EFFICIENT CAPTURE; BLOOD; PROGRESSION; SURVIVAL; TECHNOLOGY; ENRICHMENT; SYSTEMS AB Circulating tumor cells (CTCs) are one of the most crucial topics in rare cell biology and have become the focus of a significant and emerging area of cancer research. While CTC enumeration is a valid biomarker in prostate cancer, the current FDA-approved CTC technology is unable to detect CTCs in a large portion of late stage prostate cancer patients. Here we introduce the NanoVelcro CTC Chip, a device composed of a patterned silicon nanowire substrate (SiNW) and an overlaid polydimethylsiloxane (PDMS) chaotic mixer. Validated by two institutions participating in the study, the NanoVelcro Chip assay exhibits very consistent efficiency in CTC-capture from patient samples. The utilized protocol can be easily replicated at different facilities. We demonstrate the clinical utility of the NanoVelcro Chip by performing serial enumerations of CTCs in prostate cancer patients after undergoing systemic therapy. Changes in CTC numbers after 4-10 weeks of therapy were compared with their clinical responses. We observed a statistically significant reduction in CTCs counts in the clinical responders. We performed long-term follow up with serial CTC collection and enumeration in one patient observing variations in counts correlating with treatment response. This study demonstrates the consistency of the NanoVelcro Chip assay over time for CTC enumeration and also shows that continuous monitoring of CTC numbers can be employed to follow responses to different treatments and monitor disease progression. Published by Elsevier Inc. C1 [Lu, Yi-Tsung; Lichterman, Jake; Chung, Leland W. K.; Shao, Chen; Posadas, Edwin M.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. [Lu, Yi-Tsung; Lichterman, Jake; Chung, Leland W. K.; Shao, Chen; Posadas, Edwin M.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA. [Lu, Yi-Tsung; Lichterman, Jake; Chung, Leland W. K.; Shao, Chen; Posadas, Edwin M.] Cedars Sinai Med Ctr, Urol Oncol Program, Los Angeles, CA 90048 USA. [Lu, Yi-Tsung; Lichterman, Jake; Chung, Leland W. K.; Shao, Chen; Posadas, Edwin M.] Cedars Sinai Med Ctr, Urooncol Res Program, Los Angeles, CA 90048 USA. [Zhao, Libo; Shen, Qinglin; Garcia, Mitch A.; Wu, Dongxia; Hou, Shuang; Song, Min; Xu, Xiaochun; OuYang, Wei-Han; OuYang, William W. -L.; Luo, Zheng; Xuan, Xuan; Tseng, Hsian-Rong] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Zhao, Libo; Shen, Qinglin; Garcia, Mitch A.; Wu, Dongxia; Hou, Shuang; Song, Min; Xu, Xiaochun; OuYang, Wei-Han; OuYang, William W. -L.; Luo, Zheng; Xuan, Xuan; Tseng, Hsian-Rong] Univ Calif Los Angeles, Crump Inst Mol Imaging, Los Angeles, CA 90095 USA. [Zhao, Libo; Shen, Qinglin; Garcia, Mitch A.; Wu, Dongxia; Hou, Shuang; Song, Min; Xu, Xiaochun; OuYang, Wei-Han; OuYang, William W. -L.; Luo, Zheng; Xuan, Xuan; Tseng, Hsian-Rong] Univ Calif Los Angeles, Calif NanoSyst Inst CNSI, Los Angeles, CA 90095 USA. [Huang, Jiaoti] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA. [Rettig, Matthew] VA Greater Los Angeles Healthcare Syst, Div Hematol Oncol, Los Angeles, CA 90073 USA. [Rettig, Matthew] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA 90095 USA. [Rettig, Matthew] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Urol, Los Angeles, CA 90095 USA. [Shao, Chen] Fourth Mil Med Univ, Xijing Hosp, Dept Urol, Xian 710032, Peoples R China. RP Chung, LWK (reprint author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA. EM HRTseng@mednet.ucla.edu; Edwin.Posadas@csmc.edu RI Zhao, Libo/G-2421-2010; Tseng, Hsian-Rong/G-2222-2010 FU Creativity Award from Prostate Cancer Foundation (PCF); UCLA Prostate Cancer SPORE Program; NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program [R21 CA151159, R33 CA157396]; DoD Idea Award [W81XWH-11-1-0422]; PCF Young Investigator Award FX The research endeavors at UCLA were supported by a Creativity Award from Prostate Cancer Foundation (PCF), UCLA Prostate Cancer SPORE Program, and research grants (R21 CA151159 and R33 CA157396) from NIH/NCI Innovative Molecular Analysis Technologies (IMAT) Program. The research endeavors at Cedars-Sinai Medical Center were supported by DoD Idea Award (W81XWH-11-1-0422) and PCF Young Investigator Award. NR 31 TC 27 Z9 29 U1 8 U2 51 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1046-2023 EI 1095-9130 J9 METHODS JI Methods PD DEC 1 PY 2013 VL 64 IS 2 BP 144 EP 152 DI 10.1016/j.ymeth.2013.06.019 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 260AM UT WOS:000327567400008 PM 23816790 ER PT J AU Matsumoto, AM AF Matsumoto, Alvin M. TI Reproductive Endocrinology Estrogens-not just female hormones SO NATURE REVIEWS ENDOCRINOLOGY LA English DT Editorial Material ID MEN; ESTRADIOL AB In a carefully conducted, outstanding example of clinical research, Finkelstein et al. clearly demonstrate the physiological underpinnings for the action of testosterone and the relative roles of its androgenic and estrogenic effects on body composition and sexual function. This study has important clinical implications for testosterone replacement therapy of male hypogonadism. C1 VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. RP Matsumoto, AM (reprint author), VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, 1660 South Columbian Way,S-182-GRECC, Seattle, WA 98108 USA. EM alvin.matsumoto@va.gov NR 7 TC 2 Z9 2 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5029 EI 1759-5037 J9 NAT REV ENDOCRINOL JI Nat. Rev. Endocrinol. PD DEC PY 2013 VL 9 IS 12 BP 693 EP 694 DI 10.1038/nrendo.2013.211 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 257DO UT WOS:000327364000001 PM 24146027 ER PT J AU Kirkizlar, E Serban, N Sisson, JA Swann, JL Barnes, CS Williams, MD AF Kirkizlar, Eser Serban, Nicoleta Sisson, Jennifer A. Swann, Julie L. Barnes, Claire S. Williams, Michael D. TI Evaluation of Telemedicine for Screening of Diabetic Retinopathy in the Veterans Health Administration SO OPHTHALMOLOGY LA English DT Article ID COST-EFFECTIVENESS ANALYSIS; DIGITAL FUNDUS PHOTOGRAPHY; COMPLICATIONS TRIAL; UTILITY VALUES; EYE DISEASE; MELLITUS; PROGRAM; CARE; OPHTHALMOSCOPY; SPECIFICITY AB Objective: To explore the cost-effectiveness of telemedicine for the screening of diabetic retinopathy (DR) and identify changes within the demographics of a patient population after telemedicine implementation. Design: A retrospective medical chart review (cohort study) was conducted. Participants: A total of 900 type 1 and type 2 diabetic patients enrolled in a medical system with a telemedicine screening program for DR. Methods: The cost-effectiveness of the DR telemedicine program was determined by using a finite-horizon, discrete time, discounted Markov decision process model populated by parameters and testing frequency obtained from patient records. The model estimated the progression of DR and determined average quality-adjusted life years (QALYs) saved and average additional cost incurred by the telemedicine screening program. Main Outcome Measures: Diabetic retinopathy, macular edema, blindness, and associated QALYs. Results: The results indicate that telemedicine screening is cost-effective for DR under most conditions. On average, it is cost-effective for patient populations of >3500, patients aged <80 years, and all racial groups. Observable trends were identified in the screening population since the implementation of telemedicine screening: the number of known DR cases has increased, the overall age of patients receiving screenings has decreased, the percentage of nonwhites receiving screenings has increased, the average number of miles traveled by a patient to receive a screening has decreased, and the teleretinal screening participation is increasing. Conclusions: The current teleretinal screening program is effective in terms of being cost-effective and increasing population reach. Future screening policies should give consideration to the age of patients receiving screenings and the system's patient pool size because our results indicate it is not cost-effective to screen patients aged older than 80 years or in populations with <3500 patients. (C) 2013 by the American Academy of Ophthalmology. C1 [Kirkizlar, Eser] Natera Inc, San Carlos, CA USA. [Serban, Nicoleta; Sisson, Jennifer A.; Swann, Julie L.] Georgia Inst Technol, Atlanta, GA 30332 USA. [Barnes, Claire S.] US Dept Vet Affairs, VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Williams, Michael D.] US Dept Vet Affairs, Atlanta VA Med Ctr, Rehabil Res & Dev Ctr Excellence, Atlanta, GA USA. RP Swann, JL (reprint author), Georgia Inst Technol, Sch ISyE, Groseclose 0205,Room 411, Atlanta, GA 30332 USA. EM jswann@isye.gatech.edu OI Swann, Julie/0000-0003-2151-4396 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and Rehabilitation Research and Development Service [C4758W]; Health Systems Institute; Georgia Institute of Technology; Zalesky Family FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, and Rehabilitation Research and Development Service, including Career Development Award C4758W. This material was supported by a seed grant from the Health Systems Institute, Georgia Institute of Technology. This material received student funding through the Georgia Institute of Technology President Undergraduate Research Award. J.L.S. was partially supported as the Harold R. and Mary Anne Nash professor, by the Zalesky Family, and by Andrea Laliberte through gifts to the Georgia Institute of Technology. NR 41 TC 21 Z9 21 U1 0 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD DEC PY 2013 VL 120 IS 12 BP 2604 EP 2610 DI 10.1016/j.ophtha.2013.06.029 PG 7 WC Ophthalmology SC Ophthalmology GA 255OL UT WOS:000327249600046 PM 24084501 ER PT J AU Hill-Burns, EM Singh, N Ganguly, P Hamza, TH Montimurro, J Kay, DM Yearout, D Sheehan, P Frodey, K Mclear, JA Feany, MB Hanes, SD Wolfgang, WJ Zabetian, CP Factor, SA Payami, H AF Hill-Burns, E. M. Singh, N. Ganguly, P. Hamza, T. H. Montimurro, J. Kay, D. M. Yearout, D. Sheehan, P. Frodey, K. Mclear, J. A. Feany, M. B. Hanes, S. D. Wolfgang, W. J. Zabetian, C. P. Factor, S. A. Payami, H. TI A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease SO PHARMACOGENOMICS JOURNAL LA English DT Article DE SV2C; nicotine; Parkinson's disease ID DOSE TRANSDERMAL NICOTINE; SYNAPTIC VESICLE PROTEIN; SMOKING; MODEL; ASSOCIATION; TRANSPORTER; CAFFEINE; THERAPY; COFFEE; RISK AB Prior studies have established an inverse association between cigarette smoking and the risk of developing Parkinson's disease (PD), and currently, the disease-modifying potential of the nicotine patch is being tested in clinical trials. To identify genes that interact with the effect of smoking/nicotine, we conducted genome-wide interaction studies in humans and in Drosophila. We identified SV2C, which encodes a synaptic-vesicle protein in PD-vulnerable substantia nigra (P = 1 x 10(-7) for gene-smoking interaction on PD risk), and CG14691, which is predicted to encode a synaptic-vesicle protein in Drosophila (P = 2 x 10(-11) for nicotine-paraquat interaction on gene expression). SV2C is biologically plausible because nicotine enhances the release of dopamine through synaptic vesicles, and PD is caused by the depletion of dopamine. Effect of smoking on PD varied by SV2C genotype from protective to neutral to harmful (P = 5 x 10(-10)). Taken together, cross-validating evidence from humans and Drosophila suggests SV2C is involved in PD pathogenesis and it might be a useful marker for pharmacogenomics studies involving nicotine. C1 [Hill-Burns, E. M.; Singh, N.; Ganguly, P.; Hamza, T. H.; Montimurro, J.; Kay, D. M.; Sheehan, P.; Frodey, K.; Mclear, J. A.; Hanes, S. D.; Payami, H.] New York State Dept Hlth, Wadsworth Ctr, Div Genet, Albany, NY 12208 USA. [Yearout, D.; Zabetian, C. P.] Univ Washington, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Yearout, D.; Zabetian, C. P.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Feany, M. B.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Feany, M. B.] Harvard Univ, Sch Med, Boston, MA USA. [Hanes, S. D.; Wolfgang, W. J.] New York State Dept Hlth, Wadsworth Ctr, Div Infect Dis, Albany, NY 12208 USA. [Hanes, S. D.; Wolfgang, W. J.; Payami, H.] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY USA. [Hanes, S. D.] SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA. [Factor, S. A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Div Genet, 150 New Scotland Ave, Albany, NY 12208 USA. EM hpayami@wadsworth.org OI Kay, Denise/0000-0002-9928-2698; Wolfgang, William/0000-0003-1769-0215; Zabetian, Cyrus/0000-0002-7739-4306 FU National Institute of Neurological Disorders and Stroke [R01NS36960, R01NS067469]; Department of Veterans Affairs [1I01BX000531]; National Institute of Aging [P30AG08017]; Office of Research & Development, Clinical Sciences Research & Development Service, Department of Veteran Affairs; Close to the Cure Foundation; National Institutes of Health [HHSN268200782096C] FX We thank the persons with Parkinson's disease and volunteers who participated in the study. We also thank Dr John Nutt for his continued support for this project and Dr Sridar Chittur (Center for Functional Genomics at State University of New York at Albany) for processing the expression arrays. The project was funded by grants from the National Institute of Neurological Disorders and Stroke (R01NS36960 and R01NS067469). Additional support was provided by a Merit Review Award from the Department of Veterans Affairs (1I01BX000531), National Institute of Aging (P30AG08017), Office of Research & Development, Clinical Sciences Research & Development Service, Department of Veteran Affairs, and the Close to the Cure Foundation. Genotyping services were provided by the Center for Inherited Disease Research, which is funded by the National Institutes of Health (HHSN268200782096C). NR 35 TC 13 Z9 14 U1 1 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1470-269X EI 1473-1150 J9 PHARMACOGENOMICS J JI Pharmacogenomics J. PD DEC PY 2013 VL 13 IS 6 BP 530 EP 537 DI 10.1038/tpj.2012.38 PG 8 WC Genetics & Heredity; Pharmacology & Pharmacy SC Genetics & Heredity; Pharmacology & Pharmacy GA 258HJ UT WOS:000327449700008 PM 23032990 ER PT J AU Li, PY Mao, LL Zhou, GQ Leak, RK Sun, BL Chen, J Hu, XM AF Li, Peiying Mao, Leilei Zhou, Guoqing Leak, Rehana K. Sun, Bao-Liang Chen, Jun Hu, Xiaoming TI Adoptive Regulatory T-Cell Therapy Preserves Systemic Immune Homeostasis After Cerebral Ischemia SO STROKE LA English DT Article DE immunosuppression; inflammation; stroke; T-lymphocytes; regulatory ID EXPERIMENTAL STROKE; INJURY; INFECTIONS; ACTIVATION; PROMOTES; SURVIVAL; MICE AB Background and Purpose Cerebral ischemia has been shown to result in peripheral inflammatory responses followed by long-lasting immunosuppression. Our recent study demonstrated that intravenous delivery of regulatory T cells (Tregs) markedly protected against transient cerebral ischemia by suppressing neutrophil-derived matrix metallopeptidase 9 production in the periphery. However, the effect of Tregs on systemic inflammatory responses and immune status has not been fully characterized. Methods Cerebral ischemia was induced by middle cerebral artery occlusion for 60 minutes in mice or 120 minutes in rats. Tregs were isolated from donor animals by CD4 and CD25 double selection and transferred intravenously to ischemic recipients at 2 hours after middle cerebral artery occlusion. Animals were euthanized on different days after reperfusion. The effects of Tregs on systemic inflammation and immune status were evaluated using flow cytometry, ELISAs, and immunohistochemistry. Results Systemic administration of purified Tregs raises functional Tregs in the blood and peripheral organs, including spleen and lymph nodes. These exogenous Tregs remain in the blood and peripheral organs for 12 days. Functionally, Treg adoptive transfer markedly inhibits middle cerebral artery occlusion-induced elevation of inflammatory cytokines (interleukin-6 and tumor necrosis factor ) in the blood. Furthermore, Treg treatment corrects long-term lymphopenia and improves cellular immune functions after ischemic brain injury. As a result, Treg-treated animals exhibit decreased bacterial loads in the blood during recovery from cerebral ischemic attack. Conclusions Treg treatment did not exacerbate poststroke immunosuppression. On the contrary, Treg-treated animals displayed improved immune status after focal cerebral ischemia. C1 [Li, Peiying; Mao, Leilei; Chen, Jun; Hu, Xiaoming] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. [Li, Peiying; Mao, Leilei; Chen, Jun; Hu, Xiaoming] Fudan Univ, Dept Anesthesiol, Huashan Hosp, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Li, Peiying; Mao, Leilei; Chen, Jun; Hu, Xiaoming] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Zhou, Guoqing; Sun, Bao-Liang] Shandong Univ, Dept Neurol, Tai An, Shandong, Peoples R China. [Zhou, Guoqing; Sun, Bao-Liang] Shandong Univ, Key Lab Cerebral Microcirculat, Tai An, Shandong, Peoples R China. [Zhou, Guoqing; Sun, Bao-Liang] Taishan Med Coll, Affiliated Hosp, Tai An, Shandong, Peoples R China. [Leak, Rehana K.] Duquesne Univ, Div Pharmaceut Sci, Mylan Sch Pharm, Pittsburgh, PA 15219 USA. [Chen, Jun; Hu, Xiaoming] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Hu, XM (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. EM chenj2@upmc.edu; hux2@upmc.edu OI Leak, Rehana/0000-0003-2817-7417 FU American Heart Association [13SDG14570025]; National Institutes of Health [NS36736, NS43802, NS45048]; Veterans Affairs Pittsburgh Health Care System (Pittsburgh, PA); Chinese Natural Science Foundation [81070947, 81271275]; Shandong Natural Science Foundation [ZR2012HZ006] FX Dr Hu is supported by a Scientist Development Grant (13SDG14570025) from the American Heart Association. Dr Chen is supported by National Institutes of Health grants NS36736, NS43802, and NS45048 and Veterans Affairs Pittsburgh Health Care System (Pittsburgh, PA). Dr Sun is supported by Chinese Natural Science Foundation grants (81070947, 81271275) and Shandong Natural Science Foundation (ZR2012HZ006). NR 18 TC 18 Z9 18 U1 0 U2 9 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 EI 1524-4628 J9 STROKE JI Stroke PD DEC PY 2013 VL 44 IS 12 BP 3509 EP 3515 DI 10.1161/STROKEAHA.113.002637 PG 7 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 257LR UT WOS:000327386300325 PM 24092548 ER PT J AU Reinke, LF Uman, J Udris, EM Moss, BR Au, DH AF Reinke, Lynn F. Uman, Jane Udris, Edmunds M. Moss, Brianna R. Au, David H. TI Preferences for Death and Dying Among Veterans With Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE patient preferences; death and dying; end-of-life communication; chronic obstructive pulmonary disease ID OF-LIFE CARE; END; COMMUNICATION; CLINICIAN; FAMILIES; QUALITY AB Rationale: Studies identify common factors important for a good death. However, it is important for clinicians to individualize end-of-life care by eliciting patients' preferences. We sought to determine preferences for death and dying among veterans with chronic obstructive pulmonary disease (COPD) by performing a cross-sectional study. Participants (n = 376) completed a preferences about death and dying questionnaire. Results: Common themes ranked as most important by veterans include health care costs (86.6%) and avoiding strain on loved ones (78.8%). Unique items include being unafraid of dying (67.1%) and having discussed your treatment preferences with your clinician (59.3%). Conclusion: Preferences for death and dying are consistent among individuals with life-limiting illness, thus should be incorporated as core components in all end-of-life care planning. We identified unique preferences important to patients with COPD. This study suggests that clinicians need to engage in end-of-life discussions to learn about individual preferences to improve the patients' dying experience. C1 [Reinke, Lynn F.; Uman, Jane; Udris, Edmunds M.; Moss, Brianna R.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv R&D Seattle, Seattle, WA 98108 USA. [Reinke, Lynn F.] Univ Washington, Sch Nursing, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Au, David H.] Univ Washington, Sch Med, Div Pulm & Crit Care, Seattle, WA 98195 USA. RP Reinke, LF (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA. EM reinkl@uw.edu FU Health Services Research and Development, Department of Veterans Affairs [11R 02-292, TPP-61-021]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX This study was funded by Health Services Research and Development, Department of Veterans Affairs 11R 02-292 and TPP-61-021. This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 20 TC 2 Z9 2 U1 0 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD DEC PY 2013 VL 30 IS 8 BP 768 EP 772 DI 10.1177/1049909112471579 PG 5 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 255NJ UT WOS:000327246400005 PM 23298873 ER PT J AU Farless, LB Steil, N Williams, BR Bailey, FA AF Farless, Laura B. Steil, Neal Williams, Beverly Rosa Bailey, F. Amos TI Intermittent Subcutaneous Furosemide: Parenteral Diuretic Rescue for Hospice Patients With Congestive Heart Failure Resistant to Oral Diuretic SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE congestive heart failure; hospice; subcutaneous therapy; home infusion; diuretic resistance; dyspnea AB Patients with congestive heart failure (CHF) account for up to 12% of the hospice population and often experience significant symptoms related to volume overload. Diuretic therapy is the cornerstone of treatment but administration (PO) often becomes ineffective and (IV, IM) routes cause discomfort or may not be feasible to ameliorate symptoms. Subcutaneous dosing of furosemide has been explored as a potential alternative for management of CHF symptoms. We report 2 cases of CHF resistant to oral diuretic and examine the clinical utility of subcutaneous furosemide in an inpatient palliative care unit and a home hospice setting. Our case series supports the use of subcutaneous therapy as a potential alternative in palliative care and hospice patients. C1 [Farless, Laura B.; Steil, Neal; Williams, Beverly Rosa; Bailey, F. Amos] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35233 USA. RP Bailey, FA (reprint author), Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham VAMC 11G,700 South 19th St, Birmingham, AL 35233 USA. EM amos.bailey@va.gov NR 5 TC 3 Z9 3 U1 1 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD DEC PY 2013 VL 30 IS 8 BP 791 EP 792 DI 10.1177/1049909112465795 PG 2 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 255NJ UT WOS:000327246400009 PM 23136114 ER PT J AU Chopra, V Safdar, N AF Chopra, Vineet Safdar, Nasia TI Development of a Core Team for the Management of Peripherally Inserted Central Catheters Reply SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Letter ID BLOOD-STREAM INFECTION; CENTRAL VENOUS CATHETERS; RISK C1 [Chopra, Vineet] Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA. [Chopra, Vineet] Ann Arbor Vet Affairs Med Ctr, Hosp Outcomes Program Excellence, Ann Arbor, MI USA. [Chopra, Vineet] Ann Arbor Vet Affairs Med Ctr, Ctr Clin Management Res, Ann Arbor, MI USA. [Chopra, Vineet] Univ Michigan, Sch Med, Ann Arbor, MI USA. [Safdar, Nasia] Univ Wisconsin, William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Sch Med, Dept Med, Div Infect Dis, Madison, WI USA. [Safdar, Nasia] Univ Wisconsin, Infect Control Dept, Madison, WI USA. RP Chopra, V (reprint author), 2800 Plymouth Rd,Bldg 16,Room 432W, Ann Arbor, MI 48109 USA. EM vineetc@umich.edu NR 9 TC 0 Z9 0 U1 1 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD DEC 1 PY 2013 VL 34 IS 12 BP 1329 EP 1330 DI 10.1086/673997 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 252AJ UT WOS:000326976300018 PM 24225624 ER PT J AU Menschikowski, M Hagelgans, A Fuessel, S Mareninova, OA Asatryan, L Wirth, MP Siegert, G AF Menschikowski, Mario Hagelgans, Albert Fuessel, Susanne Mareninova, Olga A. Asatryan, Liana Wirth, Manfred P. Siegert, Gabriele TI Serum amyloid A, phospholipase A(2)-IIA and C-reactive protein as inflammatory biomarkers for prostate diseases SO INFLAMMATION RESEARCH LA English DT Article DE Prostate cancer; Benign prostatic hyperplasia; Serum amyloid A; Secreted phospholipase A(2); C-reactive protein; Inflammation ID NF-KAPPA-B; GROUP-II PHOSPHOLIPASE-A2; LUNG-CANCER; PROGNOSTIC MARKER; GASTRIC-CANCER; TARGET GENE; EXPRESSION; CELLS; HYPERPLASIA; RECEPTOR AB Serum amyloid A (SAA), secreted group IIA phospholipase A(2) (sPLA(2)-IIA), and C-reactive protein (CRP) are acute-phase proteins whose serum concentrations increase not only during inflammatory disorders, but also in the course of malignant diseases. In this study we analyzed serum levels of these inflammatory markers along with prostate-specific antigens (PSA) in patients with benign prostatic hyperplasia (BPH, n = 55), localized prostate cancers (PCa, n = 55), and metastatic prostate cancers (mPCa, n = 27) using immunological assays. We found that in comparison to healthy individuals (n = 55), patients with BPH, PCa and mPCa have elevated serum levels of SAA, sPLA(2)-IIA, and CRP, in addition to elevated levels of PSA. Significant differences with respect to inflammatory biomarkers were found between localized and metastatic PCa (p < 0.001), suggesting a prognostic value of these parameters. In addition, serum concentrations of SAA and sPLA(2)-IIA positively correlate with CRP in BPH patients (p < 0.05) and in patients with PCa and mPCa (p < 0.001), but not with PSA levels, Gleason score, or tumor stage, emphasizing a role of SAA and sPLA(2)-IIA as circulating biomarkers of inflammation rather than of neoplastic transformation. In contrast to PSA, which differed significantly between BPH and localized PCa patients (p < 0.01), such a difference was not found for SAA, sPLA(2)-IIA, and CRP. In order to elucidate whether the elevated levels of SAA and sPLA(2)-IIA can be caused by cancer cell-associated synthesis, in vitro studies were performed. These analyses demonstrated the expression of SAA and sPLA(2)-IIA in LNCaP and PC-3 prostate cell lines, which can be further upregulated by pro-inflammatory cytokines in a cell type-dependent manner. This might suggest that, in addition to the hepatic origin, SAA and sPLA(2)-IIA can also be synthesized and secreted by prostatic cancer tissue itself. The results of the present study emphasize the utility of SAA, sPLA(2)-IIA, and CRP as circulating biomarkers of inflammation during BPH development and PCa progression. C1 [Menschikowski, Mario; Hagelgans, Albert; Siegert, Gabriele] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Chem & Lab Med, D-01307 Dresden, Germany. [Fuessel, Susanne; Wirth, Manfred P.] Tech Univ Dresden, Med Fac Carl Gustav Carus, Dept Urol, D-01307 Dresden, Germany. [Mareninova, Olga A.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Asatryan, Liana] USC Sch Pharm, Titus Family Dept Clin Pharm & Pharmaceut Econ &, Los Angeles, CA USA. RP Menschikowski, M (reprint author), Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Chem & Lab Med, Fetscherstr 74, D-01307 Dresden, Germany. EM Mario.Menschikowski@uniklinikum-dresden.de NR 53 TC 6 Z9 6 U1 0 U2 5 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1023-3830 EI 1420-908X J9 INFLAMM RES JI Inflamm. Res. PD DEC PY 2013 VL 62 IS 12 BP 1063 EP 1072 DI 10.1007/s00011-013-0665-5 PG 10 WC Cell Biology; Immunology SC Cell Biology; Immunology GA 253IE UT WOS:000327077100007 PM 24061501 ER PT J AU Sullivan, KV Turner, NN Lancaster, DP Shah, AR Chandler, LJ Friedman, DF Blecker-Shelly, DL AF Sullivan, K. V. Turner, N. N. Lancaster, D. P. Shah, A. R. Chandler, L. J. Friedman, D. F. Blecker-Shelly, D. L. TI Superior Sensitivity and Decreased Time to Detection with the Bactec Peds Plus/F System Compared to the BacT/Alert Pediatric FAN Blood Culture System SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID STAPHYLOCOCCUS-AUREUS BACTEREMIA; ENTEROCOCCAL BACTEREMIA; STREAM INFECTIONS; BIRTH-WEIGHT; VANCOMYCIN; MEDIA; RATES; RESISTANCE; MORTALITY; CHILDREN AB Here, we compare the sensitivities and times to detection (TTD) of BacT/Alert Pediatric FAN (PF) and Bactec Peds Plus blood culture bottles. Test bottles were inoculated with 2 ml of banked whole blood, 1-ml aliquots of antibiotic suspension, and organisms diluted to simulate a bacteremia level of 10 to 100 CFU/ml. The control bottles were inoculated with 3 ml of banked blood and organism suspensions only. The organism-drug combinations were Staphylococcus epidermidis and vancomycin, methicillin-resistant Staphylococcus aureus and vancomycin, Streptococcus pneumoniae, vancomycin, and ceftriaxone, Streptococcus agalactiae, ampicillin, and cefotaxime, Escherichia coli, cefotaxime, and cefepime, Pseudomonas aeruginosa, piperacillin-tazobactam, cefepime, and gentamicin, Neisseria meningitidis and ceftriaxone, and Haemophilus influenzae and ceftriaxone. The control and test bottle combinations were tested in duplicate. The bottles were incubated for 5 days; 32 control and 104 test bottles were incubated. Overall, the bacterial recovery rates for the PF and Peds Plus bottles were 37% and 62%, 94% and 100% in the controls, 19% and 50% in the test bottles, and 33% and 92% in the bottles with vancomycin, respectively. No bacteria were recovered from the bottles with S. pneumoniae, S. agalactiae, E. coli, N. meningitidis, or H. influenzae in combination with cefotaxime or ceftriaxone. The Peds Plus system detected P. aeruginosa in bottles with cefepime and piperacillin-tazobactam, but the PF system recovered bacteria only in bottles with trough levels of piperacillin-tazobactam. The mean TTD were shorter in the Peds Plus system controls (14.2 versus 18.0 h; P = 0.001) and the test bottles (14.3 versus 17.8 h; P = 0.008) than in the PF bottles. Overall, we demonstrated superior sensitivity, TTD, and antibiotic neutralization in the Bactec Peds Plus system compared to those in the Pediatric FAN system. C1 [Sullivan, K. V.; Turner, N. N.; Lancaster, D. P.; Friedman, D. F.; Blecker-Shelly, D. L.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Sullivan, K. V.; Chandler, L. J.; Friedman, D. F.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Shah, A. R.; Chandler, L. J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. RP Sullivan, KV (reprint author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. EM otak@email.chop.edu NR 24 TC 12 Z9 12 U1 1 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD DEC PY 2013 VL 51 IS 12 BP 4083 EP 4086 DI 10.1128/JCM.02205-13 PG 4 WC Microbiology SC Microbiology GA 254EL UT WOS:000327147100030 PM 24088854 ER PT J AU Seng, EK Lovejoy, TI AF Seng, Elizabeth K. Lovejoy, Travis I. CA Project SAFER Intervention Team TI Reliability and Validity of a Treatment Fidelity Assessment for Motivational Interviewing Targeting Sexual Risk Behaviors in People Living with HIV/AIDS SO JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS LA English DT Article DE Motivational interviewing; Treatment fidelity; Psychometrics; Sexual risk behaviors; HIV/AIDS ID TREATMENT INTEGRITY CODE; RANDOMIZED CLINICAL-TRIAL; INTERRATER RELIABILITY; ASSESSING COMPETENCE; HIV; PREVENTION; ADOLESCENTS; INFECTION; PROGRAM; ADULTS AB This study psychometrically evaluates the Motivational Interviewing Treatment Integrity Code (MITI) to assess fidelity to motivational interviewing to reduce sexual risk behaviors in people living with HIV/AIDS. 74 sessions from a pilot randomized controlled trial of motivational interviewing to reduce sexual risk behaviors in people living with HIV were coded with the MITI. Participants reported sexual behavior at baseline, 3-month, and 6-months. Regarding reliability, excellent inter-rater reliability was achieved for measures of behavior frequency across the 12 sessions coded by both coders; global scales demonstrated poor intraclass correlations, but adequate percent agreement. Regarding validity, principle components analyses indicated that a two-factor model accounted for an adequate amount of variance in the data. These factors were associated with decreases in sexual risk behaviors after treatment. The MITI is a reliable and valid measurement of treatment fidelity for motivational interviewing targeting sexual risk behaviors in people living with HIV/AIDS. C1 [Seng, Elizabeth K.] VA Connecticut Healthcare Syst, Psychol Serv, West Haven, CT 06516 USA. [Seng, Elizabeth K.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Lovejoy, Travis I.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Project SAFER Intervention Team] Ohio Univ, Dept Psychol, Athens, OH 45701 USA. RP Seng, EK (reprint author), VA Connecticut Healthcare Syst, Psychol Serv, 950 Campbell Ave, West Haven, CT 06516 USA. EM seng.elizabeth@gmail.com OI Seng, Elizabeth/0000-0002-8938-4949 NR 35 TC 4 Z9 4 U1 2 U2 7 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1068-9583 EI 1573-3572 J9 J CLIN PSYCHOL MED S JI J. Clin. Psychol. Med. Settings PD DEC PY 2013 VL 20 IS 4 BP 440 EP 448 DI 10.1007/s10880-012-9343-y PG 9 WC Psychology, Clinical SC Psychology GA 253DS UT WOS:000327062600004 PM 23636311 ER PT J AU Margaretten, ME Katz, P Schmajuk, G Yelin, E AF Margaretten, Mary E. Katz, Patricia Schmajuk, Gabriela Yelin, Edward TI Missed Opportunities for Depression Screening in Patients with Arthritis in the United States SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE arthritis; depression; screening ID RHEUMATOID-ARTHRITIS; PRIMARY-CARE; OLDER-ADULTS; HEALTH-CARE; PSYCHOLOGICAL DISTRESS; PREVENTIVE-SERVICES; RISK-FACTOR; TASK-FORCE; US ADULTS; OSTEOARTHRITIS AB BACKGROUND: Arthritis affects 20 % of the adult US population and is associated with comorbid depression. Depression screening guidelines have been endorsed for high-risk groups, including persons with arthritis, in the hopes that screening will increase recognition and use of appropriate interventions. To examine national rates of depression and depression screening for patients with arthritis between 2006 and 2010. We used nationally representative cross-sections of ambulatory visits in the United States from the National Ambulatory Medical Care Survey from 2006 to 2010, which included 18,507 visits with a diagnosis of arthritis. When weighted to the US population, this total represents approximately 644 million visits. Visits where arthritis was listed among diagnoses. Outcomes were survey-weighted estimates of depression and prevalence of depression screening among patients with arthritis across patient and physician characteristics. Of the 644,419,374 visits with arthritis listed, 83,574,127 (13 %) were associated with a comorbid diagnosis of depression. The odds ratio for comorbid depression with arthritis was 1.42 (95 % CI 1.3, 1.5). Depression screening occurred at 3,835,000 (1 %) visits associated with arthritis. When examining the rates of depression screening between ambulatory visits with and without arthritis listed, there was no difference in depression screening rates; both were approximately 1 %. There was no difference in screening rates by provider type. Compared to visits with other common, chronic conditions, the prevalence of depression at arthritis visits was high (13 per 100 visits), although the prevalence of depression screening at arthritis visits was low (0.68 per 100 visits). Despite the high prevalence of depression with arthritis, screening for depression was performed at few arthritis visits, representing missed opportunities to detect a common, serious comorbidity. Improved depression screening by providers would identify affected patients, and may lead to appropriate interventions such as mental health referrals and/or treatment with anti-depressants. C1 [Margaretten, Mary E.; Katz, Patricia; Schmajuk, Gabriela; Yelin, Edward] Univ Calif San Francisco, Div Rheumatol, Dept Med, San Francisco, CA 94118 USA. [Schmajuk, Gabriela] San Francisco VA Med Ctr, Div Rheumatol, Dept Med, San Francisco, CA USA. [Margaretten, Mary E.] Arthrit Res Grp UCSF, San Francisco, CA USA. RP Margaretten, ME (reprint author), Univ Calif San Francisco, Div Rheumatol, Calif St,Suite 270, San Francisco, CA 94118 USA. EM Mary.margaretten@ucsf.edu FU National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI [KL2TR000143]; Rosalind Russell Medical Research Center for Arthritis Research FX Dr. Margaretten is supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number KL2TR000143. This papers' contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Dr. Margaretten also received support from The Rosalind Russell Medical Research Center for Arthritis Research. The funding sources had no role in the design and conduct of the study, analysis or interpretation of the data, or preparation of final approval of the manuscript prior to publication. NR 46 TC 2 Z9 2 U1 1 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2013 VL 28 IS 12 BP 1637 EP 1642 DI 10.1007/s11606-013-2541-y PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 253YY UT WOS:000327127700019 PM 23897128 ER PT J AU Koenig, CJ AF Koenig, Christopher J. TI Capsule Commentary on Betz et al., "I Wish We Could Normalize Driving Health": A Qualitative Study of Clinician Discussions with Older Drivers SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA. RP Koenig, CJ (reprint author), Univ Calif San Francisco, San Francisco Vet Adm Med Ctr, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94118 USA. EM Christopher.koenig@ucsf.edu OI Koenig, Christopher J./0000-0003-0884-4120 NR 4 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD DEC PY 2013 VL 28 IS 12 BP 1644 EP 1644 DI 10.1007/s11606-013-2515-0 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 253YY UT WOS:000327127700021 PM 23797919 ER PT J AU Robinson, JP Bradway, CW Bunting-Perry, L Avi-Itzhak, T Mangino, M Chittams, J Duda, JE AF Robinson, Joanne P. Bradway, Christine W. Bunting-Perry, Lisette Avi-Itzhak, Tamara Mangino, Marie Chittams, Jesse Duda, John E. TI Lower Urinary Tract Symptoms in Men With Parkinson Disease SO JOURNAL OF NEUROSCIENCE NURSING LA English DT Article DE lower urinary tract symptoms; men's health; nonmotor symptoms; Parkinson disease ID MICTURITION DISTURBANCE; VOIDING DYSFUNCTION; UNPLEASANT SYMPTOMS; BLADDER FUNCTION; PREVALENCE; QUESTIONNAIRE; MANAGEMENT; NEUROLOGY; DEMENTIA; UPDATE AB Purpose: The aim of this study was to examine the prevalence, presentation, and predictors of lower urinary tract symptoms (LUTS) in men with idiopathic Parkinson disease (PD). Methods: Guided by the Theory of Unpleasant Symptoms, this retrospective exploratory study used data abstracted from admission clinical records of 271 male patients with idiopathic PD enrolled in a movement disorders clinic at a large metropolitan Veterans Affairs Medical Center in the eastern region of the United States. Data from the admission questionnaire, Unified Parkinson's Disease Rating Scale, and Mini Mental State Examination were abstracted by trained research assistants. Interrater reliability for the abstraction process was 0.99 in a randomly selected 10% sample of records. Descriptive statistics were used to determine the prevalence of LUTS. Logistic regression was used to determine LUTS risk factors and predictors. Results: At least one LUTS was reported by 40.2% of participants. Incontinence was the most prevalent symptom, affecting almost 25% of participants, followed by nocturia (14.8%) and frequency (13.7%). Of the 10 identified risk factors for LUTS, four significant predictors were discovered: number of non-PD medications (p < .05), PD duration (p < .05), number of comorbidities (p < .05), and history of a hernia diagnosis (p < .05). Conclusions: Assessment for LUTS should be a component of every evaluation of a patient with PD. Our findings offer a preliminary profile of the male PD patient with LUTS, which is an important step toward effective screening, detection, and access to care and treatment. Next steps in research include further work to identify predictors of LUTS in both male and female PD populations, explore patient perspectives, begin trials of interventions for LUTS in the PD population, and analyze the economic impact. C1 [Robinson, Joanne P.] Rutgers State Univ, Sch Nursing Camden, Camden, NJ 08102 USA. [Bradway, Christine W.; Chittams, Jesse] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Bunting-Perry, Lisette; Duda, John E.] Vet Affairs Med Ctr, Parkinsons Dis Educ & Clin Ctr, Philadelphia, PA USA. [Avi-Itzhak, Tamara] CUNY York Coll, Sch Hlth & Behav Sci, Dept Occupat Therapy, Jamaica, NY 11451 USA. [Mangino, Marie] Vincent Healthcare, Erdenheim, PA USA. [Duda, John E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Robinson, JP (reprint author), Rutgers State Univ, Sch Nursing Camden, Camden, NJ 08102 USA. EM jprobins@camden.rutgers.edu RI mangino, massimo/F-5134-2011 OI mangino, massimo/0000-0002-2167-7470 NR 51 TC 5 Z9 6 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0888-0395 EI 1945-2810 J9 J NEUROSCI NURS JI J. Neurosci. Nurs. PD DEC PY 2013 VL 45 IS 6 BP 382 EP 392 DI 10.1097/JNN.0b013e3182a3cf67 PG 11 WC Clinical Neurology; Nursing SC Neurosciences & Neurology; Nursing GA 251XF UT WOS:000326966300010 PM 24217149 ER PT J AU Canterberry, M Hanlon, CA Hartwell, KJ Li, XB Owens, M LeMatty, T Prisciandaro, JJ Borckardt, J Saladin, ME Brady, KT George, MS AF Canterberry, Melanie Hanlon, Colleen A. Hartwell, Karen J. Li, Xingbao Owens, Max LeMatty, Todd Prisciandaro, James J. Borckardt, Jeffrey Saladin, Michael E. Brady, Kathleen T. George, Mark S. TI Sustained Reduction of Nicotine Craving With Real-Time Neurofeedback: Exploring the Role of Severity of Dependence SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID CINGULATE CORTEX ACTIVITY; SMOKING-CESSATION; SMOKERS; FMRI; WITHDRAWAL; RELAPSE AB Background: Neurofeedback delivered via real-time functional magnetic resonance imaging (rtfMRI) is a promising therapeutic technique being explored to facilitate self-regulation of craving in nicotine-dependent cigarette smokers. The current study examined the role of nicotine-dependence severity and the efficacy of multiple visits of neurofeedback from a single region of interest (ROI) in the anterior cingulate cortex (ACC) on craving reduction. Methods: Nine nicotine-dependent cigarette smokers participated in three rtfMRI visits that examined cue-induced craving and brain activation. Severity of nicotine dependence was assessed with the Fagerstrom Test for Nicotine Dependence. When viewing smoking-related images with instructions to "crave," patient-tailored ROIs were generated in the vicinity of the ACC. Activity levels from the ROI were fed back while participants viewed smoking cues with the instruction to reduce craving. Results: Neurofeedback from a single ROI in the ACC led to consistent decreases in self-reported craving and activation in the ACC across the three visits. Dependence severity predicted response to neurofeedback at Visit 3. Conclusions: This study builds upon previous rtfMRI studies on the regulation of nicotine craving in demonstrating that feedback from the ACC can reduce activation to smoking cues across three separate visits. Individuals with lower nicotine-dependence severity were more successful in reducing ACC activation over time. These data highlight the need to consider dependence severity in developing more individualized neurofeedback methods. C1 [Canterberry, Melanie; Hanlon, Colleen A.; Hartwell, Karen J.; Li, Xingbao; Owens, Max; LeMatty, Todd; Prisciandaro, James J.; Borckardt, Jeffrey; Saladin, Michael E.; Brady, Kathleen T.; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Hartwell, Karen J.; Brady, Kathleen T.; George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Saladin, Michael E.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA. RP Canterberry, M (reprint author), Med Univ S Carolina, Dept Psychiat, 67 President St,Room 502 North, Charleston, SC 29425 USA. EM canterbe@musc.edu FU National Institute on Drug Abuse at the National Institutes of Health [R33DA026085]; National Institutes of Health [T32DA02788, K01DA0267756] FX This work was supported by the National Institute on Drug Abuse at the National Institutes of Health (R33DA026085 to KTB and MSG). Effort was supported by the National Institutes of Health (T32DA02788 to MC and K01DA0267756 to CAH). NR 24 TC 20 Z9 20 U1 2 U2 16 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD DEC PY 2013 VL 15 IS 12 BP 2120 EP 2124 DI 10.1093/ntr/ntt122 PG 5 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 252BD UT WOS:000326978400022 PM 23935182 ER PT J AU Allott, EH Abern, MR Gerber, L Keto, CJ Aronson, WJ Terris, MK Kane, CJ Amling, CL Cooperberg, MR Moorman, PG Freedland, SJ AF Allott, E. H. Abern, M. R. Gerber, L. Keto, C. J. Aronson, W. J. Terris, M. K. Kane, C. J. Amling, C. L. Cooperberg, M. R. Moorman, P. G. Freedland, S. J. TI Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database SO PROSTATE CANCER AND PROSTATIC DISEASES LA English DT Article DE metformin; diabetes; biochemical recurrence; outcomes ID CANCER-RISK; DIABETIC-PATIENTS; INCIDENT CANCER; MORTALITY; METAANALYSIS; SURVIVAL; GLUCOSE; PEOPLE; MEN AB BACKGROUND: While epidemiologic studies suggest that metformin use among diabetics may decrease prostate cancer (PC) incidence, the effect of metformin use on PC outcome is unclear. We investigated the association between pre-operative metformin use, dose and duration of use and biochemical recurrence (BCR) in PC patients with diabetes who underwent radical prostatectomy (RP). METHODS: We conducted a retrospective cohort analysis within the Shared Equal Access Regional Cancer Hospital (SEARCH) database of 371 PC patients with diabetes who underwent RP. Time to BCR between metformin users and non-users, and by metformin dose and duration of use was assessed using multivariable Cox proportional analysis adjusted for demographic, clinical and/or pathologic features. Time to castrate-resistant PC (CRPC), metastases and PC-specific mortality were explored as secondary outcomes using unadjusted analyses. RESULTS: Of 371 diabetic men, 156 (42%) were using metformin before RP. Metformin use was associated with more recent year of surgery (P < 0.0001) but no clinical or pathologic characteristics. After adjustment for year of surgery, clinical and pathologic features, there were no associations between metformin use (hazard ratio (HR) 0.93; 95% confidence interval (CI) 0.61-1.41), high metformin dose (HR 0.96; 95% CI 0.57-1.61) or duration of use (HR 1.00; 95% CI 0.99-1.02) and time to BCR. A total of 14 patients (3.8%) developed CRPC, 10 (2.7%) distant metastases and 8 (2.2%) died from PC. Unadjusted analysis suggested that high metformin dose vs non-use was associated with increased risk of CRPC (HR 5.1; 95% CI 1.6-16.5), metastases (HR 4.8; 95% CI 1.2-18.5) and PC-specific mortality (HR 5.0; 95% CI 1.1-22.5). CONCLUSIONS: Metformin use, dose or duration of use was not associated with BCR in this cohort of diabetic PC patients treated with RP. The suggestion that higher metformin dose was associated with increased risk of CRPC, metastases and PC-specific mortality merits testing in large prospective studies with longer follow-up. C1 [Allott, E. H.; Abern, M. R.; Gerber, L.; Keto, C. J.; Freedland, S. J.] Duke Univ, Sch Med, Dept Surg, Div Urol, Durham, NC 27710 USA. [Allott, E. H.] Duke Canc Inst, Canc Prevent Detect & Control Program, Durham, NC USA. [Allott, E. H.; Freedland, S. J.] Vet Affairs Med Ctr, Urol Sect, Durham, NC USA. [Aronson, W. J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA. [Aronson, W. J.] Univ Calif Los Angeles, Sch Med, Div Urol, Los Angeles, CA 90024 USA. [Terris, M. K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA. [Terris, M. K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA. [Kane, C. J.] Univ Calif San Diego, Dept Urol, San Diego, CA 92103 USA. [Amling, C. L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR USA. [Cooperberg, M. R.] UCSF Helen Diller Family Comprehens Canc Ctr, Dept Urol, San Francisco, CA USA. [Moorman, P. G.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA. [Freedland, S. J.] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA. RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Box 2626, Durham, NC 27710 USA. EM steve.freedland@duke.edu OI Terris, Martha/0000-0002-3843-7270 FU NCI [5R25-CA126938-03]; NIH [1-R01-CA131235-01A1, 1K24CA160653] FX This study was supported by EHA: NCI 5R25-CA126938-03; SJF: NIH Grant 1-R01-CA131235-01A1 and NIH 1K24CA160653. NR 27 TC 32 Z9 32 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1365-7852 EI 1476-5608 J9 PROSTATE CANCER P D JI Prostate Cancer Prostatic Dis. PD DEC PY 2013 VL 16 IS 4 BP 391 EP 397 DI 10.1038/pcan.2013.48 PG 7 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA 252OO UT WOS:000327016600019 PM 24100644 ER PT J AU Li, CY Zeliadt, SB Hall, IJ Smith, JL Ekwueme, DU Moinpour, CM Penson, DF Thompson, IM Keane, TE Ramsey, SD AF Li, Chunyu Zeliadt, Steven B. Hall, Ingrid J. Smith, Judith Lee Ekwueme, Donatus U. Moinpour, Carol M. Penson, David F. Thompson, Ian M. Keane, Thomas E. Ramsey, Scott D. TI Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective SO SUPPORTIVE CARE IN CANCER LA English DT Article DE Informal caregiving; Prostate cancer; Local stage; Time cost; Household chores; Productivity ID QUALITY-OF-LIFE; EMPLOYMENT; TIME; MEN; SURVIVORS; CARE; ILLNESS; STATES; BREAST; WORK AB Informal care plays an important role in the overall care for people with cancer. This study estimates lost productivity and informal caregiving and associated costs among partner caregivers of localized prostate cancer patients within 1 year after diagnosis. We applied data from the Family and Cancer Therapy Selection study, a three-wave self-administered survey among patients diagnosed with localized prostate cancer and their partner caregivers in multiple clinics in the USA. Time spent was measured by the sum of working hours lost, informal caregiving hours performed, and hours spent on household chores. The national median income for women 55 years or older was used to calculate costs associated with the time spent using the opportunity cost method. Descriptive and bivariate analyses were conducted. The average working hours decreased from 14.0 h/week (SD = 17.6) to 10.9 h/week (SD = 15.9), without a significant change in responsibility/intensity at work. The mean annual time spent on informal caregiving and household chores was 65.9 h/year (SD = 172.4) and 76.2 h/year (SD = 193.3), respectively. The mean annual economic burden among partner caregivers was US$6,063 (range US$571-US$47,105) in 2009 dollars accounted for by a mean of 276.2 h (range 26-2,146) in the study sample. The time spent on informal caregiving and household chores varied by patient and caregiver characteristics. Pilot estimates on non-medical economic burden among partner caregivers (spouses) during the initial phase of the treatment provide important information for comprehensive estimation of disease burden and can be used in cost-effectiveness analyses of prostate cancer interventions. C1 [Li, Chunyu; Hall, Ingrid J.; Smith, Judith Lee; Ekwueme, Donatus U.] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Zeliadt, Steven B.; Moinpour, Carol M.; Ramsey, Scott D.] Fred Hutchinson Canc Res Ctr, Publ Hlth Serv Div, Seattle, WA 98104 USA. [Zeliadt, Steven B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Excellence, Seattle, WA USA. [Penson, David F.] Vanderbilt Univ, Med Ctr, Vanderbilt Inst Med & Publ Hlth, Nashville, TN USA. [Thompson, Ian M.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA. [Keane, Thomas E.] Med Univ S Carolina, Urol Serv, Charleston, SC 29425 USA. RP Li, CY (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway NE,MS F-76, Atlanta, GA 30341 USA. EM Cli11@cdc.gov FU Centers for Disease Control and Prevention (CDC), Prevention Research Centers Program, through the University of Washington Health Promotion Research Center [SIP 25-04 1-U48-DP-000050] FX This study was supported by the Cooperative Agreement Number SIP 25-04 1-U48-DP-000050 from the Centers for Disease Control and Prevention (CDC), Prevention Research Centers Program, through the University of Washington Health Promotion Research Center. There is no conflict of interest. The corresponding author has full access to all primary data and agree to allow the journal to review their data if requested. NR 32 TC 4 Z9 5 U1 1 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0941-4355 EI 1433-7339 J9 SUPPORT CARE CANCER JI Support. Care Cancer PD DEC PY 2013 VL 21 IS 12 BP 3461 EP 3469 DI 10.1007/s00520-013-1931-3 PG 9 WC Oncology; Health Care Sciences & Services; Rehabilitation SC Oncology; Health Care Sciences & Services; Rehabilitation GA 250YE UT WOS:000326892100028 PM 23955026 ER PT J AU Jabaji, Z Sears, CM Brinkley, GJ Lei, NY Joshi, VS Wang, JF Lewis, M Stelzner, M Martin, MG Dunn, JCY AF Jabaji, Ziyad Sears, Connie M. Brinkley, Garrett J. Lei, Nan Ye Joshi, Vaidehi S. Wang, Jiafang Lewis, Michael Stelzner, Matthias Martin, Martin G. Dunn, James C. Y. TI Use of Collagen Gel as an Alternative Extracellular Matrix for the In Vitro and In Vivo Growth of Murine Small Intestinal Epithelium SO TISSUE ENGINEERING PART C-METHODS LA English DT Article ID STEM-CELL NICHE; SELF-RENEWAL; ORGANOIDS; CULTURE; TRANSPLANTATION; MODEL; COLON; DIFFERENTIATION; IDENTIFICATION; ENGRAFTMENT AB Methods for the in vitro culture of primary small intestinal epithelium have improved greatly in recent years. A critical barrier for the translation of this methodology to the patient's bedside is the ability to grow intestinal stem cells using a well-defined extracellular matrix. Current methods rely on the use of Matrigel, a proprietary basement membrane-enriched extracellular matrix gel produced in mice that is not approved for clinical use. We demonstrate for the first time the capacity to support the long-term in vitro growth of murine intestinal epithelium in monoculture, using type I collagen. We further demonstrate successful in vivo engraftment of enteroids co-cultured with intestinal subepithelial myofibroblasts in collagen gel. Small intestinal crypts were isolated from 6 to 10 week old transgenic enhanced green fluorescent protein (eGFP+) mice and suspended within either Matrigel or collagen gel; cultures were supported using previously reported media and growth factors. After 1 week, cultures were either lysed for DNA or RNA extraction or were implanted subcutaneously in syngeneic host mice. Quantitative real-time polymerase chain reaction (qPCR) was performed to determine expansion of the transgenic eGFP-DNA and to determine the mRNA gene expression profile. Immunohistochemistry was performed on in vitro cultures and recovered in vivo explants. Small intestinal crypts reliably expanded to form enteroids in either Matrigel or collagen in both mono- and co-cultures as confirmed by microscopy and eGFP-DNA qPCR quantification. Collagen-based cultures yielded a distinct morphology with smooth enteroids and epithelial monolayer growth at the gel surface; both enteroid and monolayer cells demonstrated reactivity to Cdx2, E-cadherin, CD10, Periodic Acid-Schiff, and lysozyme. Collagen-based enteroids were successfully subcultured in vitro, whereas pure monolayer epithelial sheets did not survive passaging. Reverse transcriptase-polymerase chain reaction demonstrated evidence of Cdx2, villin 1, mucin 2, chromogranin A, lysozyme 1, and Lgr5 expression, suggesting a fully elaborated intestinal epithelium. Additionally, collagen-based enteroids co-cultured with myofibroblasts were successfully recovered after 5 weeks of in vivo implantation, with a preserved immunophenotype. These results indicate that collagen-based techniques have the capacity to eliminate the need for Matrigel in intestinal stem cell culture. This is a critical step towards producing neo-mucosa using good manufacturing practices for clinical applications in the future. C1 [Jabaji, Ziyad; Sears, Connie M.; Brinkley, Garrett J.; Lei, Nan Ye; Stelzner, Matthias; Dunn, James C. Y.] Univ Calif Los Angeles, David Geffen Sch Med UCLA, Dept Surg, Div Pediat Surg, Los Angeles, CA 90095 USA. [Joshi, Vaidehi S.; Dunn, James C. Y.] Univ Calif Los Angeles, Sch Engn, Dept Bioengn, Los Angeles, CA 90095 USA. [Wang, Jiafang; Martin, Martin G.] Univ Calif Los Angeles, Mattel Childrens Hosp, Dept Pediat, Div Gastroenterol & Nutr, Los Angeles, CA 90095 USA. [Wang, Jiafang; Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med UCLA, Los Angeles, CA 90095 USA. [Lewis, Michael] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. [Stelzner, Matthias] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Martin, Martin G.] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA. RP Dunn, JCY (reprint author), Univ Calif Los Angeles, David Geffen Sch Med UCLA, Dept Surg, Div Pediat Surg, 10833 Le Conte Ave,CHS 72-172,MC 709818, Los Angeles, CA 90095 USA. EM jdunn@mednet.ucla.edu FU National Institute of Diabetes and Digestive and Kidney Diseases U01 Intestinal Stem Cell Consortium [DK085535-01, DK085535-02S2, DK083762, DK083319]; National Institute of Allergy and Infectious Diseases FX This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases U01 Intestinal Stem Cell Consortium (DK085535-01 and DK085535-02S2), DK083762, and DK083319 and the National Institute of Allergy and Infectious Diseases. We sincerely thank Renee Bowers (UCLA) and Nazlin Sharif (West Los Angeles, VA) for their expert consultation and generous technical assistance with all elements of histology work. NR 35 TC 18 Z9 18 U1 3 U2 19 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1937-3384 EI 1937-3392 J9 TISSUE ENG PART C-ME JI Tissue Eng. Part C-Methods PD DEC 1 PY 2013 VL 19 IS 12 BP 961 EP 969 DI 10.1089/ten.tec.2012.0710 PG 9 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology SC Cell Biology; Biotechnology & Applied Microbiology GA 256IZ UT WOS:000327304900006 PM 23566043 ER PT J AU Lyddon, R Dwork, AJ Keddache, M Siever, LJ Dracheva, S AF Lyddon, Rebecca Dwork, Andrew J. Keddache, Mehdi Siever, Larry J. Dracheva, Stella TI Serotonin 2c receptor RNA editing in major depression and suicide SO WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY LA English DT Article DE RNA editing; ADAR; serotonin receptor; major depressive disorder; suicide ID PRE-MESSENGER-RNA; 5-HT2C RECEPTOR; PREFRONTAL CORTEX; SIGNAL-TRANSDUCTION; GENE; ANTAGONIST; AGONIST; PROTEIN; BRAIN; ANTIDEPRESSANTS AB Objectives. mRNA for serotonin 2C receptor (5-HT2CR) undergoes editing which results in numerous isoforms. More highly edited isoforms exhibit decreased function. We recently found greater 5-HT2CR editing in suicide victims with prior bipolar disorder (BPD) or schizophrenia (SZ) compared with non-suicide patients and normal controls (NC). This study compares suicides and non-suicides with major depressive disorder (MDDSuic and MDDNoSuic) and non-suicide NC. Methods. mRNA editing was assessed in prefrontal cortex of 24 MDDSuic, 21 MDDNoSuic, and 56 NC using next generation sequencing. mRNA expression of 5-HT2CR and editing enzymes (ADAR1-2) was assessed by real-time PCR. Results. Editing was lower in MDDNoSuic than in MDDSuic, which did not differ from NC. No differences in the 5-HT2CR or ADAR1 expression were detected. ADAR2 expression was higher in NC than in MDD subjects, but did not differ between MDDNoSuic and MDDSuic. Conclusions. Our findings suggest the presence of two factors associated with 5-HT2CR editing. One factor, which probably stems from decreased ADAR2 expression, is linked to MDD and is associated with less editing. The other, seen also in our previous study of suicide in BP and SZ, is linked to suicide alone and is associated with more editing and, therefore, less receptor function. C1 [Lyddon, Rebecca; Siever, Larry J.; Dracheva, Stella] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Lyddon, Rebecca; Siever, Larry J.; Dracheva, Stella] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA. [Dwork, Andrew J.] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA. [Dwork, Andrew J.] Columbia Univ, Dept Psychiat, New York, NY USA. [Dwork, Andrew J.] New York State Psychiat Inst & Hosp, Div Mol Imaging & Neuropathol, New York, NY 10032 USA. [Keddache, Mehdi] Cincinnati Childrens Hosp Res Fdn, Div Human Genet, Cincinnati, OH USA. RP Dracheva, S (reprint author), Bronx VA Med Ctr, Psychiat Res 4F-02,130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Stella.Dracheva@mssm.edu FU VA Merit; Hope for Depression Foundation; American Foundation for Suicide Prevention; VISN3 Mental Illness Research and Education Clinical Center (MIRECC) FX We are grateful to Mr Scott Navarrett and Ms Katie Lutz for their superb technical assistance and to Dr D.J. Jamison for his help with bioinformatics. Postmortem brain tissue was donated by The Stanley Medical Research Institute courtesy of Drs Michael B. Knable, E. Fuller Torrey, Maree J. Webster, and Robert H. Yolken. This study was supported by VA Merit award to SD, by grants from the Hope for Depression Foundation and the American Foundation for Suicide Prevention (SD), and by the VISN3 Mental Illness Research and Education Clinical Center (MIRECC) (SD, LJS). NR 57 TC 10 Z9 11 U1 0 U2 9 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1562-2975 EI 1814-1412 J9 WORLD J BIOL PSYCHIA JI World J. Biol. Psychiatry PD DEC PY 2013 VL 14 IS 8 BP 590 EP 601 DI 10.3109/15622975.2011.630406 PG 12 WC Psychiatry SC Psychiatry GA 256JT UT WOS:000327307100006 PM 22404657 ER PT J AU Tsao, CK Small, AC Kates, M Moshier, EL Wisnivesky, JP Gartrell, BA Sonpavde, G Godbold, JH Palese, MA Hall, SJ Oh, WK Galsky, MD AF Tsao, Che-kai Small, Alexander C. Kates, Max Moshier, Erin L. Wisnivesky, Juan P. Gartrell, Benjamin A. Sonpavde, Guru Godbold, James H. Palese, Michael A. Hall, Simon J. Oh, William K. Galsky, Matthew D. TI Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis SO WORLD JOURNAL OF UROLOGY LA English DT Article DE Cytoreductive nephrectomy; SEER; Targeted therapy; Tyrosine kinase inhibitor; Disparities ID SURVIVAL; CANCER; IMPACT; SURGERY; DISEASE; GENDER AB Two randomized trials published in 2001 provided level 1 evidence for the use of cytoreductive nephrectomy (CyNx) for the treatment of metastatic renal cell carcinoma (mRCC). However, the regulatory approval of vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR-TKI) in 2005 has left an "evidence void" regarding the use of CyNx. We evaluated the patterns in the use of CyNx in the cytokine and VEGFR-TKI eras, and the patient characteristics associated with the use of CyNx. The Surveillance, Epidemiology, and End Results registry was used to identify patients with histologically or cytologically confirmed stage IV RCC between 2001 and 2008. Patients were classified as treated during the cytokine (2001-2005) or VEGFR-TKI (2006-2008) eras. A multivariate logistic regression analysis was performed to calculate the odds of undergoing CyNx according to treatment era and socioeconomic characteristics. Overall, 1,112 of 2,448 patients (45 %) underwent CyNx. CyNx use remained stable between 2001 and 2005 (50 %), but decreased to 38 % in 2008. Logistic regression analysis revealed that older age (OR 0.82, 95 % CI: 0.68, 0.99), black race (OR 0.64, 95 % CI: 0.46, 0.91), Hispanic ethnicity (OR 0.71, 95 % CI: 0.54, 0.93), and treatment in the VEGFR-TKI era (OR 0.82, 95 % CI: 0.68, 0.99) were independently associated with decreased use of CyNx. Use of CyNx in the United States has declined in the VEGFR-TKI era. Older patients and minorities are less likely to receive CyNx. Results of ongoing phase III trials are needed to refine the role of this treatment modality. C1 [Tsao, Che-kai; Small, Alexander C.; Kates, Max; Moshier, Erin L.; Gartrell, Benjamin A.; Godbold, James H.; Oh, William K.; Galsky, Matthew D.] Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA. [Wisnivesky, Juan P.] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA. [Sonpavde, Guru] Texas Oncol, Houston, TX USA. [Sonpavde, Guru] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, Sect Med Oncol, Houston, TX 77030 USA. [Palese, Michael A.; Hall, Simon J.] Mt Sinai Sch Med, Dept Urol, New York, NY 10029 USA. RP Galsky, MD (reprint author), Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, 1 Gustave L Levy Pl, New York, NY 10029 USA. EM matthew.galsky@mssm.edu FU Pfizer; GlaxoSmithKline FX Dr. Sonpavde receives research support from Pfizer and is an ad board/speaker for Pfizer, Novartis, and GlaxoKlineSmith. Dr. Wisnivesky is a member of the research board of EHE International, has been a consultant for UBS and IMS Health, and received a research grant from GlaxoSmithKline. NR 23 TC 22 Z9 22 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0724-4983 EI 1433-8726 J9 WORLD J UROL JI World J. Urol. PD DEC PY 2013 VL 31 IS 6 BP 1535 EP 1539 DI 10.1007/s00345-012-1001-3 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA 253ZY UT WOS:000327130700033 PM 23223962 ER PT J AU Ioannou, GN Scott, JD Yang, Y Green, PK Beste, LA AF Ioannou, G. N. Scott, J. D. Yang, Y. Green, P. K. Beste, L. A. TI Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID HIV-INFECTED PATIENTS; ALPHA-2A PLUS RIBAVIRIN; SUSTAINED VIROLOGICAL RESPONSE; HUMAN-IMMUNODEFICIENCY-VIRUS; LIVER-RELATED DEATHS; GENOTYPE 1; HEPATOCELLULAR-CARCINOMA; PEGYLATED INTERFERON; UNITED-STATES; THERAPY AB BackgroundThe effectiveness of anti-viral treatment for hepatitis C virus (HCV) in HIV/HCV co-infected patients in real world', clinical practice is unclear. AimsTo determine the rates and predictors of sustained virological response (SVR) to anti-viral treatment for HCV with pegylated interferon (PEG-IFN) and ribavirin in HIV/HCV co-infected patients. MethodsWe identified all HIV/HCV co-infected patients who received anti-viral treatment with PEG-IFN and ribavirin in the Veterans Affairs healthcare system nationally between 2002 and 2009 (n=665). ResultsSustained virological response was achieved in 21.6% overall, 16.7% among patients with genotype 1 HCV (n=491) and 44% among patients with genotype 2 or 3 HCV (n=116). Among genotype 1-infected patients, characteristics that were negatively associated with SVR independently included baseline HCV viral load >2million IU/mL [adjusted odds ratio (AOR) 0.41, 95% CI 0.2-0.7], Black race [AOR 0.56 (0.3-0.96)], diabetes [AOR 0.42 (0.2-0.9)], baseline anaemia [AOR 0.42 (0.2-0.97)], serum aspartate aminotransferase/alanine aminotransferase ratio 1.2 [AOR 0.48 (0.2-0.97)] and use of zidovudine [AOR 0.41 (0.2-0.9)]; characteristics positively associated with SVR included a starting dose of ribavirin 1000-1200mg/day [AOR 2.0 (1.1-3.7)] and erythropoietin use during treatment [AOR 2.9 (1.6-5.0)]. Among genotype 2 or 3 infected patients, only erythropoietin use was an independent predictor of SVR [AOR 3.1 (1.2-7.8)], while a starting dose of ribavirin >800mg/day was not associated with SVR. ConclusionsSustained virological response rates achieved with PEG-IFN and ribavirin in HIV/HCV co-infected patients are low in clinical practice. The use of erythropoietin was the most important, modifiable factor associated with SVR. C1 [Ioannou, G. N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, Seattle, WA 98108 USA. [Ioannou, G. N.; Yang, Y.; Green, P. K.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98108 USA. [Ioannou, G. N.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. [Scott, J. D.] Univ Washington, Seattle, WA 98195 USA. [Beste, L. A.] Vet Affairs Puget Sound Hlth Care Syst, Div Internal Med, Seattle, WA 98108 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Abbott; Gilead; Genentech; Janssen; Merck; Vertex; Clinical Science Research and Development, Office of Research and Development, Department of Veterans Affairs [I01CX000320] FX John Scott speaks for Vertex, Merck, Gilead and Genentech, has received grant funding from Abbott, Gilead, Genentech, Janssen, Merck and Vertex, and has served as a consultant for Vertex.; The study was funded in full by Merit Review Award, grant number I01CX000320, from the Clinical Science Research and Development, Office of Research and Development, Department of Veterans Affairs (GNI). NR 38 TC 9 Z9 10 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD DEC PY 2013 VL 38 IS 11-12 BP 1373 EP 1384 DI 10.1111/apt.12524 PG 12 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA 248FR UT WOS:000326681400006 PM 24127691 ER PT J AU Assi, M Martin, S Wheat, LJ Hage, C Freifeld, A Avery, R Baddley, JW Vergidis, P Miller, R Andes, D Young, JAH Hammoud, K Huprikar, S McKinsey, D Myint, T Garcia-Diaz, J Esguerra, E Kwak, EJ Morris, M Mullane, KM Prakash, V Burdette, SD Sandid, M Dickter, J Ostrander, D Abou Antoun, S Kaul, DR AF Assi, Maha Martin, Stanley Wheat, L. Joseph Hage, Chadi Freifeld, Alison Avery, Robin Baddley, John W. Vergidis, Paschalis Miller, Rachel Andes, David Young, Jo-Anne H. Hammoud, Kassem Huprikar, Shirish McKinsey, David Myint, Thein Garcia-Diaz, Julia Esguerra, Eden Kwak, E. J. Morris, Michele Mullane, Kathleen M. Prakash, Vidhya Burdette, Steven D. Sandid, Mohammad Dickter, Jana Ostrander, Darin Abou Antoun, Smyrna Kaul, Daniel R. TI Histoplasmosis After Solid Organ Transplant SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE histoplasmosis; fungal infection; solid organ transplant ID RENAL-ALLOGRAFT RECIPIENTS; FUNGAL-INFECTIONS; DIAGNOSIS; UPDATE; TRANSMISSION; SENSITIVITY; GUIDELINES; SOCIETY AB Background. To improve our understanding of risk factors, management, diagnosis, and outcomes associated with histoplasmosis after solid organ transplant (SOT), we report a large series of histoplasmosis occurring after SOT. Methods. All cases of histoplasmosis in SOT recipients diagnosed between 1 January 2003 and 31 December 2010 at 24 institutions were identified. Demographic, clinical, and laboratory data were collected. Results. One hundred fifty-two cases were identified: kidney (51%), liver (16%), kidney/pancreas (14%), heart (9%), lung (5%), pancreas (2%), and other (2%). The median time from transplant to diagnosis was 27 months, but 34% were diagnosed in the first year after transplant. Twenty-eight percent of patients had severe disease (requiring intensive care unit admission); 81% had disseminated disease. Urine Histoplasma antigen detection was the most sensitive diagnostic method, positive in 132 of 142 patients (93%). An amphotericin formulation was administered initially to 73% of patients for a median duration of 2 weeks; step-down therapy with an azole was continued for a median duration of 12 months. Ten percent of patients died due to histoplasmosis with 72% of deaths occurring in the first month after diagnosis; older age and severe disease were risk factors for death from histoplasmosis. Relapse occurred in 6% of patients. Conclusions. Although late cases occur, the first year after SOT is the period of highest risk for histoplasmosis. In patients who survive the first month after diagnosis, treatment with an amphotericin formulation followed by an azole for 12 months is usually successful, with only rare relapse. C1 [Assi, Maha; Sandid, Mohammad; Abou Antoun, Smyrna] Univ Kansas, Sch Med, Dept Internal Med, Wichita, KS 67214 USA. [Martin, Stanley] Ohio State Univ, Med Ctr, Div Infect Dis, Columbus, OH 43210 USA. [Wheat, L. Joseph] MiraVista Diagnost, Indianapolis, IN USA. [Hage, Chadi] Indiana Univ, Dept Internal Med Pulm Crit Care & Infect Dis, Indianapolis, IN 46204 USA. [Freifeld, Alison] Univ Nebraska, Med Ctr, Dept Internal Med, Div Infect Dis, Omaha, NE USA. [Avery, Robin] Johns Hopkins Univ Med, Div Infect Dis Transplant Oncol, Baltimore, MD USA. [Baddley, John W.] Univ Alabama Birmingham, Div Infect Dis, Rochester, MN USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Rochester, MN USA. [Vergidis, Paschalis] Mayo Clin, Div Clin Microbiol, Rochester, MN USA. [Miller, Rachel] Univ Iowa, Div Infect Dis, Iowa City, IA USA. [Andes, David] Univ Wisconsin, Dept Med & Med Microbiol & Immunol, Madison, WI 53706 USA. [Young, Jo-Anne H.] Univ Minnesota, Dept Med, Div Infect Dis, Minneapolis, MN 55455 USA. [Hammoud, Kassem] Univ Kansas, Med Ctr, Div Infect Dis, Kansas City, MO USA. [Huprikar, Shirish] Icahn Sch Med Mt Sinai, Div Infect Dis, Dept Med, New York, NY USA. [McKinsey, David] Infect Dis Associates Kansas City, Kansas City, MO USA. [Myint, Thein] Univ Kentucky, Div Infect Dis, Lexington, KY 40506 USA. [Garcia-Diaz, Julia] Ochsner Med Fdn, New Orleans, LA USA. [Esguerra, Eden] St Johns Reg Med Ctr, Joplin, MO USA. [Kwak, E. J.] Univ Pittsburgh, Div Transplant Infect Dis, Pittsburgh, PA 15260 USA. [Morris, Michele] Univ Miami, Miller Sch Med, Div Infect Dis, Coral Gables, FL 33124 USA. [Mullane, Kathleen M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA. [Prakash, Vidhya] Wright Patterson Med Ctr, Dept Infect Dis, Dayton, OH USA. [Burdette, Steven D.] Wright State Univ, Boonshoft Sch Med, Div Infect Dis, Dayton, OH 45435 USA. [Dickter, Jana] Kaiser Permanente, Div Infect Dis, Fontana, CA USA. [Ostrander, Darin] Johns Hopkins Univ, Sch Med, Div Infect Dis, Transplant & Oncol Infect Dis Clin Res Ctr, Baltimore, MD 21205 USA. [Kaul, Daniel R.] Univ Michigan, Sch Med, Dept Internal Med, Div Infect Dis, Ann Arbor, MI USA. RP Kaul, DR (reprint author), Univ Michigan, Sch Med, 3120 Taubman Ctr,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM kauld@umich.edu RI Martin, Stanley/E-3600-2011; Garcia-Diaz, Julia/D-3555-2011 FU National Institutes of Health [K24 A1085118] FX This work was supported by the National Institutes of Health (grant number K24 A1085118), which supplied funds for the database from which the data were extracted (Johns Hopkins University). NR 20 TC 26 Z9 28 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD DEC 1 PY 2013 VL 57 IS 11 BP 1542 EP 1549 DI 10.1093/cid/cit593 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 247XK UT WOS:000326657000010 PM 24046304 ER PT J AU Bergman, J Litwin, MS AF Bergman, Jonathan Litwin, Mark S. TI Mapping a New Truth SO EUROPEAN UROLOGY LA English DT Editorial Material ID PROSTATE-CANCER; LIFE LOST; OUTCOMES C1 [Bergman, Jonathan; Litwin, Mark S.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA 90024 USA. [Bergman, Jonathan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Bergman, Jonathan] Univ Calif Los Angeles, Robert Wood Johnson Fdn, Clin Scholars Program, Los Angeles, CA 90024 USA. [Litwin, Mark S.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Litwin, Mark S.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. RP Bergman, J (reprint author), Univ Calif Los Angeles, Dept Urol, 924 Westwood Blvd,Suite 1000, Los Angeles, CA 90024 USA. EM jbergman@mednet.ucla.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 EI 1873-7560 J9 EUR UROL JI Eur. Urol. PD DEC PY 2013 VL 64 IS 6 BP 929 EP 930 DI 10.1016/j.eururo.2013.03.048 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA 248EY UT WOS:000326678100011 PM 23597588 ER PT J AU Carrion, IV Nedjat-Haiem, FR Marquez, DX AF Carrion, Iraida V. Nedjat-Haiem, Frances R. Marquez, David X. TI Examining Cultural Factors that Influence Treatment Decisions: a Pilot Study of Latino Men with Cancer SO JOURNAL OF CANCER EDUCATION LA English DT Article DE Cancer; Latino men; Treatment decisions; Cultural beliefs ID PROSTATE-CANCER; HEALTH DISPARITIES; CARE; LIFE; RACE/ETHNICITY; ACCULTURATION; INFORMATION; DIAGNOSIS; WOMEN; RACE AB The objective of this study was to explore beliefs and treatment decisions of foreign-born Latino men from Cuba, Mexico, Colombia, and Venezuela, who have been diagnosed with cancer and who live in Central Florida, USA. Experiences related to knowledge of diagnosis, treatment decisions, communication with health providers, family involvement, and advance care planning (ACP) discussions following the diagnosis of cancer are central to this study. This study used qualitative in-depth semi-structured interviews and thematic analysis. The interviews were conducted with 15 Latino men who have been diagnosed with cancer within the past 5 years and who reside in the community. The interviews were conducted and transcribed in Spanish and then translated into English. The median age was 55.4 years. Nine Latino men had prostate cancer, two had brain cancer, two had colorectal cancer, and two had lung cancer. Emerging themes involved the suddenness of the diagnosis, fear of dying, expectations of diagnosis-related communication, reliance on physicians for treatment decisions, limited information pertaining to ACP, family support, and role changes. Latino men's limited knowledge of cancer diagnosis and treatment options coupled with their fear led them to immediately believe that they were going to die. Knowledge gaps regarding diagnosis-related communication, treatment decisions, and ACP varied among the men. The forthright diagnosis communication and the expectation to engage in decision making are contrary to Latinos men's beliefs of reliance on health providers decisions. The findings contribute to understanding Latino men's beliefs about a cancer diagnosis and treatment decisions. C1 [Carrion, Iraida V.] Univ S Florida, Sch Social Work, Tampa, FL 33612 USA. [Nedjat-Haiem, Frances R.] Vet Affairs Greater Los Angeles Healthcare Syst, HSR&D Ctr Excellence Study Healthcare Provide Beh, Los Angeles, CA USA. [Nedjat-Haiem, Frances R.] USC Sch Social Work, Los Angeles, CA USA. [Marquez, David X.] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL 60612 USA. RP Carrion, IV (reprint author), Univ S Florida, Sch Social Work, 13301 Bruce B Downs Blvd MHC 1438, Tampa, FL 33612 USA. EM icarrion@usf.edu; nedjatha@gmail.com; marquezd@uic.edu OI Carrion, Iraida/0000-0003-4076-6644 FU Division of Population Sciences; H. Lee Moffitt Cancer Center; Research Institute and the Division for Equal Health at University of South Florida in Tampa, Florida FX The authors thank Dr. Lee Green, Dr. Richard Roetzheim, the Division of Population Sciences, H. Lee Moffitt Cancer Center and Research Institute and the Division for Equal Health at University of South Florida in Tampa, Florida for their support. They also honor the Latino men who generously participated in the study and thank Ingrid Asmar for all of her contributions as research assistant. NR 39 TC 9 Z9 9 U1 3 U2 31 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-8195 EI 1543-0154 J9 J CANCER EDUC JI J. Cancer Educ. PD DEC PY 2013 VL 28 IS 4 BP 729 EP 737 DI 10.1007/s13187-013-0522-9 PG 9 WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health GA 242ZQ UT WOS:000326286200021 PM 23881820 ER PT J AU Vij, A Kowalkowski, MA Hart, T Goltz, HH Hoffman, DJ Knight, SJ Caroll, PR Latini, DM AF Vij, Alok Kowalkowski, Marc A. Hart, Tae Goltz, Heather Honore Hoffman, David J. Knight, Sara J. Caroll, Peter R. Latini, David M. TI Symptom Management Strategies for Men with Early-Stage Prostate Cancer: Results from the Prostate Cancer Patient Education Program (PC (PEP) ) SO JOURNAL OF CANCER EDUCATION LA English DT Article DE Prostate cancer; Symptom management; Quality of life; Survivorship ID QUALITY-OF-LIFE; ERECTILE DYSFUNCTION; SEXUAL REHABILITATION; OUTCOMES; INTERVENTION; CARCINOMA; PATTERNS; NEEDS AB While the literature on prostate cancer health-related quality of life has grown extensively, little is known about symptom management strategies used by men to manage treatment-related side effects and the effectiveness of those strategies. We collected 628 symptom management reports from 98 men treated for localized prostate cancer. Participants were recruited from email lists and a prostate cancer clinic in Northern California. Data were collected using the Critical Incident Technique. Symptom management reports were assigned to categories of urinary, sexual, bowel, mental health, systemic, or "other." We calculated descriptive statistics by symptom type and management strategy effectiveness. The most common symptoms were urinary (26 %) and sexual (23 %). Participants' symptom management strategies varied widely, from medical and surgical interventions (20 %) to behavioral strategies (11 %) to diet and lifestyle interventions (12 %). The effectiveness of symptom management strategies varied, with sexual symptoms being managed effectively only 47 % of the time to mental health symptom management strategies considered effective 89 % of the time. Doing nothing was a commonly reported (15 %) response to symptoms and was effective only 14 % of the time. Men report the least effectiveness in symptom management for sexual dysfunction after prostate cancer treatment. Including men's experience with managing treatment side effects may be an important way to improve survivorship programs and make them more acceptable to men. More work is needed to find out why men frequently do nothing in response to symptoms when effective solutions exist and how providers can successfully engage such men. C1 [Vij, Alok; Kowalkowski, Marc A.; Goltz, Heather Honore] Baylor Coll Med, Houston, TX 77030 USA. [Kowalkowski, Marc A.; Goltz, Heather Honore] Michael E DeBakey VA Med Ctr, VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA. [Hart, Tae] Ryerson Univ, Dept Psychol, Toronto, ON, Canada. [Hoffman, David J.] Univ Texas Southwestern, Sch Med, Dallas, TX USA. [Knight, Sara J.] San Francisco VA Med Ctr, San Francisco, CA USA. [Knight, Sara J.; Caroll, Peter R.] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA. [Knight, Sara J.; Caroll, Peter R.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Latini, David M.] Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA. [Latini, David M.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Latini, David M.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. RP Latini, DM (reprint author), Michael E DeBakey VA Med Ctr, Mental Hlth Care Line 116,2002 Holcombe Blvd, Houston, TX 77030 USA. EM latini@bcm.edu RI Hart, Stacey/E-4819-2011 OI Kowalkowski, Marc/0000-0003-2624-4209; Goltz, Heather/0000-0002-2875-7764; Latini, David/0000-0002-6161-4861 FU National Cancer Institute [R03 CA101586]; Health Services Research & Development Center of Excellence [HFP90-020]; Michael E. DeBakey Veterans Affairs Medical Center; American Cancer Society [06-083-01-CPPB] FX This work was funded by grant R03 CA101586 from the National Cancer Institute to David M. Latini. This material is partly the result of work supported with resources and the use of facilities at the Health Services Research & Development Center of Excellence (HFP90-020), Michael E. DeBakey Veterans Affairs Medical Center. Dr. Latini is supported by Mentored Research Scholar Grant 06-083-01-CPPB from the American Cancer Society. We also would like acknowledge the assistance of Sarah Howard Joost in recruiting participants, David V. Flores and Thomas D. McNeese II in data management and coding, and Sonora Hudson, MA, in editing the manuscript. Sandra R. Wilson, PhD, provided her expertise with the Critical Incident Technique to the study team. The views expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs/Baylor College of Medicine. NR 32 TC 2 Z9 2 U1 1 U2 14 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0885-8195 EI 1543-0154 J9 J CANCER EDUC JI J. Cancer Educ. PD DEC PY 2013 VL 28 IS 4 BP 755 EP 761 DI 10.1007/s13187-013-0538-1 PG 7 WC Oncology; Education, Scientific Disciplines; Public, Environmental & Occupational Health SC Oncology; Education & Educational Research; Public, Environmental & Occupational Health GA 242ZQ UT WOS:000326286200025 PM 23996206 ER PT J AU Wilson, R Sethi, S Anzueto, A Miravitlles, M AF Wilson, Robert Sethi, Sanjay Anzueto, Antonio Miravitlles, Marc TI Antibiotics for treatment and prevention of exacerbations of chronic obstructive pulmonary disease SO JOURNAL OF INFECTION LA English DT Review DE Acute bacterial exacerbation of COPD; Chronic inflammation; Inhalation therapy; Long-term outcome; Antibiotics; Fluoroquinolones; Macrolides ID ACUTE BACTERIAL EXACERBATIONS; PSEUDOMONAS-AERUGINOSA INFECTION; CYSTIC FIBROSIS BRONCHIECTASIS; MECHANICALLY VENTILATED PATIENTS; RANDOMIZED CONTROLLED-TRIAL; CHRONIC BRONCHIAL INFECTION; COURSE 5-DAY MOXIFLOXACIN; INHALED AZTREONAM LYSINE; INHALATION SOLUTION AZLI; PLACEBO-CONTROLLED TRIAL AB Acute exacerbations (AE) can be recurrent problems for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) increasing morbidity and mortality. Evidence suggests that >= 50% of acute exacerbations involve bacteria requiring treatment with an antibiotic which should have high activity against the causative pathogens. However, sputum analysis is not a pre-requisite for antibiotic prescription in outpatients as results are delayed and patients are likely to be colonised with bacteria in the stable state. Clinicians rely on the clinical symptoms, sputum appearance and the patient's medical history to decide if an AE-COPD should be treated with antibiotics. This article reviews the available data of antibiotic trials in AE-COPD. Management of frequent exacerbators is particularly challenging for physicians. This may include antibiotic prophylaxis, especially macrolides because of anti-inflammatory properties; though successful in reducing exacerbations, concerns about resistance development remain. Inhalation of antibiotics achieves high local concentrations and minimal systemic exposure; therefore, it may represent an attractive alternative for antibiotic prophylaxis in certain COPD patients. Inhaled antibiotic prophylaxis has been successfully used in other respiratory conditions such as non-cystic fibrosis bronchiectasis which itself might be present in COPD patients who have chronic bacterial infection, particularly with Pseudomonas aeruginosa. (C) 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved. C1 [Wilson, Robert] Royal Brompton Hosp, Host Def Unit, London SW3 6NP, England. [Sethi, Sanjay] SUNY Buffalo, Div Pulm Crit Care & Sleep Med, Buffalo, NY 14260 USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. [Miravitlles, Marc] Hosp Univ Vall dHebron, Ciber Enfermedades Resp CIBERES, Dept Pneumol, Barcelona, Spain. RP Wilson, R (reprint author), Royal Brompton Hosp, Host Def Unit, Sydney St, London SW3 6NP, England. EM r.wilson@rbht.nhs.uk OI Miravitlles, Marc/0000-0002-9850-9520 FU University of Texas Health Science Center (San Antonio, TX, USA); GlaxoSmithKline; Bayer; Lilly; National Institutes of Health; Boehringer Ingelheim; Pfizer; AstraZeneca; Bayer Schering; Novartis; Talecris-Grifols; Takeda-Nycomed; Merck, Sharp Dohme; GSK; Almirall; Forest; Mpex; Sanofi-Aventis FX Antonio Anzueto has participated as a speaker in scientific meetings or courses organised and financed by various pharmaceutical companies including: AstraZeneca, Boehringer Ingelheim, Bayer, Pfizer, GlaxoSmithKline, Sanofi-Aventis. A. Anzueto has been a consultant for AstraZeneca, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Sanofi-Aventis, Bayer. He has also been the principal investigator for research grants for the University of Texas Health Science Center (San Antonio, TX, USA) and was paid for participating in a multicentre clinical trial sponsored by: GlaxoSmithKline, Bayer, Lilly and National Institutes of Health. Marc Miravitlles has received speaker fees from Boehringer Ingelheim, Pfizer, AstraZeneca, Bayer Schering, Novartis, Talecris-Grifols, Takeda-Nycomed, Merck, Sharp & Dohme and Novartis, and consulting fees from Boehringer Ingelheim, Pfizer, GSK, AstraZeneca, Bayer Schering, Novartis, Almirall, Merck, Sharp & Dohme, Talecris-Grifols and Takeda-Nycomed. Sanjay Sethi has received institutional research funds from AstraZeneca and GlaxoSmithKline. He has received lecture and/or consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Forest, Pfizer, GlaxoSmithKline, Mpex, and Novartis. Robert Wilson has received honoraria for taking part in advisory boards and presenting at meetings from Almirall, Aperion Advisors LLC, AstraZeneca, Athena Medical PR, Bayer HealthCare, Forest Laboratories (Bronchiectasis symposium), Genactis Ltd, Opticom International, Penn Technology Partnership, Resolutions Group, Rivervest, Transave, VacZine Analytics and Wyeth Pharmaceuticals. NR 124 TC 15 Z9 15 U1 2 U2 23 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 EI 1532-2742 J9 J INFECTION JI J. Infect. PD DEC PY 2013 VL 67 IS 6 BP 497 EP 515 DI 10.1016/j.jinf.2013.08.010 PG 19 WC Infectious Diseases SC Infectious Diseases GA 247BK UT WOS:000326588400001 PM 23973659 ER PT J AU Gros, DF Morland, LA Greene, CJ Acierno, R Strachan, M Egede, LE Tuerk, PW Myrick, H Frueh, BC AF Gros, Daniel F. Morland, Leslie A. Greene, Carolyn J. Acierno, Ron Strachan, Martha Egede, Leonard E. Tuerk, Peter W. Myrick, Hugh Frueh, B. Christopher TI Delivery of Evidence-Based Psychotherapy via Video Telehealth SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE Psychotherapy; Evidence-based; Telehealth; Telemental health; Telepsychology; Telepsychiatry ID POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIORAL THERAPY; HOME-BASED TELEHEALTH; FACE-TO-FACE; MENTAL-HEALTH RESEARCH; TELEMENTAL HEALTH; NONINFERIORITY TRIAL; EXPOSURE THERAPY; RANDOMIZED-TRIAL; SERVICE DELIVERY AB There has been increasing interest in using video telehealth to deliver evidence-based psychotherapies (EBPs). Telehealth may have numerous advantages over standard in-person care, including decreasing patients' and providers' costs and increasing system coverage area. However, little is known regarding the effectiveness of EBPs via video telehealth. This review had two goals, including a review of the existing literature and ongoing research on using video telehealth technologies to deliver EBPs as well as an informal survey of telehealth experts to discuss the special considerations and challenges present in adapting practices to video telehealth. Together, findings suggest that telehealth practices could represent an important component of the future of psychotherapy and clinical practice, especially in dissemination and implementation of EBPs in traditionally underserved areas and populations. C1 [Gros, Daniel F.; Acierno, Ron; Strachan, Martha; Egede, Leonard E.; Tuerk, Peter W.; Myrick, Hugh] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Gros, Daniel F.; Acierno, Ron; Strachan, Martha; Egede, Leonard E.; Tuerk, Peter W.; Myrick, Hugh] Med Univ S Carolina, Charleston, SC 29425 USA. [Morland, Leslie A.] Natl Ctr PTSD, Pacific Isl Div, Dept Vet Affairs Pacific Isl Healthcare Syst, Honolulu, HI USA. [Greene, Carolyn J.] Vet Affairs Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. [Frueh, B. Christopher] Univ Hawaii, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. [Gros, Daniel F.] Ralph H Johnson VAMC, Charleston, SC 29401 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116,109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu NR 62 TC 28 Z9 28 U1 2 U2 22 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 EI 1573-3505 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD DEC PY 2013 VL 35 IS 4 BP 506 EP 521 DI 10.1007/s10862-013-9363-4 PG 16 WC Psychology, Clinical SC Psychology GA 248WE UT WOS:000326735400009 ER PT J AU Gros, DF Gros, KS Acierno, R Frueh, BC Morland, LA AF Gros, Daniel F. Gros, Kirstin Stauffacher Acierno, Ron Frueh, B. Christopher Morland, Leslie A. TI Relation Between Treatment Satisfaction and Treatment Outcome in Veterans with Posttraumatic Stress Disorder SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT LA English DT Article DE Charleston Psychiatric Outpatient Satisfaction Scale; CPOSS; Treatmentsatisfaction; PTSD; Psychometrics ID PSYCHIATRIC-DISORDERS; HEALTH-CARE; PTSD; DEPRESSION; EXPOSURE; PREDICTORS; SERVICES; THERAPY; SCALE AB Existing measures of patient treatment satisfaction are largely characterized by a lack of psychometric evaluation, varied definitions across studies, and small numbers of items. The present study evaluated a patient treatment satisfaction questionnaire specifically designed for psychiatric outpatient treatment satisfaction, the Charleston Psychiatric Outpatient Satisfaction Scale (CPOSS), to extend previous findings by examining: 1) the psychometric properties of the CPOSS and the common domains within patient treatment satisfaction, and 2) the preliminary relations between the CPOSS and treatment outcome during exposure therapy in patients with posttraumatic stress disorder (PTSD). The present investigation included two studies. The first involved 170 combat veterans with PTSD who completed brief psychotherapy, and whose post-treatment CPOSS scores were used for the factor analytic investigations. The second study involved 63 combat veterans with PTSD who received a course of brief exposure-based psychotherapy and completed pre- and post-treatment assessments to investigate the relations between the CPOSS and treatment outcome. The first study supported the psychometric properties of the CPOSS, including identifying four psychometrically-sound subscales for: respectful care, appearance of facility, convenience of facility, and recommendation to friends/family. The second study demonstrated that the CPOSS was a significant predictor of post-treatment PTSD symptoms, relative to demographics and pre-treatment symptoms. Together, these findings support the use of the CPOSS as a valuable addition in psychiatric outpatient settings to both assess and potentially improve patient treatment satisfaction. C1 [Gros, Daniel F.; Gros, Kirstin Stauffacher; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Gros, Daniel F.; Gros, Kirstin Stauffacher; Acierno, Ron] Med Univ S Carolina, Charleston, SC 29425 USA. [Frueh, B. Christopher] Univ Hawaii, Hilo, HI 96720 USA. [Frueh, B. Christopher] Menninger Clin, Houston, TX USA. [Morland, Leslie A.] Natl Ctr PTSD, Pacific Isl Div, Dept Vet Affairs Pacific Isl Healthcare Syst, Honolulu, HI USA. [Morland, Leslie A.] Ralph H Johnson VAMC, Charleston, SC 29401 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116,109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu NR 31 TC 2 Z9 2 U1 2 U2 9 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0882-2689 EI 1573-3505 J9 J PSYCHOPATHOL BEHAV JI J. Psychopathol. Behav. Assess. PD DEC PY 2013 VL 35 IS 4 BP 522 EP 530 DI 10.1007/s10862-013-9361-6 PG 9 WC Psychology, Clinical SC Psychology GA 248WE UT WOS:000326735400010 ER PT J AU Martin, JL Dzierzewski, JM Mitchell, M Fung, CH Jouldjian, S Alessi, CA AF Martin, Jennifer L. Dzierzewski, Joseph M. Mitchell, Michael Fung, Constance H. Jouldjian, Stella Alessi, Cathy A. TI Patterns of sleep quality during and after postacute rehabilitation in older adults: a latent class analysis approach SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE ageing; latent class analysis; rehabilitation; sleep ID POST-ACUTE REHABILITATION; ILLNESS RATING-SCALE; ELDERLY PERSONS; POOR SLEEP; DEPRESSION; PAIN; POPULATION; COMPLAINTS; SYMPTOMS; RECOVERY AB Sleep quality is related to emotional, physical, psychological and cognitive functioning and functional independence in later life. After acute health events, older adults are likely to utilize postacute rehabilitation services to improve functioning and facilitate return to independent living. Patterns of how sleep changes with postacute rehabilitation, and predictors of such patterns, are unknown. The current investigation employed latent class analysis (LCA) methods to classify older adults (n=233) into groups based on patterns of self-reported sleep quality pre-illness, during postacute rehabilitation and up to 1year following postacute rehabilitation. Using LCA, older adults were grouped into (1) consistently good sleepers (46%), (2) good sleepers who transitioned into poor sleepers (34%), (3) consistently poor sleepers (14%) and (4) poor sleepers who transitioned into good sleepers (6%). In three planned analyses, pain was an independent predictor of membership in classes 1 or 2 (good pre-illness sleep quality) versus classes 3 or 4 (poor pre-illness sleep quality), and of membership in class 1 (consistently good sleep) versus class 2 (good sleep that transitioned to poor sleep). A lower Mini-Mental State Examination score was a predictor of membership in class 1 versus class 2. There were no statistically significant predictors of membership in class 3 versus class 4. Demographics, comorbidities and depressive symptoms were not significant predictors of class membership. These findings have implications for identification of older adults at risk for developing poor sleep associated with changes in health and postacute rehabilitation. The findings also suggest that pain symptoms should be targeted to improve sleep during postacute rehabilitation. C1 [Martin, Jennifer L.; Dzierzewski, Joseph M.; Fung, Constance H.; Alessi, Cathy A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Martin, Jennifer L.; Dzierzewski, Joseph M.; Mitchell, Michael; Fung, Constance H.; Jouldjian, Stella; Alessi, Cathy A.] Geriatr Res Educ & Clin Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Martin, JL (reprint author), VA GRECC 11E,16111 Plummer St, North Hills, CA 91343 USA. EM jennifer.martin@va.gov FU NIA [K23 AG028452]; UCLA Claude Pepper Older Americans Independence Center [AG-10415]; VA Health Services Research Development [IIR-01-053-1, IIR 04-321-2, AIA-03-047]; VA Advanced Geriatrics Fellowship Program; VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center FX This work was supported by NIA K23 AG028452; UCLA Claude Pepper Older Americans Independence Center (AG-10415), VA Health Services Research & Development IIR-01-053-1, IIR 04-321-2 and AIA-03-047; VA Advanced Geriatrics Fellowship Program and VA Greater Los Angeles Healthcare System Geriatric Research, Education and Clinical Center. We thank the participating facilities and their staff and the members of the research team who made this study possible; in particular, Terry Vandenberg MA, Sergio Martinez, Maryanne Devereaux, Christina Kurtz RN, Rebecca Saia, Crystal Barker RN, Jae Lee MD, David Kim PA, and Adam Webber BSc (Hons), MRCP (UK). NR 27 TC 1 Z9 1 U1 3 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 EI 1365-2869 J9 J SLEEP RES JI J. Sleep Res. PD DEC PY 2013 VL 22 IS 6 BP 640 EP 647 DI 10.1111/jsr.12066 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 250VI UT WOS:000326884000006 PM 23834036 ER PT J AU Richards, A Metzler, TJ Ruoff, LM Inslicht, SS Rao, M Talbot, LS Neylan, TC AF Richards, Anne Metzler, Thomas J. Ruoff, Leslie M. Inslicht, Sabra S. Rao, Madhu Talbot, Lisa S. Neylan, Thomas C. TI Sex differences in objective measures of sleep in post-traumatic stress disorder and healthy control subjects SO JOURNAL OF SLEEP RESEARCH LA English DT Article DE polysomnography; post-traumatic stress disorder; quantitative electroencephalography; rapid eye movement sleep; sex differences; slow wave sleep ID REM-SLEEP; EMOTIONAL MEMORY; QUALITY INDEX; PTSD; DISTURBANCES; METYRAPONE; VETERANS; HUMANS; SCALE; RISK AB A growing literature shows prominent sex effects for risk for post-traumatic stress disorder and associated medical comorbid burden. Previous research indicates that post-traumatic stress disorder is associated with reduced slow wave sleep, which may have implications for overall health, and abnormalities in rapid eye movement sleep, which have been implicated in specific post-traumatic stress disorder symptoms, but most research has been conducted in male subjects. We therefore sought to compare objective measures of sleep in male and female post-traumatic stress disorder subjects with age- and sex-matched control subjects. We used a cross-sectional, 2x2 design (post-traumatic stress disorder/controlxfemale/male) involving83 medically healthy, non-medicated adults aged 19-39years in the inpatient sleep laboratory. Visual electroencephalographic analysis demonstrated that post-traumatic stress disorder was associated with lower slow wave sleep duration (F-(3,F-82)=7.63, P=0.007) and slow wave sleep percentage (F-(3,F-82)=6.11, P=0.016). There was also a groupxsex interaction effect for rapid eye movement sleep duration (F-(3,F-82)=4.08, P=0.047) and rapid eye movement sleep percentage (F-(3,F-82)=4.30, P=0.041), explained by greater rapid eye movement sleep in post-traumatic stress disorder females compared to control females, a difference not seen in male subjects. Quantitative electroencephalography analysis demonstrated that post-traumatic stress disorder was associated with lower energy in the delta spectrum (F-(3,F-82)=6.79, P=0.011) in non-rapid eye movement sleep. Slow wave sleep and delta findings were more pronounced in males. Removal of post-traumatic stress disorder subjects with comorbid major depressive disorder, who had greater post-traumatic stress disorder severity, strengthened delta effects but reduced rapid eye movement effects to non-significance. These findings support previous evidence that post-traumatic stress disorder is associated with impairment in the homeostatic function of sleep, especially in men with the disorder. These findings suggest that groupxsex interaction effects on rapid eye movement may occur with more severe post-traumatic stress disorder or with post-traumatic stress disorder comorbid with major depressive disorder. C1 [Richards, Anne; Inslicht, Sabra S.; Rao, Madhu; Neylan, Thomas C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Richards, Anne; Metzler, Thomas J.; Ruoff, Leslie M.; Inslicht, Sabra S.; Rao, Madhu; Talbot, Lisa S.; Neylan, Thomas C.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Richards, A (reprint author), San Francisco VA Med Ctr, 4150 Clement St Box 116-C, San Francisco, CA 94121 USA. EM anne.richards@ucsf.edu FU National Institute for Mental Health [TCN: 5R01MH073978-04, 5R34MH077667-03]; Mental Illness Research and Education Clinical Center of the US Veterans Health Administration; Clinical Research Center of the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant [UL1 RR024131] FX This project was supported by grants from the National Institute for Mental Health (TCN: 5R01MH073978-04, 5R34MH077667-03), the Mental Illness Research and Education Clinical Center of the US Veterans Health Administration and the Clinical Research Center of the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 RR024131. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. This material is the result of work supported with resources and the use of facilities at the Veterans Administration Medical Center, San Francisco, California. We are grateful to Ian Campbell PhD for his scientific input and to Maryann Lenoci for her logistical and technical support. NR 30 TC 11 Z9 11 U1 1 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 EI 1365-2869 J9 J SLEEP RES JI J. Sleep Res. PD DEC PY 2013 VL 22 IS 6 BP 679 EP 687 DI 10.1111/jsr.12064 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 250VI UT WOS:000326884000011 PM 23763708 ER PT J AU Press, MJ Scanlon, DP Navathe, AS Zhu, JS Chen, W Mittler, JN Volpp, KG AF Press, Matthew J. Scanlon, Dennis P. Navathe, Amol S. Zhu, Jingsan Chen, Wei Mittler, Jessica N. Volpp, Kevin G. TI The Importance of Clinical Severity in the Measurement of Hospital Readmission Rates for Medicare Beneficiaries, 1997-2007 SO MEDICAL CARE RESEARCH AND REVIEW LA English DT Article DE readmission; quality measurement; risk adjustment; hospital care ID ACUTE MYOCARDIAL-INFARCTION; DUTY HOUR REFORM; CARE; TRANSITIONS; DISCHARGE; MORTALITY; REDUCTION; TRIAL AB In the coming years, assessing the impact of efforts to reduce hospital readmissions will be important to policy makers and hospitals. To inform such assessments, we sought to define preexisting trends in readmission rates for patients by level of clinical severity using a difference-in-differences analysis of Medicare inpatient claims data from 1997, 2002, and 2007 for patients with acute myocardial infarction and congestive heart failure. We also examined trends in length of stay, in-hospital mortality, and postdischarge mortality by severity level to provide additional context for interpreting readmission rate trends. From 1997 to 2007, the difference in readmission rates between the highest and lowest severity quartiles increased. Length of stay and in-hospital mortality decreased for all patients; however, postdischarge mortality increased for the highest-severity patients and decreased for the lowest-severity patients. Assessments of recent policy reforms and quality improvement programs should account for underlying differential trends in readmission rates based on patient severity. C1 [Press, Matthew J.] Weill Cornell Med Coll, New York, NY 10065 USA. [Scanlon, Dennis P.; Mittler, Jessica N.] Penn State Univ, State Coll, PA USA. [Navathe, Amol S.; Zhu, Jingsan; Volpp, Kevin G.] Univ Penn, Philadelphia, PA 19104 USA. [Navathe, Amol S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Chen, Wei; Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Press, MJ (reprint author), Weill Cornell Med Coll, Dept Publ Hlth, 402 E 67th St, New York, NY 10065 USA. EM map9069@med.cornell.edu FU Commonwealth Fund; Public Health at Weill Cornell Medical College FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research was funded by a grant from the Commonwealth Fund. Dr. Press is supported in part by funds provided to him as a Nanette Laitman Clinical Scholar in Public Health at Weill Cornell Medical College. NR 21 TC 3 Z9 3 U1 2 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1077-5587 EI 1552-6801 J9 MED CARE RES REV JI Med. Care Res. Rev. PD DEC PY 2013 VL 70 IS 6 BP 653 EP 665 DI 10.1177/1077558713496167 PG 13 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 250ZD UT WOS:000326895000005 PM 23877956 ER PT J AU Onur, TS Sitron, CS Dang, A AF Onur, T. S. Sitron, C. S. Dang, A. TI Co-administration of hyaluronic acid with local anaesthetics shows lower cytotoxicity than local anaesthetic treatment alone in bovine articular chondrocytes SO BONE & JOINT RESEARCH LA English DT Article DE Hyaluronic acid; Local anaesthetic; Osteoarthritis; Intra-articular injections; Chondrocytes ID KNEE OSTEOARTHRITIS; MOLECULAR-WEIGHT; BUPIVACAINE; CHONDROTOXICITY; ROPIVACAINE; EXPOSURE AB Objective To study the effect of hyaluronic acid (HA) on local anaesthetic chondrotoxicity in vitro. Methods Chondrocytes were harvested from bovine femoral condyle cartilage and isolated using collagenase-containing media. At 24 hours after seeding 15 000 cells per well onto a 96-well plate, chondrocytes were treated with media (DMEM/F12 + ITS), PBS, 1:1 lidocaine (2%): PBS, 1:1 bupivacaine (0.5%): PBS, 1:1 lidocaine (2%): HA, 1:1 bupivacaine (0.5%): HA, or 1:1 HA:PBS for one hour. Following treatment, groups had conditions removed and 24-hour incubation. Cell viability was assessed using PrestoBlue and confirmed visually using fluorescence microscopy. Results Media-treated groups had a mean of 1.55x10(4) cells/well (SEM 783). All treated cells showed statistically significant reduced viability when compared with media alone (all p < 0.003). Cells treated with bupivacaine + HA (6.70x10(3) cells/well (SEM 1.10x10(3))) survived significantly more than bupivacaine (2.44x10(3) cells/well (SEM 830)) (p < 0.001). Lidocaine + HA (1.45x10(3) cells/well (SEM 596)) was not significantly more cytotoxic than lidocaine (2.24x10(3) cells/well (SEM 341)) (p = 0.999). There was no statistical difference between the chondrotoxicities of PBS (8.49x10(3) cells/well (SEM 730) cells/well) and HA (4.75x10(3) cells/well (SEM 886)) (p = 0.294). Conclusions HA co-administration reduced anaesthetic cytotoxicity with bupivacaine but not lidocaine, suggesting different mechanisms of injury between the two. Co-administered intra-articular injections of HA with bupivacaine, but not lidocaine, may protect articular chondrocytes from local anaesthetic-associated death. C1 [Onur, T. S.; Sitron, C. S.; Dang, A.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. [Dang, A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Onur, TS (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA. EM t.s.onur17@gmail.com FU UCSF Department of Orthopaedic Surgery, Northern California Institute of Research and Education FX The authors would like to acknowledge Smith & Nephew for providing the Supartz (R) used in this study. The authors would also like to thank the following funding sources for their support of this project: UCSF Department of Orthopaedic Surgery, Northern California Institute of Research and Education. NR 20 TC 5 Z9 5 U1 1 U2 1 PU BRITISH EDITORIAL SOC BONE JOINT SURGERY PI LONDON PA 22 BUCKINGHAM STREET, LONDON WC2N 6ET, ENGLAND SN 2046-3758 J9 BONE JOINT RES JI Bone Jt. Res. PD DEC PY 2013 VL 2 IS 12 BP 270 EP 275 DI 10.1302/2046-3758.212.2000216 PG 6 WC Cell & Tissue Engineering; Orthopedics SC Cell Biology; Orthopedics GA AT2JP UT WOS:000344761200003 PM 24333946 ER PT J AU Galofre, JC Chacon, AM Latif, R AF Galofre, Juan C. Chacon, Ana M. Latif, Rauf TI Targeting thyroid diseases with TSH receptor analogs SO ENDOCRINOLOGIA Y NUTRICION LA English DT Review DE Small molecules; Thyrotropin (TSH); Thyroid; TSH-receptor; Thyroid cancer; Graves' disease AB The thyroid -stimulating hormone (TSH) receptor (TSHR) is a major regulator of thyroid function and growth, and is the key antigen in several pathological conditions including hyperthyroidism, hypothyroidism, and thyroid tumors. Various effective treatment strategies are currently available for many of these clinical conditions such as antithyroid drugs or radio-iodine therapy, but they are not devoid of side effects. In addition, treatment of complications of Graves' disease such as Graves' ophthalmopathy is often difficult and unsatisfactory using current methods. Recent advances in basic research on both in vitro and in vivo models have suggested that TSH analogs could be used for diagnosis and treatment of some of the thyroid diseases. The advent of high-throughput screening methods has resulted in a group of TSH analogs called small molecules, which have the potential to be developed as promising drugs. Small molecules are low molecular weight compounds with agonist, antagonist and, in some cases, inverse agonist activity on TSHR. This short review will focus on current advances in development of TSH analogs and their potential clinical applications. Rapid advances in this field may lead to the conduct of clinical trials of small molecules related to TSHR for the management of Graves' disease, thyroid cancer, and thyroid-related osteoporosis in the coming years. (C) 2012 SEEN. Published by Elsevier Espana, S.L. All rights reserved. C1 [Galofre, Juan C.; Chacon, Ana M.] Univ Navarra, Univ Navarra Clin, Dept Endocrinol & Nutr, E-31080 Pamplona, Spain. [Latif, Rauf] James J Peters VA Med Ctr, Mt Sinai Sch Med, Thyroid Res Unit, New York, NY USA. RP Galofre, JC (reprint author), Univ Navarra, Univ Navarra Clin, Dept Endocrinol & Nutr, E-31080 Pamplona, Spain. EM jcgalofre@unav.es NR 47 TC 9 Z9 12 U1 0 U2 3 PU ELSEVIER DOYMA SL PI BARCELONA PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN SN 1575-0922 EI 1579-2021 J9 ENDOCRINOL NUTR JI Endocrinol. Nutr. PD DEC PY 2013 VL 60 IS 10 BP 590 EP 598 PG 9 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA V43XW UT WOS:000209715100008 PM 23538281 ER PT J AU Raskind, MA Froehlich, JC Peskind, ER Rasmussen, DD AF Raskind, Murray A. Froehlich, Janice C. Peskind, Elaine R. Rasmussen, Dennis D. TI Effects of Combined Adrenoreceptor Antagonist Treatment with Prazosin and Propranolol on Alcohol Drinking in Humans and Rodents SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract DE PTSD; alcohol; prazosin; propranolol C1 [Raskind, Murray A.; Froehlich, Janice C.; Peskind, Elaine R.; Rasmussen, Dennis D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2013 VL 38 SU 2 MA M199 BP S245 EP S246 PG 2 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA V40KI UT WOS:000209477100408 ER PT J AU Reddy, F Horan, W Wynn, JK Corey-Lisle, P Maglinte, G Barch, DM Buchanan, RW Gold, J Young, J Green, MF AF Reddy, Felice Horan, William Wynn, Jonathan K. Corey-Lisle, Patricia Maglinte, Gregory Barch, Deanna M. Buchanan, Robert W. Gold, James Young, Jared Green, Michael F. TI Assessing Effort-based Decision-making in Schizophrenia with Two Novel Behavioral Paradigms SO NEUROPSYCHOPHARMACOLOGY LA English DT Meeting Abstract DE Schizophrenia; Negative symptoms; Effort-based tasks; Motivation C1 [Reddy, Felice; Horan, William; Wynn, Jonathan K.; Corey-Lisle, Patricia; Maglinte, Gregory; Barch, Deanna M.; Buchanan, Robert W.; Gold, James; Young, Jared; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0893-133X EI 1740-634X J9 NEUROPSYCHOPHARMACOL JI Neuropsychopharmacology PD DEC PY 2013 VL 38 SU 2 MA M195 BP S242 EP S243 PG 2 WC Neurosciences; Pharmacology & Pharmacy; Psychiatry SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry GA V40KI UT WOS:000209477100404 ER PT J AU Kawabori, M Hokari, M Zheng, Z Kim, JY Calosing, C Hsieh, CL Nakamura, MC Yenari, MA AF Kawabori, Masahito Hokari, Masaaki Zheng, Zhen Kim, Jong Youl Calosing, Cyrus Hsieh, Christine L. Nakamura, Mary C. Yenari, Midori A. TI Triggering Receptor Expressed on Myeloid Cells-2 Correlates to Hypothermic Neuroprotection in Ischemic Stroke SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT LA English DT Article AB Hypothermia is neuroprotective against many acute neurological insults, including ischemic stroke. We and others have previously shown that protection by hypothermia is partially associated with an anti-inflammatory effect. Phagocytes are thought to play an important role in the clearance of necrotic debris, paving the way for endogenous repair mechanisms to commence, but the effect of cooling and phagocytosis has not been extensively studied. Triggering receptor expressed on myeloid cells-2 (TREM2) is a newly identified surface receptor shown to be involved in phagocytosis. In this study, we examined the effect of therapeutic hypothermia on TREM2 expression. Mice underwent permanent middle cerebral artery occlusion (MCAO) and were treated with one of the two cooling paradigms: one where cooling (30 degrees C) began at the onset of MCAO (early hypothermia [eHT]) and another where cooling began 1 hour later (delayed hypothermia [dHT]). In both groups, cooling was maintained for 2 hours. A third group was maintained at normothermia (NT) as a control (37 degrees C). Mice from the NT and dHT groups had similar ischemic lesion sizes and neurological performance, but the eHT group showed marked protection as evidenced by a smaller lesion size and less neurological deficits up to 30 days after the insult. Microglia and macrophages increased after MCAO as early as 3 days, peaked at 7 days, and decreased by 14 days. Both hypothermia paradigms were associated with decreased numbers of microglia and macrophages at 3 and 7 days, with greater decreases in the early paradigm. However, the proportion of the TREM2-positive microglia/macrophages was actually increased among the eHT group at day 7. eHT showed a long-term neurological benefit, but neuroprotection did not correlate to immune suppression. However, hypothermic neuroprotection was associated with a relative increase in TREM2 expression, and suggests that TREM2 may serve a beneficial role in brain ischemia. C1 [Kawabori, Masahito; Hokari, Masaaki; Zheng, Zhen; Kim, Jong Youl; Calosing, Cyrus; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94115 USA. [Hsieh, Christine L.; Nakamura, Mary C.] Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94115 USA. RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94115 USA. EM yenari@alum.mit.edu FU National Institutes of Health (NIH) [NS40516, AR0038]; Veteran's Merit Awards; Uehara Foundation Research Fellowship; Veterans Affairs Career Development Award; Rosalind Russell Arthritis Center FX This work was supported by grants from National Institutes of Health (NIH) (NS40516 to M.Y. and AR0038 to M.N.) and the Veteran's Merit Awards to M.Y. and M.C.N., the Uehara Foundation Research Fellowship to M.K. and a Veterans Affairs Career Development Award to C.H. Grants to M.Y. and M.N. were administered by the Northern California Institute for Research and Education, and supported by resources of the Veterans Affairs Medical Center, San Francisco, California. M.N. also received support from the Rosalind Russell Arthritis Center. NR 51 TC 6 Z9 6 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 2153-7658 EI 2153-7933 J9 THER HYPOTHERMIA TEM JI Ther. Hypothermia Temp. Manag. PD DEC 1 PY 2013 VL 3 IS 4 BP 189 EP 198 DI 10.1089/ther.2013.0020 PG 10 WC Critical Care Medicine SC General & Internal Medicine GA V38QL UT WOS:000209357800007 PM 24380032 ER PT J AU Gong, B Pan, Y Zhao, W Knable, L Vempati, P Begum, S Ho, L Wang, J Yemul, S Barnum, S Bilski, A Gong, BY Pasinetti, GM AF Gong, Bing Pan, Yong Zhao, Wei Knable, Lindsay Vempati, Prashant Begum, Shimul Ho, Lap Wang, Jun Yemul, Shrishailam Barnum, Scott Bilski, Amanda Gong, Ben Y. Pasinetti, Giulio M. TI IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway SO MOLECULAR IMMUNOLOGY LA English DT Article DE Alzheimer's disease; Complement component C5a; IVIG; pCREB; LTP; Cognitive function ID LONG-TERM POTENTIATION; CULTURED HIPPOCAMPAL-NEURONS; INTRAVENOUS IMMUNOGLOBULIN; C5A RECEPTOR; GENE-EXPRESSION; MOUSE MODEL; CELL-DEATH; REGULATED KINASE; TRANSGENIC MICE; IN-VIVO AB Background: Complement component C5-derived C5a locally generated in the brain has been shown to protect against glutamate-induced neuronal apoptosis and beta-amyloid (A beta) toxicity, but the mechanism is not clear. In this study, we tested the hypothesis that C5a influences upstream signal transduction pathways associated with cAMP-response element-binding protein (CREB) activation, in which alterations of CREB levels are associated with cognitive deterioration in AD. Methods: CREB signaling pathway, synaptic plasticity and cognitive function were studied in C5a receptor knockout mice (C5aR(-/-)), C5a over expressing mice (C5a/GFAP) and in Tg2576 mice, an AD mouse model. Results: (1) Cognitive function is severely impaired in C5aR(-/-) mice, coincident with the down-regulated CREB/CEBP pathway in brain. (2) Either the application of recombinant-human-C5a (hrC5a) or exogenous expression of C5a in the brain of a mouse model (C5a/GFAP) enhances this pathway. (3) Application of hrC5a in brain slices from Tg2576 mice significantly improves deficits in long-term potentiation (LTP), while this effect is blocked by a specific AMPA receptor antagonist. (4) Searching for a pharmacological approach to locally mediate C5a responses in the brain, we found that low-dose human intravenous immunoglobulin (IVIG) treatment improves synaptic plasticity and cognitive function through C5a-mediated induction of the CREB/CEBP pathway, while the levels of A beta in the brain are not significantly affected. Conclusion: This study for the first time provides novel evidence suggesting that C5a may beneficially influence cognitive function in AD through an up-regulation of AMPA-CREB signaling pathway. IVIG may systematically improve cognitive function in AD brain by passing A beta toxicity. Published by Elsevier Ltd. C1 [Gong, Bing; Pan, Yong; Zhao, Wei; Knable, Lindsay; Vempati, Prashant; Begum, Shimul; Ho, Lap; Wang, Jun; Yemul, Shrishailam; Bilski, Amanda; Gong, Ben Y.; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, Ctr Excellence Novel Approaches Neurotherapeut, New York, NY 10029 USA. [Barnum, Scott] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA. [Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA. RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu FU Veterans Administration by the US National Institutes of Health; Alzheimer's Association [IIRG-08-89354, IIRG-12-242345] FX The studies described here were supported in part from a grant from the Veterans Administration by the US National Institutes of Health grants to G.M.P and by grants from Alzheimer's Association (IIRG-08-89354 and IIRG-12-242345) to B.G. We thank Dr. Ottavio Arancio for providing technical support of reported electrophysiological recording. We thank Dr. Jorg Kohl for sharing the c5a receptor antagonist reagent. NR 63 TC 17 Z9 19 U1 1 U2 49 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0161-5890 J9 MOL IMMUNOL JI Mol. Immunol. PD DEC PY 2013 VL 56 IS 4 BP 619 EP 629 DI 10.1016/j.molimm.2013.06.016 PG 11 WC Biochemistry & Molecular Biology; Immunology SC Biochemistry & Molecular Biology; Immunology GA 241XZ UT WOS:000326203300036 PM 23911420 ER PT J AU Blevins, JE Ho, JM AF Blevins, James E. Ho, Jacqueline M. TI Role of oxytocin signaling in the regulation of body weight SO REVIEWS IN ENDOCRINE & METABOLIC DISORDERS LA English DT Review DE Satiety; Meal size; Oxytocin; Hindbrain ID GLUCAGON-LIKE PEPTIDE-1; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; PROLACTIN-RELEASING PEPTIDE; DIET-INDUCED OBESITY; C-FOS EXPRESSION; CENTRAL-NERVOUS-SYSTEM; DORSAL VAGAL COMPLEX; VENTRAL TEGMENTAL AREA; BRAIN-STEM NUCLEI; HIGH-FAT DIET AB Obesity and its associated metabolic disorders are growing health concerns in the US and worldwide. In the US alone, more than two-thirds of the adult population is classified as either overweight or obese [1], highlighting the need to develop new, effective treatments for these conditions. Whereas the hormone oxytocin is well known for its peripheral effects on uterine contraction during parturition and milk ejection during lactation, release of oxytocin from somatodendrites and axonal terminals within the central nervous system (CNS) is implicated in both the formation of prosocial behaviors and in the control of energy balance. Recent findings demonstrate that chronic administration of oxytocin reduces food intake and body weight in diet-induced obese (DIO) and genetically obese rodents with impaired or defective leptin signaling. Importantly, chronic systemic administration of oxytocin out to 6 weeks recapitulates the effects of central administration on body weight loss in DIO rodents at doses that do not result in the development of tolerance. Furthermore, these effects are coupled with induction of Fos (a marker of neuronal activation) in hindbrain areas (e.g. dorsal vagal complex (DVC)) linked to the control of meal size and forebrain areas (e.g. hypothalamus, amygdala) linked to the regulation of food intake and body weight. This review assesses the potential central and peripheral targets by which oxytocin may inhibit body weight gain, its regulation by anorexigenic and orexigenic signals, and its potential use as a therapy that can circumvent leptin resistance and reverse the behavioral and metabolic abnormalities associated with DIO and genetically obese models. C1 [Blevins, James E.; Ho, Jacqueline M.] VA Puget Sound Hlth Care Syst, Off Res & Dev, Med Res Serv, Dept Vet Affairs Med Ctr, Seattle, WA 98108 USA. [Blevins, James E.; Ho, Jacqueline M.] Univ Washington, Sch Med, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. RP Blevins, JE (reprint author), VA Puget Sound Hlth Care Syst, Off Res & Dev, Med Res Serv, Dept Vet Affairs Med Ctr, Seattle, WA 98108 USA. EM jeblevin@u.washington.edu FU Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA); Department of VA Merit Review Research Program FX This material is based upon work supported by the Office of Research and Development, Medical Research Service, Department of Veterans Affairs (VA). The research in our laboratory has been supported by the Department of VA Merit Review Research Program. The authors are appreciative of the efforts by Vishwanath Anekonda, Benjamin Thompson, Denis Baskin and Bang Hwang for their assistance in critically reviewing this manuscript. NR 234 TC 23 Z9 24 U1 1 U2 26 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 1389-9155 EI 1573-2606 J9 REV ENDOCR METAB DIS JI Rev. Endocr. Metab. Disord. PD DEC PY 2013 VL 14 IS 4 BP 311 EP 329 DI 10.1007/s11154-013-9260-x PG 19 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 245JG UT WOS:000326459300002 PM 24065622 ER PT J AU Billings, CJ McMillan, GP Penman, TM Gille, SM AF Billings, Curtis J. McMillan, Garnett P. Penman, Tina M. Gille, Sun Mi TI Predicting Perception in Noise Using Cortical Auditory Evoked Potentials SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY LA English DT Article DE cortical auditory evoked potentials (CAEPs); event-related potentials (ERPs); signals in noise; signal-to-noise ratio (SNR); background noise; N1 ID RATE-INTENSITY FUNCTIONS; SENSORY GAIN-CONTROL; BROAD-BAND NOISE; SPEECH; RECOGNITION; CORTEX; SOUND; AMPLIFICATION; FREQUENCY; STIMULI AB Speech perception in background noise is a common challenge across individuals and health conditions (e.g., hearing impairment, aging, etc.). Both behavioral and physiological measures have been used to understand the important factors that contribute to perception-in-noise abilities. The addition of a physiological measure provides additional information about signal-in-noise encoding in the auditory system and may be useful in clarifying some of the variability in perception-in-noise abilities across individuals. Fifteen young normal-hearing individuals were tested using both electrophysiology and behavioral methods as a means to determine (1) the effects of signal-to-noise ratio (SNR) and signal level and (2) how well cortical auditory evoked potentials (CAEPs) can predict perception in noise. Three correlation/regression approaches were used to determine how well CAEPs predicted behavior. Main effects of SNR were found for both electrophysiology and speech perception measures, while signal level effects were found generally only for speech testing. These results demonstrate that when signals are presented in noise, sensitivity to SNR cues obscures any encoding of signal level cues. Electrophysiology and behavioral measures were strongly correlated. The best physiological predictors (e.g., latency, amplitude, and area of CAEP waves) of behavior (SNR at which 50 % of the sentence is understood) were N1 latency and N1 amplitude measures. In addition, behavior was best predicted by the 70-dB signal/5-dB SNR CAEP condition. It will be important in future studies to determine the relationship of electrophysiology and behavior in populations who experience difficulty understanding speech in noise such as those with hearing impairment or age-related deficits. C1 [Billings, Curtis J.; McMillan, Garnett P.; Penman, Tina M.; Gille, Sun Mi] Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, Portland, OR 97239 USA. [Billings, Curtis J.] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97239 USA. RP Billings, CJ (reprint author), Portland VA Med Ctr, Natl Ctr Rehabilitat Auditory Res, 3710 SW US Vet Hosp Rd NCRAR, Portland, OR 97239 USA. EM curtis.billings2@va.gov FU National Institute on Deafness and Other Communication Disorders [R03DC10914]; VA Rehabilitation Research and Development Service [C4844C, C8006W] FX We wish to thank Drs. Marjorie Leek, Robert Burkard, and Kelly Tremblay for the comments on the design of this experiment and earlier versions of this manuscript. This work was supported by a grant from the National Institute on Deafness and Other Communication Disorders (R03DC10914) and career development awards from the VA Rehabilitation Research and Development Service (C4844C and C8006W). NR 35 TC 11 Z9 13 U1 0 U2 17 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1525-3961 EI 1438-7573 J9 JARO-J ASSOC RES OTO JI JARO PD DEC PY 2013 VL 14 IS 6 BP 891 EP 903 DI 10.1007/s10162-013-0415-y PG 13 WC Neurosciences; Otorhinolaryngology SC Neurosciences & Neurology; Otorhinolaryngology GA 243AR UT WOS:000326289200008 PM 24030818 ER PT J AU Bzdok, D Laird, AR Zilles, K Fox, PT Eickhoff, SB AF Bzdok, Danilo Laird, Angela R. Zilles, Karl Fox, Peter T. Eickhoff, Simon B. TI An Investigation of the Structural, Connectional, and Functional Subspecialization in the Human Amygdala SO HUMAN BRAIN MAPPING LA English DT Article DE amygdala; data mining; parcellation; connectivity; behavior; social cognition ID BRAINS DEFAULT NETWORK; RHESUS-MONKEY; LIKELIHOOD ESTIMATION; CINGULATE CORTEX; MACAQUE MONKEY; IN-VIVO; CYTOARCHITECTONIC MAPS; ORBITOFRONTAL CORTEX; SUPERFICIAL AMYGDALA; BASOLATERAL AMYGDALA AB Although the amygdala complex is a brain area critical for human behavior, knowledge of its subspecialization is primarily derived from experiments in animals. We here employed methods for large-scale data mining to perform a connectivity-derived parcellation of the human amygdala based on whole-brain coactivation patterns computed for each seed voxel. Voxels within the histologically defined human amygdala were clustered into distinct groups based on their brain-wide coactivation maps. Using this approach, connectivity-based parcellation divided the amygdala into three distinct clusters that are highly consistent with earlier microstructural distinctions. Meta-analytic connectivity modelling then revealed the derived clusters' brain-wide connectivity patterns, while meta-data profiling allowed their functional characterization. These analyses revealed that the amygdala's laterobasal nuclei group was associated with coordinating high-level sensory input, whereas its centromedial nuclei group was linked to mediating attentional, vegetative, and motor responses. The often-neglected superficial nuclei group emerged as particularly sensitive to olfactory and probably social information processing. The results of this model-free approach support the concordance of structural, connectional, and functional organization in the human amygdala and point to the importance of acknowledging the heterogeneity of this region in neuroimaging research. Hum Brain Mapp 34:3247-3266, 2013. (c) 2012 Wiley Periodicals, Inc. C1 [Bzdok, Danilo; Eickhoff, Simon B.] Rhein Westfal TH Aachen, Dept Psychiat Psychotherapy & Psychosomat, Aachen, Germany. [Bzdok, Danilo; Zilles, Karl; Eickhoff, Simon B.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. [Bzdok, Danilo; Zilles, Karl; Eickhoff, Simon B.] Julich Aachen Res Alliance JARA Translat Brain Me, Aachen, Germany. [Zilles, Karl] Univ Dusseldorf, C&O Vogt Inst Brain Res, Dusseldorf, Germany. [Laird, Angela R.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Laird, Angela R.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Eickhoff, Simon B.] Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. RP Eickhoff, SB (reprint author), Forschungszentrum Julich, Inst Neurowissensch & Med INM 2, D-52425 Julich, Germany. EM S.Eickhoff@fz-juelich.de RI Zilles, Karl/J-9704-2013; Fox, Peter/B-4725-2010; Eickhoff, Simon/K-2061-2013 OI Zilles, Karl/0000-0001-9296-9959; Zilles, Karl/0000-0002-4705-4175; Fox, Peter/0000-0002-0465-2028; Eickhoff, Simon/0000-0001-6363-2759 FU German Research Council [IRTG 1328]; Human Brain Project [R01-MH074457-01A1]; Helmholtz Initiative on Systems-Biology FX Contract grant sponsor: German Research Council; Contract grant number: DFG, IRTG 1328; Contract grant sponsor: Human Brain Project; Contract grant number: R01-MH074457-01A1; Contract grant sponsor: Helmholtz Initiative on Systems-Biology. NR 134 TC 73 Z9 74 U1 2 U2 43 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1065-9471 EI 1097-0193 J9 HUM BRAIN MAPP JI Hum. Brain Mapp. PD DEC PY 2013 VL 34 IS 12 BP 3247 EP 3266 DI 10.1002/hbm.22138 PG 20 WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA 240BC UT WOS:000326068700011 PM 22806915 ER PT J AU Wang, MQ Rahnama, R Cheng, T Grotkopp, E Jacobs, L Limburg, S Kim, HT Kuo, AC AF Wang, Miqi Rahnama, Ruyan Cheng, Tiffany Grotkopp, Eva Jacobs, Linsey Limburg, Sonja Kim, Hubert T. Kuo, Alfred C. TI Trophic Stimulation of Articular Chondrocytes by Late-Passage Mesenchymal Stem Cells in Coculture SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE coculture; mesenchymal stem cells; chondrogenesis; trophic ID CHONDROGENIC DIFFERENTIATION; PROLIFERATION; CULTURE; HYPERTROPHY; CARTILAGE AB Coculture of mesenchymal stem cells (MSCs) with articular chondrocytes (ACs) increases glycosaminoglycan (GAG) accumulation compared to monoculture. MSCs might (1) differentiate into ACs (progenitor role) and/or (2) stimulate AC matrix metabolism (trophic role). MSCs lose the ability to undergo chondrogenesis after extended passaging. We hypothesized that MSCs act predominantly as progenitors, and that late-passage MSCs without chondrogenic potential would be unable to increase GAG in coculture. Early- and late-passage human MSCs (hMSCs) were grown in pellet monoculture under chondrogenic conditions and in pellet coculture with bovine ACs. Chondrogenesis was assessed with GAG quantification, safranin-O staining, and quantitative PCR (qPCR). Contributions of human and bovine cells were assessed with species-specific qPCR and human-specific immunostaining. Late-passage hMSCs did not undergo chondrogenesis in monoculture with chondrogenic stimuli or in coculture with ACs. Early-passage hMSCs underwent chondrogenesis only in response to chondrogenic stimuli. Coculture pellets in both cases accumulated as much GAG/DNA as monoculture AC pellets. Aggrecan transcription was not increased in coculture. Late-passage hMSCs that do not undergo chondrogenesis are capable of stimulating GAG accumulation in coculture with ACs. This supports a trophic effect of hMSCs on ACs. hMSCs may have therapeutic utility even after prolonged passaging. Published 2013 by Wiley Periodicals, Inc. on behalf of the Orthopaedic Research Society. J Orthop Res 31:1936-1942, 2013 C1 [Wang, Miqi; Rahnama, Ruyan; Cheng, Tiffany; Jacobs, Linsey; Limburg, Sonja; Kim, Hubert T.; Kuo, Alfred C.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA. [Grotkopp, Eva; Kim, Hubert T.; Kuo, Alfred C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Kuo, AC (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA. EM kuoac@orthosurg.ucsf.edu FU Orthopaedic Research and Education Foundation; Musculoskeletal Transplant Foundation FX This study was performed with the support of the Orthopaedic Research and Education Foundation and the Musculoskeletal Transplant Foundation and with the resources of the San Francisco Veterans Affairs Medical Center. NR 17 TC 11 Z9 11 U1 2 U2 12 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD DEC PY 2013 VL 31 IS 12 BP 1936 EP 1942 DI 10.1002/jor.22466 PG 7 WC Orthopedics SC Orthopedics GA 238ZG UT WOS:000325990300011 PM 24038580 ER PT J AU Gros, DF McCabe, RE Antony, MM AF Gros, Daniel F. McCabe, Randi E. Antony, Martin M. TI Using a hybrid model to investigate the comorbidity and symptom overlap between social phobia and the other anxiety disorders and unipolar mood disorders SO PSYCHIATRY RESEARCH LA English DT Article DE Social anxiety disorder; Transdiagnostic; Multidimensional Assessment of Social; Anxiety; MASA ID POSTTRAUMATIC-STRESS-DISORDER; DIMENSIONAL CLASSIFICATION-SYSTEM; RANDOMIZED CONTROLLED-TRIAL; DSM-IV ANXIETY; EMOTIONAL DISORDERS; SPECIAL SECTION; PSYCHOPATHOLOGY; FEATURES AB New hybrid models of psychopathology have been proposed that combine the current categorical approach with symptom dimensions that are common across various disorders. The present study investigated the new hybrid model of social anxiety in a large sample of participants with anxiety disorders and unipolar mood disorders to improve understanding of the comorbidity and symptom overlap between social phobia (SOC) and the other anxiety disorders and unipolar mood disorders. Six hundred and eighty two participants from a specialized outpatient clinic for anxiety treatment completed a semi-structured diagnostic interview and the Multidimensional Assessment of Social Anxiety (MASA). A hybrid model symptom profile was identified for SOC and compared with each of the other principal diagnoses. Significant group differences were identified on each of the MASA scales. Differences also were identified when common sets of comorbidities were compared within participants diagnosed with SOC. The findings demonstrated the influence of both the principal diagnosis of SOC and other anxiety disorders and unipolar mood disorders as well as the influence of comorbid diagnoses with SOC on the six symptom dimensions. These findings highlight the need to shift to transdiagnostic assessment and treatment practices that go beyond the disorder-specific focus of the current categorical diagnostic systems. Published by Elsevier Ireland Ltd. C1 [Gros, Daniel F.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Gros, Daniel F.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [McCabe, Randi E.] St Josephs Healthcare, Anxiety Treatment & Res Ctr, Hamilton, ON, Canada. [McCabe, Randi E.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada. [Antony, Martin M.] Ryerson Univ, Dept Psychol, Toronto, ON, Canada. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU Office of Research and Development; Medical Research Service; Department of Veterans Affairs FX This work was partially supported by the Office of Research and Development, Medical Research Service, and Department of Veterans Affairs. There are no conflicts of interest to disclose. We would like to thank Dr. Matthew Price for his consultation on the statistical approach in the revision of this manuscript. NR 26 TC 7 Z9 7 U1 2 U2 7 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD NOV 30 PY 2013 VL 210 IS 1 BP 188 EP 192 DI 10.1016/j.psychres.2013.05.005 PG 5 WC Psychiatry SC Psychiatry GA 250NL UT WOS:000326859400029 PM 23809463 ER PT J AU Ripoll, LH Zaki, J Perez-Rodriguez, MM Snyder, R Strike, KS Boussi, A Bartz, JA Ochsner, KN Siever, LJ New, AS AF Ripoll, Luis H. Zaki, Jamil Perez-Rodriguez, Maria Mercedes Snyder, Rebekah Strike, Kathryn Sloan Boussi, Ayelet Bartz, Jennifer A. Ochsner, Kevin N. Siever, Larry J. New, Antonia S. TI Empathic accuracy and cognition in schizotypal personality disorder SO PSYCHIATRY RESEARCH LA English DT Article DE Schizotypal personality disorder; Empathy; Personality; Working memory; Attachment; Social support ID SCHIZOPHRENIA SPECTRUM DISORDERS; SOCIAL COGNITION; WORKING-MEMORY; ADULT ATTACHMENT; EMOTION RECOGNITION; INTERPERSONAL RELATIONSHIPS; PSYCHOMETRIC SCHIZOTYPY; GENETIC VULNERABILITY; 1ST-DEGREE RELATIVES; NONCLINICAL SAMPLE AB Interpersonal dysfunction contributes to significant disability in the schizophrenia spectrum. Schizotypal Personality Disorder (SPD) is a schizophrenia-related personality demonstrating social cognitive impairment in the absence of frank psychosis. Past research indicates that cognitive dysfunction or schizotypy may account for social cognitive dysfunction in this population. We tested SPD subjects and healthy controls on the Empathic Accuracy (EA) paradigm and the Reading of the Mind in the Eyes Test (RMET), assessing the impact of EA on social support. We also explored whether EA differences could be explained by intelligence, working memory, trait empathy, or attachment avoidance. SPD subjects did not differ from controls in RMET, but demonstrated lower EA during negative valence videos, associated with lower social support. Dynamic, multimodal EA paradigms may be more effective at capturing interpersonal dysfunction than static image tasks such as RMET. Schizotypal severity, trait empathy, and cognitive dysfunction did not account for empathic dysfunction in SPD, although attachment avoidance is related to empathic differences. Empathic dysfunction for negative affect contributes to decreased social support in the schizophrenia spectrum. Future research may shed further light on potential links between attachment avoidance, empathic dysfunction, and social support. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Ripoll, Luis H.; Perez-Rodriguez, Maria Mercedes; Siever, Larry J.; New, Antonia S.] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA. [Ripoll, Luis H.; Perez-Rodriguez, Maria Mercedes; Strike, Kathryn Sloan; Boussi, Ayelet; Siever, Larry J.; New, Antonia S.] MIRECC, James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Zaki, Jamil] Stanford Univ, Dept Psychol, Stanford, CA 94305 USA. [Snyder, Rebekah; Ochsner, Kevin N.] Columbia Univ, Dept Psychol, New York, NY 10027 USA. [Bartz, Jennifer A.] McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada. RP Ripoll, LH (reprint author), Mt Sinai Sch Med, Dept Psychiat, 1 Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. RI Perez Rodriguez, Maria/B-9410-2013 OI Perez Rodriguez, Maria/0000-0001-5137-1993 FU US Dept. of Veterans' Affairs MIRECC pilot grant FX The present study was funded entirely through a US Dept. of Veterans' Affairs MIRECC pilot grant, and the authors have no other significant financial relationships to disclose. NR 121 TC 11 Z9 11 U1 6 U2 18 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD NOV 30 PY 2013 VL 210 IS 1 BP 232 EP 241 DI 10.1016/j.psychres.2013.05.025 PG 10 WC Psychiatry SC Psychiatry GA 250NL UT WOS:000326859400036 PM 23810511 ER PT J AU Smucny, J Wylie, K Rojas, D Stevens, K Olincy, A Kronberg, E Zheng, LJ Tregellas, J AF Smucny, Jason Wylie, Korey Rojas, Donald Stevens, Karen Olincy, Ann Kronberg, Eugene Zheng, Lijun Tregellas, Jason TI Evidence for gamma and beta sensory gating deficits as translational endophenotypes for schizophrenia SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE Gamma; Beta; Nicotinic; Schizophrenia; Gating ID REPEATED AUDITORY-STIMULI; RECEPTOR SUBUNIT GENE; HIPPOCAMPAL INTERNEURONS; ACETYLCHOLINE-RECEPTOR; P50 SUPPRESSION; BRAIN OSCILLATIONS; EVOKED-RESPONSE; IN-VITRO; AGONIST; HUMANS AB Thorough analysis of translational endophenotypes is needed to improve therapeutic development in schizophrenia. Abnormal sensory gating, one such endophenotype, is associated with reduced expression of the alpha 7 nicotinic receptor. However, typical gating measures such as the P50 evoked response are often low-pass filtered, and it is unclear how a7 expression affects gating at higher frequencies. Therefore, this study used time -frequency analysis to compare sensory gating at the beta and gamma frequencies between human patients and healthy controls as well as between alpha 7 heterozygote mutant mice and wild type Gating of Loral beta (15-26 Hz) and gamma (30-50 Hz) power during paired clicks was assessed from mouse in vivo hippocampal CA3 recordings. Gating was also assessed in schizophrenia patients and healthy controls using electroencephalography. Relative to wild type. u7 heLerozygore mice showed impaired gating of Loral beta and gamma power. Similarly, relative to controls, patients showed impaired gating of Loral beta and gamma power. Poor beta gating was associated with negative symptoms. These results demonstrate that schizophrenia patients and alpha 7 heLerozygoLe mice show similar deficits in gaLing high frequency power. Time frequency analysis of beta and gamma gating may thus be a translational method of assessing the genetic basis of gating deficits in schizophrenia. (C) 2013 Elsevier Ireland Ltd. All rights reserved. C1 [Smucny, Jason; Rojas, Donald; Tregellas, Jason] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA. [Wylie, Korey; Rojas, Donald; Stevens, Karen; Olincy, Ann; Tregellas, Jason] Denver VA Med Ctr, Res Serv, Denver, CO USA. [Smucny, Jason; Wylie, Korey; Rojas, Donald; Stevens, Karen; Olincy, Ann; Kronberg, Eugene; Zheng, Lijun; Tregellas, Jason] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA. RP Smucny, J (reprint author), Univ Colorado, Dept Psychiat, Anschutz Med Campus,East 17th Pl, Aurora, CO 80045 USA. EM Jason.Smucny@ucdenver.edu RI Tregellas, Jason/J-3637-2015 OI Rojas, Don/0000-0001-6560-9616; Smucny, Jason/0000-0001-5656-7987 FU VA Biomedical Laboratory and Clinical Science Research and Development Service; Brain and Behavior Foundation; Blowitz-Ridgeway Foundation FX The authors thank Robert Freedman, M.D., for assistance with manuscript preparation. This research was supported by the VA Biomedical Laboratory and Clinical Science Research and Development Service, the Brain and Behavior Foundation, and the Blowitz-Ridgeway Foundation. NR 45 TC 5 Z9 5 U1 1 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 EI 1872-7506 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD NOV 30 PY 2013 VL 214 IS 2 BP 169 EP 174 DI 10.1016/j.pscychresns.2013.07.002 PG 6 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 231QL UT WOS:000325432300011 PM 23972946 ER PT J AU McLinden, RJ LaBranche, CC Chenine, AL Polonis, VR Eller, MA Wieczorek, L Ochsenbauer, C Kappes, JC Perfetto, S Montefiori, DC Michael, NL Kim, JH AF McLinden, Robert J. LaBranche, Celia C. Chenine, Agnes-Laurence Polonis, Victoria R. Eller, Michael A. Wieczorek, Lindsay Ochsenbauer, Christina Kappes, John C. Perfetto, Stephen Montefiori, David C. Michael, Nelson L. Kim, Jerome H. TI Detection of HIV-1 Neutralizing Antibodies in a Human CD4(+)/CXCR4(+)/CCR5(+) T-Lymphoblastoid Cell Assay System SO PLOS ONE LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODIES; CROSS-CLADE NEUTRALIZATION; INFECTIOUS MOLECULAR CLONES; PROXIMAL EXTERNAL REGION; BLOOD MONONUCLEAR-CELLS; FUSION INHIBITOR T-20; SUBTYPE-C INFECTION; V3 LOOP; EFFICACY TRIAL AB Sensitive assays are needed to meaningfully assess low levels of neutralizing antibodies (NAbs) that may be important for protection against the acquisition of HIV-1 infection in vaccine recipients. The current assay of choice uses a non-lymphoid cell line (TZM-bl) that may lack sensitivity owing to over expression of CD4 and CCR5. We used transfection of a human CD4+/CXCR4+/alpha(4)beta(7)+ T-lymphoblastoid cell line (A3.01) with a CMV IE promoter-driven CCR5neo vector to stably express CCR5. The resulting line, designated A3R5, is permissive to a wide range of CCR5-tropic circulating strains of HIV-1, including HIV-1 molecular clones containing a Tat-inducible Renilla luciferase reporter gene and expressing multiple Env subtypes. Flow cytometric analysis found CCR5 surface expression on A3R5 cells to be markedly less than TZM-bl but similar to CD3.8 stimulated PBMC. More importantly, neutralization mediated by a diverse panel of monoclonal antibodies, HIV-1 positive polyclonal sera and sCD4 was consistently greater in A3R5 compared to TZM-bl cells. The A3R5 cell line provides a novel approach to guide the development and qualification of promising new HIV-1 vaccine immunogens. C1 [McLinden, Robert J.; Chenine, Agnes-Laurence; Polonis, Victoria R.; Eller, Michael A.; Wieczorek, Lindsay; Michael, Nelson L.; Kim, Jerome H.] WRAIR, Mil HIV Res Program, Silver Spring, MD USA. [LaBranche, Celia C.; Montefiori, David C.] Duke U Med Ctr, Dept Surg, Durham, NC USA. [Ochsenbauer, Christina; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kappes, John C.] Birmingham Vet Affairs Med Ctr, Res Serv, Birmingham, AL USA. [Perfetto, Stephen] NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA. RP McLinden, RJ (reprint author), WRAIR, Mil HIV Res Program, Silver Spring, MD USA. EM rmclinden@hivresearch.org FU U.S. Army Medical Research and Material Command (USAMRMC) [Y1-AI-2642-12]; National Institute of Allergy and Infectious Diseases [Y1-AI-2642-12]; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-07-2-0067]; U.S. Department of Defense (DOD) [W81XWH-07-2-0067]; Bill & Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD)/Comprehensive Antibody Vaccine Immune Monitoring Consortium (CA-VIMC) [38619, 1032144]; NIH Center for HIV/AIDS Vaccine Immunology (CHAVI) [UO1-AI067854] FX This work was supported in part by an Interagency Agreement (Y1-AI-2642-12) between U.S. Army Medical Research and Material Command (USAMRMC) and the National Institute of Allergy and Infectious Diseases. This work was also supported by a cooperative agreement (W81XWH-07-2-0067) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD). The contribution of DCM was supported by the Bill & Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD)/Comprehensive Antibody Vaccine Immune Monitoring Consortium (CA-VIMC), grant numbers 38619 and 1032144. The contribution of CO and JCK was supported by NIH Center for HIV/AIDS Vaccine Immunology (CHAVI) grant, UO1-AI067854; the Bill & Melinda Gates Foundation's Collaboration for AIDS Vaccine Discovery (CAVD)/Comprehensive Antibody Vaccine Immune Monitoring Consortium (CA-VIMC), grant numbers 38619 and 1032144; and facilities of the Virology and Genetic Sequencing cores of the UAB Center for AIDS Research (P30-AI-27767). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 103 TC 16 Z9 16 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 28 PY 2013 VL 8 IS 11 AR UNSP e77756 DI 10.1371/journal.pone.0077756 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 261IJ UT WOS:000327657900001 PM 24312168 ER PT J AU Bradley, SM Stanislawski, MA Bekelman, DB Monteith, LL Cohen, BE Hunt, SC Milek, D Schilling, JH Maddox, TM Ho, PM Shore, S Varosy, PD Rumsfeld, JS AF Bradley, Steven M. Stanislawski, Maggie A. Bekelman, David B. Monteith, Lindsey L. Cohen, Beth E. Hunt, Stephen C. Milek, Debra Schilling, John H. Maddox, Thomas M. Ho, P. Michael Shore, Supriya Varosy, Paul D. Rumsfeld, John S. TI Invasive Coronary Procedure Use and Outcomes among Patients with Post-Traumatic Stress Disorder: Insights from the VA CART Program SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Angiography; Outcomes; Longitudinal studies; Epidemiology C1 [Bradley, Steven M.; Bekelman, David B.; Maddox, Thomas M.; Ho, P. Michael; Varosy, Paul D.; Rumsfeld, John S.] VA Eastern Colorado Hlth Care Syst, Hlth Serv Rsch & Cardiol, Denver, CO USA. [Bradley, Steven M.; Bekelman, David B.; Schilling, John H.; Maddox, Thomas M.; Ho, P. Michael; Shore, Supriya; Varosy, Paul D.; Rumsfeld, John S.] Univ Colorado, Denver, CO 80202 USA. [Stanislawski, Maggie A.] VA Eastern Colorado Hlth Care Syst, VA CART Program, Denver, CO USA. [Monteith, Lindsey L.] VA Eastern Colorado Hlth Care Syst, MIRECC, Denver, CO USA. [Cohen, Beth E.] San Francisco VA Med Cntr, San Francisco, CA USA. [Cohen, Beth E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hunt, Stephen C.] VA Puget Sound Healthcare Syst, Med, Seattle, WA USA. [Hunt, Stephen C.; Milek, Debra] Univ Washington, Seattle, WA 98195 USA. [Shore, Supriya] VA Eastern Colorado Hlth Care Syst, Med, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 13055 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162902501 ER PT J AU Carson, P Anand, I Win, S Zile, M Haas, M Little, W Miller, A Lopez-Sendon, J Teerlink, J White, M Komajda, M McKelvie, RS McMurray, JJ Massie, B AF Carson, Peter Anand, Inder Win, Sithu Zile, Michael Haas, Markus Little, William Miller, Alan Lopez-Sendon, Jose Teerlink, John White, Michel Komajda, Michel McKelvie, Robert S. McMurray, John J. Massie, Barry TI Why Are patients With Heart Failure and Preserved Ejection Fraction Hospitalized? Data From I-PRESERVE SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Heart failure; Ejection fraction C1 [Carson, Peter] Washington VA Med Cntr, Washington, DC USA. [Anand, Inder; Win, Sithu] Minneapolis VAMC, Cardiol, Minneapolis, MN USA. [Zile, Michael] Charleston VAMC, Cardiol, Charleston, SC USA. [Zile, Michael] MUSC, Charleston, SC USA. [Haas, Markus] Theresienkrankenhaus, Mannheim, Germany. [Little, William] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Miller, Alan] Univ Florida Shands, Jacksonville, FL USA. [Lopez-Sendon, Jose] Hosp Univ LePaz, Madrid, Spain. [Teerlink, John; Massie, Barry] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John; Massie, Barry] San Francisco VA Med Ctr, San Francisco, CA USA. [White, Michel] Montreal Heart Cntr, Montreal, PQ, Canada. [Komajda, Michel] Univ Paris, Pitie Salpetriere Hosp, F-75252 Paris, France. [McKelvie, Robert S.] McMaster Univ, Hamilton Hlth Sci, Hamilton, ON, Canada. [McMurray, John J.] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Rsch Cntr, Glasgow, Lanark, Scotland. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 15844 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162905219 ER PT J AU Chirinos, J Shiva-Kumar, P Geraci, S Desai, S Chandrashekhar, R Jain, S Saif, H Haines, P Broderick, P Vakilipour, A Rawat, D Witschey, W Ferrari, V Akers, S AF Chirinos, Julio Shiva-Kumar, Prithvi Geraci, Salvatore Desai, Sanjal Chandrashekhar, Rahul Jain, Snigdha Saif, Hassam Haines, Philip Broderick, Preston Vakilipour, Amin Rawat, Deepa Witschey, Walter Ferrari, Victor Akers, Scott TI Relationship Between Effective Arterial Elastance and Specific Measures of Left Ventricular Afterload SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Arteries; Aging; Blood pressure; Blood vessel wall; Hemodynamics C1 [Chirinos, Julio; Shiva-Kumar, Prithvi; Desai, Sanjal; Chandrashekhar, Rahul; Jain, Snigdha; Haines, Philip; Broderick, Preston; Vakilipour, Amin; Ferrari, Victor] Univ Penn, Philadelphia, PA 19104 USA. [Geraci, Salvatore; Rawat, Deepa; Akers, Scott] Philadelphia VA Med Cntr, Philadelphia, PA USA. [Saif, Hassam] Lehigh Valley Hlth Network, Allentown, PA USA. [Witschey, Walter] Univ Penn, Cntr Magnet Resonance & Opt Imaging, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 18641 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162907478 ER PT J AU Chirinos, J Shiva-Kumar, P Chandrashekhar, R Desai, S Witschey, W Jain, S Saif, H Haines, P Broderick, P Geraci, S Vakilipour, A Rawat, D Ferrari, V Akers, S AF Chirinos, Julio Shiva-Kumar, Prithvi Chandrashekhar, Rahul Desai, Sanjal Witschey, Walter Jain, Snigdha Saif, Hassam Haines, Philip Broderick, Preston Geraci, Salvatore Vakilipour, Amin Rawat, Deepa Ferrari, Victor Akers, Scott TI Assessment of Age-Related Aortic Stiffness With Magnetic Resonance Imaging SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Aging; Arteries; Magnetic resonance imaging; Vascular; Noninvasive cardiac imaging C1 [Chirinos, Julio; Shiva-Kumar, Prithvi; Chandrashekhar, Rahul; Desai, Sanjal; Jain, Snigdha; Haines, Philip; Broderick, Preston; Vakilipour, Amin; Ferrari, Victor] Univ Penn, Philadelphia, PA 19104 USA. [Witschey, Walter] Univ Penn, Cntr Magnet Resonance & Opt Imaging, Philadelphia, PA 19104 USA. [Saif, Hassam] Lehigh Valley Hlth Network, Internal Med, Philadelphia, PA USA. [Geraci, Salvatore; Rawat, Deepa; Akers, Scott] Philadelphia VA Med Cntr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 18304 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162907305 ER PT J AU Dori, Y Rychik, J Glatz, AC Gillespie, MJ Harris, MA Fogel, M Whitehead, KK Rome, JJ Keller, M Itkin, M AF Dori, Yoav Rychik, Jack Glatz, Andrew C. Gillespie, Matthew J. Harris, Matthew A. Fogel, Mark Whitehead, Kevin K. Rome, Jonathan J. Keller, Marc Itkin, Maxim TI Lymphatic Abnormalities in Patients With Congenital Heart Disease: New Insights From Non-Contrast Magnetic Resonance Lymphangiography SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Congenital hear disease; Magnetic resonance imaging; Single ventricle C1 [Dori, Yoav; Rychik, Jack; Glatz, Andrew C.; Gillespie, Matthew J.; Harris, Matthew A.; Fogel, Mark; Whitehead, Kevin K.; Rome, Jonathan J.; Keller, Marc] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Itkin, Maxim] Philadelphia VA Med Cntr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 16061 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162905344 ER PT J AU Fletcher, RD Amdur, RL Papademetriou, V Kheirbek, R Maron, D Faselis, C Jones, RE AF Fletcher, Ross D. Amdur, Richard L. Papademetriou, Vasilios Kheirbek, Raya Maron, David Faselis, Charles Jones, Ronald E. TI Blood Pressure Control in All VA Patients From 2000 to 2011 With Analysis of Racial Disparity and Body Mass Index for Further Improvements SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Hypertension C1 [Fletcher, Ross D.; Amdur, Richard L.; Papademetriou, Vasilios; Kheirbek, Raya; Maron, David; Faselis, Charles] US Dept Vet Affairs, Washington, DC USA. [Jones, Ronald E.] US Dept Vet Affairs, Pacemaker Cntr, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 16017 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162905322 ER PT J AU Ismahil, MAM Hamid, T Bansal, SS Kingery, JR Prabhu, SD AF Ismahil, Mohamed Ameen Mohamed Hamid, Tariq Bansal, Shyam S. Kingery, Justin R. Prabhu, Sumanth D. TI Remodeling of the Mononuclear Phagocyte Network Underlies Chronic Inflammation and Disease Progression in Heart Failure: Importance of the Cardiosplenic Axis SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Heart failure; Inflammation; Dendritic cell; Immune system; Infarction C1 [Ismahil, Mohamed Ameen Mohamed; Hamid, Tariq; Bansal, Shyam S.; Prabhu, Sumanth D.] Univ Alabama Birmingham, Dept Cardiovasc Dis, Birmingham, AL USA. [Kingery, Justin R.] Univ Louisville, Dept Cardiovasc Dis, Louisville, KY 40292 USA. [Prabhu, Sumanth D.] Birmingham VAMC, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 14883 PG 2 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162904284 ER PT J AU Marzec, LN Lambert-Kerzner, A Carey, F Del Giacco, EJ Melnyk, SD Bryson, CL Fahdi, IE Bosworth, HB Fiocchi, F Ho, M AF Marzec, Lucas N. Lambert-Kerzner, Anne Carey, Fvan Del Giacco, Eric J. Melnyk, Stephanie D. Bryson, Christopher L. Fahdi, Ibrahim E. Bosworth, Hayden B. Fiocchi, Fran Ho, Michael TI Health Illiteracy and Cognitive Dysfunction Are Common in Veterans Presenting With Acute Coronary Syndrome: Insights From the MEDICATION Study SO CIRCULATION LA English DT Meeting Abstract CT Scientific Sessions and Resuscitation Science Symposium of the American-Heart-Association CY NOV 16-17, 2013 CL Dallas, TX SP Amer Heart Assoc DE Acute coronary syndromes; Cognitive function; Adherence C1 [Marzec, Lucas N.] Univ Colorado, Aurora, CO USA. [Lambert-Kerzner, Anne; Carey, Fvan; Ho, Michael] Denver VA Med Cntr, Denver, CO USA. [Del Giacco, Eric J.] John L McClellan Mem Vet Adm Med Ctr, Cent Arkansas Vet Healthcare Syst, Little Rock, AR USA. [Melnyk, Stephanie D.; Bosworth, Hayden B.] Durham VA Med Cntr, Durham, NC USA. [Bryson, Christopher L.] VA Puget Sound Hlth Care Syst, Seattle Div, Internal Med, Seattle, WA USA. [Fahdi, Ibrahim E.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. [Fiocchi, Fran] Amer Coll Cardiol, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 EI 1524-4539 J9 CIRCULATION JI Circulation PD NOV 26 PY 2013 VL 128 IS 22 SU S MA 16308 PG 1 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA AC0CR UT WOS:000332162905468 ER PT J AU Meyer, AND Payne, VL Meeks, DW Rao, R Singh, H AF Meyer, Ashley N. D. Payne, Velma L. Meeks, Derek W. Rao, Radha Singh, Hardeep TI Physicians' Diagnostic Accuracy, Confidence, and Resource Requests A Vignette Study SO JAMA INTERNAL MEDICINE LA English DT Article ID DECISION-SUPPORT; ULTRASOUND OPERATORS; MEDICINE; ERRORS; OVERCONFIDENCE; CONSULTATION; ASSOCIATION; CORRECT AB IMPORTANCE Little is known about the relationship between physicians' diagnostic accuracy and their confidence in that accuracy. OBJECTIVE To evaluate how physicians' diagnostic calibration, defined as the relationship between diagnostic accuracy and confidence in that accuracy, changes with evolution of the diagnostic process and with increasing diagnostic difficulty of clinical case vignettes. DESIGN, SETTING, AND PARTICIPANTS We recruited general internists from an online physician community and asked them to diagnose 4 previously validated case vignettes of variable difficulty (2 easier; 2 more difficult). Cases were presented in a web-based format and divided into 4 sequential phases simulating diagnosis evolution: history, physical examination, general diagnostic testing data, and definitive diagnostic testing. After each phase, physicians recorded 1 to 3 differential diagnoses and corresponding judgments of confidence. Before being presented with definitive diagnostic data, physicians were asked to identify additional resources they would require to diagnose each case (ie, additional tests, second opinions, curbside consultations, referrals, and reference materials). MAIN OUTCOMES AND MEASURES Diagnostic accuracy (scored as 0 or 1), confidence in diagnostic accuracy (on a scale of 0-10), diagnostic calibration, and whether additional resources were requested (no or yes). RESULTS A total of 118 physicians with broad geographical representation within the United States correctly diagnosed 55.3% of easier and 5.8% of more difficult cases (P < .001). Despite a large difference in diagnostic accuracy between easier and more difficult cases, the difference in confidence was relatively small (7.2 vs 6.4 out of 10, for easier and more difficult cases, respectively) (P < .001) and likely clinically insignificant. Overall, diagnostic calibration was worse for more difficult cases (P < .001) and characterized by overconfidence in accuracy. Higher confidence was related to decreased requests for additional diagnostic tests (P = .01); higher case difficulty was related to more requests for additional reference materials (P = .01). CONCLUSIONS AND RELEVANCE Our study suggests that physicians' level of confidence may be relatively insensitive to both diagnostic accuracy and case difficulty. This mismatch might prevent physicians from reexamining difficult cases where their diagnosis may be incorrect. C1 [Meyer, Ashley N. D.; Payne, Velma L.; Meeks, Derek W.; Singh, Hardeep] Vet Affairs Hlth Serv Res, Dev Ctr Excellence & Sect Hlth Serv Res, Houston, TX USA. [Meyer, Ashley N. D.; Payne, Velma L.; Meeks, Derek W.; Rao, Radha; Singh, Hardeep] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Meyer, Ashley N. D.; Payne, Velma L.; Meeks, Derek W.; Rao, Radha; Singh, Hardeep] Baylor Coll Med, Houston, TX 77030 USA. RP Singh, H (reprint author), Vet Affairs Med Ctr 152, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu OI Meyer, Ashley/0000-0001-7993-8584 FU PHS HHS [T32HP10031] NR 29 TC 26 Z9 26 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV 25 PY 2013 VL 173 IS 21 BP 1952 EP 1959 DI 10.1001/jamainternmed.2013.10081 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA AA2WG UT WOS:000330954300003 PM 23979070 ER PT J AU Dhaliwal, G AF Dhaliwal, Gurpreet TI Known Unknowns and Unknown Unknowns at the Point of Care SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID DECISION-MAKING C1 [Dhaliwal, Gurpreet] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Dept Med, Med Serv, San Francisco, CA 94143 USA. RP Dhaliwal, G (reprint author), San Francisco VA Med Ctr, 4150 Clement St 111, San Francisco, CA 94121 USA. EM gurpreet.dhaliwal@ucsf.edu NR 10 TC 3 Z9 3 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV 25 PY 2013 VL 173 IS 21 BP 1959 EP 1961 DI 10.1001/jamainternmed.2013.7494 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA AA2WG UT WOS:000330954300004 PM 23979528 ER PT J AU Good, CB Burk, M Cunningham, F AF Good, Chester B. Burk, Muriel Cunningham, Francesca TI Topical Anesthetic-Induced Methemoglobinemia and Veterans Affairs Hospitals SO JAMA INTERNAL MEDICINE LA English DT Letter C1 [Good, Chester B.; Burk, Muriel; Cunningham, Francesca] VA Ctr Medicat Safety, Hines, IL USA. [Good, Chester B.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA 15240 USA. [Good, Chester B.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. RP Good, CB (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Bldg 30,Univ Dr, Pittsburgh, PA 15240 USA. EM Chester.good@va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV 25 PY 2013 VL 173 IS 21 DI 10.1001/jamainternmed.2013.9970 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA AA2WG UT WOS:000330954300021 ER PT J AU Shen, Q Du, F Huang, SL Rodriguez, P Watts, LT Duong, TQ AF Shen, Qiang Du, Fang Huang, Shiliang Rodriguez, Pavel Watts, Lora Talley Duong, Timothy Q. TI Neuroprotective Efficacy of Methylene Blue in Ischemic Stroke: An MRI Study SO PLOS ONE LA English DT Article ID DIFFUSION; PERFUSION AB Methylene blue (MB) has unique energy-enhancing and antioxidant properties and is FDA-approved drug to treat methemoglobinemia and cyanide poisoning. This study evaluated the efficacy of MB to treat ischemic stroke in rats using longitudinal MRI and behavioral measures. Rats were subjected to 60-minute middle-cerebral-artery occlusion. In a randomized double-blinded design, vehicle or MB was administered after reperfusion. The initial lesion volumes at 30 minutes post-ischemia were not significantly different between the two groups (P = 0.92). The final infarct volumes two days after stroke increased in the vehicle group but decreased in the MB group, yielding a 30% difference in infarct volume (P = 0.03). Tracking tissue fate on a pixel-by-pixel basis showed that MB salvaged more initial core pixels compared to controls (22 +/- 3% versus 11 +/- 3%, P = 0.03), and more mismatch pixels compared to controls (83 +/- 3% versus 61 +/- 8%, P = 0.02). This study demonstrates MB treatment minimizes ischemic brain injury and improves functional outcomes. C1 [Shen, Qiang; Du, Fang; Huang, Shiliang; Watts, Lora Talley; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA. [Shen, Qiang; Rodriguez, Pavel; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA. [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular Struct Biol, San Antonio, TX 78229 USA. [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA. [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX USA. RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. EM duongt@uthscsa.edu RI Shen, Qiang/B-8784-2008 OI Shen, Qiang/0000-0002-4287-3403 FU NIH [R01NS45879, UL1TR000149]; American Heart Association [EIA0940104N, BGIA9300047] FX This work was supported in part by NIH (R01NS45879, UL1TR000149) and American Heart Association (EIA0940104N, BGIA9300047). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 16 TC 19 Z9 20 U1 0 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 21 PY 2013 VL 8 IS 11 AR e79833 DI 10.1371/journal.pone.0079833 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 259PW UT WOS:000327539800026 PM 24278191 ER PT J AU Asch, DA Nicholson, S Vujicic, M AF Asch, David A. Nicholson, Sean Vujicic, Marko TI Are We in a Medical Education Bubble Market? SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material AB Debt-to-income ratios for new physicians reveal the connection between what physicians can charge patients and what medical schools can charge students. If we aim to reduce the costs of health care, we need to reduce the costs of medical education. In November 1636, the prices of tulip bulbs in the Dutch market rose rapidly from their normal level to the point where a single bulb might sell for 10 times the annual earnings of a typical worker. Just as quickly, in May 1637, tulip-bulb prices returned to their previous values. The causes of this dramatic rise and fall remain in dispute. The event occurred during the Dutch Golden Age, when stock exchanges, central banking, and many of the fundamental structures that govern contemporary capital markets and the approaches deployed by MBAs today were developed. One modern economic analysis suggests that ... C1 [Asch, David A.] Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA. [Nicholson, Sean] Cornell Univ, Ithaca, NY USA. [Nicholson, Sean] Natl Bur Econ Res, Cambridge, MA 02138 USA. [Vujicic, Marko] Amer Dent Assoc, Chicago, IL USA. RP Asch, DA (reprint author), Univ Penn, Ctr Hlth Equ Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. OI Asch, David/0000-0002-7970-286X NR 5 TC 24 Z9 24 U1 1 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD NOV 21 PY 2013 VL 369 IS 21 BP 1973 EP 1975 DI 10.1056/NEJMp1310778 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 254KE UT WOS:000327163000002 PM 24171508 ER PT J AU Der-Martirosian, C Heslin, KC Mitchell, MN Chu, K Tran, K Dobalian, A AF Der-Martirosian, Claudia Heslin, Kevin C. Mitchell, Michael N. Chu, Karen Kim Tran Dobalian, Aram TI Comparison of the Use of H1N1 and seasonal influenza vaccinations between veterans and non-veterans in the United States, 2010 SO BMC PUBLIC HEALTH LA English DT Article DE H1N1; Seasonal flu shot; Veterans; non-Veterans; flu vaccination ID IMMUNIZATION PRACTICES ACIP; VACCINES RECOMMENDATIONS; ADVISORY-COMMITTEE; OLDER; HEALTH; PREVENTION; RESOURCE; ADULTS; RATES; CARE AB Background: Veterans of the U.S. armed forces tend to be older and have more chronic health problems than the general adult population, which may place them at greater risk of complications from influenza. Despite Centers for Disease Control and Prevention (CDC) recommendations, seasonal influenza vaccination rates for the general adult population remain well below the national goal of 80%. Achieving this goal would be facilitated by a clearer understanding of which factors influence vaccination. Methods: Using the 2010 U.S. National Health Interview Survey (NHIS), this study estimates models of two types of vaccinations (H1N1 and seasonal flu), assesses if the correlates differ for these vaccinations, and analyses the distribution of the correlates by veteran status. Results: Veterans, women, non-Hispanic whites, non-smokers, those at high risk, educated, with health insurance, and who use clinics as a usual source of care were more likely to receive both types of vaccinations. Those who were older, married, and with higher income were more likely to get vaccinated for seasonal flu, but not for H1N1. Age and number of children living in the household were found to have different effects for H1N1 compared to seasonal flu. Conclusion: Veterans are more likely to get vaccinated for seasonal influenza and H1N1 compared to the general population. This might be due to Veterans having better access to care or Veterans participating in better health care practices. Future studies should examine potential differences in flu vaccination use among Veterans using Veterans Affairs (VA) health care system vs. non-VA users. C1 [Der-Martirosian, Claudia; Heslin, Kevin C.; Mitchell, Michael N.; Chu, Karen; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA USA. [Kim Tran; Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Heslin, Kevin C.; Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. RP Der-Martirosian, C (reprint author), US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA USA. EM claudia.der-martirosian@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Office of Public Health (OPH) FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Public Health (OPH). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. NR 35 TC 0 Z9 0 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD NOV 20 PY 2013 VL 13 AR 1082 DI 10.1186/1471-2458-13-1082 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 284EX UT WOS:000329300000001 PM 24252569 ER PT J AU Goldzweig, CL Orshansky, G Paige, NM Towfigh, AA Haggstrom, DA Miake-Lye, I Beroes, JM Shekelle, PG AF Goldzweig, Caroline Lubick Orshansky, Greg Paige, Neil M. Towfigh, Ali Alexander Haggstrom, David A. Miake-Lye, Isomi Beroes, Jessica M. Shekelle, Paul G. TI Electronic Patient Portals: Evidence on Health Outcomes, Satisfaction, Efficiency, and Attitudes SO ANNALS OF INTERNAL MEDICINE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; SHARED MEDICAL-RECORD; CONGESTIVE-HEART-FAILURE; INFORMATION-TECHNOLOGY; HYPERTENSION CONTROL; COLLABORATIVE CARE; ONLINE; EXPERIENCES; INTERNET; ACCESS AB Background: Patient portals tied to provider electronic health record (EHR) systems are increasingly popular. Purpose: To systematically review the literature reporting the effect of patient portals on clinical care. Data Sources: PubMed and Web of Science searches from 1 January 1990 to 24 January 2013. Study Selection: Hypothesis-testing or quantitative studies of patient portals tethered to a provider EHR that addressed patient outcomes, satisfaction, adherence, efficiency, utilization, attitudes, and patient characteristics, as well as qualitative studies of barriers or facilitators, were included. Data Extraction: Two reviewers independently extracted data and addressed discrepancies through consensus discussion. Data Synthesis: From 6508 titles, 14 randomized, controlled trials; 21 observational, hypothesis-testing studies; 5 quantitative, descriptive studies; and 6 qualitative studies were included. Evidence is mixed about the effect of portals on patient outcomes and satisfaction, although they may be more effective when used with case management. The effect of portals on utilization and efficiency is unclear, although patient race and ethnicity, education level or literacy, and degree of comorbid conditions may influence use. Limitation: Limited data for most outcomes and an absence of reporting on organizational and provider context and implementation processes. Conclusion: Evidence that patient portals improve health outcomes, cost, or utilization is insufficient. Patient attitudes are generally positive, but more widespread use may require efforts to overcome racial, ethnic, and literacy barriers. Portals represent a new technology with benefits that are still unclear. Better understanding requires studies that include details about context, implementation factors, and cost. C1 Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. Indianapolis Vet Affairs Med Ctr, Indianapolis, IN USA. Indiana Univ Sch Med, Indianapolis, IN 46202 USA. RP Goldzweig, CL (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,111-G, Los Angeles, CA 90073 USA. EM caroline.goldzweig@va.gov FU U.S. Department of Veterans Affairs FX U.S. Department of Veterans Affairs. NR 53 TC 90 Z9 90 U1 7 U2 30 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD NOV 19 PY 2013 VL 159 IS 10 BP 677 EP + DI 10.7326/0003-4819-159-10-201311190-00006 PG 24 WC Medicine, General & Internal SC General & Internal Medicine GA 276FB UT WOS:000328732700016 PM 24247673 ER PT J AU Axelsson, M Mattsson, N Malmestrom, C Zetterberg, H Lycke, J AF Axelsson, Markus Mattsson, Niklas Malmestrom, Clas Zetterberg, Henrik Lycke, Jan TI The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis SO JOURNAL OF NEUROIMMUNOLOGY LA English DT Article DE Multiple sclerosis; Intrathecal IgG; Oligoclonal band (OCB); CXCL13; Mitoxantrone; B-cell ID STEM-CELL TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; DIAGNOSTIC-CRITERIA; PLASMA BLASTS; MS; PROTEIN; TRIAL; PANENCEPHALITIS; ABNORMALITIES AB We investigated the impact of disease duration, clinical course and immunosuppressive therapy on intrathecal IgG synthesis in multiple sclerosis (MS). Cerebrospinal fluid (CSF) was obtained twice, 8-10 years apart, from 20 MS patients and 26 healthy controls, and from 22 MS patients before and after two years of mitoxantrone treatment. The oligoclonal IgG band patterns changed in 15 patients at long-term follow-up, but were only influenced in 4 patients by mitoxantrone therapy. The CSF B-cell-regulating chemokine CXCL13 correlated with intrathecal IgG production suggesting a B-cell-dependence of intrathecal IgG synthesis in MS. (C) 2013 Elsevier B.V. All rights reserved. C1 [Axelsson, Markus; Malmestrom, Clas; Lycke, Jan] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Clin Neurosci & Rehabil, Gothenburg, Sweden. [Mattsson, Niklas; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden. [Mattsson, Niklas] Univ Calif San Francisco, San Francisco VA Med Ctr, CIND, San Francisco, CA 94143 USA. RP Axelsson, M (reprint author), Sahlgrens Univ Hosp, Dept Neurol, Bla Straket 7, S-41345 Gothenburg, Sweden. EM markus.axelsson@vgregion.se RI Malmestrom, Clas/A-8749-2012 OI Malmestrom, Clas/0000-0003-2477-0088; Lycke, Jan/0000-0002-7891-8466 FU Swedish Federal Government (LUA/ALF agreement); Swedish Society of the Neurologically Disabled; Research Foundation of the Multiple Sclerosis Society of Gothenburg; Edit Jacobson Foundation, and Biogen Idec (unconditional grants) FX This study was funded by grants from the Swedish Federal Government (LUA/ALF agreement), the Swedish Society of the Neurologically Disabled, the Research Foundation of the Multiple Sclerosis Society of Gothenburg, the Edit Jacobson Foundation, and Biogen Idec (unconditional grants). NR 49 TC 8 Z9 8 U1 0 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-5728 EI 1872-8421 J9 J NEUROIMMUNOL JI J. Neuroimmunol. PD NOV 15 PY 2013 VL 264 IS 1-2 BP 100 EP 105 DI 10.1016/j.jneuroim.2013.09.003 PG 6 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA 260AP UT WOS:000327567700013 PM 24125567 ER PT J AU Mallampalli, RK Coon, TA Glasser, JR Wang, C Dunn, SR Weathington, NM Zhao, J Zou, CB Zhao, YT Chen, BB AF Mallampalli, Rama K. Coon, Tiffany A. Glasser, Jennifer R. Wang, Claire Dunn, Sarah R. Weathington, Nathaniel M. Zhao, Jing Zou, Chunbin Zhao, Yutong Chen, Bill B. TI Targeting F Box Protein Fbxo3 To Control Cytokine-Driven Inflammation SO JOURNAL OF IMMUNOLOGY LA English DT Article ID EXPERIMENTAL COLITIS; APAG PROTEIN; MOUSE PAW; SEPSIS; FAMILY; ACTIVATION; EXPRESSION; CORTICOSTEROIDS; UBIQUITINATION; PROLIFERATION AB Cytokine-driven inflammation underlies the pathobiology of a wide array of infectious and immune-related disorders. The TNFR-associated factor (TRAF) proteins have a vital role in innate immunity by conveying signals from cell surface receptors to elicit transcriptional activation of genes encoding proinflammatory cytokines. We discovered that a ubiquitin E3 ligase F box component, termed Fbxo3, potently stimulates cytokine secretion from human inflammatory cells by mediating the degradation of the TRAF inhibitory protein, Fbxl2. Analysis of the Fbxo3 C-terminal structure revealed that the bacterial-like ApaG molecular signature was indispensible for mediating Fbxl2 disposal and stimulating cytokine secretion. By targeting this ApaG motif, we developed a highly unique, selective genus of small-molecule Fbxo3 inhibitors that by reducing TRAF protein levels, potently inhibited cytokine release from human blood mononuclear cells. The Fbxo3 inhibitors effectively lessened the severity of viral pneumonia, septic shock, colitis, and cytokine-driven inflammation systemically in murine models. Thus, pharmacological targeting of Fbxo3 might be a promising strategy for immune-related disorders characterized by a heightened host inflammatory response. C1 [Mallampalli, Rama K.; Coon, Tiffany A.; Glasser, Jennifer R.; Wang, Claire; Dunn, Sarah R.; Weathington, Nathaniel M.; Zhao, Jing; Zou, Chunbin; Zhao, Yutong; Chen, Bill B.] Univ Pittsburgh, Div Pulm Allergy & Crit Care Med, Dept Med, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.; Coon, Tiffany A.; Glasser, Jennifer R.; Wang, Claire; Dunn, Sarah R.; Weathington, Nathaniel M.; Zhao, Jing; Zou, Chunbin; Zhao, Yutong; Chen, Bill B.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA. [Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA 15213 USA. RP Mallampalli, RK (reprint author), Univ Pittsburgh, Dept Med, Med Ctr, Montefiore Hosp, Northwest 628,3459 5th Ave, Pittsburgh, PA 15213 USA. EM mallampallirk@upmc.edu; chenb@upmc.edu FU U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development; National Institutes of Health [R01 HL096376, R01 HL097376, R01 HL098174, R01 HL116472, R01 HL01916]; American Heart Association [12SDG9050005, 12SDG12040330]; U.S. Department of Veterans Affairs FX This work was supported in part by the U.S. Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. This work also was supported by a Merit Review award from the U.S. Department of Veterans Affairs and National Institutes of Health Grants R01 HL096376, R01 HL097376, and R01 HL098174 (to R.K.M.), R01 HL116472 (to B.B.C.), R01 HL01916 (to Y.Z.), and American Heart Association Awards 12SDG9050005 (to J.Z.) and 12SDG12040330 (to C.Z.). NR 49 TC 19 Z9 19 U1 0 U2 8 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-1767 EI 1550-6606 J9 J IMMUNOL JI J. Immunol. PD NOV 15 PY 2013 VL 191 IS 10 BP 5247 EP 5255 DI 10.4049/jimmunol.1300456 PG 9 WC Immunology SC Immunology GA 247AK UT WOS:000326584600038 PM 24123678 ER PT J AU Harel, NY Yigitkanli, K Fu, YG Cafferty, WBJ Strittmatter, SM AF Harel, Noam Y. Yigitkanli, Kazim Fu, Yiguang Cafferty, William B. J. Strittmatter, Stephen M. TI Multimodal exercises simultaneously stimulating cortical and brainstem pathways after unilateral corticospinal lesion SO BRAIN RESEARCH LA English DT Article DE Spinal cord injury; Corticospinal tract; Pyramidotomy; Exercise rehabilitation; Reticulospinal ID SPINAL-CORD-INJURY; RETICULAR-FORMATION; AXONAL GROWTH; MOTOR SYSTEMS; RECOVERY; TRACT; PLASTICITY; CONNECTIONS; PRIMATE; NEURONS AB In the context of injury to the corticospinal tract (CST), brainstem-origin circuits may provide an alternative system of descending motor influence. However, subcortical circuits are largely under subconscious control. To improve volitional control over spared fibers after CST injury, we hypothesized that a combination of physical exercises simultaneously stimulating cortical and brainstem pathways above the injury would strengthen corticobulbar connections through Hebbian-like mechanisms. We sought to test this hypothesis in mice with unilateral CST lesions. Ten days after pyramidotomy, mice were randomized to four training groups: (1) postural exercises designed to stimulate brainstem pathways (BS); (2) distal limb-grip exercises preferentially stimulating CST pathways (CST); (3) simultaneous multimodal exercises (BS+CST); or (4) no training (NT). Behavioral and anatomical outcomes were assessed after 20 training sessions over 4 weeks. Mice in the BS+CST training group showed a trend toward greater improvements in skilled limb performance than mice in the other groups. There were no consistent differences between training groups in gait kinematics. Anatomically, multimodal BS+CST training neither increased corticobulbar fiber density of the lesioned CST rostral to the lesion nor collateral sprouting of the unlesioned CST caudal to the lesion. Further studies should incorporate electrophysiological assessment to gauge changes in synaptic strength of direct and indirect pathways between the cortex and spinal cord in response to multimodal exercises. Published by Elsevier B.V. C1 [Harel, Noam Y.; Yigitkanli, Kazim; Fu, Yiguang; Cafferty, William B. J.; Strittmatter, Stephen M.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA. [Harel, Noam Y.; Yigitkanli, Kazim; Fu, Yiguang; Cafferty, William B. J.; Strittmatter, Stephen M.] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06520 USA. RP Harel, NY (reprint author), James J Peters Vet Affairs Med Ctr, 130 West Kingsbridge Rd,7A-13G, Bronx, NY 10468 USA. EM noam.harel@mssm.edu; kazim.yigitkanli@yale.edu; yiguang.fu@yale.edu; william.cafferty@yale.edu; stephen.strittmatter@yale.edu OI Strittmatter, Stephen/0000-0001-8188-3092 FU NINDS; Falk Medical Research Trust; Christopher and Dana Reeve Foundation; Wings for Life Foundation FX This work was funded by grants to S.M.S. from the NINDS, the Falk Medical Research Trust, the Christopher and Dana Reeve Foundation, and the Wings for Life Foundation, and a career development award to N.Y.H. from the NINDS. We also appreciate the help of Christopher Cardozo and Lauren Collier. NR 37 TC 4 Z9 4 U1 0 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0006-8993 EI 1872-6240 J9 BRAIN RES JI Brain Res. PD NOV 13 PY 2013 VL 1538 BP 17 EP 25 DI 10.1016/j.brainres.2013.07.012 PG 9 WC Neurosciences SC Neurosciences & Neurology GA 266FU UT WOS:000328009600002 PM 24055330 ER PT J AU Lam, TI Brennan-Minnella, AM Won, SJ Shen, YG Hefner, C Shi, YJ Sun, DD Swanson, RA AF Lam, Tina I. Brennan-Minnella, Angela M. Won, Seok Joon Shen, Yiguo Hefner, Colleen Shi, Yejie Sun, Dandan Swanson, Raymond A. TI Intracellular pH reduction prevents excitotoxic and ischemic neuronal death by inhibiting NADPH oxidase SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE NOX2; acidosis; Hv1; cariporide ID DEPENDENT SUPEROXIDE-PRODUCTION; NMDA RECEPTOR ACTIVATION; FOCAL CEREBRAL-ISCHEMIA; HIPPOCAMPAL-NEURONS; GLUTAMATE NEUROTOXICITY; NERVOUS-SYSTEM; NITRIC-OXIDE; CELL-DEATH; IN-VIVO; BRAIN AB Sustained activation of N-methyl-d-aspartate (NMDA) -type glutamate receptors leads to excitotoxic neuronal death in stroke, brain trauma, and neurodegenerative disorders. Superoxide production by NADPH oxidase is a requisite event in the process leading from NMDA receptor activation to excitotoxic death. NADPH oxidase generates intracellular H+ along with extracellular superoxide, and the intracellular H+ must be released or neutralized to permit continued NADPH oxidase function. In cultured neurons, NMDA-induced superoxide production and neuronal death were prevented by intracellular acidification by as little as 0.2 pH units, induced by either lowered medium pH or by inhibiting Na+/H+ exchange. In mouse brain, superoxide production induced by NMDA injections or ischemia-reperfusion was likewise prevented by inhibiting Na+/H+ exchange and by reduced expression of the Na+/H+ exchanger-1 (NHE1). Neuronal intracellular pH and neuronal Na+/H+ exchange are thus potent regulators of excitotoxic superoxide production. These findings identify a mechanism by which cell metabolism can influence coupling between NMDA receptor activation and superoxide production. C1 [Lam, Tina I.; Brennan-Minnella, Angela M.; Won, Seok Joon; Shen, Yiguo; Hefner, Colleen; Swanson, Raymond A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. [Lam, Tina I.; Brennan-Minnella, Angela M.; Won, Seok Joon; Shen, Yiguo; Hefner, Colleen; Swanson, Raymond A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA 94121 USA. [Shi, Yejie; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA. RP Swanson, RA (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA. EM raymond.swanson@ucsf.edu OI Swanson, Raymond/0000-0002-3664-5359 FU Department of Veterans Affairs; National Institutes of Health [NS081149, R01NS48216, R01NS38118] FX We thank Dr. Stephen Massa for helpful discussions. This work was supported by the Department of Veterans Affairs (R.A.S.) and by National Institutes of Health Grants NS081149 (to R.A.S.), R01NS48216 (to D.S.), and R01NS38118 (to D.S.). NR 46 TC 16 Z9 16 U1 3 U2 13 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD NOV 12 PY 2013 VL 110 IS 46 BP E4362 EP E4368 DI 10.1073/pnas.1313029110 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 250DQ UT WOS:000326830900015 PM 24163350 ER PT J AU Steinman, MA Auerbach, AD AF Steinman, Michael A. Auerbach, Andrew D. TI Managing Chronic Disease in Hospitalized Patients SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID ELDERLY-PATIENTS; DISCHARGE; ADHERENCE; COHORT C1 [Steinman, Michael A.; Auerbach, Andrew D.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA. [Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Steinman, MA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,POB 181G, San Francisco, CA 94121 USA. EM mike.steinman@ucsf.edu FU NHLBI NIH HHS [K24 HL098372]; NIA NIH HHS [1K23-AG030999, K23 AG030999] NR 7 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV 11 PY 2013 VL 173 IS 20 BP 1857 EP 1858 DI 10.1001/jamainternmed.2013.9511 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 302FD UT WOS:000330586600001 PM 23921959 ER PT J AU Singh, H Thomas, EJ AF Singh, Hardeep Thomas, Eric J. TI Origins of Diagnostic Error Reply SO JAMA INTERNAL MEDICINE LA English DT Letter ID PRIMARY-CARE C1 [Singh, Hardeep] Michael E DeBakey VA Med Ctr, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA. [Singh, Hardeep] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Thomas, Eric J.] Univ Texas Houston, Med Sch Houston, Mem Hermann Ctr Healthcare Qual & Safety, Div Gen Med,Dept Med, Houston, TX USA. RP Singh, H (reprint author), Michael E DeBakey Vet Affairs Med Ctr 152, Houston VA Hlth Serv Res & Dev Ctr Excellence, 2002 Holcombe Blvd, Houston, TX 77030 USA. EM hardeeps@bcm.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD NOV 11 PY 2013 VL 173 IS 20 BP 1926 EP 1927 DI 10.1001/jamainternmed.2013.9717 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 302FD UT WOS:000330586600021 PM 24217378 ER PT J AU Wasson, NJ Varley, CD Schwab, P Fu, RW Winthrop, KL AF Wasson, Ngoc J. Varley, Cara D. Schwab, Pascal Fu, Rongwei Winthrop, Kevin L. TI "Serious skin & soft tissue infections in rheumatoid arthritis patients taking anti-tumor necrosis factor alpha drugs: a nested case-control study" SO BMC INFECTIOUS DISEASES LA English DT Article DE Infectious skin diseases; Tumor necrosis factor-alpha; Anti-TNF therapy; Arthritis; Rheumatoid ID BACTERIAL-INFECTIONS; OPPORTUNISTIC INFECTIONS; RISK; THERAPY; ANTAGONISTS; EPIDEMIOLOGY; BIOLOGICS; DATABASES; DISEASES AB Background: Anti-tumor necrosis factor alpha (anti-TNF) drugs are very effective for the treatment of rheumatoid arthritis but may increase the risk of serious bacterial infections. We assessed the association between the risk of serious skin and soft tissue infections (SSSTI) and the use of these agents in rheumatoid arthritis patients (RA). Methods: We conducted a nested case-control study among rheumatoid arthritis patients in the Veterans Integrated Service Network 20 from 2000-2008. We identified rheumatoid arthritis patients with SSSTI, matched them to three sets of RA controls and used conditional logistic regression to compare the risk of SSSTI between patients treated and those not treated with an anti-TNF drug, after adjusting for known confounders and important covariates. Limited by the design, we could not assess (absolute) risk but only relative risk in terms of association. Results: Among the 97 cases and 291 controls, 90 percent were male, 62 percent white, with a mean age of 63 years. Twenty percent received anti-TNF drugs during the study period. Thirty-nine percent of cases and 15 percent of controls died, (OR 3.5, 95% CI: 2.033, 6.11, p < 0.01). Diabetes mellitus (37%), kidney disease (16%) and a history of skin infections (27%) were common among cases. Based on conditional logistic regression, anti-TNF use was not significantly associated with skin and soft tissue infections (OR 1.1, 95% CI: 0.61-2.03, p = 0.92). However, patients with diabetes mellitus (OR 2.5, 95% CI: 1.53-4.13, p = 0.01) or a prior history of skin infection (OR 5.7, 95% CI: 2.87-11.43, p < 0.01) were more likely to have skin and soft tissue infections. Conclusion: Use of anti-TNF therapy among RA patients was not associated with an increased risk of SSSTI, but patients with diabetes mellitus and those with a history of prior skin infection were significantly more likely to have SSSTI and mortality was higher among cases than controls in this veteran cohort. C1 [Wasson, Ngoc J.; Varley, Cara D.; Schwab, Pascal; Fu, Rongwei; Winthrop, Kevin L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Schwab, Pascal] Portland VA Med Ctr, Portland, OR USA. RP Wasson, NJ (reprint author), Oregon Hlth & Sci Univ, Portland, OR 97201 USA. EM wassonn@ohsu.edu FU NCATS NIH HHS [UL1 TR000128] NR 28 TC 4 Z9 4 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD NOV 11 PY 2013 VL 13 AR 533 DI 10.1186/1471-2334-13-533 PG 7 WC Infectious Diseases SC Infectious Diseases GA 278QW UT WOS:000328905800001 PM 24498926 ER PT J AU Harriff, MJ Burgdorf, S Kurts, C Wiertz, EJHJ Lewinsohn, DA Lewinsohn, DM AF Harriff, Melanie J. Burgdorf, Sven Kurts, Christian Wiertz, Emmanuel J. H. J. Lewinsohn, Deborah A. Lewinsohn, David M. TI TAP Mediates Import of Mycobacterium tuberculosis-Derived Peptides into Phagosomes and Facilitates Loading onto HLA-I SO PLOS ONE LA English DT Article ID CROSS-PRESENTATION; INFECTED MACROPHAGES; DENDRITIC CELLS; T-CELLS; EXOGENOUS ANTIGENS; PATHWAY; TRAFFICKING; COMPARTMENT; ORGANELLES; MOLECULES AB Processing and presentation of antigen on MHC-I class I molecules serves to present peptides derived from cytosolic proteins to CD8(+) T cells. Infection with bacteria that remain in phagosomal compartments, such as Mycobacterium tuberculosis (Mtb), provides a challenge to this immune recognition as bacterial proteins are segregated from the cytosol. Previously we identified the Mtb phagosome itself as an organelle capable of loading MHC Class I molecules with Mtb antigens. Here, we find that the TAP transporter, responsible for importing peptides into the ER for loading in Class I molecules, is both present and functional in Mtb phagosomes. Furthermore, we describe a novel peptide reagent, representing the N-terminal domain of the bovine herpes virus UL49.5 protein, which is capable of specifically inhibiting the lumenal face of TAP. Together, these results provide insight into the mechanism by which peptides from intra-phagosomal pathogens are loaded onto Class I molecules. C1 [Harriff, Melanie J.; Lewinsohn, David M.] Portland VA Med Ctr, Portland, OR 97239 USA. [Harriff, Melanie J.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Pulm & Crit Care Med, Portland, OR 97201 USA. [Burgdorf, Sven] Univ Bonn, Life & Med Sci LIMES Inst, Bonn, Germany. [Burgdorf, Sven; Kurts, Christian] Univ Bonn, IMMEI, Bonn, Germany. [Wiertz, Emmanuel J. H. J.] Univ Med Ctr Utrecht, Utrecht, Netherlands. [Wiertz, Emmanuel J. H. J.] Leiden Univ, Med Ctr, Leiden, Netherlands. [Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA. [Lewinsohn, Deborah A.; Lewinsohn, David M.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA. RP Harriff, MJ (reprint author), Portland VA Med Ctr, Portland, OR 97239 USA. EM harriffm@ohsu.edu; lewinsod@ohsu.edu; lewinsod@ohsu.edu RI Lewinsohn, David/I-4936-2013 OI Lewinsohn, David/0000-0001-9906-9494 FU National Institutes of Health [R01AI048090, T32HL083808]; Veterans Affairs Hospitals Merit Review Grant; Portland Veterans Affairs Medical Center; National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [S10-RR023432]; Oregon Health & Sciences University MMI Imaging Core FX This research was supported by National Institutes of Health Grants R01AI048090 and T32HL083808, a Veterans Affairs Hospitals Merit Review Grant, and the Portland Veterans Affairs Medical Center. The microscopy in this publication was made possible in part by Grant Number S10-RR023432 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and the Oregon Health & Sciences University MMI Imaging Core. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 1 Z9 1 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 11 PY 2013 VL 8 IS 11 AR e79571 DI 10.1371/journal.pone.0079571 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 255EG UT WOS:000327221600135 PM 24244525 ER PT J AU Liu, ML Idkowiak-Baldys, J Roddy, PL Baldys, A Raymond, J Clarke, CJ Hannun, YA AF Liu, Mengling Idkowiak-Baldys, Jolanta Roddy, Patrick L. Baldys, Aleksander Raymond, John Clarke, Christopher J. Hannun, Yusuf A. TI Sustained Activation of Protein Kinase C Induces Delayed Phosphorylation and Regulates the Fate of Epidermal Growth Factor Receptor SO PLOS ONE LA English DT Article ID BREAST-CANCER CELLS; PHOSPHOLIPASE-D; RECYCLING ENDOSOMES; COUPLED RECEPTORS; ANGIOTENSIN-II; SEQUESTRATION; DEGRADATION; PATHWAY; INTERNALIZATION; ENDOCYTOSIS AB It is well established that acute activation of members of the protein kinase C (PKC) family induced by activation of cellular receptors can transduce extracellular stimuli to intracellular signaling. However, the functions of sustained activation of PKC are not well studied. We have previously shown that sustained activation of classical PKC isoforms over 15-60 min induced the formation of the pericentrion, a subset of recycling endosomes that are sequestered perinuclearly in a PKC- and phospholipase D (PLD)-dependent manner. In this study, we investigated the role of this process in the phosphorylation of EGFR on threonine 654 (Thr-654) and in the regulation of intracellular trafficking and fate of epidermal growth factor receptor (EGFR). Sustained stimulation of the angiotensin II receptor induced translocation of the EGFR to the pericentrion, which in turn prevents full access of EGF to the EGFR. These effects required PKC and PLD activities, and direct stimulation of PKC with phorbol esters was sufficient to reproduce these effects. Furthermore, activation of PKC induced delayed phosphorylation of EGFR on Thr-654 that coincided with the formation of the pericentrion and which was dependent on PLD and endocytosis of EGFR. Thus, Thr-654 phosphorylation required the formation of the pericentrion. On the other hand, using a T654A mutant of EGFR, we find that the phosphorylation on Thr-654 was not required for translocation of EGFR to the pericentrion but was required for protection of EGFR from degradation in response to EGF. Taken together, these results demonstrate a novel role for the pericentrion in the regulation of EGFR phosphorylation, which in turn is important for the fates of EGFR. C1 [Liu, Mengling; Clarke, Christopher J.; Hannun, Yusuf A.] SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. [Liu, Mengling; Clarke, Christopher J.; Hannun, Yusuf A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA. [Liu, Mengling; Idkowiak-Baldys, Jolanta; Roddy, Patrick L.; Clarke, Christopher J.; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Baldys, Aleksander] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Baldys, Aleksander] Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC USA. [Baldys, Aleksander] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Raymond, John] Med Coll Wisconsin, Milwaukee, WI 53226 USA. RP Hannun, YA (reprint author), SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA. EM yusuf.hannun@sbumed.org FU NIH [HL43707]; Department of Veterans Affairs Merit Award [1I01BX000182]; American Heart Association Mid-Atlantic Affiliate [0725358U] FX NIH grant HL43707; Department of Veterans Affairs Merit Award 1I01BX000182; American Heart Association Mid-Atlantic Affiliate grant 0725358U. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 42 TC 1 Z9 1 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 11 PY 2013 VL 8 IS 11 AR e80721 DI 10.1371/journal.pone.0080721 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 255EG UT WOS:000327221600215 PM 24244711 ER PT J AU Lawson, KA Teteak, CJ Zou, JH Hacquebord, J Ghatan, A Zielinska-Kwiatkowska, A Fernandes, RJ Chansky, HA Yang, L AF Lawson, Kevin A. Teteak, Colin J. Zou, Junhui Hacquebord, Jacques Ghatan, Andrew Zielinska-Kwiatkowska, Anna Fernandes, Russell J. Chansky, Howard A. Yang, Liu TI Mesenchyme-specific Knockout of ESET Histone Methyltransferase Causes Ectopic Hypertrophy and Terminal Differentiation of Articular Chondrocytes SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE Arthritis; Articular cartilage; Cartilage biology; Chondrocytes; Differentiation; Epigenetics; Gene Knockout; Histone methylation ID CELL NUCLEAR ANTIGEN; ALKALINE-PHOSPHATASE; OSTEOARTHRITIC CARTILAGE; DNA FRAGMENTATION; GROWTH-PLATE; MOUSE LIMB; EXPRESSION; JOINT; APOPTOSIS; GENE AB The exact molecular mechanisms governing articular chondrocytes remain unknown in skeletal biology. In this study, we have found that ESET (an ERG-associated protein with a SET domain, also called SETDB1) histone methyltransferase is expressed in articular cartilage. To test whether ESET regulates articular chondrocytes, we carried out mesenchyme-specific deletion of the ESET gene in mice. ESET knock-out did not affect generation of articular chondrocytes during embryonic development. Two weeks after birth, there was minimal qualitative difference at the knee joints between wild-type and ESET knock-out animals. At 1 month, ectopic hypertrophy, proliferation, and apoptosis of articular chondrocytes were seen in the articular cartilage of ESET-null animals. At 3 months, additional signs of terminal differentiation such as increased alkaline phosphatase activity and an elevated level of matrix metalloproteinase (MMP)-13 were found in ESET-null cartilage. Staining for type II collagen and proteoglycan revealed that cartilage degeneration became progressively worse from 2 weeks to 12 months at the knee joints of ESET knock-out mutants. Analysis of over 14 pairs of age- and sex-matched wild-type and knock-out mice indicated that the articular chondrocyte phenotype in ESET-null mutants is 100% penetrant. Our results demonstrate that expression of ESET plays an essential role in the maintenance of articular cartilage by preventing articular chondrocytes from terminal differentiation and may have implications in joint diseases such as osteoarthritis. C1 [Lawson, Kevin A.; Teteak, Colin J.; Zou, Junhui; Hacquebord, Jacques; Ghatan, Andrew; Zielinska-Kwiatkowska, Anna; Fernandes, Russell J.; Chansky, Howard A.; Yang, Liu] Univ Washington, Dept Orthoped & Sports Med, Seattle, WA 98108 USA. [Chansky, Howard A.; Yang, Liu] Vet Affairs Puget Sound Hlth Care Syst, Res & Dev Program, Seattle, WA 98108 USA. RP Yang, L (reprint author), Univ Washington, Dept Orthoped & Sports Med, 1660 S Columbian Way,GMR 151, Seattle, WA 98108 USA. EM lyang@u.washington.edu FU National Institutes of Health [RO1 AR051455, RO1 AR057025]; Merit Review Award from the United States Department of Veterans Affairs, Office of Research and Development Biomedical Laboratory Research Program FX This work was supported in part by National Institutes of Health Grant RO1 AR051455 (to L. Y.). This work was also supported by a Merit Review Award from the United States Department of Veterans Affairs, Office of Research and Development Biomedical Laboratory Research Program (to H. A. C.).; Supported by National Institutes of Health Grant RO1 AR057025. NR 28 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 8 PY 2013 VL 288 IS 45 BP 32119 EP 32125 DI 10.1074/jbc.M113.473827 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 275MQ UT WOS:000328681700002 PM 24056368 ER PT J AU Wissemann, WT Hill-Burns, EM Zabetian, CP Factor, SA Patsopouos, N Hoglund, B Holcomb, C Donahue, RJ Thomson, G Erlich, H Payami, H AF Wissemann, William T. Hill-Burns, Erin M. Zabetian, Cyrus P. Factor, Stewart A. Patsopouos, Nikolaos Hoglund, Bryan Holcomb, Cherie Donahue, Ryan J. Thomson, Glenys Erlich, Henry Payami, Haydeh TI Association of Parkinson Disease with Structural and Regulatory Variants in the HLA Region SO AMERICAN JOURNAL OF HUMAN GENETICS LA English DT Article ID WHOLE-GENOME ASSOCIATION; GENE-EXPRESSION; C EXPRESSION; HIV CONTROL; POPULATION; SUSCEPTIBILITY; ALLELES; LOCUS; SNP AB Historically, association of disease with the major histocompatibility complex (HLA) genes has been tested with HLA alleles that encode antigen-binding affinity. The association with Parkinson disease (PD), however, was discovered with noncoding SNPs in a genome-wide association study (GWAS). We show here that several HLA-region SNPs that have since been associated with PD form two blocks tagged by rs3129882 (p = 9 x 10(-11)) and by rs9268515 and/or rs2395163 (p = 3 x 10-11). We investigated whether these SNP-associations were driven by HLA-alleles at adjacent loci. We imputed class I and class II HLA-alleles for 2000 PD cases and 1986 controls from the NeuroGenetics Research Consortium GWAS and sequenced a subset of 194 cases and 204 controls. We were therefore able to assess accuracy of two imputation algorithms against next-generation-sequencing while taking advantage of the larger imputed data sets for disease study. Additionally, we imputed HLA alleles for 843 cases and 856 controls from another GWAS for replication. PD risk was positively associated with the B*07:02_C*07:02 DRB5*01_DRB1*15:01_DQA1*01:02_DQB1*06:02 haplotype and negatively associated with the C*03:04, DRB1*04:04 and DQA1*03:01 alleles. The risk haplotype and DQA1*03:01 lost significance when conditioned on the SNPs, but C*03:04 (OR = 0.72, p = 8 x 10(-6)) and DRB1*04:04 (OR = 0.65, p = 4 x 10(-5)) remained significant. Similarly, rs3129882 and the closely linked rs9268515 and rs2395163 remained significant irrespective of HLA alleles. rs3129882 and rs2395163 are expression quantitative trait loci (eQTLs) for HLA-DR and HLA-DQ (9 x 10(-5) >= P-eQTL, 2 x 10(-79)), suggesting that HLA gene expression might influence PD. Our data suggest that PD is associated with both structural and regulatory elements in HLA. Furthermore, our study demonstrates that noncoding SNPs in the HLA region can be associated with disease irrespective of HLA alleles, and that observed associations with HLA alleles can sometimes be secondary to a noncoding variant. C1 [Wissemann, William T.; Hill-Burns, Erin M.; Donahue, Ryan J.; Payami, Haydeh] New York State Dept Hlth, Wadsworth Ctr, Div Genet, Albany, NY 12208 USA. [Zabetian, Cyrus P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Zabetian, Cyrus P.] Univ Washington, Dept Neurol, Seattle, WA 98108 USA. [Factor, Stewart A.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Patsopouos, Nikolaos] Brigham & Womens Hosp, Inst Neurosci, Dept Neurol, Program Translat NeuroPsychiat Genom, Boston, MA 02115 USA. [Patsopouos, Nikolaos] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Genet,Dept Med, Boston, MA 02115 USA. [Patsopouos, Nikolaos] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA. [Hoglund, Bryan; Holcomb, Cherie] Roche Mol Syst, Dept Human Genet, Pleasanton, CA 94588 USA. [Thomson, Glenys] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA. [Erlich, Henry] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA. [Payami, Haydeh] SUNY Albany, Dept Biomed Sci, Albany, NY 12222 USA. RP Payami, H (reprint author), New York State Dept Hlth, Wadsworth Ctr, Div Genet, Albany, NY 12208 USA. EM hpayami@wadsworth.org OI Zabetian, Cyrus/0000-0002-7739-4306 FU National Institute of Neurological Disorders and Stroke (NINDS) [R01NS36960]; Global Genetic Consortium Grant from the Michael J. Fox Foundation for Parkinson's Disease Research; Department of Veterans Affairs [1I01BX000531]; National Institutes of Aging [P30AG08017]; Office of Research Development; Clinical Sciences Research & Development Service; Department of Veteran Affairs; Close to the Cure Foundation; National Institutes of Health [HHSN272201200028C]; NINDS FX We thank the research participants. We thank Tatiana Foroud and Richard Myers for making their datasets available for replication. The project was supported by award number R01NS36960 from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by a Global Genetic Consortium Grant from the Michael J. Fox Foundation for Parkinson's Disease Research, a Merit Review Award from the Department of Veterans Affairs (1I01BX000531), the National Institutes of Aging (P30AG08017), the Office of Research & Development, the Clinical Sciences Research & Development Service, the Department of Veteran Affairs, Close to the Cure Foundation, and National Institutes of Health contract HHSN272201200028C. Funding for PROGENI and GenePD studies, which generated the data used for replication, was provided by NINDS, and the GWAS data were obtained from the NINDS database at dbGaP accession number phs000126.v1.p1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. NR 31 TC 23 Z9 23 U1 0 U2 3 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0002-9297 EI 1537-6605 J9 AM J HUM GENET JI Am. J. Hum. Genet. PD NOV 7 PY 2013 VL 93 IS 5 BP 984 EP 993 DI 10.1016/j.ajhg.2013.10.009 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA 252HU UT WOS:000326996600019 PM 24183452 ER PT J AU Whitman, CB Shreay, S Gitlin, M van Oijen, MGH Spiegel, BMR AF Whitman, Cynthia B. Shreay, Sanatan Gitlin, Matthew van Oijen, Martijn G. H. Spiegel, Brennan M. R. TI Clinical Factors and the Decision to Transfuse Chronic Dialysis Patients SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; ERYTHROPOIESIS-STIMULATING AGENTS; INCIDENT HEMODIALYSIS-PATIENTS; CONJOINT-ANALYSIS APPLICATIONS; STANDARDIZED PATIENTS; HEMATOCRIT VALUES; CHART ABSTRACTION; EPOETIN-ALPHA; ANEMIA; PREFERENCES AB Background and objectivesRed blood cell transfusion was previously the principle therapy for anemia in CKD but became less prevalent after the introduction of erythropoiesis-stimulating agents. This study used adaptive choice-based conjoint analysis to identify preferences and predictors of transfusion decision-making in CKD.Design, setting, participants, & measurementsA computerized adaptive choice-based conjoint survey was administered between June and August of 2012 to nephrologists, internists, and hospitalists listed in the American Medical Association Masterfile. The survey quantified the relative importance of 10 patient attributes, including hemoglobin levels, age, occult blood in stool, severity of illness, eligibility for transplant, iron indices, erythropoiesis-stimulating agents, cardiovascular disease, and functional status. Triggers of transfusions in common dialysis scenarios were studied, and based on adaptive choice-based conjoint-derived preferences, relative importance by performing multivariable regression to identify predictors of transfusion preferences was assessed.ResultsA total of 350 providers completed the survey (n=305 nephrologists; mean age=46 years; 21% women). Of 10 attributes assessed, absolute hemoglobin level was the most important driver of transfusions, accounting for 29% of decision-making, followed by functional status (16%) and cardiovascular comorbidities (12%); 92% of providers transfused when hemoglobin was 7.5 g/dl, independent of other factors. In multivariable regression, Veterans Administration providers were more likely to transfuse at 8.0 g/dl (odds ratio, 5.9; 95% confidence interval, 1.9 to 18.4). Although transplant eligibility explained only 5% of decision-making, nephrologists were five times more likely to value it as important compared with non-nephrologists (odds ratio, 5.2; 95% confidence interval, 2.4 to11.1).ConclusionsAdaptive choice-based conjoint analysis was useful in predicting influences on transfusion decisions. Hemoglobin level, functional status, and cardiovascular comorbidities most strongly influenced transfusion decision-making, but preference variations were observed among subgroups. C1 [Whitman, Cynthia B.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Res, Los Angeles, CA USA. [Spiegel, Brennan M. R.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Internal Med, Los Angeles, CA USA. [Whitman, Cynthia B.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, Vet Adm Ctr Outcomes Res & Educ, Los Angeles, CA USA. [Shreay, Sanatan; Gitlin, Matthew] Amgen Inc, Global Hlth Econ, Thousand Oaks, CA 91320 USA. [van Oijen, Martijn G. H.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Los Angeles, CA 90095 USA. [van Oijen, Martijn G. H.; Spiegel, Brennan M. R.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA. RP Spiegel, BMR (reprint author), 11301 Wilshire Blvd,Bldg 115,Room 215, Los Angeles, CA 90073 USA. EM bspiegel@mednet.ucla.edu FU Amgen, Inc. FX This study was supported by a research grant from Amgen, Inc. The opinions and assertions contained herein are the sole views of the authors and not to be construed as official or reflecting the views of the Department of Veterans Affairs. NR 46 TC 9 Z9 9 U1 0 U2 4 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV 7 PY 2013 VL 8 IS 11 BP 1942 EP 1951 DI 10.2215/CJN.00160113 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA 250FR UT WOS:000326836400016 PM 23929931 ER PT J AU Kraut, JA Nagami, GT AF Kraut, Jeffrey A. Nagami, Glenn T. TI The Serum Anion Gap in the Evaluation of Acid-Base Disorders: What Are Its Limitations and Can Its Effectiveness Be Improved? SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Review ID CRITICALLY-ILL PATIENTS; METABOLIC-ACIDOSIS; LABORATORY EVALUATION; CLINICAL-DIAGNOSIS; HYPERLACTATEMIA; HYPOALBUMINEMIA; MORTALITY; LACTATE; SCREEN AB The serum anion gap has been utilized to identify errors in the measurement of electrolytes, to detect paraproteins, and, most relevant to the nephrologist, to evaluate patients with suspected acid-base disorders. In regard to the latter purpose, traditionally an increased anion gap is identified when it exceeds the upper limit of normal for a particular clinical laboratory measurement. However, because there is a wide range of normal values (often 8-10 mEq/L), an increase in anion concentration can be present in the absence of an increased anion gap. In addition, the type of retained anion can affect the magnitude of the increase in anion gap relative to change in serum [HCO3-] being greater with lactic acidosis compared with ketoacidosis. This review examines the methods of calculation of the serum anion gap in textbooks and published literature, the effect of perturbations other than changes in acid-base balance, and its effectiveness in identifying mild and more severe disturbances in acid-base balance. Limitations of the present methods of determining the normal anion gap and change in the anion gap are highlighted. The possibility of identifying the baseline value for individuals to optimize the use of the calculation in the detection of metabolic acidosis is suggested. C1 [Kraut, Jeffrey A.; Nagami, Glenn T.] Vet Affairs Greater Los Angeles Healthcare Syst, Med & Res Serv, Los Angeles, CA 90073 USA. [Kraut, Jeffrey A.] Univ Calif Los Angeles, Membrane Biol Lab, Los Angeles, CA USA. [Kraut, Jeffrey A.; Nagami, Glenn T.] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare Syst, Div Nephrol, Los Angeles, CA 90095 USA. RP Kraut, JA (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Div Nephrol, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jkraut@ucla.edu FU US Department of Veterans Affairs; UCLA Academic Senate FX This review was supported by funds from the US Department of Veterans Affairs and from the UCLA Academic Senate. NR 39 TC 12 Z9 13 U1 2 U2 7 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD NOV 7 PY 2013 VL 8 IS 11 BP 2018 EP 2024 DI 10.2215/CJN.04040413 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 250FR UT WOS:000326836400024 PM 23833313 ER PT J AU Trombetta-eSilva, J Eadie, EP Zhang, YH Norris, RA Borg, TK Bradshaw, AD AF Trombetta-eSilva, Jessica Eadie, Erik P. Zhang, Yuhua Norris, Russell A. Borg, Thomas K. Bradshaw, Amy D. TI The Effects of Age and the Expression of SPARC on Extracellular Matrix Production by Cardiac Fibroblasts in 3-D Cultures SO PLOS ONE LA English DT Article ID FIBRILLAR COLLAGEN CONTENT; DIASTOLIC FUNCTION ROLE; CONNECTIVE-TISSUE; IN-VITRO; NETWORK; HEART; BIOLOGY; MUSCLE; TENDON AB Fibrillar collagen is the primary component of the cardiac interstitial extracellular matrix. This extracellular matrix undergoes dramatic changes from birth to adulthood and then into advanced age. As evidence, fibrillar collagen content was compared in sections from neonates, adult, and old hearts and was found to increase at each respective age. Cardiac fibroblasts are the principle cell type that produce and control fibrillar collagen content. To determine whether fibroblast production, processing, and deposition of collagen differed with age, primary cardiac fibroblasts from neonate, adult, and old mice were isolated and cultured in 3-dimensional (3D) fibrin gels. Fibroblasts from each age aligned in fibrin gels along points of tension and deposited extracellular matrix. By confocal microscopy, wild-type neonate fibroblasts appeared to deposit less collagen into fibrillar structures than fibroblasts from adults. However, by immunoblot analysis, differences in procollagen production and processing of collagen I were not detected in neonate versus adult fibroblasts. In contrast, fibroblasts from old mice demonstrated increased efficiency of procollagen processing coupled with decreased production of total collagen. SPARC is a collagen-binding protein previously shown to affect cardiac collagen deposition. Accordingly, in the absence of SPARC, less collagen appeared to be associated with fibroblasts of each age grown in fibrin gels. In addition, the increased efficiency of procollagen alpha 1(I) processing in old wild-type fibroblasts was not detected in old SPARC-null fibroblasts. Increased levels of fibronectin were detected in wild-type neonate fibroblasts over that of adult and old fibroblasts but not in SPARC-null neonate fibroblasts versus older ages. Immunostaining of SPARC overlapped with that of collagen I but not to that of fibronectin in 3D cultures. Hence, whereas increases in procollagen processing, influenced by SPARC expression, plausibly contribute to increased collagen deposition in old hearts, other cellular mechanisms likely affect differential collagen deposition by neonate fibroblasts. C1 [Trombetta-eSilva, Jessica; Bradshaw, Amy D.] Med Univ S Carolina, Dept Craniofacial Biol, Charleston, SC 29425 USA. [Eadie, Erik P.; Norris, Russell A.; Borg, Thomas K.] Med Univ S Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Zhang, Yuhua; Bradshaw, Amy D.] Med Univ S Carolina, Gazes Cardiac Res Inst, Dept Med, Div Cardiol, Charleston, SC 29425 USA. [Bradshaw, Amy D.] Vet Affairs Med Ctr, Ralph H Johnson Dept, Charleston, SC 29403 USA. RP Bradshaw, AD (reprint author), Med Univ S Carolina, Dept Craniofacial Biol, Charleston, SC 29425 USA. EM bradshad@musc.edu FU Research Service of the Department of Veterans Affairs [1I01BX001385-01A1]; National Heart, Lung, and Blood Institute [HL085847]; National Institute of Dental and Craniofacial Research [DE023009-02] FX This study was supported by the Research Service of the Department of Veterans Affairs (Dr. Bradshaw: 1I01BX001385-01A1) and grants from the National Heart, Lung, and Blood Institute (Dr. Borg: HL085847) and the National Institute of Dental and Craniofacial Research (Ms Trombetta-eSilva: DE023009-02). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 6 Z9 6 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 6 PY 2013 VL 8 IS 11 AR e79715 DI 10.1371/journal.pone.0079715 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 247XD UT WOS:000326656200078 PM 24223185 ER PT J AU Cholerton, B Baker, LD Craft, S AF Cholerton, Brenna Baker, Laura D. Craft, Suzanne TI Insulin, cognition, and dementia SO EUROPEAN JOURNAL OF PHARMACOLOGY LA English DT Review DE Alzheimer's disease; Insulin; Cognition; Diabetes; Aging ID CENTRAL-NERVOUS-SYSTEM; ACTIVATED-RECEPTOR-GAMMA; MODERATE ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN-E GENOTYPE; CORONARY-ARTERY-DISEASE; TRANSGENIC MOUSE MODEL; MIDLIFE BLOOD-PRESSURE; IMPAIRED OLDER-ADULTS; VASCULAR RISK-FACTORS AB Cognitive disorders of aging represent a serious threat to the social and economic welfare of current society, It is now widely recognized that pathology related to such conditions, particularly Alzheimer's disease, likely begins years or decades prior to the onset of clinical dementia symptoms. This revelation has led researchers to consider candidate mechanisms precipitating the cascade of neuropathological events that eventually lead to clinical Alzheimer's disease. Insulin, a hormone with potent effects in the brain, has recently received a great deal of attention for its potential beneficial and protective role in cognitive function. Insulin resistance, which refers to the reduced sensitivity of target tissues to the favorable effects of insulin, is related to multiple chronic conditions known to impact cognition and increase dementia risk. With insulin resistance-associated conditions reaching epidemic proportions, the prevalence of Alzheimer's disease and other cognitive disorders will continue to rise exponentially. Fortunately, these chronic insulin-related conditions are amenable to pharmacological intervention. As a result, novel therapeutic strategies that focus on increasing insulin sensitivity in the brain may be an important target for protecting or treating cognitive decline. The following review will highlight our current understanding of the role of insulin in brain, potential mechanisms underlying the link between insulin resistance and dementia, and current experimental therapeutic strategies aimed at improving cognitive function via modifying the brain's insulin sensitivity. (C) 2013 Elsevier B.V. All rights reserved. C1 [Cholerton, Brenna] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Cholerton, Brenna] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Baker, Laura D.; Craft, Suzanne] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA. RP Craft, S (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA. EM suzcraft@wakehealth.edu FU NIA NIH HHS [P50 AG005136, R01 AG010880] NR 143 TC 49 Z9 49 U1 5 U2 23 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0014-2999 EI 1879-0712 J9 EUR J PHARMACOL JI Eur. J. Pharmacol. PD NOV 5 PY 2013 VL 719 IS 1-3 BP 170 EP 179 DI 10.1016/j.ejphar.2013.08.008 PG 10 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 258VQ UT WOS:000327487200020 PM 24070815 ER PT J AU Miquel, M Spampinato, U Latxague, C Aviles-Olmos, I Bader, B Bertram, K Bhatia, K Burbaud, P Burghaus, L Cho, JW Cuny, E Danek, A Foltynie, T Ruiz, PJG Gimenez-Roldan, S Guehl, D Guridi, J Hariz, M Jarman, P Kefalopoulou, ZM Limousin, P Lipsman, N Lozano, AM Moro, E Ngy, D Rodriguez-Oroz, MC Shang, HF Shin, H Walker, RH Yokochi, F Zrinzo, L Tison, F AF Miquel, Marie Spampinato, Umberto Latxague, Chrystelle Aviles-Olmos, Iciar Bader, Benedikt Bertram, Kelly Bhatia, Kailash Burbaud, Pierre Burghaus, Lothar Cho, Jin Whan Cuny, Emmanuel Danek, Adrian Foltynie, Thomas Garcia Ruiz, Pedro J. Gimenez-Roldan, Santiago Guehl, Dominique Guridi, Jorge Hariz, Marwan Jarman, Paul Kefalopoulou, Zinovia Maria Limousin, Patricia Lipsman, Nir Lozano, Andres M. Moro, Elena Ngy, Dhita Cruz Rodriguez-Oroz, Maria Shang, Huifang Shin, Hyeeun Walker, Ruth H. Yokochi, Fusako Zrinzo, Ludvic Tison, Francois TI Short and Long Term Outcome of Bilateral Pallidal Stimulation in Chorea-Acanthocytosis SO PLOS ONE LA English DT Article ID DEEP-BRAIN-STIMULATION; PRIMARY GENERALIZED DYSTONIA; PARKINSONS-DISEASE; GLOBUS-PALLIDUS; FOLLOW-UP; HUNTINGTONS-DISEASE; RATING-SCALE; NEUROACANTHOCYTOSIS; DISORDERS; NEURODEGENERATION AB Background: Chorea-acanthocytosis (ChAc) is a neuroacanthocytosis syndrome presenting with severe movement disorders poorly responsive to drug therapy. Case reports suggest that bilateral deep brain stimulation (DBS) of the ventro-postero-lateral internal globus pallidus (GPi) may benefit these patients. To explore this issue, the present multicentre (n=12) retrospective study collected the short and long term outcome of 15 patients who underwent DBS. Methods: Data were collected in a standardized way 2-6 months preoperatively, 1-5 months (early) and 6 months or more (late) after surgery at the last follow-up visit (mean follow-up: 29.5 months). Results: Motor severity, assessed by the Unified Huntington's Disease Rating Scale-Motor Score, UHDRS-MS), was significantly reduced at both early and late post-surgery time points (mean improvement 54.3% and 44.1%, respectively). Functional capacity (UHDRS-Functional Capacity Score) was also significantly improved at both post-surgery time points (mean 75.5% and 73.3%, respectively), whereas incapacity (UHDRS-Independence Score) improvement reached significance at early post-surgery only (mean 37.3%). Long term significant improvement of motor symptom severity (>= 20 % from baseline) was observed in 61.5 % of the patients. Chorea and dystonia improved, whereas effects on dysarthria and swallowing were variable. Parkinsonism did not improve. Linear regression analysis showed that preoperative motor severity predicted motor improvement at both post-surgery time points. The most serious adverse event was device infection and cerebral abscess, and one patient died suddenly of unclear cause, 4 years after surgery. Conclusion: This study shows that bilateral DBS of the GPi effectively reduces the severity of drug-resistant hyperkinetic movement disorders such as present in ChAc. C1 [Miquel, Marie; Spampinato, Umberto; Latxague, Chrystelle; Tison, Francois] CHU Bordeaux, Serv Neurol, Bordeaux, France. [Miquel, Marie] CH Francois Mitterrand, Serv Neurol, Pau, France. [Spampinato, Umberto] Univ Bordeaux, INSERM, U862, Neuroctr Magendie, Bordeaux, France. [Spampinato, Umberto; Aviles-Olmos, Iciar; Foltynie, Thomas; Hariz, Marwan; Kefalopoulou, Zinovia Maria; Limousin, Patricia; Zrinzo, Ludvic] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, Unit Funct Neurosurg, London, England. [Bader, Benedikt; Danek, Adrian] Univ Munich, Neurol Klin & Poliklin, Munich, Germany. [Bertram, Kelly] Alfred Hosp, Melbourne, Vic, Australia. [Bertram, Kelly] Monash Univ, Van Cleef Roet Ctr Nervous Dis, Melbourne, Vic 3004, Australia. [Bhatia, Kailash] UCL, Inst Neurol, Sobell Dept Motor Neurosci & Movement Disorders, London, England. [Burbaud, Pierre; Guehl, Dominique] CHU Bordeaux, Serv Neurophysiol Clin, Bordeaux, France. [Burghaus, Lothar] Univ Hosp Cologne, Dept Neurol, Cologne, Germany. [Cho, Jin Whan; Shin, Hyeeun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul, South Korea. [Cuny, Emmanuel] CHU Bordeaux, Serv Neurochirurg, Bordeaux, France. [Garcia Ruiz, Pedro J.] Fdn Jimenez Diaz, Dept Neurol, E-28040 Madrid, Spain. [Gimenez-Roldan, Santiago] Univ Gregorio Maranon, Gen Hosp, Serv Neurol, Madrid, Spain. [Guridi, Jorge] Univ Navarra Clin, Dept Neurol & Neurosurg, Pamplona, Spain. [Jarman, Paul] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England. [Lipsman, Nir; Lozano, Andres M.] Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada. [Moro, Elena] Univ Toronto, Toronto Western Hosp, Univ Hlth Network, Morton & Gloria Shulman Movement Disorders Ctr, Toronto, ON M5T 2S8, Canada. [Moro, Elena] Univ Hosp Ctr Grenoble, Dept Psychiat & Neurol, Movement Disorders Ctr, Grenoble, France. [Ngy, Dhita; Walker, Ruth H.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA. [Ngy, Dhita] Avicenna Med Ctr, New York, NY USA. [Cruz Rodriguez-Oroz, Maria] Univ Hosp Donostia, BioDonostia Res Inst, Dept Neurol, Neurosci Unit, San Sebastian, Spain. [Shang, Huifang] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu 610064, Sichuan, Peoples R China. [Walker, Ruth H.] James J Peters Vet Affairs Med Ctr, Dept Neurol, Bronx, NY USA. [Yokochi, Fusako] Tokyo Metropolitan Neurol Hosp, Dept Neurol, Fuchu, Tokyo, Japan. [Tison, Francois] Univ Bordeaux, Inst Malad Neurodegenerat, UMR 5293, Bordeaux, France. [Tison, Francois] CNRS, Inst Malad Neurodegenerat, UMR 5293, Bordeaux, France. RP Spampinato, U (reprint author), CHU Bordeaux, Serv Neurol, Bordeaux, France. EM umberto.spampinato@inserm.fr OI Bhatia, Kailash/0000-0001-8185-286X FU ERA-net E-Rare consortium European Multidisciplinary Initiative on Neuroacanthocytosis (EMINA); Neuroacanthocytosis Advocacy; EMINA consortium [BMBF 01GM1003] FX This study was supported by the ERA-net E-Rare consortium European Multidisciplinary Initiative on Neuroacanthocytosis (EMINA); www.e-rare.eu/node/474. Western blot analysis for chorein was performed with the financial support of the Neuroacanthocytosis Advocacy and the EMINA consortium (BMBF 01GM1003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 12 Z9 13 U1 0 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD NOV 5 PY 2013 VL 8 IS 11 AR e79241 DI 10.1371/journal.pone.0079241 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 247EE UT WOS:000326597400054 PM 24223913 ER PT J AU Franklin, WA Haney, J Merrick, DT Jones, KL Gowan, K Van Bokoven, A Bunn, P Miller, Y Aisner, D AF Franklin, Wilbur A. Haney, Jerry Merrick, Daniel T. Jones, Kenneth L. Gowan, Katherine Van Bokoven, Adrie Bunn, Paul Miller, York Aisner, Dara TI TRANSITIONING TO NEXT GEN TESTING OF LUNG CARCINOMA SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Sequencing; Next Generation; mutations; predictive C1 [Franklin, Wilbur A.; Haney, Jerry; Jones, Kenneth L.; Gowan, Katherine; Van Bokoven, Adrie; Aisner, Dara] Univ Colorado Anschutz Med Campus, Aurora, CO USA. [Merrick, Daniel T.; Miller, York] Univ Colorado, Denver Vet Affairs Med Ctr, Boulder, CO 80309 USA. [Bunn, Paul] Univ Colorado Denver AMS, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA MO01.03 BP S254 EP S255 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624901077 ER PT J AU Keith, R Wagh, A Friedman, M Merrick, DT Choo, K Hickey, G Hudish, T Johnson, M Tennis, M Dwyer-Nield, L AF Keith, Robert Wagh, Ajay Friedman, Micah Merrick, Daniel T. Choo, Kevin Hickey, Greg Hudish, Tyler Johnson, Micah Tennis, Meredith Dwyer-Nield, Lori TI CHANGES IN PULMONARY IMMUNE CELL RECRUITMENT AND FUNCTION DURING CIGARETTE SMOKE-INDUCED LUNG CARCINOGENESIS IN MICE SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Lung cancer; chemoprevention; inflammation; smoking C1 [Keith, Robert; Johnson, Micah] Univ Colorado Denver, Denver VAMC, Denver, CO USA. [Wagh, Ajay; Merrick, Daniel T.; Hickey, Greg] Univ Colorado, Denver VAMC, Boulder, CO 80309 USA. [Friedman, Micah; Choo, Kevin; Hudish, Tyler] Denver VAMC, Denver, CO USA. [Tennis, Meredith] Univ Colorado Anschutz Med Campus, Aurora, CO USA. [Dwyer-Nield, Lori] Univ Colorado Denver, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.03-007 BP S764 EP S764 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624903283 ER PT J AU Merrick, DT Edwards, MG Franklin, W Sugita, M Miller, Y Friedman, M Dwyer-Nield, L Tennis, M Choo, K Hickey, G Kennedy, T Van Bokhoven, A Heasley, L Hirsch, FR Bunn, PA Geraci, M Keith, RL Nemenoff, R AF Merrick, Daniel T. Edwards, Michael G. Franklin, Wilbur Sugita, Michio Miller, York Friedman, Micah Dwyer-Nield, Lori Tennis, Meredith Choo, Kevin Hickey, Greg Kennedy, Tim Van Bokhoven, Adrie Heasley, Lynn Hirsch, Fred R. Bunn, Paul A. Geraci, Mark Keith, Robert L. Nemenoff, Raphael TI PATHWAY ANALYSIS OF GENE EXPRESSION PROFILES THAT DISTINGUISH PERSISTENT FROM REGRESSIVE BRONCHIAL DYSPLASIA INDICATE SYNERGISTIC ROLE FOR POLO-LIKE KINASE 1 (PLK1) AND EPOXIDE HYDROLASE 3 (EPHX3) IN MALIGNANT PROGRESSION SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE bronchial dysplasia; Malignant progression; Epoxide hydrolase 3; Polo-like kinase 1 C1 [Merrick, Daniel T.; Miller, York; Friedman, Micah; Choo, Kevin; Keith, Robert L.] Denver VAMC, Denver, CO USA. [Edwards, Michael G.; Franklin, Wilbur; Sugita, Michio; Dwyer-Nield, Lori; Tennis, Meredith; Hickey, Greg; Van Bokhoven, Adrie; Heasley, Lynn; Hirsch, Fred R.; Bunn, Paul A.; Geraci, Mark; Nemenoff, Raphael] Univ Colorado, Boulder, CO 80309 USA. [Kennedy, Tim] Presbyterian St Lukes Hosp, Denver, CO 80218 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA O12.02 BP S179 EP S180 PG 2 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624900220 ER PT J AU Ostroff, R Mehan, MR Williams, S Franklin, W Feser, W Baron, A Geraci, M Merrick, DT Keith, R Miller, Y AF Ostroff, Rachel Mehan, Michael R. Williams, Stephen Franklin, Wilbur Feser, William Baron, Anna Geraci, Mark Merrick, Daniel T. Keith, Robert Miller, York TI DISCOVERY OF CIRCULATING PROTEIN BIOMARKERS OF LUNG DYSPLASIA SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE dysplasia; Proteomic analysis; Biomarkers C1 [Ostroff, Rachel; Mehan, Michael R.; Williams, Stephen] Somalogic, Boulder, CO USA. [Franklin, Wilbur; Feser, William; Baron, Anna; Geraci, Mark] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA. [Merrick, Daniel T.; Keith, Robert; Miller, York] Univ Colorado, Denver Vet Affairs Med Ctr, Boulder, CO 80309 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.02-014 BP S756 EP S756 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624903269 ER PT J AU Ostroff, R Mehan, MR Williams, S Niculescu-Mizil, A Franklin, W Merrick, DT Van Bokhoven, A Wolf, H Feser, W Baron, A Miller, Y AF Ostroff, Rachel Mehan, Michael R. Williams, Stephen Niculescu-Mizil, Alexandru Franklin, Wilbur Merrick, Daniel T. Van Bokhoven, Adrie Wolf, Holly Feser, William Baron, Anna Miller, York TI PROTEOMIC INSIGHTS WITH LUNG CANCER TUMORS BASED ON HISTOPATHOLOGIC SUBTYPES AND GENOTYPES SO JOURNAL OF THORACIC ONCOLOGY LA English DT Meeting Abstract DE Tumor markers; Proteomic analysis; Driver mutation; Histology markers C1 [Ostroff, Rachel; Mehan, Michael R.; Williams, Stephen] Somalogic, Boulder, CO USA. [Niculescu-Mizil, Alexandru] Nec Labs Amer, Princeton, NJ USA. [Franklin, Wilbur; Van Bokhoven, Adrie; Wolf, Holly; Feser, William; Baron, Anna] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA. [Merrick, Daniel T.; Miller, York] Univ Colorado, Denver Vet Affairs Med Ctr, Boulder, CO 80309 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1556-0864 EI 1556-1380 J9 J THORAC ONCOL JI J. Thorac. Oncol. PD NOV PY 2013 VL 8 SU 2 MA P2.02-015 BP S757 EP S757 PG 1 WC Oncology; Respiratory System SC Oncology; Respiratory System GA AM1RE UT WOS:000339624903270 ER PT J AU Finley, EP Pugh, JA Lanham, HJ Leykum, LK Cornell, J Veerapaneni, P Parchman, ML AF Finley, Erin P. Pugh, Jacqueline A. Lanham, Holly Jordan Leykum, Luci K. Cornell, John Veerapaneni, Poornachand Parchman, Michael L. TI Relationship Quality and Patient-Assessed Quality of Care in VA Primary Care Clinics: Development and Validation of the Work Relationships Scale SO ANNALS OF FAMILY MEDICINE LA English DT Article DE relationships; primary care; quality of care; patient satisfaction; Veteran's Administration ID RELATIONSHIP-CENTERED CARE; HEALTH-CARE; VETERANS; TRANSFORMATION AB PURPOSE Efforts to better understand the impact of clinic member relationships on care quality in primary care clinics have been limited by the absence of a validated instrument to assess these relationships. The purpose of this study was to develop and validate a scale assessing relationships within primary care clinics. METHODS The Work Relationships Scale (WRS) was developed and administered as part of a survey of learning and relationships among 17 Department of Veterans Affairs (VA) primary care clinics. A Rasch partial-credit model and principal components analysis were used to evaluate item performance, select the final items for inclusion, and establish unidimensionality for the WRS. The WRS was then validated against semistructured clinic member interviews and VA Survey of Healthcare Experiences of Patients (SHEP) data. RESULTS Four hundred fifty-seven clinicians and staff completed the clinic survey, and 247 participated in semistructured interviews. WRS scores were significantly associated with clinic-level reporting for 2 SHEP variables: overall rating of personal doctor/nurse (r(2) = 0.43, P <. 01) and overall rating of health care (r(2) = 0.25, P <. 05). Interview data describing relationship characteristics were consistent with variability in WRS scores across low-scoring and high-scoring clinics. CONCLUSIONS The WRS shows promising validity as a measure assessing the quality of relationships in primary care settings; moreover, primary care clinics with lower WRS scores received poorer patient quality ratings for both individual clinicians and overall health care. Relationships play an important role in shaping care delivery and should be assessed as part of efforts to improve patient care within primary care settings. C1 [Finley, Erin P.; Pugh, Jacqueline A.; Lanham, Holly Jordan; Leykum, Luci K.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Finley, Erin P.; Pugh, Jacqueline A.; Lanham, Holly Jordan; Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Lanham, Holly Jordan] Univ Texas Austin, McCombs Sch Business, Austin, TX 78712 USA. [Lanham, Holly Jordan; Veerapaneni, Poornachand] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. [Cornell, John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biostat & Epidemiol, San Antonio, TX 78229 USA. [Parchman, Michael L.] Grp Hlth Cooperat Puget Sound, MacColl Ctr Hlth Care Innovat, Grp Hlth Res Inst, Seattle, WA USA. RP Finley, EP (reprint author), VERDICT Res Unit 11C6, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM finleye@uthscsa.edu OI Pugh, Jacqueline/0000-0003-4933-141X; Parchman, Michael/0000-0001-7129-2889; Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (HSRD) [IIR 06-063]; National Institute of Mental Health [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI) FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (HSR&D) project no. IIR 06-063. Dr. Finley is an investigator with the Implementation Research Institute, George Warren Brown School of Social Work, Washington University, St. Louis; through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research & Development Service, Quality Enhancement Research Initiative (QUERI). NR 24 TC 11 Z9 11 U1 0 U2 12 PU ANNALS FAMILY MEDICINE PI LEAWOOD PA 11400 TOMAHAWK CREEK PARKWAY, LEAWOOD, KS 66211-2672 USA SN 1544-1709 EI 1544-1717 J9 ANN FAM MED JI Ann. Fam. Med. PD NOV-DEC PY 2013 VL 11 IS 6 BP 543 EP 549 DI 10.1370/afm.1554 PG 7 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA AI3XU UT WOS:000336799800007 PM 24218378 ER PT J AU Parikh, AR Kim, B Pantoja, P Tisnado, DM Ahluwalia, SC Walling, AM Asch, SM Lorenz, K AF Parikh, Aparna Raj Kim, Benjamin Pantoja, Philip Tisnado, Diana M. Ahluwalia, Sangeeta C. Walling, Anne M. Asch, Steven M. Lorenz, Karl TI How is KRAS testing associated with treatment and supportive care for patients with metastatic colorectal cancer? VA national assist project SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 Univ Calif San Francisco, Div Hematol & Oncol, San Francisco, CA 94143 USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 64 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500065 ER PT J AU Shelton, JB Ochotorena, L Bennett, CJ Shekelle, P Goldzweig, C AF Shelton, Jeremy B. Ochotorena, Lee Bennett, Carol J. Shekelle, Paul Goldzweig, Caroline TI Reducing inappropriate PSA-based prostate cancer screening in men age 75 or older with a highly specific computerized clinical decision support tool. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT ASCO's Quality Care Symposium CY NOV 01-02, 2013 CL San Diego, CA SP ASCO C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD NOV 1 PY 2013 VL 31 IS 31 SU S MA 233 PG 1 WC Oncology SC Oncology GA AG6YR UT WOS:000335565500227 ER PT J AU Levitan, EB Lewis, CE Tinker, LF Eaton, CB Ahmed, A Manson, JE Snetselaar, LG Martin, LW Trevisan, M Howard, BV Shikany, JM AF Levitan, Emily B. Lewis, Cora E. Tinker, Lesley F. Eaton, Charles B. Ahmed, Ali Manson, JoAnn E. Snetselaar, Linda G. Martin, Lisa W. Trevisan, Maurizio Howard, Barbara V. Shikany, James M. TI Mediterranean and DASH Diet Scores and Mortality in Women With Heart Failure SO CIRCULATION-HEART FAILURE LA English DT Article DE diet; heart failure; mortality; nutrition ID STOP HYPERTENSION; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; LIFE-STYLE; RISK; ADHERENCE; PREVENTION; QUALITY; ASSOCIATIONS; PROTEIN AB Background Current dietary recommendations for patients with heart failure (HF) are largely based on data from non-HF populations; evidence on associations of dietary patterns with outcomes in HF is limited. We therefore evaluated associations of Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diet scores with mortality among postmenopausal women with HF. Methods and Results Women's Health Initiative participants were followed up from the date of HF hospitalization through the date of death or last participant contact before August 2009. Mediterranean and DASH diet scores were calculated from food-frequency questionnaires. Cox proportional hazards models adjusted for demographics, health behaviors, and health status were used to calculate hazard ratios and 95% confidence intervals (CI). For a median of 4.6 years of follow-up, 1385 of 3215 (43.1%) participants who experienced a HF hospitalization died. Multivariable-adjusted hazard ratios were 1 (reference), 1.05 (95% CI, 0.89-1.24), 0.97 (95% CI, 0.81-1.17), and 0.85 (95% CI, 0.70-1.02) across quartiles of the Mediterranean diet score (P trend=0.08) and 1 (reference), 1.04 (95% CI, 0.89-1.21), 0.83 (95% CI, 0.70-0.98), and 0.84 (95% CI, 0.70-1.00) across quartiles of the DASH diet score (P trend=0.01). Diet score components, vegetables, nuts, and whole grain intake, were inversely associated with mortality. Conclusions Higher DASH diet scores were associated with modestly lower mortality in women with HF, and there was a nonsignificant trend toward an inverse association with Mediterranean diet scores. These data provide support for the concept that dietary recommendations developed for other cardiovascular conditions or general populations may also be appropriate in patients with HF. Clinical Trial Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT00000611. C1 [Levitan, Emily B.; Lewis, Cora E.; Ahmed, Ali; Shikany, James M.] Univ Alabama Birmingham, Birmingham, AL 35924 USA. [Ahmed, Ali] Birmingham VA Med Ctr, Birmingham, AL USA. [Tinker, Lesley F.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Eaton, Charles B.] Brown Univ, Providence, RI 02912 USA. [Manson, JoAnn E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA. [Snetselaar, Linda G.] Univ Iowa, Iowa City, IA USA. [Martin, Lisa W.] George Washington Univ, Washington, DC USA. [Trevisan, Maurizio] CUNY City Coll, New York, NY 10031 USA. [Howard, Barbara V.] MedStar Hlth Res Inst, Hyattsville, MD USA. [Howard, Barbara V.] Georgetown Howard Univ Ctr Clin & Translat Sci, Washington, DC USA. RP Levitan, EB (reprint author), Univ Alabama Birmingham, Dept Epidemiol, 1530 3rd Ave S,RPHB 230K, Birmingham, AL 35924 USA. EM elevitan@uab.edu FU National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C] FX The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, and HHSN271201100004C. NR 35 TC 23 Z9 23 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD NOV PY 2013 VL 6 IS 6 BP 1116 EP 1123 DI 10.1161/CIRCHEARTFAILURE.113.000495 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA AD4AY UT WOS:000333189500004 PM 24107587 ER PT J AU Paucar, M Xiang, FQ Moore, R Walker, R Winnberg, E Svenningsson, P AF Paucar, Martin Xiang, Fengqing Moore, Richard Walker, Ruth Winnberg, Elisabeth Svenningsson, Per TI Genotype-phenotype analysis in inherited prion disease with eight octapeptide repeat insertional mutation SO PRION LA English DT Article DE PRNP polymorphic codon 129; octapeptide repeat insertions (OPRI); Huntington disease-like 1; inherited prion disease (IPD); base pair insertions (BPI); Huntington's disease; PRNP ID CREUTZFELDT-JAKOB-DISEASE; PRP KNOCKOUT MICE; PROTEIN GENE; ONSET; SUSCEPTIBILITY; HETEROGENEITY; DEMENTIA; FEATURES; SCRAPIE; FAMILY AB A minority of inherited prion diseases (IPD) are caused by four to 12 extra octapeptide repeat insertions (OPRI) in the prion protein gene (PRNP). Only four families affected by IPD with 8-OPRI have been reported, one of them was a three-generation Swedish kindred in which four of seven affected subjects had chorea which was initially attributed to Huntington's disease (HD). Following the exclusion of HD, this phenotype was labeled Huntington disease-like 1 (HDL1). Here, we provide an update on the Swedish 8-OPRI family, describe the clinical features of one of its affected members with video-recordings, compare the four 8-OPRI families and study the effect of PRNP polymorphic codon 129 and gender on phenotype. Surprisingly, the Swedish kindred displayed the longest survival of all of the 8-OPRI families with a mean of 15.1 years from onset of symptoms. Subjects with PRNP polymorphic codon 129M in the mutated allele had significantly earlier age of onset, longer survival and earlier age of death than 129V subjects. Homozygous 129MM had earlier age of onset than 129VV. Females had a significantly earlier age of onset and earlier age of death than males. Up to 50% of variability in age of onset was conferred by the combined effect of PRNP polymorphic codon 129 and gender. An inverse correlation between early age of onset and long survival was found for this mutation. C1 [Paucar, Martin; Svenningsson, Per] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden. [Paucar, Martin; Svenningsson, Per] Karolinska Univ Hosp, Dept Neurol, Stockholm, Sweden. [Xiang, Fengqing] Karolinska Inst, Ctr Mol Med, Dept Womans & Childrens Hlth, Stockholm, Sweden. [Walker, Ruth] James Peters Vet Med Affair Ctr, Bronx, NY USA. [Walker, Ruth] Mt Sinai Sch Med, New York, NY USA. [Winnberg, Elisabeth] Ersta Skondal Univ Coll, Dept Caring Sci, Stockholm, Sweden. RP Paucar, M (reprint author), Karolinska Inst, Ctr Mol Med, Stockholm, Sweden. EM martin.paucar-arce@karolinska.se OI Xiang, Fengqing/0000-0003-0892-1536; Paucar, Martin/0000-0003-3735-1480 NR 37 TC 1 Z9 1 U1 0 U2 5 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1933-6896 EI 1933-690X J9 PRION JI Prion PD NOV-DEC PY 2013 VL 7 IS 6 BP 501 EP 510 DI 10.4161/pri.27260 PG 10 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA AC0QP UT WOS:000332200100006 PM 24275071 ER PT J AU Margolis, A Young, H Lis, J Schuna, A AF Margolis, Amanda Young, Henry Lis, Jennifer Schuna, Arthur TI A telepharmacy intervention to improve inhaler adherence in veterans with chronic obstructive pulmonary disease SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY LA English DT Letter ID CARE C1 [Margolis, Amanda] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA. [Margolis, Amanda; Lis, Jennifer; Schuna, Arthur] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA. [Young, Henry] Univ Georgia, Coll Pharm, Clin & Adm Pharm, Athens, GA 30602 USA. RP Margolis, A (reprint author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA. EM arpitterle@wisc.edu FU NCATS NIH HHS [UL1 TR000427, 9U54TR000021]; NCRR NIH HHS [1UL1RR025011, UL1 RR025011] NR 8 TC 1 Z9 2 U1 0 U2 0 PU AMER SOC HEALTH-SYSTEM PHARMACISTS PI BETHESDA PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA SN 1079-2082 EI 1535-2900 J9 AM J HEALTH-SYST PH JI Am. J. Health-Syst. Pharm. PD NOV 1 PY 2013 VL 70 IS 21 BP 1875 EP 1876 DI 10.2146/ajhp120241 PG 2 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA AB4SS UT WOS:000331780800006 PM 24128957 ER PT J AU Smolderen, KG Whooley, MA AF Smolderen, Kim G. Whooley, Mary A. TI Psychological Distress and Medication Adherence Creating Order Out of Chaos? SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Editorial Material DE Editorials; hypertension; medication adherence; myocardial infarction ID CORONARY-HEART-DISEASE; SOUL C1 [Smolderen, Kim G.] Tilburg Univ, Ctr Res Psychol Somat Dis, NL-5000 LE Tilburg, Netherlands. [Smolderen, Kim G.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA. [Whooley, Mary A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Whooley, Mary A.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. RP Smolderen, KG (reprint author), Tilburg Univ, Dept Med Psychol, POB 90153,Room T505, NL-5000 LE Tilburg, Netherlands. EM k.g.e.smolderen@gmail.com RI Smolderen, Kim/B-8078-2015 NR 10 TC 1 Z9 1 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2013 VL 6 IS 6 BP 615 EP 616 DI 10.1161/CIRCOUTCOMES.113.000633 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 298ZA UT WOS:000330362400006 PM 24221835 ER PT J AU Clarke, CL Grunwald, GK Allen, LA Baron, AE Peterson, PN Brand, DW Magid, DJ Masoudi, FA AF Clarke, Christina L. Grunwald, Gary K. Allen, Larry A. Baron, Anna E. Peterson, Pamela N. Brand, David W. Magid, David J. Masoudi, Frederick A. TI Natural History of Left Ventricular Ejection Fraction in Patients With Heart Failure SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE heart failure; outcomes assessment; prognosis; ventricular ejection fraction ID ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; MULTISTATE MODEL; PANEL-DATA; CARVEDILOL; SURVIVAL; DYSFUNCTION; GUIDELINES; METOPROLOL; MORTALITY AB Background-Patients with heart failure (HF) are typically designated as having reduced or preserved ejection fraction (HFREF, HFPEF) because of the importance of left ventricular ejection fraction (LVEF) on therapeutic decisions and prognosis. Such designations are not necessarily static, yet few data exist to describe the natural history of LVEF over time. Methods and Results-We identified 2413 patients from Kaiser Permanente Colorado with a primary discharge diagnosis of HF between January 1, 2001, and December 31, 2008, who had >= 2 LVEF measurements separated by >= 30 days. We used multi-state Markov modeling to examine transitions among HFREF, HFPEF, and death. We observed a total of 8183 transitions. Women were more likely than men to transition from HFREF to HFPEF (hazard ratio, 1.85; 95% confidence interval, 1.38-2.47). Patients who were adherent to beta-blockers were more likely to transition from HFREF to HFPEF (hazard ratio, 1.53; 95% confidence interval, 1.10-2.13) compared with patients who were nonadherent to beta-blockers, whereas angiotensin-converting enzyme or angiotensin II receptor blocker adherence was not associated with LVEF transitions. Patients who had a previous myocardial infarction were more likely to transition from HFPEF to HFREF (hazard ratio, 1.75; 95% confidence interval, 1.26-2.42). Conclusions-In this cohort of patients with HF, LVEF is a dynamic factor related to sex, coexisting conditions, and drug therapy. These findings have implications for left ventricular systolic function ascertainment in patients with HF and support evidence-based therapy use, especially beta-blockers. C1 [Clarke, Christina L.; Allen, Larry A.; Peterson, Pamela N.; Brand, David W.; Magid, David J.; Masoudi, Frederick A.] Kaiser Permanente Colorado Inst Hlth Res, Denver, CO 80231 USA. [Grunwald, Gary K.; Baron, Anna E.] Denver VA Med Ctr, Denver, CO USA. [Peterson, Pamela N.] Denver Hlth Med Ctr, Denver, CO USA. [Grunwald, Gary K.; Allen, Larry A.; Baron, Anna E.; Peterson, Pamela N.; Magid, David J.; Masoudi, Frederick A.] Univ Colorado Anschutz Med Campus, Denver, CO USA. RP Clarke, CL (reprint author), Kaiser Permanente Colorado Inst Hlth Res, 10065 E Harvard Ave,Suite 300, Denver, CO 80231 USA. EM Christina.L.Clarke@kp.org FU National Heart, Lung, and Blood Institute (Bethesda, MD) [K23 HL105896]; Agency for Healthcare Research and Quality [K08 HS019814-01]; National Heart, Lung, and Blood Institute [1RC1HL099395] FX Dr Allen is supported by grant K23 HL105896 from the National Heart, Lung, and Blood Institute (Bethesda, MD) and reports that he has provided consulting services for Amgen, Inc and Johnson & Johnson. Dr Peterson is supported by grant K08 HS019814-01 from the Agency for Healthcare Research and Quality. Dr Magid was supported by grant 1RC1HL099395 from the National Heart, Lung, and Blood Institute during the conduct of this research and creation of the article. The other authors report no conflicts. NR 26 TC 8 Z9 8 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2013 VL 6 IS 6 BP 680 EP + DI 10.1161/CIRCOUTCOMES.111.000045 PG 15 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 298ZA UT WOS:000330362400016 PM 24129973 ER PT J AU Heidenreich, PA Lin, ST Knowles, JW Perez, M Maddox, TM Ho, MP Rumsfeld, JS Sahay, A Massie, BM Tsai, TT Witteles, RM AF Heidenreich, Paul A. Lin, Shoutzu Knowles, Joshua W. Perez, Marco Maddox, Thomas M. Ho, Michael P. Rumsfeld, John S. Sahay, Anju Massie, Barry M. Tsai, Thomas T. Witteles, Ronald M. TI Variation in Use of Left Ventriculography in the Veterans Affairs Health Care System SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES LA English DT Article DE cardiac catheterization; cardiac imaging techniques; small-area analysis ID CARDIOVASCULAR-COMPUTED-TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; AMERICAN-HEART-ASSOCIATION; CRITERIA WORKING GROUP; NUCLEAR-CARDIOLOGY; EJECTION FRACTION; APPROPRIATENESS CRITERIA; CORONARY INTERVENTION; MAGNETIC-RESONANCE; TASK-FORCE AB Background-Contrast left ventriculography is a method of measuring left ventricular function usually performed at the discretion of the invasive cardiologist during cardiac catheterization. We sought to determine variation in the use of left ventriculography in the Veterans Affairs (VA) Health Care System. Methods and Results-We identified adult patients who underwent cardiac catheterization including coronary angiography between 2000 and 2009 in the VA Health Care System. We determined patient and hospital predictors of the use of left ventriculography as well as the variation in use across VA facilities. Results were validated using data from the VA's Clinical Assessment, Reporting, and Tracking (CART) program. Of 457 170 cardiac catheterization procedures among 336 853 patients, left ventriculography was performed on 263 695 (58%) patients. Use of left ventriculography decreased over time (64% in 2000 to 50% in 2009) and varied markedly across facilities (< 1-> 95% of cardiac catheterizations). Patient factors explained little of the large variation in use between facilities. When the cohort was restricted to those with an echocardiogram in the prior 30 days and no intervening event, left ventriculography was still performed in 50% of cases. Conclusions-There is large variation in the use of left ventriculography across VA facilities that is not explained by patient characteristics. C1 [Heidenreich, Paul A.; Lin, Shoutzu; Sahay, Anju] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Heidenreich, Paul A.; Knowles, Joshua W.; Perez, Marco; Witteles, Ronald M.] Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA. [Maddox, Thomas M.; Ho, Michael P.; Rumsfeld, John S.; Tsai, Thomas T.] VA Eastern Colorado Hlth Care Syst, Denver, CO USA. [Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Heidenreich, PA (reprint author), VA Palo Alto Hlth Care Syst, 111C,3801 Miranda Ave, Palo Alto, CA 94304 USA. EM paul.heidenreich@va.gov OI Heidenreich, Paul/0000-0001-7730-8490 FU Veteran Administration's Quality Enhancement and Research Initiative [04, 326]; American Heart Association [10FTF3360005]; VA Health Services Research and Development Career Development Award [09-415] FX Dr Heidenreich is supported by a grant from the Veteran Administration's Quality Enhancement and Research Initiative 04 to 326. Dr Knowles is supported by an American Heart Association National Fellow-to-Faculty transition award 10FTF3360005. Dr Maddox is supported by a grant from the VA Health Services Research and Development Career Development Award (09-415). NR 22 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1941-7705 EI 1941-7713 J9 CIRC-CARDIOVASC QUAL JI Circ.-Cardiovasc. Qual. Outcomes PD NOV PY 2013 VL 6 IS 6 BP 687 EP 693 DI 10.1161/CIRCOUTCOMES.113.000199 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 298ZA UT WOS:000330362400017 PM 24192569 ER PT J AU Eberhart, MG Yehia, BR Hillier, A Voytek, CD Blank, MB Frank, I Metzger, DS Brady, KA AF Eberhart, Michael G. Yehia, Baligh R. Hillier, Amy Voytek, Chelsea D. Blank, Michael B. Frank, Ian Metzger, David S. Brady, Kathleen A. TI Behind the Cascade: Analyzing Spatial Patterns Along the HIV Care Continuum SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE GIS; spatial patterns; care linkage; retention; viral suppression ID ANTIRETROVIRAL THERAPY; DELAYED ENTRY; MEDICAL-CARE; 2ND-ORDER ANALYSIS; VIRAL SUPPRESSION; RISK-FACTORS; HEALTH-CARE; PREVENTION; RETENTION; DIAGNOSIS AB Background: Successful HIV treatment as prevention requires individuals to be tested, aware of their status, linked to and retained in care, and virally suppressed. Spatial analysis may be useful for monitoring HIV care by identifying geographic areas with poor outcomes. Methods: Retrospective cohort of 1704 people newly diagnosed with HIV identified from Philadelphia's Enhanced HIV/AIDS Reporting System in 2008-2009, with follow-up to 2011. Outcomes of interest were not linked to care, not linked to care within 90 days, not retained in care, and not virally suppressed. Spatial patterns were analyzed using K-functions to identify "hot spots" for targeted intervention. Geographic components were included in regression analyses along with demographic factors to determine their impact on each outcome. Results: Overall, 1404 persons (82%) linked to care; 75% (1059/1404) linked within 90 days; 37% (526/1059) were retained in care; and 72% (379/526) achieved viral suppression. Fifty-nine census tracts were in hot spots, with no overlap between outcomes. Persons residing in geographic areas identified by the local K-function analyses were more likely to not link to care [adjusted odds ratio 1.76 (95% confidence interval: 1.30 to 2.40)], not link to care within 90 days (1.49, 1.12-1.99), not be retained in care (1.84, 1.39-2.43), and not be virally suppressed (3.23, 1.87-5.59) than persons not residing in the identified areas. Conclusions: This study is the first to identify spatial patterns as a strong independent predictor of linkage to care, retention in care, and viral suppression. Spatial analyses are a valuable tool for characterizing the HIV epidemic and treatment cascade. C1 [Eberhart, Michael G.; Brady, Kathleen A.] Philadelphia Dept Publ Hlth, AIDS Activ Coordinating Off, Philadelphia, PA 19107 USA. [Yehia, Baligh R.; Brady, Kathleen A.] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Yehia, Baligh R.] Philadelphia Vet Affairs Ctr Hlth Equ Res & Promo, Philadelphia, PA USA. [Hillier, Amy] Univ Penn, Sch Design, Philadelphia, PA 19104 USA. [Voytek, Chelsea D.; Blank, Michael B.; Metzger, David S.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Frank, Ian] Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA. [Metzger, David S.] Treatment Res Inst, Philadelphia, PA USA. RP Eberhart, MG (reprint author), Philadelphia Dept Publ Hlth, AIDS Activ Coordinating Off, 1101 Market St,8th Floor, Philadelphia, PA 19107 USA. EM michael.eberhart@phila.gov RI Metzger, David/D-9499-2012 FU Centers for Disease Control and Prevention [PS13-130202, U62/003959]; DC Developmental Center for AIDS Research [5P30AI087714]; [P30-AI45008]; [K23-MH097647] FX Supported in part by a cooperative agreement with the Centers for Disease Control and Prevention (PS13-130202, # U62/003959). Preparation of this manuscript was supported in part by supplemental funds to the grant 5P30AI087714 (DC Developmental Center for AIDS Research) for the Enhanced Comprehensive HIV Prevention Planning Initiative (CFAR ECHPP Initiative), as well as the following grants: P30-AI45008, K23-MH097647. The sponsors had no involvement in the research or resulting publication. NR 47 TC 20 Z9 20 U1 3 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD NOV 1 PY 2013 VL 64 SU 1 BP S42 EP S51 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 300JW UT WOS:000330461200007 PM 24126447 ER PT J AU Baxter, LE Campbell, A DeShields, M Levounis, P Martin, JA McNicholas, L Payte, JT Salsitz, EA Taylor, T Wilford, BB AF Baxter, Louis E., Sr. Campbell, Anthony DeShields, Michael Levounis, Petros Martin, Judith A. McNicholas, Laura Payte, J. Thomas Salsitz, Edwin A. Taylor, Trusandra Wilford, Bonnie B. TI Safe Methadone Induction and Stabilization Report of an Expert Panel SO JOURNAL OF ADDICTION MEDICINE LA English DT Review DE methadone; methadone dosing; methadone induction; methadone mortality; methadone overdose; opioid agonist treatment ID MAINTENANCE TREATMENT; OVERDOSE DEATHS; OPIOID DEPENDENCE; UNITED-STATES; INTERINDIVIDUAL VARIABILITY; HEROIN-ADDICTION; TOXICITY; MORTALITY; EPIDEMIC; PLASMA AB Objectives: Methadone is a well-studied, safe, and effective medication when dispensed and consumed properly. However, a number of studies have identified elevated rates of overdose and death in patients being treated with methadone for either addiction or chronic pain. Among patients being treated with methadone in federally certified opioid treatment programs, deaths most often occur during the induction and stabilization phases of treatment. To address this issue, the federal Substance Abuse and Mental Health Services Administration invited the American Society of Addiction Medicine to convene an expert panel to develop a consensus statement on methadone induction and stabilization, with recommendations to reduce the risk of patient overdose or death related to methadone maintenance treatment of addiction. Methods: A comprehensive literature search of English-language publications (1979-2011) was conducted via MEDLINE and EM-BASE. Methadone Action Group members evaluated the resulting information and collaborated in formulating the consensus statement presented here, which subsequently was reviewed by more than 100 experts in the field. Results: Published data indicate that deaths during methadone induction occur because the initial dose is too high, the dose is increased too rapidly, or the prescribed methadone interacts with another drug. Therefore, the Methadone Action Group has developed recommendations to help methadone providers avoid or minimize these risks. Conclusions: Careful management of methadone induction and stabilization, coupled with patient education and increased clinical vigilance, can save lives in this vulnerable patient population. C1 [Baxter, Louis E., Sr.] Amer Soc Addict Med, Methadone Act Grp, Chevy Chase, MD USA. [Baxter, Louis E., Sr.] Profess Assistance Program New Jersey, Princeton, NJ USA. [Baxter, Louis E., Sr.] Univ Med & Dent New Jersey, Princeton, NJ USA. [Campbell, Anthony] Substance Abuse & Mental Hlth Serv Adm, US Publ Hlth Serv, Ctr Substance Abuse Treatment, Rockville, MD USA. [Campbell, Anthony] Substance Abuse & Mental Hlth Serv Adm, Div Pharmacol Therapies, Ctr Substance Abuse Treatment, Rockville, MD USA. [DeShields, Michael] Camden Cty Hlth Serv Ctr, Blackwood, NJ USA. [Levounis, Petros] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07103 USA. [Martin, Judith A.] City & Cty San Francisco, Dept Publ Hlth, Community Behav Hlth Serv, San Francisco, CA USA. [Martin, Judith A.] City & Cty San Francisco, Dept Publ Hlth, Substance Abuse Serv, San Francisco, CA USA. [McNicholas, Laura] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [McNicholas, Laura] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Payte, J. Thomas] Colonial Management Grp LP, Wimberly, TX USA. [Salsitz, Edwin A.] Albert Einstein Med Ctr, New York, NY USA. [Salsitz, Edwin A.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Taylor, Trusandra] JEVS Human Serv, Philadelphia, PA USA. [Wilford, Bonnie B.] JBS Int Inc, Ctr Hlth Serv & Outcomes Res, Easton, MD 21601 USA. RP Wilford, BB (reprint author), JBS Int Inc, Ctr Hlth Serv & Outcomes Res, 210 Marlboro Ave,Ste 31,PMB 187, Easton, MD 21601 USA. EM bbwilford@aol.com FU Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services FX Supported by the Substance Abuse and Mental Health Services Administration of the US Department of Health and Human Services. No funding was accepted from commercial sources. SAMHSA had no role in the data collection, analysis, or manuscript preparation. NR 89 TC 13 Z9 13 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD NOV-DEC PY 2013 VL 7 IS 6 BP 377 EP 386 DI 10.1097/01.ADM.0000435321.39251.d7 PG 10 WC Substance Abuse SC Substance Abuse GA 300KV UT WOS:000330463700001 PM 24189172 ER PT J AU Bhatnagar, R Phelps, L Rietz, K Juergens, T Russell, D Miller, N Ahearn, E AF Bhatnagar, Ritu Phelps, Lori Rietz, Kristi Juergens, Timothy Russell, Douglas Miller, Nathan Ahearn, Eileen TI The Effects of Mindfulness Training on Post-Traumatic Stress Disorder Symptoms and Heart Rate Variability in Combat Veterans SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE LA English DT Article C1 [Bhatnagar, Ritu; Miller, Nathan; Ahearn, Eileen] Univ Wisconsin Hosp & Clin, Madison, WI 53705 USA. [Bhatnagar, Ritu; Phelps, Lori; Rietz, Kristi; Juergens, Timothy; Russell, Douglas; Ahearn, Eileen] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Bhatnagar, R (reprint author), Univ Wisconsin Hosp & Clin, 600 Highland Ave, Madison, WI 53705 USA. EM ritusb@yahoo.com NR 10 TC 11 Z9 11 U1 2 U2 15 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1075-5535 EI 1557-7708 J9 J ALTERN COMPLEM MED JI J. Altern. Complement Med. PD NOV PY 2013 VL 19 IS 11 BP 860 EP 861 DI 10.1089/acm.2012.0602 PG 2 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 300JL UT WOS:000330460100002 PM 23738678 ER PT J AU Zhu, L Zhong, MH Zhao, JY Rhee, H Caesar, I Knight, EM Volpicelli-Daley, L Bustos, V Netzer, W Liu, LJ Lucast, L Ehrlich, ME Robakis, NK Gandy, SE Cai, DM AF Zhu, Li Zhong, Minghao Zhao, Jiaying Rhee, Hannah Caesar, Ina Knight, Elysse M. Volpicelli-Daley, Laura Bustos, Victor Netzer, William Liu, Lijuan Lucast, Louise Ehrlich, Michelle E. Robakis, Nikolaos K. Gandy, Samuel E. Cai, Dongming TI Reduction of Synaptojanin 1 Accelerates A beta Clearance and Attenuates Cognitive Deterioration in an Alzheimer Mouse Model SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID AMYLOID-PRECURSOR-PROTEIN; GAMMA-SECRETASE; IN-VIVO; PRESENILIN-MUTATIONS; EARLY ENDOSOMES; DOWN-SYNDROME; DISEASE; METABOLISM; MICE; PHOSPHORYLATION AB Recent studies link synaptojanin 1 (synj1), the main phosphoinositol (4,5)-biphosphate phosphatase (PI(4,5)P-2-degrading enzyme) in the brain and synapses, to Alzheimer disease. Here we report a novel mechanism by which synj1 reversely regulates cellular clearance of amyloid-beta (A beta). Genetic down-regulation of synj1 reduces both extracellular and intracellular A beta levels in N2a cells stably expressing the Swedish mutant of amyloid precursor protein (APP). Moreover, synj1 haploinsufficiency in an Alzheimer disease transgenic mouse model expressing the Swedish mutant APP and the presenilin-1 mutant Delta E9 reduces amyloid plaque load, as well as A beta(40) and A beta(42) levels in hippocampus of 9-month-old animals. Reduced expression of synj1 attenuates cognitive deficits in these transgenic mice. However, reduction of synj1 does not affect levels of full-length APP and the C-terminal fragment, suggesting that A beta generation by beta- and gamma-secretase cleavage is not affected. Instead, synj1 knockdown increases A beta uptake and cellular degradation through accelerated delivery to lysosomes. These effects are partially dependent upon elevated PI(4,5)P-2 with synj1 down-regulation. In summary, our data suggest a novel mechanism by which reduction of a PI(4,5)P-2-degrading enzyme, synj1, improves amyloid-induced neuropathology and behavior deficits through accelerating cellular A beta clearance. C1 [Zhu, Li; Zhao, Jiaying; Rhee, Hannah; Caesar, Ina; Knight, Elysse M.; Ehrlich, Michelle E.; Gandy, Samuel E.; Cai, Dongming] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Zhu, Li; Zhao, Jiaying; Rhee, Hannah; Caesar, Ina; Knight, Elysse M.; Ehrlich, Michelle E.; Gandy, Samuel E.; Cai, Dongming] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Robakis, Nikolaos K.] Icahn Sch Med Mt Sinai, Dept Psychiat Neurosci & Expt Therapeut, New York, NY 10029 USA. [Zhu, Li; Zhao, Jiaying; Rhee, Hannah; Caesar, Ina; Knight, Elysse M.; Ehrlich, Michelle E.; Gandy, Samuel E.; Cai, Dongming] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Zhong, Minghao] New York Med Coll, Dept Pathol, Vahalla, NY 10595 USA. [Volpicelli-Daley, Laura; Liu, Lijuan; Lucast, Louise] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06519 USA. [Volpicelli-Daley, Laura; Liu, Lijuan; Lucast, Louise] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06519 USA. [Bustos, Victor; Netzer, William] Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10065 USA. RP Cai, DM (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. EM dongming.cai@mssm.edu OI knight, Elysse/0000-0001-8372-1214 FU National Institutes of Health [NS047229]; Department of Neurology and Friedman Brain Institute of Icahn Mount Sinai School of Medicine; Ellison Foundation; National Institutes of Health-National Cancer Institute Shared Resources Grant [5R24CA095823-04]; National Science Foundation Major Research Instrumentation Grant [DBI-9724504]; National Institutes of Health Shared Instrumentation Grant [1S10RR09145-01] FX This work was supported, in whole or in part, by National Institutes of Health Grant NS047229 (to N.R.). This work was also supported by a seed fund provided to Dongming Cai by the Department of Neurology and Friedman Brain Institute of Icahn Mount Sinai School of Medicine, funds from the Ellison Foundation (to P.D.), National Institutes of Health-National Cancer Institute Shared Resources Grant 5R24CA095823-04, National Science Foundation Major Research Instrumentation Grant DBI-9724504, and National Institutes of Health Shared Instrumentation Grant 1S10RR09145-01. NR 48 TC 14 Z9 15 U1 1 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD NOV 1 PY 2013 VL 288 IS 44 BP 32050 EP 32063 DI 10.1074/jbc.M113.504365 PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA 302HX UT WOS:000330596200056 PM 24052255 ER PT J AU Raposo, RAS Abdel-Mohsen, M Holditch, SJ Kuebler, PJ Cheng, RG Eriksson, EM Liao, W Pillai, SK Nixon, DF AF Raposo, Rui Andre Saraiva Abdel-Mohsen, Mohamed Holditch, Sara J. Kuebler, Peter J. Cheng, Rex G. Eriksson, Emily M. Liao, Wilson Pillai, Satish K. Nixon, Douglas F. TI Increased expression of intrinsic antiviral genes in HLA-B*57-positive individuals SO JOURNAL OF LEUKOCYTE BIOLOGY LA English DT Article DE restriction factors; HIV-1; HLA class I ID HIV-1 INFECTION; IN-VITRO; SAMHD1 RESTRICTS; T-LYMPHOCYTES; CCR5; REPLICATION; PROGRESSION; ALLELE; CELLS; VIVO AB The genetic background of HIV-1-infected subjects, particularly the HLA class I haplotype, appears to be critical in determining disease progression rates, thought to be a result of the role of HIV-1-specific CD8(+) T cell responses. The HLA-B*57 allele is strongly associated with viremic suppression and slower disease progression. However, there is considerable heterogeneity in HIV-1 disease progression rates among HLAB* 57-positive subjects, suggesting that additional factors may help to contain viral replication. In this report, we investigated the association between host restriction factors, other established immunological parameters, and HLA type in HIV-1-seronegative individuals. Our results demonstrate that healthy, uninfected HLA-B*57-positive individuals exhibit significantly higher gene-expression levels of host restriction factors, such as APOBEC3A, APOBEC3B, BST-2/tetherin, and ISG15. Interestingly, HLA-B*57 individuals have significantly lower CD4(+) T cell frequencies but harbor slightly more activated CD4(+) T cells compared with their HLA-B*35 counterparts. We detected significant correlations between CD4(+) T cell activation and expression of several APOBEC3 family members, BST-2/tetherin, SAMHD1, and TRIM5 alpha in HLA-B*57-positive individuals. To our knowledge, this is the first report showing distinct associations between host restriction factors and HLA class I genotype. Our results provide insights into natural protection mechanisms and immunity against HIV-1 that fall outside of classical HLA-mediated effects. C1 [Raposo, Rui Andre Saraiva; Holditch, Sara J.; Kuebler, Peter J.; Cheng, Rex G.; Eriksson, Emily M.; Nixon, Douglas F.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94110 USA. [Abdel-Mohsen, Mohamed; Pillai, Satish K.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94110 USA. [Liao, Wilson] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94110 USA. [Pillai, Satish K.] Blood Syst Res Inst, San Francisco, CA USA. [Pillai, Satish K.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. RP Nixon, DF (reprint author), Univ Calif San Francisco, Div Expt Med, 1001 Potrero Ave,Bldg 3,Room 603,Box 1234, San Francisco, CA 94110 USA. EM douglas.nixon@ucsf.edu OI Nixon, Douglas/0000-0002-2801-1786; Raposo, R. Andre/0000-0001-5435-0290 FU U.S. National Institutes of Health (NIH) [AI093179, 1K01DA024654, K08AR057763]; Peter and Shelagh Godsoe Family Foundation thorough the AIDS Research Institute at UCSF; UCSF-Gladstone Institute of Virology & Immunology Center for AIDS Research [P30-AI027763]; Academic Senate under UCSF Resource Allocation Program; Howard Hughes Medical Institute; American-Scandinavian Foundation; Creative and Novel Ideas in HIV Research Program [P30 AI027767-24]; National Institute of Allergies and Infectious Diseases; U.S. NIH; International AIDS Society; Office of AIDS Research FX This work was supported by grants from the U.S. National Institutes of Health (NIH)(AI093179 to D.F.N.; 1K01DA024654 to S. K. P.; and K08AR057763 to W. L.), the Peter and Shelagh Godsoe Family Foundation thorough the AIDS Research Institute at UCSF (to P.J.K. and D.F.N.), the UCSF-Gladstone Institute of Virology & Immunology Center for AIDS Research (P30-AI027763 to R. A. S. R.), and, in part, from a grant provided by the Academic Senate under UCSF Resource Allocation Program awards (to D.F.N.). Fellowship funding was provided from the Howard Hughes Medical Institute to R. G. C. and from the American-Scandinavian Foundation to E. M. E. Further funding was from the Creative and Novel Ideas in HIV Research Program through a supplement to the University of Alabama at Birmingham Center for AIDS Research funding (P30 AI027767-24 to W. L.), made possible by collaborative efforts of the Office of AIDS Research; National Institute of Allergies and Infectious Diseases, U.S. NIH; and International AIDS Society. NR 44 TC 9 Z9 9 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0741-5400 EI 1938-3673 J9 J LEUKOCYTE BIOL JI J. Leukoc. Biol. PD NOV PY 2013 VL 94 IS 5 BP 1051 EP 1059 DI 10.1189/jlb.0313150 PG 9 WC Cell Biology; Hematology; Immunology SC Cell Biology; Hematology; Immunology GA 301MZ UT WOS:000330537700021 PM 23929683 ER PT J AU Holland, CT Odinokova, IV Lugea, A Shalbueva, N Mareninova, OA Gukovsky, I Gukovskaya, AS AF Holland, C. T. Odinokova, I. V. Lugea, A. Shalbueva, N. Mareninova, O. A. Gukovsky, I. Gukovskaya, A. S. TI Mitochondria Regulate Trypsinogen Activation in Pancreatitis SO PANCREAS LA English DT Meeting Abstract C1 VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1354 EP 1354 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400099 ER PT J AU Li, L Waldron, RT Lugea, A Pandol, SJ AF Li, L. Waldron, R. T. Lugea, A. Pandol, S. J. TI Hyperglycemia and Hyperinsulinemia Promote Pancreatic Stellate Cells Activation and Galectin-3 Expression: Potential Role in Pancreatic Cancer Development SO PANCREAS LA English DT Meeting Abstract C1 [Li, L.; Waldron, R. T.; Lugea, A.; Pandol, S. J.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Waldron, R. T.; Lugea, A.; Pandol, S. J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Li, L.] Southeast Univ, Zhongda Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China. NR 0 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1362 EP 1363 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400132 ER PT J AU Yuan, J Liu, Y Tan, T Li, L Pandol, SJ AF Yuan, J. Liu, Y. Tan, T. Li, L. Pandol, S. J. TI Alcohol-induced Experimental Pancreatitis: Role of Protein Kinase D SO PANCREAS LA English DT Meeting Abstract C1 Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0885-3177 EI 1536-4828 J9 PANCREAS JI Pancreas PD NOV PY 2013 VL 42 IS 8 BP 1390 EP 1391 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 300MQ UT WOS:000330468400244 ER PT J AU Sarber, KM Dion, GR Weitzel, EK McMains, KC AF Sarber, Kathleen M. Dion, Gregory Robert Weitzel, Erik K. McMains, Kevin C. TI Approaching Chronic Sinusitis SO SOUTHERN MEDICAL JOURNAL LA English DT Review DE chronic rhinosinusitis; chronic sinusitis; nasal airway obstruction; nasal irrigation; rhinosinusitis ID COMMON VARIABLE IMMUNODEFICIENCY; FUROATE NASAL SPRAY; REFRACTORY CHRONIC RHINOSINUSITIS; RANDOMIZED CONTROLLED-TRIAL; ALLERGIC FUNGAL SINUSITIS; CYSTIC-FIBROSIS; DOUBLE-BLIND; LONG-TERM; ANTIBODY DEFICIENCY; COMPUTED-TOMOGRAPHY AB Chronic sinusitis is a common disease that encompasses a number of syndromes that are characterized by sinonasal mucosal inflammation. Chronic sinusitis can be defined as two or more of the following symptoms lasting for more than 12 consecutive weeks: discolored rhinorrhea, postnasal drip, nasal obstruction, facial pressure or pain, or decreased sense of smell. Chronic sinusitis is further classified as chronic sinusitis with polyposis, chronic sinusitis without polyposis, or allergic fungal sinusitis using physical examination, and histologic and radiographic findings. Treatment methods for chronic sinusitis are based upon categorization of the disease and include oral and inhaled corticosteroids, nasal saline irrigations, and antibiotics in selected patients. Understanding the various forms of chronic sinusitis and managing and ruling out comorbidities are key to successful management of this common disorder. C1 San Antonio Mil Med Ctr, Ft Sam Houston, TX USA. Wilford Hall Ambulatory Surg Ctr, San Antonio, TX USA. Audie L Murphy Vet Hosp, San Antonio, TX USA. RP Dion, GR (reprint author), Dept Otolaryngol, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA. EM greg.r.dion.mil@mail.mil NR 77 TC 2 Z9 2 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0038-4348 EI 1541-8243 J9 SOUTH MED J JI South.Med.J. PD NOV PY 2013 VL 106 IS 11 BP 642 EP 648 DI 10.1097/SMJ.0000000000000018 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 298VB UT WOS:000330351500011 PM 24192597 ER PT J AU Piette, JD Aikens, JE Trivedi, R Parrish, D Standiford, C Marinec, NS Striplin, D Bernstein, SJ AF Piette, John D. Aikens, James E. Trivedi, Ranak Parrish, Diana Standiford, Connie Marinec, Nicolle S. Striplin, Dana Bernstein, Steven J. TI Depression Self-Management Assistance Using Automated Telephonic Assessments and Social Support SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; INTERACTIVE VOICE RESPONSE; QUALITY-OF-LIFE; PRIMARY-CARE; CHRONIC ILLNESS; MOBILE ASSESSMENT; MENTAL-DISORDERS; HEALTH; TIME; INTERVENTIONS AB Objective: To understand patient participation in interactive voice response (IVR) depression monitoring and Self-management support calls and estimate the workload from clinical alerts based on patients' IVR reports. Study Design: Observational study from program implementation in 13 community- and university-based primary care practices. Methods: Patients with depression were identified using electronic records and enrolled by telephone. Patients were asked to complete IVR assessments weekly; those with significantly improved symptoms had the option of completing assessments monthly. Patients could enroll with an informal caregiver who received automated feedback based on patients' IVR reports. Clinicians received alerts regarding significant changes in the scores on the Patient Health Questionnaire 9-item depression measure, antidepressant adherence problems, or suicidal ideation. Results: A total of 387 patients were followed for 12,042 weeks. More than half (59%) opted to participate with a caregiver. Patients completed 68% of 7912 attempted IVR assessments. Assessment completion was unrelated to patients' depressive symptoms and was higher among those who participated with a caregiver, were married, had more comorbidities, or reported missing a prior appointment. Assessment completion was lower when patients received monthly versus weekly assessment attempts. Clinical alerts were generated during 4.9% of follow-up weeks; most represented medication adherence problems (2.8%). Alerts indicating suicidal ideation were rare (0.2% of patient-weeks). Conclusions: IVR support calls represent a viable strategy for increasing access to depression monitoring and self-management assistance in primary care. These programs generate a manageable number of alerts, most of which can be triaged with limited physician involvement. C1 [Piette, John D.; Marinec, Nicolle S.; Striplin, Dana; Bernstein, Steven J.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI 48113 USA. [Piette, John D.; Parrish, Diana; Marinec, Nicolle S.; Striplin, Dana; Bernstein, Steven J.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Aikens, James E.] Univ Michigan, Sch Med, Dept Family Med, Ann Arbor, MI USA. [Trivedi, Ranak] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence Outcomes Older Adults, Seattle, WA USA. [Trivedi, Ranak] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. RP Piette, JD (reprint author), VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, HSR&D Ctr Excellence, POB 130170, Ann Arbor, MI 48113 USA. EM jpiette@umich.edu FU University of Michigan Health System Faculty Group Practice; Blue Cross and Blue Shield of Michigan; National Institute of Mental Health [R01 MH096699-01]; National Institute of Diabetes and Sigestive Kidney Diseases [P30DK092926] FX Funding was provided by the University of Michigan Health System Faculty Group Practice, Blue Cross and Blue Shield of Michigan, and grant R01 MH096699-01 from the National Institute of Mental Health. Funding for Dr Piette and Dr Trivedi was from their VA Career Scientist and Career Development awards. Other financial support came from grant number P30DK092926 from the National Institute of Diabetes and Sigestive Kidney Diseases. NR 51 TC 12 Z9 13 U1 2 U2 11 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD NOV PY 2013 VL 19 IS 11 BP 892 EP 900 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 297PM UT WOS:000330267400003 PM 24511987 ER PT J AU DiMartini, A Cruz, RJ Dew, MA Myaskovsky, L Goodpaster, B Fox, K Kim, KH Fontes, P AF DiMartini, Andrea Cruz, Ruy J., Jr. Dew, Mary Amanda Myaskovsky, Larissa Goodpaster, Bret Fox, Kristen Kim, Kevin H. Fontes, Paulo TI Muscle Mass Predicts Outcomes Following Liver Transplantation SO LIVER TRANSPLANTATION LA English DT Article ID NUTRITIONAL ASSESSMENT; COMPUTED-TOMOGRAPHY; BODY-COMPOSITION; CIRRHOSIS; PREVALENCE; VALIDATION; MORTALITY; INDEX; AREA AB For patients with end-stage liver disease, commonly used indices of nutritional status (ie, body weight and body mass index) are often inflated because of fluid overload (ie, ascites and peripheral edema), and this results in an underdiagnosis of malnutrition. Because muscle is the largest protein reservoir in the body, an estimate of the muscle mass may be a more reliable and valid estimate of nutritional status. Therefore, we used pretransplant computed tomography data for 338 liver transplantation (LT) candidates to identify muscle and fat mass on the basis of a specific abdominal transverse section commonly used in body composition analyses, and we investigated the contribution of this measure to specific post-LT outcomes. We found that the majority of our patients (68%) could be defined as cachectic. For men, muscle mass predicted many important posttransplant outcomes, including intensive care unit (ICU) stay, total length of stay (LOS), and days of intubation. Muscle mass was a significant predictor of survival and also predicted disposition to home versus another facility. For women, muscle mass predicted ICU stay, total LOS, and days of intubation, but the effect was modest. Muscle mass did not predict survival or disposition for women. In conclusion, because pretransplant muscle mass is associated with many important postoperative outcomes, we discuss these findings in the context of possible pretransplant interventions for either improving or sustaining muscle mass before surgery. Liver Transpl 19:1172-1180, 2013. (c) 2013 AASLD. C1 [DiMartini, Andrea; Cruz, Ruy J., Jr.; Fontes, Paulo] Univ Pittsburgh, Med Ctr, Dept Transplantat Surg, Pittsburgh, PA USA. [DiMartini, Andrea; Dew, Mary Amanda; Myaskovsky, Larissa; Fox, Kristen] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Med Ctr, Pittsburgh, PA 15260 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Med Ctr, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Med Ctr, Pittsburgh, PA 15261 USA. [Myaskovsky, Larissa; Goodpaster, Bret] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA. [Goodpaster, Bret] Univ Pittsburgh, Dept Hlth & Phys Educ, Med Ctr, Pittsburgh, PA USA. [Kim, Kevin H.] Univ Pittsburgh, Dept Educ Psychol, Med Ctr, Pittsburgh, PA USA. [DiMartini, Andrea; Cruz, Ruy J., Jr.; Fontes, Paulo] Univ Pittsburgh, Med Ctr, Starzl Transplant Inst, Pittsburgh, PA USA. [Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Kim, Kevin H.] Univ Pittsburgh, Joseph M Katz Grad Sch Business, Pittsburgh, PA 15260 USA. RP DiMartini, A (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM dimartiniaf@upmc.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK066266, NOT-OD-09-056N]; National Center for Research Resources of the National Institutes of Health; National Institutes of Health Roadmap for Medical Research [5UL1 RR024153-04] FX This research was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (grant R01 DK066266 and administrative supplement NOT-OD-09-056N) and by the National Center for Research Resources (a component of the National Institutes of Health) and the National Institutes of Health Roadmap for Medical Research (grant 5UL1 RR024153-04). The contents are solely the responsibility of the authors and do not necessarily represent the official view of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Center for Research Resources, or the National Institutes of Health. Information on the National Center for Research Resources is available at http://www.ncrr.nih.gov. NR 17 TC 21 Z9 21 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD NOV PY 2013 VL 19 IS 11 BP 1172 EP 1180 DI 10.1002/lt.23724 PG 9 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA 295NE UT WOS:000330122000002 PM 23960026 ER PT J AU Stengel, A Mori, M Tache, Y AF Stengel, A. Mori, M. Tache, Y. TI The role of nesfatin-1 in the regulation of food intake and body weight: recent developments and future endeavors SO OBESITY REVIEWS LA English DT Article DE Food intake; hypothalamus; nesfatin-1; NUCB2 ID CENTRAL-NERVOUS-SYSTEM; CORTICOTROPIN-RELEASING HORMONE; GESTATIONAL DIABETES-MELLITUS; SATIETY MOLECULE NESFATIN-1; PITUITARY-ADRENAL AXIS; CORD BLOOD NESFATIN-1; OREXIN MESSENGER-RNA; INTER-MEAL INTERVALS; PARAVENTRICULAR NUCLEUS; INSULIN-SECRETION AB Nesfatin-1 was discovered in 2006 and introduced as a potential novel anorexigenic modulator of food intake and body weight. The past years have witnessed increasing evidence establishing nesfatin-1 as a potent physiological inhibitor of food intake and body weight and unravelled nesfatin-1's interaction with other brain transmitters to exert its food consumption inhibitory effect. As observed for other anorexigenic brain neuropeptides, nesfatin-1 is also likely to exert additional, if not pleiotropic, actions in the brain and periphery. Recent studies established the prominent expression of the nesfatin-1 precursor, nucleobindin2 (NUCB2), in the stomach and pancreas, where nesfatin-1 influences endocrine secretion. This review will highlight the current experimental state-of-knowledge on the effects of NUCB2/nesfatin-1 on food intake, body weight and glucose homeostasis. Potential implications in human obesity will be discussed in relation to the evidence of changes in circulating levels of NUCB2/nesfatin-1 in disease states, the occurrence of genetic NUCB2 polymorphisms and - in contrast to several other hormones - the independence of leptin signalling known to be blunted under conditions of chronically increased body weight. C1 [Stengel, A.] Charite, Charite Ctr Internal Med & Dermatol, Div Gen Internal & Psychosomat Med, D-13353 Berlin, Germany. [Mori, M.] Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gumma 371, Japan. [Tache, Y.] Univ Calif Los Angeles, Dept Med, Div Digest Dis, CURE Digest Dis Res Ctr, Los Angeles, CA 90024 USA. [Tache, Y.] Univ Calif Los Angeles, Div Digest Dis, Ctr Neurobiol Stress, Los Angeles, CA USA. [Tache, Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Tache, Y (reprint author), VA GLA Healthcare Syst, CURE Bldg 115,Room 117,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ytache@mednet.ucla.edu FU NIDDK NIH HHS [R01 DK-33061, DK-41301, P30 DK041301, R01 DK033061, R37 DK033061] NR 100 TC 19 Z9 19 U1 2 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1467-7881 EI 1467-789X J9 OBES REV JI Obes. Rev. PD NOV PY 2013 VL 14 IS 11 BP 859 EP 870 DI 10.1111/obr.12063 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 295HJ UT WOS:000330106900001 PM 23980879 ER PT J AU Holman, KM Carr, JA Baddley, JW Hook, EW AF Holman, Katherine M. Carr, James Andrew Baddley, John W. Hook, Edward W., III TI Sexual History Taking and Sexually Transmitted Infection Screening in Patients Initiating Erectile Dysfunction Medication Therapy SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID RISK; HIV; SILDENAFIL; BEHAVIOR; DISEASES; ADULTS; MEN AB Background: Erectile dysfunction medications are being prescribed frequently; however, little is known about the amount of sexual health screening occurring in this setting. Methods: A retrospective cohort study evaluating sexual health and sexually transmitted infection screening occurring in veterans receiving initial erectile dysfunction medication prescription was conducted. Results: A total of 252 patients received initial erectile dysfunction medication prescriptions between October 1, 2009, and December 31, 2009; had at least 1 health care provider visit 12 months before the date of initial prescription; and had no documentation of previous erectile dysfunction medication use. Approximately 3% of these patients had any aspect of a sexual history recorded in the 24 months surrounding initial erectile dysfunction medication prescription. Sexually transmitted infection screening was 9.9% for syphilis, 4.8% for HIV, and 4.3% for gonorrhea/chlamydia before prescription, with only a slight increase in HIV screening after prescription. Conclusions: Minimal sexual health assessment is being performed during the time surrounding initial prescription of erectile dysfunction medication. Further work needs to evaluate patient and provider barriers to basic elements of sexual health care, such as taking sexual histories or screening for sexually transmitted infections. C1 [Holman, Katherine M.] Birmingham Vet Affairs Med Ctr, Dept Qual Management, Birmingham, AL USA. [Holman, Katherine M.; Baddley, John W.; Hook, Edward W., III] Birmingham Vet Affairs Med Ctr, Dept Med, Div Infect Dis, Birmingham, AL USA. [Holman, Katherine M.; Baddley, John W.] Univ Alabama Birmingham, Div Infect Dis, Dept Med, Birmingham, AL 35294 USA. [Carr, James Andrew] Birmingham Vet Affairs Med Ctr, Div Infect Dis, Dept Pharm, Birmingham, AL USA. [Carr, James Andrew] Birmingham Vet Affairs Med Ctr, Div Infect Dis, Dept Internal Med, Birmingham, AL USA. RP Holman, KM (reprint author), Univ Alabama Birmingham, Div Infect Dis, Dept Med, 1900 Univ Blvd THT 229, Birmingham, AL 35294 USA. EM holmkm@uab.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD NOV PY 2013 VL 40 IS 11 BP 836 EP 838 DI 10.1097/OLQ.0000000000000031 PG 3 WC Infectious Diseases SC Infectious Diseases GA 297FU UT WOS:000330241900002 PM 24113402 ER PT J AU Stice, E Figlewicz, DP Gosnell, BA Levine, AS Pratt, WE AF Stice, Eric Figlewicz, Dianne P. Gosnell, Blake A. Levine, Allen S. Pratt, Wayne E. TI The contribution of brain reward circuits to the obesity epidemic SO NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS LA English DT Review DE Obesity; Feeding; Reward; Reinforcement; Mesolimbic dopamine system; Opioids; Food addiction; Drug addiction; Food abuse ID MU-OPIOID RECEPTORS; EXCESSIVE SUGAR INTAKE; DIET-INDUCED OBESITY; ENERGY REGULATORY SIGNALS; MEDIAL PREFRONTAL CORTEX; INDUCED DOPAMINE RELEASE; FOOD-SEEKING BEHAVIOR; NUCLEUS-ACCUMBENS; SUBTHALAMIC NUCLEUS; DORSAL STRIATUM AB One of the defining characteristics of the research of Ann E. Kelley was her recognition that the neuroscience underlying basic learning and motivation processes also shed significant light upon mechanisms underlying drug addiction and maladaptive eating patterns. In this review, we examine the parallels that exist in the neural pathways that process both food and drug reward, as determined by recent studies in animal models and human neuroimaging experiments. We discuss contemporary research that suggests that hyperphagia leading to obesity is associated with substantial neurochemical changes in the brain. These findings verify the relevance of reward pathways for promoting consumption of palatable, calorically dense foods, and lead to the important question of whether changes in reward circuitry in response to intake of such foods serve a causal role in the development and maintenance of some cases of obesity. Finally, we discuss the potential value for future studies at the intersection of the obesity epidemic and the neuroscience of motivation, as well as the potential concerns that arise from viewing excessive food intake as an "addiction". We suggest that it might be more useful to focus on overeating that results in frank obesity, and multiple health, interpersonal, and occupational negative consequences as a form of food "abuse". (C) 2012 Elsevier Ltd. All rights reserved. C1 [Stice, Eric] Oregon Res Inst, Eugene, OR 97403 USA. [Figlewicz, Dianne P.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Gosnell, Blake A.] Univ Minnesota, Dept Food Sci & Nutr, St Paul, MN 55108 USA. [Levine, Allen S.] Univ Minnesota, Coll Food Agr & Nat Resource Sci, St Paul, MN 55108 USA. [Pratt, Wayne E.] Wake Forest Univ, Dept Psychol, Winston Salem, NC 27109 USA. RP Pratt, WE (reprint author), Wake Forest Univ, Dept Psychol, POB 7778 Reynolda Stn, Winston Salem, NC 27109 USA. EM estice@ori.org; latte@u.washington.edu; bgosnell@umn.edu; aslevine@umn.edu; prattwe@wfu.edu FU NIH [R1MH064560A, DK080760, DK092468, DK40963]; NIH/NIDA [R01DA021280]; NIH/NIDDK [P30DK50456]; [DA030618] FX Eric Stice is a Senior Research Scientist at Oregon Research Institute; his research cited herein was supported by NIH grants R1MH064560A, DK080760, and DK092468. Dianne Figlewicz Lattemann is a Senior Research Career Scientist, Biomedical Laboratory Research Program, Department of Veterans Affairs Puget Sound Health Care System, Seattle, Washington; and her research cited in this paper has been supported by NIH grant DK40963. The research by Blake A. Gosnell and Allen S. Levine was supported by NIH/NIDA (R01DA021280) (ASL, BAG) and NIH/NIDDK (P30DK50456) (ASL). Wayne E. Pratt is currently supported by DA030618. NR 164 TC 59 Z9 61 U1 8 U2 56 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7634 EI 1873-7528 J9 NEUROSCI BIOBEHAV R JI Neurosci. Biobehav. Rev. PD NOV PY 2013 VL 37 IS 9 SI SI BP 2047 EP 2058 DI 10.1016/j.neubiorev.2012.12.001 PN A PG 12 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 292EE UT WOS:000329884200012 PM 23237885 ER PT J AU Wangelin, BC Powers, MB Smits, JAJ Tuerk, PW AF Wangelin, Bethany C. Powers, Mark B. Smits, Jasper A. J. Tuerk, Peter W. TI Enhancing exposure therapy for PTSD with yohimbine HCL: Protocol for a double-blind, randomized controlled study implementing subjective and objective measures of treatment outcome SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Randomized controlled trial; Posttraumatic stress disorder; Prolonged exposure; Yohimbine HCL; Skin conductance; Heart rate ID POSTTRAUMATIC-STRESS-DISORDER; PLACEBO-CONTROLLED TRIAL; UNIPOLAR MOOD DISORDERS; SCRIPT-DRIVEN IMAGERY; PROLONGED EXPOSURE; FEAR EXTINCTION; D-CYCLOSERINE; PSYCHOMETRIC PROPERTIES; VETERANS; CHECKLIST AB Prolonged exposure (PE) therapy is considered a gold standard protocol for the treatment of PTSD, and it is associated with large treatment effect sizes in combat veteran samples. However, considering high rates of PTSD in the present veteran population, ongoing research work is important toward improving treatment efficiency by decreasing time to symptom amelioration and increasing the amount of symptom amelioration. The proposed research aims to enhance exposure therapy outcomes for veterans with PTSD via combination treatment with PE and yohimbine hydrochloride (HCL), an alpha-2 adrenergic receptor antagonist. The proposed investigation entails a randomized, placebo-controlled trial investigating the effect of a single administration of,yohimbine HCL (paired with the first session of imaginal exposure) on outcome of PE in 40 veterans with PTSD. An additional goal is to establish a pragmatic method of tracking psychophysiological measures over the course of therapy for incorporation into future clinical psychotherapy trials. Thus, in addition to traditional self- and clinician-reported psychological outcomes, heart rate and skin conductance reactivity will be measured during a standard trauma-specific imagery task before, during, and after PE treatment. We will further investigate whether changes in psychophysiological measures predict changes in patient- and clinician-reported outcome measures. Published by Elsevier Inc. C1 [Wangelin, Bethany C.; Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, Mental Hlth Serv Line, Charleston, SC 29401 USA. [Wangelin, Bethany C.; Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29401 USA. [Powers, Mark B.; Smits, Jasper A. J.] So Methodist Univ, Dept Psychol, Dallas, TX 75205 USA. RP Wangelin, BC (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St 116, Charleston, SC 29401 USA. EM wangelin@musc.edu RI Smits, Jasper/A-4350-2008; Powers, Mark/G-6269-2017 OI Smits, Jasper/0000-0001-7128-9807; Powers, Mark/0000-0001-7898-073X; Smits, Jasper/0000-0003-1633-9693 FU Career Development Award from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (PI) [CDA-2] FX Dr. Tuerk's portion of this work was supported by a Career Development Award (CDA-2) from the Department of Veteran Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research and Development (PI: Peter W. Tuerk). NR 68 TC 5 Z9 5 U1 4 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD NOV PY 2013 VL 36 IS 2 BP 319 EP 326 DI 10.1016/j.cct.2013.08.003 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA 283RS UT WOS:000329265300001 PM 23939512 ER PT J AU Mukete, BN Rosendorff, C AF Mukete, Bertrand N. Rosendorff, Clive TI Effects of low-dose thiazide diuretics on fasting plasma glucose And serum potassium-a meta-analysis SO JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION LA English DT Article DE Chlorthalidone; diuretics; glucose; hydrochlorothiazide; hypertension; hypokalemia; potassium; thiazide ID ISOLATED SYSTOLIC HYPERTENSION; LIPID-LOWERING TREATMENT; ATTACK TRIAL ALLHAT; BLOOD-PRESSURE; CLINICAL-TRIALS; ANTIHYPERTENSIVE EFFICACY; CARDIOVASCULAR EVENTS; ELDERLY PROGRAM; LONG-TERM; HYDROCHLOROTHIAZIDE AB This study is a meta-analysis of the metabolic profile (fasting plasma glucose and serum potassium) of low-dose thiazide and thiazide-like diuretics. The meta-analysis involved 10 randomized controlled clinical trials with a total sample size of 17,636 and 17,947 for the potassium and glucose arms respectively. The random effect model was used to calculate the odds ratio with 95 percent confidence interval. The cumulative mean change of fasting plasma glucose was +0.20 mmol/L (+3.6 mg/dL) for the diuretic arm versus +0.12 mmol/L (+2.2 mg/dL) for the comparator arm The cumulative mean change of serum potassium was -0.22 mmol/L (-0.22 mEq/L) for the diuretic arm versus +0.05 mmol/L (+0.05 mEq/L) for the comparator arm. The aggregate odds ratio for having higher fasting plasma glucose in subjects on low-dose thiazide versus non-thiazide antihypertensive was 1.22 (1.11 to 1.33; P < .01). The odds ratio for having a lower serum potassium in subjects on low-dose thiazide versus non-thiazide antihypertensive was 0.36 (0.27 to 0.49; P < .01). The magnitude of the observed change in fasting plasma glucose associated with low-dose thiazide diuretic use, while statistically significant, does not appear to place patients at clinically significant risk. On the other hand, the observed change in serum potassium was also statistically significant, and may be clinically significant in patients whose baseline potassium concentration is low or low-normal, and could predispose at-risk patients, such as those with ischemic heart disease, to ventricular arrhythmias. Published by Elsevier Inc. on behalf of American Society of Hypertension. C1 [Mukete, Bertrand N.] Mt Sinai Sch Med, Leon & Norma Hess Ctr Sci & Med, Cardiovasc Res Ctr, New York, NY USA. [Rosendorff, Clive] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Rosendorff, Clive] James J Peters VA Med Ctr, Bronx, NY USA. RP Rosendorff, C (reprint author), Mt Sinai Sch Med, James J Peters VA Med Ctr, Dept Med, 130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM clive.rosendorff@va.gov NR 47 TC 10 Z9 10 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1933-1711 EI 1878-7436 J9 J AM SOC HYPERTENS JI J. Am. Soc. Hypertens. PD NOV-DEC PY 2013 VL 7 IS 6 BP 454 EP 466 DI 10.1016/j.jash.2013.05.004 PG 13 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 283UP UT WOS:000329272800008 PM 23800570 ER PT J AU Jarrett, RB Minhajuddin, A Gershenfeld, H Friedman, ES Thase, ME AF Jarrett, Robin B. Minhajuddin, Abu Gershenfeld, Howard Friedman, Edward S. Thase, Michael E. TI Preventing Depressive Relapse and Recurrence in Higher-Risk Cognitive Therapy Responders A Randomized Trial of Continuation Phase Cognitive Therapy, Fluoxetine, or Matched Pill Placebo SO JAMA PSYCHIATRY LA English DT Article ID MAJOR DEPRESSION; BEHAVIOR-THERAPY; FOLLOW-UP; ANTIDEPRESSANT MEDICATION; DISORDER; DESIGN; OUTPATIENTS; ACTIVATION; REMISSION; PHYSICIAN AB IMPORTANCE Strategies to improve the course of recurrent major depressive disorder have great public health relevance. To reduce the risk of relapse/recurrence after acute phase cognitive therapy (CT), a continuation phase model of therapy may improve outcomes. OBJECTIVES To test the efficacy of continuation phase CT (C-CT) and fluoxetine for relapse prevention in a pill placebo (PBO)-controlled randomized trial and compare the durability of prophylaxis after discontinuation of treatments. DESIGN A sequential, 3-stage design with an acute phase (all patients received 12 weeks of CT); 8-month experimental phase (responders at higher risk were randomized to C-CT, fluoxetine, or PBO); and 24 months of longitudinal, posttreatment follow-up. SETTING Two university-based specialty clinics. PATIENTS A total of 523 adults with recurrent major depressive disorder began acute phase CT, of which 241 higher-risk responders were randomized and 181 subsequently entered the follow-up. INTERVENTIONS Cognitive therapy responders at higher risk for relapse were randomized to receive 8 months of C-CT (n = 86), fluoxetine (n = 86), or PBO (n = 69). MAIN OUTCOMES AND MEASURES Survival analyses of relapse/recurrence rates, as determined by blinded evaluators using DSM-IV criteria and the Longitudinal Interval Follow-up Evaluation. RESULTS As predicted, the C-CT or fluoxetine groups were significantly less likely to relapse than the PBO group across 8 months. Relapse/recurrence rates for C-CT and fluoxetine were nearly identical during the 8 months of treatment, although C-CT patients were more likely to accept randomization, stayed in treatment longer, and attended more sessions than those in the fluoxetine and PBO groups. Contrary to prediction, relapse/recurrence rates following the discontinuation of C-CT and fluoxetine did not differ. CONCLUSIONS AND RELEVANCE Relapse risk was reduced by both C-CT and fluoxetine in an enriched randomization sampling only CT responders. The preventive effects of C-CT were not significantly more durable than those of fluoxetine after treatment was stopped, suggesting that some higher-risk patients may require alternate longer-term interventions. C1 [Jarrett, Robin B.; Gershenfeld, Howard] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Minhajuddin, Abu] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Friedman, Edward S.; Thase, Michael E.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Dept Psychiat, Philadelphia, PA USA. RP Jarrett, RB (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA. EM robin.jarrett@utsouthwestern.edu FU National Institute of Mental Health [K24 MH001571, R01 MH058397, R01 MH069619, R01 MH058356, R01 MH069618]; Eli Lilly and Co FX This study was supported by grants K24 MH001571, R01 MH058397, and R01 MH069619 (Dr Jarrett) and by R01 MH058356 and R01 MH069618 (Dr Thase) from the National Institute of Mental Health. We acknowledge the unrestricted support of Eli Lilly and Co, which provided fluoxetine and matched pill placebo for the first 6 years of the study. Thereafter, study materials were purchased and prepared to appear identical for both sites by the pharmacy at The University of Texas Southwestern Medical Center. NR 54 TC 25 Z9 26 U1 5 U2 15 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 2168-622X EI 2168-6238 J9 JAMA PSYCHIAT JI JAMA Psychiatry PD NOV PY 2013 VL 70 IS 11 BP 1152 EP 1160 DI 10.1001/jamapsychiatry.2013.1969 PG 9 WC Psychiatry SC Psychiatry GA 279GP UT WOS:000328948700007 PM 24005123 ER PT J AU Planet, PJ LaRussa, SJ Dana, A Smith, H Xu, A Ryan, C Uhlemann, AC Boundy, S Goldberg, J Narechania, A Kulkarni, R Ratner, AJ Geoghegan, JA Kolokotronis, SO Prince, A AF Planet, Paul J. LaRussa, Samuel J. Dana, Ali Smith, Hannah Xu, Amy Ryan, Chanelle Uhlemann, Anne-Catrin Boundy, Sam Goldberg, Julia Narechania, Apurva Kulkarni, Ritwij Ratner, Adam J. Geoghegan, Joan A. Kolokotronis, Sergios-Orestis Prince, Alice TI Emergence of the Epidemic Methicillin-Resistant Staphylococcus aureus Strain USA300 Coincides with Horizontal Transfer of the Arginine Catabolic Mobile Element and speG-mediated Adaptations for Survival on Skin SO MBIO LA English DT Article ID INNATE ANTIMICROBIAL PEPTIDES; FIBRONECTIN-BINDING PROTEIN; BIOFILM FORMATION; HUMAN KERATINOCYTES; MAXIMUM-LIKELIHOOD; MIXED MODELS; POLYAMINES; FIBRINOGEN; INFECTIONS; VIRULENCE AB The arginine catabolic mobile element (ACME) is the largest genomic region distinguishing epidemic USA300 strains of methicillin-resistant Staphylococcus aureus (MRSA) from other S. aureus strains. However, the functional relevance of ACME to infection and disease has remained unclear. Using phylogenetic analysis, we have shown that the modular segments of ACME were assembled into a single genetic locus in Staphylococcus epidermidis and then horizontally transferred to the common ancestor of USA300 strains in an extremely recent event. Acquisition of one ACME gene, speG, allowed USA300 strains to with-stand levels of polyamines (e. g., spermidine) produced in skin that are toxic to other closely related S. aureus strains. speG-mediated polyamine tolerance also enhanced biofilm formation, adherence to fibrinogen/fibronectin, and resistance to antibiotic and keratinocyte-mediated killing. We suggest that these properties gave USA300 a major selective advantage during skin infection and colonization, contributing to the extraordinary evolutionary success of this clone. IMPORTANCE Over the past 15 years, methicillin-resistant Staphylococcus aureus (MRSA) has become a major public health problem. It is likely that adaptations in specific MRSA lineages (e. g., USA300) drove the spread of MRSA across the United States and allowed it to replace other, less-virulent S. aureus strains. We suggest that one major factor in the evolutionary success of MRSA may have been the acquisition of a gene (speG) that allows S. aureus to evade the toxicity of polyamines (e. g., spermidine and spermine) that are produced in human skin. Polyamine tolerance likely gave MRSA multiple fitness advantages, including the formation of more-robust biofilms, increased adherence to host tissues, and resistance to antibiotics and killing by human skin cells. C1 [Planet, Paul J.; LaRussa, Samuel J.; Smith, Hannah; Xu, Amy; Ryan, Chanelle; Goldberg, Julia; Kulkarni, Ritwij; Ratner, Adam J.; Prince, Alice] Columbia Univ, Dept Pediat, Div Pediat Infect Dis, Coll Phys & Surg, New York, NY 10027 USA. [Planet, Paul J.; Narechania, Apurva; Kolokotronis, Sergios-Orestis] Amer Museum Nat Hist, Sackler Inst Comparat Genom, New York, NY 10024 USA. [Dana, Ali] James J Peters Vet Affairs Med Ctr, Dept Dermatol, Bronx, NY USA. [Uhlemann, Anne-Catrin] Columbia Univ, Coll Phys & Surg, Dept Internal Med, Div Infect Dis, New York, NY USA. [Boundy, Sam] Virginia Commonwealth Univ, Sch Med, Dept Internal Med, Div Infect Dis, Richmond, VA USA. [Geoghegan, Joan A.] Trinity Coll Dublin, Moyne Inst Prevent Med, Dept Microbiol, Dublin, Ireland. [Kolokotronis, Sergios-Orestis] Fordham Univ, Dept Biol Sci, Bronx, NY 10458 USA. RP Planet, PJ (reprint author), Columbia Univ, Dept Pediat, Div Pediat Infect Dis, Coll Phys & Surg, New York, NY 10027 USA. EM pjp23@columbia.edu RI Kolokotronis, Sergios-Orestis/A-1910-2009 OI Kolokotronis, Sergios-Orestis/0000-0003-3309-8465; Boundy, Sam/0000-0003-0541-1776; Ratner, Adam/0000-0003-1761-794X FU [UL1 TR000040]; [NIH R01 HL079395]; [NIH RO1 AI 103854] FX This work was supported by grants to P.J.P. (UL1 TR000040) and A. S. P. (NIH R01 HL079395 and NIH RO1 AI 103854). NR 62 TC 27 Z9 27 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD NOV-DEC PY 2013 VL 4 IS 6 AR e00889-13 DI 10.1128/mBio.00889-13 PG 10 WC Microbiology SC Microbiology GA 282LZ UT WOS:000329174500037 PM 24345744 ER PT J AU Coker, J Tucker, J Estrada, C AF Coker, Joshua Tucker, Jesse Estrada, Carlos TI Nominal group technique: a tool for course evaluation SO MEDICAL EDUCATION LA English DT News Item C1 [Estrada, Carlos] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Estrada, C (reprint author), Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, 732 FOT 510 20th St South, Birmingham, AL 35294 USA. EM cestrada@uab.edu NR 1 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0308-0110 EI 1365-2923 J9 MED EDUC JI Med. Educ. PD NOV PY 2013 VL 47 IS 11 BP 1145 EP 1145 DI 10.1111/medu.12324 PG 1 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 282EN UT WOS:000329153200045 PM 24117592 ER PT J AU Buccheri, RK Trygstad, LN Buffum, MD Birmingham, P Dowling, GA AF Buccheri, Robin Kay Trygstad, Louise Nigh Buffum, Martha D. Birmingham, Patricia Dowling, Glenna A. TI Self-Management of Unpleasant Auditory Hallucinations A Tested Practice Model SO JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES LA English DT Article ID COMMAND HALLUCINATIONS; BEHAVIORAL-MANAGEMENT; SCHIZOPHRENIA; VOICES; HARM AB Individuals who experience auditory hallucinations (AH) frequently report hearing unpleasant voices saying disturbing things to them, making derogatory remarks about them, or commanding them to do something, including harming themselves or someone else. The Self-Management of Unpleasant Auditory Hallucinations Practice Model was developed to help psychiatric-mental health nurses in both inpatient and outpatient settings implement evidence-based nursing care for voice hearers who are distressed by unpleasant voices. The model's utility extends to nursing education, administration, and research. The model is comprised of three parts: (a) Assessment of Voice Hearer's Experience, (b) Nursing Interventions, and (c) Voice Hearer's Expected Positive Outcomes. These three parts of the model describe nursing assessments conducted with an interview guide and two self-report tools, nursing interventions that teach strategies to manage unpleasant AH in a 10-session course or individually, and evaluation of voice hearer outcomes with two self-report tools. Copyright (C) SLACK Incorporated C1 [Buccheri, Robin Kay; Trygstad, Louise Nigh] Univ San Francisco, Sch Nursing & Hlth Profess, San Francisco, CA 94117 USA. [Buffum, Martha D.; Birmingham, Patricia] San Francisco VA Med Ctr, San Francisco, CA USA. [Buffum, Martha D.] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA. [Dowling, Glenna A.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA. RP Buccheri, RK (reprint author), Univ San Francisco, Sch Nursing & Hlth Profess, Cowell Hall 222,2130 Fulton St, San Francisco, CA 94117 USA. EM buccherir@usfca.edu NR 24 TC 2 Z9 2 U1 3 U2 13 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0279-3695 EI 1938-2413 J9 J PSYCHOSOC NURS MEN JI J. Psychosoc. Nurs. Ment. Health Serv. PD NOV PY 2013 VL 51 IS 11 BP 26 EP 34 DI 10.3928/02793695-20130731-02 PG 9 WC Nursing SC Nursing GA 276EW UT WOS:000328732000011 PM 23938067 ER PT J AU Mori, T Seeman, T Crandall, CJ Merkin, S Binkley, N Greendale, GA Karlamangla, AS AF Mori, T. Seeman, T. Crandall, C. J. Merkin, S. Binkley, N. Greendale, G. A. Karlamangla, A. S. TI ALLOSTATIC LOAD AND BONE STRENGTH: FINDINGS FROM THE MIDLIFE IN THE US STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Mori, T.] VA Greater Los Angeles Healthcare Syst, Ctr Geriatr Res Educ & Clin, Los Angeles, CA USA. [Mori, T.; Seeman, T.; Merkin, S.; Greendale, G. A.; Karlamangla, A. S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Geriatr, Los Angeles, CA 90095 USA. [Crandall, C. J.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med, Los Angeles, CA 90095 USA. [Binkley, N.] Univ Wisconsin, Osteoporosis Clin Ctr, Madison, WI USA. [Binkley, N.] Univ Wisconsin, Res Program, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 15 EP 16 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442101072 ER PT J AU Brown, RT Kiely, DK Bharel, M Mitchell, SL AF Brown, R. T. Kiely, D. K. Bharel, M. Mitchell, S. L. TI USE OF ACUTE CARE SERVICES AMONG OLDER HOMELESS ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Brown, R. T.] Univ Calif San Francisco, Div Geriatr, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Kiely, D. K.; Mitchell, S. L.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA. [Bharel, M.] Boston Hlth Care Homeless Program, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 37 EP 37 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442101188 ER PT J AU Gerhard, L Schoeps, D AF Gerhard, L. Schoeps, D. TI EXPANDING VETERAN-DIRECTED RESPITE (VDR) TO CAREGIVERS ENROLLED IN VA'S CSP SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Gerhard, L.] Adm Community Living, Washington, DC USA. [Schoeps, D.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 126 EP 126 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102117 ER PT J AU Schoeps, D Gerhard, L AF Schoeps, D. Gerhard, L. TI THE VETERAN-DIRECTED HCBS PROGRAM AND REBALANCING VA'S LONG-TERM CARE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Schoeps, D.] US Dept Vet Affairs, Washington, DC USA. [Gerhard, L.] Adm Community Living, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 126 EP 126 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102116 ER PT J AU Taylor, L Henius, J Kabat, M AF Taylor, L. Henius, J. Kabat, M. TI IMPLEMENTATION OF VA'S CAREGIVER SUPPORT PROGRAM (CSP) SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Taylor, L.; Henius, J.; Kabat, M.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 126 EP 126 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102118 ER PT J AU Taylor, L Henius, J Kabat, M AF Taylor, L. Henius, J. Kabat, M. TI RESULTS AND FINDINGS FROM AN EVALUATION OF VA'S CSP SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Taylor, L.; Henius, J.; Kabat, M.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 126 EP 127 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102119 ER PT J AU Dzierzewski, JM Fung, C Jouldjian, S Alessi, C Irwin, M Martin, JL AF Dzierzewski, J. M. Fung, C. Jouldjian, S. Alessi, C. Irwin, M. Martin, J. L. TI DAYTIME SLEEP IS ASSOCIATED WITH 6-MONTH CHANGE IN COGNITIVE FUNCTIONING IN AT-RISK OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Dzierzewski, J. M.; Fung, C.; Alessi, C.; Irwin, M.; Martin, J. L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Dzierzewski, J. M.; Fung, C.; Jouldjian, S.; Alessi, C.; Irwin, M.; Martin, J. L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RI Irwin, Michael/H-4870-2013 OI Irwin, Michael/0000-0002-1502-8431 NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 135 EP 136 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102160 ER PT J AU Brommelhoff, J Melrose, RJ Natta, LE Narvaez, TA Sultzer, DL AF Brommelhoff, J. Melrose, R. J. Natta, L. E. Narvaez, T. A. Sultzer, D. L. TI NEUROPSYCHOLOGICAL CORRELATES OF DEPRESSION IN ALZHEIMER'S DISEASE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Brommelhoff, J.; Melrose, R. J.; Natta, L. E.; Narvaez, T. A.; Sultzer, D. L.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Melrose, R. J.; Sultzer, D. L.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 155 EP 155 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102243 ER PT J AU Nagel, CL Quinones, AR Liang, J Blaum, C Cigolle, C AF Nagel, C. L. Quinones, A. R. Liang, J. Blaum, C. Cigolle, C. TI COGNITIVE IMPAIRMENT, PROXY INTERVIEWS, AND INCONSISTENT LONGITUDINAL REPORTING OF CHRONIC DISEASE SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Nagel, C. L.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA. [Quinones, A. R.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA. [Quinones, A. R.] Portland VA Med Ctr, Portland, OR USA. [Liang, J.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Blaum, C.] NYU, Sch Med, New York, NY USA. [Cigolle, C.] Univ Michigan, Dept Family Med, Ann Arbor, MI 48109 USA. [Cigolle, C.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Cigolle, C.] VA Ann Arbor Geriatr Res Educ & Clin Ctr GRECC, Ann Arbor, MI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 169 EP 170 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442102302 ER PT J AU Genes, N Shapiro, JS Abraham, G Grudzen, C Hwang, U Nassisi, D Baumlin, K AF Genes, N. Shapiro, J. S. Abraham, G. Grudzen, C. Hwang, U. Nassisi, D. Baumlin, K. TI GEDI WISE: HEALTH IT - ENHANCED GERIATRIC EMERGENCY DEPARTMENT SCREENING AND CARE COORDINATION SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Genes, N.; Shapiro, J. S.; Abraham, G.; Grudzen, C.; Hwang, U.; Nassisi, D.; Baumlin, K.] Icahn Sch Med Mt Sinai, New York, NY USA. [Hwang, U.] James J Peters VAMC, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 213 EP 213 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442103053 ER PT J AU Dodge, HH Mattek, NC Austin, D Hayes, T Kaye, J AF Dodge, H. H. Mattek, N. C. Austin, D. Hayes, T. Kaye, J. TI IN-HOME WALKING SPEEDS AND VARIABILITY TRAJECTORIES ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Dodge, H. H.; Mattek, N. C.; Austin, D.; Hayes, T.; Kaye, J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dodge, H. H.] Univ Michigan, Ann Arbor, MI 48109 USA. [Dodge, H. H.] Univ Pittsburgh, Pittsburgh, PA USA. [Kaye, J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 230 EP 230 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442103138 ER PT J AU Lin, F Roiland, R Chen, D AF Lin, F. Roiland, R. Chen, D. TI EXECUTIVE FUNCTION, STRESS REGULATION, AND FRAILTY IN OLDER ADULTS WITH METABOLIC SYNDROME SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Lin, F.; Chen, D.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Roiland, R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 316 EP 317 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104093 ER PT J AU Chodosh, J Connor, M Guzman, J Connor, KI Harrell, K Leff, A Castle, S AF Chodosh, J. Connor, M. Guzman, J. Connor, K. I. Harrell, K. Leff, A. Castle, S. TI MEETING THE CHALLENGE OF PROVIDING SPECIALTY DEMENTIA CARE TO RURAL VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Chodosh, J.; Connor, M.; Guzman, J.; Connor, K. I.; Harrell, K.; Leff, A.; Castle, S.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chodosh, J.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 392 EP 392 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104449 ER PT J AU Hung, WW Kramer, B Barczi, S Thielke, SM Rossi, MI Caprio, TV Howe, JL AF Hung, W. W. Kramer, B. Barczi, S. Thielke, S. M. Rossi, M. I. Caprio, T. V. Howe, J. L. TI A NOVEL PROGRAM TO LINK GERIATRIC TEAM TO RURAL CLINICS (GRECC CONNECT) SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Hung, W. W.; Howe, J. L.] James J Peters VA Med Ctr, GRECC, Bronx, NY USA. [Hung, W. W.; Howe, J. L.] Mt Sinai Sch Med, New York, NY USA. [Kramer, B.] West Los Angeles VA Med Ctr, GRECC, Los Angeles, CA USA. [Barczi, S.] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Thielke, S. M.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA. [Rossi, M. I.] VA Pittsburgh Hlth Care Syst, GRECC, Pittsburgh, PA USA. [Caprio, T. V.] Univ Rochester, Canandaigua Rochester VA Med Ctr, Rochester, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 392 EP 392 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442104448 ER PT J AU Chodosh, J Price, R Cadogan, M Osterweil, D Czerwinski, A Tan, ZS Miller-Martinez, D Frank, J AF Chodosh, J. Price, R. Cadogan, M. Osterweil, D. Czerwinski, A. Tan, Z. S. Miller-Martinez, D. Frank, J. TI IMPROVING NURSING FACILITY DEPRESSION CARE USING MENTORED PRACTICE IMPROVEMENT EDUCATION (PIE) SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Chodosh, J.] VA Greater Los Angeles Hlth Syst, Los Angeles, CA USA. [Chodosh, J.; Price, R.; Cadogan, M.; Osterweil, D.; Tan, Z. S.; Miller-Martinez, D.; Frank, J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Osterweil, D.] Calif Assoc Long Term Care Med, Los Angeles, CA USA. [Czerwinski, A.] Lawson & Associates, Sacramento, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 412 EP 412 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105022 ER PT J AU Spira, AP Covinsky, K Rebok, G Punjabi, N Redline, S Stone, KL Yaffe, K AF Spira, A. P. Covinsky, K. Rebok, G. Punjabi, N. Redline, S. Stone, K. L. Yaffe, K. TI SLEEP-DISORDERED BREATHING AND FUNCTIONAL DECLINE IN OLDER WOMEN SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Spira, A. P.; Rebok, G.; Punjabi, N.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Covinsky, K.; Yaffe, K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Punjabi, N.] Johns Hopkins Sch Med, Baltimore, MD USA. [Redline, S.] Harvard Univ, Sch Med, Boston, MA USA. [Stone, K. L.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 488 EP 488 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105371 ER PT J AU Dodge, HH Bowman, M Mattek, NC Kaye, J AF Dodge, H. H. Bowman, M. Mattek, N. C. Kaye, J. TI CONVERSATIONAL ENGAGEMENT AS A MEANS TO ENHANCE COGNITIVE FUNCTIONS: A TECHNOLOGY-ENABLED RANDOMIZED CONTROLLED TRIAL SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Dodge, H. H.; Bowman, M.; Mattek, N. C.; Kaye, J.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dodge, H. H.] Univ Michigan, Ann Arbor, MI 48109 USA. [Dodge, H. H.] Univ Pittsburgh, Pittsburgh, PA USA. [Kaye, J.] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 515 EP 515 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442105495 ER PT J AU Byers, AL Beristianos, M Neylan, TC Covinsky, K Yaffe, K AF Byers, A. L. Beristianos, M. Neylan, T. C. Covinsky, K. Yaffe, K. TI LATE-LIFE PTSD AND RISK OF MORTALITY: THE IMPORTANCE OF COMORBIDITIES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Byers, A. L.; Beristianos, M.; Neylan, T. C.; Yaffe, K.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Byers, A. L.; Beristianos, M.; Neylan, T. C.; Covinsky, K.; Yaffe, K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Beristianos, M.] Calif Sch Profess Psychol, San Francisco, CA USA. [Covinsky, K.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, K.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 538 EP 538 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106042 ER PT J AU Ford, B Buys, DR Allman, RM Sawyer, P AF Ford, B. Buys, D. R. Allman, R. M. Sawyer, P. TI NEIGHBORHOOD DISADVANTAGE IS ASSOCIATED WITH HOSPITAL USE AMONG OLDER ADULTS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Ford, B.; Buys, D. R.; Allman, R. M.; Sawyer, P.] Birmingham VA Med Ctr, GRECC, Birmingham, AL USA. [Ford, B.; Buys, D. R.; Allman, R. M.; Sawyer, P.] Univ Alabama Birmingham, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 542 EP 542 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106063 ER PT J AU Sheldon, G Rao, S Kinosian, B Stallard, P AF Sheldon, G. Rao, S. Kinosian, B. Stallard, P. TI SMALL AREA ESTIMATES OF CATASTROPHICALLY DISABLED VETERANS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Sheldon, G.; Rao, S.; Kinosian, B.; Stallard, P.] US Dept Vet Affairs, Washington, DC USA. [Sheldon, G.] George Washington Univ, Dept Econ, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 555 EP 555 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106130 ER PT J AU Prigerson, HG Garrido, MM AF Prigerson, H. G. Garrido, M. M. TI WHAT ASPECTS OF TERMINAL CARE BEST PREDICT FAMILY CAREGIVERS' BEREAVEMENT ADJUSTMENT?: EVIDENCE FROM THE COPING WITH CANCER STUDY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Prigerson, H. G.] Harvard Dana Farber, Med Oncol Psychosocial Onc, Boston, MA USA. [Garrido, M. M.] James J Peters VAMC, Bronx, NY USA. [Garrido, M. M.] Icahn Sch Med Mt Sinai, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 558 EP 559 PG 2 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106148 ER PT J AU Carrion, IV Nedjat-Haiem, FR Macip-Billbe, M AF Carrion, I. V. Nedjat-Haiem, F. R. Macip-Billbe, M. TI RESILIENCE AND COPING AMONG OLDER LATINO MEN AND WOMEN WITH A CANCER DIAGNOSIS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Carrion, I. V.; Macip-Billbe, M.] Univ S Florida, Tampa, FL USA. [Nedjat-Haiem, F. R.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 579 EP 579 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106254 ER PT J AU McLean, RR Peters, KW Cawthon, P Fragala, M Kenny, A Castaneda-Sceppa, C Studenski, S Dam, TL AF McLean, R. R. Peters, K. W. Cawthon, P. Fragala, M. Kenny, A. Castaneda-Sceppa, C. Studenski, S. Dam, T. L. TI LONGITUDINAL ASSOCIATION OF FNIH SARCOPENIA CRITERIA AND INCIDENT MOBILITY IMPAIRMENT AND MORTALITY SO GERONTOLOGIST LA English DT Meeting Abstract C1 [McLean, R. R.] Hebrew SeniorLife Inst Aging Res, Boston, MA USA. [McLean, R. R.] Harvard Univ, Sch Med, Boston, MA USA. [Peters, K. W.; Cawthon, P.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Fragala, M.; Kenny, A.] Univ Connecticut, Ctr Hlth, Farmington, CT USA. [Fragala, M.] Univ Cent Florida, Orlando, FL 32816 USA. [Castaneda-Sceppa, C.] Northeastern Univ, Bouve Coll Hlth Sci, Boston, MA 02115 USA. [Studenski, S.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Studenski, S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Dam, T. L.] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 594 EP 594 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106333 ER PT J AU Howe, JL Griffith, JL AF Howe, J. L. Griffith, J. L. TI RURAL INTERDISCIPLINARY TEAM TRAINING (RITT): INFUSING GERIATRICS THROUGHOUT TEAM-BASED PRIMARY CARE CLINICS IN THE UNITED STATES SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Howe, J. L.; Griffith, J. L.] Mt Sinai Sch Med, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. [Howe, J. L.; Griffith, J. L.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 609 EP 609 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106405 ER PT J AU Newell, DA Kramer, B AF Newell, D. A. Kramer, B. TI VA GERIATRIC SCHOLARS PROGRAM: WEB-BASED EDUCATION IN KEY GERIATRICS TOPICS SO GERONTOLOGIST LA English DT Meeting Abstract C1 [Newell, D. A.] Soulut Consulting, Gainesville, FL USA. [Kramer, B.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Kramer, B.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0016-9013 EI 1758-5341 J9 GERONTOLOGIST JI Gerontologist PD NOV PY 2013 VL 53 SU 1 BP 609 EP 609 PG 1 WC Gerontology SC Geriatrics & Gerontology GA 258EN UT WOS:000327442106408 ER PT J AU Amorosa, VK Luetkemeyer, A Kang, M Johnson, VA Umbleja, T Haas, DW Yesmin, S Bardin, MC Chung, RT Alston-Smith, B Tebas, P Peters, MG AF Amorosa, Valerianna K. Luetkemeyer, Anne Kang, Minhee Johnson, Victoria A. Umbleja, Triin Haas, David W. Yesmin, Suria Bardin, Matthew C. Chung, Ray T. Alston-Smith, Beverly Tebas, Pablo Peters, Marion G. TI Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naive to HCV Therapy: Results of the ACTG A5269 Trial SO HIV CLINICAL TRIALS LA English DT Article DE genotype 1; hepatitis C; HIV; nitazoxanide; pegylated interferon; ribavirin ID CHRONIC HEPATITIS-C; HOMEOSTASIS MODEL ASSESSMENT; SIMPLE NONINVASIVE INDEX; VIROLOGICAL RESPONSE; SIGNIFICANT FIBROSIS; INSULIN-RESISTANCE; VIRUS; PROGRAM; PREDICT; PLASMA AB Background: We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-nave HIV-1/HCV genotype 1 coinfected persons. Methods: Prospective, single-arm study in which subjects received 4-week lead-in (NTZ 500 mg twice daily) followed by 48 weeks of NTZ, PEG-IFN, and WBR. We compared the HCV virologic responses of these subjects to historical controls from the completed ACTG study A5178 who received PEG-IFN and WBR and had similar subject characteristics. Primary endpoints were early virologic response and complete early virologic response (EVR and cEVR). Results: Among 67 subjects (78% male; 48% Black; median age, 50 years), EVR was achieved in 65.7% (90% CI, 55.0%-75.3%), cEVR in 38.8% (28.8%-49.6%). and SVR in 32.8% (23.4%-43.5%). EVR was higher with NTZ (51.4% in A5178; P = .03), but the sustained virologic response (SVR) proportion was similar (27.3% in A5178; P = .24). In contrast to A5178, SVR was similar across IL28B genotypes. Overall, NTZ was safe and well-tolerated. Conclusion: Whereas EVR proportion improved significantly in this pilot study, the addition of NTZ to PEG-IFN/WBR did not significantly improve SVR compared to historical controls. NTZ may be associated with an attenuation of the effect of IL28B on HCV treatment response. C1 [Amorosa, Valerianna K.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Amorosa, Valerianna K.; Tebas, Pablo] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Luetkemeyer, Anne; Peters, Marion G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Kang, Minhee; Umbleja, Triin] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA. [Johnson, Victoria A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Johnson, Victoria A.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA. [Haas, David W.] Vanderbilt Univ Sch Med, Nashville, TN USA. [Yesmin, Suria] ACTG Operat Ctr, Silver Spring, MD USA. [Bardin, Matthew C.] Romark Labs LC, Tampa, FL USA. [Chung, Ray T.] Harvard Univ, Sch Med, Boston, MA USA. [Alston-Smith, Beverly] NIAID, Div Aids, NIH, Bethesda, MD 20892 USA. RP Amorosa, VK (reprint author), Philadelphia VAMC, Dept Med, Univ & Woodlawn Ave,8th Floor, Philadelphia, PA 19010 USA. EM valerianna.amorosa@uphs.upenn.edu FU National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health [UL1RR024989]; NIH Roadmap for Medical Research FX This publication was made possible by the Clinical and Translational Science Collaborative of Cleveland grant UL1RR024989 from the National Center for Advancing Translational Sciences (NCATS) component of the National Institutes of Health and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. NR 17 TC 3 Z9 3 U1 0 U2 2 PU THOMAS LAND PUBLISHERS, INC PI ST LOUIS PA 255 JEFFERSON RD, ST LOUIS, MO 63119-3627 USA SN 1528-4336 EI 1945-5771 J9 HIV CLIN TRIALS JI HIV Clin. Trials PD NOV-DEC PY 2013 VL 14 IS 6 BP 274 EP 283 DI 10.1310/hct1408-274 PG 10 WC Infectious Diseases; Pharmacology & Pharmacy SC Infectious Diseases; Pharmacology & Pharmacy GA 272EQ UT WOS:000328443500002 PM 24334180 ER PT J AU Bagnell, ME LeardMann, CA McMaster, HS Boyko, EJ Smith, B Granado, NS Smith, TC AF Bagnell, Melissa E. LeardMann, Cynthia A. McMaster, Hope S. Boyko, Edward J. Smith, Besa Granado, Nisara S. Smith, Tyler C. TI The Association of Predeployment and Deployment-Related Factors on Dimensions of Postdeployment Wellness in US Military Service Members SO AMERICAN JOURNAL OF HEALTH PROMOTION LA English DT Article DE Wellness; Health Promotion; Military Personnel; Physical Fitness; Combat; Prevention Research ID POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; READJUSTMENT RATING-SCALE; HEALTH-CARE UTILIZATION; MILLENNIUM COHORT; MENTAL-HEALTH; GENDER-DIFFERENCES; CIGARETTE-SMOKING; PSYCHOMETRIC PROPERTIES; LONGITUDINAL ASSESSMENT AB Purpose. To assess the effects of predeployment and deployment-related factors on dimensions of wellness following deployment. Design. Prospective longitudinal study. The dependent variable was dimensions of wellness. Independent variables were measured in terms of modifiable, nonmodifiable, and military factors, such as sex, race/ethnicity, service branch, smoking status, and combat experience. Setting. A large military cohort participating in the Millennium Cohort Study. Subjects. Included 10,228 participants who deployed in support of the operations in Iraq and Afghanistan. Measures. Dimensions of wellness were measured by using standardized instruments assessing self-reported physical health, mental health, and stress. Covariates were measured by using self-reported and electronic data. Analysis. Factors of postdeployment wellness were assessed by using ordinal logistic regression. Results. Most participants (78.7%) were categorized as "moderately well" post deployment. Significant modifiable predeployment predictors of postdeployment wellness included normal/underweight body mass index (odds ratio [OR] = 1.72, p < .05). Military factors significantly associated with wellness included not experiencing combat (OR = .56, p < .05), member of Air Force (OR = 2.02, p < .05) or Navy/Coast Guard (OR = 1.47, p < .05), and combat specialist occupation (OR = 1.22, p < .05). Conclusion. Multiple modifiable factors associated with postdeployment wellness were identified, which may help inform medical and military leadership on potential strategies to ensure a well force. Those trained in combat roles were more likely to be well post deployment though this apparent benefit was not conferred onto those reporting combat experiences. C1 [Bagnell, Melissa E.; LeardMann, Cynthia A.; McMaster, Hope S.; Smith, Besa; Granado, Nisara S.; Smith, Tyler C.] Naval Hlth Res Ctr, Dept Deployment Hlth Res, San Diego, CA 92106 USA. [Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA. [Smith, Tyler C.] Natl Univ, Sch Hlth & Human Serv, Dept Community Hlth, San Diego, CA USA. RP LeardMann, CA (reprint author), Naval Hlth Res Ctr, Dept Deployment Hlth Res, 140 Sylvester Rd, San Diego, CA 92106 USA. EM leardmann@med.navy.mil OI Boyko, Edward/0000-0002-3695-192X NR 76 TC 0 Z9 0 U1 5 U2 11 PU AMER JOURNAL HEALTH PROMOTION INC PI TROY PA PO BOX 1254, TROY, MI 48099-1254 USA SN 0890-1171 EI 2168-6602 J9 AM J HEALTH PROMOT JI Am. J. Health Promot. PD NOV-DEC PY 2013 VL 28 IS 2 BP E56 EP E66 DI 10.4278/ajhp.120727-QUAN-366 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 268UP UT WOS:000328196400008 PM 23621754 ER PT J AU Schlosser, RJ Soler, ZM AF Schlosser, Rodney J. Soler, Zachary M. TI Evidence-based treatment of chronic rhinosinusitis with nasal polyps SO AMERICAN JOURNAL OF RHINOLOGY & ALLERGY LA English DT Article; Proceedings Paper CT North American Rhinology and Allergy Conference CY JAN 31-FEB 03, 2013 CL Fajardo, PR ID ENDOSCOPIC SINUS SURGERY; EXACERBATED RESPIRATORY-DISEASE; ASPIRIN DESENSITIZATION-TREATMENT; ALLERGIC FUNGAL RHINOSINUSITIS; RANDOMIZED CONTROLLED-TRIAL; MAXIMAL MEDICAL THERAPY; QUALITY-OF-LIFE; DOUBLE-BLIND; POSTOPERATIVE CARE; STEROID-THERAPY AB Background: Chronic rhinosinusitis with nasal polyps (CRSwNPs) is the most challenging form of CRS to treat. Clinical practices vary widely among physicians around the world, often with little evidence to support current therapies. Methods: This study evaluates various medical and surgical treatments with a focus on the highest levels of evidence. Recommendations for various therapies are provided based on consensus panels and evidence-based reviews. Results: Therapies with the strongest evidence and recommendations for CRSwNPs include oral steroids and topical nasal steroid sprays. There is also reasonable evidence for surgery, to include perioperative oral steroids and postoperative oral antibiotics for at least 2 weeks. There is little evidence to support other therapies, including commonly used modalities such as oral antibiotics, antihistamines, and immunotherapy. Conclusion: CRSwNPs is a heterogenous disorder that currently has very few therapies supported by strong evidence. It is likely that in the near future, a more refined understanding of CRSwNPs will permit clinicians to tailor therapies using high-level evidence with improved outcomes. C1 [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. [Schlosser, Rodney J.; Soler, Zachary M.] Med Univ S Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. RP Schlosser, RJ (reprint author), 135 Rutledge Ave,Suite 1130,MSC 250550, Charleston, SC 29425 USA. EM schlossr@musc.edu NR 58 TC 8 Z9 8 U1 0 U2 6 PU OCEAN SIDE PUBLICATIONS INC PI PROVIDENCE PA 95 PITMAN ST, PROVIDENCE, RI 02906 USA SN 1945-8924 EI 1945-8932 J9 AM J RHINOL ALLERGY JI Am. J. Rhinol. Allergy PD NOV-DEC PY 2013 VL 27 IS 6 BP 461 EP 466 DI 10.2500/ajra.2013.27.3982 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA 272HZ UT WOS:000328452400014 PM 24274220 ER PT J AU Olsen, RHJ Allen, CN Derkach, VA Phillips, TJ Belknap, JK Raber, J AF Olsen, Reid H. J. Allen, Charles N. Derkach, Victor A. Phillips, Tamara J. Belknap, John K. Raber, Jacob TI Impaired memory and reduced sensitivity to the circadian period lengthening effects of methamphetamine in mice selected for high methamphetamine consumption SO BEHAVIOURAL BRAIN RESEARCH LA English DT Article DE Circadian; Water maze; Methamphetamine; Glutamate receptors; GluA1/2; Spatial memory ID AMPA RECEPTOR SUBUNITS; SUPRACHIASMATIC NUCLEUS; DRUG-ADDICTION; ENHANCED LTP; MUTANT MICE; GLUTAMATE; MECHANISMS; RHYTHMS; GLUR2; VULNERABILITY AB Drug abuse runs in families suggesting the involvement of genetic risk factors. Differences in addiction-related neurobiological systems, including learning and memory and circadian rhythms, may exist prior to developing addiction. We characterized the cognitive phenotypes and the free-running circadian period of mouse lines selectively bred for high methamphetamine (MA) drinking (MA high drinking or MAHDR) and low MA drinking (MA low drinking or MALDR). MA-naive MALDR mice showed spatial memory retention while MAHDR mice did not. MA-naive MAHDR mice had elevated hippocampal levels of the AMPA receptor subunits GluA2 (old terminology: GluR2), but not GluA1 (old terminology: GluR1). There were no line differences in the free running period (tau) when only water was available. During a 25 mg/L MA solution access period (vs water), there was an increase in tau in MALDR but not MAHDR mice, although MAHDR mice consumed significantly more MA. During a 50 mg/L MA solution access period (vs water), both lines showed an increased tau. There was a positive correlation between MA consumption and tau from baseline in MALDR, but not MAHDR, mice. Thus, a heritable proclivity for elevated MA self-administration may be associated with impairments in hippocampus-dependent memory and reduced sensitivity to effects of MA on lengthening of the circadian period. (C) 2013 Elsevier B.V. All rights reserved. C1 [Olsen, Reid H. J.; Allen, Charles N.; Phillips, Tamara J.; Belknap, John K.; Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA. [Allen, Charles N.] Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA. [Derkach, Victor A.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA. [Phillips, Tamara J.; Belknap, John K.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA. [Phillips, Tamara J.; Belknap, John K.; Raber, Jacob] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97239 USA. [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Raber, Jacob] Oregon Hlth & Sci Univ, Div Neurosci ONPRC, Portland, OR 97239 USA. RP Raber, J (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 8131 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM raberj@ohsu.edu FU Department of Veterans Affairs [NS036607, P50 DA018165] FX This work was supported by NS036607, P50 DA018165, the Department of Veterans Affairs, and the development account of Dr Raber. We thank Nathan Rogers for the graphical art. NR 42 TC 5 Z9 5 U1 0 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-4328 EI 1872-7549 J9 BEHAV BRAIN RES JI Behav. Brain Res. PD NOV 1 PY 2013 VL 256 BP 197 EP 204 DI 10.1016/j.bbr.2013.08.015 PG 8 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA 267JO UT WOS:000328094100024 PM 23954232 ER PT J AU Stidd, DA Vogelsang, K Krahl, SE Langevin, JP Fellous, JM AF Stidd, David A. Vogelsang, Kimberly Krahl, Scott E. Langevin, Jean-Philippe Fellous, Jean-Marc TI Amygdala Deep Brain Stimulation Is Superior to Paroxetine Treatment in a Rat Model of Posttraumatic Stress Disorder SO BRAIN STIMULATION LA English DT Article DE Amygdala; Deep brain stimulation; Paroxetine; Posttraumatic stress disorder; Psychosurgery ID MEDIAL PREFRONTAL CORTEX; ELEVATED PLUS-MAZE; BLOOD-FLOW; PTSD; ANXIETY; VETERANS; PLACEBO; SERTRALINE; SEROTONIN; BEHAVIOR AB Background: Posttraumatic stress disorder (PTSD) is a very debilitating disease refractory to current treatment with selective serotonin reuptake inhibitors (SSRIs) in up to 30 percent of patients, illustrating the need for new treatments of PTSD. Neuroimaging studies have shown increased activity of the amygdala of patients with PTSD. Objective/hypothesis: To investigate amygdala deep brain stimulation (DBS) as a possible novel treatment for PTSD and compare it to current treatment with a commonly used SSRI, paroxetine, in a rat PTSD model. Methods: A PTSD model was created by subjecting rats to inescapable foot shocks in the presence of a conspicuous ball. Response to treatment was measured as a decreased burying behavior when presented with the same ball 1 and 2 weeks after the shocks. Rats were treated with either daily intraperitoneal paroxetine injections or amygdala DBS via an electrode implanted 1 week prior to shocks. Generalized anxiety was assessed using an elevated plus maze. Results: Animals treated with amygdala DBS showed less ball burying at 2 weeks relative to the animals treated with paroxetine. The animals treated with paroxetine, however, had a lower general anxiety level compared to the DBS-treated group. Conclusions: In this PTSD model, paroxetine was found to decrease the measured general anxiety level of rats that underwent the PTSD protocol, but did not counteract shock-induced hyper-vigilance toward the trauma-associated object (ball). Amygdala DBS, however, did decrease shock-induced hyper-vigilance as measured by a lower burying time, but had no effect on general anxiety assessed in the elevated plus maze. By attenuating amygdala function, DBS may act to treat the cause of PTSD, hyperactive amygdala function, and may be a promising novel alternative in cases of PTSD refractory to current pharmacological treatments. Published by Elsevier Inc. C1 [Stidd, David A.] Univ Arizona, Div Neurosurg, Tucson, AZ 85724 USA. [Vogelsang, Kimberly] Univ Arizona, Dept Physiol, Tucson, AZ 85724 USA. [Krahl, Scott E.; Langevin, Jean-Philippe] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Krahl, Scott E.; Langevin, Jean-Philippe] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA. [Fellous, Jean-Marc] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA. [Fellous, Jean-Marc] Univ Arizona, Program Appl Math, Tucson, AZ 85721 USA. RP Langevin, JP (reprint author), VA Greater Los Angeles Healthcare Syst Surg & Per, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM Jean-Philippe.Langevin@va.gov FU National Science Foundation/National Institutes of Health [CRCNS-IIS-1010172]; Department of Surgery, University of Arizona; VISN 18 New Investigator Award, Department of Veterans Affairs FX Financial disclosures: This work was supported by the National Science Foundation/National Institutes of Health grant CRCNS-IIS-1010172; a grant from the Department of Surgery, University of Arizona; and a VISN 18 New Investigator Award, Department of Veterans Affairs. NR 34 TC 13 Z9 14 U1 1 U2 10 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV PY 2013 VL 6 IS 6 BP 837 EP 844 DI 10.1016/j.brs.2013.05.008 PG 8 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 264VH UT WOS:000327908600002 PM 23835167 ER PT J AU Krieg, TD Salinas, FS Narayana, S Fox, PT Mogul, DJ AF Krieg, Todd D. Salinas, Felipe. S. Narayana, Shalini Fox, Peter T. Mogul, David J. TI PET-Based Confirmation of Orientation Sensitivity of TMS-Induced Cortical Activation in Humans SO BRAIN STIMULATION LA English DT Article DE TMS; Cortex; PET; MRI; Orientation; Cerebral blood flow ID TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; DORSOLATERAL PREFRONTAL CORTEX; SURFACE-BASED ANALYSIS; ELECTRIC-FIELD; BRAIN-STIMULATION; MECHANISMS; EXCITABILITY; MODULATION; EXCITATION AB Background: Currently, it is difficult to predict precise regions of cortical activation in response to transcranial magnetic stimulation (TMS). Most analytical approaches focus on applied magnetic field strength in the target region as the primary factor, placing activation on the gyral crowns. However, imaging studies support M1 targets being typically located in the sulcal banks. Objective/hypothesis: To more thoroughly investigate this inconsistency, we sought to determine whether neocortical surface orientation was a critical determinant of regional activation. Methods: MR images were used to construct cortical and scalp surfaces for 18 subjects. The angle (theta) between the cortical surface normal and its nearest scalp normal for similar to 50,000 cortical points per subject was used to quantify cortical location (i.e., gyral vs. sulcal). TMS-induced activations of primary motor cortex (M1) were compared to brain activations recorded during a finger-tapping task using concurrent positron emission tomographic (PET) imaging. Results: Brain activations were primarily sulcal for both the TMS and task activations (P < 0.001 for both) compared to the overall cortical surface orientation. Also, the location of maximal blood flow in response to either TMS or finger-tapping correlated well using the cortical surface orientation angle or distance to scalp (P < 0.001 for both) as criteria for comparison between different neocortical activation modalities. Conclusion: This study provides further evidence that a major factor in cortical activation using TMS is the orientation of the cortical surface with respect to the induced electric field. The results show that, despite the gyral crown of the cortex being subjected to a larger magnetic field magnitude, the sulcal bank of M1 had larger cerebral blood flow (CBF) responses during TMS. (C) 2013 Elsevier Inc. All rights reserved. C1 [Krieg, Todd D.; Mogul, David J.] IIT, Dept Biomed Engn, Chicago, IL 60616 USA. [Salinas, Felipe. S.; Narayana, Shalini; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Narayana, Shalini] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Mogul, DJ (reprint author), IIT, Dept Biomed Engn, Wishnick Hall 314,3255 S Dearborn St, Chicago, IL 60616 USA. EM mogul@iit.edu RI Fox, Peter/B-4725-2010 OI Fox, Peter/0000-0002-0465-2028 FU Achievement Rewards for College Scientists (ARCS) Chicago chapter; Ruth L. Kirschstein National Research Service Award from the National Institute of Neurological Disorders and Stroke [NIH/NINDS F32 NS066694]; Veterans Administration Merit Award FX Partial support for this work was provided by Achievement Rewards for College Scientists (ARCS) Chicago chapter (to TDK), the Ruth L. Kirschstein National Research Service Award from the National Institute of Neurological Disorders and Stroke (NIH/NINDS F32 NS066694 to FSS), and the Veterans Administration Merit Award (to PTF). NR 57 TC 6 Z9 6 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV PY 2013 VL 6 IS 6 BP 898 EP 904 DI 10.1016/j.brs.2013.05.007 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 264VH UT WOS:000327908600010 PM 23827648 ER PT J AU Borckardt, JJ Nahas, ZH Teal, J Lisanby, SH McDonald, WM Avery, D Durkalski, V Pavlicova, M Long, JM Sackeim, HA George, MS AF Borckardt, Jeffrey J. Nahas, Ziad H. Teal, John Lisanby, Sarah H. McDonald, William M. Avery, David Durkalski, Valerie Pavlicova, Martina Long, James M. Sackeim, Harold A. George, Mark S. TI The Painfulness of Active, but not Sham, Transcranial Magnetic Stimulation Decreases Rapidly Over Time: Results From the Double-Blind Phase of the OPT-TMS Trial SO BRAIN STIMULATION LA English DT Article DE TMS; Transcranial magnetic stimulation; Pain; Depression; OPT-TMS; Clinical trial; Sham ID PREFRONTAL CORTEX; PAIN; DEPRESSION; MOOD; RTMS; THERAPY AB Background: Daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) over several weeks is an FDA approved treatment for major depression. Although rTMS is generally safe when administered using the FDA guidelines, there are a number of side effects that can make it difficult for patients to complete a course of rTMS. Many patients report that rTMS is painful, although patients appear to accommodate to the initial painfulness. The reduction in pain is hypothesized to be due to prefrontal stimulation and is not solely explained by accommodation to the stimulation. Methods: In a recent 4 site randomized controlled trial (using an active electrical sham stimulation system) investigating the antidepressant effects of daily left dorsolateral prefrontal rTMS (Optimization of TMS, or OPT-TMS), the procedural painfulness of TMS was assessed before and after each treatment session. Computerized visual analog scale ratings were gathered before and after each TMS session in the OPT-TMS trial. Stimulation was delivered with an iron core figure-8 coil (Neuronetics) with the following parameters: 10 Hz, 120% MT (EMG-defined), 4 s pulse train, 26 s inter-train interval, 3000 pulses per session, one 37.5 min session per day. After each session, procedural pain (pain at the beginning of the TMS session, pain toward the middle, and pain toward then end of the session) ratings were collected at all 4 sites. From the 199 patients randomized, we had usable data from 142 subjects for the initial 15 TMS sessions (double-blind phase) delivered over 3 weeks (142 x 2 x 15 = 4260 rating sessions). Results: The painfulness of real TMS was initially higher than that of the active sham condition. Over the 15 treatment sessions, subjective reports of the painfulness of rTMS (during the beginning, middle and end of the session) decreased significantly 37% from baseline in those receiving active TMS, with no change in painfulness in those receiving sham. This reduction, although greatest in the first few days, continued steadily over the 3 weeks. Overall, there was a decay rate of 1.56 VAS points per session in subjective painfulness of the procedure in those receiving active TMS. Discussion: The procedural pain of left, prefrontal rTMS decreases over time, independently of other emotional changes, and only in those receiving active TMS. These data suggest that actual TMS stimulation of prefrontal cortex maybe related to the reduction in pain, and that it is not a non-specific accommodation to pain. This painfulness reduction softly corresponds with later clinical outcome. Further work is needed to better understand this phenomenon and whether acute within-session or over time painfulness changes might be used as short-term biomarkers of antidepressant response. (C) 2013 Elsevier Inc. All rights reserved. C1 [Borckardt, Jeffrey J.; Nahas, Ziad H.; Teal, John; George, Mark S.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29482 USA. [Borckardt, Jeffrey J.] Med Univ S Carolina, Dept Anesthesia & Perioperat Med, Charleston, SC 29482 USA. [Nahas, Ziad H.] Amer Univ Beirut, Dept Psychiat, Beirut, Lebanon. [Lisanby, Sarah H.] Duke Univ, Brain Stimulat & Neurophysiol Div, Dept Psychiat & Behav Sci, Durham, NC USA. [McDonald, William M.] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Avery, David] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Durkalski, Valerie] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29482 USA. [Pavlicova, Martina] Columbia Univ, Biostat Dept, New York, NY USA. [Long, James M.] James Long Co, Caroga Lake, NY USA. [Sackeim, Harold A.] Columbia Univ, Dept Psychiat, New York, NY USA. [Sackeim, Harold A.] Columbia Univ, Dept Radiol, New York, NY USA. [George, Mark S.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Borckardt, JJ (reprint author), Med Univ S Carolina, Brain Stimulat Lab BSL, Dept Psychiat & Behav Sci, 502 N IOP,67 President St, Charleston, SC 29482 USA. EM borckard@musc.edu FU NIMH [5R01MH069929, 5R01MH069887, 5R01MH069896, 5R01MH069895, 5R01MH069886] FX Supported by the NIMH as the Optimization of TMS for Depression Trial, (OPT-TMS) involving grants 5R01MH069929 PI: Avery, David, 5R01MH069887 PI: George, Mark, 5R01MH069896 PI: George, Mark, 5R01MH069895 PI: Lisanby, Sarah, 5R01MH069886 PI: McDonald, William. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. NR 16 TC 7 Z9 7 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1935-861X EI 1876-4754 J9 BRAIN STIMUL JI Brain Stimul. PD NOV PY 2013 VL 6 IS 6 BP 925 EP 928 DI 10.1016/j.brs.2013.04.009 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 264VH UT WOS:000327908600014 PM 23769413 ER PT J AU Boockvar, K AF Boockvar, Kenneth TI Pain Therapeutics in Older Adults SO CLINICAL THERAPEUTICS LA English DT Editorial Material ID KNEE OSTEOARTHRITIS; MANAGEMENT; IMPACT; EFFICACY; MEDICATION; FRACTURES; MODERATE; FALLS; LIFE; CARE C1 [Boockvar, Kenneth] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. [Boockvar, Kenneth] Jewish Home Lifecare, Res Inst Aging, New York, NY USA. [Boockvar, Kenneth] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY USA. RP Boockvar, K (reprint author), James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. OI Boockvar, Kenneth/0000-0003-1165-5558 NR 29 TC 0 Z9 0 U1 1 U2 2 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2013 VL 35 IS 11 BP 1656 EP 1658 DI 10.1016/j.clinthera.2013.09.024 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 267LF UT WOS:000328098500002 PM 24139094 ER PT J AU Weiner, DK Moore, CG Morone, NE Lee, ES Kwoh, CK AF Weiner, Debra K. Moore, Charity G. Morone, Natalia E. Lee, Edward S. Kwoh, C. Kent TI Efficacy of Periosteal Stimulation for Chronic Pain Associated With Advanced Knee Osteoarthritis: A Randomized, Controlled Clinical Trial SO CLINICAL THERAPEUTICS LA English DT Article DE acupuncture; chronic pain; knee osteoarthritis; older adults; periosteal stimulation ID HEALTH SURVEY SF-36; PHYSICAL PERFORMANCE BATTERY; WESTERN-ONTARIO-UNIVERSITY; LOWER-EXTREMITY FUNCTION; ILLNESS RATING-SCALE; SELF-EFFICACY; ACUPUNCTURE ANALGESIA; CRITICAL-APPRAISAL; PLACEBO ANALGESIA; OLDER-ADULTS AB Background: Because of morbidity associated with painful knee osteoarthritis (OA) and commonly prescribed analgesics, patients often pursue complementary and alternative modalities (eg, acupuncture). Clinical trials have demonstrated modest therapeutic efficacy of traditional Chinese acupuncture for knee OA pain, and patients with advanced disease have largely been excluded. We have previously demonstrated preliminary short-term tolerability and efficacy of periosteal stimulation therapy (PST) (ie, electrical stimulation of the periosteum facilitated by acupuncture needles) for older adults with advanced knee OA. Objective: This study evaluated the sustained efficacy of PST and boosters for treating chronic pain with advanced knee OA. Methods: One hundred ninety participants age >50 years with Kellgren-Lawrence grade 3 or 4 knee OA and chronic pain were randomized to (1) PST (once a week for 10 weeks) followed by PST boosters for 6 months (once every 2 weeks 2 times, then once a month), (2) control PST (ie, periosteal needles and brief electrical stimulation of control points) once a week for 10 weeks, or (3) PST for 10 weeks followed by control PST boosters for 6 months. Change in the Western Ontario and McMaster Universities Osteoarthritis Index pain score immediately after the 10-week intervention and at 6-month follow-up (9 months after baseline) was the primary outcome. OMERACT-OARSI (Outcome Measures in Rheumatology Clinical Trials Osteoarthritis Research Society International) criteria also were evaluated. Secondary measures of outcome included (1) physical performance (Short Physical Performance Battery, gait speed, Timed Up and Go, and timed stair climb); (2) psychological factors (depressive symptoms measured with the Center for Epidemiologic Studies Depression scale, coping measured with the catastrophizing subscale of the Coping Strategies Questionnaire, and self-efficacy measured with the Arthritis Self-Efficacy Scale); (3) health-related quality of life measured with the Medical Outcomes Study 36-Item Short-Form Health Survey; (4) rescue pain medication use tracked with diaries; and (5) health care utilization and interim physical activity were monitored via monthly telephone calls. Results: After adjustment for pain at baseline, the PST and control booster did not differ from controls at 10 weeks (difference, 1.3; 95% CI, -0.10 to 2.8; P = 0.0683) or 9 months (difference, 1.1; 95% CI, -0.32 to 2.6; P = 0.13). The PST and PST booster group had similar improvement compared with controls at 10 weeks (baseline adjusted difference, 1.1; 95% CI, -0.34 to 2.5; P = 0.1369) but significantly more improvement at 9 months (baseline adjusted difference, 1.5; 95% CI, 0.069 to 3.0; P = 0.0401). Baseline depressive symptoms, low self-efficacy, higher difficulty performing daily activities, and greater knee stiffness predicted a lower likelihood of response. Conclusion: PST plus PST boosters in patients age >50 with advanced knee OA were well-tolerated and modestly reduced pain. Published by Elsevier HS Journals, Inc. C1 [Weiner, Debra K.; Morone, Natalia E.] Vet Adm Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Lee, Edward S.] Vet Adm Pittsburgh Healthcare Syst, Primary Care Serv Line, Pittsburgh, PA USA. [Weiner, Debra K.; Moore, Charity G.; Morone, Natalia E.; Lee, Edward S.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA. [Weiner, Debra K.; Moore, Charity G.; Morone, Natalia E.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Kwoh, C. Kent] Univ Arizona, Div Rheumatol & Clin Immunol, Tucson, AZ USA. [Kwoh, C. Kent] Univ Arizona, Arthrit Ctr, Tucson, AZ USA. RP Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov OI Moore, Charity/0000-0002-0060-0124 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. The contents of this report do not represent the views of the Department of Veterans Affairs or the US government. The authors thank David Mortell, LAc, for his participation in the intervention portion of the study; Ms. Kimberly Hayes, Ms. Lisa Gaston, Mr. Wilbert Schrader, Mr. Jonathan Squeglia, and Ms. Catherine Harris for their assistance with preparation of regulatory documents and data collection; Ms. Diane Comer for her assistance with data analysis; and Ms. Terry Sefcik for her assistance with data management and processing. NR 86 TC 8 Z9 9 U1 3 U2 15 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2013 VL 35 IS 11 BP 1703 EP 1720 DI 10.1016/j.clinthera.2013.09.025 PG 18 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 267LF UT WOS:000328098500006 PM 24184053 ER PT J AU Morone, NE Weiner, DK AF Morone, Natalia E. Weiner, Debra K. TI Pain as the Fifth Vital Sign: Exposing the Vital Need for Pain Education SO CLINICAL THERAPEUTICS LA English DT Editorial Material ID LOW-BACK-PAIN; OLDER-ADULTS; UNITED-STATES; COMPLICATIONS; PROGRAMS; FRACTURE; SURGERY; RISK C1 [Morone, Natalia E.; Weiner, Debra K.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Ctr Res Hlth Care, Div Gen Internal Med, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Div Geriatr, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA USA. RP Morone, NE (reprint author), 7180 Highland Dr,Mail Code 00GR H, Pittsburgh, PA 15206 USA. EM Natalia.Morone@va.gov FU NIA NIH HHS [R01 AG034078]; NIAID NIH HHS [HHSN271201100111U]; PHS HHS [HHSN271201100111U] NR 24 TC 13 Z9 16 U1 2 U2 6 PU ELSEVIER PI BRIDGEWATER PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA SN 0149-2918 EI 1879-114X J9 CLIN THER JI Clin. Ther. PD NOV PY 2013 VL 35 IS 11 BP 1728 EP 1732 DI 10.1016/j.clinthera.2013.10.001 PG 5 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 267LF UT WOS:000328098500008 PM 24145043 ER PT J AU Cohen, BE Neylan, TC Yaffe, K Samuelson, KW Li, YM Barnes, DE AF Cohen, Beth E. Neylan, Thomas C. Yaffe, Kristine Samuelson, Kristin W. Li, Yongmei Barnes, Deborah E. TI Posttraumatic Stress Disorder and Cognitive Function: Findings From the Mind Your Heart Study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ADMINISTERED PTSD SCALE; DEPRESSIVE SYMPTOMS; ALZHEIMERS-DISEASE; SLEEP QUALITY; OLDER-ADULTS; PSYCHOMETRIC PROPERTIES; HEALTH BEHAVIORS; CATEGORY FLUENCY; RISK-FACTORS; US VETERANS AB Objective: Prior studies have found that the patients with posttraumatic stress disorder (PTSD) have poorer performance on cognitive tests than patients without PTSD, but the underlying mechanisms remain unknown. We examined the association between PTSD and cognitive function in a large cohort and evaluated the role of potential biological and behavioral mediators. Method: A cohort of 535 adult outpatients (<= 65 years) without dementia, stroke, or other neurologic disorders was recruited from 2 Veterans Affairs medical centers between February 2008 and June 2010. PTSD was assessed with the Clinician Administered PTSD Scale (CAPS) using DSM-IV-TR criteria. Cognitive function tests included processing speed, Trails A and B, letter fluency, category fluency, and verbal learning and recognition. Linear regression was used to evaluate the association between PTSD and cognitive function test scores and to assess potential mediators of the association. Results: For our analyses of PTSD and cognitive function, we combined 178 participants who met criteria for full PTSD and 18 who met criteria for partial PTSD and had a CAPS score > 40. After adjusting for demographics, these participants with PTSD scored significantly worse on processing speed (0.30 standard deviations [SDs], P <=.001), category fluency (0.23 SDs, P=.01), verbal learning (0.30 SDs, P=.001), and verbal recognition (0.18 SDs, P=.048) than those without PTSD. These associations were largely accounted for by health behaviors, vascular risk factors, and depression. Conclusions: In this cohort of veterans under age 65 years without known neurologic disease, patients with versus without PTSD had significantly poorer performance in several domains of cognitive function, particularly in tests involving processing speed, executive function, and learning. These cognitive deficits were largely explained by modifiable risk factors. Interventions targeted at these risk factors might minimize the impact of PTSD on cognitive decline and dementia risk as patients age. (C) Copyright 2013 Physicians Postgraduate Press, Inc. C1 [Cohen, Beth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Neylan, Thomas C.; Yaffe, Kristine; Samuelson, Kristin W.; Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine; Barnes, Deborah E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cohen, Beth E.; Li, Yongmei] Vet Affairs Med Ctr, San Francisco, CA 94121 USA. [Neylan, Thomas C.; Yaffe, Kristine; Samuelson, Kristin W.; Barnes, Deborah E.] Vet Affairs Med Ctr, Mental Hlth Serv, San Francisco, CA 94121 USA. [Samuelson, Kristin W.] Alliant Int Univ, San Francisco, CA USA. RP Cohen, BE (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM Beth.Cohen@ucsf.edu FU National Heart, Lung, and Blood Institute [K23 HL 094765-0]; Irene Perstein Foundation; University of California, San Francisco; National Center for Research Resources through University of California, San Francisco; National Center for Advancing Translational Sciences, National Institutes of Health, through University of California, San Francisco; Clinical and Translational Science Institute [UL1 RR024131] FX The Mind Your Heart Study was supported by the National Heart, Lung, and Blood Institute (K23 HL 094765-0), by the Irene Perstein Foundation, and by departmental funds from the University of California, San Francisco. Publication of this article was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through University of California, San Francisco, Clinical and Translational Science Institute grant UL1 RR024131. NR 69 TC 15 Z9 16 U1 4 U2 21 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD NOV PY 2013 VL 74 IS 11 BP 1063 EP 1070 DI 10.4088/JCP.12m08291 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 268OL UT WOS:000328180300001 PM 24330891 ER PT J AU Hammond, TG Stodieck, L Birdsall, HH Becker, JL Koenig, P Hammond, JS Gunter, MA Allen, PL AF Hammond, Timothy G. Stodieck, Louis Birdsall, Holly H. Becker, Jeanne L. Koenig, Paul Hammond, Jeffrey S. Gunter, Margaret A. Allen, Patricia L. TI Effects of Microgravity on the Virulence of Listeria monocytogenes, Enterococcus faecalis, Candida albicans, and Methicillin-Resistant Staphylococcus aureus SO ASTROBIOLOGY LA English DT Article ID NEMATODE CAENORHABDITIS-ELEGANS; ENTERICA SEROVAR TYPHIMURIUM; ROTATING-WALL VESSEL; GENE-EXPRESSION; INNATE IMMUNITY; SPACE-FLIGHT; SPACEFLIGHT; GROWTH; WEIGHTLESSNESS; CLINOSTAT AB To evaluate effects of microgravity on virulence, we studied the ability of four common clinical pathogensListeria monocytogenes, methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, and Candida albicansto kill wild type Caenorhabditis elegans (C. elegans) nematodes at the larval and adult stages. Simultaneous studies were performed utilizing spaceflight, clinorotation in a 2-D clinorotation device, and static ground controls. The feeding rate of worms for killed E. coli was unaffected by spaceflight or clinorotation. Nematodes, microbes, and growth media were separated until exposed to true or modeled microgravity, then mixed and grown for 48h. Experiments were terminated by paraformaldehyde fixation, and optical density measurements were used to assay residual microorganisms. Spaceflight was associated with reduced virulence for Listeria, Enterococcus, MRSA, and Candida for both larval and adult C. elegans. These are the first data acquired with a direct in vivo assay system in space to demonstrate virulence. Clinorotation reproduced the effects of spaceflight in some, but not all, virulence assays: Candida and Enterococcus were less virulent for larval worms but not adult worms, whereas virulence of MRSA and Listeria were unaffected by clinorotation in tests with both adult and larval worms. We conclude that four common clinical microorganisms are all less virulent in space. Key Words: VirulenceSpaceflightNematodesClinorotationMicrogravityMicroorganism. Astrobiology 13, 1081-1090. C1 [Hammond, Timothy G.; Allen, Patricia L.] Duke Univ, Sch Med, Durham VA Med Ctr, Res & Dev Serv, Durham, NC USA. [Hammond, Timothy G.] Duke Univ, Sch Med, Div Nephrol, Dept Internal Med, Durham, NC USA. [Hammond, Timothy G.; Birdsall, Holly H.] US Dept Vet Affairs, Off Res & Dev, Washington, DC 20420 USA. [Hammond, Timothy G.] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Hammond, Timothy G.] George Washington Sch Med, Dept Internal Med, Nephrol Sect, Washington, DC USA. [Stodieck, Louis; Koenig, Paul] Univ Colorado, Boulder, CO 80309 USA. [Birdsall, Holly H.] Baylor Coll Med, Dept Otorhinolaryngol, Houston, TX 77030 USA. [Birdsall, Holly H.] Baylor Coll Med, Dept Immunol & Psychiat, Houston, TX 77030 USA. [Becker, Jeanne L.] Astrogenetix LLC, Austin, TX USA. [Hammond, Jeffrey S.] Inst Med Res, Durham, NC USA. [Gunter, Margaret A.] Georgia Dept Publ Hlth, Macon, GA USA. RP Hammond, TG (reprint author), US Dept Vet Affairs, Off Res & Dev, Vet Hlth Adm, 810 Vermont Ave 10P9, Washington, DC 20420 USA. EM Timothy.Hammond@va.gov FU SpaceHab/Astrotech; Astrogenetix Inc.; International Space Station National Lab Pathfinder program FX These studies were supported by SpaceHab/Astrotech and Astrogenetix Inc. We thank NASA for spaceflight access under the auspices of the International Space Station National Lab Pathfinder program. We thank Anthony Johnson for technical assistance. NR 35 TC 4 Z9 6 U1 0 U2 12 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1531-1074 EI 1557-8070 J9 ASTROBIOLOGY JI Astrobiology PD NOV 1 PY 2013 VL 13 IS 11 BP 1081 EP 1090 DI 10.1089/ast.2013.0986 PG 10 WC Astronomy & Astrophysics; Biology; Geosciences, Multidisciplinary SC Astronomy & Astrophysics; Life Sciences & Biomedicine - Other Topics; Geology GA 258CA UT WOS:000327434900006 PM 24283929 ER PT J AU Hall, YN Choi, AI Xu, P Smith, NL Boyko, EJ AF Hall, Yoshio N. Choi, Andy I. Xu, Ping Smith, Nicholas L. Boyko, Edward J. TI Predictors of End-stage Renal Disease in the Urban Poor SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE End-stage renal disease; chronic kidney disease; urban poor; race or ethnicity; public health care; disparities ID CHRONIC KIDNEY-DISEASE; CARDIOVASCULAR EVENTS; RACIAL-DIFFERENCES; RISK-FACTORS; PROTEINURIA; HIV; OUTCOMES; ASSOCIATION; DISPARITIES; PROGRESSION AB We sought to examine the influence of social and clinical factors on risk of progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD) in the urban poor. We studied 15,353 individuals with moderate-to-advanced CKD who received ambulatory care within a large public health system during 1996-2005. The primary outcome was progression to ESRD. Overall, 559 cases of ESRD occurred over a median follow-up of 2.8 years. Among traditional predictors of ESRD, younger age, male sex, non-White race/ethnicity, public health insurance coverage, diabetes, lower kidney function, higher proteinuria, lower hemoglobin level, and lower serum albumin concentration were significantly associated with a higher adjusted ESRD risk (p<.001 for all). There was no significant association between HIV/AIDS (p=.07), viral hepatitis (p=.11), or non-English language (p=.27) and ESRD risk. Our results highlight the importance of addressing traditional risk factors for progressive CKD to reduce the disproportionate burden of ESRD among disadvantaged populations. C1 [Hall, Yoshio N.; Xu, Ping] Univ Washington, Kidney Res Inst, Dept Med, Seattle, WA 98104 USA. [Choi, Andy I.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Choi, Andy I.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Choi, Andy I.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Hall, Yoshio N.; Smith, Nicholas L.; Boyko, Edward J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Hall, YN (reprint author), Univ Washington, Kidney Res Inst, 325 9th Ave, Seattle, WA 98104 USA. EM ynhall@u.washington.edu OI Boyko, Edward/0000-0002-3695-192X FU NCRR NIH HHS [KL2 RR024130, UL1 RR024131]; NIDDK NIH HHS [K23 DK 080645, K23 DK 087900, K23 DK080645, K23 DK087900] NR 39 TC 6 Z9 6 U1 2 U2 6 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD NOV PY 2013 VL 24 IS 4 BP 1686 EP 1700 PG 15 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 251CG UT WOS:000326904800025 PM 24185164 ER PT J AU Sun, L Pan, JP Peng, YZ Wu, Y Li, JH Liu, X Qin, YW Bauman, WA Cardozo, C Zaidi, M Qin, WP AF Sun, Li Pan, Jiangping Peng, Yuanzhen Wu, Yong Li, Jianghua Liu, Xuan Qin, Yiwen Bauman, William A. Cardozo, Christopher Zaidi, Mone Qin, Weiping TI Anabolic steroids reduce spinal cord injury-related bone loss in rats associated with increased Wnt signaling SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Spinal cord injuries; Nandrolone; Androgens; Hypogonadism; Bone loss; Wnt signaling ID EXPRESSION; DIFFERENTIATION; ANDROGENS; TURNOVER; CELLS; GENE AB Background: Spinal cord injury (SCI) causes severe bone loss. At present, there is no practical treatment to delay or prevent bone loss in individuals with motor-complete SCI. Hypogonadism is common in men after SCI and may exacerbate bone loss. The anabolic steroid nandrolone reduces bone loss due to microgravity or nerve transection. Objective: To determine whether nandrolone reduced bone loss after SCI and, if so, to explore the mechanisms of nandrolone action. Methods: Male rats with complete transection of the spinal cord were administered nandrolone combined with a physiological replacement dose of testosterone, or vehicle, beginning on day 29 after SCI and continued for 28 days. Results: SCI reduced distal femoral and proximal tibial bone mineral density (BMD) by 25 and 16%, respectively, at 56 days. This bone loss was attenuated by nandrolone. In ex vivo osteoclasts cultures, SCI increased mRNA levels for tartrate-resistant acid phosphatase (TRAP) and calcitonin receptor; nandrolone-normalized expression levels of these transcripts. In ex vivo osteoblast cultures, SCI increased receptor activator of NF-kB ligand (RANKL) mRNA levels but did not alter osteoprotegerin (OPG) mRNA expression; nandrolone-increased expression of OPG and OPG/RANKL ratio. SCI reduced mRNA levels of Wnt signaling-related genes Wnt3a, low-density lipoprotein receptor-related protein 5 (LRP5), Fzd5, Tcf7, and ectodermal-neural cortex 1 (ENC1) in osteoblasts, whereas nandrolone increased expression of each of these genes. Conclusions: The results demonstrate that nandrolone reduces bone loss after SCI. A potential mechanism is suggested by our findings wherein nandrolone modulates genes for differentiation and activity of osteoclasts and osteoblasts, at least in part, through the activation of Wnt signaling. C1 [Sun, Li; Peng, Yuanzhen; Li, Jianghua; Liu, Xuan; Zaidi, Mone] Mt Sinai Sch Med, Mt Sinai Bone Program, New York, NY USA. [Pan, Jiangping; Wu, Yong; Qin, Yiwen; Bauman, William A.; Cardozo, Christopher; Qin, Weiping] James J Peters VA Med Ctr, Ctr Excellence Med Consequences SCI, Bronx, NY 10468 USA. [Bauman, William A.; Cardozo, Christopher; Qin, Weiping] Mt Sinai Sch Med, Dept Med, New York, NY USA. [Bauman, William A.; Cardozo, Christopher] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA. RP Qin, WP (reprint author), James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Weiping.qin@mssm.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service [B3347K, B4616R, B4162C]; Department of Defense [SC090504]; NIH [AG23176, DK 70525, DK 80459] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service Grants B3347K, B4616R, and B4162C, the Department of Defense Grant SC090504, and NIH Grants (AG23176, DK 70525, and DK 80459). NR 19 TC 15 Z9 15 U1 1 U2 7 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2013 VL 36 IS 6 BP 616 EP 622 DI 10.1179/2045772312Y.0000000020 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 264JC UT WOS:000327871900006 PM 24090150 ER PT J AU Locatelli, SM LaVela, SL Hogan, TP Goldstein, B AF Locatelli, Sara M. LaVela, Sherri L. Hogan, Timothy P. Goldstein, Barry TI Influenza infection control guidance provided to staff at Veterans Affairs facilities for veterans with spinal cord injury during a pandemic SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Infection control; Hygiene; Vaccination; Immunization; Patient education; Veterans; Spinal cord injuries; Paraplegia; Tetraplegia; Influenza; Human; Pandemics; Access to care ID DEATH; CONTAMINATION; VACCINATION; ENVIRONMENT AB Context/objective: To assess guidance provided to staff at Veterans Affairs (VA) healthcare facilities on H1N1 influenza infection control for veterans with spinal cord injuries and disorders (SCI/D). Study design: Cross-sectional qualitative semi-structured interviews. Setting: Thirty-three VA healthcare facilities from throughout the United States that provide care to veterans with SCI/D. Participants: Thirty-three infection control key informants, each representing a VA healthcare facility. Interventions: None. Outcome measures: Infection control practices, including vaccination practices, hospital preparedness, and recommendations for future pandemics, both in general and specifically to SCI/D. Results: Most (n = 26, 78.8%) infection control key informants believed veterans with SCI/D were at increased risk for influenza and complications, but only 17 (51.5%) said veterans with SCI/D were treated as a priority group for vaccination at their facilities. There was little special guidance provided for treating veterans with SCI/D, and most (n = 28, 84.8%) informants said that infection control procedures and recommendations were applied universally. Yet, 10 key informants discussed 'unique challenges' to infection control in the SCI/D population. Informants discussed the potential for infectious agents to be spread through shared and common use equipment and the necessity of including caregivers in any vaccination or educational campaigns. Conclusion: Greater input by experts knowledgeable about SCI/D is recommended to adequately address pandemic influenza within healthcare facilities where individuals with SCI/D receive care. C1 [Locatelli, Sara M.; LaVela, Sherri L.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL USA. [Locatelli, Sara M.; LaVela, Sherri L.; Goldstein, Barry] Edward Hines Jr VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL USA. [LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA. [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Adm Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA. [Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Adm Hosp, eHlth Qual Enhancement Res Initiat, Natl eHlth QUERI Coordinating Ctr, Bedford, MA 01730 USA. [Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA. [Goldstein, Barry] VA Puget Sound Healthcare Syst, SCI Healthcare Grp, Seattle, WA USA. RP Locatelli, SM (reprint author), 5000 S 5th Ave 151H, Hines, IL 60141 USA. EM Sara.Locatelli@va.gov FU Office of Research and Development, Health Services Research and Development; Spinal Cord Injury Quality Enhancement Research Initiative, of the Department of Veterans Affairs [RRP 10-046] FX This material is based on work supported by the Office of Research and Development, Health Services Research and Development, and Spinal Cord Injury Quality Enhancement Research Initiative, of the Department of Veterans Affairs (Project number: RRP 10-046). This study reflects only the authors' opinions and does not necessarily reflect the official position of the Department of Veterans Affairs. NR 26 TC 2 Z9 2 U1 1 U2 2 PU MANEY PUBLISHING PI LEEDS PA STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PD NOV PY 2013 VL 36 IS 6 BP 666 EP 671 DI 10.1179/2045772313Y.0000000112 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA 264JC UT WOS:000327871900013 PM 24090346 ER PT J AU Favinger, J Bastawrous, S Bhargava, P AF Favinger, Jennifer Bastawrous, Sarah Bhargava, Puneet TI Management of Acute Contrast Media Reactions: Assessing Preparedness of a Tertiary Care Veterans Affairs Medical Center SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY LA English DT Editorial Material C1 [Favinger, Jennifer; Bastawrous, Sarah; Bhargava, Puneet] Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA. [Bastawrous, Sarah; Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. [Bastawrous, Sarah; Bhargava, Puneet] Univ Washington, Sch Med, Seattle, WA USA. RP Bhargava, P (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mail Box 358280, Seattle, WA 98108 USA. EM bhargp@uw.edu OI Bastawrous, Sarah/0000-0002-7690-3121; Bhargava, Puneet/0000-0002-3849-9666 NR 6 TC 4 Z9 4 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1546-1440 J9 J AM COLL RADIOL JI J. Am. Coll. Radiol. PD NOV PY 2013 VL 10 IS 11 BP 872 EP 874 DI 10.1016/j.jacr.2012.12.019 PG 3 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 257WI UT WOS:000327418100018 PM 23433785 ER PT J AU Lalwani, N Moshiri, M Lee, JH Bhargava, P Dighe, MK AF Lalwani, Neeraj Moshiri, Mariam Lee, Jean H. Bhargava, Puneet Dighe, Manjiri K. TI Magnetic Resonance Imaging of Pelvic Floor Dysfunction SO RADIOLOGIC CLINICS OF NORTH AMERICA LA English DT Article DE Pelvic floor dysfunction; MR defecography; Cystocele; Rectocele; Incontinence; Constipation; Anismus; Descending perineal syndrome ID FLUOROSCOPIC CYSTOCOLPOPROCTOGRAPHY; EVACUATION PROCTOGRAPHY; MR DEFECOGRAPHY; ORGAN PROLAPSE; DISORDERS; SUPINE; DIAGNOSIS; POSITIONS; DESCENT AB Pelvic floor dysfunction is largely a complex problem of multiparous and postmenopausal women and is associated with pelvic floor or organ descent. Physical examination can underestimate the extent of the dysfunction and misdiagnose the disorders. Functional magnetic resonance (MR) imaging is emerging as a promising tool to evaluate the dynamics of the pelvic floor and use for surgical triage and operative planning. This article reviews the anatomy and pathology of pelvic floor dysfunction, typical imaging findings, and the current role of functional MR imaging. C1 [Lalwani, Neeraj] Univ Washington, Dept Radiol, Seattle, WA 98104 USA. [Moshiri, Mariam; Lee, Jean H.; Dighe, Manjiri K.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. RP Lalwani, N (reprint author), Univ Washington, Dept Radiol, Box 359728,325 9th Ave, Seattle, WA 98104 USA. EM neerajl@uw.edu RI Lalwani, Neeraj/A-3490-2011 OI Lalwani, Neeraj/0000-0001-5514-2805; Bhargava, Puneet/0000-0002-3849-9666 NR 40 TC 12 Z9 17 U1 3 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0033-8389 EI 1557-8275 J9 RADIOL CLIN N AM JI Radiol. Clin. N. Am. PD NOV PY 2013 VL 51 IS 6 BP 1127 EP + DI 10.1016/j.rcl.2013.07.004 PG 15 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 261QR UT WOS:000327680200013 PM 24210448 ER PT J AU Wilhelm, CJ Hashimoto, JG Roberts, ML Loftis, JM Wiren, KM AF Wilhelm, C. J. Hashimoto, J. G. Roberts, M. L. Loftis, J. M. Wiren, K. M. TI Immune response to chronic alcohol predicts neurotoxicity and is dependent on sex SO ALCOHOL LA English DT Meeting Abstract CT Alcohol-and-Immunology-Research-Interest-Group (AIRIG) Meeting on Alcohol and Inflammatory Responses CY NOV 22, 2013 CL Loyola Univ Chicago, Hlth Sci Campus, Dept Surg, Maywood, IL SP Alcohol & Immunol Res Interest Grp HO Loyola Univ Chicago, Hlth Sci Campus, Dept Surg C1 Portland VA Med Ctr, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR 97239 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-8329 EI 1873-6823 J9 ALCOHOL JI Alcohol PD NOV PY 2013 VL 47 IS 7 MA 33 BP 576 EP 576 PG 1 WC Substance Abuse; Pharmacology & Pharmacy; Toxicology SC Substance Abuse; Pharmacology & Pharmacy; Toxicology GA 260FX UT WOS:000327581500042 ER PT J AU Marcus, EA Vagin, O Tokhtaeva, E Sachs, G Scott, DR AF Marcus, Elizabeth A. Vagin, Olga Tokhtaeva, Elmira Sachs, George Scott, David R. TI Helicobacter pylori impedes acid-induced tightening of gastric epithelial junctions SO AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY LA English DT Article DE Helicobacter pylori; gastric epithelium; apical acidity ID CANCER CELL-LINES; GENE-EXPRESSION; INTERCELLULAR SPACES; ENVIRONMENTAL PH; BARRIER FUNCTION; BETA-CATENIN; INFECTION; UREASE; ACTIVATION; INTERLEUKIN-8 AB Gastric infection by Helicobacter pylori is the most common cause of ulcer disease and gastric cancer. The mechanism of progression from gastritis and inflammation to ulcers and cancer in a fraction of those infected is not definitively known. Significant acidity is unique to the gastric environment and is required for ulcer development. The interplay between gastric acidity and H. pylori pathogenesis is important in progression to advanced disease. The aim of this study was to characterize the impact of acid on gastric epithelial integrity and cytokine release and how H. pylori infection alters these responses. Human gastric epithelial (HGE-20) cells were grown on porous inserts, and survival, barrier function, and cytokine release were studied at various apical pH levels in the presence and absence of H. pylori. With apical acidity, gastric epithelial cells demonstrate increased barrier function, as evidenced by increased transepithelial electrical resistance (TEER) and decreased paracellular permeability. This effect is reduced in the presence of wild-type, but not urease knockout, H. pylori. The epithelial inflammatory response is also modulated by acidity and H. pylori infection. Without H. pylori, epithelial IL-8 release decreases in acid, while IL-6 release increases. In the presence of H. pylori, acidic pH diminishes the magnitude of the previously reported increase in IL-8 and IL-6 release. H. pylori interferes with the gastric epithelial response to acid, contributing to altered barrier function and inflammatory response. H. pylori diminishes acid-induced tightening of cell junctions in a urease-dependent manner, suggesting that local pH elevation promotes barrier compromise and progression to mucosal damage. C1 [Marcus, Elizabeth A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90073 USA. [Vagin, Olga; Tokhtaeva, Elmira; Sachs, George; Scott, David R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90073 USA. [Sachs, George] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA. [Marcus, Elizabeth A.; Vagin, Olga; Tokhtaeva, Elmira; Sachs, George; Scott, David R.] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Scott, DR (reprint author), Univ Calif Los Angeles, DGSOM, VA GLAHS, 11301 Wilshire Blvd,Bldg 113,Rm 324, Los Angeles, CA 90073 USA. EM dscott@UCLA.edu FU National Institutes of Health [K12 HD-034610, P30 DK-41301, DK-053642]; Department of Veterans Affairs [1I01BX001006] FX This work was supported by National Institutes of Health Grants K12 HD-034610 (E. A. Marcus), P30 DK-41301 (E. A. Marcus), and DK-053642 (G. Sachs) and Department of Veterans Affairs Grant 1I01BX001006 (G. Sachs). NR 74 TC 6 Z9 6 U1 0 U2 2 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1857 EI 1522-1547 J9 AM J PHYSIOL-GASTR L JI Am. J. Physiol.-Gastroint. Liver Physiol. PD NOV PY 2013 VL 305 IS 10 BP G731 EP G739 DI 10.1152/ajpgi.00209.2013 PG 9 WC Gastroenterology & Hepatology; Physiology SC Gastroenterology & Hepatology; Physiology GA 257OD UT WOS:000327393400008 PM 23989011 ER PT J AU Brawner, BM Volpe, EM Stewart, JM Gomes, MM AF Brawner, Bridgette M. Volpe, Ellen M. Stewart, Jennifer M. Gomes, Melissa M. TI Attitudes and beliefs toward biobehavioural research participation: voices and concerns of urban adolescent females receiving outpatient mental health treatment SO ANNALS OF HUMAN BIOLOGY LA English DT Article DE Biological specimens; research subject recruitment; research ethics ID PLANNED BEHAVIOR; DEPRESSIVE SYMPTOMS; PSYCHIATRIC-DISORDERS; CLINICAL DEPRESSION; RISK BEHAVIORS; CONDOM USE; HEART-RATE; BIOMARKERS; ASSOCIATION; DISEASE AB Background: Biobehavioural research methodology can be invasive and burdensome for participants - particularly adolescents with mental illnesses. Human biological researchers should consider how methodological impositions may hinder adolescent research participation. However, literature on adolescent's voices and concerns toward biobehavioural research participation is virtually non-existent. Aim: This study was designed to determine adolescents' perceptions of participation in research involving the collection of biomarkers via blood, saliva and/or urine samples. Subjects and methods: Urban adolescent females (aged 12-19) receiving outpatient mental health treatment (n = 37) participated in focus groups with concurrent survey administration to explore attitudes, beliefs and willingness/intentions toward biobehavioural research participation. Results: Participants had favourable attitudes toward biobehavioural research and were amenable to provide each specimen type. Mistrust for research emerged, however, and concerns related to privacy and confidentiality were expressed. Conclusion: Participant recruitment is a critical component in study design and implementation; this includes knowledge of population-specific recruitment barriers and facilitators. This innovative paper provides a context for the research participants' decision-making process, strategies to allay fears and concerns and concrete areas to target in research-related interventions. Although the findings are from a specific, US-based sample, the implications warrant replication of the research in other geosocial settings. C1 [Brawner, Bridgette M.; Volpe, Ellen M.; Stewart, Jennifer M.] Univ Penn, Sch Nursing, Ctr Hlth Equ Res, Ctr Global Womens Hlth, Philadelphia, PA 19104 USA. [Gomes, Melissa M.] Virginia Commonwealth Univ, Sch Nursing, Dept Family & Community Hlth Nursing, Richmond, VA USA. RP Brawner, BM (reprint author), Univ Penn, Sch Nursing, Nursing Ctr Hlth Equity Res, Ctr Global Womens Hlth, Curie Blvd,Room 419, Philadelphia, PA 19104 USA. EM brawnerb@nursing.upenn.edu FU Distinguished Postdoctoral Fellowship at the University of Pennsylvania; NIH [T32NR007100]; National Institute of Nursing Research FX This research was supported by the Distinguished Postdoctoral Fellowship at the University of Pennsylvania awarded to Dr Bridgette M. Brawner and the NIH Award Number T32NR007100, Research on Vulnerable Women, Children and Families from the National Institute of Nursing Research to Drs Volpe, Stewart and Gomes. The authors thank the participants for generously giving of their time to participate in the study. The authors also wish to acknowledge Ehriel Fannin, Kristine Quiambao, Janaiya Reason, Jazz Robinson, Margaret Tait and Danielle Stevenson for their assistance with data collection. NR 60 TC 6 Z9 6 U1 3 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0301-4460 EI 1464-5033 J9 ANN HUM BIOL JI Ann. Hum. Biol. PD NOV-DEC PY 2013 VL 40 IS 6 BP 485 EP 495 DI 10.3109/03014460.2013.806590 PG 11 WC Anthropology; Biology; Public, Environmental & Occupational Health SC Anthropology; Life Sciences & Biomedicine - Other Topics; Public, Environmental & Occupational Health GA 255SH UT WOS:000327259600004 PM 23822716 ER PT J AU Hu, X Zhang, F Leak, RK Zhang, W Iwai, M Stetler, RA Dai, Y Zhao, A Gao, Y Chen, J AF Hu, X. Zhang, F. Leak, R. K. Zhang, W. Iwai, M. Stetler, R. A. Dai, Y. Zhao, A. Gao, Y. Chen, J. TI Transgenic Overproduction of Omega-3 Polyunsaturated Fatty Acids Provides Neuroprotection and Enhances Endogenous Neurogenesis After Stroke SO CURRENT MOLECULAR MEDICINE LA English DT Article DE Oligodendrogenesis; omega-3 polyunsaturated fatty acids; neurogenesis; neuroprotection; stroke ID FOCAL CEREBRAL-ISCHEMIA; NEURAL STEM-CELLS; DOCOSAHEXAENOIC ACID; FISH CONSUMPTION; AGED RATS; BRAIN; IMPROVES; RISK; OMEGA-3-FATTY-ACIDS; TRANSPLANTATION AB Strokes are devastating as there are no current therapies to prevent the long term neurological deficits that they cause. Soon after ischemic stroke, there is proliferation and differentiation of neural stem/progenitor cells as an important mechanism for neuronal restoration. However, endogenous neurogenesis by itself is insufficient for effective brain repair after stroke as most newborn neurons do not survive. One fascinating strategy for stroke treatment would thus be maintaining the survival and/or promoting the differentiation of endogenous neural stem/progenitor cells. Using transgenic (Tg) mice over-expressing the C. elegans fat-1 gene encoding an enzyme that converts endogenous omega-6 to omega-3 polyunsaturated fatty acids (n-3 PUFAs), we showed that fat-1 Tg mice with chronically elevated brain levels of n-3 PUFAs exhibited less brain damage and significantly improved long-term neurological performance compared to wild type littermates. Importantly, post-stroke neurogenesis occurred more robustly in fat-1 Tg mice after focal ischemia. This was manifested by enhanced neural stem cell proliferation/differentiation and increased migration of neuroblasts to the ischemic sites where neuroblasts matured into resident neurons. Moreover, these neurogenic effects were accompanied by significantly increased oligodendrogenesis. Our results suggest that n-3 PUFA supplementation is a potential neurogenic and oligodendrogenic treatment to naturally improve post-stroke brain repair and long-term functional recovery. C1 [Hu, X.; Zhang, F.; Stetler, R. A.; Chen, J.] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA. [Hu, X.; Zhang, F.; Zhang, W.; Stetler, R. A.; Gao, Y.; Chen, J.] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200433, Peoples R China. [Hu, X.; Zhang, F.; Zhang, W.; Stetler, R. A.; Gao, Y.; Chen, J.] Fudan Univ, Inst Brain Sci, Shanghai 200433, Peoples R China. [Leak, R. K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA. [Dai, Y.; Zhao, A.] Nanjing Med Univ, Ctr Metab Dis Res, Nanjing, Jiangsu, Peoples R China. [Hu, X.; Zhang, F.; Iwai, M.; Stetler, R. A.; Chen, J.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. [Hu, X.; Zhang, F.; Iwai, M.; Stetler, R. A.; Chen, J.] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA. RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA. EM yqgao@shmu.edu.cn; chenj2@upmc.edu RI Gao, Yanqin/I-6790-2016 OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417; Zhang, Feng/0000-0001-7275-9989 FU VA RRD Merit Review; NIH [NS036736, NS045048, NS056118]; AHA [13SDG14570025, 10SDG2560122]; Chinese Natural Science Foundation [30670642, 30870794, 81020108021]; VA Career Research Scientist Award; RK Mellon Endowed Chair for Cerebrovascular Disease Research at the University of Pittsburgh FX X.H. and F.Z. contributed equally to the study. This work was supported by the VA RR&D Merit Review (to J.C.), NIH grants NS036736, NS045048, and NS056118 (to J.C.), and AHA grants 13SDG14570025 (to X. H.) and 10SDG2560122 (to F.Z.). Y.G. was supported by Chinese Natural Science Foundation grants no. 30670642, 30870794, and 81020108021. J.C. is a recipient of the VA Career Research Scientist Award and also supported by the RK Mellon Endowed Chair for Cerebrovascular Disease Research at the University of Pittsburgh. The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. NR 27 TC 13 Z9 13 U1 0 U2 9 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1566-5240 EI 1875-5666 J9 CURR MOL MED JI Curr. Mol. Med. PD NOV PY 2013 VL 13 IS 9 BP 1465 EP 1473 PG 9 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA 258GC UT WOS:000327446300007 PM 23971733 ER PT J AU An, NF Janech, MG Bland, AM Lazarchick, J Arthur, JM Kang, YB AF An, Ningfei Janech, Michael G. Bland, Alison M. Lazarchick, John Arthur, John M. Kang, Yubin TI Proteomic analysis of murine bone marrow niche microenvironment identifies thioredoxin as a novel agent for radioprotection and for enhancing donor cell reconstitution SO EXPERIMENTAL HEMATOLOGY LA English DT Article ID HEMATOPOIETIC STEM-CELLS; OXIDATIVE STRESS; NOD/SCID MICE; MAMMALIAN THIOREDOXIN; PROGENITOR CELLS; LIFE-SPAN; G-CSF; ENGRAFTMENT; DISEASE; REPOPULATION AB Hematopoiesis is regulated by the bone marrow (BM) niche microenvironment. We recently found that posttransplant administration of AMD3100 (a specific and reversible CXCR4 antagonist) enhanced donor cell engraftment and promoted recovery of all donor cell lineages in a congeneic mouse transplant model. We hypothesized that AMD3100 enhances donor cell reconstitution in part by modulating the levels and constitution of soluble factors in the niche microenviromnent. In the current study, the effects of the BM extracellular fluid (supernatant) from AMD3100-treated transplant recipient mice on colony-forming units (CFUs) were examined. A semiquantitative, mass spectrometry-based proteomics approach was used to screen for differentially expressed proteins between the BM supernatants of PBS-treated transplant mice and AMD3100-treated transplant mice. A total of 178 proteins were identified in the BM supernatants. Thioredoxin was among the 32 proteins that displayed greater than a twofold increase in spectral counts in the BM supernatant of AMD3100-treated transplant mice. We found that thioredoxin increased CFUs in a dose-dependent manner. Thioredoxin improved hematopoiesis in irradiated mice and protected mice from radiation-related death. Furthermore, ex vivo exposure to thioredoxin for 24 hours enhanced the long-term repopulation of hematopoietic stem cells. Additionally, combined posttransplant administration of thioredoxin and AMD3100 improved hematologic recovery in primary and secondary transplant recipient mice. Our studies demonstrated that factors in the BM niche microenvironment play a critical role in hematopoiesis. Identifying these factors provides clues on potential novel targets that can be used to enhance hematologic recovery in hematopoietic stem cell transplan'tation. (C) 2013 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. C1 [An, Ningfei; Kang, Yubin] Med Univ S Carolina, Div Hematol Oncol, Charleston, SC 29425 USA. [Janech, Michael G.; Bland, Alison M.; Arthur, John M.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA. [Lazarchick, John] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA. [Arthur, John M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Kang, YB (reprint author), Med Univ S Carolina, Dept Med, Div Hematol Oncol, Hollings Canc Ctr, 86 Jonathan Lucas St,Room HO307, Charleston, SC 29425 USA. EM kangy@musc.edu OI Janech, Michael/0000-0002-3202-4811 FU MUSC Hollings Cancer Center; Hollings Cancer Center ACS IRG; ASCO Conquer Cancer Foundation; National Institutes of Health [1K08HL 103780-01A1, 3P30CA138313-01S3] FX We thank Richard Peppler and Haiqun Zeng at the HCC Flow Cytometry Core for performing flow cytometry analysis and Henning Schade and Dzmitry Haviazheu for their technical assistance. This work is supported by MUSC Hollings Cancer Center Startup Fund, Hollings Cancer Center ACS IRG, ASCO Conquer Cancer Foundation Career Development Award, National Institutes of Health grants 1K08HL 103780-01A1 and 3P30CA138313-01S3. This manuscript is the result of work supported with resources and the use of facilities at the Ralph H. Johnson VA Medical Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funding agents. NR 53 TC 2 Z9 5 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0301-472X EI 1873-2399 J9 EXP HEMATOL JI Exp. Hematol. PD NOV PY 2013 VL 41 IS 11 BP 944 EP 956 DI 10.1016/j.exphem.2013.08.004 PG 13 WC Hematology; Medicine, Research & Experimental SC Hematology; Research & Experimental Medicine GA 257VU UT WOS:000327416700004 PM 23994289 ER PT J AU Ledoux, WR Shofer, JB Cowley, MS Ahroni, JH Cohen, V Boyko, EJ AF Ledoux, William R. Shofer, Jane B. Cowley, Matthew S. Ahroni, Jessie H. Cohen, Victoria Boyko, Edward J. TI Diabetic foot ulcer incidence in relation to plantar pressure magnitude and measurement location SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Plantar pressure; Diabetic foot ulcer; Hallux; Heel; Metatarsal; Epidemiology ID RISK; NEUROPATHY; REGRESSION; VETERANS; EVENTS; SHEAR AB Aims: We prospectively examined the relationship between site-specific peak plantar pressure (PPP) and ulcer risk. Researchers have previously reported associations between diabetic foot ulcer and elevated plantar foot pressure, but the effect of location-specific pressures has not been studied. Methods: Diabetic subjects (n = 591) were enrolled from a single VA hospital. Five measurements of in-shoe plantar pressure were collected using F-Scan. Pressures were measured at 8 areas: heel, lateral midfoot, medial midfoot, first metatarsal, second through fourth metatarsal, fifth metatarsal, hallux, and other toes. The relationship between incident plantar foot ulcer and PPP or pressure-time integral (PTI) was assessed using Cox regression. Results: During follow-up (2.4 years), 47 subjects developed plantar ulcers (10 heel, 12 metatarsal, 19 hallux, 6 other). Overall mean PPP was higher for ulcer subjects (219 vs. 194 kPa), but the relationship differed by site (the metatarsals with ulcers had higher pressure, while the opposite was true for the hallux and heel). A statistical analysis was not performed on the means, but hazard ratios from a Cox survival analysis were nonsignificant for PPP across all sites and when adjusted for location. However, when the metatarsals were considered separately, higher baseline PPP was significantly associated with greater ulcer risk; at other sites, this relationship was nonsignificant. Hazard ratios for all PTI data were nonsignificant. Conclusions: Location must be considered when assessing the relationship between PPP and plantar ulceration. Published by Elsevier Inc. C1 [Ledoux, William R.; Shofer, Jane B.; Cowley, Matthew S.] VA Puget Sound Hlth Care Syst, RR&D Ctr Excellence Limb Loss Prevent & Prosthet, Seattle, WA USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. [Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA. [Ahroni, Jessie H.] VA Puget Sound Hlth Care Syst, Dept Surg, Seattle, WA USA. [Ahroni, Jessie H.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA. [Cohen, Victoria; Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.] Univ Washington, Dept Med, Seattle, WA USA. RP Ledoux, WR (reprint author), VA Puget Sound, MS 151,1660 S Columbian Way, Seattle, WA 98108 USA. EM wrledoux@u.washington.edu RI Ledoux, William/K-6815-2015 OI Ledoux, William/0000-0003-4982-7714; Boyko, Edward/0000-0002-3695-192X FU Department of Veterans Affairs, RRD service [A2661C, A4843C, A99-1499A] FX This work was supported in part by the Department of Veterans Affairs, RR&D service grant numbers A2661C, A4843C and A99-1499A. NR 26 TC 15 Z9 16 U1 2 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD NOV-DEC PY 2013 VL 27 IS 6 BP 621 EP 626 DI 10.1016/j.jdiacomp.2013.07.004 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 257UZ UT WOS:000327414600016 PM 24012295 ER PT J AU Boyko, EJ AF Boyko, Edward J. TI Observational research - opportunities and limitations SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Review DE Epidemiology; Bias; Causal Inference; Confounding; Pharmacoepidemiology; Randomized Controlled Trial ID PROPENSITY SCORE METHODS; PHYSICIAN DECISION THRESHOLDS; TYPE-2 DIABETES-MELLITUS; BLOOD-GLUCOSE CONTROL; SURROGATE END-POINTS; CARDIOVASCULAR-DISEASE; MENDELIAN RANDOMIZATION; CONTROLLED-TRIALS; CAUSAL INFERENCE; RISK AB Medical research continues to progress in its ability to identify treatments and characteristics associated with benefits and adverse outcomes. The principal engine for the evaluation of treatment efficacy is the randomized controlled trial (RCT). Due to the cost and other considerations, RCTs cannot address all clinically important decisions. Observational research often is used to address issues not addressed or not addressable by RCTs. This article provides an overview of the benefits and limitations of observational research to serve as a guide to the interpretation of this category of research designs in diabetes investigations. The potential for bias is higher in observational research but there are design and analysis features that can address these concerns although not completely eliminate them. Pharmacoepidemiologic research may provide important information regarding relative safety and effectiveness of diabetes pharmaceuticals. Such research must effectively address the important issue of confounding by indication in order to produce clinically meaningful results. Other methods such as instrumental variable analysis are being employed to enable stronger causal inference but these methods also require fulfillment of several key assumptions that may or may not be realistic. Nearly all clinical decisions involve probabilistic reasoning and confronting uncertainly, so a realistic goal for observational research may not be the high standard set by RCTs but instead the level of certainty needed to influence a diagnostic or treatment decision. Published by Elsevier Inc. C1 [Boyko, Edward J.] VA Puget Sound Hlth Care Syst, Epidemiol Res & Informat Ctr, Seattle, WA USA. [Boyko, Edward J.] Univ Washington, Sch Med, Seattle, WA USA. RP Boyko, EJ (reprint author), 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM eboyko@uw.edu OI Boyko, Edward/0000-0002-3695-192X FU VA Epidemiologic Research and Information Center; Diabetes Research Center at the University of Washington [DK-017047] FX Grant Support: VA Epidemiologic Research and Information Center; the Diabetes Research Center at the University of Washington (DK-017047). NR 50 TC 5 Z9 5 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD NOV-DEC PY 2013 VL 27 IS 6 BP 642 EP 648 DI 10.1016/j.jdiacomp.2013.07.007 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 257UZ UT WOS:000327414600020 PM 24055326 ER PT J AU Carlson, RM Dux, K Stuck, RM AF Carlson, Russell M. Dux, Katherine Stuck, Rodney M. TI Ultrasound Imaging for Diagnosis of Plantar Plate Ruptures of the Lesser Metatarsophalangeal Joints: A Retrospective Case Series SO JOURNAL OF FOOT & ANKLE SURGERY LA English DT Article DE magnetic resonance image; metatarsal; sensitivity and specificity; toe ID INSTABILITY; MRI AB Tears of the plantar plate can be a source of significant forefoot pain, leading to alterations of foot function and gait. The objective of the present retrospective study was to further determine the value of ultrasound imaging in diagnosing plantar plate tears after clinical evaluation through a comparison of the ultrasound and intraoperative examination findings. Eight patients were identified who, had undergone surgical intervention for a painful lesser metatarsophalangeal joint after ultrasound examination to diagnose a plantar plate pathologic entity. The intraoperative examination findings were used to calculate the sensitivity, specificity, and positive and negative predictive values of ultrasound in the diagnosis of plantar plate tears. The sensitivity and specificity of the ultrasound examination was 1 and 0.6, respectively. The positive and negative predictive value was 0.6 and 1, respectively. An ultrasound examination in the diagnosis of lesser metatarsophalangeal joint plantar plate tears displayed comparable sensitivity in identifying the pathologic features when compared with magnetic resonance imaging, with considerably less financial cost for the examination. (C) 2013 by the American College of Foot and Ankle Surgeons. All rights reserved. C1 [Carlson, Russell M.] ORA Orthoped, Moline, IL 61265 USA. [Dux, Katherine; Stuck, Rodney M.] Loyola Univ, Stritch Sch Med, Dept Orthoped Surg & Rehabil, Maywood, IL 60153 USA. [Stuck, Rodney M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Surg Serv, Hines, IL 60141 USA. RP Carlson, RM (reprint author), ORA Orthoped, 520 Valley View Dr,100, Moline, IL 61265 USA. EM russell.carlson32@gmail.com NR 13 TC 3 Z9 3 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1067-2516 EI 1542-2224 J9 J FOOT ANKLE SURG JI J. Foot Ankle Surg. PD NOV-DEC PY 2013 VL 52 IS 6 BP 786 EP 788 DI 10.1053/j.jfas.2013.05.009 PG 3 WC Orthopedics; Surgery SC Orthopedics; Surgery GA 251DT UT WOS:000326908700019 PM 23870658 ER PT J AU Hammermeister, K Bronsert, M Henderson, WG Coombs, L Hosokawa, P Brandt, E Bryan, C Valuck, R West, D Liaw, W Ho, M Pace, W AF Hammermeister, Karl Bronsert, Michael Henderson, William G. Coombs, Letoynia Hosokawa, Patrick Brandt, Elias Bryan, Cathy Valuck, Robert West, David Liaw, Winston Ho, Michael Pace, Wilson TI Risk-Adjusted Comparison of Blood Pressure and Low-Density Lipoprotein (LDL) Noncontrol in Primary Care Offices SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Blood Pressure; Cholesterol; Clinical Practice Guideline; Electronic Health Records; Feedback; Health Information Management ID AFFAIRS SURGICAL RISK; CARDIAC-SURGERY; ACHIEVABLE BENCHMARKS; HEART-DISEASE; OF-CARE; QUALITY; IMPROVEMENT; OUTCOMES; METAANALYSIS; CHOLESTEROL AB Objectives: Population-level control of modifiable cardiovascular disease (CVD) risk factors is suboptimal. The objectives of this study were (1) to demonstrate the use of electronically downloaded electronic health record (EHR) data to assess guideline concordance in a large cohort of primary care patients, (2) to provide a contemporary assessment of blood pressure (BP) and low-density lipoprotein (LDL) noncontrol in primary care, and (3) to demonstrate the effect of risk adjustment of rates of noncontrol of BP and LDL for differences in patient mix on these clinic-level performance measures. Methods: This was an observational comparative effectiveness study that included 232,172 adult patients >= 18 years old with >= 1 visit within 2 years in 33 primary care clinics with EHRs. The main measures were rates of BP and LDL noncontrol based on current guidelines and were calculated from electronically downloaded EHR data. Rates of noncontrol were risk-adjusted using multivariable models of patient-level variables. Results: Overall, 16.0% of the 227,122 patients with known BP and 14.9% of the 136,771 patients with known LDL were uncontrolled. Clinic-level, risk-adjusted BP noncontrol ranged from 7.7% to 26.5%, whereas that for LDL ranged from 5.8% to 23.6%. Rates of noncontrol exceeded an achievable benchmark for 85% (n = 28) and 79% (n = 26) of the 33 clinics for BP and LDL, respectively. Risk adjustment significantly influences clinic rank order for rate of noncontrol. Conclusions: We demonstrated that the use of electronic collection of data from a large cohort of patients from fee-for-service primary care clinics is feasible for the audit of and feedback on BP and LDL noncontrol. Rates of noncontrol for most clinics are substantially higher than those achievable. Risk adjustment of noncontrol rates results in a rank-order of clinics very different from that achieved with nonadjusted data. C1 [Hammermeister, Karl; Bronsert, Michael; Henderson, William G.; Hosokawa, Patrick; West, David; Pace, Wilson] Univ Colorado, Sch Med, Colorado Hlth Outcomes Program, Aurora, CO USA. [Hammermeister, Karl; Ho, Michael] Univ Colorado, Sch Med, Div Cardiol, Aurora, CO USA. [Coombs, Letoynia; West, David; Pace, Wilson] Univ Colorado, Sch Med, Dept Family Med, Aurora, CO USA. [Henderson, William G.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Brandt, Elias; Pace, Wilson] Amer Acad Family Phys, Natl Res Network, Leawood, KS USA. [Bryan, Cathy] DI Consulting, Dallas, TX USA. [Valuck, Robert] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO USA. [Liaw, Winston] Virginia Commonwealth Univ, Fairfax Family Med Residency Program, Fairfax, VA USA. [Ho, Michael] Denver VA Med Ctr, Denver, CO USA. RP Hammermeister, K (reprint author), Colorado Hlth Outcomes Program, Mail Stop F443,UPI Bldg,13199 East Montview Blvd,, Aurora, CO 80045 USA. EM karl.hammermeister@ucdenver.edu FU National Institutes of Health, National Heart, Lung, and Blood Institute [1RC1HL101071-01] FX This work was supported by The National Institutes of Health, National Heart, Lung, and Blood Institute Grant no. 1RC1HL101071-01. NR 30 TC 3 Z9 3 U1 1 U2 5 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 EI 1558-7118 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD NOV-DEC PY 2013 VL 26 IS 6 BP 658 EP E8 DI 10.3122/jabfm.2013.06.130017 PG 19 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 251KV UT WOS:000326928500008 PM 24204062 ER PT J AU Gupta, H Gupta, PK Schuller, D Fang, X Miller, WJ Modrykamien, A Wichman, TO Morrow, LE AF Gupta, Himani Gupta, Prateek K. Schuller, Dan Fang, Xiang Miller, Weldon J. Modrykamien, Ariel Wichman, Tammy O. Morrow, Lee E. TI Development and Validation of a Risk Calculator for Predicting Postoperative Pneumonia SO MAYO CLINIC PROCEEDINGS LA English DT Article ID AFFAIRS SURGICAL RISK; PULMONARY COMPLICATIONS; MULTIVARIATE-ANALYSIS; ABDOMINAL-SURGERY; HOSPITAL COSTS; CARDIAC RISK; SMOKING; CARE; QUALITY; DETERMINANTS AB Objective: To identify preoperative factors associated with an increased risk of postoperative pneumonia and subsequently develop and validate a risk calculator. Patients and Methods: The American College of Surgeons' National Surgical Quality Improvement Program, a multicenter, prospective data set (2007-2008) was used. Univariate and multivariate logistic regression analyses were performed. The 2007 data set (N = 211,410) served as the training set, and the 2008 data set (N = 257,385) served as the validation set. Results: In the training set, 3825 patients (1.8%) experienced postoperative pneumonia. Patients who experienced postoperative pneumonia had a significantly higher 30-day mortality (17.0% vs 1.5%; P<.001). On multivariate logistic regression analysis, 7 preoperative predictors of postoperative pneumonia were identified: age, American Society of Anesthesiologists class, chronic obstructive pulmonary disease, dependent functional status, preoperative sepsis, smoking before operation, and type of operation. The risk model based on the training data set was subsequently validated on the validation data set, with model performance being very similar (C statistic: 0.860 and 0.855, respectively). The high C statistic indicates excellent predictive performance. The risk model was used to develop an interactive risk calculator. Conclusion: Preoperative variables associated with an increased risk of postoperative pneumonia include age, American Society of Anesthesiologists class, chronic obstructive pulmonary disease, dependent functional status, preoperative sepsis, smoking before operation, and type of operation. The validated risk calculator provides a risk estimate for postoperative pneumonia and is anticipated to aid in surgical decision making and informed patient consent. (C) 2013 Mayo Foundation for Medical Education and Research C1 [Gupta, Himani] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. [Gupta, Prateek K.] Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA. [Schuller, Dan; Modrykamien, Ariel; Wichman, Tammy O.; Morrow, Lee E.] Creighton Univ, Div Pulm Crit Care & Sleep Med, Dept Med, Omaha, NE 68178 USA. [Fang, Xiang] Creighton Univ, Omaha, NE 68178 USA. [Miller, Weldon J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Morrow, Lee E.] VA Nebraska & Western Iowa Hlth Care Syst, Omaha, NE USA. RP Gupta, PK (reprint author), Univ Wisconsin Hosp & Clin, Dept Surg, Madison, WI 53792 USA. EM pgupta@uwhealth.org NR 38 TC 20 Z9 20 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD NOV PY 2013 VL 88 IS 11 BP 1241 EP 1249 DI 10.1016/j.mayocp.2013.06.027 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 258TA UT WOS:000327480400014 PM 24182703 ER PT J AU Hughes, C Howard, IM AF Hughes, Christina Howard, Ileana M. TI Spasticity Management in Multiple Sclerosis SO PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA LA English DT Article DE Spasticity; Multiple sclerosis; Antispasticity; Chemodenervation; Intrathecal baclofen ID SHOCK-WAVE THERAPY; ALTERNATIVE MEDICINE USE; TOXIN TYPE-A; INTRATHECAL BACLOFEN; ELECTRICAL-STIMULATION; CEREBRAL-PALSY; MUSCLE STRETCH; CHRONIC STROKE; DOUBLE-BLIND; FOLLOW-UP AB Spasticity is a prevalent and potentially disabling symptom common in individuals with multiple sclerosis. Adequate evaluation and management of spasticity requires a careful assessment of the patient's history to determine functional impact of spasticity and potential exacerbating factors, and physical examination to determine the extent of the condition and culpable muscles. A host of options for spasticity management are available: therapeutic exercise, physical modalities, complementary/alternative medicine interventions, oral medications, chemodenervation, and implantation of an intrathecal baclofen pump. Choice of treatment hinges on a combination of the extent of symptoms, patient preference, and availability of services. C1 [Hughes, Christina] Virginia Mason Med Ctr, Dept Phys Med & Inpatient Neuro Rehabil, Seattle, WA 98111 USA. [Howard, Ileana M.] Vet Affairs Puget Sound Hlth Care Syst, Rehabil Care Serv, Seattle, WA 98108 USA. RP Hughes, C (reprint author), Virginia Mason Med Ctr, Dept Phys Med & Inpatient Neuro Rehabil, Mailstop H4-469,1100 9th Ave, Seattle, WA 98111 USA. EM pmrdoc@mac.com NR 40 TC 12 Z9 12 U1 3 U2 19 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1047-9651 EI 1558-1381 J9 PHYS MED REH CLIN N JI Phys. Med. Rehabil. Clin. N. Am. PD NOV PY 2013 VL 24 IS 4 BP 593 EP + DI 10.1016/j.pmr.2013.07.003 PG 13 WC Rehabilitation SC Rehabilitation GA 261QN UT WOS:000327679800004 PM 24314678 ER PT J AU Tuerk, PW Wangelin, B Rauch, SAM Dismuke, CE Yoder, M Myrick, H Eftekhari, A Acierno, R AF Tuerk, Peter W. Wangelin, Bethany Rauch, Sheila A. M. Dismuke, Clara E. Yoder, Matthew Myrick, Hugh Eftekhari, Afsoon Acierno, Ron TI Health Service Utilization Before and After Evidence-Based Treatment for PTSD SO PSYCHOLOGICAL SERVICES LA English DT Article DE PTSD; prolonged exposure; veterans; service utilization; cost ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE THERAPY; COCAINE-DEPENDENT INDIVIDUALS; MALE VIETNAM VETERANS; AFGHANISTAN VETERANS; RANDOMIZED-TRIAL; IRAQ; SYMPTOMS; WAR; DIAGNOSES AB Posttraumatic stess disorder (PTSD) is associated with functional impairment, co-occurring diagnoses, and increased health care utilization. Associated high demand for health care services is an important contributor to the large public-health cost of PTSD. Treatments incorporating exposure therapy are efficacious in ameliorating or eliminating PTSD symptoms. Accordingly, the Veterans Health Administration has made significant investments toward nationwide dissemination of a manualized exposure therapy protocol, prolonged exposure (PE). PE is effective with veterans; however, the relationship between PE and mental health service utilization is unknown. The current study investigates PE as it relates to actual tracked mental health service utilization in an urban VA medical center. A sample of 60 veterans with a diagnosis of PTSD was used to examine mental health service utilization in the 12-months prior to and 12-months after being offered PE. Hierarchical Linear Models and traditional repeated-measures ANOVA were used to estimate R-2- and d-type effect sizes for service utilization. Associated estimated cost saving are reported. PE was associated with large reductions in symptoms and diagnosis remission. Treatment was also associated with statistically significant, large reductions in mental health service utilization for veterans who completed treatment. Findings suggest that expanding access to PE can increase access to mental health services in general by decreasing ongoing demand for specialty care clinical services. C1 [Tuerk, Peter W.; Wangelin, Bethany; Yoder, Matthew; Myrick, Hugh; Acierno, Ron] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv Line, Charleston, SC USA. [Tuerk, Peter W.; Wangelin, Bethany; Yoder, Matthew; Myrick, Hugh; Acierno, Ron] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Rauch, Sheila A. M.] Ann Arbor Healthcare Syst, Vet Affairs, Res Serv, Ann Arbor, MI USA. [Rauch, Sheila A. M.] Ann Arbor Healthcare Syst, Vet Affairs, Mental Hlth Serv, Ann Arbor, MI USA. [Rauch, Sheila A. M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. [Dismuke, Clara E.] Ralph H Johnson Dept Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA. [Eftekhari, Afsoon] Vet Affairs Palo Alto Hlth Care Syst, Natl Ctr Posttraumat Stress Disorder, Disseminat & Training Div, Palo Alto, CA USA. RP Tuerk, PW (reprint author), RHJ VAMC, 109 Bee St, Charleston, SC 29401 USA. EM Tuerk@musc.edu RI Rauch, Sheila/K-4450-2015 OI Rauch, Sheila/0000-0001-9686-4011 NR 54 TC 21 Z9 21 U1 0 U2 4 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD NOV PY 2013 VL 10 IS 4 BP 401 EP 409 DI 10.1037/a0030549 PG 9 WC Psychology, Clinical SC Psychology GA 254QZ UT WOS:000327182400006 PM 23148769 ER PT J AU Harris, AHS Ellerbe, L Reeder, RN Bowe, T Gordon, AJ Hagedorn, H Oliva, E Lembke, A Kivlahan, D Trafton, JA AF Harris, Alex H. S. Ellerbe, Laura Reeder, Rachelle N. Bowe, Thomas Gordon, Adam J. Hagedorn, Hildi Oliva, Elizabeth Lembke, Anna Kivlahan, Daniel Trafton, Jodie A. TI Pharmacotherapy for Alcohol Dependence: Perceived Treatment Barriers and Action Strategies Among Veterans Health Administration Service Providers SO PSYCHOLOGICAL SERVICES LA English DT Article DE alcohol dependence; health care providers; medications; pharmacotherapy; veterans ID USE DISORDERS; ADDICTION TREATMENT; MEDICATIONS; NALTREXONE; PHYSICIAN; ATTITUDES AB Although access to and consideration of pharmacological treatments for alcohol dependence are consensus standards of care, receipt of these medications by patients is generally rare and highly variable across treatment settings. The goal of the present project was to survey and interview the clinicians, managers, and pharmacists affiliated with addiction treatment programs within Veterans Health Administration (VHA) facilities to learn about their perceptions of barriers and facilitators regarding greater and more reliable consideration of pharmacological treatments for alcohol dependence. Fifty-nine participants from 19 high-adopting and 11 low-adopting facilities completed the survey (facility-level response rate = 50%) and 23 participated in a structured interview. The top 4 barriers to increased consideration and use of pharmacotherapy for alcohol dependence were consistent across high- and low-adopting facilities and included perceived low patient demand, pharmacy procedures or formulary restrictions, lack of provider skills or knowledge regarding pharmacotherapy for alcohol dependence, and lack of confidence in treatment effectiveness. Low patient demand was rated as the most important barrier for oral naltrexone and disulfiram, whereas pharmacy or formulary restrictions were rated as the most important barrier for acamprosate and extended-release naltrexone. The 4 strategies rated across low-and high-adopting facilities as most likely to facilitate consideration and use of pharmacotherapy for alcohol dependence were more education to patients about existing medications, more education to health care providers about medications, increased involvement of physicians in treatment for alcohol dependence, and more compelling research on existing medications. This knowledge provides a foundation for designing, deploying, and evaluating targeted implementation efforts. C1 [Harris, Alex H. S.; Ellerbe, Laura; Reeder, Rachelle N.; Bowe, Thomas] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA. [Harris, Alex H. S.; Ellerbe, Laura; Reeder, Rachelle N.; Bowe, Thomas; Oliva, Elizabeth; Trafton, Jodie A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Gordon, Adam J.] VA Pittsburgh Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Hagedorn, Hildi] VA Minneapolis Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA. [Oliva, Elizabeth; Trafton, Jodie A.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA USA. [Lembke, Anna] Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA. [Kivlahan, Daniel] VA Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Kivlahan, Daniel] Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Harris, AHS (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd, Menlo Pk, CA 94025 USA. EM Alexander.Harris2@va.gov NR 30 TC 16 Z9 16 U1 2 U2 7 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1541-1559 EI 1939-148X J9 PSYCHOL SERV JI Psychol. Serv. PD NOV PY 2013 VL 10 IS 4 BP 410 EP 419 DI 10.1037/a0030949 PG 10 WC Psychology, Clinical SC Psychology GA 254QZ UT WOS:000327182400007 PM 23356858 ER PT J AU Cook, JM Thompson, R Harb, GC Ross, RJ AF Cook, Joan M. Thompson, Richard Harb, Gerlinde C. Ross, Richard J. TI Cognitive-Behavioral Treatment for Posttraumatic Nightmares: An Investigation of Predictors of Dropout and Outcome SO PSYCHOLOGICAL TRAUMA-THEORY RESEARCH PRACTICE AND POLICY LA English DT Article DE stress disorders; posttraumatic; psychotherapy; nightmares; treatment outcome; dropout ID IMAGERY REHEARSAL THERAPY; SEXUAL ASSAULT SURVIVORS; RANDOMIZED CONTROLLED-TRIAL; SLEEP QUALITY INDEX; STRESS-DISORDER; CLINICAL-TRIAL; PTSD; VETERANS; INSOMNIA; EXPOSURE AB This study examined factors predicting treatment dropout and outcome in 124 male Vietnam War veterans with chronic, severe posttraumatic stress disorder treated in a randomized controlled trial of two cognitive-behavioral group therapies for combat-related nightmares. Though significant bivariate predictors of dropout in the imagery rehearsal condition included non-African American race, use of selective serotonin reuptake inhibitors, more traumas, and lower perceived treatment credibility, none of these variables uniquely predicted dropout in multivariate analyses. In the sleep and nightmare management condition, only low avoidance symptoms predicted dropout. Use of benzodiazepines and higher reexperiencing symptoms predicted posttreatment nightmare frequency in imagery rehearsal; although baseline sleep quality and higher avoidance symptoms predicted posttreatment sleep quality. In sleep and nightmare management, only poorer sleep quality predicted posttreatment nightmares, although poorer baseline sleep quality and higher avoidance symptoms predicted posttreatment sleep quality. Practical and clinical implications, including the use of "socialization" strategies (e.g., patient testimonials, in-depth explanation of treatment rationale), are discussed. C1 [Cook, Joan M.] Yale Sch Med, Dept Psychiat, West Haven, CT 06516 USA. [Cook, Joan M.] Natl Ctr PTSD, West Haven, CT USA. [Thompson, Richard] Univ Illinois, Juvenile Justice Ctr, Chicago, IL USA. [Harb, Gerlinde C.] Philadelphia Dept Vet Affairs, Dept Behav Hlth, Philadelphia, PA USA. [Ross, Richard J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Ross, Richard J.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Cook, JM (reprint author), Yale Sch Med, Dept Psychiat, 950 Campbell Ave,NEPEC 182, West Haven, CT 06516 USA. EM joan.cook@yale.edu NR 57 TC 1 Z9 1 U1 2 U2 11 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1942-9681 EI 1942-969X J9 PSYCHOL TRAUMA-US JI Psychol. Trauma PD NOV PY 2013 VL 5 IS 6 BP 545 EP 553 DI 10.1037/a0030724 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA 259UR UT WOS:000327552300006 ER PT J AU Shi, J Longo, FM Massa, SM AF Shi, Jian Longo, Frank M. Massa, Stephen M. TI A Small Molecule p75(NTR) Ligand Protects Neurogenesis After Traumatic Brain Injury SO STEM CELLS LA English DT Article DE Traumatic brain injury; Neurotrophin; Neurogenesis; Hippocampus ID P75 NEUROTROPHIN RECEPTOR; CELL-ADHESION MOLECULE; REGULATES HIPPOCAMPAL NEUROGENESIS; NERVE GROWTH-FACTOR; SPINAL-CORD-INJURY; DENTATE GYRUS; IN-VITRO; PROGENITOR CELLS; UP-REGULATION; EXPRESSION PATTERNS AB The p75 neurotrophin receptor (p75(NTR)) influences the proliferation, survival, and differentiation of neuronal precursors and its expression is induced in injured brain, where it regulates cell survival. Here, we test the hypotheses that pharmacologic modulation of p75(NTR) signaling will promote neural progenitor survival and proliferation, and improve outcomes of traumatic brain injury (TBI). LM11A-31, an orally available, blood-brain barrier-permeant small-molecule p75(NTR) signaling modulator, significantly increased proliferation and survival, and decreased JNK phosphorylation, in hippocampal neural stem/progenitor cells in culture expressing wild-type p75(NTR), but had no effect on cells expressing a mutant neurotrophin-unresponsive form of the receptor. The compound also enhanced the production of mature neurons from adult hippocampal neural progenitors in vitro. In vivo, intranasal administration of LM11A-31 decreased postinjury hippocampal and cortical neuronal death, neural progenitor cell death, gliogenesis, and microglial activation, and enhanced long-term hippocampal neurogenesis and reversed spatial memory impairments. LM11A-31 diminished the postinjury increase of SOX2-expressing early progenitor cells, but protected and increased the proliferation of endogenous polysialylated-neural cell adhesion molecule positive intermediate progenitors, and restored the long-term production of mature granule neurons. These findings suggest that modulation of p75(NTR) actions using small molecules such as LM11A-31 may constitute a potent therapeutic strategy for TBI. Stem Cells2013;31:2561-2574 C1 [Shi, Jian; Massa, Stephen M.] Dept Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA USA. [Shi, Jian; Massa, Stephen M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Longo, Frank M.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA. RP Massa, SM (reprint author), San Francisco VA Med Ctr, Dept Neurol 127, 4150 Clement St, San Francisco, CA 94121 USA. EM Stephen.Mas-sa@ucsf.edu FU Department of Defense [DOD DAMD17-03-1-0532]; Veterans Administration FX These studies were supported by the Department of Defense (DOD DAMD17-03-1-0532 to SMM); and the Veterans Administration (SMM). NR 76 TC 19 Z9 21 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1066-5099 EI 1549-4918 J9 STEM CELLS JI Stem Cells PD NOV PY 2013 VL 31 IS 11 BP 2561 EP 2574 DI 10.1002/stem.1516 PG 14 WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology GA 252QY UT WOS:000327025600025 PM 23940017 ER PT J AU Breitner, J Baker, L Drye, L Evans, D Lyketsos, C Ryan, L Zandi, P Baker, L Breitner, J Saucedo, HH Anau, J Cholerton, B Kramer, K Zandi, P Drye, L Casper, AS Meinert, C Martin, B Jenkins, G McCaffrey, L Meinert, J Vaidya, V Ahuja, A May, P Ryan, L Lyketsos, CG Steinberg, M Brandt, J Pedroso, JJ Bergey, A Gogel, C Smith, L Kraus, J Stern, RA Green, RC Gavett, B Mwicigi, J Baldwin, L McGowan, T Johnson, P Qiu, W Frederick, J Raghavan, S Rossi, C Mandell, A Dinizo, D Roth, MT Porsteinsson, A Ismail, MS Weber, M Brand, C Richard, J Stear, K Schepp, S Cosman, K Martin, K Craft, S Baker, L Dahl, D Garrett, G Tidwell, J Thielke, S Smith, L Arbuckle, M Strong, W Ladenberg, J Callaghan, M Watson, S Skinner, J Bowton, K Sabbagh, M Belden, C Liebsack, C Davis, K Arnieri, L Malek-Ahmadi, M Nicholson, L Jacobson, S Schwartz, E Mullan, M Luis, C Parrish, J Faircloth, M Ervin, T Girard, J Burke, D Keegan, A Evans, D AF Breitner, John Baker, Laura Drye, Lea Evans, Denis Lyketsos, Constantine Ryan, Laurie Zandi, Peter Baker, Laura Breitner, John Saucedo, Hector Hernandez Anau, Jane Cholerton, Brenna Kramer, Kirise Zandi, Peter Drye, Lea Casper, Anne Shanklin Meinert, Curtis Martin, Barbara Jenkins, Gabrielle McCaffrey, Lee Meinert, Jill Vaidya, Vijay Ahuja, Alka May, Pat Ryan, Laurie Lyketsos, Constantine G. Steinberg, Martin Brandt, Jason Pedroso, Julia J. Bergey, Alyssa Gogel, Carol Smith, Lynn Kraus, Jennifer Stern, Robert A. Green, Robert C. Gavett, Brandon Mwicigi, Jane Baldwin, Lorraine McGowan, Theresa Johnson, Patricia Qiu, Wendy Frederick, Jamie Raghavan, Sumati Rossi, Carol Mandell, Alan Dinizo, Daniella Roth, Mary Tara Porsteinsson, Anton Ismail, M. Saleem Weber, Miriam Brand, Connie Richard, Jennifer Stear, Kelly Schepp, Sue Cosman, Kelly Martin, Kimberly Craft, Suzanne Baker, Laura Dahl, Deborah Garrett, Grace Tidwell, Jamie Thielke, Stephen Smith, Lauren Arbuckle, Matthew Strong, William Ladenberg, Juliet Callaghan, Maureen Watson, Stennis Skinner, Jeannine Bowton, Kaysha Sabbagh, Marwan Belden, Christine Liebsack, Carolyn Davis, Kathryn Arnieri, Lauren Malek-Ahmadi, Michael Nicholson, Lisa Jacobson, Sandra Schwartz, Elliot Mullan, Michael Luis, Cheryl Parrish, Julia Faircloth, Marlee Ervin, Terry Girard, Janette Burke, Deborah Keegan, Andrew Evans, Denis CA Alzheimer's Dis Antiinflammatory TI Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) The Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group SO ALZHEIMERS & DEMENTIA LA English DT Article DE Prevention; Clinical trial; Alzheimer's disease; Nonsteroidal anti-inflammatory drug; Naproxen; Celecoxib ID DOUBLE-BLIND; DRUGS; ROFECOXIB; NAPROXEN; PLACEBO; INHIBITION; CELECOXIB; ASPIRIN; DESIGN; NSAIDS AB Objectives: The Alzheimer's Disease Anti-inflammatory Prevention Trial Follow-up Study (ADAPT-FS) was designed to evaluate the efficacy of naproxen and celecoxib for the primary prevention of Alzheimer's disease (AD) several years after cessation of treatment in ADAPT. Methods: ADAPT was a randomized, double-masked, multicenter clinical trial of naproxen or celecoxib vs placebo (1:1:1.5 assignment ratio) at six U.S.-based clinics. The trial enrolled 2528 people between 2001 and 2004. Treatments were discontinued in December 2004 and participants were monitored regularly until 2007. In 2010 and 2011, ADAPT-FS screened 1537 participants by telephone and, if indicated, examined them in person using standardized clinical assessments. The primary outcome was time to diagnosis of AD. Death index searches were performed for participants not located. Results: Eighty-nine additional AD events were identified (24 celecoxib, 25 naproxen, and 40 placebo) yielding a total of 161 events (48 [6.6% of randomized participants] celecoxib, 43 [6.0%] naproxen, and 70 [6.5%] placebo) across ADAPT and ADAPT-FS. Adjusted hazard ratios (HRs) comparing each treatment with placebo showed no overall reduction in risk of AD: HR celecoxib vs placebo, 1.03 (95% confidence interval [CI], 0.72-1.50; P = .86); HR naproxen vs placebo, 0.92 (95% CI, 0.62-1.35; P = .66). There were 349 deaths (110 [15.2%] celecoxib, 96 [13.4%] naproxen, and 143 [13.2%] placebo). Risk of death was similar for the naproxen- and placebo-assigned groups (HR, 0.99; 95% CI, 0.76-1.28; P = .93) and slightly higher for celecoxib compared with the placebo-assigned group (HR, 1.15; 95% CI, 0.90-1.48; P = .27). Conclusions: These results acquired during a follow-up of approximately 7 years (which included a median of less than 1.5 years of treatment) do not support the hypothesis that celecoxib or naproxen prevent AD in adults with a family history of dementia. 2013 The Alzheimer's Association. All rights reserved. C1 [Breitner, John; Baker, Laura; Breitner, John] Douglas Mental Hlth Univ Inst, Ctr Studies Prevent Alzheimers Dis, Montreal, PQ, Canada. [Breitner, John; Baker, Laura; Breitner, John] McGill Univ, Montreal, PQ, Canada. [Baker, Laura; Porsteinsson, Anton; Ismail, M. Saleem; Weber, Miriam; Brand, Connie; Richard, Jennifer; Stear, Kelly; Schepp, Sue; Cosman, Kelly; Martin, Kimberly] Veteran Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Baker, Laura; Zandi, Peter; Porsteinsson, Anton; Ismail, M. Saleem; Weber, Miriam; Brand, Connie; Richard, Jennifer; Stear, Kelly; Schepp, Sue; Cosman, Kelly; Martin, Kimberly] Univ Washington, Sch Med, Seattle, WA USA. [Drye, Lea; Zandi, Peter; Saucedo, Hector Hernandez; Anau, Jane; Cholerton, Brenna; Kramer, Kirise] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Evans, Denis; Mullan, Michael; Luis, Cheryl; Parrish, Julia; Faircloth, Marlee; Ervin, Terry; Girard, Janette; Burke, Deborah; Keegan, Andrew; Evans, Denis] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA. [Lyketsos, Constantine; Ryan, Laurie] Johns Hopkins Sch Med, Baltimore, MD 60612 USA. [Ryan, Laurie] NIA, Bethesda, MD 20892 USA. [Zandi, Peter] Vet Affairs Puget Sound Hlth Care Syst, Res Grp Resource Ctr Chairmans Off, Seattle, WA USA. [Zandi, Peter; Drye, Lea; Casper, Anne Shanklin; Meinert, Curtis; Martin, Barbara; Jenkins, Gabrielle; McCaffrey, Lee; Meinert, Jill; Vaidya, Vijay; Ahuja, Alka; May, Pat] NIA, Project Off, Bethesda, MD 20892 USA. [Lyketsos, Constantine G.; Steinberg, Martin; Brandt, Jason; Pedroso, Julia J.; Bergey, Alyssa; Gogel, Carol; Smith, Lynn; Kraus, Jennifer] Boston Univ, Sch Med, Boston, MA 02118 USA. [Stern, Robert A.; Green, Robert C.; Gavett, Brandon; Mwicigi, Jane; Baldwin, Lorraine; McGowan, Theresa; Johnson, Patricia; Qiu, Wendy; Frederick, Jamie; Raghavan, Sumati; Rossi, Carol; Mandell, Alan; Dinizo, Daniella; Roth, Mary Tara] Univ Rochester, Sch Med, Rochester, NY USA. [Craft, Suzanne; Baker, Laura; Dahl, Deborah; Garrett, Grace; Tidwell, Jamie; Thielke, Stephen; Smith, Lauren; Arbuckle, Matthew; Strong, William; Ladenberg, Juliet; Callaghan, Maureen; Watson, Stennis; Skinner, Jeannine; Bowton, Kaysha] Sun Hlth Res Inst, Sun City, AZ USA. [Sabbagh, Marwan; Belden, Christine; Liebsack, Carolyn; Davis, Kathryn; Arnieri, Lauren; Malek-Ahmadi, Michael; Nicholson, Lisa; Jacobson, Sandra; Schwartz, Elliot] Roskamp Inst Memory Clin, Tampa, FL USA. RP Breitner, J (reprint author), Douglas Mental Hlth Univ Inst, Ctr Studies Prevent Alzheimers Dis, Montreal, PQ, Canada. EM ldrye@jhsph.edu FU National Institute on Aging (NIA) [U01 AG15477, 2U01 AG015477-06A2]; N. Bud Grossman Center for Memory Research and Care; Minnesota Medical Foundation FX Funding for this study was provided by the National Institute on Aging (NIA) U01 AG15477 and 2U01 AG015477-06A2, the N. Bud Grossman Center for Memory Research and Care, and the Minnesota Medical Foundation. NR 28 TC 25 Z9 25 U1 2 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1552-5260 EI 1552-5279 J9 ALZHEIMERS DEMENT JI Alzheimers. Dement. PD NOV PY 2013 VL 9 IS 6 BP 714 EP 723 DI 10.1016/j.jalz.2012.11.012 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA 254NP UT WOS:000327172700012 ER PT J AU Bhatt, SP Dransfield, MT AF Bhatt, Surya P. Dransfield, Mark T. TI AECOPD: Acute Exacerbations of Chronic Obstructive Cardiopulmonary Disease? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material ID ARTERIAL STIFFNESS; PULMONARY-DISEASE; MYOCARDIAL-INFARCTION; COPD; MORTALITY; RISK; STROKE C1 [Bhatt, Surya P.; Dransfield, Mark T.] Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35294 USA. [Dransfield, Mark T.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Bhatt, SP (reprint author), Univ Alabama Birmingham, UAB Lung Hlth Ctr, Birmingham, AL 35294 USA. NR 19 TC 2 Z9 3 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2013 VL 188 IS 9 BP 1046 EP 1048 DI 10.1164/rccm.201309-1651ED PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 251WJ UT WOS:000326962700003 PM 24180438 ER PT J AU Miravitlles, M Anzueto, A AF Miravitlles, Marc Anzueto, Antonio TI Antibiotics for Acute and Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE exacerbations of chronic obstructive pulmonary disease; antibiotics; bacteria; prevention; colonization ID CHRONIC BRONCHIAL INFECTION; PLACEBO-CONTROLLED TRIAL; ACUTE EXACERBATIONS; CYSTIC-FIBROSIS; PSEUDOMONAS-AERUGINOSA; INHALED TOBRAMYCIN; SPUTUM PURULENCE; TRACT INFECTIONS; SEVERE COPD; AZITHROMYCIN AB Prevention and effective treatment of exacerbations are major objectives in the management of patients with chronic obstructive pulmonary disease (COPD). Antibiotics are mainstay treatment for patients with severe COPD with an acute exacerbation that includes increased sputum purulence and worsening shortness of breath. Although such treatment is associated with clinical benefit, treatment failure and relapse rates may be high, particularly in cases of inadequate antibiotic therapy through incomplete resolution of the initial exacerbation and persistent bacterial infection. These aspects have led to recommendations for a stratified approach to antibiotic therapy based on patient characteristics associated with increased risk factors for failure. Patients at greatest risk for poor outcome (i.e., those with severe COPD) are likely to derive greatest benefit from early treatment with antibiotics. Long-term or intermittent antibiotic treatment has been shown to prevent COPD exacerbations and hospitalizations. These effects may be achieved by reducing bacterial load in the airways in stable state and/or bronchial inflammation. Although systemic antibiotics are likely to remain the core treatment for patients with moderate to severe exacerbated COPD, inhaled antibiotics may represent a more optimal approach for the treatment and prevention of COPD exacerbations in the future. Regardless of the route of administration, further studies are required to evaluate the potential long-term adverse events of antibiotics and the development of bacterial resistance. C1 [Miravitlles, Marc] Hosp Univ Vall dHebron, Dept Pneumol, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Barcelona, Spain. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA. [Anzueto, Antonio] Audie L Murphy Mem Vet Hosp Div, South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Anzueto, A (reprint author), Audie L Murphy Mem Vet Adm Med Ctr, Pulm Dis Sect 111E, 7400 Merton Minter Blvd, San Antonio, TX 78284 USA. EM anzueto@uthscsa.edu OI Miravitlles, Marc/0000-0002-9850-9520 NR 64 TC 14 Z9 20 U1 0 U2 8 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD NOV 1 PY 2013 VL 188 IS 9 BP 1052 EP 1057 DI 10.1164/rccm.201302-0289PP PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 251WJ UT WOS:000326962700006 PM 23924286 ER PT J AU Everett, C Thorpe, C Palta, M Carayon, P Bartels, C Smith, MA AF Everett, Christine Thorpe, Carolyn Palta, Mari Carayon, Pascale Bartels, Christie Smith, Maureen A. TI Physician Assistants And Nurse Practitioners Perform Effective Roles On Teams Caring For Medicare Patients With Diabetes SO HEALTH AFFAIRS LA English DT Article ID PRIMARY-CARE; AMBULATORY-CARE; UNITED-STATES; OUTCOMES; MANAGEMENT; QUALITY; SYSTEMS; HEALTH; TIME AB One approach to the patient-centered medical home, particularly for patients with chronic illnesses, is to include physician assistants (PAs) and nurse practitioners (NPs) on primary care teams. Using Medicare claims and electronic health record data from a large physician group, we compared outcomes for two groups of adult Medicare patients with diabetes whose conditions were at various levels of complexity: those whose care teams included PAs or NPs in various roles, and those who received care from physicians only. Outcomes were generally equivalent in thirteen comparisons. In four comparisons, outcomes were superior for the patients receiving care from PAs or NPs, but in three other comparisons the outcomes were superior for patients receiving care from physicians only. Specific roles performed by PAs and NPs were associated with different patterns in the measure of the quality of diabetes care and use of health care services. No role was best for all outcomes. Our findings suggest that patient characteristics, as well as patients' and organizations' goals, should be considered when determining when and how to deploy PAs and NPs on primary care teams. Accordingly, training and policy should continue to support role flexibility for these health professionals. C1 [Everett, Christine] Duke Univ, Sch Med, Dept Community & Family Med, Physician Assistant Program, Durham, NC 27705 USA. [Thorpe, Carolyn] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Thorpe, Carolyn] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15260 USA. [Palta, Mari; Carayon, Pascale; Smith, Maureen A.] Univ Wisconsin, Madison, WI 53706 USA. [Bartels, Christie] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. RP Everett, C (reprint author), Duke Univ, Sch Med, Dept Community & Family Med, Physician Assistant Program, Durham, NC 27705 USA. EM christine.everett@duke.edu FU Agency for Healthcare Research and Quality [R21 HS017646, R01 HS018368]; Health Innovation Program; Clinical and Translational Science Award program of the National Institutes of Health's National Center for Advancing Translational Sciences [UL1TR000427]; University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program; Agency for Healthcare Research and Quality/National Research Service Award T32 Institutional Training Program [5-T32-HS00083]; American Academy of Physician Assistants Breitman-Dorn Fellowship; National Insititute of Arthritis and Musculoskeletal and Skin Diseases [K23 AR062381-01] FX This material was presented at IMPACT, the American Academy of Physician Assistants' 2013 Physician Assistant Conference, in Washington, D. C., May 2013. Funding for this project was provided by the Agency for Healthcare Research and Quality (Grant Nos. R21 HS017646 and R01 HS018368). Additional support was provided by the Health Innovation Program by providing assistance with Institutional Review Board application, Medicare data management, creation of variables, and manuscript formatting; the Community-Academic Partnerships core of the University of Wisconsin Institute for Clinical and Translational Research (Grant No. UL1TR000427 from the Clinical and Translational Science Award program of the National Institutes of Health's National Center for Advancing Translational Sciences); and the University of Wisconsin School of Medicine and Public Health from the Wisconsin Partnership Program, which provided funding to the Health Innovation Program. Christine Everett was supported by the Agency for Healthcare Research and Quality/National Research Service Award T32 Institutional Training Program (Grant No. 5-T32-HS00083) and the American Academy of Physician Assistants Breitman-Dorn Fellowship. Christie Bartels was supported by the National Insititute of Arthritis and Musculoskeletal and Skin Diseases (Grant No. K23 AR062381-01). No other funding source had a role in the design or conduct; data collection, management, analysis or interpretation; or preparation, review, or approval of the manuscript. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the National Institutes of Health, Department of Veterans Affairs, or the US government. NR 30 TC 17 Z9 17 U1 0 U2 14 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD NOV PY 2013 VL 32 IS 11 BP 1942 EP 1948 DI 10.1377/hlthaff.2013.0506 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 250HN UT WOS:000326841400013 PM 24191084 ER PT J AU Bachhuber, MA Cunningham, CO AF Bachhuber, Marcus A. Cunningham, Chinazo O. TI For-Profit Treatment Of Opioid Addiction SO HEALTH AFFAIRS LA English DT Letter C1 [Bachhuber, Marcus A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. [Cunningham, Chinazo O.] Albert Einstein Coll Med, Bronx, NY 10467 USA. RP Bachhuber, MA (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. OI Bachhuber, Marcus/0000-0002-5610-8382 FU NIDA NIH HHS [R01 DA032110, R25 DA023021, R34 DA031066] NR 3 TC 0 Z9 0 U1 0 U2 2 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD NOV PY 2013 VL 32 IS 11 BP 2060 EP 2060 DI 10.1377/hlthaff.2013.1100 PG 1 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 250HN UT WOS:000326841400036 PM 24191105 ER PT J AU Croymans, DM Paparisto, E Lee, MM Brandt, N Le, BK Lohan, D Lee, CC Roberts, CK AF Croymans, Daniel M. Paparisto, Ergit Lee, Mary M. Brandt, Nina Le, Brian K. Lohan, Derek Lee, Cathy C. Roberts, Christian K. TI Resistance training improves indices of muscle insulin sensitivity and beta-cell function in overweight/obese, sedentary young men SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE insulin sensitivity; strength training; exercise; OGTT; glucose tolerance ID GLUCOSE-TOLERANCE TEST; RANDOMIZED CONTROLLED-TRIAL; SKELETAL-MUSCLE; DIABETES-MELLITUS; GLYCEMIC CONTROL; GENE-EXPRESSION; FATTY LIVER; WEIGHT-LOSS; OLDER MEN; EXERCISE AB We examined the effects of RT on oral glucose tolerance test (OGTT)-derived indices of muscle insulin sensitivity, hepatic insulin resistance, beta-cell function, and skeletal muscle proteins related to glucose transport in overweight/obese, sedentary young men. Twenty-eight participants [median body mass index (BMI) 30.9 kg/m(2); age 22 yr] completed 12 wk of RT (3 sessions/wk) and were assessed for changes in OGTT-derived indices, resting metabolic rate, body composition, serum adipokines, and skeletal muscle protein content [hexokinase 2 (HK2), glucose transporter type 4 (GLUT4), RAC-beta serine/threonine-protein kinase (AKT2), glycogen synthase kinase 3 beta, and insulin receptor substrate 1]. Individualized responses to RT were also evaluated. RT significantly improved insulin and glucose area under the curve (both P < 0.03). With the use of OGTT indices of insulin action, we noted improved muscle insulin sensitivity index (mISI; P = 0.03) and oral disposition index (P = 0.03). BMI, lean body mass (LBM), and relative strength also increased (all P < 0.03), as did skeletal muscle protein content of HK2, GLUT4, and AKT2 (26-33%; all P < 0.02). Hepatic insulin resistance index, adiponectin, leptin, and total amylin did not change. Further analysis demonstrated the presence of highly individualized responsiveness to RT for glucose tolerance and other outcomes. RT improved oral indices of muscle insulin sensitivity and beta-cell function but not hepatic insulin resistance in overweight/obese young men. In addition to the increase in LBM, the improvements in insulin action may be due, in part, to increases in key insulin signaling proteins. C1 [Croymans, Daniel M.; Lee, Cathy C.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Croymans, Daniel M.; Paparisto, Ergit; Lee, Mary M.; Brandt, Nina; Le, Brian K.; Roberts, Christian K.] Univ Calif Los Angeles, Exercise & Metab Dis Res Lab, Translat Sci Sect, Sch Nursing, Los Angeles, CA 90095 USA. [Lohan, Derek] Galway Univ Hosp, Galway, Ireland. [Lee, Cathy C.] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Lee, Cathy C.] Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. RP Roberts, CK (reprint author), Univ Calif Los Angeles, Exercise & Metab Dis Res Lab, Translat Sci Sect, Sch Nursing, 700 Tiverton Ave, Los Angeles, CA 90095 USA. EM croberts@ucla.edu FU American Heart Association (BGIA) [0765139Y]; National Heart, Lung, and Blood Institute [P50 HL105188]; National Institute of Diabetes and Digestive and Kidney Diseases [DK090406]; National Center for Advancing Translational Sciences through UCLA Clinical and Translational Science Institute (CTSI) [UL1TR000124] FX Support for this work was provided by the American Heart Association (BGIA #0765139Y to C. K. Robers), National Heart, Lung, and Blood Institute (P50 HL105188 to C. K. Roberts), National Institute of Diabetes and Digestive and Kidney Diseases (DK090406 to C. K. Roberts), and National Center for Advancing Translational Sciences through UCLA Clinical and Translational Science Institute (CTSI) Grant UL1TR000124. NR 49 TC 11 Z9 11 U1 0 U2 17 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD NOV PY 2013 VL 115 IS 9 BP 1245 EP 1253 DI 10.1152/japplphysiol.00485.2013 PG 9 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA 246XV UT WOS:000326576000005 PM 23970530 ER PT J AU Huynh, TN Walling, AM Le, TX Kleerup, EC Liu, HH Wenger, NS AF Huynh, Thanh N. Walling, Anne M. Le, Thuy X. Kleerup, Eric C. Liu, Honghu Wenger, Neil S. TI Factors Associated with Palliative Withdrawal of Mechanical Ventilation and Time to Death after Withdrawal SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article ID INTENSIVE-CARE-UNIT; OF-LIFE CARE; CRITICALLY-ILL; HOSPITALIZED-PATIENTS; END; SUPPORT; ICU AB Background: In imminently dying patients, mechanical ventilation withdrawal is often a comfort measure and avoids prolonging the dying process. Objective: The aim of the study was to identify factors associated with palliative withdrawal of mechanical ventilation and time to death after extubation. Methods: Logistic regression models were used to identify factors associated with palliative withdrawal of mechanical ventilation. Cox proportional hazards models were used to determine factors associated with time to death after extubation. We retrospectively evaluated 322 patients who died on mechanical ventilation or after palliative ventilator withdrawal at a single tertiary care center. Results: Of the 322 ventilated deaths, 159 patients had palliative withdrawal of mechanical ventilation and 163 patients died on the ventilator. Clinical service was associated with palliative withdrawal of mechanical ventilation: Patients withdrawn from the ventilator were less likely to be on the surgery service and more likely to be on the neurology/neurosurgical service. The median time to death was 0.9 hours (range 0-165 hours). Fraction of inspired oxygen (FIO2) greater than 70% (hazard ratio [HR] 1.92, 95% confidence interval [CI ]1.24-2.99) and a requirement for vasopressors (HR 2.06, 95% CI 1.38-3.09) were associated with shorter time to death. Being on the neurology/neurosurgical service at the time of ventilator withdrawal was associated with a longer time to death (HR 0.60, 95% CI 0.39-0.92). Conclusions: Palliative withdrawal of mechanical ventilation was performed in only half of dying mechanically ventilated patients. Because clinical service rather than physiologic parameters are associated with withdrawal, targeted interventions may improve withdrawal decisions. Considering FIO2 and vasopressor requirements may facilitate counseling families about anticipated time to death. C1 [Huynh, Thanh N.; Kleerup, Eric C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA. [Walling, Anne M.; Wenger, Neil S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Le, Thuy X.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Liu, Honghu] Univ Calif Los Angeles, Sch Dent, Div Publ Hlth & Community Dent, Los Angeles, CA 90024 USA. [Walling, Anne M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Walling, Anne M.] RAND Hlth, Santa Monica, CA USA. RP Huynh, TN (reprint author), Dept Med, Div Pulm & Crit Care Med, Box 951690,37-131 CHS, Los Angeles, CA 90095 USA. EM thuynh@mednet.ucla.edu FU Kennamer Fellowship; NIH Loan Repayment Program; National Palliative Care Research Center Career Development Award FX This project was supported by a donation from Mary Kay Farley to RAND Health. Dr. Huynh was supported by the Kennamer Fellowship and the NIH Loan Repayment Program. Dr. Walling was supported by a National Palliative Care Research Center Career Development Award. NR 18 TC 8 Z9 8 U1 1 U2 7 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD NOV 1 PY 2013 VL 16 IS 11 BP 1368 EP 1374 DI 10.1089/jpm.2013.0142 PG 7 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 250VQ UT WOS:000326884800013 PM 24083651 ER PT J AU Lee, CG Schwartz, AV Yaffe, K Hillier, TA LeBlanc, ES Cawthon, PM AF Lee, Christine G. Schwartz, Ann V. Yaffe, Kristine Hillier, Teresa A. LeBlanc, Erin S. Cawthon, Peggy M. CA Osteoporotic Fractures Res Grp TI Changes in Physical Performance in Older Women According to Presence and Treatment of Diabetes Mellitus SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE elderly; diabetes mellitus; insulin sensitizer; physical performance; walk speed ID IMPAIRED FASTING GLUCOSE; COGNITIVE IMPAIRMENT; INSULIN-RESISTANCE; SKELETAL-MUSCLE; METFORMIN INCREASES; BODY-COMPOSITION; ADULTS; HEALTH; DISABILITY; RISK AB ObjectivesTo determine whether older women with diabetes mellitus have a greater longitudinal decline in physical performance than those without and whether any decline differs according to insulin sensitizer use. DesignProspective cohort study. SettingBaltimore, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela, Pennsylvania. ParticipantsCommunity-dwelling women (mean age 78.53.6) enrolled in the Study of Osteoporotic Fractures in 1997-98 and restudied 4.90.6years later (N=2,864). MeasurementsWomen were categorized as having no diabetes mellitus (n=2,680) or having diabetes mellitus (n=184). A prescription medication inventory was used to determine use of insulin sensitizers (metformin and thiazolidinedione). The outcomes were longitudinal changes in physical performance measures, including grip strength, usual walk speed, and rapid walk speed. ResultsEstimates from fully adjusted models showed that women with diabetes mellitus had greater declines in usual walk speed (-0.16m/s, 95% confidence interval (CI)=-0.19 to -0.14) and rapid walk speed (-0.21m/s, 95% CI=-0.24 to -0.17) than those without (usual walk speed -0.11m/s, 95% CI=-0.12 to -0.11, P<.001; rapid walk speed -0.15m/s, 95% CI=-0.16 to -0.14; P=.005). Women with diabetes mellitus taking insulin sensitizers had less decline in usual walk speed than those not taking insulin sensitizers (P<.001). Declines in grip strength did not differ significantly by diabetes mellitus status or insulin sensitizer use. ConclusionOlder women with diabetes mellitus have a greater decline in walk speed, but not grip strength, than older women without diabetes mellitus. Clinical studies in older adults to determine whether diabetes mellitus treatments such as insulin sensitizers can prevent loss in walk speed and mobility are needed. C1 [Lee, Christine G.] Oregon Hlth & Sci Univ, Vet Affairs Med Ctr, Res Serv, Portland, OR 97201 USA. [Lee, Christine G.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Lee, Christine G.; Hillier, Teresa A.; LeBlanc, Erin S.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA. [Schwartz, Ann V.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Cawthon, Peggy M.] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. RP Lee, CG (reprint author), Portland VA Med Ctr, Res Serv, 3710 SW US Vet Hosp Rd,R&D 45, Portland, OR 97239 USA. EM leechr@ohsu.edu FU National Institute on Aging [R01AG005407, R01AR35582, R01AR35583, R01AR35584, R01AG005394, R01AG027574, R01AG027576]; Office of Research on Women's Health; National Institute of Child Health and Human Development, Building Interdisciplinary Research Careers in Women's Health Grant [HD043488-08]; GlaxoSmithKline; Amgen; Merck; National Institutes of Health FX The Study of Osteoporotic Fractures is supported by National Institutes of Health funding. The National Institute on Aging provides support under Grants R01AG005407, R01AR35582, R01AR35583, R01AR35584, R01AG005394, R01AG027574, and R01AG027576. Christine G. Lee was supported by the Office of Research on Women's Health and the National Institute of Child Health and Human Development, Building Interdisciplinary Research Careers in Women's Health Grant HD043488-08. Ann V. Schwartz has served as a consultant for GlaxoSmithKline and has received research support from GlaxoSmithKline, Amgen, and Merck. Kristine Yaffe has served as a consultant for Novartis and on Data and Safety Monitoring Boards for Pfizer, Medivation, and Takeda Pharmaceuticals. Peggy M. Cawthon has received research support from Amgen and Merck. NR 37 TC 7 Z9 7 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2013 VL 61 IS 11 BP 1872 EP 1878 DI 10.1111/jgs.12502 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 251VZ UT WOS:000326961300003 PM 24219188 ER PT J AU Nazir, A LaMantia, M Chodosh, J Khan, B Campbell, N Hui, S Boustani, M AF Nazir, Arif LaMantia, Michael Chodosh, Joshua Khan, Babar Campbell, Noll Hui, Siu Boustani, Malaz TI Interaction Between Cognitive Impairment and Discharge Destination and Its Effect on Rehospitalization SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE rehospitalization; cognitive impairment; discharge destination ID RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; HOSPITAL DISCHARGE; 30-DAY READMISSION; HEART-FAILURE; CARE; DEMENTIA; INTERVENTIONS; PHYSICIANS; DISEASE AB ObjectivesTo evaluate the effect of cognitive impairment on rehospitalization in older adults. DesignOne-year longitudinal study. SettingMedical service of an urban, 340-bed public hospital in Indianapolis between July 2006 and March 2008. ParticipantsIndividuals aged 65 and older admitted to the medical service (N=976). MeasurementsRehospitalization was defined as any hospital admission after the index admission. Participant demographics, discharge destination, Charlson Comorbidity Index, Acute Physiology Score, and prior hospitalizations were measured as the confounders. Participants were considered to have cognitive impairment if they had two or more errors on the Short Portable Mental Status Questionnaire. ResultsAfter adjusting for confounders, a significant interaction between cognitive impairment and discharge location was found to predict rehospitalization rate (P=.008) and time to 1-year rehospitalization (P=.03). Participants with cognitive impairment discharged to a facility had a longer time to rehospitalization (median 142days) than participants with no cognitive impairment (median 98days) (hazard ratio (HR)=0.77, 95% confidence interval (CI)=0.58-1.02, P=.07), whereas participants with cognitive impairment discharged to home had a slightly shorter time to rehospitalization (median 182days) than those without cognitive impairment (median 224days) (HR=1.15, 95% CI=0.92-1.43, P=.23). These two nonsignificant HRs in opposite directions were significantly different from each other (P=.03). ConclusionDischarge destination modifies the association between cognitive impairment and rehospitalization. Of participants discharged to a facility, those without cognitive impairment had higher rehospitalization rates, whereas the rates were similar between cognitively impaired and intact participants discharged to the community. C1 [Nazir, Arif; LaMantia, Michael; Khan, Babar; Hui, Siu; Boustani, Malaz] Indiana Univ, Sch Med, Indianapolis, IN 46202 USA. [LaMantia, Michael; Khan, Babar; Campbell, Noll; Hui, Siu; Boustani, Malaz] Indiana Univ, Ctr Aging Res, Indianapolis, IN USA. [LaMantia, Michael; Khan, Babar; Campbell, Noll; Hui, Siu; Boustani, Malaz] Regenstrief Inst Inc, Indianapolis, IN USA. [Chodosh, Joshua] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Chodosh, Joshua] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Campbell, Noll] Purdue Univ, Coll Pharm, W Lafayette, IN USA. RP Nazir, A (reprint author), Indiana Univ, Sch Med, Indianapolis, IN 46202 USA. EM anazir@iu.edu OI Chodosh, Joshua/0000-0001-7784-4306 FU Health Resources and Services Administration; National Institute on Aging [R01AG034205, K23-AG043476]; John A. Hartford Foundation Center for Excellence in Geriatric Medicine FX This work was supported by grants from a Geriatric Academic Career Award through the Health Resources and Services Administration; R01AG034205 and K23-AG043476 from the National Institute on Aging, and the John A. Hartford Foundation Center for Excellence in Geriatric Medicine. NR 33 TC 7 Z9 7 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2013 VL 61 IS 11 BP 1958 EP 1963 DI 10.1111/jgs.12501 PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 251VZ UT WOS:000326961300016 PM 24219196 ER PT J AU Ahalt, C Trestman, RL Rich, JD Greifinger, RB Williams, BA AF Ahalt, Cyrus Trestman, Robert L. Rich, Josiah D. Greifinger, Robert B. Williams, Brie A. TI Paying the Price: The Pressing Need for Quality, Cost, and Outcomes Data to Improve Correctional Health Care for Older Prisoners SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE correctional health; health disparities; healthcare value; older prisoners; research ID DISPARITIES; INCARCERATION; MEDICINE; RELEASE; AGENDA; SYSTEM; RISK AB Despite a recent decline in the U.S. prison population, the older prisoner population is growing rapidly. U.S. prisons are constitutionally required to provide health care to prisoners. As the population ages, healthcare costs rise, states are forced to cut spending, and many correctional agencies struggle to meet this legal standard of care. Failure to meet the healthcare needs of older prisoners, who now account for nearly 10% of the prison population, can cause avoidable suffering in a medically vulnerable population and violation of the constitutional mandate for timely access to an appropriate level of care while incarcerated. Older prisoners who cannot access adequate health care in prison also affect community healthcare systems because more than 95% of prisoners are eventually released, many to urban communities where healthcare disparities are common and acute healthcare resources are overused. A lack of uniform quality and cost data has significantly hampered innovations in policy and practice to improve value in correctional health care (achieving desired health outcomes at sustainable costs). With their unique knowledge of complex chronic disease management, experts in geriatrics are positioned to help address the aging crisis in correctional health care. This article delineates the basic health, cost, and outcomes data that geriatricians and gerontologists need to respond to this crisis, identifies gaps in the available data, and anticipates barriers to data collection that, if addressed, could enable clinicians and policy-makers to evaluate and improve the value of geriatric prison health care. C1 [Ahalt, Cyrus; Williams, Brie A.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94118 USA. [Trestman, Robert L.] Univ Connecticut, Ctr Hlth, Farmington, CT USA. [Rich, Josiah D.] Brown Med Sch, Providence, RI USA. [Rich, Josiah D.] Brown Univ, Ctr Prisoner Hlth & Human Rights, Providence, RI 02912 USA. [Rich, Josiah D.] Miriam Hosp, Providence, RI 02906 USA. [Greifinger, Robert B.] CUNY John Jay Coll Criminal Justice, New York, NY 10019 USA. [Williams, Brie A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. RP Williams, BA (reprint author), Univ Calif San Francisco, Div Geriatr, 3333California St,Suite 380, San Francisco, CA 94118 USA. EM brie.williams@ucsf.edu FU National Institute of Aging [K23AG033102]; Jacob & Valeria Langeloth Foundation; University of California at San Francisco (UCSF) Program for the Aging Century; UCSF Older Americans Independence Center; National Institute of Drug Abuse [K24DA022112] FX Dr. Williams is supported by the National Institute of Aging (K23AG033102), The Jacob & Valeria Langeloth Foundation, The University of California at San Francisco (UCSF) Program for the Aging Century, and the UCSF Older Americans Independence Center. Dr. Rich is supported by the National Institute of Drug Abuse (K24DA022112). Dr. Williams is an employee of the Department of Veterans Affairs. NR 47 TC 15 Z9 15 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD NOV PY 2013 VL 61 IS 11 BP 2013 EP 2019 DI 10.1111/jgs.12510 PG 7 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 251VZ UT WOS:000326961300024 PM 24219203 ER PT J AU Whitney, N Kareus, S Cetas, JS Chung, K Brodsky, M AF Whitney, Nathaniel Kareus, Seth Cetas, Justin S. Chung, Kathryn Brodsky, Matthew TI Bilateral Deep Brain Stimulation Targeting Ventralis Intermedius Nucleus to Treat a Professional Musician's Task-Specific Tremor SO MOVEMENT DISORDERS LA English DT Letter ID PRIMARY WRITING TREMOR; DYSTONIA; WRITERS; CRAMP C1 [Whitney, Nathaniel; Cetas, Justin S.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA. [Kareus, Seth; Chung, Kathryn; Brodsky, Matthew] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Cetas, Justin S.; Chung, Kathryn; Brodsky, Matthew] Portland VA Med Ctr, Portland, OR USA. RP Brodsky, M (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. EM brodskym@ohsu.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-3185 EI 1531-8257 J9 MOVEMENT DISORD JI Mov. Disord. PD NOV PY 2013 VL 28 IS 13 BP 1896 EP 1897 DI 10.1002/mds.25577 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 250NN UT WOS:000326859600030 PM 23893475 ER PT J AU Rosansky, SJ Cancarini, G Clark, WF Eggers, P Germaine, M Glassock, R Goldfarb, DS Harris, D Hwang, SJ Imperial, EB Johansen, KL Kalantar-Zadeh, K Moist, LM Rayner, B Steiner, R Zuo, L AF Rosansky, Steven J. Cancarini, Giovanni Clark, William F. Eggers, Paul Germaine, Michael Glassock, Richard Goldfarb, David S. Harris, David Hwang, Shang-Jyh Imperial, Edwina Brown Johansen, Kirsten L. Kalantar-Zadeh, Kamyar Moist, Louise M. Rayner, Brian Steiner, Robert Zuo, Li TI Dialysis Initiation: What's the Rush? SO SEMINARS IN DIALYSIS LA English DT Article ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; QUALITY-OF-LIFE; NATIONAL COOPERATIVE DIALYSIS; HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS; MAINTENANCE HEMODIALYSIS; NUTRITIONAL PARAMETERS; STARTING DIALYSIS; MEMBRANE FLUX AB The recent trend to early initiation of dialysis (at eGFR >10ml/min/1.73m(2)) appears to have been based on conventional wisdoms that are not supported by evidence. Observational studies using administrative databases report worse comorbidity-adjusted dialysis survival with early dialysis initiation. Although some have concluded that the IDEAL randomized controlled trial of dialysis start provided evidence that patients become symptomatic with late dialysis start, there is no definitive support for this view. The potential harms of early start of dialysis, including the loss of residual renal function (RRF), have been well documented. The rate of RRF loss (renal function trajectory) is an important consideration for the timing of the dialysis initiation decision. Patients with low glomerular filtration rate (GFR) may have sufficient RRF to be maintained off dialysis for years. Delay of dialysis start until a working arterio-venous access is in place seems prudent in light of the lack of harm and possible benefit of late dialysis initiation. Prescribing frequent hemodialysis is not recommended when dialysis is initiated early. The benefits of early initiation of chronic dialysis after episodes of congestive heart failure or acute kidney injury require further study. There are no data to show that early start benefits diabetics or other patient groups. Preemptive start of dialysis in noncompliant patients may be necessary to avoid complications. The decision to initiate dialysis requires informed patient consent and a joint decision by the patient and dialysis provider. Possible talking points for obtaining informed consent are provided. C1 [Rosansky, Steven J.] Univ SC, Sch Publ Hlth, WJBDVA Hosp, Dorn Res Inst, Columbia, SC USA. [Cancarini, Giovanni] AO Spedali Civili, OU Nephrol, Brescia, Italy. [Cancarini, Giovanni] Univ Brescia, Brescia, Italy. [Clark, William F.] Western Univ Canada, London Hlth Sci Ctr, London, ON, Canada. [Eggers, Paul] NIDDK, Bethesda, MD 20892 USA. [Germaine, Michael] Tufts Univ, Sch Med, Baystate Med Ctr, Springfield, MA 01199 USA. [Glassock, Richard] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Goldfarb, David S.] New York Harbor VA Healthcare Syst, Langone Med Ctr, Nephrol Sect, New York, NY USA. [Goldfarb, David S.] NYU, New York, NY USA. [Harris, David] Univ Sydney, Westmead Millennium Inst, Sydney, Australia. [Hwang, Shang-Jyh] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Nephrol, Kaohsiung, Taiwan. [Imperial, Edwina Brown] Hammersmith Hosp, Renal & Transplant Ctr, London, England. [Johansen, Kirsten L.] Univ Calif San Francisco, San Francisco VA Med Ctr, Div Nephrol, San Francisco, CA 94143 USA. [Johansen, Kirsten L.] Nephrol Sect, San Francisco, CA USA. [Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Sch Med, UC Irvine Med Ctr, Div Nephrol & Hypertens, Irvine, CA USA. [Moist, Louise M.] Univ Western Ontario, Schulich Sch Med & Dent, London Hlth Sci Ctr, Kidney Clin Res Unit, London, ON, Canada. [Rayner, Brian] Groote Schuur Hosp, Div Nephrol & Hypertens, ZA-7925 Cape Town, South Africa. [Rayner, Brian] Univ Cape Town, ZA-7925 Cape Town, South Africa. [Steiner, Robert] Univ Calif San Diego, San Diego Med Ctr, San Diego, CA 92103 USA. [Zuo, Li] Peking Univ, Hosp 1, Inst Nephrol, Renal Div,Key Lab,Minist Hlth, Beijing, Peoples R China. RP Rosansky, SJ (reprint author), Dorn Res Inst, 526 N Trenholm Rd, Columbia, SC 29206 USA. EM sjrcra@yahoo.com OI Rayner, Brian/0000-0002-0167-9591; Goldfarb, David/0000-0002-9215-1273; Kalantar-Zadeh, Kamyar/0000-0002-8666-0725 NR 73 TC 16 Z9 16 U1 0 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD NOV PY 2013 VL 26 IS 6 BP 650 EP 657 DI 10.1111/sdi.12134 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 252SK UT WOS:000327030200005 PM 24066675 ER PT J AU Treit, K Lam, D O'Hare, AM AF Treit, Kathryn Lam, Daniel O'Hare, Ann M. TI Timing of Dialysis Initiation in the Geriatric Population: Toward a Patient-centered Approach SO SEMINARS IN DIALYSIS LA English DT Article ID CHRONIC KIDNEY-DISEASE; SHARED DECISION-MAKING; STAGE RENAL-DISEASE; CONSERVATIVE MANAGEMENT; OF-LIFE; ELDERLY-PATIENTS; UNITED-STATES; OLDER-ADULTS; END; CARE AB Over the last 10-15years, the incidence of treated end-stage renal disease (ESRD) among older adults has increased and dialysis is being initiated at progressively higher levels of estimated glomerular filtration rate (eGFR). Average life expectancy after dialysis initiation among older adults is quite limited, and many experience an escalation of care and loss of independence after starting dialysis. Available data suggest that treatment decisions about dialysis initiation in older adults in the United States are guided more by system- than by patient-level factors. Stronger efforts are thus needed to ensure that treatment decisions for older adults with advanced kidney disease are optimally aligned with their goals and preferences. There is growing interest in more conservative approaches to the management of advanced kidney disease in older patients who prefer not to initiate dialysis and those for whom the harms of dialysis are expected to outweigh the benefits. A number of small single center studies, mostly from the United Kingdom report similar survival among the subset of older adults with a high burden of comorbidity treated with dialysis vs. those managed conservatively. However, the incidence of treated ESRD in older US adults is several-fold higher than in the United Kingdom, despite a similar prevalence of chronic kidney disease, suggesting large differences in the social, cultural, and economic context in which dialysis treatment decisions unfold. Thus, efforts may be needed to adapt conservative care models developed outside the United States to optimally meet the needs of US patients. More flexible approaches toward dialysis prescription and better integration of treatment decisions about conservative care with those related to modality selection will likely be helpful in meeting the needs of individual patients. Regardless of the chosen treatment strategy, time can often be a critical ally in centering care on what matters most to the patient, and a flexible and iterative approach of re-evaluation and redirection may often be needed to ensure that treatment strategies are fully aligned with patient priorities. C1 [Treit, Kathryn; Lam, Daniel; O'Hare, Ann M.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA. [O'Hare, Ann M.] VA Puget Sound Healthcare Syst, Seattle, WA USA. RP O'Hare, AM (reprint author), 1660 South Columbian Way, Seattle, WA 98108 USA. EM Ann.OHare@va.gov NR 50 TC 18 Z9 18 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD NOV PY 2013 VL 26 IS 6 BP 682 EP 689 DI 10.1111/sdi.12131 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA 252SK UT WOS:000327030200009 PM 24112631 ER PT J AU Johansen, KL Delgado, C Bao, YR Tamura, MK AF Johansen, Kirsten L. Delgado, Cynthia Bao, Yeran Tamura, Manjula Kurella TI Frailty and Dialysis Initiation SO SEMINARS IN DIALYSIS LA English DT Article ID GLOMERULAR-FILTRATION-RATE; SURVIVAL; MORTALITY; OLDER; START; HEMODIALYSIS; COMORBIDITY; PREDICTION; DISABILITY; DISEASE AB Frailty is a physiologic state of increased vulnerability to stressors that results from decreased physiologic reserves or dysregulation of multiple physiologic systems. The construct of frailty has been operationalized as a composite of poor physical function, exhaustion, low physical activity, and weight loss. Several studies have now examined the prevalence of frailty among chronic kidney disease (CKD) or end-stage renal disease (ESRD) patients and have found frailty to be more common among individuals with CKD than among those without. Furthermore, frailty is associated with adverse outcomes among incident dialysis patients, including higher risk of hospitalization and death. Recent evidence shows that frail patients are started on dialysis earlier (at a higher estimated glomerular filtration rate [eGFR]) on average than nonfrail patients, but it remains unclear whether these patients' frailty is a result of uremia or is independent of CKD. The survival disadvantage that has been associated with early initiation of dialysis in observational studies could be mediated in part through confounding on the basis of unmeasured frailty. However, available data do not suggest improvement in frailty upon initiation of dialysis; rather, the trajectory appears to be toward higher levels of dependence in activities of daily living (ADLs) after dialysis initiation. Overall, there are no data to suggest that frail patients derive any benefit from early initiation of dialysis either in the form of improved survival or functional status. C1 [Johansen, Kirsten L.; Delgado, Cynthia] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA. [Johansen, Kirsten L.; Delgado, Cynthia] San Francisco VA Med Ctr, Nephrol Sect, San Francisco, CA 94121 USA. [Bao, Yeran] John Muir Med Grp, Walnut Creek, CA USA. [Tamura, Manjula Kurella] Geriatr Res & Educ Clin Ctr, Palo Alto, CA USA. [Tamura, Manjula Kurella] Stanford Univ, Sch Med, Dept Med, VA Hlth Care Syst, Palo Alto, CA 94304 USA. [Tamura, Manjula Kurella] Stanford Univ, Sch Med, Dept Med, Div Nephrol, Palo Alto, CA 94304 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St,111J, San Francisco, CA 94121 USA. EM kirsten.johansen@ucsf.edu RI Kurella Tamura, Manjula/C-8284-2014 OI Kurella Tamura, Manjula/0000-0001-5227-2479 FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [1K24DK085153]; VA Career Development Award FX Dr. Johansen is supported by 1K24DK085153 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr. Delgado is supported by a VA Career Development Award. NR 36 TC 11 Z9 12 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD NOV PY 2013 VL 26 IS 6 BP 690 EP 696 DI 10.1111/sdi.12126 PG 7 WC Urology & Nephrology SC Urology & Nephrology GA 252SK UT WOS:000327030200010 PM 24004376 ER PT J AU Watnick, S AF Watnick, Suzanne TI Financial and Medico-Legal Implications of Late-Start Dialysis: Understanding the Present Policies through a Window of Past Performance SO SEMINARS IN DIALYSIS LA English DT Article ID STAGE RENAL-DISEASE; EARLY INITIATION; HEMODIALYSIS; COMORBIDITY; IMPROVEMENT; MORTALITY; SURVIVAL; FAILURE; PATIENT AB In the United States, multiple stakeholders have impacted the timing of dialysis initiation for patients with end-stage renal disease. The optimal policy to start dialysis for this vulnerable population remains unknown. Historically, patients initiated dialysis weeks after the appearance of uremic symptoms. This changed not only due to an evolution in medical providers' practice but also due to changes in the care delivery system, the political imperatives, and the economic driving forces surrounding the care of these patients. One large randomized control trial looked at patient outcomes with strategies of early versus late start. The trial included an economic analysis. Depending on the specific comparison, cost was either lower in the late-start group or was equivalent between groups. This result would tend to favor a late-start strategy, where patients had an additional 6months of dialysis-free time. However, the generalizability of this analysis has been questioned. Future care models that would include patients before and after dialysis initiation would be ideal to study cost and quality at the time of this transition of care. The recently implemented CMS Quality Incentive Program is one mechanism that could use such findings to implement a high-value strategy for patients starting chronic dialysis therapies. C1 [Watnick, Suzanne] Oregon Hlth & Sci Univ, Div Nephrol & Hypertens, Portland, OR 97201 USA. [Watnick, Suzanne] Portland VA Med Ctr, Portland, OR 97207 USA. [Watnick, Suzanne] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Watnick, S (reprint author), Portland VA Med Ctr, P3NEPH,3710 SW US Vet Hosp Rd, Portland, OR 97207 USA. EM Suzanne.Watnick@va.gov NR 41 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD NOV PY 2013 VL 26 IS 6 BP 702 EP 705 DI 10.1111/sdi.12135 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA 252SK UT WOS:000327030200012 PM 24118409 ER PT J AU Liu, QL Zhu, XL Xu, LS Fu, YC Garvey, WT AF Liu, Qinglan Zhu, Xiaolin Xu, Lusheng Fu, Yuchang Garvey, W. Timothy TI 6-Mercaptopurine augments glucose transport activity in skeletal muscle cells in part via a mechanism dependent upon orphan nuclear receptor NR4A3 SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article DE NR4A3; 6-mercaptopurine; glucose transport; gloucose transporter 4 translocation; Akt substrate of 160 kDa; insulin action; skeletal muscle ID ANTINEOPLASTIC AGENT 6-MERCAPTOPURINE; ACUTE LYMPHOBLASTIC-LEUKEMIA; LIGAND-BINDING DOMAIN; GENE-EXPRESSION; GLUT4 TRANSLOCATION; INSULIN-RESISTANCE; METABOLIC DISEASE; AS160; PHOSPHORYLATION; NOR-1 AB The purine anti-metabolite 6-mercaptopurine (6-MP) is widely used for the treatment of leukemia and inflammatory diseases. The cellular effects of 6-MP on metabolism remain unknown; however, 6-MP was recently found to activate the orphan nuclear receptor NR4A3 in skeletal muscle cell lines. We have reported previously that NR4A3 (also known as NOR-1, MINOR) is a positive regulator of insulin sensitivity in adipocytes. To further explore the role of NR4A3 activation in insulin action, we explored whether 6-MP activation of NR4A3 could modulate glucose transport system activity in L6 skeletal muscle cells. We found that 6-MP increased both NR4A3 expression and NR4A3 transcriptional activity and enhanced glucose transport activity via increasing GLUT4 translocation in both basal and insulin-stimulated L6 cells in an NR4A3-dependent manner. Furthermore, 6-MP increased levels of phospho-AS160, although this effect was not modulated by NR4A3 overexpression or knockdown. These primary findings provide a novel proof of principle that 6-MP, a small molecule NR4A3 agonist, can augment glucose uptake in insulin target cells, although this occurs via both NR4A3-dependent and -independent actions; the latter is related to an increase in phospho-AS160. These results establish a novel target for development of new treatments for insulin resistance. C1 [Liu, Qinglan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Zhu, Xiaolin; Xu, Lusheng; Fu, Yuchang; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Liu, QL (reprint author), Univ Alabama Birmingham, Shelby Bldg 1231,1825 Univ Blvd, Birmingham, AL 35294 USA. EM chinglan@uab.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [DK-083562, DK-038764]; Merit Review Program of the Department of Veterans Affairs; Alabama Drug Discovery Alliance FX This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (DK-083562 and DK-038764 to W. T. Garvey), the Merit Review Program of the Department of Veterans Affairs (W. T. Garvey), and the Alabama Drug Discovery Alliance (W. T. Garvey and Y. Fu). NR 44 TC 1 Z9 2 U1 1 U2 9 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD NOV PY 2013 VL 305 IS 9 BP E1081 EP E1092 DI 10.1152/ajpendo.00169.2013 PG 12 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA 246YU UT WOS:000326578600004 PM 24022864 ER PT J AU Harada, CN Love, MCN Triebel, KL AF Harada, Caroline N. Love, Marissa C. Natelson Triebel, Kristen L. TI Normal Cognitive Aging SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Mild cognitive impairment; Dementia; Aging; Cognition ID WHITE-MATTER INTEGRITY; OLDER-ADULTS; ALZHEIMERS-DISEASE; LEISURE ACTIVITIES; LIFE-STYLE; MENTAL FLEXIBILITY; BRAIN ACTIVITY; REDUCED RISK; AGE; MEMORY AB Even those who do not experience dementia or mild cognitive impairment may experience subtle cognitive changes associated with aging. Normal cognitive changes can affect an older adult's everyday function and quality of life, and a better understanding of this process may help clinicians distinguish normal from disease states. This article describes the neurocognitive changes observed in normal aging, followed by a description of the structural and functional alterations seen in aging brains. Practical implications of normal cognitive aging are then discussed, followed by a discussion of what is known about factors that may mitigate age-associated cognitive decline. C1 [Harada, Caroline N.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Div Gerontol Geriatr & Palliat Care, Birmingham, AL 35294 USA. [Love, Marissa C. Natelson] Univ Alabama Birmingham, Div Memory Disorders & Behav Neurol, Dept Neurol, Birmingham, AL 35233 USA. [Triebel, Kristen L.] Univ Alabama Birmingham, Dept Neurol, Sparks Ctr, Birmingham, AL 35294 USA. RP Harada, CN (reprint author), Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Div Gerontol Geriatr & Palliat Care, CH 19-201,1720 2nd Ave South, Birmingham, AL 35294 USA. EM charada@uabmc.edu FU Donald W. Reynolds Foundation; NIH [KL2TR000166] FX Dr Harada, Donald W. Reynolds Foundation; Dr Natelson Love, None; Dr Triebel, NIH KL2TR000166: Triebel, PI. NR 96 TC 41 Z9 45 U1 7 U2 30 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD NOV PY 2013 VL 29 IS 4 BP 737 EP + DI 10.1016/j.cger.2013.07.002 PG 17 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 247XX UT WOS:000326659400002 PM 24094294 ER PT J AU Courtney, DL AF Courtney, Donald L. TI Dealing with Mild Cognitive Impairment Help for Patients and Caregivers SO CLINICS IN GERIATRIC MEDICINE LA English DT Article DE Mild cognitive impairment; Alzheimer disease; Activities of daily living; Dementia progression; Cognitive training ID RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS; DRIVING CESSATION; NURSING-HOME; DEMENTIA; SPEED; INDIVIDUALS; EXERCISE; PEOPLE; HEALTH AB Mild cognitive impairment (MCI) is a unique entity in the spectrum of syndromes of cognitive loss. Many patients referred for evaluation of memory loss come with an assumption that they already have dementia. When patients are diagnosed with MCI, they and their caregivers have to deal with the challenge of uncertainties. Patient and family education must stress the uncertainty of whether the deficits will progress. This article aims to guide the clinician who has reached a diagnosis of MCI and is working with the patient and family on coping with the uncertainties of MCI. C1 Med Univ S Carolina, Sect Geriatr Med 11G, Div Gen & Geriatr Med, Dept Med,Ralph H Johnson VA Med Ctr, Charleston, SC 29401 USA. RP Courtney, DL (reprint author), Med Univ S Carolina, Sect Geriatr Med 11G, Div Gen & Geriatr Med, Dept Med,Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. EM Donald.Courtney2@va.gov NR 25 TC 3 Z9 4 U1 1 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0749-0690 EI 1879-8853 J9 CLIN GERIATR MED JI Clin. Geriatr. Med. PD NOV PY 2013 VL 29 IS 4 BP 895 EP + DI 10.1016/j.cger.2013.07.010 PG 12 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA 247XX UT WOS:000326659400010 PM 24094302 ER PT J AU Gros, DF Price, M Yuen, EK Acierno, R AF Gros, Daniel F. Price, Matthew Yuen, Erica K. Acierno, Ron TI PREDICTORS OF COMPLETION OF EXPOSURE THERAPY IN OEF/OIF VETERANS WITH POSTTRAUMATIC STRESS DISORDER SO DEPRESSION AND ANXIETY LA English DT Article DE Operation Enduring Freedom; Operation Iraqi Freedom; posttraumatic stress disorder; exposure therapy; dropout; social support; disability ID MENTAL-HEALTH PROBLEMS; RANDOMIZED CONTROLLED-TRIAL; IRAQI FREEDOM VETERANS; BEHAVIORAL ACTIVATION; AFGHANISTAN VETERANS; PTSD; DEPRESSION; DEPLOYMENT; SERVICES; CARE AB BackgroundDespite large-scale dissemination and implementation efforts of evidence-based psychotherapy to veterans from Operation Enduring/Iraqi Freedom (OEF/OIF), little is known regarding the factors that contribute to the successful completion of these treatments in this high-risk population. The present study investigated predictors of treatment completion during a standardized exposure-based psychotherapy for PTSD. MethodsNinety-two OEF/OIF combat veterans enrolled in a randomized controlled trial for an eight session exposure-based psychotherapy for PTSD. All participants completed structured clinical interviews and several background and symptom questionnaires. Of the initial 92 participants, 28% of the sample (n = 26) discontinued treatment prior to completion of the trial. ResultsPredictors of discontinuation of treatment were assessed with a hierarchical logistic regression. Disability status was positively associated with treatment discontinuation, and postdeployment social support was negatively associated with discontinuation. In contrast to previous findings, other factors, such as age and PTSD symptomatology, were not identified as significant predictors. ConclusionsThe present study suggested that disability status at the start of treatment increases the risk for treatment discontinuation whereas increased social support buffers against discontinuation. Together, these findings highlight the importance of increased assessment and early intervention when these factors are present to potentially reduce treatment discontinuation and improve treatment outcomes in OEF/OIF veterans with PTSD. C1 [Gros, Daniel F.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv Line, Charleston, SC 29401 USA. [Gros, Daniel F.; Acierno, Ron] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Price, Matthew] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA. [Yuen, Erica K.] Univ Tampa, Dept Psychol, Tampa, FL 33606 USA. RP Gros, DF (reprint author), Ralph H Johnson Vet Affairs Med Ctr, VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU Department of Defense [W81XWH-07-PTSD-IIRA] FX Contract grant sponsor: Department of Defense Grant; Contract grant number: W81XWH-07-PTSD-IIRA (PI: Acierno) NR 39 TC 13 Z9 13 U1 3 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1091-4269 EI 1520-6394 J9 DEPRESS ANXIETY JI Depress. Anxiety PD NOV PY 2013 VL 30 IS 11 BP 1107 EP 1113 DI 10.1002/da.22207 PG 7 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA 246AW UT WOS:000326509200007 PM 24151141 ER PT J AU Lesogor, A Cohn, JN Latini, R Tognoni, G Krum, H Massie, B Zalewski, A Kandra, A Hua, TA Gimpelewicz, C AF Lesogor, Anastasia Cohn, Jay N. Latini, Roberto Tognoni, Gianni Krum, Henry Massie, Barry Zalewski, Andrew Kandra, Albert Hua, Tsushung A. Gimpelewicz, Claudio TI Interaction between baseline and early worsening of renal function and efficacy of reninangiotensinaldosterone system blockade in patients with heart failure: insights from the Val-HeFT study SO EUROPEAN JOURNAL OF HEART FAILURE LA English DT Article DE Valsartan; Heart failure; Prognosis; eGFR; EWRF ID ANGIOTENSIN-RECEPTOR BLOCKER; GLOMERULAR-FILTRATION-RATE; MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; TASK-FORCE; VALSARTAN; DYSFUNCTION; SURVIVAL; MORTALITY; ENALAPRIL AB We evaluated the effect of (dual) reninangiotensinaldosterone system (RAAS) blockade with valsartan and an ACE inhibitor [92.7 of patients were treated with an ACE inhibitor in the Valsartan in Heart Failure Trial (Val-HeFT)] in patients with NYHA class IIIV heart failure (HF) and reduced EF on cardiovascular (CV) death and HF hospitalization by subgroups and by presence of early worsening of renal function (EWRF) and according to baseline estimated glomerular filtration rate (eGFR). We analysed the data from 5010 patients enrolled in the Val-HeFT study. A total of 2346 (46.8) patients had baseline renal impairment (i.e. baseline eGFR 60 mL/min/1.73 m(2)). Further, 425 patients (8.6) had EWRF (i.e. eGFR decrease 20 within 1 month after randomization), whereas 4503 patients (91.4) had 20 decline in eGFR. Overall, the difference between valsartan and placebo on the composite endpoint of CV death and HF hospitalization was significant [P 0.0005; hazard ratio (HR) 0.83, 95 confidence interval (CI) 0.750.92)]. In patients with baseline renal impairment, the difference between the treatment groups was also significant (P 0.0002; HR 0.76, 95 CI 0.660.88). Patients with EWRF had higher risk of CV death and HF hospitalization vs. those without ERWF (P 0.0001; HR 1.44, 95 CI 1.211.71), and within the EWRF group a significant difference was also observed between valsartan and placebo (P 0.0086; HR 0.63, 95 CI 0.450.89). However, the interaction between treatment and eGFR at Month 1 was not significant (P 0.1160). Benefits were maintained in patients with renal dysfunction at baseline and those who experienced EWRF. C1 [Lesogor, Anastasia; Kandra, Albert; Gimpelewicz, Claudio] Novartis Pharma AG, Basel, Switzerland. [Cohn, Jay N.] Univ Minnesota, Sch Med, Dept Med, Div Cardiovasc, Minneapolis, MN 55455 USA. [Latini, Roberto] Ist Ric Farmacol Mario Negri, Milan, Italy. [Tognoni, Gianni] Consorzio Mario Negri Sud, Chieti, Italy. [Krum, Henry] Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Monash Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic 3181, Australia. [Massie, Barry] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Massie, Barry] San Francisco VA Med Ctr, Div Cardiol, San Francisco, CA USA. [Zalewski, Andrew; Hua, Tsushung A.] Novartis Pharmaceut, E Hanover, NJ USA. RP Cohn, JN (reprint author), Univ Minnesota, Sch Med, Dept Med, Div Cardiovasc, Minneapolis, MN 55455 USA. EM cohnx001@umn.edu FU Novartis Pharma AG, Basel, Switzerland FX Novartis Pharma AG, Basel, Switzerland. The Val-HeFT study was funded by Novartis Pharma AG, Basel, Switzerland. NR 31 TC 22 Z9 22 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1388-9842 EI 1879-0844 J9 EUR J HEART FAIL JI Eur. J. Heart Fail. PD NOV PY 2013 VL 15 IS 11 BP 1236 EP 1244 DI 10.1093/eurjhf/hft089 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 248SR UT WOS:000326723200006 PM 23787721 ER PT J AU Tehrani, S Rozelle, C Solomon, A Steele, EA AF Tehrani, S. Rozelle, C. Solomon, A. Steele, E. A. TI Comment on 'Spontaneous haemorrhage in an eyelid hidrocystoma in a patient treated with clopidogrel' SO EYE LA English DT Letter C1 [Tehrani, S.; Steele, E. A.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA. [Rozelle, C.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA. [Solomon, A.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA. [Solomon, A.; Steele, E. A.] Portland VA Med Ctr, Portland, OR USA. RP Tehrani, S (reprint author), Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA. EM steeleer@ohsu.edu OI Tehrani, Shandiz/0000-0001-6083-3336 NR 1 TC 1 Z9 1 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0950-222X EI 1476-5454 J9 EYE JI Eye PD NOV PY 2013 VL 27 IS 11 BP 1326 EP 1327 DI 10.1038/eye.2013.170 PG 3 WC Ophthalmology SC Ophthalmology GA 251VA UT WOS:000326957700017 PM 23949492 ER PT J AU Edderkaoui, M Lugea, A Hui, HX Eibl, G Lu, QY Moro, A Lu, XY Li, G Go, VL Pandol, SJ AF Edderkaoui, Mouad Lugea, Aurelia Hui, Hongxiang Eibl, Guido Lu, Qing-Yi Moro, Aune Lu, Xuyang Li, Gang Go, Vay-Liang Pandol, Stephen J. TI Ellagic Acid and Embelin Affect Key Cellular Components of Pancreatic Adenocarcinoma, Cancer, and Stellate Cells SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL LA English DT Article ID FACTOR-KAPPA-B; APOPTOSIS; MICROENVIRONMENT; PROLIFERATION; SUPPRESSION; XENOGRAFTS; INHIBITION; EXPRESSION; CARCINOMA; SURVIVAL AB Ellagic acid is a polyphenolic phytochemical present in many fruits and nuts with anticancer properties demonstrated in experimental tumor studies. Embelin is a benzoquinone phytochemical isolated from the Japanese herb Ardisiae Japonicae and has been shown to induce apoptosis in cancer cells. We found that ellagic acid and embelin each dose-dependently increased apoptosis and inhibited proliferation in human pancreatic cancer cells, MIA PaCa-2 and HPAF-II cells, and in pancreatic stellate cells, which are progenitors of pancreatic cancer desmoplasia. In each of these cell types, combinations of ellagic acid and embelin at low micromolar concentrations (0.5-3M) induced synergistic increases in apoptosis and decreases in proliferation. Ellagic acid decreased NF-B transcriptional activity, whereas embelin decreased STAT-3 phosphorylation and protein expression of its downstream target survivin in cancer cells. In vivo dietary ellagic acid alone or in combination with embelin decreased tumor size and tumor cellularity in a subcutaneous xenograft mouse model of pancreatic cancer. These results show that ellagic acid and embelin interact with divergent intracellular signaling pathways resulting in augmentation of apoptosis and inhibition of proliferation at low micromolar concentrations for the key cellular components of pancreatic adenocarcinoma. C1 [Edderkaoui, Mouad; Lugea, Aurelia; Hui, Hongxiang; Pandol, Stephen J.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Edderkaoui, Mouad; Lugea, Aurelia; Hui, Hongxiang; Eibl, Guido; Lu, Qing-Yi; Moro, Aune; Lu, Xuyang; Li, Gang; Go, Vay-Liang; Pandol, Stephen J.] Univ Calif Los Angeles, Ctr Excellence Pancreat Dis, Los Angeles, CA USA. [Edderkaoui, Mouad; Pandol, Stephen J.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Pandol, SJ (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,Bldg 258, Los Angeles, CA 90073 USA. EM stephen.pandol@cshs.org FU UCLA Center for Excellence in Pancreatic Diseases [NCCAM: 1 P01 AT003960]; Department of Veterans Affairs; NIAAA [K01 AA019996, R01 AA019954] FX We acknowledge the support of the Animal and Morphology Cores of the UCLA Center for Excellence in Pancreatic Diseases (P01AT003960) for their assistance with the xenograft model of pancreatic cancer. This work was supported by the UCLA Center for Excellence in Pancreatic Diseases (NCCAM: 1 P01 AT003960), the Department of Veterans Affairs, and two NIAAA awards (K01 AA019996 to Mouad Edderkaoui and R01 AA019954 to Aurelia Lugea). Mouad Edderkaoui and Aurelia Lugea contributed equally to this work. NR 36 TC 10 Z9 16 U1 0 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0163-5581 EI 1532-7914 J9 NUTR CANCER JI Nutr. Cancer PD NOV 1 PY 2013 VL 65 IS 8 BP 1232 EP 1244 DI 10.1080/01635581.2013.832779 PG 13 WC Oncology; Nutrition & Dietetics SC Oncology; Nutrition & Dietetics GA 251HL UT WOS:000326918300015 PM 24127740 ER PT J AU Goldman, RL Canterberry, M Borckardt, JJ Madan, A Byrne, TK George, MS O'Neil, PM Hanlon, CA AF Goldman, Rachel L. Canterberry, Melanie Borckardt, Jeffrey J. Madan, Alok Byrne, T. Karl George, Mark S. O'Neil, Patrick M. Hanlon, Colleen A. TI Executive Control Circuitry Differentiates Degree of Success in Weight Loss Following Gastric-Bypass Surgery SO OBESITY LA English DT Article ID BARIATRIC SURGERY; PREFRONTAL CORTEX; DRUG-ADDICTION; BRAIN ACTIVITY; CALORIE FOODS; OBESITY; MODULATION; ACTIVATION; IMPACT; ADULTS AB Objective: While overall success rates of bariatric surgery are high, approximately 20% of patients either regain or never lose the expected amount of weight. The purpose of this study was to determine whether, after gastric-bypass surgery, the degree of weight loss can be differentiated based on the neural response to food cues. Design and Methods: In this functional MRI study, 31 post-surgical patients viewed food and neutral images in two counterbalanced runs during which they were either instructed to "crave" or to "resist" craving. The neural response to food cues was assessed within and between runs for all participants, and further analyzed between more successful (n = 24) and less successful (n = 7) groups. More successful was defined by meeting 50% excess weight loss. Results: Overall, instructions to "crave" elicited significant activity in the dorsomedial prefrontal cortex (PFC) whereas "resist" elicited significant activity in the dorsolateral PFC (DLPFC). Between groups there was no brain difference when instructed to "crave." The more successful participants however had significantly more activity in the DLPFC when instructed to "resist." Conclusions: These findings suggest that the ability to mobilize neural circuits involved in executive control post-gastric-bypass surgery may be a unique component of successful outcome post-surgery. C1 [Goldman, Rachel L.; Canterberry, Melanie; Borckardt, Jeffrey J.; Madan, Alok; George, Mark S.; O'Neil, Patrick M.; Hanlon, Colleen A.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA. [Borckardt, Jeffrey J.] Dept Anesthesiol & Perioperat Med, Charleston, SC USA. [Byrne, T. Karl; George, Mark S.] Med Univ S Carolina, Dept Surg, Dept Neurol & Radiol, Charleston, SC 29425 USA. [George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Goldman, RL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA. EM Rachel.goldman2@nyumc.org OI Goldman, Rachel/0000-0001-6147-3934 FU Covidien through Obesity Society; [K01DA027756]; [T32DA02788] FX This study was supported by Covidien through a grant from the Obesity Society. The following grants enabled Drs. Canterberry and Hanlon to contribute to this study: K01DA027756 (to C. H.) and T32DA02788 (to M.C.). NR 36 TC 11 Z9 11 U1 2 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD NOV PY 2013 VL 21 IS 11 BP 2189 EP 2196 DI 10.1002/oby.20575 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 247RO UT WOS:000326637400005 PM 24136926 ER PT J AU Evans, ME Kralovic, SM Simbartl, LA Freyberg, RW Obrosky, DS Roselle, GA Jain, R AF Evans, Martin E. Kralovic, Stephen M. Simbartl, Loretta A. Freyberg, Ron W. Obrosky, D. Scott Roselle, Gary A. Jain, Rajiv TI Veterans Affairs methicillin-resistant Staphylococcus aureus prevention initiative associated with a sustained reduction in transmissions and health care-associated infections SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Veterans health care; MDRO; Methicillin-resistant organism; Infection prevention ID BLOOD AB Implementation of a methicillin-resistant Staphylococcus aureus (MRSA) Prevention Initiative was associated with significant declines in MRSA transmission and MRSA health care-associated infection rates in Veterans Affairs acute care facilities nationwide in the 33-month period from October 2007 through June 2010. Here, we show continuing declines in MRSA transmissions (P=.004 for trend, Poisson regression) and MRSA health care-associated infections (P<.001) from July 2010 through June 2012. The Veterans Affairs Initiative was associated with these effects, sustained over 57 months, in a large national health care system. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Evans, Martin E.] VA Cent Off, Patient Care Serv, Natl Infect Dis Serv, VHA MRSA MDRO Program Off, Lexington, KY USA. [Evans, Martin E.] Lexington VA Med Ctr, Lexington, KY USA. [Evans, Martin E.] Univ Kentucky, Sch Med, Dept Internal Med, Lexington, KY 40536 USA. [Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] VA Cent Off, Patient Care Serv, Natl Infect Dis Serv, Cincinnati, OH USA. [Kralovic, Stephen M.; Simbartl, Loretta A.; Roselle, Gary A.] Cincinnati VA Med Ctr, Cincinnati, OH USA. [Kralovic, Stephen M.; Roselle, Gary A.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA. [Freyberg, Ron W.] VA Off Informat & Analyt, Cincinnati, OH USA. [Obrosky, D. Scott] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Jain, Rajiv] VA Cent Off, Patient Care Serv, Washington, DC USA. RP Evans, ME (reprint author), 1101 Vet Dr, Lexington, KY USA. EM Martin.Evans@va.gov NR 7 TC 11 Z9 11 U1 1 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD NOV PY 2013 VL 41 IS 11 BP 1093 EP 1095 DI 10.1016/j.ajic.2013.04.015 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 242KY UT WOS:000326241700030 PM 24176769 ER PT J AU Yang, J Wheeler, SE Velikoff, M Kleaveland, KR LaFemina, MJ Frank, JA Chapman, HA Christensen, PJ Kim, KK AF Yang, Jibing Wheeler, Sarah E. Velikoff, Miranda Kleaveland, Kathryn R. LaFemina, Michael J. Frank, James A. Chapman, Harold A. Christensen, Paul J. Kim, Kevin K. TI Activated Alveolar Epithelial Cells Initiate Fibrosis through Secretion of Mesenchymal Proteins SO AMERICAN JOURNAL OF PATHOLOGY LA English DT Article ID IDIOPATHIC PULMONARY-FIBROSIS; USUAL INTERSTITIAL PNEUMONIA; TISSUE GROWTH-FACTOR; LIVER FIBROSIS; LUNG FIBROSIS; FIBROBLASTS DERIVE; PROPEPTIDE LEVELS; TRANSGENIC MICE; BETA RECEPTOR; TRANSITION AB Fibrosis is characterized by accumulation of activated fibroblasts and pathological deposition of fibrillar collagens. Activated fibroblasts overexpress matrix proteins and release factors that promote further recruitment of activated fibroblasts, leading to progressive fibrosis. The contribution of epithelial cells to this process remains unknown. Epithelium-directed injury may lead to activation of epithelial cells with phenotypes and functions similar to activated fibroblasts. Prior reports that used a reporter gene fate-mapping strategy are limited in their ability to investigate the functional significance of epithelial cell-derived mesenchymal proteins during fibrogenesis. We found that lung epithelial cell-derived collagen I activates fibroblast collagen receptor discoidin domain receptor-2, contributes significantly to fibrogenesis, and promotes resolution of lung inflammation. Alveolar epithelial cells undergoing transforming growth factor-beta-mediated mesenchymal transition express several other secreted profibrotic factors and are capable of activating lung fibroblasts. These studies provide direct evidence that activated epithelial cells produce mesenchymal proteins that initiate a cycle of fibrogenic effector cell activation, leading to progressive fibrosis. Therapy targeted at epithelial cell production of type I collagen offers a novel pathway for abrogating this progressive cycle and for Limiting tissue fibrosis but may lead to sustained Lung injury/inflammation. C1 [Yang, Jibing; Velikoff, Miranda; Kleaveland, Kathryn R.; Christensen, Paul J.; Kim, Kevin K.] Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA. [Wheeler, Sarah E.; Chapman, Harold A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Wheeler, Sarah E.; Chapman, Harold A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA. [LaFemina, Michael J.; Frank, James A.] Univ Calif San Francisco, Dept Med, San Francisco VA Med Ctr, San Francisco, CA USA. RP Kim, KK (reprint author), 109 Zina Pitcher Pl,BSRB 4061, Ann Arbor, MI 48109 USA. EM kevkim@med.umich.edu FU NIH [R01 HL108904, K08 HL085290, RO1 HL44712] FX Supported by NIH grants R01 HL108904 (K.K.K.), K08 HL085290 (K.K.K.), and RO1 HL44712 (H.A.C.). NR 66 TC 18 Z9 18 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9440 EI 1525-2191 J9 AM J PATHOL JI Am. J. Pathol. PD NOV PY 2013 VL 183 IS 5 BP 1559 EP 1570 DI 10.1016/j.ajpath.2013.07.016 PG 12 WC Pathology SC Pathology GA 246QE UT WOS:000326553400022 PM 24012677 ER PT J AU Ivers, NM Schwalm, JD Jackevicius, CA Guo, H Tu, JV Natarajan, M AF Ivers, Noah M. Schwalm, J. -D. Jackevicius, Cynthia A. Guo, Helen Tu, Jack V. Natarajan, Madhu TI Length of Initial Prescription at Hospital Discharge and Long-term Medication Adherence for Elderly Patients With Coronary Artery Disease: A Population-Level Study SO CANADIAN JOURNAL OF CARDIOLOGY LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; PRIMARY-CARE; STATIN THERAPY; SECONDARY PREVENTION; ADMINISTRATIVE DATA; AFTER-DISCHARGE; ASSOCIATION; DISCONTINUATION; PHYSICIANS; MORTALITY AB Background: Patient adherence to cardiac secondary prevention medications declines over time. We examined whether the length of the initial prescription at hospital discharge after coronary angiography would be associated with long-term adherence. Methods: We conducted a population-level cohort study to examine adherence to cardiac medications for 18 months after coronary angiography in elderly patients with coronary artery disease (CAD). We identified patients with clinical indications for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACE-I/ARB), beta-blockers (BB), and/or statins. In each medication class cohort, we defined high adherence as proportion of days covered (PDC) > 80%. The length of the initial prescription was defined as 0-30 days, 31-60 days, and more than 60 days. We controlled for patient sociodemographic factors, previous adherence, and comorbidities. Results: The ACE-I/ARB cohort included 13,305 patients, the BB cohort included 5,792 patients, and the statin cohort included 16,134 patients. Using < 30 days as the reference, initial prescriptions covering at least 60 days were more likely to result in high long-term adherence for ACE-I/ARB (adjusted odds ratio [aOR], 4.1; 95% confidence interval [CI], 3.6-4.7); BB (aOR, 2.4; 95% CI, 1.9-3.1), and statins (aOR, 3.0; 95% CI, 2.6-3.4). More than 80% of patients had outpatient follow-up with a primary care provider within 30 days, and this did not vary based on length of initial prescription. Conclusions: Giving patients longer prescriptions for cardiac secondary prevention medications at hospital discharge seems to increase the likelihood of high long-term adherence in elderly patients. C1 [Ivers, Noah M.] Womens Coll Hosp, Family Practice Hlth Ctr, Toronto, ON M5S1B3, Canada. [Ivers, Noah M.] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada. [Schwalm, J. -D.; Natarajan, Madhu] Hamilton Gen Hosp, Heart Invest Unit, Hamilton, ON, Canada. [Schwalm, J. -D.; Natarajan, Madhu] McMaster Univ, Populat Hlth Res Unit, Hamilton, ON, Canada. [Jackevicius, Cynthia A.] Western Univ Hlth Sci, Coll Pharm, Pomona, CA USA. [Jackevicius, Cynthia A.] Vet Affairs Greater Los Angeles Hlth Care Syst, Dept Pharm, Los Angeles, CA USA. [Jackevicius, Cynthia A.] Univ Hlth Network, Dept Pharm, Toronto, ON, Canada. [Jackevicius, Cynthia A.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada. [Jackevicius, Cynthia A.; Guo, Helen; Tu, Jack V.] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Tu, Jack V.] Univ Toronto, Sunnybrook Schulich Heart Ctr, Toronto, ON, Canada. [Natarajan, Madhu] Cardiac Care Network Ontario, Toronto, ON, Canada. RP Ivers, NM (reprint author), Womens Coll Hosp, Dept Family & Community Med, 77 Grenville St, Toronto, ON M5S1B3, Canada. EM noah.ivers@utoronto.ca FU Canadian Institutes for Health Research (CIHR); Department of Family and Community Medicine, University of Toronto; McMaster University; Canada Research Chair in Health Services Research; HSFO; Cardiac Care Network of Ontario (CCN); CIHR; Ontario Ministry of Health and Long-Term Care (MOHLTC) FX Dr Ivers is supported by Fellowship awards from the Canadian Institutes for Health Research (CIHR) and the Department of Family and Community Medicine, University of Toronto. Dr Schwalm is supported by a New Investigator award from McMaster University. Dr Tu is supported by a Canada Research Chair in Health Services Research and a Career Investigator Award from the HSFO.; This study was funded by the Cardiac Care Network of Ontario (CCN) and CIHR. Institute for Clinical Evaluative Sciences (ICES) and CCN are funded by the Ontario Ministry of Health and Long-Term Care (MOHLTC). CCN serves as system support to the MOHLTC, Local Health Integration Networks, and service providers and is dedicated to improving quality, efficiency, access, and equity in the delivery of the continuum of adult cardiac services in Ontario. The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by CCN, ICES, or the Ontario MOHLTC is intended or should be inferred. NR 40 TC 9 Z9 10 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0828-282X EI 1916-7075 J9 CAN J CARDIOL JI Can. J. Cardiol. PD NOV PY 2013 VL 29 IS 11 BP 1408 EP 1414 DI 10.1016/j.cjca.2013.04.009 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 242VG UT WOS:000326270800012 PM 23816280 ER PT J AU Cohen, E Spiegel, B AF Cohen, Erica Spiegel, Brennan TI Limited Evidence for the Existence of Postdiverticulitis Irritable Bowel Syndrome Reply SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Letter ID DIVERTICULAR-DISEASE C1 [Cohen, Erica; Spiegel, Brennan] Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. RP Cohen, E (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA. NR 5 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD NOV PY 2013 VL 11 IS 11 BP 1521 EP 1522 DI 10.1016/j.cgh.2013.08.005 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 235YS UT WOS:000325759900030 PM 23954651 ER PT J AU Kemmerly, T Kaunitz, JD AF Kemmerly, Thomas Kaunitz, Jonathan D. TI Gastroduodenal mucosal defense SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Review DE apoptosis; gastrointestinal defense; Helicobacter pylori; mucins; oxidative stress ID INDUCED GASTRIC-ULCER; HELICOBACTER-PYLORI; CYCLOOXYGENASE INHIBITORS; ANTIINFLAMMATORY DRUGS; OXIDATIVE STRESS; RATS; INDOMETHACIN; DAMAGE; CYSTEAMINE; EXPRESSION AB Purpose of reviewTo review recent developments in the field of gastroduodenal mucosal defense.Recent findingsResearch in the field of gastroduodenal mucosal defense has focused on continued elucidation of molecular mechanisms that protect the mucosa and influence healing at the cellular level. Review of literature over the past year reveals focus on familiar processes such as superoxide dismutase, nitric oxide, heme oxygenase-1, neutrophil infiltration, cysteamine, mucin, hydrogen sulfide, ghrelin, adiponectin and the influence of Helicobacter pylori, but also brings into light new processes such as the balance between apoptosis and cellular proliferation, as well as the influence of other organ systems such as the bone marrow and central nervous system on the gastrointestinal tract.SummaryThese new published findings contribute to our overall understanding of gastroduodenal defense and suggest innovative avenues of future research and possible novel therapeutic targets. C1 [Kemmerly, Thomas] Cedars Sinai Med Residency Program, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Greater Angeles Veteran Affairs Healthcare Syst, WLAVA Med Ctr, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA 90024 USA. [Kaunitz, Jonathan D.] CURE, Digest Dis Res Ctr, Dept Med, Los Angeles, CA USA. [Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA USA. RP Kaunitz, JD (reprint author), W Los Angeles Vet Affairs Med Ctr, Bldg 114,Room 217E, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU BLRD VA [I01 BX001245] NR 33 TC 6 Z9 9 U1 0 U2 22 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 EI 1531-7056 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2013 VL 29 IS 6 BP 642 EP 649 DI 10.1097/MOG.0b013e328365d42e PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 247AH UT WOS:000326583900011 PM 24100725 ER PT J AU Abraham, NS Castillo, DL AF Abraham, Neena S. Castillo, Diana L. TI Novel anticoagulants: bleeding risk and management strategies SO CURRENT OPINION IN GASTROENTEROLOGY LA English DT Review DE acute gastrointestinal hemorrhage; apixaban; dabigatran; endoscopy ID ACUTE CORONARY SYNDROME; NONVALVULAR ATRIAL-FIBRILLATION; FACTOR XA INHIBITOR; ORAL ANTICOAGULANTS; ANTIPLATELET THERAPY; NATIONWIDE COHORT; PREDICTING STROKE; TASK-FORCE; DABIGATRAN; APIXABAN AB Purpose of reviewTo quantify the novel oral anticoagulant (NOAC)-related gastrointestinal bleeding, summarize the management strategies and highlight the knowledge gaps.Recent findingsDabigatran, rivaroxaban and apixaban differ from warfarin with their fixed oral dose and no requirement for routine monitoring. Patients at highest risk of thromboembolism benefit most from NOACs; however, there is a clinically significant risk for NOAC-related gastrointestinal bleeding. The management of NOACs in the acute and elective setting differs from that used with warfarin.SummaryThe magnitude of gastrointestinal risk is still unclear because of paucity of literature. Current risk-stratification models are incomplete and cannot be used solely to predict future risk. The periendoscopic management requires an understanding of drug half-life, metabolism and patient's ability to excrete the agent. Acute bleeding management relies on fluid resuscitation to promote renal excretion of active metabolite, withholding the doses and timely management of endoscopic stigmata. The administration of coagulation factors (fresh frozen plasma, prothrombin complex concentrates or recombinant activated FVII) is more successful in reversing the activity of the upstream inhibitors of coagulation (rivaroxaban and apixaban) than dabigatran which is a direct thrombin inhibitor. C1 [Abraham, Neena S.] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Scottsdale, AZ 85259 USA. [Castillo, Diana L.] Houston Hlth Serv Res & Dev Ctr Excellence, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. RP Abraham, NS (reprint author), Mayo Clin, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA. EM abraham.neena@mayo.edu NR 27 TC 11 Z9 11 U1 0 U2 21 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0267-1379 EI 1531-7056 J9 CURR OPIN GASTROEN JI Curr. Opin. Gastroenterol. PD NOV PY 2013 VL 29 IS 6 BP 676 EP 683 DI 10.1097/MOG.0b013e328365d415 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 247AH UT WOS:000326583900015 PM 24100724 ER PT J AU Recht, M Liel, MS Turner, RT Klein, RF Taylor, JA AF Recht, M. Liel, M. S. Turner, R. T. Klein, R. F. Taylor, J. A. TI The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption SO HAEMOPHILIA LA English DT Article DE factor VIII deficiency; osteopenia; osteoporosis ID SEVERE HEMOPHILIA; OSTEOCLAST DIFFERENTIATION; ACTIVATED RECEPTOR-1; CYTOKINE EXPRESSION; MINERAL DENSITY; OSTEOPOROSIS; THROMBIN; OSTEOPROTEGERIN; OSTEOBLASTS; INVOLVEMENT AB Osteopenia and osteoporosis have increasingly become a recognized morbidity of factor VIII (FVIII) deficiency. Recently, we demonstrated that FVIII knockout (KO) mice had significantly decreased bone mass and bone strength despite the fact that they did not have haemarthroses. The aim of this study was to explore the mechanism of bone disease associated with FVIII deficiency. We compared biochemical markers of bone formation and osteoclastogenesis, inflammatory cytokines, as well as static and dynamic histomorphometry of genetically engineered FVIII KO male mice to those of wild-type (WT) controls. At 20weeks of age, FVIII KO mice, as well as WT controls, were sacrificed. Serum and bones were obtained at the time of sacrifice to study biochemical markers of bone formation (osteocalcin) and osteoclastogenesis (receptor activator of nuclear factor kappa- and osteoprotegerin), levels of inflammatory cytokines (interleukin-1 and interferon-) and to perform static and dynamic histomorphometry of tibia cancellous bone. There was no difference in the biochemical markers of bone formation or osteoclastogenesis. However, there were differences in the two bone-associated cytokines studied. In addition, histomorphometric examination revealed cancellous osteopenia in FVIII KO mice as evidenced by decreased bone area and trabecular number and increased trabecular separation. Bone formation parameters were normal in FVIII KO mice. In contrast, osteoclast-lined bone perimeter was increased. These data demonstrate that bone disease in FVIII KO mice is due to an increased rate of bone resorption. C1 [Recht, M.; Liel, M. S.; Taylor, J. A.] Oregon Hlth & Sci Univ, Hemophilia Ctr, Portland, OR 97239 USA. [Liel, M. S.; Taylor, J. A.] Portland VA Med Ctr, Portland, OR USA. [Turner, R. T.] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA. [Klein, R. F.] Oregon Hlth & Sci Univ, Div Endocrinol, Bone & Mineral Res Unit, Portland, OR 97239 USA. RP Recht, M (reprint author), Oregon Hlth & Sci Univ, Hemophilia Ctr, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM rechtm@ohsu.edu FU CSL Behring Foundation; The Hemophilia Center at OHSU FX We thank Emily Larson and Sigrid Holmgren for their technical assistance. This research was funded by a pilot grant from the CSL Behring Foundation and The Hemophilia Center at OHSU. NR 28 TC 10 Z9 10 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-8216 EI 1365-2516 J9 HAEMOPHILIA JI Haemophilia PD NOV PY 2013 VL 19 IS 6 BP 908 EP 912 DI 10.1111/hae.12195 PG 5 WC Hematology SC Hematology GA 240NZ UT WOS:000326105100039 PM 23731369 ER PT J AU Buehring, B Viswanathan, R Binkley, N Busse, W AF Buehring, Bjoern Viswanathan, Ravi Binkley, Neil Busse, William TI Glucocorticoid-induced osteoporosis: An update on effects and management SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Glucocorticoid; inhaled and oral corticosteroid; asthma; growth; osteoporosis; bisphosphonates ID BONE-MINERAL DENSITY; INHALED BECLOMETHASONE DIPROPIONATE; LONG-TERM TREATMENT; ADULT HEIGHT; FLUTICASONE PROPIONATE; ASTHMATIC-CHILDREN; OFFICIAL POSITIONS; CORTICOSTEROID USE; CHILDHOOD ASTHMA; SECONDARY OSTEOPOROSIS AB Glucocorticoids remain a cornerstone of guideline-based management of persistent asthma and allergic diseases. Glucocorticoid-induced osteoporosis (GIO) is the most common iatrogenic cause of secondary osteoporosis and an issue of concern for physicians treating patients with inhaled or oral glucocorticoids either continuously or intermittently. Patients with GIO experience fragility fractures at better dual-energy x-ray absorptiometry T-scores than those with postmenopausal or age-related osteoporosis. This might be explained, at least in part, by the effects of glucocorticoids not only on osteoclasts but also on osteoblasts and osteocytes. Effective options to detect and manage GIO exist, and a management algorithm has been published by the American College of Rheumatology to provide treatment guidance for clinicians. This review will summarize GIO epidemiology and pathophysiology and assess the role of inhaled and oral glucocorticoids in asthmatic adults and children, with particular emphasis on the effect of such therapies on bone health. Lastly, we will review the American College of Rheumatology GIO guidelines and discuss diagnostic and therapeutic strategies to mitigate the risk of GIO and fragility fractures. C1 [Buehring, Bjoern; Binkley, Neil] Univ Wisconsin, Sch Med & Publ Hlth, Osteoporosis Res Program, Div Geriatr & Gerontol, Madison, WI 53705 USA. [Buehring, Bjoern; Binkley, Neil] William S Middleton Mem Vet Adm Med Ctr, GRECC, Madison, WI USA. [Viswanathan, Ravi; Busse, William] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Sect Allergy Pulm & Crit Care, Madison, WI 53705 USA. RP Buehring, B (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Osteoporosis Res Program, Sect Geriatr & Gerontol,Dept Med, 2870 Univ Ave,Suite 100, Madison, WI 53705 USA. EM bbuehring@medicine.wisc.edu; rviswanathan@medicine.wisc.edu RI Buehring, Bjoern/L-5581-2013 OI Buehring, Bjoern/0000-0003-3841-624X FU Merck; Lilly; Amgen; Novartis; GlaxoSmithKline; MedImmune; Genentech; Boston Scientific; ICON; National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases; NIH/National Heart, Lung, and Blood Institute FX N. Binkley has consultant arrangements with Merck and Lilly and has received grants from Merck, Lilly, and Amgen. W. Busse is on the Merck Board; has received consultancy fees from Amgen, Novartis, GlaxoSmithKline, MedImmune, Genentech, Boston Scientific, and ICON; has received research support from the National Institutes of Health (NIH)/National Institutes of Allergy and Infectious Diseases and the NIH/National Heart, Lung, and Blood Institute; and has received royalties from Elsevier. The rest of the authors declare they have no relevant conflicts of interest. NR 92 TC 38 Z9 40 U1 0 U2 17 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 EI 1097-6825 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD NOV PY 2013 VL 132 IS 5 BP 1019 EP 1030 DI 10.1016/j.jaci.2013.08.040 PG 12 WC Allergy; Immunology SC Allergy; Immunology GA 242JH UT WOS:000326235600001 PM 24176682 ER PT J AU Hatano, H Strain, MC Scherzer, R Bacchetti, P Wentworth, D Hoh, R Martin, JN McCune, JM Neaton, JD Tracy, RP Hsue, PY Richman, DD Deeks, SG AF Hatano, Hiroyu Strain, Matthew C. Scherzer, Rebecca Bacchetti, Peter Wentworth, Deborah Hoh, Rebecca Martin, Jeffrey N. McCune, Joseph M. Neaton, James D. Tracy, Russell P. Hsue, Priscilla Y. Richman, Douglas D. Deeks, Steven G. TI Increase in 2-Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE HIV; raltegravir intensification; 2-LTR circles; ongoing viral replication; D-dimer ID T-CELL-ACTIVATION; ANTIRETROVIRAL THERAPY; DISEASE PROGRESSION; IMMUNE ACTIVATION; COAGULATION; ADULTS; AIDS; REPLICATION; SUPPRESSION; MARKERS AB Background. The degree to which human immunodeficiency virus (HIV) continues to replicate during antiretroviral therapy (ART) is controversial. We conducted a randomized, double-blind, placebo-controlled study to assess whether raltegravir intensification reduces low-level viral replication, as defined by an increase in the level of 2-long terminal repeat (2-LTR) circles. Methods. Thirty-one subjects with an ART-suppressed plasma HIV RNA level of <40 copies/mL and a CD4(+) T-cell count of >= 350 cells/mm(3) for >= 1 year were randomly assigned to receive raltegravir 400 mg twice daily or placebo for 24 weeks. 2-LTR circles were analyzed by droplet digital polymerase chain reaction at weeks 0, 1, 2, and 8. Results. The median duration of ART suppression was 3.8 years. The raltegravir group had a significant increase in the level of 2-LTR circles, compared to the placebo group. The week 1 to 0 ratio was 8.8-fold higher (P = .0025) and the week 2 to 0 ratio was 5.7-fold higher (P = .023) in the raltegravir vs. placebo group. Intensification also led to a statistically significant decrease in the D-dimer level, compared to placebo (P = .045). Conclusions. Raltegravir intensification resulted in a rapid increase in the level of 2-LTR circles in a proportion of subjects, indicating that low-level viral replication persists in some individuals even after long-term ART. Intensification also reduced the D-dimer level, a coagulation biomarker that is predictive of morbidity and mortality among patients receiving treatment for HIV infection. C1 [Hatano, Hiroyu; Scherzer, Rebecca; Hoh, Rebecca; McCune, Joseph M.; Hsue, Priscilla Y.; Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Bacchetti, Peter; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Scherzer, Rebecca] San Francisco VA Med Ctr, Dept Med, San Diego, CA USA. [Strain, Matthew C.; Richman, Douglas D.] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA. [Strain, Matthew C.; Richman, Douglas D.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Wentworth, Deborah; Neaton, James D.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA. [Tracy, Russell P.] Univ Vermont, Dept Pathol, Colchester, Essex, England. [Tracy, Russell P.] Univ Vermont, Dept Biochem, Colchester, Essex, England. RP Hatano, H (reprint author), San Francisco Gen Hosp, Bldg 80,Ward 84,995 Potrero Ave, San Francisco, CA 94110 USA. EM hhatano@php.ucsf.edu FU National Institute of Allergy and Infectious Diseases [R01 AI087145, K24 AI069994, AI080193, AI69432, AI047745, AI74621]; Delaney AIDS Research Enterprise [U19 AI0961090]; Collaboratory for AIDS Research on Eradication [U19 AI096113]; National Heart Lung and Blood Institute [R01 HL095130]; American Foundation for AIDS Research [106710-40-RGRL]; UCSF/Gladstone Institute of Virology & Immunology Center for AIDS Research (CFAR) [P30 AI027763]; University of California, San Diego, CFAR [AI306214]; University of California, San Francisco, Clinical and Translational Research Institute Clinical Research Center [UL1 RR024131]; Center for AIDS Prevention Studies [P30 MH62246]; CFAR Network of Integrated Systems [R24 AI067039]; Department of Veterans Affairs FX This work was supported by the National Institute of Allergy and Infectious Diseases (grants R01 AI087145, K24 AI069994, AI080193, AI69432, AI047745, and AI74621); the Delaney AIDS Research Enterprise (grant U19 AI0961090); the Collaboratory for AIDS Research on Eradication (grant U19 AI096113); the National Heart Lung and Blood Institute (grant R01 HL095130); the American Foundation for AIDS Research (grant 106710-40-RGRL); the UCSF/Gladstone Institute of Virology & Immunology Center for AIDS Research (CFAR; grant P30 AI027763); the University of California, San Diego, CFAR (grant AI306214); the University of California, San Francisco, Clinical and Translational Research Institute Clinical Research Center (grant UL1 RR024131); the Center for AIDS Prevention Studies (grant P30 MH62246); the CFAR Network of Integrated Systems (grant R24 AI067039); and the Department of Veterans Affairs. NR 36 TC 70 Z9 70 U1 1 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2013 VL 208 IS 9 BP 1436 EP 1442 DI 10.1093/infdis/jit453 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 244HD UT WOS:000326377500013 PM 23975885 ER PT J AU Cheng, SJ Clancy, CJ Xu, WJ Schneider, F Hao, BH Mitchell, AP Nguyen, MH AF Cheng, Shaoji Clancy, Cornelius J. Xu, Wenjie Schneider, Frank Hao, Binghua Mitchell, Aaron P. Hong Nguyen, M. TI Profiling of Candida albicans Gene Expression During Intra-abdominal Candidiasis Identifies Biologic Processes Involved in Pathogenesis SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Candida albicans; intra-abdominal candidiasis; in vivo gene expression; nanoString; RIM101; SAP5 ID SECRETED ASPARTYL PROTEINASES; ABSCESS FORMATION; SURGICAL PATIENTS; VIRULENCE GENE; INFECTION; PERITONITIS; PH; INVASION; MODEL; DEGRADATION AB Background. The pathogenesis of intra-abdominal candidiasis is poorly understood. Methods. Mice were intraperitoneally infected with Candida albicans (1 x 106 colony-forming units) and sterile stool. nanoString assays were used to quantitate messenger RNA for 145 C. albicans genes within the peritoneal cavity at 48 hours. Results. Within 6 hours after infection, mice developed peritonitis, characterized by high yeast burdens, neutrophil influx, and a pH of 7.9 within peritoneal fluid. Organ invasion by hyphae and early abscess formation were evident 6 and 24 hours after infection, respectively; abscesses resolved by day 14. nanoString assays revealed adhesion and responses to alkaline pH, osmolarity, and stress as biologic processes activated in the peritoneal cavity. Disruption of the highly-expressed gene RIM101, which encodes an alkaline-regulated transcription factor, did not impact cellular morphology but reduced both C. albicans burden during early peritonitis and C. albicans persistence within abscesses. RIM101 influenced expression of 49 genes during intra-abdominal candidiasis, including previously unidentified Rim101 targets. Overexpression of the RIM101-dependent gene SAP5, which encodes a secreted protease, restored the ability of a rim101 mutant to persist within abscesses. Conclusions. A mouse model of intra-abdominal candidiasis is valuable for studying pathogenesis and C. albicans gene expression. RIM101 contributes to persistence within intra-abdominal abscesses, at least in part through activation of SAP5. C1 [Cheng, Shaoji; Clancy, Cornelius J.; Hao, Binghua; Hong Nguyen, M.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15203 USA. [Schneider, Frank] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15203 USA. [Clancy, Cornelius J.] VA Pittsburgh Hlth Syst, Med Serv, Pittsburgh, PA USA. [Xu, Wenjie; Mitchell, Aaron P.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA. RP Clancy, CJ (reprint author), Univ Pittsburgh, Scaife Hall,Ste 871, Pittsburgh, PA 15203 USA. EM cjc76@pitt.edu OI Mitchell, Aaron/0000-0002-0868-4000 FU Department of Medicine, University of Pittsburgh; National Institutes of Health [R01 AI070272] FX This work was supported by the Department of Medicine, University of Pittsburgh (to C. J. C. and M. H. N.) and the National Institutes of Health (grant R01 AI070272 to A. P. M.). NR 43 TC 20 Z9 20 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD NOV 1 PY 2013 VL 208 IS 9 BP 1529 EP 1537 DI 10.1093/infdis/jit335 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 244HD UT WOS:000326377500025 PM 24006479 ER PT J AU Harrington, AT Peltier, C Hwang, S Clarridge, JE AF Harrington, A. T. Peltier, C. Hwang, S. Clarridge, J. E. TI Comparison of Two Sample-to-Result Nucleic Acid Detection Methods for the Detection of Toxigenic Clostridium difficile in Clinical Stool Specimens SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Molecular-Pathology (AMP) CY NOV 14-16, 2013 CL Phoenix, AZ SP Assoc Mol Pathol C1 [Harrington, A. T.; Peltier, C.; Hwang, S.; Clarridge, J. E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2013 VL 15 IS 6 BP 900 EP 900 PG 1 WC Pathology SC Pathology GA 248BF UT WOS:000326668000229 ER PT J AU Nham, P Moatamed, F Phan, RT AF Nham, P. Moatamed, F. Phan, R. T. TI A Low-Cost High-Throughput Multiple SNPs Simultaneous Genotyping (MSSG) Assay for Thrombophilia Risk Factors SO JOURNAL OF MOLECULAR DIAGNOSTICS LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Molecular-Pathology (AMP) CY NOV 14-16, 2013 CL Phoenix, AZ SP Assoc Mol Pathol C1 [Nham, P.; Moatamed, F.; Phan, R. T.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-1578 EI 1943-7811 J9 J MOL DIAGN JI J. Mol. Diagn. PD NOV PY 2013 VL 15 IS 6 BP 934 EP 934 PG 1 WC Pathology SC Pathology GA 248BF UT WOS:000326668000355 ER PT J AU Lakin, JR Smith, AK AF Lakin, Joshua R. Smith, Alexander K. TI Opening It Up For More Questions: Racial Disparities in Hospice Use SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT LA English DT Editorial Material C1 [Lakin, Joshua R.] Univ Calif San Francisco, Palliat Care Program, San Francisco, CA 94143 USA. [Lakin, Joshua R.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. EM aksmith@ucsf.edu FU NIA NIH HHS [K23 AG040772, P30 AG044281] NR 2 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0885-3924 EI 1873-6513 J9 J PAIN SYMPTOM MANAG JI J. Pain Symptom Manage. PD NOV PY 2013 VL 46 IS 5 BP 617 EP 617 DI 10.1016/j.jpainsymman.2013.06.001 PG 1 WC Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology SC Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology GA 242JQ UT WOS:000326236900004 PM 23953597 ER PT J AU Morris, BJ Krieger, JN AF Morris, Brian J. Krieger, John N. TI Does Male Circumcision Affect Sexual Function, Sensitivity, or Satisfaction?-A Systematic Review SO JOURNAL OF SEXUAL MEDICINE LA English DT Review DE Circumcision; Erectile Function; Sexual Satisfaction; Premature Ejaculation; Ejaculatory Latency; Penile Sensitivity; Penile Sensation; Male Sexual Function and Pleasure ID DECREASES PENILE SENSITIVITY; LIFELONG PREMATURE EJACULATION; TOUCH PRESSURE THRESHOLDS; MUCOSAL CUFF LENGTH; LARGE COHORT; LATENCY TIME; ADULT PENIS; MEN; PREVALENCE; HEALTH AB IntroductionCircumcision of males is commonly carried out worldwide for reasons of health, medical need, esthetics, tradition, or religion. Whether circumcision impairs or improves male sexual function or pleasure is controversial. AimsThe study aims to conduct a systematic review of the scientific literature. MethodsA systematic review of published articles retrieved using keyword searches of the PubMed, EMBASE, and Cochrane databases was performed. Main Outcome MeasuresThe main outcome measure is the assessment of findings in publications reporting original data relevant to the search terms and rating of quality of each study based on established criteria. ResultsSearches identified 2,675 publications describing the effects of male circumcision on aspects of male sexual function, sensitivity, sensation, or satisfaction. Of these, 36 met our inclusion criteria of containing original data. Those studies reported a total of 40,473 men, including 19,542 uncircumcised and 20,931 circumcised. Rated by the Scottish Intercollegiate Guidelines Network grading system, 2 were 1++ (high quality randomized controlled trials) and 34 were case-control or cohort studies (11 high quality: 2++; 10 well-conducted: 2+; 13 low quality: 2-). The 1++, 2++, and 2+ studies uniformly found that circumcision had no overall adverse effect on penile sensitivity, sexual arousal, sexual sensation, erectile function, premature ejaculation, ejaculatory latency, orgasm difficulties, sexual satisfaction, pleasure, or pain during penetration. Support for these conclusions was provided by a meta-analysis. Impairment in one or more parameters was reported in 10 of the 13 studies rated as 2-. These lower-quality studies contained flaws in study design (11), selection of cases and/or controls (5), statistical analysis (4), and/or data interpretation (6); five had multiple problems. ConclusionThe highest-quality studies suggest that medical male circumcision has no adverse effect on sexual function, sensitivity, sexual sensation, or satisfaction. Morris BJ and Krieger JN. Does male circumcision affect sexual function, sensitivity, or satisfaction?A systematic review. J Sex Med 2013;10:2644-2657. C1 [Morris, Brian J.] Univ Sydney, Sch Med Sci, Sydney, NSW 2006, Australia. [Krieger, John N.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA. [Krieger, John N.] VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA. RP Morris, BJ (reprint author), Univ Sydney, Sch Med Sci, Bldg F13, Sydney, NSW 2006, Australia. EM brian.morris@sydney.edu.au NR 59 TC 38 Z9 39 U1 5 U2 27 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD NOV PY 2013 VL 10 IS 11 BP 2644 EP 2657 DI 10.1111/jsm.12293 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA 245LT UT WOS:000326465900005 PM 23937309 ER PT J AU Dai, Y Gu, LY Yuan, WJ Yu, Q Ni, ZH Ross, MJ Kaufman, L Xiong, HB Salant, DJ He, JC Chuang, PY AF Dai, Yan Gu, Leyi Yuan, Weijie Yu, Qing Ni, Zhaohui Ross, Michael J. Kaufman, Lewis Xiong, Huabao Salant, David J. He, John C. Chuang, Peter Y. TI Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis SO KIDNEY INTERNATIONAL LA English DT Article DE glomerulonephritis; glomerulus; podocyte; proliferation; signaling ID PROGRESSIVE CRESCENTIC GLOMERULONEPHRITIS; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; COLLAPSING GLOMERULOPATHY; EXPRESSION; INJURY; MOUSE; STAT3; MICE; NEPHROPATHY; PROLIFERATION AB Activation of signal transducer and activator of transcription (STAT) 3 correlates with proliferation of extracapillary glomerular epithelial cells and the extent of renal injury in glomerulonephritis. To delineate the role of STAT3 in glomerular epithelial cell proliferation, we examined the development of nephrotoxic serum-induced glomerulonephritis in mice with and without podocyte-restricted STAT3 deletion. Mice with STAT3 deletion in podocytes developed less crescents and loss of renal function compared with those without STAT3 deletion. Proliferation of glomerular cells, loss of podocyte markers, and recruitment of parietal epithelial cells were found in nephritic mice without STAT3 deletion, but mitigated in nephritic mice with podocyte STAT3 deletion. Glomerular expression of pro-inflammatory STAT3 target genes was significantly reduced in nephritic mice with, compared with those without, podocyte STAT3 deletion. However, the extent of glomerular immune complex deposition was not different. Podocytes with STAT3 deletion were resistant to interleukin-6-induced STAT3 phosphorylation and pro-inflammatory STAT3 target gene expression. Thus, podocyte STAT3 activation is critical for the development of crescentic glomerulonephritis. C1 [Dai, Yan; Ross, Michael J.; Kaufman, Lewis; He, John C.; Chuang, Peter Y.] Mt Sinai Sch Med, Dept Med, Div Nephrol, New York, NY 10029 USA. [Dai, Yan; Yuan, Weijie; Yu, Qing] Shanghai Jiao Tong Univ, Sch Med, Div Nephrol, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China. [Gu, Leyi; Ni, Zhaohui] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Renal, Shanghai 200030, Peoples R China. [Gu, Leyi; Ni, Zhaohui] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Mol Cell Lab Kidney Dis, Shanghai 200030, Peoples R China. [Xiong, Huabao] Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA. [Salant, David J.] Boston Univ, Renal Sect, Boston, MA 02215 USA. [He, John C.] James J Peters Vet Affairs Med Ctr, Renal Sect, Bronx, NY USA. RP Chuang, PY (reprint author), Mt Sinai Sch Med, Dept Med, Div Nephrol, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. EM peter.chuang@mssm.edu FU NIH [1R01DK078897, 1R01DK088541-01A1, 5K08DK082760]; Veterans Affairs Merit Review Award [1I01BX000345]; Chinese 973 Fund [2012CB517601] FX We thank Pete Mundel (Massachusetts General Hospital, Boston) for sharing cultured conditionally immortalized podocytes. JCH is supported by NIH 1R01DK078897 and 1R01DK088541-01A1 and a Veterans Affairs Merit Review Award 1I01BX000345; PYC is supported by NIH 5K08DK082760. LG, ZN, and JCH are supported by Chinese 973 Fund 2012CB517601. NR 42 TC 14 Z9 14 U1 0 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD NOV PY 2013 VL 84 IS 5 BP 950 EP 961 DI 10.1038/ki.2013.197 PG 12 WC Urology & Nephrology SC Urology & Nephrology GA 245YG UT WOS:000326500400016 PM 23842188 ER PT J AU Mehrotra, R Peralta, CA Chen, SC Li, SY Sachs, M Shah, A Norris, K Saab, G Whaley-Connell, A Kestenbaum, B McCullough, PA AF Mehrotra, Rajnish Peralta, Carmen A. Chen, Shu-Cheng Li, Suying Sachs, Michael Shah, Anuja Norris, Keith Saab, Georges Whaley-Connell, Adam Kestenbaum, Bryan McCullough, Peter A. CA Kidney Early Evaluation Program TI No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease SO KIDNEY INTERNATIONAL LA English DT Article DE barrier to care; cardiovascular disease; chronic kidney disease; end-stage renal disease; mortality; phosphorus ID CORONARY-ARTERY CALCIFICATION; VASCULAR CALCIFICATION; PHOSPHATE CONCENTRATIONS; SOCIOECONOMIC-STATUS; MINERAL METABOLISM; MORTALITY; CALCIUM; DIALYSIS; ATHEROSCLEROSIS; RESTRICTION AB Whether higher serum phosphorus levels are associated with a higher risk for death and/or progression of chronic kidney disease (CKD) is not well established, and whether the association is confounded by access and barriers to care is unknown. To answer these questions, data of 10,672 individuals identified to have CKD (estimated glomerular filtration rate <60 ml/min per 1.73 m(2)) from those participating in a community-based screening program were analyzed. Over a median follow-up of 2.3 years, there was no association between quartiles of serum phosphorus and all-cause mortality (adjusted hazards ratio for serum phosphorus over 3.3 to 3.7, over 3.7 to 4.1, and over 4.1 mg/dl, respectively: 1.22 (0.95-1.56), 1.00 (0.76-1.32), and 1.00 (0.75-1.33); reference, serum phosphorus of 3.3 mg/dl and below). Individuals in the highest quartile for serum phosphorus had a significantly higher risk for progression to end-stage renal disease (ESRD) (unadjusted hazards ratio, 6.72 (4.16-10.85)); however, the risk became nonsignificant on adjustment for potential confounders. There was no appreciable change in hazards ratio with inclusion of variables related to access and barriers to care. Additional analyses in subgroups based on 12 different variables yielded similar negative associations. Thus, in the largest cohort of individuals with early-stage CKD to date, we could not validate an independent association of serum phosphorus with risk for death or progression to ESRD. C1 [Mehrotra, Rajnish; Sachs, Michael; Kestenbaum, Bryan] Univ Washington, Kidney Res Inst, Seattle, WA 98104 USA. [Mehrotra, Rajnish; Sachs, Michael; Kestenbaum, Bryan] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA. [Peralta, Carmen A.] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94143 USA. [Chen, Shu-Cheng; Li, Suying] Chron Dis Res Grp, Minneapolis, MN USA. [Shah, Anuja] Harbor UCLA, Los Angeles Biomed Res Inst, Torrance, CA USA. [Norris, Keith] Charles Drew Univ, Los Angeles, CA USA. [Saab, Georges] Metro Hlth Med Ctr, Cleveland, OH USA. [Whaley-Connell, Adam] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA. [Whaley-Connell, Adam] Univ Missouri, Columbia Sch Med, Columbia, MO USA. [McCullough, Peter A.] St John Providence Hlth Syst, Providence Hosp & Med Ctr, Southfield, MI USA. [McCullough, Peter A.] St John Providence Hlth Syst, Providence Hosp & Med Ctr, Novi, MI USA. RP Mehrotra, R (reprint author), Univ Washington, Div Nephrol, 325 9th Ave,Box 359606, Seattle, WA 98104 USA. EM rmehrotr@uw.edu OI Whaley-Connell, Adam/0000-0001-8955-5560 FU NIH [U54MD007598, UL1TR000124, P30AG021684, P20MD000182]; [RO1DK95668] FX RM is supported by RO1DK95668. KN is supported in part by NIH grants U54MD007598, UL1TR000124, P30AG021684, and P20MD000182. NR 36 TC 23 Z9 24 U1 0 U2 18 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0085-2538 EI 1523-1755 J9 KIDNEY INT JI Kidney Int. PD NOV PY 2013 VL 84 IS 5 BP 989 EP 997 DI 10.1038/ki.2013.145 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA 245YG UT WOS:000326500400020 PM 23615501 ER PT J AU Henriquez, OA Schlosser, RJ Mace, JC Smith, TL Soler, ZM AF Henriquez, Oswaldo A. Schlosser, Rodney J. Mace, Jess C. Smith, Timothy L. Soler, Zachary M. TI Impact of Synechiae After Endoscopic Sinus Surgery on Long-Term Outcomes in Chronic Rhinosinusitis SO LARYNGOSCOPE LA English DT Article DE Chronic; sinusitis; outcomes; assessment AB Objectives/HypothesisSynechiae are one of the most common unwanted outcomes after endoscopic sinus surgery (ESS) for chronic rhinosinusitis (CRS). However, there has been scant investigation into the true significance of synechiae formation after ESS. The aim of this study was to evaluate the impact of synechiae formation on health-related quality of life (HRQoL) outcomes after ESS in patients with CRS. Study DesignProspective, multi-institutional cohort. MethodsRhinosinusitis Disability Index (RSDI) and Chronic Sinusitis Survey (CSS) scores were measured in adult patients before and after undergoing ESS for CRS. Differences in HRQoL were evaluated between those who developed sinonasal synechiae and those who did not, controlling for demographic factors, medical comorbidities, and measures of disease severity at baseline. ResultsA total of 286 patients underwent ESS, with 55 (19.2%) developing synechiae in the follow-up period. Patients developing synechiae reported significantly less improvement on the RSDI total scores (13.5 vs. 21.4, P=0.008), RSDI physical subscores (5.3 vs. 8.3, P=0.007), RSDI emotional subscores (2.9 vs. 5.8, P = 0.008), CSS total scores (14.5 vs. 21.2, P = 0.093), and CSS symptom subscores (19.9 vs 30.3, P = 0.069) compared to those who did not develop synechiae postoperatively. These differences persisted even after controlling for baseline differences in disease severity. ConclusionsSynechiae of the sinonasal cavity commonly occurs following ESS, particularly in those undergoing revision surgeries. Although both groups improve, the degree of HRQoL improvement appears to be less in those who form postoperative synechiae after surgery compared to those who do not. C1 [Henriquez, Oswaldo A.; Schlosser, Rodney J.; Soler, Zachary M.] Med Univ S Carolina, Div Rhinol & Sinus Surg, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. [Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA. [Mace, Jess C.; Smith, Timothy L.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Div Rhinol & Sinus Surg, Oregon Sinus Ctr, Portland, OR 97201 USA. RP Soler, ZM (reprint author), Med Univ S Carolina, Div Rhinol & Sinus Surg, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA. EM solerz@musc.edu FU National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health, Bethesda, MD [2R01 DC005805]; VA Merit; NeilMed; Medtronic; Arthrocare FX Zachary M. Soler, MD, MSc Jess C. Mace, MPH, and Timothy L. Smith, MD, MPH are supported by a grant from the National Institute on Deafness and Other Communication Disorders (NIDCD), one of the National Institutes of Health, Bethesda, MD. (2R01 DC005805; PI: T. L. Smith). Public clinical trial registration ID#NCT01332136: (http://www.clinicaltrials.gov). Timothy L. Smith, MD is also a consultant for Intersect ENT (Palo Alto, CA.), which is not affiliated in any way with this investigation. Rodney J. Schlosser, MD is a consultant for Brain-LAB, Olympus, and Sunovion and receives grant support from a VA Merit, NeilMed, Medtronic, and Arthrocare. None of these are affiliated with this study. The authors have no other funding, financial relationships, or conflicts of interest to disclose. NR 19 TC 9 Z9 10 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD NOV PY 2013 VL 123 IS 11 BP 2615 EP 2619 DI 10.1002/lary.24150 PG 5 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA 242IA UT WOS:000326231200018 PM 23670876 ER PT J AU Oates, JC Mashmoushi, AK Shaftman, SR Gilkeson, GS AF Oates, J. C. Mashmoushi, A. K. Shaftman, S. R. Gilkeson, G. S. TI NADPH oxidase and nitric oxide synthase-dependent superoxide production is increased in proliferative lupus nephritis SO LUPUS LA English DT Article DE Lupus nephritis; systemic lupus erythematosus; nitric oxide; endothelial nitric oxide synthase; NADPH oxidase; proliferative lupus nephritis; superoxide; oxidation-reduction; inflammation ID HUMAN ENDOTHELIAL-CELLS; MRL-LPR/LPR MICE; AUTOIMMUNE-DISEASE; OXIDATIVE STRESS; GENETIC-ANALYSIS; ERYTHEMATOSUS; GLOMERULONEPHRITIS; 3-NITROTYROSINE; EXPRESSION; TETRAHYDROBIOPTERIN AB Objective Lupus nephritis (LN) is an immune complex-mediated glomerulonephritis. Proliferative LN (PLN, ISN/RPS classes III and IV)) often leads to renal injury or failure despite traditional induction and maintenance therapy. Successful targeted therapeutic development requires insight into mediators of inflammation in PLN. Superoxide (SO) and its metabolites are mediators of the innate immune response through their ability to mediate reduction-oxidation signaling. Endothelial nitric oxide synthase (eNOS) modulates inflammatory responses in endothelial cells. We hypothesized that markers of SO production would be increased in active PLN and that SO production would be dependent on the activity of select enzymes in the renal cortex. Methods Patients with systemic lupus erythematosus were enrolled at the time of renal biopsy for active LN of all classes. Serum collected at baseline was analyzed by HPLC with electrochemical detection for markers of SO production (durable modifications of serum protein Tyr ultimately requiring SO as a substrate). Renal cortex from MRL/MpJ-FAS(lpr) (MRL/lpr) mice with and without functional eNOS was analyzed during active disease for superoxide (SO) production with and without inhibitors of SO-producing enzymes. Results Serum protein modifications indicative of total SO production were significantly higher in patients with PLN. These markers were increased in association with more active, inflammatory PLN. Mice lacking functional eNOS had 80% higher levels of renal cortical SO during active disease, and inhibitors of nitric oxide synthase and NADPH oxidase reduced these levels by 60% and 77%, respectively. Conclusion These studies demonstrate that SO production is unique to active PLN in a NOS and NADPH oxidase-dependent fashion. These findings suggest the emulating or augmenting eNOS activity or inhibiting NADPH oxidase SO production may be targets of therapy in patients with PLN. The markers of SO production used in this study could rationally be used to select SO-modulating therapies and serve as pharmacodynamic indicators for dose titration. C1 [Oates, J. C.; Mashmoushi, A. K.; Gilkeson, G. S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA. [Shaftman, S. R.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA. [Oates, J. C.; Gilkeson, G. S.] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA. RP Oates, JC (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol, 96 Jonathan Lucas St,MSC 637, Charleston, SC 29425 USA. EM oatesjc@musc.edu FU Arthritis Foundation, Atlanta, GA; University Research Committee at the Medical University of SC; Medical University of SC General Clinical Research Center [NIH] [MO1RR001070]; Medical University of SC Clinical and Translational Science Award [UL1TR000062, U54RR026107]; Division of Rheumatology and Immunology Multidisciplinary Clinical Research Center [P60AR062755]; National Institutes of Health [K08AR002193, AI047469, AR045476, AR04745]; Ralph H. Johnson VAMC Medical Research Service; Department of Veterans Affairs Career Development, Research Enhancement Awards FX This work was supported by the Arthritis Foundation, Atlanta, GA, the University Research Committee at the Medical University of SC, the Medical University of SC General Clinical Research Center [NIH grant number MO1RR001070], the Medical University of SC Clinical and Translational Science Award [grant number UL1TR000062, formerly U54RR026107], the Division of Rheumatology and Immunology Multidisciplinary Clinical Research Center [grant number P60AR062755], and National Institutes of Health [grant numbers K08AR002193, AI047469, AR045476, and AR04745], the Ralph H. Johnson VAMC Medical Research Service, and the Department of Veterans Affairs Career Development, Research Enhancement Awards. NR 47 TC 2 Z9 2 U1 0 U2 3 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0961-2033 EI 1477-0962 J9 LUPUS JI Lupus PD NOV PY 2013 VL 22 IS 13 BP 1361 EP 1370 DI 10.1177/0961203313507988 PG 10 WC Rheumatology SC Rheumatology GA 239GY UT WOS:000326011800006 PM 24106214 ER PT J AU Qiao, DH Meyer, K Friedl, A AF Qiao, Dianhua Meyer, Kristy Friedl, Andreas TI Glypican 1 Stimulates S Phase Entry and DNA Replication in Human Glioma Cells and Normal Astrocytes (Retracted article. See vol. 36, pg. 2105, 2016) SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article; Retracted Publication ID SKP2 AUTOINDUCTION LOOP; TRANSGENIC MICE; BRAIN CANCER; CYCLE; GLIOBLASTOMA; GENE; P53; INSTABILITY; INHIBITORS; STABILITY AB Malignant gliomas are highly lethal neoplasms with limited treatment options. We previously found that the heparan sulfate proteoglycan glypican 1 (GPC1) is universally and highly expressed in human gliomas. In this study, we investigated the biological activity of GPC1 expression in both human glioma cells and normal astrocytes in vitro. Expression of GPC1 inactivates the G(1)/S checkpoint and strongly stimulates DNA replication. Constitutive expression of GPC1 causes DNA rereplication and DNA damage, suggesting a mutagenic activity for GPC1. GPC1 expression leads to a significant downregulation of the tumor suppressors pRb, Cip/Kip cyclin-dependent kinase inhibitors (CKIs), and CDH1, and upregulation of the pro-oncogenic proteins cyclin E, cyclin-dependent kinase 2 (CDK2), Skp2, and Cdt1. These GPC1-induced changes are accompanied by a significant reduction in all types of D cyclins, which is independent of serum supplementation. It is likely that GPC1 stimulates the so-called Skp2 autoinduction loop, independent of cyclin D-CDK4/6. Knockdown of Skp2, CDK2, or cyclin E, three key elements within the network modulated by GPC1, results in a reduction of the S phase and aneuploid fractions, implying a functional role for these regulators in GPC1-induced S phase entry and DNA rereplication. In addition, a significant activation of both the extracellular signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways by GPC1 is seen in normal human astrocytes even in the presence of growth factor supplement. Both pathways are constitutively activated in human gliomas. The surprising magnitude and the mitogenic and mutagenic nature of the effect exerted by GPC1 on the cell cycle imply that GPC1 may play an important role in both glioma tumorigenesis and growth. C1 [Qiao, Dianhua; Meyer, Kristy; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA. [Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs Med Ctr, Madison, WI 53705 USA. [Friedl, Andreas] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA. RP Friedl, A (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA. EM afriedl@wisc.edu FU UWCCC [P30 CA014520]; Biomedical Laboratory Research and Development Service of the VA Office of Research and Development [I01BX000137] FX This work was supported by UWCCC core grant P30 CA014520 and by award number I01BX000137 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development. NR 45 TC 11 Z9 11 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 EI 1098-5549 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD NOV PY 2013 VL 33 IS 22 BP 4408 EP 4421 DI 10.1128/MCB.00238-13 PG 14 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA 240LX UT WOS:000326099000005 PM 24019070 ER PT J AU Heckman, TG Heckman, BD Anderson, T Lovejoy, TI Mohr, D Sutton, M Bianco, JA Gau, JT AF Heckman, Timothy G. Heckman, Bernadette D. Anderson, Timothy Lovejoy, Travis I. Mohr, David Sutton, Mark Bianco, Joseph A. Gau, Jen-Tzer TI Supportive-Expressive and Coping Group Teletherapies for HIV-Infected Older Adults: A Randomized Clinical Trial SO AIDS AND BEHAVIOR LA English DT Article DE HIV; AIDS; Teletherapy; Supportive-expressive group therapy; Coping ID COGNITIVE-BEHAVIOR THERAPY; METASTATIC BREAST-CANCER; CHILDHOOD SEXUAL-ABUSE; ANTIRETROVIRAL THERAPY; GROUP-PSYCHOTHERAPY; GROUP INTERVENTION; RURAL PERSONS; DEPRESSION; HIV/AIDS; OUTCOMES AB This clinical trial tested whether telephone-administered supportive-expressive group therapy or coping effectiveness training reduce depressive symptoms in HIV-infected older adults. Participants from 24 states (N = 361) completed the Geriatric Depression Scale at pre-intervention, post-intervention, and 4- and 8-month follow-up and were randomized to one of three study arms: (1) 12 weekly sessions of telephone-administered, supportive-expressive group therapy (tele-SEGT; n = 122); (2) 12 weekly sessions of telephone-administered, coping effectiveness training (tele-CET; n = 118); or (3) a standard of care (SOC) control group (n = 121). Tele-SEGT participants reported fewer depressive symptoms than SOC controls at post-intervention (M-SEGT = 11.9, M-SOC = 14.3) and 4- (M-SEGT = 12.5, M-SOC = 14.4) and 8-month follow-up (M-SEGT = 12.7, M-SOC = 14.5) and fewer depressive symptoms than tele-CET participants at post-intervention (M-SEGT = 12.4, M-CET = 13.6) and 8-month follow-up (M-SEGT = 12.7, M-CET = 14.1). Tele-CET participants reported no statistically significant differences from SOC controls in GDS values at any assessment period. Tele-SEGT constitutes an efficacious treatment to reduce depressive symptoms in HIV-infected older adults. C1 [Heckman, Timothy G.; Sutton, Mark; Gau, Jen-Tzer] Ohio Univ, Dept Geriatr Med Gerontol, Heritage Coll Osteopath Med, Athens, OH 45701 USA. [Heckman, Timothy G.; Sutton, Mark] Univ Georgia, Coll Publ Hlth, Coverdell Ctr 130D, Athens, GA 30602 USA. [Heckman, Bernadette D.; Anderson, Timothy] Ohio Univ, Dept Psychol, Athens, OH 45701 USA. [Heckman, Bernadette D.] Univ Georgia, Dept Counseling & Human Dev Serv, Athens, GA 30602 USA. [Lovejoy, Travis I.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR USA. [Mohr, David] Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL USA. [Bianco, Joseph A.] Ohio Univ, Dept Social Med, Heritage Coll Osteopath Med, Athens, OH 45701 USA. RP Heckman, TG (reprint author), Univ Georgia, Coll Publ Hlth, Coverdell Ctr 130D, 500 DW Brooks Dr, Athens, GA 30602 USA. EM heckman@uga.edu FU NCATS NIH HHS [UL1 TR000150]; NIMH NIH HHS [R01 MH078749] NR 45 TC 8 Z9 9 U1 2 U2 16 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD NOV PY 2013 VL 17 IS 9 BP 3034 EP 3044 DI 10.1007/s10461-013-0441-0 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 240QW UT WOS:000326113100018 PM 23474642 ER PT J AU Strobel, B McManus, L Leong, S Blow, F Slaymaker, V Berrettini, W Gordon, AJ O'Brien, C Oslin, D AF Strobel, Brittany McManus, Lauren Leong, Shirley Blow, Frederic Slaymaker, Valerie Berrettini, Wade Gordon, Adam J. O'Brien, Charles Oslin, David TI A Cross-Sectional Study of Attitudes About the Use of Genetic Testing for Clinical Care Among Patients with an Alcohol Use Disorder SO ALCOHOL AND ALCOHOLISM LA English DT Article ID MU-OPIOID-RECEPTOR; NALTREXONE RESPONSE; MALE TWINS; DEPENDENCE; ASSOCIATIONS; SAMPLE; ABUSE; OPRM1 AB Aim: Modification and individualization of medical treatments due to genetic testing has the potential to revolutionize healthcare delivery. As evidence mounts that genetic testing may improve treatment decisions for patients with alcohol use disorder (AUD), we explored patient concerns and attitudes toward genetic testing. Methods: Subjects of two USA cross-sectional AUD studies were surveyed regarding their attitudes regarding the use of genetic testing for AUD treatment. Results: Four hundred and fifty-seven participants were surveyed. Overall, subjects showed a high degree of willingness to provide DNA for clinical use and recognized genetics as important to the pathophysiology of a number of disorders including AUD. There were, however, significant concerns expressed related to insurance denial or employment problems. Conclusion: We found that patients enrolled in AUD studies had some concerns about use of genetic testing. The patients in these two samples were, however, willing and knowledgeable about providing DNA samples. C1 [Strobel, Brittany; McManus, Lauren; O'Brien, Charles] Univ Penn, Treatment Res Ctr, Philadelphia, PA 19104 USA. [Leong, Shirley] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA. [Blow, Frederic] UMATS, Ann Arbor, MI 48109 USA. [Slaymaker, Valerie] Hazelden Grad Sch Addict Studies, Ctr City, MN 55012 USA. [Berrettini, Wade] Univ Penn, Perelman Sch Med, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA 15206 USA. [Oslin, David] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Oslin, D (reprint author), Univ Penn, Perelman Sch Med, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM oslin@upenn.edu FU NIAAA [AA017164]; Department of Veteran Affairs; Huss Family FX Funding for this study was provided by NIAAA Grant AA017164; funding support was also provided by the Department of Veteran Affairs by the center grant for the VISN 4 Mental Illness Research, Education, and Clinical Center at the Philadelphia VA Medical Center. Funding was also provided from the Huss Family through a generous donation to the Hazelden foundation. None of the funding sources had a role in study design; in the collection, analysis and interpretation of data; in the writing of the report or in the decision to submit the paper for publication. NR 19 TC 1 Z9 1 U1 1 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0735-0414 EI 1464-3502 J9 ALCOHOL ALCOHOLISM JI Alcohol Alcohol. PD NOV-DEC PY 2013 VL 48 IS 6 BP 700 EP 703 DI 10.1093/alcalc/agt130 PG 4 WC Substance Abuse SC Substance Abuse GA 239AJ UT WOS:000325993500012 PM 23926212 ER PT J AU Zhou, YB Wu, JM Kucik, DF White, NB Redden, DT Szalai, AJ Bullard, DC Edberg, JC AF Zhou, Yebin Wu, Jianming Kucik, Dennis F. White, Nathan B. Redden, David T. Szalai, Alexander J. Bullard, Daniel C. Edberg, Jeffrey C. TI Multiple Lupus-Associated ITGAM Variants Alter Mac-1 Functions on Neutrophils SO ARTHRITIS AND RHEUMATISM LA English DT Article ID I DOMAIN; INTEGRIN REGULATION; LEUKOCYTE ADHESION; LATERAL MOBILITY; FC-GAMMA; RECEPTOR; ERYTHEMATOSUS; CD11B; PHAGOCYTOSIS; SUSCEPTIBILITY AB ObjectiveMultiple studies have demonstrated that single-nucleotide polymorphisms (SNPs) in the ITGAM locus (including the nonsynonymous SNPs rs1143679, rs1143678, and rs1143683) are associated with systemic lupus erythematosus (SLE). ITGAM encodes the protein CD11b, a subunit of the 2 integrin Mac-1. The purpose of this study was to determine the effects of ITGAM genetic variation on the biologic functions of neutrophil Mac-1. MethodsNeutrophils from ITGAM-genotyped and -sequenced healthy donors were isolated for functional studies. The phagocytic capacity of neutrophil ITGAM variants was probed with complement-coated erythrocytes, serum-treated zymosan, heat-treated zymosan, and IgG-coated erythrocytes. The adhesion capacity of ITGAM variants, in adhering to either purified intercellular adhesion molecule 1 or tumor necrosis factor -stimulated endothelial cells, was assessed in a flow chamber. Expression levels of total CD11b and activation of CD11b were assessed by flow cytometry. ResultsMac-1-mediated neutrophil phagocytosis, determined in cultures with 2 different complement-coated particles, was significantly reduced in individuals with nonsynonymous variant alleles of ITGAM. This reduction in phagocytosis was related to variation at either rs1143679 (in the -propeller region) or rs1143678/rs1143683 (highly linked SNPs in the cytoplasmic/calf-1 regions). Phagocytosis mediated by Fc receptors was also significantly reduced in donors with variant ITGAM alleles. Similarly, firm adhesion of neutrophils was significantly reduced in individuals with variant ITGAM alleles. These functional alterations were not attributable to differences in total receptor expression or activation. ConclusionThe nonsynonymous ITGAM variants rs1143679 and rs1143678/rs113683 contribute to altered Mac-1 function on neutrophils. These results underscore the need to consider multiple nonsynonymous SNPs when assessing the functional consequences of ITGAM variation on immune cell processes and the risk of SLE. C1 [Zhou, Yebin; Wu, Jianming; Kucik, Dennis F.; White, Nathan B.; Redden, David T.; Szalai, Alexander J.; Bullard, Daniel C.; Edberg, Jeffrey C.] Univ Alabama Birmingham, Birmingham, AL 35294 USA. [Kucik, Dennis F.] Birmingham VA Med Ctr, Birmingham, AL USA. RP Edberg, JC (reprint author), Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, 1825 Univ Blvd,Room 207 Shelby Bldg, Birmingham, AL 35294 USA. EM jedberg@uab.edu OI Zhou, Yebin/0000-0002-4410-1909 FU NIH [P01-AR-49084, 5P30-AR-048311, R21-AR-058864, R21-DA-026956]; NIH (National Center for Advancing Translational Sciences) [UL1-TR-000165]; Lupus Research Institute FX Supported by the NIH (grants P01-AR-49084, 5P30-AR-048311, R21-AR-058864, and R21-DA-026956, and grant UL1-TR-000165 from the National Center for Advancing Translational Sciences) and the Lupus Research Institute. NR 44 TC 16 Z9 16 U1 2 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0004-3591 EI 1529-0131 J9 ARTHRITIS RHEUM-US JI Arthritis Rheum. PD NOV PY 2013 VL 65 IS 11 BP 2907 EP 2916 DI 10.1002/art.38117 PG 10 WC Rheumatology SC Rheumatology GA 241AG UT WOS:000326138200020 PM 23918739 ER PT J AU Danz, MS Hempel, S Lim, YW Shanman, R Motala, A Stockdale, S Shekelle, P Rubenstein, L AF Danz, Margie Sherwood Hempel, Susanne Lim, Yee-Wei Shanman, Roberta Motala, Aneesa Stockdale, Susan Shekelle, Paul Rubenstein, Lisa TI Incorporating evidence review into quality improvement: meeting the needs of innovators SO BMJ QUALITY & SAFETY LA English DT Article DE Quality improvement; Evidence-based medicine; Medical homes ID FULL SYSTEMATIC REVIEWS; EVIDENCE-BASED MEDICINE; COLLABORATIVE CARE; POLICY-MAKERS; DEPRESSION; INTERVENTIONS AB Background Achieving quality improvement (QI) aims often requires local innovation. Without objective evidence review, innovators may miss previously tested approaches, rely on biased information, or use personal preferences in designing and implementing local QI programmes. Aim To develop a practical, responsive approach to evidence review for QI innovations aimed at both achieving the goals of the Patient Centered Medical Home (PCMH) and developing an evidence-based QI culture. Design Descriptive organisational case report. Methods As part of a QI initiative to develop and spread innovations for achieving the Veterans Affairs (VA) PCMH (termed Patient Aligned Care Team, or PACT), we involved a professional evidence review team (consisting of review experts, an experienced librarian, and administrative support) in responding to the evidence needs of front-line primary care innovators. The review team developed a systematic approach to responsive innovation evidence review (RIER) that focused on innovator needs in terms of time frame, type of evidence and method of communicating results. To assess uptake and usefulness of the RIERs, and to learn how the content and process could be improved, we surveyed innovation leaders. Results In the first 16months of the QI initiative, we produced 13 RIERs on a variety of topics. These were presented as 6-15-page summaries and as slides at a QI collaborative. The RIERs focused on innovator needs (eg, topic overviews, how innovations are carried out, or contextual factors relevant to implementation). All 17 innovators who responded to the survey had read at least one RIER; 50% rated the reviews as very useful and 31%, as probably useful. Conclusions These responsive evidence reviews appear to be a promising approach to integrating evidence review into QI processes. C1 [Danz, Margie Sherwood; Hempel, Susanne; Lim, Yee-Wei; Shanman, Roberta; Motala, Aneesa; Shekelle, Paul; Rubenstein, Lisa] RAND Corp, Santa Monica, CA 90401 USA. [Danz, Margie Sherwood; Stockdale, Susan; Shekelle, Paul; Rubenstein, Lisa] Vet Affairs Greater Los Angeles Healthcare Syst, North Hills, CA USA. [Lim, Yee-Wei] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Epidemiol & Publ Hlth, Singapore 117595, Singapore. RP Danz, MS (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA. EM mjsdanz@gmail.com FU VA Office of Patient Care Services FX This work was undertaken as part of the Veterans Affairs PACT Demonstration Laboratory initiative, supporting and evaluating VA transition to a patient-centred medical home. Funding for the PACT Demonstration Laboratory initiative is provided by the VA Office of Patient Care Services. Study# 2011-0521: Patient Centered Medical Home Innovation Evidence-Based Support and Evaluation. NR 24 TC 2 Z9 2 U1 0 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD NOV PY 2013 VL 22 IS 11 BP 931 EP 939 DI 10.1136/bmjqs-2012-001722 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 239TO UT WOS:000326048700009 PM 23832925 ER PT J AU El-Serag, HB Alsarraj, A Richardson, P Davila, JA Kramer, JR Durfee, J Kanwal, F AF El-Serag, Hashem B. Alsarraj, Abeer Richardson, Peter Davila, Jessica A. Kramer, Jennifer R. Durfee, Janet Kanwal, Fasiha TI Hepatocellular Carcinoma Screening Practices in the Department of Veterans Affairs: Findings from a National Facility Survey SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Viral hepatitis; Epidemiology; Hepatoma; Liver cancer ID UNITED-STATES; SURVEILLANCE AB Previous studies suggest low rates of hepatocellular carcinoma (HCC) screening in clinical practice. There is little information on the provider- and healthcare-facility-related factors that explain the use of HCC screening. We used data from the 2007 Survey to Assess Hepatitis C Care in Veterans Health Administration that collected information regarding the care of patients with hepatitis C virus (HCV) from 138 of 140 Veterans Administration healthcare facilities nationwide. All providers caring for veterans with HCV were invited to respond. In addition, each facility was asked to identify a lead HCV clinician to respond to facility-specific questions. Our outcome was a response concordant with HCC screening guidelines [HCC screening in patients with cirrhosis or in patients with chronic hepatitis B virus (HBV), and screening every 6 or 12 months]. A total of 268 providers responded (98 % facility participation rate). Of these, 190 respondents (70.9 %) reported recommending HCC screening with guideline-concordant risk groups and frequency. Providers reporting guideline-concordant HCC screening practices were significantly more likely to have expertise in liver disease (MD, gastroenterologists or hepatologists), routinely screen for varices, prescribe HCV treatment, and refer or manage patients with liver transplant. The availability of HCC-specific treatments on site was the main facility factor associated with guideline-concordant HCC screening. Self-reported rates of guideline-concordant HCC screening are considerably higher than those seen in routine VA practice. Provider expertise in liver disease and the perceived availability of HCC treatment including transplantation in the local facility are important factors driving self-reported HCC screening practices. C1 [El-Serag, Hashem B.; Alsarraj, Abeer; Richardson, Peter; Davila, Jessica A.; Kramer, Jennifer R.; Kanwal, Fasiha] Michael E DeBakey VA Med Ctr, Houston HSR&D Ctr Excellence, Houston, TX 77030 USA. [El-Serag, Hashem B.; Kanwal, Fasiha] Michael E DeBakey VA Med Ctr, Sect Gastroenterol & Hepatol, Houston, TX USA. [El-Serag, Hashem B.; Alsarraj, Abeer; Richardson, Peter; Davila, Jessica A.; Kramer, Jennifer R.; Kanwal, Fasiha] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Alsarraj, Abeer; Richardson, Peter; Davila, Jessica A.; Kramer, Jennifer R.] Michael E DeBakey VA Med Ctr, Sect Hlth Serv Res, Houston, TX USA. [Durfee, Janet] US Dept Vet Affairs, Off Publ Hlth, Washington, DC USA. RP El-Serag, HB (reprint author), Michael E DeBakey VA Med Ctr, Houston HSR&D Ctr Excellence, 2002 Holcombe Blvd 152, Houston, TX 77030 USA. EM hasheme@bcm.edu FU NIH [R01 CA125487]; Houston VA HSR&D Center of Excellence [HFP90-020] FX This work is funded in part by NIH grant R01 CA125487 and in part by the Houston VA HSR&D Center of Excellence (HFP90-020). NR 15 TC 5 Z9 5 U1 0 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD NOV PY 2013 VL 58 IS 11 BP 3117 EP 3126 DI 10.1007/s10620-013-2794-7 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 241SU UT WOS:000326188800012 PM 23868438 ER PT J AU Matsunaga, J Schlax, PJ Haake, DA AF Matsunaga, James Schlax, Paula J. Haake, David A. TI Role for cis-Acting RNA Sequences in the Temperature-Dependent Expression of the Multiadhesive Lig Proteins in Leptospira interrogans SO JOURNAL OF BACTERIOLOGY LA English DT Article ID THERMOSENSOR CONTROLS EXPRESSION; RPOS MESSENGER-RNA; ESCHERICHIA-COLI; OUTER-MEMBRANE; BORRELIA-BURGDORFERI; GENE-EXPRESSION; TRANSLATIONAL EFFICIENCY; EXTRACELLULAR RELEASE; QUANTITATIVE-ANALYSIS; SECONDARY STRUCTURE AB The spirochete Leptospira interrogans causes a systemic infection that provokes a febrile illness. The putative lipoproteins LigA and LigB promote adhesion of Leptospira to host proteins, interfere with coagulation, and capture complement regulators. In this study, we demonstrate that the expression level of the LigA and LigB proteins was substantially higher when L. interrogans proliferated at 37 C instead of the standard culture temperature of 30 degrees C. The RNA comprising the 175-nucleotide 5' untranslated region (UTR) and first six lig codons, whose sequence is identical in ligA and ligB, is predicted to fold into two distinct stem-loop structures separated by a single-stranded region. The ribosome-binding site is partially sequestered in double-stranded RNA within the second structure. Toeprint analysis revealed that in vitro formation of a 30S-tRNA(fMet)-mRNA ternary complex was inhibited unless a 5' deletion mutation disrupted the second stem-loop structure. To determine whether the lig sequence could mediate temperature-regulated gene expression in vivo, the 5' UTR and the first six codons were inserted between the Escherichia coli L-arabinose promoter and bgaB (beta-galactosidase from Bacillus stearothermophilus) to create a translational fusion. The lig fragment successfully conferred thermoregulation upon the beta-galactosidase reporter in E. coli. The second stem-loop structure was sufficient to confer thermoregulation on the reporter, while sequences further upstream in the 5' UTR slightly diminished expression at each temperature tested. Finally, the expression level of beta-galactosidase was significantly higher when point mutations predicted to disrupt base pairs in the second structure were introduced into the stem. Compensatory mutations that maintained base pairing of the stem without restoring the wild-type sequence reinstated the inhibitory effect of the 5' UTR on expression. These results indicate that ligA and ligB expression is limited by double-stranded RNA that occludes the ribosome-binding site. At elevated temperatures, the ribosome-binding site is exposed to promote translation initiation. C1 [Matsunaga, James] Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. [Haake, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Infect Dis, Los Angeles, CA USA. [Matsunaga, James; Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA. [Haake, David A.] Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90024 USA. [Schlax, Paula J.] Bates Coll, Program Biol Chem, Lewiston, ME 04240 USA. RP Matsunaga, J (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Res Serv, Los Angeles, CA USA. EM jamesm@ucla.edu FU Veterans Affairs Merit Review award; Public Health Service from the National Institute of Allergy and Infectious Diseases [AI-034431]; National Center for Research Resources [5P20RR016463]; National Institute of General Medical Sciences from the National Institutes of Health [8 P20 GM103423] FX This study was supported by a Veterans Affairs Merit Review award (to J.M.) and Public Health Service grant AI-034431 from the National Institute of Allergy and Infectious Diseases (to D. A. H.). P.J.S. was supported by National Center for Research Resources grant 5P20RR016463 and National Institute of General Medical Sciences grant 8 P20 GM103423 from the National Institutes of Health. NR 72 TC 12 Z9 12 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 EI 1098-5530 J9 J BACTERIOL JI J. Bacteriol. PD NOV PY 2013 VL 195 IS 22 BP 5092 EP 5101 DI 10.1128/JB.00663-13 PG 10 WC Microbiology SC Microbiology GA 240JR UT WOS:000326092400012 PM 24013626 ER PT J AU Van Daele, CM De Meyer, T De Buyzere, ML Gillebert, TC Denil, SLIJ Bekaert, S Chirinos, JA De Backer, GG De Bacquer, D Rietzschel, ER AF Van Daele, Caroline M. De Meyer, Tim De Buyzere, Marc L. Gillebert, Thierry C. Denil, Simon L. I. J. Bekaert, Sofie Chirinos, Julio A. De Backer, Guy G. De Bacquer, Dirk Rietzschel, Ernst R. CA Asklepios Investigators TI Family History of Cardiovascular Disease and Offspring Echocardiographic Left Ventricular Structure and Function: The Asklepios Study SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY LA English DT Article DE Left ventricular structure; Left ventricular function; Echocardiography; Family history; Cardiovascular disease ID CORONARY-HEART-DISEASE; ENVIRONMENTAL-INFLUENCES; ARTERIAL PULSE; PLACENTAL SIZE; BLOOD-PRESSURE; RISK-FACTOR; ADULT LIFE; BODY-SIZE; MASS; FAILURE AB Background: Moderate to small heritability has been observed for left ventricular (LV) structure and function in genetic epidemiology and genomewide association studies. The aim of this study was to explore whether this would be mirrored in an independent association between LV structure and function and a family history (FH) of cardiovascular disease (CVD) in a large population of middle-aged adults. Methods: Subjects enrolled in the Asklepios Study, a population-based sample of 2,524 male and female volunteers, aged 35 to 55 years, free of overt CVD at baseline, were studied. LV structure and function were assessed using transthoracic echocardiography (by a single sonographer). FH data spanning 4 generations were acquired using a questionnaire. Results: In unadjusted analyses, only small effects of FH of CVD on LV structure (relative wall thickness, P =.042; interventricular septal thickness, P =.002; LV mass, P =.038; allometrically adjusted LV mass, P =.014) and diastolic function (mitral annular e', P =.02) were observed. After adjusting for the more adverse risk factor profile associated with FH, no significant associations persisted. These results did not appreciably change using a more extended definition of FH of CVD or FH of hypertension. Conclusions: A positive FH for CVD was associated with differences in offspring cardiac structure and function, largely mediated by (but not independent from) a more adverse risk profile in those subjects with positive FH. C1 [Van Daele, Caroline M.; De Buyzere, Marc L.; Gillebert, Thierry C.; Rietzschel, Ernst R.] Ghent Univ Hosp, Dept Cardiovasc Dis, Ghent, Belgium. [De Meyer, Tim; Denil, Simon L. I. J.] Univ Ghent, Fac Biosci Engn, Dept Math Modelling Stat & Bioinformat, B-9000 Ghent, Belgium. [Bekaert, Sofie] Ghent Univ Hosp, Clin Res Ctr Ghent, Bimetra, Ghent, Belgium. [Chirinos, Julio A.] Univ Penn, Perelman Sch Med, Hosp Univ Penn, Philadelphia, PA 19104 USA. [Chirinos, Julio A.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [De Backer, Guy G.; De Bacquer, Dirk; Rietzschel, Ernst R.] Univ Ghent, Fac Med & Hlth Sci, Dept Publ Hlth, B-9000 Ghent, Belgium. RP Van Daele, CM (reprint author), Univ Ghent, Dept Cardiovasc Dis, Pintelaan 185,Bldg 10K12IE, B-9000 Ghent, Belgium. EM caroline.vandaele@ugent.be OI Gillebert, Thierry/0000-0002-3832-919X FU Fund for Scientific Research-Flanders (FWO) [G042703, G083810N] FX The Asklepios Study is supported by the Fund for Scientific Research-Flanders (FWO research grants G042703 and G083810N). NR 56 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0894-7317 J9 J AM SOC ECHOCARDIOG JI J. Am. Soc. Echocardiogr. PD NOV PY 2013 VL 26 IS 11 BP 1290 EP U197 DI 10.1016/j.echo.2013.07.024 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 242IN UT WOS:000326232600008 PM 23993692 ER PT J AU Maxwell, JL Keysor, JJ Niu, JB Singh, JA Wise, BL Frey-Law, L Nevitt, MC Felson, DT AF Maxwell, Jessica L. Keysor, Julie J. Niu, Jingbo Singh, Jasvinder A. Wise, Barton L. Frey-Law, Laura Nevitt, Michael C. Felson, David T. TI Participation Following Knee Replacement: The MOST Cohort Study SO PHYSICAL THERAPY LA English DT Article ID JOINT REPLACEMENT; OLDER-ADULTS; TOTAL HIP; ARTHROPLASTY; OUTCOMES; DISABILITY; HEALTH; PREDICTORS; LIMITATIONS; POPULATION AB Background. Participation is an important, yet seldom studied, outcome after total knee replacement (TKR). Objective. The purpose of this study was to investigate the extent and predictors of participation and participation restriction among people after TKR. Materials and Methods. This study investigated the changes in pain, function, and participation scores (measured using a subscale of the Late-Life Function and Disability Instrument) from pre-TKR to >= 1 year post-TKR among a subsample of participants from the Multicenter Osteoarthritis Study (MOST) longitudinal cohort (MOST is funded by the National Institutes of Health). The proportions of individuals with participation restriction pre-TKR and >= 1 and >= 2 years post-TKR were calculated for all participants and for important demographic subgroups. The association between demographic and clinical factors and participation was estimated using linear regression. The association between demographic and clinical factors and participation restriction was estimated using logistic regression. Results. There were 292 individuals with outcome data >= 1 year post-TKR. Of these, 218 (75%) had data pre-TKR and >= 1 year post-TKR and 160 (55%) had data >= 2 years post-TKR. There were mean improvements in pain, function, and participation at >= 1 and 2 years. However, approximately 30% of the study sample had participation restriction pre-TKR and post-TKR, and the proportion decreased significantly only for those <65 years old. Non-whites had a higher proportion of participation restriction than any other subgroup (41% >= 1 year, 48% >= 2 years). Female sex and non-white race were associated with a worse participation score, and several demographic and modifiable factors were associated with participation restriction following TKR. Limitations. The time between pre-TKR and post-TKR assessment varied across study participants, and data were not available on their rehabilitation utilization. Conclusions. Although there was a mean increase in participation >= 1 year following TKR, participation restriction was common. The likelihood of low participation was increased among women, non-whites, and those with depressive symptoms, severe pain in either knee, or worse pre-TKR function. C1 [Maxwell, Jessica L.] Boston Univ, Dept Phys Therapy & Athlet Training, Coll Hlth & Rehabil Sci, Sargent Coll, Boston, MA 02215 USA. [Keysor, Julie J.] Boston Univ, Sch Med, Coll Hlth & Rehabil Sci, Clin Epidemiol Res & Training Unit, Boston, MA 02215 USA. [Niu, Jingbo; Felson, David T.] Boston Univ, Sch Med, Clin Epidemiol Res & Training Unit, Boston, MA 02215 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Div Rheumatol, Birmingham, AL 35294 USA. [Wise, Barton L.] Univ Calif Davis, Dept Internal Med, Div Rheumatol Allergy & Clin Immunol, Sch Med, Davis, CA 95616 USA. [Frey-Law, Laura] Univ Iowa, Dept Phys Therapy & Rehabil Sci, Carver Coll Med, Iowa City, IA USA. [Nevitt, Michael C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Maxwell, JL (reprint author), Boston Univ, Dept Phys Therapy & Athlet Training, Coll Hlth & Rehabil Sci, Sargent Coll, 635 Commonwealth Ave,Room 623, Boston, MA 02215 USA. EM jmaxwell@bu.edu OI Wise, Barton/0000-0002-6540-6031 FU National Institute on Aging; National Institutes of Health [U01-AG18820, U01-AG19069, U01-AG18832, U01-AG18947, AR47785]; American College of Rheumatology Rheumatology Research Foundation Rheumatology Scientist Development Award; NIDRR [H133B100003-11] FX The MOST Study was supported by the National Institute on Aging and by the following National Institutes of Health grants: U01-AG18820 (Dr Felson), U01-AG19069 (Dr Nevitt), U01-AG18832, U01-AG18947, and AR47785. Funding for this project also was provided by the American College of Rheumatology Rheumatology Research Foundation Rheumatology Scientist Development Award (Dr Maxwell) and by NIDRR H133B100003-11 (Dr Maxwell). NR 28 TC 8 Z9 8 U1 0 U2 12 PU AMER PHYSICAL THERAPY ASSOC PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 USA SN 0031-9023 EI 1538-6724 J9 PHYS THER JI Phys. Ther. PD NOV PY 2013 VL 93 IS 11 BP 1467 EP 1474 DI 10.2522/ptj.20130109 PG 8 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA 242BM UT WOS:000326212400004 PM 23813082 ER PT J AU Ford, JM Mathalon, DH Roach, BJ Keedy, SK Reilly, JL Gershon, ES Sweeney, JA AF Ford, Judith M. Mathalon, Daniel H. Roach, Brian J. Keedy, Sarah K. Reilly, James L. Gershon, Elliot S. Sweeney, John A. TI Neurophysiological Evidence of Corollary Discharge Function During Vocalization in Psychotic Patients and Their Nonpsychotic First-Degree Relatives SO SCHIZOPHRENIA BULLETIN LA English DT Article DE psychosis; corollary discharge; ERP; N1; first-degree relatives ID AUDITORY-CORTEX; CORTICAL RESPONSIVENESS; SPEECH PRODUCTION; SCHIZOPHRENIA; DYSFUNCTION; SYMPTOMS; SCALE; HALLUCINATIONS; DISORDERS; PROBANDS AB Predictions about sensations resulting from motor acts are instantiated through neural mechanisms such as the corollary discharge. With each action, the corollary discharge provides an unconscious comparison between predicted and actual sensations resulting from the action; closer matches result in greater suppression of sensation. This mechanism is disrupted in schizophrenia (SZ) and may contribute to, or reflect a failure to, distinguish self- from externally generated experiences, a hallmark of psychosis. We asked whether disruption is specific to SZ or is seen in other psychotic illnesses and in first-degree relatives of psychotic patients. Corollary discharge function was assessed in SZ patients (n = 30), schizoaffective (SA) patients (n = 19), bipolar patients with a history of psychosis (BPP; n = 39), nonpsychotic relatives of SZ (n = 30), SA (n = 23), and BPP (n = 50) patients, and healthy controls (n = 43). The N1 component of the event-related potential, reflecting auditory cortical responses to sounds, was elicited by speech sound onset as subjects talked and later when they listened to a recording of those sounds. N1 was suppressed during talking compared to N1 during listening, consistent with the suppressive action of the corollary discharge mechanism. Suppression was significantly reduced in SZ and BPP patients, with a similar trend in the smaller SA group. Patient groups did not differ, and unaffected relatives did not differ from controls or probands. The failure to monitor sensations resulting from self-generated actions, implicating corollary discharge dysfunction, may be a common feature across affective and nonaffective psychosis. Data from unaffected family members do not indicate that this is a marker of psychosis risk. C1 [Ford, Judith M.; Mathalon, Daniel H.; Roach, Brian J.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Keedy, Sarah K.; Gershon, Elliot S.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA. [Reilly, James L.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA. [Sweeney, John A.] Univ Texas, Dept Psychiat, Southwestern Dallas, TX USA. [Sweeney, John A.] Univ Texas, Dept Pediat, Southwestern Dallas, TX USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, Psychiat Serv 116D, 4150 Clement St, San Francisco, CA 94121 USA. EM Judith.ford@ucsf.edu RI Keedy, Sarah/H-6557-2014 OI Keedy, Sarah/0000-0002-2139-9271; Roach, Brian/0000-0002-3264-1465; Mathalon, Daniel/0000-0001-6090-4974 FU Veterans Administration [1l01CX000497-01]; National Institute of Mental Health [MH-58262, MH077862, MH085485] FX This work was supported by the Veterans Administration (Merit Review 1l01CX000497-01, Research Career Scientist to Dr Ford), and National Institute of Mental Health (MH-58262 to Dr Ford, Dr Roach, Dr Mathalon; MH077862 and MH085485 to Dr Sweeney, Dr Reilly, Dr Keedy, Dr Gershon). NR 45 TC 11 Z9 11 U1 0 U2 10 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD NOV PY 2013 VL 39 IS 6 BP 1272 EP 1280 DI 10.1093/schbul/sbs129 PG 9 WC Psychiatry SC Psychiatry GA 241TC UT WOS:000326189700014 PM 23155183 ER PT J AU McFarland, LV Raugi, GJ Reiber, GE AF McFarland, Lynne V. Raugi, Gregory J. Reiber, Gayle E. TI Primary Care Provider and Imaging Technician Satisfaction with a Teledermatology Project in Rural Veterans Health Administration Clinics SO TELEMEDICINE AND E-HEALTH LA English DT Article DE teledermatology; quality improvement; satisfaction; Veterans Affairs ID RANDOMIZED-CONTROLLED-TRIAL; TECHNOLOGY ACCEPTANCE MODEL; PATIENT SATISFACTION; TELEMEDICINE; TELEHEALTH; DERMATOLOGY; ADOPTION; QUESTIONNAIRE; MANAGEMENT; DIFFUSION AB Objective:Assessment of a multisite rural teledermatology project between 2009 and 2012 in four Pacific Northwest states that trained primary care providers and imaging technicians in state-of-the-art techniques of telemedicine.Materials and Methods:In 2012, we assessed provider and imaging technician acceptability and satisfaction with a 32-item survey instrument based on the Patient Satisfaction Questionnaire developed by Ware et al. (Eval Program Plann 1983;6:247-63) and modified for telemedicine by Kraai et al. (J Card Fail 2011;17:684-690). Survey questions covered eight satisfaction domains: interpersonal manner, technical quality, accessibility, finances, efficacy, continuity, physical environment, and availability.Results:Overall, 71% of the primary care providers and 94% of the imaging technicians reported being satisfied or extremely satisfied with the teledermatology project. Most (95%) providers found the continuing education classes on dermatology diagnosis and treatment topics useful, and 86% reported teledermatology was a good addition to regular patient services. Most (97%) of the imaging technicians were satisfied with the ability of teledermatology to improve the description of dermatology conditions using images of the lesions or rashes, and 91% were satisfied with the convenience of teledermatology. Challenges reported by both providers and imaging technicians include an increase in workload due to more patient visits related to dermatology care and limited information technology support.Conclusions:Given the Veterans Health Administration's initiatives to promote accessible health care to underserved Veterans using telehealth, these findings can inform future program designs for teledermatology. C1 [McFarland, Lynne V.; Raugi, Gregory J.; Reiber, Gayle E.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Dept Vet Affairs, Seattle, WA 98101 USA. [McFarland, Lynne V.] Univ Washington, Dept Med Chem, Sch Publ Hlth, Seattle, WA 98195 USA. [Reiber, Gayle E.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA. [Reiber, Gayle E.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA. [Raugi, Gregory J.] VA Puget Sound Hlth Care Syst, Hosp & Specialty Med Serv, Teledermatol Sect, Dept Vet Affairs, Seattle, WA 98101 USA. RP McFarland, LV (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Dept Vet Affairs, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA. EM Lynne.McFarland@va.gov FU Office of Rural Health, Veterans Health Administration, U.S. Department of Veterans Affairs; VA Health Services Research and Development for the Senior Career Scientist Award [RCS 98-353] FX The authors acknowledge the rural primary care providers and imaging technicians in VISN 20 who dedicated their time and energy to this project in this project. This material is based on work supported by the Office of Rural Health, Veterans Health Administration, U.S. Department of Veterans Affairs, and support from VA Health Services Research and Development for the Senior Career Scientist Award RCS 98-353 to G.E.R. NR 39 TC 12 Z9 12 U1 1 U2 9 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-5627 EI 1556-3669 J9 TELEMED E-HEALTH JI Telemed. e-Health PD NOV 1 PY 2013 VL 19 IS 11 BP 815 EP 825 DI 10.1089/tmj.2012.0327 PG 11 WC Health Care Sciences & Services SC Health Care Sciences & Services GA 241QU UT WOS:000326183100003 PM 24053115 ER PT J AU Kliger, AS Foley, RN Goldfarb, DS Goldstein, SL Johansen, K Singh, A Szczech, L AF Kliger, Alan S. Foley, Robert N. Goldfarb, David S. Goldstein, Stuart L. Johansen, Kirsten Singh, Ajay Szczech, Lynda TI KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Editorial Material ID CHRONIC KIDNEY-DISEASE; LOW TRANSFERRIN SATURATION; INTRAVENOUS IRON TREATMENT; HEMODIALYSIS-PATIENTS; FERRIC GLUCONATE; NANDROLONE DECANOATE; CHILDREN; THERAPY; TRIAL; ERYTHROPOIETIN AB The 2012 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline for Anemia in Chronic Kidney Disease provides clinicians with comprehensive evidence-based recommendations to improve patient care. In this commentary, we review these recommendations and the underlying evidence. Most recommendations are well reasoned. For some, the evidence is unclear and recommendations require some qualification. While the KDIGO guideline stresses the potential risks of intravenous iron therapy, withholding iron might have its own risks. The recommendation to avoid hemoglobin levels falling below 9 g/dL sets a lower bound of "acceptability" that may increase blood transfusion. Given the lack of research supporting the optimal transfusion strategy for end-stage renal disease patients, it is difficult to weigh the risks and benefits of red blood cell transfusion. We find a paucity of evidence that hemoglobin concentration targeted between 11 and 11.5 g/dL is associated with a safety risk. Although the evidence that erythropoiesis-stimulating agent use improves patient quality of life is poor, it is possible that the instruments used to measure quality of life may not be well attuned to the needs of chronic kidney disease or dialysis patients. Our last section focuses specifically on the recommendations to treat anemia in children. (C) 2013 by the National Kidney Foundation, Inc. C1 [Kliger, Alan S.] Yale Univ, Sch Med, New Haven, CT USA. [Kliger, Alan S.] Yale New Haven Med Ctr, New Haven, CT 06504 USA. [Foley, Robert N.] Minneapolis Med Res Fdn Inc, Minneapolis, MN USA. [Goldfarb, David S.] US Dept Vet Affairs, New York, NY USA. [Goldstein, Stuart L.] Cincinnati Childrens Hosp, Cincinnati, OH USA. [Goldstein, Stuart L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA. [Johansen, Kirsten] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. [Singh, Ajay] Brigham & Womens Hosp, Boston, MA 02115 USA. [Szczech, Lynda] Durham Nephrol Associates, Durham, NC USA. RP Kliger, AS (reprint author), Yale New Haven Hlth Syst, 300 George St,Rm 487, New Haven, CT 06510 USA. EM alan.kliger@ynhh.org OI Goldfarb, David/0000-0002-9215-1273 NR 33 TC 36 Z9 38 U1 0 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD NOV PY 2013 VL 62 IS 5 BP 849 EP 859 DI 10.1053/j.ajkd.2013.06.008 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 238XP UT WOS:000325985600003 PM 23891356 ER PT J AU Maguen, S Burkman, K AF Maguen, Shira Burkman, Kristine TI Combat-Related Killing: Expanding Evidence-Based Treatments for PTSD SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Editorial Material DE posttraumatic stress disorder; killing; veteran; treatment ID MENTAL-HEALTH SYMPTOMS; IMPACT; WAR AB Despite its prevalence, killing in war is an experience that may not fit neatly into existing models of posttraumatic stress disorder (PTSD) and its treatment. The context in which killing occurred may be complex. Furthermore, while killing may certainly be fear based, an individual may have also killed in response to losing someone close and experiencing sadness and anger, as opposed to fear. While evidence-based treatments for PTSD may be a good starting point for killing-related trauma, we argue that existing treatments need to be expanded. Complex killing-related cognitions that may not be anticipated or identified, moral injury, self-forgiveness, and loss are all important issues that arise that may need to be addressed in greater detail. Consequently, we have developed a 6- to 8-session individual treatment module for those impacted by killing in war, expressly designed for use with existing evidence-based treatments for PTSD, currently being validated for use in clinical practice. We see this module as supplementary, rather than as a replacement, building on the skills that veterans have already learned within these treatments. By expanding the types of treatments we offer those who have killed in war, we can ensure that we are providing veterans with comprehensive treatment that takes the complexities of war and its aftermath into account. C1 [Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Maguen, S (reprint author), San Francisco VA Med Ctr, 4150 Clement St 116-P, San Francisco, CA 94121 USA. EM Shira.Maguen@va.gov NR 10 TC 9 Z9 9 U1 1 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 EI 1878-187X J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD NOV PY 2013 VL 20 IS 4 BP 476 EP 479 PG 4 WC Psychology, Clinical SC Psychology GA 238OA UT WOS:000325956100011 ER PT J AU Rauch, SAM Smith, E Duax, J Tuerk, P AF Rauch, Sheila A. M. Smith, Erin Duax, Jeanne Tuerk, Peter TI A Data-Driven Perspective: Response to Commentaries by Maguen and Burkman (2013) and Steenkamp et al. (2013) SO COGNITIVE AND BEHAVIORAL PRACTICE LA English DT Editorial Material DE PTSD; treatment; combat; moral injury; guilt ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE THERAPY; COGNITIVE-PROCESSING THERAPY; INJECTION-INJURY PHOBIA; THREAT-RELEVANT STIMULI; FEMALE RAPE VICTIMS; PTSD; VETERANS; DISGUST; TRIAL AB We respond to commentary from Maguen and Burkman (2013-this issue) and Steenkamp et al. (2013-this issue) on our presentation of how to use PE to treat PTSD resulting from perceived perpetration (Smith et al., 2013-this issue). We focus our response on the distinction between moral injury, which can result in many potential mental health outcomes, with various treatment plans coming out of the patient's presentation, and treatment of PTSD resulting from trauma that may or may not include moral injury. We then focus on the strong evidence base that supports the use of PE for PTSD across trauma types and across many complicated patient presentations, including evidence within veteran populations. We respond to common misunderstandings of PE and Emotional Processing Theory that underlie this treatment model. Specifically, we discuss the flexibility that is inherent in the PE model, reassert that PE focuses on whatever emotion/s are present and provoked by direct confrontation of traumatic material (e.g., reminders, memories), and discuss that habituation is not the only process at work in PE. As such, shame and guilt related to moral injury can be effectively addressed, as noted in Smith et al. Finally, rather than developing a new and unproven model of treatment as the commentaries propose, we assert that given the strong evidence base for efficacy and effectiveness of PE for PTSD and the significant and ongoing investment in dissemination of PE, continued support for providers on how to effectively use PE with difficult patients is warranted. C1 [Rauch, Sheila A. M.; Smith, Erin; Duax, Jeanne] VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA. [Rauch, Sheila A. M.; Smith, Erin; Duax, Jeanne] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA. [Tuerk, Peter] Ralph H Johnson VAMC, Charleston, SC USA. [Tuerk, Peter] Med Univ S Carolina, Charleston, SC 29425 USA. RP Rauch, SAM (reprint author), VA Ann Arbor Healthcare Syst, PTSD Clin Team, 2215 Fuller Rd 116C, Ann Arbor, MI 48105 USA. EM sherauch@med.umich.edu RI Rauch, Sheila/K-4450-2015 OI Rauch, Sheila/0000-0001-9686-4011 NR 31 TC 2 Z9 2 U1 1 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1077-7229 EI 1878-187X J9 COGN BEHAV PRACT JI Cogn. Behav. Pract. PD NOV PY 2013 VL 20 IS 4 BP 480 EP 484 PG 5 WC Psychology, Clinical SC Psychology GA 238OA UT WOS:000325956100012 ER PT J AU Hanlon, J Schmader, K AF Hanlon, Joseph T. Schmader, Kenneth E. TI The Medication Appropriateness Index at 20: Where It Started, Where It Has Been, and Where It May Be Going SO DRUGS & AGING LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; ADVERSE DRUG-REACTIONS; OLDER-ADULTS; PRIMARY-CARE; HOSPITALIZED-PATIENTS; PRESCRIBING CRITERIA; GERIATRIC INPATIENTS; ELDERLY-PATIENTS; RELIABILITY; OUTPATIENTS AB Potentially inappropriate prescribing for older adults is a major public health concern. While there are multiple measures of potentially inappropriate prescribing, the medication appropriateness index (MAI) is one of the most common implicit approaches published in the scientific literature. The objective of this narrative review is to describe findings regarding the MAI's reliability, comparison of the MAI with other quality measures of potentially inappropriate prescribing, its predictive validity with important health outcomes, and its responsiveness to change within the framework of randomized controlled trials. A search restricted to English-language literature involving humans aged 65+ years from January 1992 to June 2013 was conducted using MEDLINE and EMBASE databases using the search term 'medication appropriateness index'. A manual search of the reference lists from identified articles and the authors' article files, book chapters, and recent reviews was conducted to identify additional articles. A total of 26 articles were identified for inclusion in this narrative review. The main findings were that the MAI has acceptable inter- and intra-rater reliability, it more frequently detects potentially inappropriate prescribing than a commonly used set of explicit criteria, it predicts adverse health outcomes, and it is able to demonstrate the positive impact of interventions to improve this public health problem. We conclude that the MAI may serve as a valuable tool for measuring potentially inappropriate prescribing in older adults. C1 [Hanlon, Joseph T.] Univ Pittsburgh, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med, Geriatr Pharmaceut Outcomes & Geroinformat Res &, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Dept Geriatr Med, Pittsburgh, PA 15213 USA. [Schmader, Kenneth E.] Duke Univ, Med Ctr, Sch Med, Dept Med,Div Geriatr, Durham, NC 27710 USA. [Schmader, Kenneth E.] Durham Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Durham, NC USA. RP Hanlon, J (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufman Med Bldg Suite 514,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu FU National Institute on Aging Grants [R01-AG 027017, P30-AG02482, K07-AG033174, P30-AG028716]; Healthcare Research and Quality Grant [R01-HS018721] FX Supported in part by the National Institute on Aging Grants (R01-AG 027017, P30-AG024827, K07-AG033174, P30-AG028716), and an Agency for Healthcare Research and Quality Grant (R01-HS018721). The authors report no potential conflicts of interest. NR 46 TC 21 Z9 23 U1 1 U2 17 PU ADIS INT LTD PI AUCKLAND PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND SN 1170-229X EI 1179-1969 J9 DRUG AGING JI Drugs Aging PD NOV PY 2013 VL 30 IS 11 BP 893 EP 900 DI 10.1007/s40266-013-0118-4 PG 8 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA 236VL UT WOS:000325827400005 PM 24062215 ER PT J AU Mahon, K Perez-Rodriguez, MM Gunawardane, N Burdick, KE AF Mahon, K. Perez-Rodriguez, M. M. Gunawardane, N. Burdick, K. E. TI Dimensional endophenotypes in bipolar disorder: Affective dysregulation and psychosis proneness SO JOURNAL OF AFFECTIVE DISORDERS LA English DT Article DE Bipolar disorder; Endophenotype; Temperament; Schizotypy ID TEMPS-A; AFFECTIVE TEMPERAMENTS; MOOD DISORDERS; HYPERTHYMIC TEMPERAMENT; SCHIZOTYPAL DIMENSIONS; PERSONALITY-TRAITS; SPECTRUM ILLNESS; RATING-SCALE; I DISORDER; FAMILY AB Background: The clinical phenotype of bipolar disorder (BPD) is heterogeneous and the genetic architecture of the disorder is complex and not well understood. Given these complications, it is possible that the identification of intermediate phenotypes ("endophenotypes") will be useful in elucidating the complex genetic mechanisms that result in the disorder. The examination of unaffected relatives is critical in determining whether a particular trait is genetically-relevant to BPD. However, few dimensional traits related to BPD have been assessed in unaffected relatives of patients. Methods: We assessed affective temperament and schizotypy in 55 discordant sibling pairs and 113 healthy controls (HCs) using the Temperament Evaluation of Memphis, Pisa, Paris. and San Diego, Auto-questionnaire version (TEMPS-A) to assess affective temperament and the Schizotypal Personality Questionnaire (SPQ) to assess schizotypy. Results: BPD patients scored significantly higher than HCs on all subscales of the SPQ and on all but one subscale (hyperthymic) of the TEMPS-A (all p < 0.01). Siblings demonstrated scores that were significantly intermediate to patients and HCs on the anxious subscale of the TEMPS-A and on the interpersonal deficits and disorganized subscales of the SPQ. Limitations: We did not investigate the BPD spectrum as most patients were diagnosed with BPD (n=47). Most of the patients had experienced psychosis (n=42) and so we were unable to examine whether psychosis status impacted upon affective temperament or schizotypy in patients or their siblings. Conclusion: These data suggest that schizotypy and affective temperament represent dimensional traits that are likely to underlie the genetic risk for BPD. (C) 2013 Elsevier B.V. All rights reserved. C1 [Mahon, K.; Perez-Rodriguez, M. M.; Burdick, K. E.] Mt Sinai Sch Med, Dept Psychiat & Neurosci, Friedman Brain Inst, New York, NY 10029 USA. [Perez-Rodriguez, M. M.] James J Peters Vet Affairs Med Ctr, Mental Hlth Patient Care Ctr, Bronx, NY USA. [Perez-Rodriguez, M. M.] James J Peters Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, Bronx, NY USA. [Gunawardane, N.] SUNY Buffalo, Sch Med, Buffalo, NY 14260 USA. RP Mahon, K (reprint author), Mt Sinai Sch Med, Dept Psychiat & Neurosci, Friedman Brain Inst, New York, NY 10029 USA. EM katie.mahon@mssm.edu RI Burdick, Katherine/G-6124-2012; Perez Rodriguez, Maria/B-9410-2013 OI Perez Rodriguez, Maria/0000-0001-5137-1993 FU National Institute of Mental Health (NIMH) [1R03MH079995, 1K23MH077807]; Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment; Medical Research Service of the Veterans Affairs James J Peters VAMC; Department of Veterans Affairs NY/NJ (VISN3) Mental Illness Research, Education, and Clinical Center (MIRECC) FX This research is supported by grants from the National Institute of Mental Health (NIMH) including 1R03MH079995 and 1K23MH077807 (to KEE). Additional support (to MPR) was provided by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the Veterans Affairs James J Peters VAMC, and the Department of Veterans Affairs NY/NJ (VISN3) Mental Illness Research, Education, and Clinical Center (MIRECC). NR 34 TC 13 Z9 13 U1 1 U2 8 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0165-0327 EI 1573-2517 J9 J AFFECT DISORDERS JI J. Affect. Disord. PD NOV PY 2013 VL 151 IS 2 BP 695 EP 701 DI 10.1016/j.jad.2013.08.003 PG 7 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA 231QR UT WOS:000325432900039 PM 23993441 ER PT J AU Black, DM Schafer, AL AF Black, Dennis M. Schafer, Anne L. TI The Search for the Optimal Anabolic Osteoporosis Therapy SO JOURNAL OF BONE AND MINERAL RESEARCH LA English DT Article ID HORMONE-RELATED PROTEIN; PARATHYROID-HORMONE; POSTMENOPAUSAL OSTEOPOROSIS; RANDOMIZED-TRIAL; BONE-DENSITY; TERIPARATIDE; ALENDRONATE; WOMEN; COMBINATION; STRENGTH C1 [Black, Dennis M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA. [Schafer, Anne L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94107 USA. [Schafer, Anne L.] San Francisco VA Med Ctr, Endocrine Res Unit, San Francisco, CA USA. RP Black, DM (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, 185 Berry St,Lobby 5,Suite 5700, San Francisco, CA 94107 USA. EM dblack@psg.ucsf.edu FU Department of Veterans Affairs [5 IK2 CX000549-03] FX This work was supported by the Department of Veterans Affairs under grant 5 IK2 CX000549-03 (to ALS). NR 26 TC 5 Z9 6 U1 0 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0884-0431 EI 1523-4681 J9 J BONE MINER RES JI J. Bone Miner. Res. PD NOV PY 2013 VL 28 IS 11 BP 2263 EP 2265 DI 10.1002/jbmr.2104 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 239KZ UT WOS:000326024000003 PM 24115189 ER PT J AU Safdar, N O'Horo, JC Maki, DG AF Safdar, N. O'Horo, J. C. Maki, D. G. TI Arterial catheter-related bloodstream infection: incidence, pathogenesis, risk factors and prevention SO JOURNAL OF HOSPITAL INFECTION LA English DT Article DE Catheter infection; Bloodstream infection; Arterial catheter ID INTENSIVE-CARE UNITS; RANDOMIZED-TRIAL; DEVICES; CHLORHEXIDINE; BACTEREMIA; GUIDELINES; PLACEMENT; INSERTION; DURATION AB Background: Arterial catheters are essential in critical care for haemodynamic and blood gas monitoring. The risk of infection remains ill defined. Aims: To delineate the incidence, pathogenesis and risk factors for arterial catheterrelated bloodstream infection (BSI). Methods: Arterial catheters in two randomized trials in 1998e2000 were studied prospectively. One trial studied the effect of a 1% chlorhexidinee75% alcohol solution for cutaneous antisepsis for intravascular catheters, and the other trial studied the efficacy of a chlorhexidine-impregnated sponge dressing, both for prevention of catheter-related BSI. At catheter removal, skin of the insertion site, catheter segments, hub and infusatewere cultured quantitatively in all cases. Catheter-related BSI was confirmed by concordance between isolates from the catheter and from blood cultures by restriction-fragment DNA subtyping. Risk factors for arterial catheter-related BSI were determined using univariate analysis. Findings: Of 834 arterial catheters studied (3273 catheter-days), 109 (13%) were colonized and 11 caused bacteraemia (1.3%, 3.4 per 1000 catheter-days). The majority of catheterrelated BSIs were acquired extraluminally from skin of the insertion site (63%). The risk of arterial catheter-related BSI was comparable with that for short-term non-cuffed central venous catheters (2.7%, 5.9 per 1000 CVC-days). Conclusion: In patients in intensive care with cryptogenic sepsis or bacteraemia, arterial catheter-related BSI must also be suspected and excluded. The most common route of infection is extraluminal; as such, novel technologies shown to prevent bloodstream infection with CVCs, such as chlorhexidine for cutaneous antisepsis and chlorhexidineimpregnated dressings, may also be of benefit with arterial catheters. Published by Elsevier Ltd on behalf of the Healthcare Infection Society. C1 [Safdar, N.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Safdar, N.; Maki, D. G.] Univ Wisconsin, Sch Med, Infect Dis Sect, Dept Med, Madison, WI USA. [O'Horo, J. C.] Mayo Clin, Dept Pulm & Crit Care Med, Rochester, MN USA. RP Safdar, N (reprint author), Univ Wisconsin Hosp & Clin, 600 Highland Ave, Madison, WI 53792 USA. EM ns2@medicine.wisc.edu RI O'Horo, John/A-8787-2013; O'Horo, John/N-8681-2013 OI O'Horo, John/0000-0002-0880-4498; O'Horo, John/0000-0002-0880-4498 NR 33 TC 8 Z9 10 U1 0 U2 12 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0195-6701 EI 1532-2939 J9 J HOSP INFECT JI J. Hosp. Infect. PD NOV PY 2013 VL 85 IS 3 BP 189 EP 195 DI 10.1016/j.jhin.2013.06.018 PG 7 WC Infectious Diseases SC Infectious Diseases GA 237IG UT WOS:000325862100004 PM 24070632 ER PT J AU Gregory, KJ Herman, EJ Ramsey, AJ Hammond, AS Byun, NE Stauffer, SR Manka, JT Jadhav, S Bridges, TM Weaver, CD Niswender, CM Steckler, T Drinkenburg, WH Ahnaou, A Lavreysen, H Macdonald, GJ Bartolome, JM Mackie, C Hrupka, BJ Caron, MG Daigle, TL Lindsley, CW Conn, PJ Jones, CK AF Gregory, K. J. Herman, E. J. Ramsey, A. J. Hammond, A. S. Byun, N. E. Stauffer, S. R. Manka, J. T. Jadhav, S. Bridges, T. M. Weaver, C. D. Niswender, C. M. Steckler, T. Drinkenburg, W. H. Ahnaou, A. Lavreysen, H. Macdonald, G. J. Bartolome, J. M. Mackie, C. Hrupka, B. J. Caron, M. G. Daigle, T. L. Lindsley, C. W. Conn, P. J. Jones, C. K. TI N-Aryl Piperazine Metabotropic Glutamate Receptor 5 Positive Allosteric Modulators Possess Efficacy in Preclinical Models of NMDA Hypofunction and Cognitive Enhancement SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID IN-VIVO ACTIVITY; ANTIPSYCHOTIC-LIKE ACTIVITY; RAT BEHAVIORAL-MODELS; PREFRONTAL CORTEX; MGLU(5) RECEPTOR; SCHIZOPHRENIA; DISCOVERY; SITE; PHARMACOLOGY; MICE AB Impaired transmission through glutamatergic circuits has been postulated to play a role in the underlying pathophysiology of schizophrenia. Furthermore, inhibition of the N-methyl-D-aspartate (NMDA) subtype of ionotropic glutamate receptors (NMDAR) induces a syndrome that recapitulates many of the symptoms observed in patients with schizophrenia. Selective activation of metabotropic glutamate receptor subtype 5 (mGlu(5)) may provide a novel therapeutic approach for treatment of symptoms associated with schizophrenia through facilitation of transmission through central glutamatergic circuits. Here, we describe the characterization of two novel N-aryl piperazine mGlu(5) positive allosteric modulators (PAMs): 2-(4-(2-(benzyloxy)acetyl)piperazin-1-yl) benzonitrile (VU0364289) and 1-(4-(2,4-difluorophenyl)piperazin-1-yl)-2-((4-fluorobenzyl) oxy) ethanone (DPFE). VU0364289 and DPFE induced robust leftward shifts in the glutamate concentration-response curves for Ca2+ mobilization and extracellular signal-regulated kinases 1 and 2 phosphorylation. Both PAMs displayed micromolar affinity for the common mGlu(5) allosteric binding site and high selectivity for mGlu(5). VU0364289 and DPFE possessed suitable pharmacokinetic properties for dosing in vivo and produced robust dose-related effects in reversing amphetamine-induced hyperlocomotion, a preclinical model predictive of antipsychotic-like activity. In addition, DPFE enhanced acquisition of contextual fear conditioning in rats and reversed behavioral deficits in a mouse model of NMDAR hypofunction. In contrast, DPFE had no effect on reversing apomorphine-induced disruptions of prepulse inhibition of the acoustic startle reflex. These mGlu(5) PAMs also increased monoamine levels in the prefrontal cortex, enhanced performance in a hippocampal-mediated memory task, and elicited changes in electroencephalogram dynamics commensurate with procognitive effects. Collectively, these data support and extend the role for the development of novel mGlu(5) PAMs for the treatment of psychosis and cognitive deficits observed in individuals with schizophrenia. C1 [Gregory, K. J.; Herman, E. J.; Hammond, A. S.; Byun, N. E.; Stauffer, S. R.; Manka, J. T.; Jadhav, S.; Bridges, T. M.; Weaver, C. D.; Niswender, C. M.; Lindsley, C. W.; Conn, P. J.; Jones, C. K.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA. [Gregory, K. J.; Herman, E. J.; Hammond, A. S.; Byun, N. E.; Stauffer, S. R.; Manka, J. T.; Jadhav, S.; Bridges, T. M.; Weaver, C. D.; Niswender, C. M.; Lindsley, C. W.; Conn, P. J.; Jones, C. K.] Vanderbilt Univ, Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA. [Gregory, K. J.] Monash Univ, MIPS, Parkville, Vic, Australia. [Ramsey, A. J.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 1A1, Canada. [Byun, N. E.] Vanderbilt Univ, Inst Imaging & Sci, Beerse, Belgium. [Steckler, T.; Drinkenburg, W. H.; Ahnaou, A.; Lavreysen, H.; Macdonald, G. J.; Mackie, C.; Hrupka, B. J.] Janssen Res & Dev, Beerse, Belgium. [Bartolome, J. M.] Janssen Res & Dev, Toledo, Spain. [Caron, M. G.; Daigle, T. L.] Duke Univ, Dept Cell Biol, Durham, NC USA. [Lindsley, C. W.] Vanderbilt Univ, Med Ctr, Dept Chem, Nashville, TN 37232 USA. [Jones, C. K.] US Dept Vet Affairs, Nashville, TN USA. RP Jones, CK (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA. EM carrie.jones@vanderbilt.edu OI Drinkenburg, Wilhelmus/0000-0002-1095-7995; Gregory, Karen/0000-0002-3833-2137 FU National Institutes of Health National Institute of Mental Health [R01 MH062646, R01 MH073853]; National Institutes of Health National Institute on Drug Abuse [F32 DA 030026]; National Institutes of Health National Institute of Neurologic Disorders and Stroke [5R01 NS031373-15]; Johnson Johnson; National Health and Medical Research Council (Australia); American-Australian Association Merck Co. Foundation; NARSAD-Maltz; Canadian Institutes of Health [258294] FX This work was supported by the National Institutes of Health National Institute of Mental Health [Grants R01 MH062646 and R01 MH073853]; National Institutes of Health National Institute on Drug Abuse [Grant F32 DA 030026]; and National Institutes of Health National Institute of Neurologic Disorders and Stroke [Grant 5R01 NS031373-15]; an industry-sponsored contract from Johnson & Johnson; a National Health and Medical Research Council (Australia) Overseas Biomedical Postdoctoral Training fellowship (to K.J.G.); an American-Australian Association Merck Co. Foundation fellowship (to K.J.G.); a NARSAD-Maltz Investigator Award (to K.J.G.); and the Canadian Institutes of Health [Grant 258294] (to A.J.R.). NR 63 TC 19 Z9 19 U1 2 U2 6 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD NOV PY 2013 VL 347 IS 2 BP 438 EP 457 DI 10.1124/jpet.113.206623 PG 20 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 238HE UT WOS:000325934400019 PM 23965381 ER PT J AU Fu, JL Zhang, HM Zhang, H Kamat, A Yeh, CK Zhang, BX AF Fu, Jian-Liang Zhang, Hong-Mei Zhang, Hua Kamat, Amrita Yeh, Chih-Ko Zhang, Bin-Xian TI A melatonin-based fluorescence method for the measurement of mitochondrial complex III function in intact cells SO JOURNAL OF PINEAL RESEARCH LA English DT Article DE cancer; electron transfer; H2DCF; melatonin; mitochondrial complex III; Qi site ID OXIDATIVE STRESS; SKELETAL-MUSCLE; GENERATION; GLAND; RAT; METABOLISM; BC(1); MICE; IV AB Mitochondrial complex III (MC-3) plays a pivotal role in electron transfer and oxidative phosphorylation. Impaired MC-3 functions may contribute to a variety of diseases by interrupting normal bioenergetics and increasing reactive oxygen production and oxidative stress. Currently, MC-3 function is assessed by measuring the cytochrome c reductase activity spectrophotometrically in isolated mitochondria or MC-3. The cytoplasmic microenvironment critical for mitochondrial complex functions may be depleted during these isolation processes. The development of a reliable method to measure MC-3 activities in intact cells or tissues is highly desirable. This report describes a novel fluorescence-based method to assess MC-3 functions, i.e., Qi site electron transfer, in the intact cells. Human mesangial and teratocarcinoma NT2 cells were used to demonstrate that melatonin-induced oxidation of 2,7-dichlorodihydrofluorescein (H2DCF) was inhibited by antimycin A, the MC-3 Qi site-specific inhibitor, but not by myxothiazol, the MC-3 Qo site-specific inhibitor, nor rotenone, the mitochondrial complex I inhibitor. These results indicate that melatonin-induced oxidation of H2DCF is reflecting MC-3 Qi site electron transfer activities. Modifying structures of the side groups at the R3 and R5 positions of the indole ring of melatonin diminished its efficacy for inducing H2DCF oxidation, suggesting a specific interaction of melatonin with the MC-3 Qi site. These results suggest that the fluorogenic property of melatonin-induced H2DCF oxidation provides a MC-3 Qi site electron transfer-specific measurement in intact cells. Interestingly, using this method, the Qi site electron transfer activity in transformed or immortalized cells was found to be significantly higher than the nontransformed cells. C1 [Fu, Jian-Liang; Zhang, Hong-Mei; Zhang, Hua; Kamat, Amrita; Yeh, Chih-Ko; Zhang, Bin-Xian] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA. [Fu, Jian-Liang] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Neurol, Shanghai 200030, Peoples R China. [Zhang, Hong-Mei] Fourth Mil Med Univ, Xijing Hosp, Dept Clin Oncol, Xian 710032, Peoples R China. [Yeh, Chih-Ko; Zhang, Bin-Xian] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. RP Zhang, BX (reprint author), South Texas Vet Hlth Care Syst, Audie L Murphy Div, Geriatr Res Educ & Clin Ctr, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM zhangb2@uthscsa.edu FU Mike Hogg Fund; National Science Foundation of China [30900673]; Science and Technology Development Program of Shaanxi Province, China [2013KJXX-91]; Scientific Research Foundation of Department of Health of Shaanxi Province, China [2012D13]; NIH; American Heart Association; Department of Veterans Affair FX Hua Zhang's current address: Department of Geriatrics, Xijing Hospital, Xi'An, China This study is partially supported by the Mike Hogg Fund (BXZ), and grants from The National Science Foundation of China (30900673, HMZ), Science and Technology Development Program of Shaanxi Province, China (2013KJXX-91), Scientific Research Foundation of Department of Health of Shaanxi Province, China (2012D13), NIH (CKY & Yuyu Sun), American Heart Association (AK), and Department of Veterans Affair (CKY). NR 34 TC 3 Z9 3 U1 0 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0742-3098 EI 1600-079X J9 J PINEAL RES JI J. Pineal Res. PD NOV PY 2013 VL 55 IS 4 BP 364 EP 370 DI 10.1111/jpi.12079 PG 7 WC Endocrinology & Metabolism; Neurosciences; Physiology SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology GA 234EJ UT WOS:000325623700003 PM 23952718 ER PT J AU El-Gabalawy, R Tsai, J Harpaz-Rotem, I Hoff, R Sareen, J Pietrzak, RH AF El-Gabalawy, Renee Tsai, Jack Harpaz-Rotem, Ilan Hoff, Rani Sareen, Jitender Pietrzak, Robert H. TI Predominant typologies of psychopathology in the United States: A latent class analysis SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Epidemiology; Comorbidity; Axis I disorders; Axis II disorders; Suicide; Quality of life ID NATIONAL-EPIDEMIOLOGIC-SURVEY; ALCOHOL-USE-DISORDER; INTERVIEW SCHEDULE AUDADIS; GENERAL-POPULATION SAMPLE; PSYCHIATRIC DIAGNOSTIC MODULES; COMORBIDITY SURVEY REPLICATION; COGNITIVE-BEHAVIORAL THERAPY; ENVIRONMENTAL RISK-FACTORS; COMMON MENTAL-DISORDERS; SUBSTANCE USE DISORDERS AB Background: Latent class analysis (LCA) offers a parsimonious way of classifying common typologies of psychiatric comorbidity. We used LCA to identify the nature and correlates of predominant typologies of Axis I and II disorders in a large and comprehensive population-based sample of U.S. adults. Methods: We analyzed data from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (2004-2005; n = 34,653), a population-based sample of U.S. adults. We derived latent classes based on all assessed Axis land II disorders and examined the relationship between the identified Axis I classes and lifetime psychiatric disorders and suicide attempts, and physical and mental health-related quality of life. Results: A four-class solution was optimal in characterizing predominant typologies of both Axis I and II disorders. For Axis I disorders, these included low psychopathology (n = 28,935, 84.0%), internalizing (n = 3693, 9.9%), externalizing (n = 1426, 4.5%), and high psychopathology (n = 599, 1.6%) classes. For Axis II disorders, these included no/low personality disorders (n = 31,265, 90.9%), obsessive/paranoid (n = 1635, 4.6%), borderline/dysregulated (n = 1319, 3.4%), and highly comorbid (n = 434, 1.1%) classes. Compared to the low psychopathology class, all other Axis I classes had significantly increased odds of mental disorders, elevated Axis II classes, suicide attempts and poorer quality of life, with the high psychopathology class having the overall highest rates of these correlates, with the exception of substance use disorders. Compared to the low psychopathology class, the internalizing and externalizing classes had increased rates of mood and anxiety disorders, and substance use disorders, respectively. Conclusion: Axis I and II psychopathology among U.S. adults may be best represented by four predominant typologies. Characterizing co-occurring patterns of psychopathology using person-based typologies represents a higher-order classification system that may be useful in clinical and research settings. Published by Elsevier Ltd. C1 [El-Gabalawy, Renee] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada. [El-Gabalawy, Renee; Tsai, Jack; Harpaz-Rotem, Ilan; Hoff, Rani; Pietrzak, Robert H.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Tsai, Jack] VA New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [El-Gabalawy, Renee; Harpaz-Rotem, Ilan; Hoff, Rani; Pietrzak, Robert H.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, West Haven, CT USA. [Sareen, Jitender] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada. RP Pietrzak, RH (reprint author), VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Clin Neurosci Div, 950 Campbell Ave 151E, West Haven, CT USA. EM robert.pietrzak@yale.edu FU Vanier Canada Graduate Scholarship; Manitoba Graduate Scholarship; Canada Graduate Scholarship Michael Smith Foreign Supplement; Manitoba Health Research Council Chair; U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder and a private donation; National Institute on Alcohol Abuse and Alcoholism; National Institute on Drug Abuse FX This work was supported by a Vanier Canada Graduate Scholarship, Manitoba Graduate Scholarship and Canada Graduate Scholarship Michael Smith Foreign Supplement (Ms. El-Gabalawy), Manitoba Health Research Council Chair (Dr. Sareen), the U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder and a private donation (Dr. Pietrzak). The NESARC was conducted and funded by the National Institute on Alcohol Abuse and Alcoholism, with supplemental support from the National Institute on Drug Abuse. We thank the NIAAA and the US Census Bureau field representatives who administrated the NESARC interviews and made it available for researchers. NR 58 TC 4 Z9 4 U1 3 U2 14 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD NOV PY 2013 VL 47 IS 11 BP 1649 EP 1657 DI 10.1016/j.jpsychires2013.07.028 PG 9 WC Psychiatry SC Psychiatry GA 237AW UT WOS:000325841600014 PM 23978394 ER EF